activity_id,mol_chembl_id,compound_name,assay_chembl_id,assay_type,assay_cell_type,assay_organism,pref_name,description,standard_type,standard_relation,standard_value,standard_units,canonical_smiles,doc_chembl_id,title,journal,year,volume,issue,first_page,last_page,doi,pubmed_id,patent_id
111517,CHEMBL71472,"Ethyl-sulfamic acid 5-tert-butyl-4-{4-hydroxy-6-[2-(4-hydroxy-phenyl)-ethyl]-6-methyl-2-oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-2-methyl-phenyl ester",CHEMBL660952,A,,,Cytochrome P450 2C9,Inhibition of Cytochrome P450 2C9 at 1 uM,Inhibition,=,0.0,%,CCNS(=O)(=O)Oc1cc(C(C)(C)C)c(SC2=C(O)OC(C)(CCc3ccc(O)cc3)CC2=O)cc1C,CHEMBL1131822,"Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.",Bioorg. Med. Chem. Lett.,1999.0,9,15,2217,2222,10.1016/s0960-894x(99)00360-1,10465549.0,
111518,CHEMBL71472,"Ethyl-sulfamic acid 5-tert-butyl-4-{4-hydroxy-6-[2-(4-hydroxy-phenyl)-ethyl]-6-methyl-2-oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-2-methyl-phenyl ester",CHEMBL660951,A,,,Cytochrome P450 2C9,Inhibition of Cytochrome P450 2C9 at 10 uM,Inhibition,=,6.0,%,CCNS(=O)(=O)Oc1cc(C(C)(C)C)c(SC2=C(O)OC(C)(CCc3ccc(O)cc3)CC2=O)cc1C,CHEMBL1131822,"Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.",Bioorg. Med. Chem. Lett.,1999.0,9,15,2217,2222,10.1016/s0960-894x(99)00360-1,10465549.0,
111519,CHEMBL71472,"Ethyl-sulfamic acid 5-tert-butyl-4-{4-hydroxy-6-[2-(4-hydroxy-phenyl)-ethyl]-6-methyl-2-oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-2-methyl-phenyl ester",CHEMBL660950,A,,,Cytochrome P450 2C9,Inhibition of Cytochrome P450 2C9 at 100 uM,Inhibition,=,46.0,%,CCNS(=O)(=O)Oc1cc(C(C)(C)C)c(SC2=C(O)OC(C)(CCc3ccc(O)cc3)CC2=O)cc1C,CHEMBL1131822,"Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.",Bioorg. Med. Chem. Lett.,1999.0,9,15,2217,2222,10.1016/s0960-894x(99)00360-1,10465549.0,
136755,CHEMBL285759,"(S)-6-[2-(4-Amino-phenyl)-ethyl]-3-(2-tert-butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6-isopropyl-5,6-dihydro-pyran-2-one",CHEMBL660952,A,,,Cytochrome P450 2C9,Inhibition of Cytochrome P450 2C9 at 1 uM,Inhibition,=,2.0,%,Cc1cc(SC2=C(O)O[C@](CCc3ccc(N)cc3)(C(C)C)CC2=O)c(C(C)(C)C)cc1CO,CHEMBL1131822,"Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.",Bioorg. Med. Chem. Lett.,1999.0,9,15,2217,2222,10.1016/s0960-894x(99)00360-1,10465549.0,
136756,CHEMBL285759,"(S)-6-[2-(4-Amino-phenyl)-ethyl]-3-(2-tert-butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6-isopropyl-5,6-dihydro-pyran-2-one",CHEMBL660948,A,,,Cytochrome P450 2C9,Inhibition of Cytochrome P450 2C9 at 10 uM,Inhibition,=,12.0,%,Cc1cc(SC2=C(O)O[C@](CCc3ccc(N)cc3)(C(C)C)CC2=O)c(C(C)(C)C)cc1CO,CHEMBL1131822,"Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.",Bioorg. Med. Chem. Lett.,1999.0,9,15,2217,2222,10.1016/s0960-894x(99)00360-1,10465549.0,
136757,CHEMBL285759,"(S)-6-[2-(4-Amino-phenyl)-ethyl]-3-(2-tert-butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6-isopropyl-5,6-dihydro-pyran-2-one",CHEMBL660949,A,,,Cytochrome P450 2C9,Inhibition of Cytochrome P450 2C9 at 100 uM,Inhibition,=,59.0,%,Cc1cc(SC2=C(O)O[C@](CCc3ccc(N)cc3)(C(C)C)CC2=O)c(C(C)(C)C)cc1CO,CHEMBL1131822,"Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.",Bioorg. Med. Chem. Lett.,1999.0,9,15,2217,2222,10.1016/s0960-894x(99)00360-1,10465549.0,
395199,CHEMBL2114404,"3-(4-Amino-2-tert-butyl-5-methyl-phenylsulfanyl)-4-hydroxy-6-[2-(4-hydroxy-phenyl)-ethyl]-6-isopropyl-5,6-dihydro-pyran-2-one",CHEMBL819613,A,,,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9 at 1 uM,Inhibition,=,93.2,%,Cc1cc(SC2=C(O)O[C@](CCc3ccc(O)cc3)(C(C)C)CC2=O)c(C(C)(C)C)cc1N,CHEMBL1132961,"5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.",J. Med. Chem.,2000.0,43,5,843,858,10.1021/jm990281p,10715152.0,
395200,CHEMBL2114404,"3-(4-Amino-2-tert-butyl-5-methyl-phenylsulfanyl)-4-hydroxy-6-[2-(4-hydroxy-phenyl)-ethyl]-6-isopropyl-5,6-dihydro-pyran-2-one",CHEMBL819612,A,,,Cytochrome P450 2C9,Inhibition of cytochrome P450 at 10 uM,Inhibition,=,75.5,%,Cc1cc(SC2=C(O)O[C@](CCc3ccc(O)cc3)(C(C)C)CC2=O)c(C(C)(C)C)cc1N,CHEMBL1132961,"5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.",J. Med. Chem.,2000.0,43,5,843,858,10.1021/jm990281p,10715152.0,
395201,CHEMBL2114404,"3-(4-Amino-2-tert-butyl-5-methyl-phenylsulfanyl)-4-hydroxy-6-[2-(4-hydroxy-phenyl)-ethyl]-6-isopropyl-5,6-dihydro-pyran-2-one",CHEMBL819611,A,,,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9 at 100 uM,Inhibition,=,21.6,%,Cc1cc(SC2=C(O)O[C@](CCc3ccc(O)cc3)(C(C)C)CC2=O)c(C(C)(C)C)cc1N,CHEMBL1132961,"5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.",J. Med. Chem.,2000.0,43,5,843,858,10.1021/jm990281p,10715152.0,
407141,CHEMBL115,"(S)-1-[(2S,4R)-2-Hydroxy-4-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-5-phenyl-pentyl]-4-pyridin-3-ylmethyl-piperazine-2-carboxylic acid tert-butylamide",CHEMBL819613,A,,,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9 at 1 uM,Inhibition,=,93.0,%,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O,CHEMBL1132961,"5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.",J. Med. Chem.,2000.0,43,5,843,858,10.1021/jm990281p,10715152.0,
407142,CHEMBL115,"(S)-1-[(2S,4R)-2-Hydroxy-4-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-5-phenyl-pentyl]-4-pyridin-3-ylmethyl-piperazine-2-carboxylic acid tert-butylamide",CHEMBL819612,A,,,Cytochrome P450 2C9,Inhibition of cytochrome P450 at 10 uM,Inhibition,=,89.0,%,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O,CHEMBL1132961,"5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.",J. Med. Chem.,2000.0,43,5,843,858,10.1021/jm990281p,10715152.0,
407143,CHEMBL115,"(S)-1-[(2S,4R)-2-Hydroxy-4-((1S,2R)-2-hydroxy-indan-1-ylcarbamoyl)-5-phenyl-pentyl]-4-pyridin-3-ylmethyl-piperazine-2-carboxylic acid tert-butylamide",CHEMBL819611,A,,,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9 at 100 uM,Inhibition,=,68.0,%,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O,CHEMBL1132961,"5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.",J. Med. Chem.,2000.0,43,5,843,858,10.1021/jm990281p,10715152.0,
408278,CHEMBL168839,"4-Cyano-benzenesulfonic acid 5-tert-butyl-4-{4-hydroxy-6-[2-(4-hydroxy-phenyl)-ethyl]-6-isopropyl-2-oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-2-methyl-phenyl ester (0.40H2O)",CHEMBL819613,A,,,Cytochrome P450 2C9,Inhibition of cytochrome P450 2C9 at 1 uM,Inhibition,=,83.5,%,Cc1cc(SC2=C(O)OC(CCc3ccc(O)cc3)(C(C)C)CC2=O)c(C(C)(C)C)cc1OS(=O)(=O)c1ccc(C#N)cc1,CHEMBL1132961,"5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.",J. Med. Chem.,2000.0,43,5,843,858,10.1021/jm990281p,10715152.0,
408279,CHEMBL168839,"4-Cyano-benzenesulfonic acid 5-tert-butyl-4-{4-hydroxy-6-[2-(4-hydroxy-phenyl)-ethyl]-6-isopropyl-2-oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-2-methyl-phenyl ester (0.40H2O)",CHEMBL819612,A,,,Cytochrome P450 2C9,Inhibition of cytochrome P450 at 10 uM,Inhibition,=,18.1,%,Cc1cc(SC2=C(O)OC(CCc3ccc(O)cc3)(C(C)C)CC2=O)c(C(C)(C)C)cc1OS(=O)(=O)c1ccc(C#N)cc1,CHEMBL1132961,"5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.",J. Med. Chem.,2000.0,43,5,843,858,10.1021/jm990281p,10715152.0,
633525,CHEMBL113060,2-Chloro-4-[5-(4-fluoro-phenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridine,CHEMBL661222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of Cytochrome P450 2C9 at 10 uM,Inhibition,=,65.0,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(Cl)c2)[nH]1,CHEMBL1145851,Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.,J. Med. Chem.,2003.0,46,15,3230,3244,10.1021/jm030766k,12852754.0,
635730,CHEMBL10,4-[5-(4-Fluoro-phenyl)-2-(4-methanesulfinyl-phenyl)-3H-imidazol-4-yl]-pyridine,CHEMBL661222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of Cytochrome P450 2C9 at 10 uM,Inhibition,=,75.0,%,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,CHEMBL1145851,Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.,J. Med. Chem.,2003.0,46,15,3230,3244,10.1021/jm030766k,12852754.0,
638268,CHEMBL113419,4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridine,CHEMBL661222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of Cytochrome P450 2C9 at 10 uM,Inhibition,=,72.4,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccncc2)[nH]1,CHEMBL1145851,Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.,J. Med. Chem.,2003.0,46,15,3230,3244,10.1021/jm030766k,12852754.0,
643188,CHEMBL323734,"N-{4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3-(2,2,6,6-tetramethyl-piperidin-4-yl)-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide",CHEMBL661222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of Cytochrome P450 2C9 at 10 uM,Inhibition,=,2.6,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)=O)c2)n1C1CC(C)(C)NC(C)(C)C1,CHEMBL1145851,Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.,J. Med. Chem.,2003.0,46,15,3230,3244,10.1021/jm030766k,12852754.0,
650279,CHEMBL111456,4-[5-(4-Fluoro-phenyl)-2-(4-methanesulfinyl-benzylsulfanyl)-1H-imidazol-4-yl]-pyridine,CHEMBL661222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of Cytochrome P450 2C9 at 10 uM,Inhibition,=,72.7,%,C[S+]([O-])c1ccc(CSc2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,CHEMBL1145851,Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.,J. Med. Chem.,2003.0,46,15,3230,3244,10.1021/jm030766k,12852754.0,
651559,CHEMBL323479,"4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3-(2,2,6,6-tetramethyl-piperidin-4-yl)-3H-imidazol-4-yl]-pyridine",CHEMBL661222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of Cytochrome P450 2C9 at 10 uM,Inhibition,=,7.9,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccncc2)n1C1CC(C)(C)NC(C)(C)C1,CHEMBL1145851,Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.,J. Med. Chem.,2003.0,46,15,3230,3244,10.1021/jm030766k,12852754.0,
656221,CHEMBL111364,4-[4-(4-fluorophenyl)-2-(methylsulfanyl)-1H-imidazol-5-yl]-N-(1-phenylethyl)pyridin-2-amine,CHEMBL661222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of Cytochrome P450 2C9 at 10 uM,Inhibition,=,79.0,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)[nH]1,CHEMBL1145851,Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.,J. Med. Chem.,2003.0,46,15,3230,3244,10.1021/jm030766k,12852754.0,
657337,CHEMBL111210,4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-2-isopropoxy-pyridine,CHEMBL661222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of Cytochrome P450 2C9 at 10 uM,Inhibition,=,67.5,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(OC(C)C)c2)[nH]1,CHEMBL1145851,Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.,J. Med. Chem.,2003.0,46,15,3230,3244,10.1021/jm030766k,12852754.0,
658664,CHEMBL432798,N-{4-[5-(4-Fluoro-phenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide,CHEMBL661222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of Cytochrome P450 2C9 at 10 uM,Inhibition,=,27.6,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)=O)c2)n1C,CHEMBL1145851,Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.,J. Med. Chem.,2003.0,46,15,3230,3244,10.1021/jm030766k,12852754.0,
661090,CHEMBL324977,{4-[5-(4-Fluoro-phenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenyl-ethyl)-amine,CHEMBL661222,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of Cytochrome P450 2C9 at 10 uM,Inhibition,=,83.3,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)c3ccccc3)c2)n1C,CHEMBL1145851,Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.,J. Med. Chem.,2003.0,46,15,3230,3244,10.1021/jm030766k,12852754.0,
1417135,CHEMBL351231,4-{2-[2-((R)-2-Methyl-pyrrolidin-1-yl)-ethyl]-benzofuran-5-yl}-benzonitrile,CHEMBL836210,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 at 2 uM assessed by effect on rate of oxidation of Tolbutamide hydroxylation upon incubation with human liver microsomes,Inhibition,=,0.0,%,C[C@@H]1CCCN1CCc1cc2cc(-c3ccc(C#N)cc3)ccc2o1,CHEMBL1139496,4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.,J. Med. Chem.,2005.0,48,1,38,55,10.1021/jm040118g,15634000.0,
1417257,CHEMBL351231,4-{2-[2-((R)-2-Methyl-pyrrolidin-1-yl)-ethyl]-benzofuran-5-yl}-benzonitrile,CHEMBL836214,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 at 20 uM assessed by its effect on rate of oxidation of Tolbutamide hydroxylation upon incubation with human liver microsomes,Inhibition,=,21.9,%,C[C@@H]1CCCN1CCc1cc2cc(-c3ccc(C#N)cc3)ccc2o1,CHEMBL1139496,4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.,J. Med. Chem.,2005.0,48,1,38,55,10.1021/jm040118g,15634000.0,
1606078,CHEMBL194760,1-(2-Fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid,CHEMBL885113,A,,Homo sapiens,Cytochrome P450 2C9,Interaction with human cytochrome P450 isoform 2C9 expressed in baculovirus-insect cells,Inhibition,=,83.0,uM,O=C(O)C1(c2ccc(-c3ccccc3)c(F)c2)CC1,CHEMBL1141070,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,2005.0,48,18,5705,5720,10.1021/jm0502541,16134939.0,
1606246,CHEMBL196070,5-[1-(2-Fluoro-4'-trifluoromethyl-biphenyl-4-yl)-ethyl]-1H-tetrazole,CHEMBL885129,A,,Homo sapiens,Cytochrome P450 2C9,Interaction with human cytochrome P450 isoform 2C9 expressed in baculovirus-insect cells at 100 uM,Inhibition,>,50.0,%,CC(c1ccc(-c2ccc(C(F)(F)F)cc2)c(F)c1)c1nnn[nH]1,CHEMBL1141070,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,2005.0,48,18,5705,5720,10.1021/jm0502541,16134939.0,
1606260,CHEMBL197305,N-[2-(2-Fluoro-4'-trifluoromethyl-biphenyl-4-yl)-propionyl]-methanesulfonamide,CHEMBL885129,A,,Homo sapiens,Cytochrome P450 2C9,Interaction with human cytochrome P450 isoform 2C9 expressed in baculovirus-insect cells at 100 uM,Inhibition,>,50.0,%,CC(C(=O)NS(C)(=O)=O)c1ccc(-c2ccc(C(F)(F)F)cc2)c(F)c1,CHEMBL1141070,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,2005.0,48,18,5705,5720,10.1021/jm0502541,16134939.0,
1606270,CHEMBL382746,"3-[1-(2-Fluoro-4'-trifluoromethyl-biphenyl-4-yl)-ethyl]-4H-[1,2,4]oxadiazol-5-one",CHEMBL885129,A,,Homo sapiens,Cytochrome P450 2C9,Interaction with human cytochrome P450 isoform 2C9 expressed in baculovirus-insect cells at 100 uM,Inhibition,>,50.0,%,CC(c1ccc(-c2ccc(C(F)(F)F)cc2)c(F)c1)c1noc(O)n1,CHEMBL1141070,Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.,J. Med. Chem.,2005.0,48,18,5705,5720,10.1021/jm0502541,16134939.0,
1653889,CHEMBL420311,"6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide",CHEMBL859697,A,,Homo sapiens,Cytochrome P450 2C9,Percent inhibitory activity against human CYP2C9 at 1uM,Inhibition,=,-5.0,%,NC(=O)C1CCCc2c1[nH]c1ccc(Cl)cc21,CHEMBL1140425,Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1.,J. Med. Chem.,2005.0,48,25,8045,8054,10.1021/jm050522v,16335928.0,
1653903,CHEMBL115600,"6-methyl-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide",CHEMBL859697,A,,Homo sapiens,Cytochrome P450 2C9,Percent inhibitory activity against human CYP2C9 at 1uM,Inhibition,=,-9.0,%,Cc1ccc2[nH]c3c(c2c1)CCCC3C(N)=O,CHEMBL1140425,Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1.,J. Med. Chem.,2005.0,48,25,8045,8054,10.1021/jm050522v,16335928.0,
1653916,CHEMBL112265,"2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide",CHEMBL859697,A,,Homo sapiens,Cytochrome P450 2C9,Percent inhibitory activity against human CYP2C9 at 1uM,Inhibition,=,-8.0,%,NC(=O)C1CCCc2c1[nH]c1ccccc21,CHEMBL1140425,Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1.,J. Med. Chem.,2005.0,48,25,8045,8054,10.1021/jm050522v,16335928.0,
1653929,CHEMBL446446,"2-chloro-5,6,7,8,9,10-hexahydrocyclohepta[b]indole-6-carboxylic acid amide",CHEMBL859697,A,,Homo sapiens,Cytochrome P450 2C9,Percent inhibitory activity against human CYP2C9 at 1uM,Inhibition,=,11.0,%,NC(=O)C1CCCCc2c1[nH]c1ccc(Cl)cc21,CHEMBL1140425,Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1.,J. Med. Chem.,2005.0,48,25,8045,8054,10.1021/jm050522v,16335928.0,
1705448,CHEMBL206387,"2-[5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-ureidomethyl-biphenyl-3-yl]-succinic acid",CHEMBL867761,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,40.0,%,N=C(N)c1ccc2[nH]c(-c3cc(C(CC(=O)O)C(=O)O)cc(-c4cc(CNC(N)=O)ccc4O)c3O)nc2c1,CHEMBL1146111,"Factor VIIa inhibitors: chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model.",Bioorg. Med. Chem. Lett.,2006.0,16,7,2037,2041,10.1016/j.bmcl.2005.12.059,16412633.0,
1792710,CHEMBL216884,5-(5-((benzylamino)methyl)pyridin-2-yl)-N-hydroxythiophene-2-carboxamide,CHEMBL908806,A,,Homo sapiens,Cytochrome P450 2C9,Percent inhibition of CYP450 2C9 at 1 uM concentration,Inhibition,=,-14.0,%,O=C(NO)c1ccc(-c2ccc(CNCc3ccccc3)cn2)s1,CHEMBL1137593,Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,2007.0,17,2,363,369,10.1016/j.bmcl.2006.10.045,17107790.0,
1792711,CHEMBL217716,"5-(1-(2-(benzo[d][1,3]dioxol-5-ylmethylamino)ethyl)-1H-pyrazol-3-yl)-N-hydroxythiophene-2-carboxamide",CHEMBL908806,A,,Homo sapiens,Cytochrome P450 2C9,Percent inhibition of CYP450 2C9 at 1 uM concentration,Inhibition,=,0.0,%,O=C(NO)c1ccc(-c2ccn(CCNCc3ccc4c(c3)OCO4)n2)s1,CHEMBL1137593,Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,2007.0,17,2,363,369,10.1016/j.bmcl.2006.10.045,17107790.0,
1792712,CHEMBL98,Octanedioic acid hydroxyamide phenylamide,CHEMBL908806,A,,Homo sapiens,Cytochrome P450 2C9,Percent inhibition of CYP450 2C9 at 1 uM concentration,Inhibition,=,28.0,%,O=C(CCCCCCC(=O)Nc1ccccc1)NO,CHEMBL1137593,Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.,Bioorg. Med. Chem. Lett.,2007.0,17,2,363,369,10.1016/j.bmcl.2006.10.045,17107790.0,
1819021,CHEMBL374926,"benzene-1,2,4,5-tetraamine",CHEMBL919483,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as (S)-Flurbiprofen hydroxylation at 1 uM,Inhibition,=,50.0,%,Nc1cc(N)c(N)cc1N,CHEMBL1142940,Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9.,J. Med. Chem.,2007.0,50,6,1158,1165,10.1021/jm060706p,17311370.0,
1821143,CHEMBL376896,1-methoxy-4-(4-methoxyphenylsulfonyl)benzene,CHEMBL919481,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as (S)-Flurbiprofen hydroxylation,Inhibition,=,-25.0,%,COc1ccc(S(=O)(=O)c2ccc(OC)cc2)cc1,CHEMBL1142940,Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9.,J. Med. Chem.,2007.0,50,6,1158,1165,10.1021/jm060706p,17311370.0,
1821176,CHEMBL220339,"(4-fluorophenyl)(imidazo[2,1-b]thiazol-5-yl)methanone",CHEMBL919482,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as (S)-Flurbiprofen hydroxylation at 100 uM,Inhibition,=,50.0,%,O=C(c1ccc(F)cc1)c1cnc2sccn12,CHEMBL1142940,Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9.,J. Med. Chem.,2007.0,50,6,1158,1165,10.1021/jm060706p,17311370.0,
1821177,CHEMBL220620,"1-(3,4-dichloro-phenyl)-5-imino-3-methyl-4-thioxo-imidazolidin-2-one",CHEMBL919482,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as (S)-Flurbiprofen hydroxylation at 100 uM,Inhibition,=,50.0,%,CN1C(=O)N(c2ccc(Cl)c(Cl)c2)C(=N)C1=S,CHEMBL1142940,Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9.,J. Med. Chem.,2007.0,50,6,1158,1165,10.1021/jm060706p,17311370.0,
1832888,CHEMBL220175,4-[(4-carboxybenzene)sulfonyl]benzoic acid,CHEMBL919481,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as (S)-Flurbiprofen hydroxylation,Inhibition,=,-5.0,%,O=C(O)c1ccc(S(=O)(=O)c2ccc(C(=O)O)cc2)cc1,CHEMBL1142940,Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9.,J. Med. Chem.,2007.0,50,6,1158,1165,10.1021/jm060706p,17311370.0,
1832889,CHEMBL446,"4-Amino-N-(4,6-dimethyl-pyrimidin-2-yl)-benzenesulfonamide",CHEMBL919481,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as (S)-Flurbiprofen hydroxylation,Inhibition,=,-18.8,%,Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1,CHEMBL1142940,Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9.,J. Med. Chem.,2007.0,50,6,1158,1165,10.1021/jm060706p,17311370.0,
1832890,CHEMBL21,4-Amino-benzenesulfonamide,CHEMBL919481,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as (S)-Flurbiprofen hydroxylation,Inhibition,=,-17.8,%,Nc1ccc(S(N)(=O)=O)cc1,CHEMBL1142940,Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9.,J. Med. Chem.,2007.0,50,6,1158,1165,10.1021/jm060706p,17311370.0,
1832891,CHEMBL439,4-Amino-N-pyrimidin-2-yl-benzenesulfonamide,CHEMBL919481,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as (S)-Flurbiprofen hydroxylation,Inhibition,=,-17.1,%,Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1,CHEMBL1142940,Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9.,J. Med. Chem.,2007.0,50,6,1158,1165,10.1021/jm060706p,17311370.0,
1832892,CHEMBL443,4-Amino-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide,CHEMBL919481,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as (S)-Flurbiprofen hydroxylation,Inhibition,=,-17.1,%,Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1,CHEMBL1142940,Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9.,J. Med. Chem.,2007.0,50,6,1158,1165,10.1021/jm060706p,17311370.0,
1832893,CHEMBL342457,4-(4-Nitro-benzenesulfonyl)-phenylamine,CHEMBL919481,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as (S)-Flurbiprofen hydroxylation,Inhibition,=,-10.6,%,Nc1ccc(S(=O)(=O)c2ccc([N+](=O)[O-])cc2)cc1,CHEMBL1142940,Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9.,J. Med. Chem.,2007.0,50,6,1158,1165,10.1021/jm060706p,17311370.0,
1832894,CHEMBL219828,dibenzothiophene,CHEMBL919481,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 assessed as (S)-Flurbiprofen hydroxylation,Inhibition,=,-10.6,%,c1ccc2c(c1)sc1ccccc12,CHEMBL1142940,Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9.,J. Med. Chem.,2007.0,50,6,1158,1165,10.1021/jm060706p,17311370.0,
1838597,CHEMBL10,4-[5-(4-Fluoro-phenyl)-2-(4-methanesulfinyl-phenyl)-3H-imidazol-4-yl]-pyridine,CHEMBL914447,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9 at 10 uM,Inhibition,=,75.0,%,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,CHEMBL1149257,Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position.,J. Med. Chem.,2004.0,47,25,6311,6325,10.1021/jm0496584,15566301.0,
1838604,CHEMBL221568,N-{4-[5-(4-fluorophenyl)-2-methylsulfanyl-3-(2-piperidin-1-ylethyl)-3H-imidazol-4-yl]pyridin-2-yl}acetamide,CHEMBL914447,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9 at 10 uM,Inhibition,=,5.0,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)=O)c2)n1CCN1CCCCC1,CHEMBL1149257,Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position.,J. Med. Chem.,2004.0,47,25,6311,6325,10.1021/jm0496584,15566301.0,
1838605,CHEMBL427104,N-{4-[5-(4-fluorophenyl)-3-[2-(2-hydroxyethoxy)ethyl]-2-methylsulfanyl-3H-imidazol-4-yl]pyridin-2-yl}acetamide,CHEMBL914447,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9 at 10 uM,Inhibition,=,18.5,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)=O)c2)n1CCOCCO,CHEMBL1149257,Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position.,J. Med. Chem.,2004.0,47,25,6311,6325,10.1021/jm0496584,15566301.0,
1838606,CHEMBL426183,N-{4-[5-(4-fluorophenyl)-3-(2-methoxyethyl)-2-methylsulfanyl-3H-imidazol-4-yl]pyridin-2-yl}acetamide,CHEMBL914447,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver CYP2C9 at 10 uM,Inhibition,=,23.5,%,COCCn1c(SC)nc(-c2ccc(F)cc2)c1-c1ccnc(NC(C)=O)c1,CHEMBL1149257,Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position.,J. Med. Chem.,2004.0,47,25,6311,6325,10.1021/jm0496584,15566301.0,
1953731,CHEMBL234951,"(RS)-2-chloro-N-(1-((R)-2,3-dihydroxypropyl)-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl)-6H-thieno[2,3-b]pyrrole-5-carboxamide",CHEMBL889966,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,50.0,%,O=C(NC1Cc2ccccc2N(C[C@@H](O)CO)C1=O)c1cc2cc(Cl)sc2[nH]1,CHEMBL1146283,"Development of potent, orally active 1-substituted-3,4-dihydro-2-quinolone glycogen phosphorylase inhibitors.",Bioorg. Med. Chem. Lett.,2007.0,17,2,394,399,10.1016/j.bmcl.2006.10.037,17095214.0,
1975112,CHEMBL393364,"N-{2-[6-(2,4-diamino-6-ethyl-pyrimidin-5-yl)-2-methyl-3-oxo-2-(3-chloro-phenyl)-2,3-dihydro-benzo[1,4]-oxazin-4-yl]-ethyl}-acetamide",CHEMBL898584,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,11.0,%,CCc1nc(N)nc(N)c1-c1ccc2c(c1)N(CCNC(C)=O)C(=O)C(C)(c1cccc(Cl)c1)O2,CHEMBL1149625,"Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.",Bioorg. Med. Chem.,2007.0,15,17,5912,5949,10.1016/j.bmc.2007.05.069,17574423.0,
2044392,CHEMBL246834,"8a-(4-(pyridin-4-yl)benzyl)-2-(4-tert-butylphenylsulfonyl)-1,2,3,4,8,8a-hexahydroisoquinolin-6(7H)-one",CHEMBL942002,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 1 uM,Inhibition,=,76.0,%,CC(C)(C)c1ccc(S(=O)(=O)N2CCC3=CC(=O)CCC3(Cc3ccc(-c4ccncc4)cc3)C2)cc1,CHEMBL1139829,2-Benzenesulfonyl-8a-benzyl-hexahydro-2H-isoquinolin-6-ones as selective glucocorticoid receptor antagonists.,Bioorg. Med. Chem. Lett.,2007.0,17,20,5704,5708,10.1016/j.bmcl.2007.07.055,17822897.0,
2069385,CHEMBL251429,"5-((1-(2-fluorobenzyl)piperidin-4-yl)methoxy)quinazoline-2,4-diamine",CHEMBL945036,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,50.0,%,Nc1nc(N)c2c(OCC3CCN(Cc4ccccc4F)CC3)cccc2n1,CHEMBL1140748,"Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.",J. Med. Chem.,2008.0,51,3,449,469,10.1021/jm061475p,18205293.0,
2072531,CHEMBL414913,3-(6-(4-fluorophenyl)-2-methoxynaphthalen-1-yl)pyridine,CHEMBL927600,A,,,Cytochrome P450 2C9,Inhibition of hepatic CYP2C9 at 1 uM,Inhibition,=,66.0,%,COc1ccc2cc(-c3ccc(F)cc3)ccc2c1-c1cccnc1,CHEMBL1140785,"Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17.",Bioorg. Med. Chem. Lett.,2008.0,18,1,267,273,10.1016/j.bmcl.2007.10.079,18024111.0,
2072532,CHEMBL414913,3-(6-(4-fluorophenyl)-2-methoxynaphthalen-1-yl)pyridine,CHEMBL927601,A,,,Cytochrome P450 2C9,Inhibition of hepatic CYP2C9 at 10 uM,Inhibition,=,54.0,%,COc1ccc2cc(-c3ccc(F)cc3)ccc2c1-c1cccnc1,CHEMBL1140785,"Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17.",Bioorg. Med. Chem. Lett.,2008.0,18,1,267,273,10.1016/j.bmcl.2007.10.079,18024111.0,
2072547,CHEMBL254328,"10,13-Dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol",CHEMBL927600,A,,,Cytochrome P450 2C9,Inhibition of hepatic CYP2C9 at 1 uM,Inhibition,=,17.0,%,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,CHEMBL1140785,"Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17.",Bioorg. Med. Chem. Lett.,2008.0,18,1,267,273,10.1016/j.bmcl.2007.10.079,18024111.0,
2072548,CHEMBL157101,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",CHEMBL927600,A,,,Cytochrome P450 2C9,Inhibition of hepatic CYP2C9 at 1 uM,Inhibition,=,21.0,%,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,CHEMBL1140785,"Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17.",Bioorg. Med. Chem. Lett.,2008.0,18,1,267,273,10.1016/j.bmcl.2007.10.079,18024111.0,
2072549,CHEMBL402099,1-((3-(6-methoxynaphthalen-2-yl)phenyl)methyl)-1H-imidazole,CHEMBL927600,A,,,Cytochrome P450 2C9,Inhibition of hepatic CYP2C9 at 1 uM,Inhibition,=,97.0,%,COc1ccc2cc(-c3cccc(Cn4ccnc4)c3)ccc2c1,CHEMBL1140785,"Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17.",Bioorg. Med. Chem. Lett.,2008.0,18,1,267,273,10.1016/j.bmcl.2007.10.079,18024111.0,
2072550,CHEMBL254326,6-(3-(pyridin-4-yl)phenyl)naphthalen-2-ol,CHEMBL927600,A,,,Cytochrome P450 2C9,Inhibition of hepatic CYP2C9 at 1 uM,Inhibition,=,94.0,%,Oc1ccc2cc(-c3cccc(-c4ccncc4)c3)ccc2c1,CHEMBL1140785,"Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17.",Bioorg. Med. Chem. Lett.,2008.0,18,1,267,273,10.1016/j.bmcl.2007.10.079,18024111.0,
2072551,CHEMBL253935,1-((6-(4-fluorophenyl)-2-methoxynaphthalen-1-yl)methyl)-1H-imidazole,CHEMBL927600,A,,,Cytochrome P450 2C9,Inhibition of hepatic CYP2C9 at 1 uM,Inhibition,=,100.0,%,COc1ccc2cc(-c3ccc(F)cc3)ccc2c1Cn1ccnc1,CHEMBL1140785,"Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17.",Bioorg. Med. Chem. Lett.,2008.0,18,1,267,273,10.1016/j.bmcl.2007.10.079,18024111.0,
2072552,CHEMBL254328,"10,13-Dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol",CHEMBL927601,A,,,Cytochrome P450 2C9,Inhibition of hepatic CYP2C9 at 10 uM,Inhibition,=,51.0,%,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,CHEMBL1140785,"Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17.",Bioorg. Med. Chem. Lett.,2008.0,18,1,267,273,10.1016/j.bmcl.2007.10.079,18024111.0,
2072553,CHEMBL157101,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",CHEMBL927601,A,,,Cytochrome P450 2C9,Inhibition of hepatic CYP2C9 at 10 uM,Inhibition,=,75.0,%,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,CHEMBL1140785,"Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17.",Bioorg. Med. Chem. Lett.,2008.0,18,1,267,273,10.1016/j.bmcl.2007.10.079,18024111.0,
2072554,CHEMBL402099,1-((3-(6-methoxynaphthalen-2-yl)phenyl)methyl)-1H-imidazole,CHEMBL927601,A,,,Cytochrome P450 2C9,Inhibition of hepatic CYP2C9 at 10 uM,Inhibition,=,100.0,%,COc1ccc2cc(-c3cccc(Cn4ccnc4)c3)ccc2c1,CHEMBL1140785,"Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17.",Bioorg. Med. Chem. Lett.,2008.0,18,1,267,273,10.1016/j.bmcl.2007.10.079,18024111.0,
2072555,CHEMBL254326,6-(3-(pyridin-4-yl)phenyl)naphthalen-2-ol,CHEMBL927601,A,,,Cytochrome P450 2C9,Inhibition of hepatic CYP2C9 at 10 uM,Inhibition,=,97.0,%,Oc1ccc2cc(-c3cccc(-c4ccncc4)c3)ccc2c1,CHEMBL1140785,"Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17.",Bioorg. Med. Chem. Lett.,2008.0,18,1,267,273,10.1016/j.bmcl.2007.10.079,18024111.0,
2072556,CHEMBL253935,1-((6-(4-fluorophenyl)-2-methoxynaphthalen-1-yl)methyl)-1H-imidazole,CHEMBL927601,A,,,Cytochrome P450 2C9,Inhibition of hepatic CYP2C9 at 10 uM,Inhibition,=,100.0,%,COc1ccc2cc(-c3ccc(F)cc3)ccc2c1Cn1ccnc1,CHEMBL1140785,"Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17.",Bioorg. Med. Chem. Lett.,2008.0,18,1,267,273,10.1016/j.bmcl.2007.10.079,18024111.0,
2074012,CHEMBL253868,[4-(4-amino-biphenyl-3-ylcarbamoyl)-benzyl]-carbamic acid pyridin-3-ylmethyl ester,CHEMBL927774,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,69.0,%,Nc1ccc(-c2ccccc2)cc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,CHEMBL1140803,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,Bioorg. Med. Chem. Lett.,2008.0,18,2,726,731,10.1016/j.bmcl.2007.11.047,18060775.0,
2074013,CHEMBL253227,N-(4-amino-biphenyl-3-yl)-4-[(cyclohexanecarbonyl-amino)-methyl]-benzamide,CHEMBL927774,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,32.0,%,Nc1ccc(-c2ccccc2)cc1NC(=O)c1ccc(CNC(=O)C2CCCCC2)cc1,CHEMBL1140803,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,Bioorg. Med. Chem. Lett.,2008.0,18,2,726,731,10.1016/j.bmcl.2007.11.047,18060775.0,
2074014,CHEMBL398617,N-(4-amino-biphenyl-3-yl)-4-(propionylamino-methyl)-benzamide,CHEMBL927774,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,28.0,%,CCC(=O)NCc1ccc(C(=O)Nc2cc(-c3ccccc3)ccc2N)cc1,CHEMBL1140803,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,Bioorg. Med. Chem. Lett.,2008.0,18,2,726,731,10.1016/j.bmcl.2007.11.047,18060775.0,
2074015,CHEMBL253226,N-(4-amino-biphenyl-3-yl)-4-(butyrylamino-methyl)-benzamide,CHEMBL927774,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,27.0,%,CCCC(=O)NCc1ccc(C(=O)Nc2cc(-c3ccccc3)ccc2N)cc1,CHEMBL1140803,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,Bioorg. Med. Chem. Lett.,2008.0,18,2,726,731,10.1016/j.bmcl.2007.11.047,18060775.0,
2074016,CHEMBL398420,[4-(4-amino-biphenyl-3-ylcarbamoyl)-benzyl]-carbamic acid methyl ester,CHEMBL927774,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,46.0,%,COC(=O)NCc1ccc(C(=O)Nc2cc(-c3ccccc3)ccc2N)cc1,CHEMBL1140803,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,Bioorg. Med. Chem. Lett.,2008.0,18,2,726,731,10.1016/j.bmcl.2007.11.047,18060775.0,
2074017,CHEMBL400046,[4-(4-amino-biphenyl-3-ylcarbamoyl)-benzyl]-carbamic acid ethyl ester,CHEMBL927774,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,35.0,%,CCOC(=O)NCc1ccc(C(=O)Nc2cc(-c3ccccc3)ccc2N)cc1,CHEMBL1140803,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,Bioorg. Med. Chem. Lett.,2008.0,18,2,726,731,10.1016/j.bmcl.2007.11.047,18060775.0,
2074018,CHEMBL400044,[4-(4-amino-biphenyl-3-ylcarbamoyl)-benzyl]-carbamic acid phenyl ester,CHEMBL927774,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,21.0,%,Nc1ccc(-c2ccccc2)cc1NC(=O)c1ccc(CNC(=O)Oc2ccccc2)cc1,CHEMBL1140803,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,Bioorg. Med. Chem. Lett.,2008.0,18,2,726,731,10.1016/j.bmcl.2007.11.047,18060775.0,
2074019,CHEMBL252409,[4-(4-amino-biphenyl-3-ylcarbamoyl)-benzyl]-carbamic acid benzyl ester,CHEMBL927774,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,27.0,%,Nc1ccc(-c2ccccc2)cc1NC(=O)c1ccc(CNC(=O)OCc2ccccc2)cc1,CHEMBL1140803,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,Bioorg. Med. Chem. Lett.,2008.0,18,2,726,731,10.1016/j.bmcl.2007.11.047,18060775.0,
2074020,CHEMBL253870,[4-(4-amino-biphenyl-3-ylcarbamoyl)-benzyl]-carbamic acid pyridin-2-ylmethyl este,CHEMBL927774,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,67.0,%,Nc1ccc(-c2ccccc2)cc1NC(=O)c1ccc(CNC(=O)OCc2ccccn2)cc1,CHEMBL1140803,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,Bioorg. Med. Chem. Lett.,2008.0,18,2,726,731,10.1016/j.bmcl.2007.11.047,18060775.0,
2074021,CHEMBL253869,N-(4-amino-biphenyl-3-yl)-4-[(3-pyridin-3-yl-propionylamino)-methyl]-benzamide,CHEMBL927774,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,73.0,%,Nc1ccc(-c2ccccc2)cc1NC(=O)c1ccc(CNC(=O)CCc2cccnc2)cc1,CHEMBL1140803,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,Bioorg. Med. Chem. Lett.,2008.0,18,2,726,731,10.1016/j.bmcl.2007.11.047,18060775.0,
2085664,CHEMBL403195,"N-((1R,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((2R,4R)-4-phenoxypyrrolidin-2-yl)propan-2-yl)-3-((R)-2-(methoxymethyl)pyrrolidine-1-carbonyl)-5-methylbenzamide",CHEMBL930076,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,>,30.0,uM,COC[C@H]1CCCN1C(=O)c1cc(C)cc(C(=O)N[C@@H](Cc2cc(F)cc(F)c2)[C@H](O)[C@H]2C[C@@H](Oc3ccccc3)CN2)c1,CHEMBL1143205,Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor.,Bioorg. Med. Chem. Lett.,2008.0,18,1,418,422,10.1016/j.bmcl.2007.10.053,17980584.0,
2093297,CHEMBL272481,1-(1-(4-(4-fluorophenyl)thiophen-2-yl)propyl)-1H-imidazole,CHEMBL930917,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 at 1 uM,Inhibition,=,94.0,%,CCC(c1cc(-c2ccc(F)c(F)c2)cs1)n1ccnc1,CHEMBL1141584,"Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure.",Bioorg. Med. Chem.,2008.0,16,4,1992,2010,10.1016/j.bmc.2007.10.094,18061460.0,
2093298,CHEMBL272481,1-(1-(4-(4-fluorophenyl)thiophen-2-yl)propyl)-1H-imidazole,CHEMBL930918,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 at 10 uM,Inhibition,=,100.0,%,CCC(c1cc(-c2ccc(F)c(F)c2)cs1)n1ccnc1,CHEMBL1141584,"Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure.",Bioorg. Med. Chem.,2008.0,16,4,1992,2010,10.1016/j.bmc.2007.10.094,18061460.0,
2093301,CHEMBL254328,"10,13-Dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol",CHEMBL930917,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 at 1 uM,Inhibition,=,17.0,%,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,CHEMBL1141584,"Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure.",Bioorg. Med. Chem.,2008.0,16,4,1992,2010,10.1016/j.bmc.2007.10.094,18061460.0,
2093302,CHEMBL157101,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",CHEMBL930917,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 at 1 uM,Inhibition,=,21.0,%,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,CHEMBL1141584,"Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure.",Bioorg. Med. Chem.,2008.0,16,4,1992,2010,10.1016/j.bmc.2007.10.094,18061460.0,
2093303,CHEMBL273191,1-(1-(4-thiophen-3-ylphenyl)ethyl)-1H-imidazole,CHEMBL930917,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 at 1 uM,Inhibition,=,75.0,%,CC(c1ccc(-c2ccsc2)cc1)n1ccnc1,CHEMBL1141584,"Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure.",Bioorg. Med. Chem.,2008.0,16,4,1992,2010,10.1016/j.bmc.2007.10.094,18061460.0,
2093304,CHEMBL403475,1-(1-(4-thiophen-3-yl-phenyl)propyl)-1Himidazole,CHEMBL930917,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 at 1 uM,Inhibition,=,81.0,%,CCC(c1ccc(-c2ccsc2)cc1)n1ccnc1,CHEMBL1141584,"Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure.",Bioorg. Med. Chem.,2008.0,16,4,1992,2010,10.1016/j.bmc.2007.10.094,18061460.0,
2093305,CHEMBL254328,"10,13-Dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol",CHEMBL930918,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 at 10 uM,Inhibition,=,51.0,%,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,CHEMBL1141584,"Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure.",Bioorg. Med. Chem.,2008.0,16,4,1992,2010,10.1016/j.bmc.2007.10.094,18061460.0,
2093306,CHEMBL157101,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",CHEMBL930918,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 at 10 uM,Inhibition,=,75.0,%,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,CHEMBL1141584,"Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure.",Bioorg. Med. Chem.,2008.0,16,4,1992,2010,10.1016/j.bmc.2007.10.094,18061460.0,
2093307,CHEMBL273191,1-(1-(4-thiophen-3-ylphenyl)ethyl)-1H-imidazole,CHEMBL930918,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 at 10 uM,Inhibition,=,89.0,%,CC(c1ccc(-c2ccsc2)cc1)n1ccnc1,CHEMBL1141584,"Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure.",Bioorg. Med. Chem.,2008.0,16,4,1992,2010,10.1016/j.bmc.2007.10.094,18061460.0,
2093308,CHEMBL403475,1-(1-(4-thiophen-3-yl-phenyl)propyl)-1Himidazole,CHEMBL930918,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 at 10 uM,Inhibition,=,74.0,%,CCC(c1ccc(-c2ccsc2)cc1)n1ccnc1,CHEMBL1141584,"Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure.",Bioorg. Med. Chem.,2008.0,16,4,1992,2010,10.1016/j.bmc.2007.10.094,18061460.0,
2115959,CHEMBL982,nalmefene,CHEMBL951229,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,35.5,%,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,CHEMBL1142345,"Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.",J. Med. Chem.,2008.0,51,6,1913,1924,10.1021/jm701060e,18298057.0,
2115970,CHEMBL411916,"17-cyclopropylmethyl-3,14-beta-dihydroxy-4,5-alpha-epoxy-6-[(3'-dimethylamino)benzamido]morphinan",CHEMBL951229,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,23.1,%,CN(C)c1cccc(C(=O)NC2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)c1,CHEMBL1142345,"Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.",J. Med. Chem.,2008.0,51,6,1913,1924,10.1021/jm701060e,18298057.0,
2115972,CHEMBL272215,"17-cyclopropylmethyl-3,14-beta-dihydroxy-4,5-alpha-epoxy-6-beta-[(3',4'-dichloro)benzamido]morphinan",CHEMBL951229,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,32.3,%,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc(Cl)c(Cl)c1,CHEMBL1142345,"Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.",J. Med. Chem.,2008.0,51,6,1913,1924,10.1021/jm701060e,18298057.0,
2115973,CHEMBL409458,"17-cyclopropylmethyl-3,14-beta-dihydroxy-4,5-alpha-epoxy-6-beta-[(4'-chloro)benzamido]morphinan",CHEMBL951229,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,28.1,%,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc(Cl)cc1,CHEMBL1142345,"Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.",J. Med. Chem.,2008.0,51,6,1913,1924,10.1021/jm701060e,18298057.0,
2130114,CHEMBL429712,"4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{[3-(4-methylpiperazin-1-yl)propyl]amino}-3-quinolinecarbonitrile",CHEMBL922060,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,<,34.0,%,COc1cc(Nc2c(C#N)cnc3cc(NCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl,CHEMBL1144048,Facile preparation of new 4-phenylamino-3-quinolinecarbonitrile Src kinase inhibitors via 7-fluoro intermediates: identification of potent 7-amino analogs.,Bioorg. Med. Chem.,2008.0,16,1,405,412,10.1016/j.bmc.2007.09.028,17905586.0,
2130118,CHEMBL261531,"4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-{[3-(dimethylamino)propyl]amino}-6-methoxy-3-quinolinecarbonitrile",CHEMBL922060,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,<,34.0,%,COc1cc(Nc2c(C#N)cnc3cc(NCCCN(C)C)c(OC)cc23)c(Cl)cc1Cl,CHEMBL1144048,Facile preparation of new 4-phenylamino-3-quinolinecarbonitrile Src kinase inhibitors via 7-fluoro intermediates: identification of potent 7-amino analogs.,Bioorg. Med. Chem.,2008.0,16,1,405,412,10.1016/j.bmc.2007.09.028,17905586.0,
2164581,CHEMBL427913,5-(4-chlorobenzylsulfinyl)-6-chloro-2-cyclohexyl-1H-benzo[d]imidazole,CHEMBL928181,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,<,50.0,%,[O-][S+](Cc1ccc(Cl)cc1)c1cc2nc(C3CCCCC3)[nH]c2cc1Cl,CHEMBL1144814,5-Sulfonyl-benzimidazoles as selective CB2 agonists.,Bioorg. Med. Chem. Lett.,2008.0,18,8,2574,2579,10.1016/j.bmcl.2008.03.048,18394887.0,
2164685,CHEMBL411504,2-tert-butyl-5-(2-ethoxypyridin-4-sulfonyl)-1-tetrahydropyran-4-ylmethyl)-1H-benzimidazole,CHEMBL933754,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,94.0,%,CCOc1cc(S(=O)(=O)c2ccc3c(c2)nc(C(C)(C)C)n3CC2CCOCC2)ccn1,CHEMBL1144814,5-Sulfonyl-benzimidazoles as selective CB2 agonists.,Bioorg. Med. Chem. Lett.,2008.0,18,8,2574,2579,10.1016/j.bmcl.2008.03.048,18394887.0,
2165367,CHEMBL256982,"N-(2-chloro-5-(1H-imidazol-2-yl)-5,6,7,8-tetrahydronaphthalen-1-yl)methanesulfonamide",CHEMBL934641,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,25.0,%,CS(=O)(=O)Nc1c(Cl)ccc2c1CCCC2c1ncc[nH]1,CHEMBL1145605,Novel 2-imidazoles as potent and selective alpha1A adrenoceptor partial agonists.,Bioorg. Med. Chem. Lett.,2008.0,18,9,2930,2934,10.1016/j.bmcl.2008.03.070,18400496.0,
2171512,CHEMBL403553,"(R)-2-(3-aminopiperidin-1-yl)-3-(but-2-ynyl)-5-((4-methylquinazolin-2-yl)methyl)-3H-imidazo[4,5-d]pyridazin-4(5H)-one",CHEMBL925958,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,>,50.0,uM,CC#CCn1c(N2CCC[C@@H](N)C2)nc2cnn(Cc3nc(C)c4ccccc4n3)c(=O)c21,CHEMBL1145558,"3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors.",Bioorg. Med. Chem. Lett.,2008.0,18,11,3158,3162,10.1016/j.bmcl.2008.04.075,18485703.0,
2248046,CHEMBL495575,5-(Phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide,CHEMBL1012654,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,0.0,%,O=S(=O)(NC1CCNCC1)c1cc(S(=O)(=O)c2ccccc2)ccc1C(F)(F)F,CHEMBL1139350,Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides.,J. Med. Chem.,2009.0,52,1,105,116,10.1021/jm801144h,19072540.0,
2248047,CHEMBL449276,tert-Butyl (2S)-2-{[4-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]-sulfonyl}amino)piperidin-1-yl]carbonyl}pyrrolidine-1-carboxylate,CHEMBL1012654,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,9.0,%,CC(C)(C)OC(=O)N1CCC[C@H]1C(=O)N1CCC(NS(=O)(=O)c2cc(S(=O)(=O)c3ccccc3)ccc2C(F)(F)F)CC1,CHEMBL1139350,Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides.,J. Med. Chem.,2009.0,52,1,105,116,10.1021/jm801144h,19072540.0,
2248048,CHEMBL455476,"N-{1-[1-(3,3-Dimethylbutanoyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide",CHEMBL1012654,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,30.0,%,CC(C)(C)CC(=O)N1CCC[C@H]1C(=O)N1CCC(NS(=O)(=O)c2cc(S(=O)(=O)c3ccccc3)ccc2C(F)(F)F)CC1,CHEMBL1139350,Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides.,J. Med. Chem.,2009.0,52,1,105,116,10.1021/jm801144h,19072540.0,
2248049,CHEMBL503825,(2S)-N-(tert-Butyl)-2-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-1-yl]carbonyl}pyrrolidine-1-carboxamide,CHEMBL1012654,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,0.0,%,CC(C)(C)NC(=O)N1CCC[C@H]1C(=O)N1CCC(NS(=O)(=O)c2cc(S(=O)(=O)c3ccccc3)ccc2C(F)(F)F)CC1,CHEMBL1139350,Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides.,J. Med. Chem.,2009.0,52,1,105,116,10.1021/jm801144h,19072540.0,
2248050,CHEMBL451431,"N-{1-[1-(3,3-Dimethylbutyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide",CHEMBL1012654,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,0.0,%,CC(C)(C)CCN1CCC[C@H]1C(=O)N1CCC(NS(=O)(=O)c2cc(S(=O)(=O)c3ccccc3)ccc2C(F)(F)F)CC1,CHEMBL1139350,Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides.,J. Med. Chem.,2009.0,52,1,105,116,10.1021/jm801144h,19072540.0,
2274022,CHEMBL492301,"7-(4-(2-chlorophenoxy)piperidin-1-ylsulfonyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine",CHEMBL1030740,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,<,50.0,%,O=S(=O)(c1ccc2c(c1)CCNCC2)N1CCC(Oc2ccccc2Cl)CC1,CHEMBL1153351,7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization.,Bioorg. Med. Chem. Lett.,2009.0,19,7,1871,1875,10.1016/j.bmcl.2009.02.071,19269173.0,
2277832,CHEMBL460480,"5-((4-(2-(4-tert-Butylphenyl)-1H-benzo[d]imidazol-4-yl)piperazin-1-yl)methyl)-1-ethylpyrimidine-2,4(1H,3H)-dione",CHEMBL954327,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,34.0,%,CCn1cc(CN2CCN(c3cccc4[nH]c(-c5ccc(C(C)(C)C)cc5)nc34)CC2)c(=O)[nH]c1=O,CHEMBL1153337,Small molecule antagonists of the gonadotropin-releasing hormone (GnRH) receptor: structure-activity relationships of small heterocyclic groups appended to the 2-phenyl-4-piperazinyl-benzimidazole template.,Bioorg. Med. Chem. Lett.,2009.0,19,7,1986,1990,10.1016/j.bmcl.2009.02.043,19251413.0,
2277833,CHEMBL493344,2-(4-tert-butylphenyl)-4-(4-((2-methyl-1-propyl-1H-imidazol-4-yl)methyl)piperazin-1-yl)-1H-benzo[d]imidazole,CHEMBL954327,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,19.0,%,CCCn1cc(CN2CCN(c3cccc4[nH]c(-c5ccc(C(C)(C)C)cc5)nc34)CC2)nc1C,CHEMBL1153337,Small molecule antagonists of the gonadotropin-releasing hormone (GnRH) receptor: structure-activity relationships of small heterocyclic groups appended to the 2-phenyl-4-piperazinyl-benzimidazole template.,Bioorg. Med. Chem. Lett.,2009.0,19,7,1986,1990,10.1016/j.bmcl.2009.02.043,19251413.0,
2277834,CHEMBL492327,"2-(4-tert-butylphenyl)-4-(4-((1,2-dimethyl-1H-imidazol-4-yl)methyl)piperazin-1-yl)-1H-benzo[d]imidazole",CHEMBL954327,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,12.0,%,Cc1nc(CN2CCN(c3cccc4[nH]c(-c5ccc(C(C)(C)C)cc5)nc34)CC2)cn1C,CHEMBL1153337,Small molecule antagonists of the gonadotropin-releasing hormone (GnRH) receptor: structure-activity relationships of small heterocyclic groups appended to the 2-phenyl-4-piperazinyl-benzimidazole template.,Bioorg. Med. Chem. Lett.,2009.0,19,7,1986,1990,10.1016/j.bmcl.2009.02.043,19251413.0,
2277835,CHEMBL493565,4-(4-((1-butyl-5-methyl-1H-imidazol-4-yl)methyl)piperazin-1-yl)-2-(4-tert-butylphenyl)-1H-benzo[d]imidazole,CHEMBL954327,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,53.0,%,CCCCn1cnc(CN2CCN(c3cccc4[nH]c(-c5ccc(C(C)(C)C)cc5)nc34)CC2)c1C,CHEMBL1153337,Small molecule antagonists of the gonadotropin-releasing hormone (GnRH) receptor: structure-activity relationships of small heterocyclic groups appended to the 2-phenyl-4-piperazinyl-benzimidazole template.,Bioorg. Med. Chem. Lett.,2009.0,19,7,1986,1990,10.1016/j.bmcl.2009.02.043,19251413.0,
2277836,CHEMBL521674,2-(4-tert-butylphenyl)-4-(4-((1-ethyl-5-methyl-1H-imidazol-4-yl)methyl)piperazin-1-yl)-1H-benzo[d]imidazole,CHEMBL954327,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,27.0,%,CCn1cnc(CN2CCN(c3cccc4[nH]c(-c5ccc(C(C)(C)C)cc5)nc34)CC2)c1C,CHEMBL1153337,Small molecule antagonists of the gonadotropin-releasing hormone (GnRH) receptor: structure-activity relationships of small heterocyclic groups appended to the 2-phenyl-4-piperazinyl-benzimidazole template.,Bioorg. Med. Chem. Lett.,2009.0,19,7,1986,1990,10.1016/j.bmcl.2009.02.043,19251413.0,
2277837,CHEMBL494400,2-(4-tert-butylphenyl)-4-(4-((2-methyl-1H-imidazol-4-yl)methyl)piperazin-1-yl)-1H-benzo[d]imidazole,CHEMBL954327,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,23.0,%,Cc1nc(CN2CCN(c3cccc4[nH]c(-c5ccc(C(C)(C)C)cc5)nc34)CC2)c[nH]1,CHEMBL1153337,Small molecule antagonists of the gonadotropin-releasing hormone (GnRH) receptor: structure-activity relationships of small heterocyclic groups appended to the 2-phenyl-4-piperazinyl-benzimidazole template.,Bioorg. Med. Chem. Lett.,2009.0,19,7,1986,1990,10.1016/j.bmcl.2009.02.043,19251413.0,
2361463,CHEMBL493082,3-[3-(4-Methoxybenzyl)naphthalen-2-yl]pyridine,CHEMBL971583,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus-infected insect microsomes at 10 uM,Inhibition,=,92.0,%,COc1ccc(Cc2cc3ccccc3cc2-c2cccnc2)cc1,CHEMBL1140083,Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.,J. Med. Chem.,2008.0,51,19,6138,6149,10.1021/jm800683c,18763754.0,
2361464,CHEMBL493082,3-[3-(4-Methoxybenzyl)naphthalen-2-yl]pyridine,CHEMBL971594,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus-infected insect microsomes at 1 uM,Inhibition,=,51.0,%,COc1ccc(Cc2cc3ccccc3cc2-c2cccnc2)cc1,CHEMBL1140083,Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.,J. Med. Chem.,2008.0,51,19,6138,6149,10.1021/jm800683c,18763754.0,
2361483,CHEMBL492891,4-(3-Pyridin-3-yl-naphthalene-2-carbonyl)benzonitrile,CHEMBL971583,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus-infected insect microsomes at 10 uM,Inhibition,=,74.0,%,N#Cc1ccc(C(=O)c2cc3ccccc3cc2-c2cccnc2)cc1,CHEMBL1140083,Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.,J. Med. Chem.,2008.0,51,19,6138,6149,10.1021/jm800683c,18763754.0,
2361484,CHEMBL494713,3-[6-Methoxy-3-(4-methoxybenzyl)naphthalen-2-yl]pyridine,CHEMBL971583,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus-infected insect microsomes at 10 uM,Inhibition,=,98.0,%,COc1ccc(Cc2cc3cc(OC)ccc3cc2-c2cccnc2)cc1,CHEMBL1140083,Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.,J. Med. Chem.,2008.0,51,19,6138,6149,10.1021/jm800683c,18763754.0,
2361485,CHEMBL524011,4-(3-Pyridin-3-yl-naphthalen-2-ylmethyl)benzonitrile,CHEMBL971583,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus-infected insect microsomes at 10 uM,Inhibition,=,96.0,%,N#Cc1ccc(Cc2cc3ccccc3cc2-c2cccnc2)cc1,CHEMBL1140083,Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.,J. Med. Chem.,2008.0,51,19,6138,6149,10.1021/jm800683c,18763754.0,
2361486,CHEMBL492891,4-(3-Pyridin-3-yl-naphthalene-2-carbonyl)benzonitrile,CHEMBL971594,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus-infected insect microsomes at 1 uM,Inhibition,=,35.0,%,N#Cc1ccc(C(=O)c2cc3ccccc3cc2-c2cccnc2)cc1,CHEMBL1140083,Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.,J. Med. Chem.,2008.0,51,19,6138,6149,10.1021/jm800683c,18763754.0,
2361487,CHEMBL494713,3-[6-Methoxy-3-(4-methoxybenzyl)naphthalen-2-yl]pyridine,CHEMBL971594,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus-infected insect microsomes at 1 uM,Inhibition,=,96.0,%,COc1ccc(Cc2cc3cc(OC)ccc3cc2-c2cccnc2)cc1,CHEMBL1140083,Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.,J. Med. Chem.,2008.0,51,19,6138,6149,10.1021/jm800683c,18763754.0,
2361488,CHEMBL524011,4-(3-Pyridin-3-yl-naphthalen-2-ylmethyl)benzonitrile,CHEMBL971594,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus-infected insect microsomes at 1 uM,Inhibition,=,78.0,%,N#Cc1ccc(Cc2cc3ccccc3cc2-c2cccnc2)cc1,CHEMBL1140083,Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.,J. Med. Chem.,2008.0,51,19,6138,6149,10.1021/jm800683c,18763754.0,
2415211,CHEMBL474678,"(2R,4S)-N1-(4-Chlorophenyl)-4-(2,4-difluorophenyl)-4-hydroxy-N2-(5-(2-oxopyridin-1(2H)-yl)pyridin-2-yl)pyrrolidine-1,2-dicarboxamide",CHEMBL956060,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,9.53,%,O=C(Nc1ccc(-n2ccccc2=O)cn1)[C@H]1C[C@](O)(c2ccc(F)cc2F)CN1C(=O)Nc1ccc(Cl)cc1,CHEMBL1153922,"Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active Factor Xa inhibitors with extended duration of action.",Bioorg. Med. Chem.,2009.0,17,6,2501,2511,10.1016/j.bmc.2009.01.063,19231206.0,
2452086,CHEMBL494666,{4-[4-(4-Fluoro-phenyl)-2-methylsulfanyl-1H-imidazol-5-yl]-pyridin-2-yl}-(1-phenyl-propyl)-,CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,80.0,%,CCC(Nc1cc(-c2[nH]c(SC)nc2-c2ccc(F)cc2)ccn1)c1ccccc1,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2452110,CHEMBL10,4-[5-(4-Fluoro-phenyl)-2-(4-methanesulfinyl-phenyl)-3H-imidazol-4-yl]-pyridine,CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,87.0,%,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2452111,CHEMBL481952,trans-4-{4-[4-(4-Fluoro-phenyl)-3-(2-methoxy-ethyl)-2-methylsulfanyl-1H-imidazol-5-yl]-pyridin-2-ylamino}-cyclohexanol,CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,40.0,%,COCCn1c(SC)nc(-c2ccc(F)cc2)c1-c1ccnc(N[C@H]2CC[C@H](O)CC2)c1,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2452112,CHEMBL481943,Cyclohexyl-{4-[4-(4-fluoro-phenyl)-3-(2-methoxy-ethyl)-2-methylsulfanyl-1H-imidazol-5-yl]-pyridin-2-yl}-amine,CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,73.0,%,COCCn1c(SC)nc(-c2ccc(F)cc2)c1-c1ccnc(NC2CCCCC2)c1,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2452113,CHEMBL516460,{4-[4-(4-Fluoro-phenyl)-3-(2-methoxy-ethyl)-2-methylsulfanyl-1H-imidazol-5-yl]-pyridin-2-yl}-((S)-1-phenyl-ethyl)-amine,CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,85.0,%,COCCn1c(SC)nc(-c2ccc(F)cc2)c1-c1ccnc(N[C@@H](C)c2ccccc2)c1,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2452114,CHEMBL479998,{4-[4-(4-Fluoro-phenyl)-3-(2-methoxy-ethyl)-2-methylsulfanyl-1H-imidazol-5-yl]-pyridin-2-yl}-((R)-1-phenyl-ethyl)-amine,CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,71.0,%,COCCn1c(SC)nc(-c2ccc(F)cc2)c1-c1ccnc(N[C@H](C)c2ccccc2)c1,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2452115,CHEMBL479991,{4-[4-(4-Fluoro-phenyl)-3-methyl-2-methylsulfanyl-1H-imidazol-5-yl]-pyridin-2-yl}-((S)-1-phenyl-ethyl)-amine,CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,66.0,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(N[C@@H](C)c3ccccc3)c2)n1C,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2452116,CHEMBL479990,{4-[4-(4-Fluoro-phenyl)-3-methyl-2-methylsulfanyl-1H-imidazol-5-yl]-pyridin-2-yl}-((R)-1-phenyl-ethyl)-amine,CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,78.0,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(N[C@H](C)c3ccccc3)c2)n1C,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2452117,CHEMBL480957,4-[4-(4-Fluoro-phenyl)-2-methylsulfanyl-1H-imidazol-5-yl]-2-p-tolyloxy-pyridine,CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,81.0,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(Oc3ccc(C)cc3)c2)[nH]1,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2452118,CHEMBL480952,{4-[4-(4-Fluoro-phenyl)-2-methylsulfanyl-1H-imidazol-5-yl]-pyridin-2-yl}-(tetrahydro-furan-2-ylmethyl)-amine,CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,47.0,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NCC3CCCO3)c2)[nH]1,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2452119,CHEMBL521091,1-{4-[4-(4-Fluoro-phenyl)-2-methylsulfanyl-1H-imidazol-5-yl]-pyridin-2-ylamino}-propan-2-ol,CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,39.0,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NCC(C)O)c2)[nH]1,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2452120,CHEMBL518964,"(1,5-Dimethyl-hexyl)-{4-[4-(4-fluoro-phenyl)-2-methylsulfanyl-1H-imidazol-5-yl]-pyridin-2-yl}-amine",CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,76.0,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)CCCC(C)C)c2)[nH]1,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2452121,CHEMBL481765,"(1,2-Dimethyl-propyl)-{4-[4-(4-fluoro-phenyl)-2-methylsulfanyl-1H-imidazol-5-yl]-pyridin-2-yl}-amine",CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,75.0,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)C(C)C)c2)[nH]1,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2452122,CHEMBL481912,Cyclohexylmethyl-{4-[4-(4-fluoro-phenyl)-2-methylsulfanyl-1H-imidazol-5-yl]-pyridin-2-yl}-amine,CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,73.0,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NCC3CCCCC3)c2)[nH]1,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2452123,CHEMBL482112,{4-[4-(4-Fluoro-phenyl)-2-methylsulfanyl-1H-imidazol-5-yl]-pyridin-2-yl}-pyridin-3-ylmethylamine,CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,77.0,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NCc3cccnc3)c2)[nH]1,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2452124,CHEMBL481883,{4-[4-(4-Fluoro-phenyl)-2-methylsulfanyl-1H-imidazol-5-yl]-pyridin-2-yl}-pyridin-2-ylmethylamine,CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,52.0,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NCc3ccccn3)c2)[nH]1,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2452125,CHEMBL481882,{4-[4-(4-Fluoro-phenyl)-2-methylsulfanyl-1H-imidazol-5-yl]-pyridin-2-yl}-furan-2-ylmethylamine,CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,71.0,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NCc3ccco3)c2)[nH]1,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2452126,CHEMBL452471,{4-[4-(4-Fluoro-phenyl)-2-methylsulfanyl-1H-imidazol-5-yl]-pyridin-2-yl}-thiophen-2-ylmethylamine,CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,82.0,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NCc3cccs3)c2)[nH]1,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2452127,CHEMBL493669,{4-[4-(4-Fluoro-phenyl)-2-methylsulfanyl-1H-imidazol-5-yl]-pyridin-2-yl}-(1-methyl-3-phenylpropyl)-,CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,88.0,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)CCc3ccccc3)c2)[nH]1,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2452128,CHEMBL494871,{4-[4-(4-Fluoro-phenyl)-2-methylsulfanyl-1H-imidazol-5-yl]-pyridin-2-yl}-indan-1-yl-amine,CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,84.0,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC3CCc4ccccc43)c2)[nH]1,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2452189,CHEMBL519617,{4-[4-(4-Fluoro-phenyl)-2-methylsulfanyl-1H-imidazol-5-yl]-pyridin-2-yl}-(2-thiophen-2-yl-ethyl)-amine,CHEMBL1013136,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,93.0,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NCCc3cccs3)c2)[nH]1,CHEMBL1155084,"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.",J. Med. Chem.,2008.0,51,14,4122,4149,10.1021/jm701529q,18578517.0,
2469946,CHEMBL510515,"N-(4-(pyridin-4-yl)thiazol-2-yl)-2,3-dihydrobenzo[b][1,4]dioxine-2-carboxamide",CHEMBL1030555,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,96.0,%,O=C(Nc1nc(-c2ccncc2)cs1)C1COc2ccccc2O1,CHEMBL1142492,Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.,J. Med. Chem.,2008.0,51,21,6642,6645,10.1021/jm800986w,18834107.0,
2469947,CHEMBL485213,"N-(4-(pyridin-4-yl)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-2-carboxamide",CHEMBL1030555,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,64.0,%,O=C(Nc1ccc(-c2ccncc2)cc1)C1COc2ccccc2O1,CHEMBL1142492,Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.,J. Med. Chem.,2008.0,51,21,6642,6645,10.1021/jm800986w,18834107.0,
2469948,CHEMBL485214,"N-(4-(1H-pyrazol-4-yl)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-2-carboxamide",CHEMBL1030555,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,87.0,%,O=C(Nc1ccc(-c2c[nH]cn2)cc1)C1COc2ccccc2O1,CHEMBL1142492,Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.,J. Med. Chem.,2008.0,51,21,6642,6645,10.1021/jm800986w,18834107.0,
2469949,CHEMBL485215,"N-(2-methoxy-4-(1H-pyrazol-4-yl)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-2-carboxamide",CHEMBL1030555,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,93.0,%,COc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1,CHEMBL1142492,Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.,J. Med. Chem.,2008.0,51,21,6642,6645,10.1021/jm800986w,18834107.0,
2469950,CHEMBL521179,Chroman-3-carboxylic acid [2-(2-dimethylamino-ethoxy)-4-(1H-pyrazol-4-yl)-phenyl]-amide,CHEMBL1030555,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,80.0,%,CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1,CHEMBL1142492,Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.,J. Med. Chem.,2008.0,51,21,6642,6645,10.1021/jm800986w,18834107.0,
2505160,CHEMBL481322,"(R)-2-(5-chloro-4-(methoxymethyl)-2,3-dihydro-1H-inden-1-yl)-1H-imidazole",CHEMBL947756,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,35.0,%,COCc1c(Cl)ccc2c1CC[C@H]2c1ncc[nH]1,CHEMBL1141007,"Novel 2-imidazoles as potent, selective and CNS penetrant alpha1A adrenoceptor partial agonists.",Bioorg. Med. Chem. Lett.,2008.0,18,24,6437,6440,10.1016/j.bmcl.2008.10.066,18980842.0,
2505168,CHEMBL474796,"(R)-3-fluoro-1-((5-fluoro-1-(1H-imidazol-2-yl)-2,3-dihydro-1H-inden-4-yl)methyl)-1H-pyrazole",CHEMBL947756,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,50.0,%,Fc1ccn(Cc2c(F)ccc3c2CC[C@H]3c2ncc[nH]2)n1,CHEMBL1141007,"Novel 2-imidazoles as potent, selective and CNS penetrant alpha1A adrenoceptor partial agonists.",Bioorg. Med. Chem. Lett.,2008.0,18,24,6437,6440,10.1016/j.bmcl.2008.10.066,18980842.0,
2507996,CHEMBL513425,"(R)-3-amino-1-(2-benzoyl-1,2-diazepan-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one",CHEMBL1034783,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,71.5,%,N[C@@H](CC(=O)N1CCCCCN1C(=O)c1ccccc1)Cc1cc(F)c(F)cc1F,CHEMBL1141018,Synthesis and biological evaluation of homopiperazine derivatives with beta-aminoacyl group as dipeptidyl peptidase IV inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,24,6525,6529,10.1016/j.bmcl.2008.10.076,18996694.0,
2508002,CHEMBL482154,"(R)-4-(4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-1,4-diazepane-1-carbonyl)benzoic acid hydrochloride",CHEMBL1034783,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,103.2,%,Cl.N[C@@H](CC(=O)N1CCCN(C(=O)c2ccc(C(=O)O)cc2)CC1)Cc1cc(F)c(F)cc1F,CHEMBL1141018,Synthesis and biological evaluation of homopiperazine derivatives with beta-aminoacyl group as dipeptidyl peptidase IV inhibitors.,Bioorg. Med. Chem. Lett.,2008.0,18,24,6525,6529,10.1016/j.bmcl.2008.10.076,18996694.0,
2508780,CHEMBL484340,(5R)-3-(4-(1-cyclohexylethoxy)benzyl)-5-methyloxazolidin-2-one,CHEMBL1002095,A,,,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 at 3 mM,Inhibition,=,27.0,%,CC(Oc1ccc(CN2C[C@@H](C)OC2=O)cc1)C1CCCCC1,CHEMBL1138441,"3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimization.",Bioorg. Med. Chem. Lett.,2009.0,19,9,2524,2529,10.1016/j.bmcl.2009.03.032,19328692.0,
2563251,CHEMBL476954,"(S)-N-(2,3-dichlorobenzyl)-N-(pyrrolidin-3-yl)isobutyramide",CHEMBL993596,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,<,40.0,%,CC(C)C(=O)N(Cc1cccc(Cl)c1Cl)[C@H]1CCNC1,CHEMBL1155858,Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity.,Bioorg. Med. Chem. Lett.,2008.0,18,15,4355,4359,10.1016/j.bmcl.2008.06.071,18621528.0,
2581946,CHEMBL461548,2-methyl-N-phenethyl-5-(phenylsulfonyl)benzenesulfonamide,CHEMBL961565,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,41.0,%,Cc1ccc(S(=O)(=O)c2ccccc2)cc1S(=O)(=O)NCCc1ccccc1,CHEMBL1151763,Identification of diarylsulfone sulfonamides as secreted frizzled related protein-1 (sFRP-1) inhibitors.,J. Med. Chem.,2008.0,51,24,7670,7672,10.1021/jm801069w,19053830.0,
2581962,CHEMBL474926,"N-[2-(3,4-Dimethoxyphenyl)ethyl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide",CHEMBL961565,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,84.0,%,CCc1ccc(S(=O)(=O)c2ccccc2)cc1S(=O)(=O)NCCc1ccc(OC)c(OC)c1,CHEMBL1151763,Identification of diarylsulfone sulfonamides as secreted frizzled related protein-1 (sFRP-1) inhibitors.,J. Med. Chem.,2008.0,51,24,7670,7672,10.1021/jm801069w,19053830.0,
2581963,CHEMBL474115,2-Ethyl-5-(phenylsulfonyl)-N-(3-pyrrolidin-1-ylpropyl)benzenesulfonamide,CHEMBL961565,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,25.0,%,CCc1ccc(S(=O)(=O)c2ccccc2)cc1S(=O)(=O)NCCCN1CCCC1,CHEMBL1151763,Identification of diarylsulfone sulfonamides as secreted frizzled related protein-1 (sFRP-1) inhibitors.,J. Med. Chem.,2008.0,51,24,7670,7672,10.1021/jm801069w,19053830.0,
2581964,CHEMBL473916,N-[3-(Dimethylamino)propyl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide,CHEMBL961565,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,14.0,%,CCc1ccc(S(=O)(=O)c2ccccc2)cc1S(=O)(=O)NCCCN(C)C,CHEMBL1151763,Identification of diarylsulfone sulfonamides as secreted frizzled related protein-1 (sFRP-1) inhibitors.,J. Med. Chem.,2008.0,51,24,7670,7672,10.1021/jm801069w,19053830.0,
2586415,CHEMBL509011,"2-(3,4-dihydro-2H-chromen-3-yl)-6-(1H-pyrazol-4-yl)benzo[d]oxazole",CHEMBL1010069,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,80.0,%,c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3o1)CO2,CHEMBL1152196,Benzimidazole- and benzoxazole-based inhibitors of Rho kinase.,Bioorg. Med. Chem. Lett.,2008.0,18,24,6390,6393,10.1016/j.bmcl.2008.10.095,18996009.0,
2586419,CHEMBL455659,"2-(3,4-dihydro-2H-chromen-3-yl)-6-(1H-pyrazol-4-yl)-1H-benzo[d]imidazole",CHEMBL1010069,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,84.0,%,c1ccc2c(c1)CC(c1nc3ccc(-c4cn[nH]c4)cc3[nH]1)CO2,CHEMBL1152196,Benzimidazole- and benzoxazole-based inhibitors of Rho kinase.,Bioorg. Med. Chem. Lett.,2008.0,18,24,6390,6393,10.1016/j.bmcl.2008.10.095,18996009.0,
2586423,CHEMBL452734,"2-(3,4-dihydro-2H-chromen-3-yl)-6-(pyridin-4-yl)-1H-benzo[d]imidazole",CHEMBL1010069,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,95.0,%,c1ccc2c(c1)CC(c1nc3ccc(-c4ccncc4)cc3[nH]1)CO2,CHEMBL1152196,Benzimidazole- and benzoxazole-based inhibitors of Rho kinase.,Bioorg. Med. Chem. Lett.,2008.0,18,24,6390,6393,10.1016/j.bmcl.2008.10.095,18996009.0,
2586427,CHEMBL454654,"4-(2-(3,4-dihydro-2H-chromen-3-yl)-3H-benzo[d]imidazol-5-yl)pyrimidin-2-amine",CHEMBL1010069,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,13.0,%,Nc1nccc(-c2ccc3nc(C4COc5ccccc5C4)[nH]c3c2)n1,CHEMBL1152196,Benzimidazole- and benzoxazole-based inhibitors of Rho kinase.,Bioorg. Med. Chem. Lett.,2008.0,18,24,6390,6393,10.1016/j.bmcl.2008.10.095,18996009.0,
2586431,CHEMBL454624,"4-(2-(3,4-dihydro-2H-chromen-3-yl)benzo[d]oxazol-6-yl)pyrimidin-2-amine",CHEMBL1010069,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,-8.0,%,Nc1nccc(-c2ccc3nc(C4COc5ccccc5C4)oc3c2)n1,CHEMBL1152196,Benzimidazole- and benzoxazole-based inhibitors of Rho kinase.,Bioorg. Med. Chem. Lett.,2008.0,18,24,6390,6393,10.1016/j.bmcl.2008.10.095,18996009.0,
2607206,CHEMBL473384,"{4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]bicyclo[2.2.2]oct-1-yl}acetic Acid",CHEMBL1023063,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 30 uM,Inhibition,<,25.0,%,CC1(C)Oc2ncnc(N)c2N=C1c1ccc(C23CCC(CC(=O)O)(CC2)CC3)cc1,CHEMBL1152806,"Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor.",J. Med. Chem.,2009.0,52,6,1558,1568,10.1021/jm801507v,19256504.0,
2638268,CHEMBL505335,"(R)-3-(1-phenylethylamino)-4-(pyridin-3-ylamino)cyclobut-3-ene-1,2-dione",CHEMBL1011423,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,1.0,%,C[C@@H](Nc1c(Nc2cccnc2)c(=O)c1=O)c1ccccc1,CHEMBL1136863,Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2).,Bioorg. Med. Chem.,2009.0,17,9,3342,3351,10.1016/j.bmc.2009.03.041,19364658.0,
2640524,CHEMBL506744,"6-(5-fluoro-2-(pyrimidin-5-yl)phenyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole",CHEMBL970462,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,<,10.0,%,Fc1ccc(-c2cncnc2)c(C2Cc3nccn3C2)c1,CHEMBL1136911,"6,7-Dihydro-5H-pyrrolo[1,2-a] imidazoles as potent and selective alpha1A adrenoceptor partial agonists.",Bioorg. Med. Chem. Lett.,2009.0,19,11,3113,3117,10.1016/j.bmcl.2009.03.166,19414260.0,
2699149,CHEMBL561339,"N,N-Diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl)benzamide",CHEMBL1059017,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,11.4,%,CCN(CC)C(=O)c1ccc(C2=CC3(CCNCC3)Oc3ccccc32)c(O)c1,CHEMBL1153522,"Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747).",J. Med. Chem.,2009.0,52,18,5685,5702,10.1021/jm900773n,19694468.0,
2990031,CHEMBL585725,"N-(4-(3-Methyl-1H-1,2,4-triazol-1-yl)phenyl)-4-(3-morpholinophenyl)pyrimidin-2-amine",CHEMBL1042607,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM after 15 mins,Inhibition,=,43.0,%,Cc1ncn(-c2ccc(Nc3nccc(-c4cccc(N5CCOCC5)c4)n3)cc2)n1,CHEMBL1156783,"Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors.",J. Med. Chem.,2010.0,53,1,419,431,10.1021/jm901351f,19947601.0,
2990032,CHEMBL571434,3-(2-(4-(2-Methyl-2H-tetrazol-5-yl)phenylamino)pyrimidin-4-yl)-5-morpholinobenzonitrile,CHEMBL1042607,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM after 15 mins,Inhibition,=,7.0,%,Cn1nnc(-c2ccc(Nc3nccc(-c4cc(C#N)cc(N5CCOCC5)c4)n3)cc2)n1,CHEMBL1156783,"Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors.",J. Med. Chem.,2010.0,53,1,419,431,10.1021/jm901351f,19947601.0,
2990033,CHEMBL584899,"3-Morpholino-5-(2-(4-(3-(pyridin-2-yl)-1H-1,2,4-triazol-1-yl)-phenylamino)pyrimidin-4-yl)benzonitrile",CHEMBL1042607,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM after 15 mins,Inhibition,=,-2.0,%,N#Cc1cc(-c2ccnc(Nc3ccc(-n4cnc(-c5ccccn5)n4)cc3)n2)cc(N2CCOCC2)c1,CHEMBL1156783,"Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors.",J. Med. Chem.,2010.0,53,1,419,431,10.1021/jm901351f,19947601.0,
2990034,CHEMBL585951,"4-(3-Fluoro-5-morpholinophenyl)-N-(4-(3-morpholino-1H-1,2,4-triazol-1-yl)phenyl)pyrimidin-2-amine",CHEMBL1042607,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM after 15 mins,Inhibition,=,75.0,%,Fc1cc(-c2cc[nH]/c(=N/c3ccc(-n4cnc(N5CCOCC5)n4)cc3)n2)cc(N2CCOCC2)c1,CHEMBL1156783,"Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors.",J. Med. Chem.,2010.0,53,1,419,431,10.1021/jm901351f,19947601.0,
2990218,CHEMBL565789,4-{(S)-2-[4-(4-Chlorophenoxy)phenoxymethyl]pyrrolidin-1-yl}-butyric Acid,CHEMBL1041819,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,<,50.0,%,O=C(O)CCCN1CCC[C@H]1COc1ccc(Oc2ccc(Cl)cc2)cc1,CHEMBL1156785,Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis.,J. Med. Chem.,2010.0,53,2,573,585,10.1021/jm900838g,19950900.0,
3002534,CHEMBL567561,(S)-5-oxo-5-(4-(pentyloxycarbonyl)piperazin-1-yl)-4-(2-phenyl-6-(4-(pyrrolidine-1-carbonyl)piperidin-1-yl)pyrimidine-4-carboxamido)pentanoic acid,CHEMBL1042529,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM after 30 mins,Inhibition,<,25.0,%,CCCCCOC(=O)N1CCN(C(=O)[C@H](CCC(=O)O)NC(=O)c2cc(N3CCC(C(=O)N4CCCC4)CC3)nc(-c3ccccc3)n2)CC1,CHEMBL1156077,Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.,Bioorg. Med. Chem. Lett.,2009.0,19,21,6148,6156,10.1016/j.bmcl.2009.09.017,19796941.0,
3002535,CHEMBL570387,(S)-4-(6-(4-(diethylcarbamoyl)piperidin-1-yl)-2-phenylpyrimidine-4-carboxamido)-5-oxo-5-(4-(pentyloxycarbonyl)piperazin-1-yl)pentanoic acid,CHEMBL1042529,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM after 30 mins,Inhibition,<,25.0,%,CCCCCOC(=O)N1CCN(C(=O)[C@H](CCC(=O)O)NC(=O)c2cc(N3CCC(C(=O)N(CC)CC)CC3)nc(-c3ccccc3)n2)CC1,CHEMBL1156077,Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.,Bioorg. Med. Chem. Lett.,2009.0,19,21,6148,6156,10.1016/j.bmcl.2009.09.017,19796941.0,
3002536,CHEMBL567740,(S)-4-(6-(4-(ethylcarbamoyl)piperidin-1-yl)-2-phenylpyrimidine-4-carboxamido)-5-oxo-5-(4-(pentyloxycarbonyl)piperazin-1-yl)pentanoic acid,CHEMBL1042529,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM after 30 mins,Inhibition,<,25.0,%,CCCCCOC(=O)N1CCN(C(=O)[C@H](CCC(=O)O)NC(=O)c2cc(N3CCC(C(=O)NCC)CC3)nc(-c3ccccc3)n2)CC1,CHEMBL1156077,Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.,Bioorg. Med. Chem. Lett.,2009.0,19,21,6148,6156,10.1016/j.bmcl.2009.09.017,19796941.0,
3002537,CHEMBL570295,(S)-5-(4-(butoxycarbonyl)piperazin-1-yl)-4-(6-(4-(ethylcarbamoyl)piperidin-1-yl)-2-phenylpyrimidine-4-carboxamido)-5-oxopentanoic acid,CHEMBL1042529,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM after 30 mins,Inhibition,<,25.0,%,CCCCOC(=O)N1CCN(C(=O)[C@H](CCC(=O)O)NC(=O)c2cc(N3CCC(C(=O)NCC)CC3)cc(-c3ccccc3)n2)CC1,CHEMBL1156077,Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.,Bioorg. Med. Chem. Lett.,2009.0,19,21,6148,6156,10.1016/j.bmcl.2009.09.017,19796941.0,
3002538,CHEMBL570385,(S)-4-(6-(4-carbamoylpiperidin-1-yl)-2-phenylpyrimidine-4-carboxamido)-5-oxo-5-(4-(pentyloxycarbonyl)piperazin-1-yl)pentanoic acid,CHEMBL1042529,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM after 30 mins,Inhibition,<,25.0,%,CCCCCOC(=O)N1CCN(C(=O)[C@H](CCC(=O)O)NC(=O)c2cc(N3CCC(C(N)=O)CC3)nc(-c3ccccc3)n2)CC1,CHEMBL1156077,Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.,Bioorg. Med. Chem. Lett.,2009.0,19,21,6148,6156,10.1016/j.bmcl.2009.09.017,19796941.0,
3002539,CHEMBL571812,(S)-4-(4-(4-(methoxymethyl)piperidin-1-yl)-6-phenylpyrimidine-2-carboxamido)-5-oxo-5-(4-(pentyloxycarbonyl)piperazin-1-yl)pentanoic acid,CHEMBL1042529,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM after 30 mins,Inhibition,<,25.0,%,CCCCCOC(=O)N1CCN(C(=O)[C@H](CCC(=O)O)NC(=O)c2nc(-c3ccccc3)cc(N3CCC(COC)CC3)n2)CC1,CHEMBL1156077,Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.,Bioorg. Med. Chem. Lett.,2009.0,19,21,6148,6156,10.1016/j.bmcl.2009.09.017,19796941.0,
3002540,CHEMBL567468,(S)-4-(6-(4-(methoxymethyl)piperidin-1-yl)-2-phenylpyrimidine-4-carboxamido)-5-oxo-5-(4-(pentyloxycarbonyl)piperazin-1-yl)pentanoic acid,CHEMBL1042529,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM after 30 mins,Inhibition,<,25.0,%,CCCCCOC(=O)N1CCN(C(=O)[C@H](CCC(=O)O)NC(=O)c2cc(N3CCC(COC)CC3)nc(-c3ccccc3)n2)CC1,CHEMBL1156077,Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.,Bioorg. Med. Chem. Lett.,2009.0,19,21,6148,6156,10.1016/j.bmcl.2009.09.017,19796941.0,
3002541,CHEMBL567709,(S)-4-(6-(4-(2-hydroxyethoxy)piperidin-1-yl)-2-phenylpyrimidine-4-carboxamido)-5-oxo-5-(4-(pentyloxycarbonyl)piperazin-1-yl)pentanoic acid,CHEMBL1042529,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM after 30 mins,Inhibition,<,25.0,%,CCCCCOC(=O)N1CCN(C(=O)[C@H](CCC(=O)O)NC(=O)c2cc(N3CCC(OCCO)CC3)nc(-c3ccccc3)n2)CC1,CHEMBL1156077,Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.,Bioorg. Med. Chem. Lett.,2009.0,19,21,6148,6156,10.1016/j.bmcl.2009.09.017,19796941.0,
3002542,CHEMBL567915,(S)-5-oxo-5-(4-(pentyloxycarbonyl)piperazin-1-yl)-4-(2-phenyl-6-(4-(pyrrolidin-1-ylmethyl)piperidin-1-yl)pyrimidine-4-carboxamido)pentanoic acid,CHEMBL1042529,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM after 30 mins,Inhibition,<,25.0,%,CCCCCOC(=O)N1CCN(C(=O)[C@H](CCC(=O)O)NC(=O)c2cc(N3CCC(CN4CCCC4)CC3)nc(-c3ccccc3)n2)CC1,CHEMBL1156077,Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.,Bioorg. Med. Chem. Lett.,2009.0,19,21,6148,6156,10.1016/j.bmcl.2009.09.017,19796941.0,
3002543,CHEMBL567416,(S)-4-(6-(4-((methylamino)methyl)piperidin-1-yl)-2-phenylpyrimidine-4-carboxamido)-5-oxo-5-(4-(pentyloxycarbonyl)piperazin-1-yl)pentanoic acid,CHEMBL1042529,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM after 30 mins,Inhibition,<,25.0,%,CCCCCOC(=O)N1CCN(C(=O)[C@H](CCC(=O)O)NC(=O)c2cc(N3CCC(CNC)CC3)nc(-c3ccccc3)n2)CC1,CHEMBL1156077,Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.,Bioorg. Med. Chem. Lett.,2009.0,19,21,6148,6156,10.1016/j.bmcl.2009.09.017,19796941.0,
3002544,CHEMBL567050,(S)-4-(4-(4-(aminomethyl)piperidin-1-yl)-6-phenylpyrimidine-2-carboxamido)-5-oxo-5-(4-(pentyloxycarbonyl)piperazin-1-yl)pentanoic acid,CHEMBL1042529,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM after 30 mins,Inhibition,<,25.0,%,CCCCCOC(=O)N1CCN(C(=O)[C@H](CCC(=O)O)NC(=O)c2nc(-c3ccccc3)cc(N3CCC(CN)CC3)n2)CC1,CHEMBL1156077,Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.,Bioorg. Med. Chem. Lett.,2009.0,19,21,6148,6156,10.1016/j.bmcl.2009.09.017,19796941.0,
3002545,CHEMBL571584,(S)-4-(6-(4-(aminomethyl)piperidin-1-yl)-2-phenylpyrimidine-4-carboxamido)-5-oxo-5-(4-(pentyloxycarbonyl)piperazin-1-yl)pentanoic acid,CHEMBL1042529,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM after 30 mins,Inhibition,<,25.0,%,CCCCCOC(=O)N1CCN(C(=O)[C@H](CCC(=O)O)NC(=O)c2cc(N3CCC(CN)CC3)nc(-c3ccccc3)n2)CC1,CHEMBL1156077,Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.,Bioorg. Med. Chem. Lett.,2009.0,19,21,6148,6156,10.1016/j.bmcl.2009.09.017,19796941.0,
3002546,CHEMBL570152,(S)-5-oxo-5-(4-(pentyloxycarbonyl)piperazin-1-yl)-4-(2-phenyl-6-(4-(pyrrolidin-1-yl)piperidin-1-yl)pyrimidine-4-carboxamido)pentanoic acid,CHEMBL1042529,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM after 30 mins,Inhibition,<,25.0,%,CCCCCOC(=O)N1CCN(C(=O)[C@H](CCC(=O)O)NC(=O)c2cc(N3CCC(N4CCCC4)CC3)nc(-c3ccccc3)n2)CC1,CHEMBL1156077,Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.,Bioorg. Med. Chem. Lett.,2009.0,19,21,6148,6156,10.1016/j.bmcl.2009.09.017,19796941.0,
3005576,CHEMBL562476,"(1S,2R)-1-(1H-indol-1-yl)-3-(methylamino)-1-phenylpropan-2-ol",CHEMBL1039156,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,<,20.0,%,CNC[C@@H](O)[C@H](c1ccccc1)n1ccc2ccccc21,CHEMBL1155305,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",Bioorg. Med. Chem. Lett.,2009.0,19,17,5029,5032,10.1016/j.bmcl.2009.07.053,19632110.0,
3016798,CHEMBL565547,"4-Benzyl-2-methyl-7,8,9,10-tetrahyd ro-6H-1,3,3a,5,8-pentaaza-cyclohept a[e]indene",CHEMBL1041017,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,<,10.0,%,Cc1nc2c3c(nc(Cc4ccccc4)n2n1)CCNCC3,CHEMBL1155340,Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.,Bioorg. Med. Chem. Lett.,2009.0,19,17,4999,5003,10.1016/j.bmcl.2009.07.063,19646865.0,
3070184,CHEMBL982,nalmefene,CHEMBL1074509,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,35.0,%,C=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,CHEMBL1152554,Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.,Bioorg. Med. Chem.,2009.0,17,18,6671,6681,10.1016/j.bmc.2009.07.069,19683449.0,
3070185,CHEMBL593214,"17-Cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-6beta-[(4'-methyl)benzamido]morphinan-oxalate",CHEMBL1074509,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,12.0,%,Cc1ccc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1.O=C(O)C(=O)O,CHEMBL1152554,Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.,Bioorg. Med. Chem.,2009.0,17,18,6671,6681,10.1016/j.bmc.2009.07.069,19683449.0,
3070186,CHEMBL611929,"17-Cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-6beta-[(4'-trimethylfluoro)benzamido]morphinan-oxalate",CHEMBL1074509,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,9.0,%,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc(C(F)(F)F)cc1.O=C(O)C(=O)O,CHEMBL1152554,Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.,Bioorg. Med. Chem.,2009.0,17,18,6671,6681,10.1016/j.bmc.2009.07.069,19683449.0,
3070187,CHEMBL611930,"17-Cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-6beta-[(4'-bromo)benzamido]morphinan-oxalate",CHEMBL1074509,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,8.0,%,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc(Br)cc1.O=C(O)C(=O)O,CHEMBL1152554,Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.,Bioorg. Med. Chem.,2009.0,17,18,6671,6681,10.1016/j.bmc.2009.07.069,19683449.0,
3070188,CHEMBL611931,"17-Cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-6beta-[(4'-iodo)benzamido]morphinan-oxalate",CHEMBL1074509,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,7.0,%,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc(I)cc1.O=C(O)C(=O)O,CHEMBL1152554,Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.,Bioorg. Med. Chem.,2009.0,17,18,6671,6681,10.1016/j.bmc.2009.07.069,19683449.0,
3070189,CHEMBL611932,"17-Cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-6beta-[(4'-t-butyl)benzamido]morphinan-oxalate",CHEMBL1074509,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,5.0,%,CC(C)(C)c1ccc(C(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1.O=C(O)C(=O)O,CHEMBL1152554,Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.,Bioorg. Med. Chem.,2009.0,17,18,6671,6681,10.1016/j.bmc.2009.07.069,19683449.0,
3070190,CHEMBL593215,"3,4-dichloro-N-[(1S,5R,13R,14R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-yl]benzamide oxalic acid",CHEMBL1074509,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,7.0,%,O=C(N[C@@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5)c1ccc(Cl)c(Cl)c1.O=C(O)C(=O)O,CHEMBL1152554,Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.,Bioorg. Med. Chem.,2009.0,17,18,6671,6681,10.1016/j.bmc.2009.07.069,19683449.0,
3082332,CHEMBL604687,"(S)-3-(5-((1-acetylpyrrolidin-2-yl)methoxy)-3-(tert-butylthio)-1-(4-chlorobenzyl)-1H-indol-2-yl)-2,2-dimethylpropanoic acid",CHEMBL1072025,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,93.0,%,CC(=O)N1CCC[C@H]1COc1ccc2c(c1)c(SC(C)(C)C)c(CC(C)(C)C(=O)O)n2Cc1ccc(Cl)cc1,CHEMBL1153124,"5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.",Bioorg. Med. Chem. Lett.,2010.0,20,1,213,217,10.1016/j.bmcl.2009.10.131,19914828.0,
3082340,CHEMBL610185,"(S)-3-(5-((1-acetylindolin-2-yl)methoxy)-3-(tert-butylthio)-1-(4-chlorobenzyl)-1H-indol-2-yl)-2,2-dimethylpropanoic acid",CHEMBL1072025,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,96.0,%,CC(=O)N1c2ccccc2C[C@H]1COc1ccc2c(c1)c(SC(C)(C)C)c(CC(C)(C)C(=O)O)n2Cc1ccc(Cl)cc1,CHEMBL1153124,"5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.",Bioorg. Med. Chem. Lett.,2010.0,20,1,213,217,10.1016/j.bmcl.2009.10.131,19914828.0,
3082342,CHEMBL609877,"(S)-3-(5-((1-acetylindolin-2-yl)methoxy)-1-(4-chlorobenzyl)-3-isobutyl-1H-indol-2-yl)-2,2-dimethylpropanoic acid",CHEMBL1072025,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,>,80.0,%,CC(=O)N1c2ccccc2C[C@H]1COc1ccc2c(c1)c(CC(C)C)c(CC(C)(C)C(=O)O)n2Cc1ccc(Cl)cc1,CHEMBL1153124,"5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.",Bioorg. Med. Chem. Lett.,2010.0,20,1,213,217,10.1016/j.bmcl.2009.10.131,19914828.0,
3082344,CHEMBL610190,"(S)-3-(5-((1-acetylindolin-2-yl)methoxy)-3-benzyl-1-(4-chlorobenzyl)-1H-indol-2-yl)-2,2-dimethylpropanoic acid",CHEMBL1072025,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,>,80.0,%,CC(=O)N1c2ccccc2C[C@H]1COc1ccc2c(c1)c(Cc1ccccc1)c(CC(C)(C)C(=O)O)n2Cc1ccc(Cl)cc1,CHEMBL1153124,"5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.",Bioorg. Med. Chem. Lett.,2010.0,20,1,213,217,10.1016/j.bmcl.2009.10.131,19914828.0,
3082345,CHEMBL610469,"(S)-3-(5-((1-acetylindolin-2-yl)methoxy)-1-(4-chlorobenzyl)-3-(3,3-dimethylbutyl)-1H-indol-2-yl)-2,2-dimethylpropanoic acid",CHEMBL1072025,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,>,80.0,%,CC(=O)N1c2ccccc2C[C@H]1COc1ccc2c(c1)c(CCC(C)(C)C)c(CC(C)(C)C(=O)O)n2Cc1ccc(Cl)cc1,CHEMBL1153124,"5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitor.",Bioorg. Med. Chem. Lett.,2010.0,20,1,213,217,10.1016/j.bmcl.2009.10.131,19914828.0,
3097561,CHEMBL590078,"(+)-7-methyl-3,4,4a,5-tetrahydro-1H-pyrazino[1,2-a]quinazolin-6(2H)-one",CHEMBL1066806,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,>,50.0,%,Cc1cccc2c1C(=O)NC1CNCCN21,CHEMBL1158511,Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.,Bioorg. Med. Chem. Lett.,2010.0,20,3,1128,1133,10.1016/j.bmcl.2009.12.014,20022752.0,
3122580,CHEMBL604102,(3R)-1-[3-(1-Naphthylsulfonyl)-1H-indazol-5-yl]pyrrolidin-3-amine,CHEMBL1073470,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,73.0,%,N[C@@H]1CCN(c2ccc3[nH]nc(S(=O)(=O)c4cccc5ccccc45)c3c2)C1,CHEMBL1157614,5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.,J. Med. Chem.,2010.0,53,6,2521,2527,10.1021/jm901674f,20170099.0,
3185704,CHEMBL1084411,(E)-4-(4-methyl-1H-indol-5-ylamino)-5-(2-(6-((4-methylpiperazin-1-yl)methyl)pyridin-2-yl)vinyl)nicotinonitrile,CHEMBL1105153,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,10.0,%,Cc1c(Nc2c(C#N)cncc2/C=C/c2cccc(CN3CCN(C)CC3)n2)ccc2[nH]ccc12,CHEMBL1155381,Optimization of 5-vinylaryl-3-pyridinecarbonitriles as PKCtheta inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,6,1965,1968,10.1016/j.bmcl.2010.01.119,20153643.0,
3250439,CHEMBL1092638,"2-(4-tert-butylphenyl)-8-(4-((2-ethyl-5-methyl-1H-imidazol-4-yl)methyl)piperazin-1-yl)imidazo[1,2-a]pyridine",CHEMBL1115142,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,6.0,%,CCc1nc(CN2CCN(c3cccn4cc(-c5ccc(C(C)(C)C)cc5)nc34)CC2)c(C)[nH]1,CHEMBL1156984,Synthesis and biological evaluation of piperazinyl heterocyclic antagonists of the gonadotropin releasing hormone (GnRH) receptor.,Bioorg. Med. Chem. Lett.,2010.0,20,8,2512,2515,10.1016/j.bmcl.2010.02.099,20236823.0,
3250440,CHEMBL1088866,"2-(4-tert-butylphenyl)-8-(4-((1-ethyl-5-methyl-1H-imidazol-4-yl)methyl)piperazin-1-yl)imidazo[1,2-a]pyridine",CHEMBL1115142,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,10.0,%,CCn1cnc(CN2CCN(c3cccn4cc(-c5ccc(C(C)(C)C)cc5)nc34)CC2)c1C,CHEMBL1156984,Synthesis and biological evaluation of piperazinyl heterocyclic antagonists of the gonadotropin releasing hormone (GnRH) receptor.,Bioorg. Med. Chem. Lett.,2010.0,20,8,2512,2515,10.1016/j.bmcl.2010.02.099,20236823.0,
3250441,CHEMBL1091579,"5-((4-(2-(4-tert-butylphenyl)imidazo[1,2-a]pyridin-8-yl)piperazin-1-yl)methyl)-1-ethylpyrimidine-2,4(1H,3H)-dione",CHEMBL1115142,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,0.0,%,CCn1cc(CN2CCN(c3cccn4cc(-c5ccc(C(C)(C)C)cc5)nc34)CC2)c(=O)[nH]c1=O,CHEMBL1156984,Synthesis and biological evaluation of piperazinyl heterocyclic antagonists of the gonadotropin releasing hormone (GnRH) receptor.,Bioorg. Med. Chem. Lett.,2010.0,20,8,2512,2515,10.1016/j.bmcl.2010.02.099,20236823.0,
3250442,CHEMBL521674,2-(4-tert-butylphenyl)-4-(4-((1-ethyl-5-methyl-1H-imidazol-4-yl)methyl)piperazin-1-yl)-1H-benzo[d]imidazole,CHEMBL1115142,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,27.0,%,CCn1cnc(CN2CCN(c3cccc4[nH]c(-c5ccc(C(C)(C)C)cc5)nc34)CC2)c1C,CHEMBL1156984,Synthesis and biological evaluation of piperazinyl heterocyclic antagonists of the gonadotropin releasing hormone (GnRH) receptor.,Bioorg. Med. Chem. Lett.,2010.0,20,8,2512,2515,10.1016/j.bmcl.2010.02.099,20236823.0,
3254572,CHEMBL1092257,benzyl 1-acetyl-2-(4-(methylsulfonyl)benzyl)pyrrolidine-2-carboxylate,CHEMBL1105309,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 50 uM,Inhibition,<,30.0,%,CC(=O)N1CCCC1(Cc1ccc(S(C)(=O)=O)cc1)C(=O)OCc1ccccc1,CHEMBL1156993,Benzyl prolinate derivatives as novel selective KCC2 blockers.,Bioorg. Med. Chem. Lett.,2010.0,20,8,2542,2545,10.1016/j.bmcl.2010.02.092,20299216.0,
3264451,CHEMBL563985,"Methyl 4-(6-(4-(3-methylureido)phenyl)-4-morpholino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate",CHEMBL1104622,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,<,20.0,%,CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1,CHEMBL1157009,"Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.",J. Med. Chem.,2009.0,52,24,8010,8024,10.1021/jm9013828,19894727.0,
3264452,CHEMBL1098248,"methyl 4-(4-morpholino-6-(4-(3-(4-(2-morpholinoethyl)phenyl)ureido)phenyl)-1Hpyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate",CHEMBL1104622,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,58.0,%,COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)Nc5ccc(CCN6CCOCC6)cc5)cc4)nc32)CC1,CHEMBL1157009,"Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.",J. Med. Chem.,2009.0,52,24,8010,8024,10.1021/jm9013828,19894727.0,
3264453,CHEMBL1098247,"methyl 4-(6-(4-(3-(4-(2-(4-methylpiperazin-1-yl)ethyl)phenyl)ureido)phenyl)-4-morpholino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate",CHEMBL1104622,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,<,10.0,%,COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)Nc5ccc(CCN6CCN(C)CC6)cc5)cc4)nc32)CC1,CHEMBL1157009,"Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.",J. Med. Chem.,2009.0,52,24,8010,8024,10.1021/jm9013828,19894727.0,
3264454,CHEMBL1098246,"4-(4-morpholino-6-(4-(3-(4-(2-(pyrrolidin-1-yl)ethyl)phenyl)ureido)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate",CHEMBL1104622,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,<,10.0,%,COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)Nc5ccc(CCN6CCCC6)cc5)cc4)nc32)CC1,CHEMBL1157009,"Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.",J. Med. Chem.,2009.0,52,24,8010,8024,10.1021/jm9013828,19894727.0,
3264455,CHEMBL556947,"Methyl 4-(6-(4-(3-(4-(4-methylpiperazin-1-yl)phenyl)ureido)phenyl)-4-morpholino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate",CHEMBL1104622,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,<,10.0,%,COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)Nc5ccc(N6CCN(C)CC6)cc5)cc4)nc32)CC1,CHEMBL1157009,"Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.",J. Med. Chem.,2009.0,52,24,8010,8024,10.1021/jm9013828,19894727.0,
3264456,CHEMBL1098244,"methyl 4-(6-{4-[(anilinocarbonyl)amino]phenyl}-4-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate",CHEMBL1104622,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,<,20.0,%,COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)Nc5ccccc5)cc4)nc32)CC1,CHEMBL1157009,"Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.",J. Med. Chem.,2009.0,52,24,8010,8024,10.1021/jm9013828,19894727.0,
3264457,CHEMBL562999,"Methyl 4-(6-{4-[(cyclopropylcarbamoyl)amino]phenyl}-4-morpholin-4-yl-1Hpyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate",CHEMBL1104622,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,<,20.0,%,COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NC5CC5)cc4)nc32)CC1,CHEMBL1157009,"Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.",J. Med. Chem.,2009.0,52,24,8010,8024,10.1021/jm9013828,19894727.0,
3264458,CHEMBL561907,"Methyl 4-[6-(4-{[(2-fluoroethyl)carbamoyl]amino}phenyl)-4-morpholin-4-yl-1Hpyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate",CHEMBL1104622,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,<,20.0,%,COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NCCF)cc4)nc32)CC1,CHEMBL1157009,"Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.",J. Med. Chem.,2009.0,52,24,8010,8024,10.1021/jm9013828,19894727.0,
3264459,CHEMBL1095932,"Isopropyl 4-(6-(4-(3-Methylureido)phenyl)-4-morpholino-1Hpyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate",CHEMBL1104622,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,23.0,%,CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC(C)C)CC4)c3n2)cc1,CHEMBL1157009,"Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.",J. Med. Chem.,2009.0,52,24,8010,8024,10.1021/jm9013828,19894727.0,
3264461,CHEMBL1098243,"tert-butyl 4-(6-{4-[(cyclopropylcarbamoyl)amino]phenyl}-4-morpholin-4-yl-1Hpyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate",CHEMBL1104622,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,40.0,%,CC(C)(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NC5CC5)cc4)nc32)CC1,CHEMBL1157009,"Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.",J. Med. Chem.,2009.0,52,24,8010,8024,10.1021/jm9013828,19894727.0,
3264462,CHEMBL1097942,"isopropyl 4-(6-{4-[(cyclopropylcarbamoyl)amino]phenyl}-4-morpholin-4-yl-1Hpyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate",CHEMBL1104622,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,40.0,%,CC(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NC5CC5)cc4)nc32)CC1,CHEMBL1157009,"Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.",J. Med. Chem.,2009.0,52,24,8010,8024,10.1021/jm9013828,19894727.0,
3264463,CHEMBL1098242,"tert-butyl 4-[6-(4-{[(2-fluoroethyl)carbamoyl]amino}phenyl)-4-morpholin-4-yl-1Hpyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate",CHEMBL1104622,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,40.0,%,CC(C)(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NCCF)cc4)nc32)CC1,CHEMBL1157009,"Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.",J. Med. Chem.,2009.0,52,24,8010,8024,10.1021/jm9013828,19894727.0,
3264464,CHEMBL1094981,"isopropyl 4-[6-(4-{[(2-fluoroethyl)carbamoyl]amino}phenyl)-4-morpholin-4-yl-1Hpyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate",CHEMBL1104622,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,40.0,%,CC(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NCCF)cc4)nc32)CC1,CHEMBL1157009,"Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.",J. Med. Chem.,2009.0,52,24,8010,8024,10.1021/jm9013828,19894727.0,
3264465,CHEMBL1095933,"tert-Butyl 4-(6-(4-(3-Methylureido)phenyl)-4-morpholino-1Hpyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate",CHEMBL1104622,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,23.0,%,CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC(C)(C)C)CC4)c3n2)cc1,CHEMBL1157009,"Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.",J. Med. Chem.,2009.0,52,24,8010,8024,10.1021/jm9013828,19894727.0,
3275396,CHEMBL76,"N*4*-(7-Chloro-quinolin-4-yl)-N*1*,N*1*-diethyl-pentane-1,4-diamine (Chloroquine)",CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,114.0,%,CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3275397,CHEMBL180671,"N*1*,N*1*-Diethyl-N*4*-(7-phenoxy-quinolin-4-yl)-pentane-1,4-diamine",CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,118.0,%,CCN(CC)CCCC(C)Nc1ccnc2cc(Oc3ccccc3)ccc12,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3275398,CHEMBL1087464,"N1,N1-diethyl-N4-(7-(trifluoromethoxy)quinolin-4-yl)pentane-1,4-diamine",CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,105.0,%,CCN(CC)CCCC(C)Nc1ccnc2cc(OC(F)(F)F)ccc12,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3275399,CHEMBL144539,"N*1*,N*1*-Diethyl-N*4*-(7-trifluoromethyl-quinolin-4-yl)-pentane-1,4-diamine",CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,103.0,%,CCN(CC)CCCC(C)Nc1ccnc2cc(C(F)(F)F)ccc12,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3275400,CHEMBL1087469,"N1-(7-chloroquinolin-4-yl)-N3-(cyclopropylmethyl)-N3-propylpropane-1,3-diamine",CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,102.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)CC1CC1,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3275401,CHEMBL1087470,"N1-(bicyclo[2.2.1]hept-5-en-2-ylmethyl)-N3-(7-chloroquinolin-4-yl)-N1-propylpropane-1,3-diamine",CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,109.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)CC1CC2C=CC1C2,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3275402,CHEMBL1087837,"N1-(7-chloroquinolin-4-yl)-N3-propyl-N3-(thiophen-3-ylmethyl)propane-1,3-diamine",CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,98.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1ccsc1,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3275403,CHEMBL1087964,"N1-(7-chloroquinolin-4-yl)-N3-(furan-3-ylmethyl)-N3-propylpropane-1,3-diamine",CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,113.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1ccoc1,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3275404,CHEMBL1088374,"N1-(benzo[d][1,3]dioxol-4-ylmethyl)-N3-(7-chloroquinolin-4-yl)-N1-propylpropane-1,3-diamine",CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,119.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1cccc2c1OCO2,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3275405,CHEMBL1088375,"N1-(7-chloroquinolin-4-yl)-N3-propyl-N3-(pyridin-2-ylmethyl)propane-1,3-diamine",CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,107.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1ccccn1,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3275406,CHEMBL208948,2-({[3-(7-chloroquinolin-4-ylamino)propyl]propylamino}-methyl)-6-methoxyphenol,CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,97.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1cccc(OC)c1O,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3275407,CHEMBL214262,2-({[3-(7-chloroquinolin-4-ylamino)propyl]propylamino}-methyl)-4-trifluoromethoxyphenol,CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,96.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1cc(OC(F)(F)F)ccc1O,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3275408,CHEMBL212164,"N-(5-chlorofuran-2-ylmethyl)-N'-(7-chloroquinolin-4-yl)-Npropylpropane-1,3-diamine",CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,98.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1ccc(Cl)o1,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3275409,CHEMBL213403,2-({[3-(7-chloroquinolin-4-ylamino)propyl]propylamino}-methyl)-4-methoxyphenol,CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,107.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1cc(OC)ccc1O,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3275410,CHEMBL1088514,"N1-(7-chloroquinolin-4-yl)-N3-propyl-N3-(2-(trifluoromethoxy)benzyl)propane-1,3-diamine",CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,93.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1ccccc1OC(F)(F)F,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3275411,CHEMBL376939,"N'-(7-chloroquinolin-4-yl)-N-(2-fluoro-6-methoxybenzyl)-Npropylpropane-1,3-diamine",CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,104.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1c(F)cccc1OC,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3275412,CHEMBL210188,"N'-(7-chloroquinolin-4-yl)-N-(5-methylfuran-2-ylmethyl)-Npropylpropane-1,3-diamine",CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,85.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1ccc(C)o1,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3275413,CHEMBL213559,"N'-(7-chloroquinolin-4-yl)-N-(5-fluoro-2-methoxybenzyl)-Npropylpropane-1,3-diamine",CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,102.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1cc(F)ccc1OC,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3275414,CHEMBL1088123,"N-Benzo[1,3]dioxol-4-ylmethyl-N'-(7-chloroquinolin-4-yl)propane-1,3-diamine",CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,98.0,%,Clc1ccc2c(NCCCNCc3cccc4c3OCO4)ccnc2c1,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3275415,CHEMBL1088254,2-{[3-(7-Chloroquinolin-4-ylamino)propylamino]methyl}-4-methoxyphenol,CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,102.0,%,COc1ccc(O)c(CNCCCNc2ccnc3cc(Cl)ccc23)c1,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3275416,CHEMBL1088255,2-{[3-(7-Chloroquinolin-4-ylamino)propylamino]methyl}-6-methoxyphenol,CHEMBL1103798,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 1 uM by LC-MS/MS analysis relative to control,Inhibition,=,108.0,%,COc1cccc(CNCCCNc2ccnc3cc(Cl)ccc23)c1O,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277195,CHEMBL76,"N*4*-(7-Chloro-quinolin-4-yl)-N*1*,N*1*-diethyl-pentane-1,4-diamine (Chloroquine)",CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,128.0,%,CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277196,CHEMBL180671,"N*1*,N*1*-Diethyl-N*4*-(7-phenoxy-quinolin-4-yl)-pentane-1,4-diamine",CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,115.0,%,CCN(CC)CCCC(C)Nc1ccnc2cc(Oc3ccccc3)ccc12,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277197,CHEMBL1087464,"N1,N1-diethyl-N4-(7-(trifluoromethoxy)quinolin-4-yl)pentane-1,4-diamine",CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,145.0,%,CCN(CC)CCCC(C)Nc1ccnc2cc(OC(F)(F)F)ccc12,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277198,CHEMBL144539,"N*1*,N*1*-Diethyl-N*4*-(7-trifluoromethyl-quinolin-4-yl)-pentane-1,4-diamine",CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,126.0,%,CCN(CC)CCCC(C)Nc1ccnc2cc(C(F)(F)F)ccc12,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277199,CHEMBL1087469,"N1-(7-chloroquinolin-4-yl)-N3-(cyclopropylmethyl)-N3-propylpropane-1,3-diamine",CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,121.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)CC1CC1,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277200,CHEMBL1087470,"N1-(bicyclo[2.2.1]hept-5-en-2-ylmethyl)-N3-(7-chloroquinolin-4-yl)-N1-propylpropane-1,3-diamine",CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,73.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)CC1CC2C=CC1C2,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277201,CHEMBL1087837,"N1-(7-chloroquinolin-4-yl)-N3-propyl-N3-(thiophen-3-ylmethyl)propane-1,3-diamine",CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,96.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1ccsc1,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277202,CHEMBL1087964,"N1-(7-chloroquinolin-4-yl)-N3-(furan-3-ylmethyl)-N3-propylpropane-1,3-diamine",CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,104.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1ccoc1,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277203,CHEMBL1088374,"N1-(benzo[d][1,3]dioxol-4-ylmethyl)-N3-(7-chloroquinolin-4-yl)-N1-propylpropane-1,3-diamine",CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,122.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1cccc2c1OCO2,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277204,CHEMBL1088375,"N1-(7-chloroquinolin-4-yl)-N3-propyl-N3-(pyridin-2-ylmethyl)propane-1,3-diamine",CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,108.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1ccccn1,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277205,CHEMBL208948,2-({[3-(7-chloroquinolin-4-ylamino)propyl]propylamino}-methyl)-6-methoxyphenol,CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,106.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1cccc(OC)c1O,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277206,CHEMBL214262,2-({[3-(7-chloroquinolin-4-ylamino)propyl]propylamino}-methyl)-4-trifluoromethoxyphenol,CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,79.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1cc(OC(F)(F)F)ccc1O,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277207,CHEMBL212164,"N-(5-chlorofuran-2-ylmethyl)-N'-(7-chloroquinolin-4-yl)-Npropylpropane-1,3-diamine",CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,79.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1ccc(Cl)o1,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277208,CHEMBL213403,2-({[3-(7-chloroquinolin-4-ylamino)propyl]propylamino}-methyl)-4-methoxyphenol,CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,128.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1cc(OC)ccc1O,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277209,CHEMBL1088514,"N1-(7-chloroquinolin-4-yl)-N3-propyl-N3-(2-(trifluoromethoxy)benzyl)propane-1,3-diamine",CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,63.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1ccccc1OC(F)(F)F,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277210,CHEMBL376939,"N'-(7-chloroquinolin-4-yl)-N-(2-fluoro-6-methoxybenzyl)-Npropylpropane-1,3-diamine",CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,100.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1c(F)cccc1OC,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277211,CHEMBL210188,"N'-(7-chloroquinolin-4-yl)-N-(5-methylfuran-2-ylmethyl)-Npropylpropane-1,3-diamine",CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,46.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1ccc(C)o1,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277212,CHEMBL213559,"N'-(7-chloroquinolin-4-yl)-N-(5-fluoro-2-methoxybenzyl)-Npropylpropane-1,3-diamine",CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,93.0,%,CCCN(CCCNc1ccnc2cc(Cl)ccc12)Cc1cc(F)ccc1OC,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277213,CHEMBL1088123,"N-Benzo[1,3]dioxol-4-ylmethyl-N'-(7-chloroquinolin-4-yl)propane-1,3-diamine",CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,115.0,%,Clc1ccc2c(NCCCNCc3cccc4c3OCO4)ccnc2c1,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277214,CHEMBL1088254,2-{[3-(7-Chloroquinolin-4-ylamino)propylamino]methyl}-4-methoxyphenol,CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,102.0,%,COc1ccc(O)c(CNCCCNc2ccnc3cc(Cl)ccc23)c1,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3277215,CHEMBL1088255,2-{[3-(7-Chloroquinolin-4-ylamino)propylamino]methyl}-6-methoxyphenol,CHEMBL1103804,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as metabolite produced at 10 uM by LC-MS/MS analysis relative to control,Inhibition,=,108.0,%,COc1cccc(CNCCCNc2ccnc3cc(Cl)ccc23)c1O,CHEMBL1157913,Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.,J. Med. Chem.,2010.0,53,9,3685,3695,10.1021/jm100057h,20361799.0,
3304077,CHEMBL1084762,"2-((1R,2R)-2-(2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamido)-2,3-dihydro-1H-inden-1-yl)acetic acid",CHEMBL1120666,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,50.0,%,O=C(O)C[C@@H]1c2ccccc2C[C@H]1NC(=O)c1cc2sc(Cl)c(Cl)c2[nH]1,CHEMBL1158622,Discovery of a series of indan carboxylic acid glycogen phosphorylase inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,12,3511,3514,10.1016/j.bmcl.2010.04.147,20493691.0,
3304078,CHEMBL1084328,"(S)-2-((1R,2R)-2-(2,3-dichloro-4H-thieno[3,2-b]pyrrole-5-carboxamido)-2,3-dihydro-1H-inden-1-yl)-4-methoxybutanoic acid",CHEMBL1120666,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,50.0,%,COCCC(C(=O)O)[C@@H]1c2ccccc2C[C@H]1NC(=O)c1cc2sc(Cl)c(Cl)c2[nH]1,CHEMBL1158622,Discovery of a series of indan carboxylic acid glycogen phosphorylase inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,12,3511,3514,10.1016/j.bmcl.2010.04.147,20493691.0,
3307166,CHEMBL1086332,1-(biphenyl-4-yl)-3-(4-(piperidin-1-yl)butyl)urea,CHEMBL1118790,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM by Gentest method,Inhibition,=,2.0,%,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccccc2)cc1,CHEMBL1155527,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,2010.0,53,11,4379,4389,10.1021/jm901692q,20465311.0,
3307167,CHEMBL1086333,1-(2'-methoxybiphenyl-4-yl)-3-(4-(piperidin-1-yl)butyl)urea,CHEMBL1118790,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM by Gentest method,Inhibition,=,-2.0,%,COc1ccccc1-c1ccc(NC(=O)NCCCCN2CCCCC2)cc1,CHEMBL1155527,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,2010.0,53,11,4379,4389,10.1021/jm901692q,20465311.0,
3307168,CHEMBL1085379,1-(2'-fluorobiphenyl-4-yl)-3-(4-(piperidin-1-yl)butyl)urea,CHEMBL1118790,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM by Gentest method,Inhibition,=,-1.0,%,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccccc2F)cc1,CHEMBL1155527,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,2010.0,53,11,4379,4389,10.1021/jm901692q,20465311.0,
3307169,CHEMBL1084631,1-(4'-fluorobiphenyl-4-yl)-3-(4-(piperidin-1-yl)butyl)urea,CHEMBL1118790,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM by Gentest method,Inhibition,=,-16.0,%,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccc(F)cc2)cc1,CHEMBL1155527,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,2010.0,53,11,4379,4389,10.1021/jm901692q,20465311.0,
3307170,CHEMBL1084876,1-(4-(6-fluoropyridin-3-yl)phenyl)-3-(4-(piperidin-1-yl)butyl)urea,CHEMBL1118790,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM by Gentest method,Inhibition,=,-18.0,%,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccc(F)nc2)cc1,CHEMBL1155527,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,2010.0,53,11,4379,4389,10.1021/jm901692q,20465311.0,
3307171,CHEMBL1084363,1-(4-Piperidin-1-ylbutyl)-3-(4-pyridin-2-ylphenyl)urea,CHEMBL1118790,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM by Gentest method,Inhibition,=,0.0,%,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccccn2)cc1,CHEMBL1155527,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,2010.0,53,11,4379,4389,10.1021/jm901692q,20465311.0,
3307172,CHEMBL1084364,1-(6-phenylpyridin-3-yl)-3-(4-(piperidin-1-yl)butyl)urea,CHEMBL1118790,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM by Gentest method,Inhibition,=,-4.0,%,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccccc2)nc1,CHEMBL1155527,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,2010.0,53,11,4379,4389,10.1021/jm901692q,20465311.0,
3307855,CHEMBL1084365,1-(6-(2-methoxyphenyl)pyridin-3-yl)-3-(4-(piperidin-1-yl)butyl)urea,CHEMBL1118790,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM by Gentest method,Inhibition,=,6.0,%,COc1ccccc1-c1ccc(NC(=O)NCCCCN2CCCCC2)cn1,CHEMBL1155527,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,2010.0,53,11,4379,4389,10.1021/jm901692q,20465311.0,
3307856,CHEMBL1083485,1-(6-(2-fluorophenyl)pyridin-3-yl)-3-(4-(piperidin-1-yl)butyl)urea,CHEMBL1118790,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM by Gentest method,Inhibition,=,-10.0,%,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccccc2F)nc1,CHEMBL1155527,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,2010.0,53,11,4379,4389,10.1021/jm901692q,20465311.0,
3307857,CHEMBL1083787,1-[6-(4-Fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl)urea,CHEMBL1118790,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM by Gentest method,Inhibition,=,-17.0,%,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccc(F)cc2)nc1,CHEMBL1155527,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,2010.0,53,11,4379,4389,10.1021/jm901692q,20465311.0,
3307858,CHEMBL1083788,"1-(6'-fluoro-2,3'-bipyridin-5-yl)-3-(4-(piperidin-1-yl)butyl)urea",CHEMBL1118790,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM by Gentest method,Inhibition,=,-10.0,%,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccc(F)nc2)nc1,CHEMBL1155527,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,2010.0,53,11,4379,4389,10.1021/jm901692q,20465311.0,
3307859,CHEMBL1086577,"1-(2,2'-bipyridin-5-yl)-3-(4-(piperidin-1-yl)butyl)urea",CHEMBL1118790,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM by Gentest method,Inhibition,=,-3.0,%,O=C(NCCCCN1CCCCC1)Nc1ccc(-c2ccccn2)nc1,CHEMBL1155527,"Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).",J. Med. Chem.,2010.0,53,11,4379,4389,10.1021/jm901692q,20465311.0,
3309557,CHEMBL1755,Conivaptan,CHEMBL1120499,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,498.58,%,Cc1nc2c([nH]1)CCN(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)c1ccccc1-2,CHEMBL1155536,Synthesis and evaluation of azabicyclo[3.2.1]octane derivatives as potent mixed vasopressin antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,12,3742,3745,10.1016/j.bmcl.2010.04.068,20471258.0,
3309558,CHEMBL1083703,"(4-(benzo[b]thiophen-3-yl)-3-methoxyphenyl)((1S,5R)-1,3,3-trimethyl-6-azabicyclo[3.2.1]octan-6-yl)methanone",CHEMBL1120499,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,419.59,%,COc1cc(C(=O)N2C[C@]3(C)C[C@H]2CC(C)(C)C3)ccc1-c1csc2ccccc12,CHEMBL1155536,Synthesis and evaluation of azabicyclo[3.2.1]octane derivatives as potent mixed vasopressin antagonists.,Bioorg. Med. Chem. Lett.,2010.0,20,12,3742,3745,10.1016/j.bmcl.2010.04.068,20471258.0,
3344844,CHEMBL189568,butyl (5-isobutylthien-2-yl)sulfonylcarbamate derivative,CHEMBL1167163,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM by spectrofluorimetry,Inhibition,=,94.0,%,CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2ccnc2)cc1,CHEMBL1165972,Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.,Bioorg. Med. Chem.,2010.0,18,12,4570,4590,10.1016/j.bmc.2010.03.064,20493713.0,
3344845,CHEMBL1164270,N-Butyloxycarbonyl-3-[4-(4-methyl-imidazole-1-ylmethyl)-phenyl]-5-iso-butyl-thiophene-2-sulfonamide,CHEMBL1167163,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM by spectrofluorimetry,Inhibition,=,37.0,%,CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2cnc(C)c2)cc1,CHEMBL1165972,Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.,Bioorg. Med. Chem.,2010.0,18,12,4570,4590,10.1016/j.bmc.2010.03.064,20493713.0,
3344846,CHEMBL1165505,N-Butyloxycarbonyl-3-[4-(4-trifluoromethyl-1Himidazole-1-ylmethyl)-phenyl]-5-iso-butyl-thiophene-2-sulfonamide,CHEMBL1167163,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM by spectrofluorimetry,Inhibition,=,31.0,%,CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2cnc(C(F)(F)F)c2)cc1,CHEMBL1165972,Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.,Bioorg. Med. Chem.,2010.0,18,12,4570,4590,10.1016/j.bmc.2010.03.064,20493713.0,
3344847,CHEMBL1164560,N-Butyloxycarbonyl-3-(4-pyrazole-1-yl-methylphenyl)-5-iso-butylthiophene-2-sulfonamide,CHEMBL1167163,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM by spectrofluorimetry,Inhibition,=,23.0,%,CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2cccn2)cc1,CHEMBL1165972,Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.,Bioorg. Med. Chem.,2010.0,18,12,4570,4590,10.1016/j.bmc.2010.03.064,20493713.0,
3344848,CHEMBL1164561,N-Butyloxycarbonyl-3-[4-(3-trifluoromethyl-1H-pyrazole-1-ylmethyl)-phenyl]-5-iso-butyl-thiophene-2-sulfonamide,CHEMBL1167163,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM by spectrofluorimetry,Inhibition,=,56.0,%,CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2ccc(C(F)(F)F)n2)cc1,CHEMBL1165972,Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.,Bioorg. Med. Chem.,2010.0,18,12,4570,4590,10.1016/j.bmc.2010.03.064,20493713.0,
3344849,CHEMBL1164870,N-Butyloxycarbonyl-3-[4-(2-oxo-pyrrolidin-1-yl-methyl)-phenyl]-5-iso-butylthiophene-2-sulfonamide,CHEMBL1167163,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM by spectrofluorimetry,Inhibition,=,24.0,%,CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(CN2CCCC2=O)cc1,CHEMBL1165972,Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.,Bioorg. Med. Chem.,2010.0,18,12,4570,4590,10.1016/j.bmc.2010.03.064,20493713.0,
3344850,CHEMBL1163775,N-Butyloxycarbonyl-3-[4-(3-methyl-2-oxoimidazolidin-1-yl-methyl)-phenyl]-5-iso-butylthiophene-2-sulfonamide,CHEMBL1167163,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM by spectrofluorimetry,Inhibition,=,24.0,%,CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(CN2CCN(C)C2=O)cc1,CHEMBL1165972,Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.,Bioorg. Med. Chem.,2010.0,18,12,4570,4590,10.1016/j.bmc.2010.03.064,20493713.0,
3344851,CHEMBL1165496,"N-Butyloxycarbonyl-3-[4-(3-methyl-2,5-dioxoimidazolidin-1-yl-methyl)-phenyl]-5-iso-butyl-thiophene-2-sulfonamide",CHEMBL1167163,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM by spectrofluorimetry,Inhibition,=,40.0,%,CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(CN2C(=O)CN(C)C2=O)cc1,CHEMBL1165972,Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.,Bioorg. Med. Chem.,2010.0,18,12,4570,4590,10.1016/j.bmc.2010.03.064,20493713.0,
3344852,CHEMBL1164104,"N-Butyloxycarbonyl-3-[4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl-methyl)-phenyl]-5-iso-butyl-thiophene-2-sulfonamide",CHEMBL1167163,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM by spectrofluorimetry,Inhibition,=,38.0,%,CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(CN2C(=O)N(C)C(C)(C)C2=O)cc1,CHEMBL1165972,Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.,Bioorg. Med. Chem.,2010.0,18,12,4570,4590,10.1016/j.bmc.2010.03.064,20493713.0,
3344853,CHEMBL1165729,N-Butyloxycarbonyl-3-[4-(piperidin-4-one-1-ylmethyl)-phenyl]-5-iso-butyl-thiophene-2-sulfonamide,CHEMBL1167163,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM by spectrofluorimetry,Inhibition,=,71.0,%,CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(CN2CCC(=O)CC2)cc1,CHEMBL1165972,Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.,Bioorg. Med. Chem.,2010.0,18,12,4570,4590,10.1016/j.bmc.2010.03.064,20493713.0,
3344854,CHEMBL1164113,N-Butyloxycarbonyl-3-[4-(thiazole-2-ylmethyl)-phenyl]-5-iso-butyl-thiophene-2-sulfonamide,CHEMBL1167163,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM by spectrofluorimetry,Inhibition,=,86.0,%,CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cc2nccs2)cc1,CHEMBL1165972,Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.,Bioorg. Med. Chem.,2010.0,18,12,4570,4590,10.1016/j.bmc.2010.03.064,20493713.0,
3344855,CHEMBL1164531,N-Butyloxycarbonyl-3-(4-oxazol-2-yl-methylphenyl)-5-iso-butylthiophene-2-sulfonamide,CHEMBL1167163,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM by spectrofluorimetry,Inhibition,=,83.0,%,CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cc2ncco2)cc1,CHEMBL1165972,Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.,Bioorg. Med. Chem.,2010.0,18,12,4570,4590,10.1016/j.bmc.2010.03.064,20493713.0,
3344856,CHEMBL1164533,N-Butyloxycarbonyl-3-[4-(thiazole-2-carbonyl)-phenyl]-5-iso-butylthiophene-2-sulfonamide,CHEMBL1167163,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM by spectrofluorimetry,Inhibition,=,92.0,%,CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(C(=O)c2nccs2)cc1,CHEMBL1165972,Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.,Bioorg. Med. Chem.,2010.0,18,12,4570,4590,10.1016/j.bmc.2010.03.064,20493713.0,
3344857,CHEMBL1165175,N-Butyloxycarbonyl-3-[4-(1-methyl-1H-imidazole-2-carbonyl)-phenyl]-5-iso-butylthiophene-2-sulfonamide,CHEMBL1167163,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM by spectrofluorimetry,Inhibition,=,38.0,%,CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(C(=O)c2nccn2C)cc1,CHEMBL1165972,Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.,Bioorg. Med. Chem.,2010.0,18,12,4570,4590,10.1016/j.bmc.2010.03.064,20493713.0,
3344858,CHEMBL1165260,N-Butyloxycarbonyl-3-[4-(oxazole-2-carbonyl)-phenyl]-5-iso-butylthiophene-2-sulfonamide,CHEMBL1167163,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM by spectrofluorimetry,Inhibition,=,75.0,%,CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(C(=O)c2ncco2)cc1,CHEMBL1165972,Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.,Bioorg. Med. Chem.,2010.0,18,12,4570,4590,10.1016/j.bmc.2010.03.064,20493713.0,
3344883,CHEMBL189568,butyl (5-isobutylthien-2-yl)sulfonylcarbamate derivative,CHEMBL1167157,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,94.0,%,CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2ccnc2)cc1,CHEMBL1165972,Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.,Bioorg. Med. Chem.,2010.0,18,12,4570,4590,10.1016/j.bmc.2010.03.064,20493713.0,
3383105,CHEMBL1209274,2-acetamido-N-(3-(3-tert-butyl-5-(3-phenylureido)-1H-pyrazol-1-yl)benzyl)acetamide,CHEMBL1211978,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,0.0,%,CC(=O)NCC(=O)NCc1cccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccccc2)c1,CHEMBL1208762,Enhanced selectivity profile of pyrazole-urea based DFG-out p38alpha inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,16,4885,4891,10.1016/j.bmcl.2010.06.073,20620059.0,
3383110,CHEMBL1209564,N-(3-(3-tert-butyl-5-(3-phenylureido)-1H-pyrazol-1-yl)benzyl)-2-(3-methyl-1H-pyrazol-1-yl)acetamide,CHEMBL1211978,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,5.0,%,Cc1ccn(CC(=O)NCc2cccc(-n3nc(C(C)(C)C)cc3NC(=O)Nc3ccccc3)c2)n1,CHEMBL1208762,Enhanced selectivity profile of pyrazole-urea based DFG-out p38alpha inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,16,4885,4891,10.1016/j.bmcl.2010.06.073,20620059.0,
3383111,CHEMBL1209482,N-(3-(3-tert-butyl-5-(3-phenylureido)-1H-pyrazol-1-yl)benzyl)-2-(2-oxopyridin-1(2H)-yl)acetamide,CHEMBL1211978,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,6.0,%,CC(C)(C)c1cc(NC(=O)Nc2ccccc2)n(-c2cccc(CNC(=O)Cn3ccccc3=O)c2)n1,CHEMBL1208762,Enhanced selectivity profile of pyrazole-urea based DFG-out p38alpha inhibitors.,Bioorg. Med. Chem. Lett.,2010.0,20,16,4885,4891,10.1016/j.bmcl.2010.06.073,20620059.0,
3398241,CHEMBL1214750,"(2,4-Dihydroxy-5-isopropyl-phenyl)-(5-dimethylaminomethyl-1,3dihydroisoindol-2-yl)-methanone",CHEMBL1219236,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,50.0,%,CC(C)c1cc(C(=O)N2Cc3ccc(CN(C)C)cc3C2)c(O)cc1O,CHEMBL1212880,"Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.",J. Med. Chem.,2010.0,53,16,5956,5969,10.1021/jm100060b,20662534.0,
3398243,CHEMBL1214827,"(2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(4-methyl-piperazin-1-ylmethyl)-1,3-dihydro-isoindol-2-yl]-methanone",CHEMBL1219236,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,50.0,%,CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O,CHEMBL1212880,"Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.",J. Med. Chem.,2010.0,53,16,5956,5969,10.1021/jm100060b,20662534.0,
3399087,CHEMBL1215912,2-(1-(4-Chlorophenyl)cyclopropyl)-8-ethyl-3-hydroxy-6-(trifluoromethyl)quinoline-4-carboxylic Acid,CHEMBL1219458,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,43.0,%,CCc1cc(C(F)(F)F)cc2c(C(=O)O)c(O)c(C3(c4ccc(Cl)cc4)CC3)nc12,CHEMBL1212936,"Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.",J. Med. Chem.,2010.0,53,16,6003,6017,10.1021/jm9013696,20718494.0,
3399088,CHEMBL1215911,2-(1-(4-Chlorophenyl)cyclopropyl)-3-hydroxy-8-methyl-6-(trifluoromethyl)quinoline-4-carboxylic Acid,CHEMBL1219458,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,42.0,%,Cc1cc(C(F)(F)F)cc2c(C(=O)O)c(O)c(C3(c4ccc(Cl)cc4)CC3)nc12,CHEMBL1212936,"Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.",J. Med. Chem.,2010.0,53,16,6003,6017,10.1021/jm9013696,20718494.0,
3399089,CHEMBL1215906,6-Bromo-2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic Acid,CHEMBL1219458,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,65.0,%,O=C(O)c1c(O)c(C2(c3ccc(Cl)cc3)CC2)nc2c(C(F)(F)F)cc(Br)cc12,CHEMBL1212936,"Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.",J. Med. Chem.,2010.0,53,16,6003,6017,10.1021/jm9013696,20718494.0,
3399090,CHEMBL1215905,6-Chloro-2-(1-(4-chlorophenyl)cyclopropyl)-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic Acid,CHEMBL1219458,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,72.0,%,O=C(O)c1c(O)c(C2(c3ccc(Cl)cc3)CC2)nc2c(C(F)(F)F)cc(Cl)cc12,CHEMBL1212936,"Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.",J. Med. Chem.,2010.0,53,16,6003,6017,10.1021/jm9013696,20718494.0,
3399091,CHEMBL1215904,2-(1-(4-Chlorophenyl)cyclopropyl-6-ethyl-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic Acid,CHEMBL1219458,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,81.0,%,CCc1cc(C(F)(F)F)c2nc(C3(c4ccc(Cl)cc4)CC3)c(O)c(C(=O)O)c2c1,CHEMBL1212936,"Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.",J. Med. Chem.,2010.0,53,16,6003,6017,10.1021/jm9013696,20718494.0,
3399092,CHEMBL1215903,2-(1-(4-Chlorophenyl)cyclopropyl)-3-hydroxy-6-methyl-8-(trifluoromethyl)quinoline-4-carboxylic Acid,CHEMBL1219458,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,72.0,%,Cc1cc(C(F)(F)F)c2nc(C3(c4ccc(Cl)cc4)CC3)c(O)c(C(=O)O)c2c1,CHEMBL1212936,"Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.",J. Med. Chem.,2010.0,53,16,6003,6017,10.1021/jm9013696,20718494.0,
3399093,CHEMBL1215902,"2-(1-(4-Chlorophenyl)cyclopropyl)-3-hydroxy-6,8-dimethylquinoline-4-carboxylic Acid",CHEMBL1219458,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,17.0,%,Cc1cc(C)c2nc(C3(c4ccc(Cl)cc4)CC3)c(O)c(C(=O)O)c2c1,CHEMBL1212936,"Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.",J. Med. Chem.,2010.0,53,16,6003,6017,10.1021/jm9013696,20718494.0,
3399094,CHEMBL1215897,"2-(1-(4-Fluorophenyl)cyclopropyl)-3-hydroxy-6,8-dimethylquinoline-4-carboxylic Acid",CHEMBL1219458,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,55.0,%,Cc1cc(C)c2nc(C3(c4ccc(F)cc4)CC3)c(O)c(C(=O)O)c2c1,CHEMBL1212936,"Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.",J. Med. Chem.,2010.0,53,16,6003,6017,10.1021/jm9013696,20718494.0,
3399095,CHEMBL1215896,"3-Hydroxy-7,8-dimethyl-2-(1-p-tolyl-cyclopropyl)-quinoline-4-carboxylic Acid",CHEMBL1219458,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,47.0,%,Cc1ccc(C2(c3nc4c(C)c(C)ccc4c(C(=O)O)c3O)CC2)cc1,CHEMBL1212936,"Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.",J. Med. Chem.,2010.0,53,16,6003,6017,10.1021/jm9013696,20718494.0,
3399096,CHEMBL1215895,"3-Hydroxy-6,8-dimethyl-2-(1-p-tolylcyclopropyl)quinoline-4-carboxylic Acid",CHEMBL1219458,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,55.0,%,Cc1ccc(C2(c3nc4c(C)cc(C)cc4c(C(=O)O)c3O)CC2)cc1,CHEMBL1212936,"Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.",J. Med. Chem.,2010.0,53,16,6003,6017,10.1021/jm9013696,20718494.0,
3399097,CHEMBL1215894,6-Ethyl-3-hydroxy-2-(1-phenylcyclopropyl)-8-(trifluoromethyl)-quinoline-4-carboxylic Acid,CHEMBL1219458,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,86.0,%,CCc1cc(C(F)(F)F)c2nc(C3(c4ccccc4)CC3)c(O)c(C(=O)O)c2c1,CHEMBL1212936,"Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.",J. Med. Chem.,2010.0,53,16,6003,6017,10.1021/jm9013696,20718494.0,
3399098,CHEMBL1215893,3-Hydroxy-6-methyl-2-(1-phenylcyclopropyl)-8-(trifluoromethyl)-quinoline-4-carboxylic Acid,CHEMBL1219458,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,87.0,%,Cc1cc(C(F)(F)F)c2nc(C3(c4ccccc4)CC3)c(O)c(C(=O)O)c2c1,CHEMBL1212936,"Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.",J. Med. Chem.,2010.0,53,16,6003,6017,10.1021/jm9013696,20718494.0,
3399099,CHEMBL1215887,"3-Hydroxy-6,8-dimethyl-2-(1-phenylcyclopropyl)quinoline-4-carboxylic Acid",CHEMBL1219458,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,54.0,%,Cc1cc(C)c2nc(C3(c4ccccc4)CC3)c(O)c(C(=O)O)c2c1,CHEMBL1212936,"Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.",J. Med. Chem.,2010.0,53,16,6003,6017,10.1021/jm9013696,20718494.0,
3403460,CHEMBL1215403,"Methyl 4-(2-Chloro-4-fluorophenyl)-5-cyano-1,4-dihydro-2,6-dimethylpyridine-3-carboxylate",CHEMBL1219580,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,44.0,%,COC(=O)C1=C(C)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,CHEMBL1212896,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,J. Med. Chem.,2010.0,53,16,5970,5978,10.1021/jm100506y,20672820.0,
3403461,CHEMBL1215406,"Methyl 4-(2-Chlorophenyl)-5-cyano-1,4-dihydro-6-methyl-2-propylpyridine-3-carboxylate",CHEMBL1219580,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,83.0,%,CCCC1=C(C(=O)OC)C(c2ccccc2Cl)C(C#N)=C(C)N1,CHEMBL1212896,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,J. Med. Chem.,2010.0,53,16,5970,5978,10.1021/jm100506y,20672820.0,
3403462,CHEMBL1215550,"Methyl 4-(2-Chloro-4-fluorophenyl)-5-cyano-6-methyl-2-(trifluoromethyl)-1,4-dihydropyridine-3-carboxylate",CHEMBL1219580,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,72.0,%,COC(=O)C1=C(C(F)(F)F)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,CHEMBL1212896,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,J. Med. Chem.,2010.0,53,16,5970,5978,10.1021/jm100506y,20672820.0,
3406877,CHEMBL1215526,"(R)-N-(2-(2-(Dimethylamino)ethoxy)-5-fluoro-4-(1H-pyrazol-4-yl)phenyl)-2-ethyl-1,2,3,4-tetra-hydroisoquinoline-3-carboxamide",CHEMBL1219167,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,70.0,%,CCN1Cc2ccccc2C[C@@H]1C(=O)Nc1cc(F)c(-c2cn[nH]c2)cc1OCCN(C)C,CHEMBL1212924,Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors.,J. Med. Chem.,2010.0,53,15,5727,5737,10.1021/jm100579r,20684608.0,
3406885,CHEMBL1215524,"(R)-N-(2-(2-(Dimethylamino)ethoxy)-5-fluoro-4-(1H-pyrazol-4-yl)phenyl)-1,2,3,4-tetrahydroiso-quinoline-3-carboxamide",CHEMBL1219167,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,62.0,%,CN(C)CCOc1cc(-c2cn[nH]c2)c(F)cc1NC(=O)[C@H]1Cc2ccccc2CN1,CHEMBL1212924,Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors.,J. Med. Chem.,2010.0,53,15,5727,5737,10.1021/jm100579r,20684608.0,
3407935,CHEMBL1215304,"(R)-6-Methoxy-N-(2-((1-methylpiperidin-4-yl)methoxy)-4-(1Hpyrazol-4-yl)phenyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide",CHEMBL1219167,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,45.0,%,COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCC1CCN(C)CC1)NC2,CHEMBL1212924,Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors.,J. Med. Chem.,2010.0,53,15,5727,5737,10.1021/jm100579r,20684608.0,
3407950,CHEMBL1215171,"(R)-N-(2-(2-(Dimethylamino)ethoxy)-4-(1H-pyrazol-4-yl)-phenyl)-6-methoxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxamide",CHEMBL1219167,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,31.0,%,COc1ccc2c(c1)C[C@H](C(=O)Nc1ccc(-c3cn[nH]c3)cc1OCCN(C)C)NC2,CHEMBL1212924,Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors.,J. Med. Chem.,2010.0,53,15,5727,5737,10.1021/jm100579r,20684608.0,
3433344,CHEMBL370595,5-chloro-2-(2-chloro-4-nitrophenoxy)phenol,CHEMBL1246349,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,>,85.0,%,O=[N+]([O-])c1ccc(Oc2ccc(Cl)cc2O)c(Cl)c1,CHEMBL1240506,Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase.,J. Med. Chem.,2010.0,53,17,6287,6300,10.1021/jm9017724,20698542.0,
3433348,CHEMBL1234746,3-chloro-4-(2-hydroxy-4-propylphenoxy)benzonitrile,CHEMBL1246349,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,>,85.0,%,CCCc1ccc(Oc2ccc(C#N)cc2Cl)c(O)c1,CHEMBL1240506,Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase.,J. Med. Chem.,2010.0,53,17,6287,6300,10.1021/jm9017724,20698542.0,
5125279,CHEMBL1645007,(3-(3-phenylprop-1-ynyl)phenyl)(4-(pyridin-2-yl)piperazin-1-yl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,2.0,%,O=C(c1cccc(C#CCc2ccccc2)c1)N1CCN(c2ccccn2)CC1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125280,CHEMBL1645020,(4-methoxy-3-(pyridin-2-ylethynyl)phenyl)(4-(pyrimidin-4-yl)piperazin-1-yl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,14.0,%,COc1ccc(C(=O)N2CCN(c3ccncn3)CC2)cc1C#Cc1ccccn1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125281,CHEMBL1645019,(4-methoxy-3-(pyridin-2-ylethynyl)phenyl)(4-(pyridin-2-yl)piperazin-1-yl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,16.0,%,COc1ccc(C(=O)N2CCN(c3ccccn3)CC2)cc1C#Cc1ccccn1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125282,CHEMBL1645008,(4-(pyridin-2-yl)piperazin-1-yl)(3-(pyridin-2-ylethynyl)phenyl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,22.0,%,O=C(c1cccc(C#Cc2ccccn2)c1)N1CCN(c2ccccn2)CC1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125283,CHEMBL1645021,(4-methoxy-3-((6-methylpyridin-2-yl)ethynyl)phenyl)(4-(pyridin-2-yl)piperazin-1-yl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,28.0,%,COc1ccc(C(=O)N2CCN(c3ccccn3)CC2)cc1C#Cc1cccc(C)n1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125284,CHEMBL1645023,(4-methoxy-3-(pyridin-2-ylethynyl)phenyl)(4-(5-methylpyridin-2-yl)piperazin-1-yl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,29.0,%,COc1ccc(C(=O)N2CCN(c3ccc(C)cn3)CC2)cc1C#Cc1ccccn1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125285,CHEMBL1645022,(4-methoxy-3-(thiazol-2-ylethynyl)phenyl)(4-(pyridin-2-yl)piperazin-1-yl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,33.0,%,COc1ccc(C(=O)N2CCN(c3ccccn3)CC2)cc1C#Cc1nccs1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125286,CHEMBL1645013,(4-methoxy-3-(phenylethynyl)phenyl)(4-(pyrazin-2-yl)piperazin-1-yl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,34.0,%,COc1ccc(C(=O)N2CCN(c3cnccn3)CC2)cc1C#Cc1ccccc1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125287,CHEMBL1645009,(3-(phenylethynyl)phenyl)(4-(pyrazin-2-yl)piperazin-1-yl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,35.0,%,O=C(c1cccc(C#Cc2ccccc2)c1)N1CCN(c2cnccn2)CC1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125288,CHEMBL1645018,(3-((3-chlorophenyl)ethynyl)-4-methoxyphenyl)(4-(pyrimidin-4-yl)piperazin-1-yl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,43.0,%,COc1ccc(C(=O)N2CCN(c3ccncn3)CC2)cc1C#Cc1cccc(Cl)c1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125289,CHEMBL1645002,(3-(phenylethynyl)phenyl)(4-(pyridin-2-yl)piperazin-1-yl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,50.0,%,O=C(c1cccc(C#Cc2ccccc2)c1)N1CCN(c2ccccn2)CC1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125290,CHEMBL1645017,(4-methyl-3-(phenylethynyl)phenyl)(4-(pyrazin-2-yl)piperazin-1-yl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,50.0,%,Cc1ccc(C(=O)N2CCN(c3cnccn3)CC2)cc1C#Cc1ccccc1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125291,CHEMBL1645014,(4-methoxy-3-(phenylethynyl)phenyl)(4-(pyrimidin-4-yl)piperazin-1-yl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,53.0,%,COc1ccc(C(=O)N2CCN(c3ccncn3)CC2)cc1C#Cc1ccccc1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125292,CHEMBL1645012,(4-methoxy-3-(phenylethynyl)phenyl)(4-(pyridin-2-yl)piperazin-1-yl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,55.0,%,COc1ccc(C(=O)N2CCN(c3ccccn3)CC2)cc1C#Cc1ccccc1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125293,CHEMBL1645004,(3-((3-aminophenyl)ethynyl)phenyl)(4-(pyridin-2-yl)piperazin-1-yl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,58.0,%,Nc1cccc(C#Cc2cccc(C(=O)N3CCN(c4ccccn4)CC3)c2)c1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125294,CHEMBL1645003,(3-((3-methoxyphenyl)ethynyl)phenyl)(4-(pyridin-2-yl)piperazin-1-yl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,60.0,%,COc1cccc(C#Cc2cccc(C(=O)N3CCN(c4ccccn4)CC3)c2)c1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125295,CHEMBL1645006,(4-(pyridin-2-yl)piperazin-1-yl)(3-(p-tolylethynyl)phenyl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,65.0,%,Cc1ccc(C#Cc2cccc(C(=O)N3CCN(c4ccccn4)CC3)c2)cc1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125296,CHEMBL1645011,(4-(5-methylpyridin-2-yl)piperazin-1-yl)(3-(phenylethynyl)phenyl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,67.0,%,Cc1ccc(N2CCN(C(=O)c3cccc(C#Cc4ccccc4)c3)CC2)nc1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125297,CHEMBL1645016,(4-methyl-3-(phenylethynyl)phenyl)(4-(pyridin-2-yl)piperazin-1-yl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,69.0,%,Cc1ccc(C(=O)N2CCN(c3ccccn3)CC2)cc1C#Cc1ccccc1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125298,CHEMBL1645015,(4-methoxy-3-(phenylethynyl)phenyl)(4-(5-methylpyridin-2-yl)piperazin-1-yl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,72.0,%,COc1ccc(C(=O)N2CCN(c3ccc(C)cn3)CC2)cc1C#Cc1ccccc1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125299,CHEMBL1645010,(3-(phenylethynyl)phenyl)(4-(pyrimidin-4-yl)piperazin-1-yl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,75.0,%,O=C(c1cccc(C#Cc2ccccc2)c1)N1CCN(c2ccncn2)CC1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5125300,CHEMBL1645005,(3-((4-methoxyphenyl)ethynyl)phenyl)(4-(pyridin-2-yl)piperazin-1-yl)methanone,CHEMBL1646003,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,79.0,%,COc1ccc(C#Cc2cccc(C(=O)N3CCN(c4ccccn4)CC3)c2)cc1,CHEMBL1641557,3-(Pyridin-2-yl-ethynyl)benzamide metabotropic glutamate receptor 5 negative allosteric modulators: hit to lead studies.,Bioorg. Med. Chem. Lett.,2011.0,21,1,195,199,10.1016/j.bmcl.2010.11.038,21126874.0,
5140548,CHEMBL1641802,2-(3-1H-indazol-5-ylureido)-5-tert-butyl-N-(2-hydroxyethyl)thiophene-3-carboxamide,CHEMBL1646061,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM by LC/MS/MS analysis,Inhibition,=,30.0,%,CC(C)(C)c1cc(C(=O)NCCO)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1,CHEMBL1641460,Potent and selective thiophene urea-templated inhibitors of S6K.,Bioorg. Med. Chem. Lett.,2011.0,21,2,849,852,10.1016/j.bmcl.2010.11.069,21185721.0,
5140549,CHEMBL1641801,2-(3-1H-indazol-5-ylureido)-5-tert-butyl-N-(2-methoxyethyl)thiophene-3-carboxamide,CHEMBL1646061,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM by LC/MS/MS analysis,Inhibition,=,14.0,%,COCCNC(=O)c1cc(C(C)(C)C)sc1NC(=O)Nc1ccc2[nH]ncc2c1,CHEMBL1641460,Potent and selective thiophene urea-templated inhibitors of S6K.,Bioorg. Med. Chem. Lett.,2011.0,21,2,849,852,10.1016/j.bmcl.2010.11.069,21185721.0,
5140550,CHEMBL1641800,2-(3-1H-indazol-5-ylureido)-5-tert-butyl-N-cyclopropylthiophene-3-carboxamide,CHEMBL1646061,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM by LC/MS/MS analysis,Inhibition,=,11.0,%,CC(C)(C)c1cc(C(=O)NC2CC2)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1,CHEMBL1641460,Potent and selective thiophene urea-templated inhibitors of S6K.,Bioorg. Med. Chem. Lett.,2011.0,21,2,849,852,10.1016/j.bmcl.2010.11.069,21185721.0,
5140551,CHEMBL1641799,2-(3-1H-indazol-5-ylureido)-5-tert-butylthiophene-3-carboxylic acid,CHEMBL1646061,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM by LC/MS/MS analysis,Inhibition,=,55.0,%,CC(C)(C)c1cc(C(=O)O)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1,CHEMBL1641460,Potent and selective thiophene urea-templated inhibitors of S6K.,Bioorg. Med. Chem. Lett.,2011.0,21,2,849,852,10.1016/j.bmcl.2010.11.069,21185721.0,
5140552,CHEMBL1641798,1-(5-tert-butylthiophen-2-yl)-3-(1H-indazol-5-yl)urea,CHEMBL1646061,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM by LC/MS/MS analysis,Inhibition,=,52.0,%,CC(C)(C)c1ccc(NC(=O)Nc2ccc3[nH]ncc3c2)s1,CHEMBL1641460,Potent and selective thiophene urea-templated inhibitors of S6K.,Bioorg. Med. Chem. Lett.,2011.0,21,2,849,852,10.1016/j.bmcl.2010.11.069,21185721.0,
5140553,CHEMBL1641790,1-(5-tert-butyl-3-((2-(dimethylamino)ethyl)carbamoyl)thiophen-2-yl)-3-(1H-indazol-5-yl)urea,CHEMBL1646061,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM by LC/MS/MS analysis,Inhibition,=,0.0,%,CN(C)CCNC(=O)c1cc(C(C)(C)C)sc1NC(=O)Nc1ccc2[nH]ncc2c1,CHEMBL1641460,Potent and selective thiophene urea-templated inhibitors of S6K.,Bioorg. Med. Chem. Lett.,2011.0,21,2,849,852,10.1016/j.bmcl.2010.11.069,21185721.0,
5151154,CHEMBL1651461,2-Benzyl-4-(5-methyl-1H-pyrazol-3-ylamino)-2H-phthalazin-1-one,CHEMBL1656345,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,42.0,%,Cc1cc(Nc2nn(Cc3ccccc3)c(=O)c3ccccc23)n[nH]1,CHEMBL1649093,"Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase.",J. Med. Chem.,2011.0,54,1,312,319,10.1021/jm101346r,21128645.0,
5151165,CHEMBL1651489,2-Isopropyl-4-(5-methyl-1H-pyrazol-3-ylamino)-2H-phthalazin-1-one,CHEMBL1656345,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,>,50.0,%,Cc1cc(Nc2nn(C(C)C)c(=O)c3ccccc23)n[nH]1,CHEMBL1649093,"Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase.",J. Med. Chem.,2011.0,54,1,312,319,10.1021/jm101346r,21128645.0,
5151167,CHEMBL1615165,4-(5-Methyl-2H-pyrazole-3-ylamino)phenyl-2H-phthalazin-1-one,CHEMBL1656345,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,>,50.0,%,Cc1cc(Nc2nn(-c3ccccc3)c(=O)c3ccccc23)n[nH]1,CHEMBL1649093,"Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase.",J. Med. Chem.,2011.0,54,1,312,319,10.1021/jm101346r,21128645.0,
5236339,CHEMBL1683506,"(R)-2-(4-(((S)-3-((R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)thiazolidine-2-carboxamido)methyl)phenylamino)-3-methylbutanoic acid hydrochloride",CHEMBL1686389,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,26.8,%,CC(C)[C@@H](Nc1ccc(CNC(=O)[C@@H]2SCCN2C(=O)C[C@H](N)Cc2cc(F)c(F)cc2F)cc1)C(=O)O.Cl,CHEMBL1681678,Discovery of β-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors.,Bioorg. Med. Chem. Lett.,2011.0,21,5,1366,1370,10.1016/j.bmcl.2011.01.041,21306895.0,
5240921,CHEMBL1683575,1-(4-chlorobenzyl)-N-(diaminomethylene)-5-methyl-1H-imidazole-4-carboxamide,CHEMBL1685370,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,<,1.0,%,Cc1c(C(=O)N=C(N)N)ncn1Cc1ccc(Cl)cc1,CHEMBL1681746,"N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors.",Bioorg. Med. Chem. Lett.,2011.0,21,6,1621,1625,10.1016/j.bmcl.2011.01.113,21324691.0,
5310531,CHEMBL1688889,"1-(6-((2-(Dimethylamino)ethyl)(methyl)amino)-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carbonyl)-3-(3-isopropoxyphenyl)urea Hydrochloride",CHEMBL1693916,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 1 uM,Inhibition,=,11.0,%,Cc1nn(C)c2nc(N(C)CCN(C)C)c(C(=O)NC(=O)Nc3cccc(OC(C)C)c3)cc12.Cl,CHEMBL1687928,"Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.",J. Med. Chem.,2011.0,54,6,1667,1681,10.1021/jm1012903,21341682.0,
5310532,CHEMBL1688889,"1-(6-((2-(Dimethylamino)ethyl)(methyl)amino)-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carbonyl)-3-(3-isopropoxyphenyl)urea Hydrochloride",CHEMBL1693917,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 100 uM,Inhibition,=,36.0,%,Cc1nn(C)c2nc(N(C)CCN(C)C)c(C(=O)NC(=O)Nc3cccc(OC(C)C)c3)cc12.Cl,CHEMBL1687928,"Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.",J. Med. Chem.,2011.0,54,6,1667,1681,10.1021/jm1012903,21341682.0,
6164079,CHEMBL1765205,"8-Pyridin-3-yl-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one",CHEMBL1768380,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect microsomes at 10 uM,Inhibition,=,41.0,%,O=C1CCc2cc(-c3cccnc3)cc3c2N1CC3,CHEMBL1765045,"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.",J. Med. Chem.,2011.0,54,7,2307,2319,10.1021/jm101470k,21384875.0,
6164080,CHEMBL1765206,"9-Pyridin-3-yl-1,2,6,7-tetrahydro-5H-pyrido[3,2,1-ij]quinolin-3-one",CHEMBL1768380,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect microsomes at 10 uM,Inhibition,=,40.0,%,O=C1CCc2cc(-c3cccnc3)cc3c2N1CCC3,CHEMBL1765045,"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.",J. Med. Chem.,2011.0,54,7,2307,2319,10.1021/jm101470k,21384875.0,
6164081,CHEMBL1765207,"8-(5-Methoxypyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one",CHEMBL1768380,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect microsomes at 10 uM,Inhibition,=,42.0,%,COc1cncc(-c2cc3c4c(c2)CCN4C(=O)CC3)c1,CHEMBL1765045,"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.",J. Med. Chem.,2011.0,54,7,2307,2319,10.1021/jm101470k,21384875.0,
6164082,CHEMBL1765208,"9-(5-Methoxypyridin-3-yl)-1,2,6,7-tetrahydro-5H-pyrido[3,2,1-ij]quinolin-3-one",CHEMBL1768380,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect microsomes at 10 uM,Inhibition,=,63.0,%,COc1cncc(-c2cc3c4c(c2)CCC(=O)N4CCC3)c1,CHEMBL1765045,"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.",J. Med. Chem.,2011.0,54,7,2307,2319,10.1021/jm101470k,21384875.0,
6164083,CHEMBL1765215,"9-Isoquinolin-4-yl-1,2,6,7-tetrahydro-5H-pyrido[3,2,1-ij]quinolin-3-one",CHEMBL1768380,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect microsomes at 10 uM,Inhibition,=,97.0,%,O=C1CCc2cc(-c3cncc4ccccc34)cc3c2N1CCC3,CHEMBL1765045,"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.",J. Med. Chem.,2011.0,54,7,2307,2319,10.1021/jm101470k,21384875.0,
6164084,CHEMBL1765221,"8-[5-(3-Fluorophenyl)-pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo-[3,2,1-ij]quinolin-4-one",CHEMBL1768380,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect microsomes at 10 uM,Inhibition,=,79.0,%,O=C1CCc2cc(-c3cncc(-c4cccc(F)c4)c3)cc3c2N1CC3,CHEMBL1765045,"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.",J. Med. Chem.,2011.0,54,7,2307,2319,10.1021/jm101470k,21384875.0,
6164085,CHEMBL1765205,"8-Pyridin-3-yl-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one",CHEMBL1768381,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect microsomes at 1 uM,Inhibition,=,6.0,%,O=C1CCc2cc(-c3cccnc3)cc3c2N1CC3,CHEMBL1765045,"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.",J. Med. Chem.,2011.0,54,7,2307,2319,10.1021/jm101470k,21384875.0,
6164086,CHEMBL1765206,"9-Pyridin-3-yl-1,2,6,7-tetrahydro-5H-pyrido[3,2,1-ij]quinolin-3-one",CHEMBL1768381,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect microsomes at 1 uM,Inhibition,=,19.0,%,O=C1CCc2cc(-c3cccnc3)cc3c2N1CCC3,CHEMBL1765045,"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.",J. Med. Chem.,2011.0,54,7,2307,2319,10.1021/jm101470k,21384875.0,
6164087,CHEMBL1765207,"8-(5-Methoxypyridin-3-yl)-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one",CHEMBL1768381,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect microsomes at 1 uM,Inhibition,=,23.0,%,COc1cncc(-c2cc3c4c(c2)CCN4C(=O)CC3)c1,CHEMBL1765045,"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.",J. Med. Chem.,2011.0,54,7,2307,2319,10.1021/jm101470k,21384875.0,
6164088,CHEMBL1765208,"9-(5-Methoxypyridin-3-yl)-1,2,6,7-tetrahydro-5H-pyrido[3,2,1-ij]quinolin-3-one",CHEMBL1768381,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect microsomes at 1 uM,Inhibition,=,34.0,%,COc1cncc(-c2cc3c4c(c2)CCC(=O)N4CCC3)c1,CHEMBL1765045,"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.",J. Med. Chem.,2011.0,54,7,2307,2319,10.1021/jm101470k,21384875.0,
6164089,CHEMBL1765215,"9-Isoquinolin-4-yl-1,2,6,7-tetrahydro-5H-pyrido[3,2,1-ij]quinolin-3-one",CHEMBL1768381,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect microsomes at 1 uM,Inhibition,=,73.0,%,O=C1CCc2cc(-c3cncc4ccccc34)cc3c2N1CCC3,CHEMBL1765045,"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.",J. Med. Chem.,2011.0,54,7,2307,2319,10.1021/jm101470k,21384875.0,
6164090,CHEMBL1765221,"8-[5-(3-Fluorophenyl)-pyridin-3-yl]-1,2,5,6-tetrahydro-4H-pyrrolo-[3,2,1-ij]quinolin-4-one",CHEMBL1768381,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect microsomes at 1 uM,Inhibition,=,39.0,%,O=C1CCc2cc(-c3cncc(-c4cccc(F)c4)c3)cc3c2N1CC3,CHEMBL1765045,"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.",J. Med. Chem.,2011.0,54,7,2307,2319,10.1021/jm101470k,21384875.0,
6166300,CHEMBL1766003,"3-Imidazol-1-yl-2,2-dimethyl-3-[4-(naphthalen-1-ylamino)-phenyl]-propionic acid Methyl Ester",CHEMBL1768199,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 0.4 uM,Inhibition,=,48.0,%,COC(=O)C(C)(C)C(c1ccc(Nc2cccc3ccccc23)cc1)n1ccnc1,CHEMBL1764976,Small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26): synthesis and biological evaluation of imidazole methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates.,J. Med. Chem.,2011.0,54,8,2778,2791,10.1021/jm101583w,21428449.0,
6166301,CHEMBL1766005,3-Imidazol-1-yl-2-methyl-3-[4-(naphthalen-2-ylamino)-phenyl]-propionic acid Methyl Ester,CHEMBL1768199,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 0.4 uM,Inhibition,=,41.0,%,COC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1ccnc1,CHEMBL1764976,Small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26): synthesis and biological evaluation of imidazole methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates.,J. Med. Chem.,2011.0,54,8,2778,2791,10.1021/jm101583w,21428449.0,
6166302,CHEMBL1766008,"3-[4-(Benzooxazol-2-ylamino)-phenyl]-3-imidazol-1-yl-2,2-dimethylpropionic acid Methyl Ester",CHEMBL1768199,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 0.4 uM,Inhibition,=,45.0,%,COC(=O)C(C)(C)C(c1ccc(Nc2nc3ccccc3o2)cc1)n1ccnc1,CHEMBL1764976,Small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26): synthesis and biological evaluation of imidazole methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates.,J. Med. Chem.,2011.0,54,8,2778,2791,10.1021/jm101583w,21428449.0,
6166303,CHEMBL1766009,"3-[4-(Benzothiazol-2-ylamino)-phenyl]-3-imidazol-1-yl-2,2-dimethylpropionic acidMethyl Ester",CHEMBL1768199,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 0.4 uM,Inhibition,=,87.0,%,COC(=O)C(C)(C)C(c1ccc(Nc2nc3ccccc3s2)cc1)n1ccnc1,CHEMBL1764976,Small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26): synthesis and biological evaluation of imidazole methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates.,J. Med. Chem.,2011.0,54,8,2778,2791,10.1021/jm101583w,21428449.0,
6178470,CHEMBL1771472,"(S)-N-((3-(4-([1,2,4]triazolo[4,3-a]pyrimidin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)ethanethioamide",CHEMBL1771821,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,15.0,%,CC(=S)NC[C@H]1CN(c2ccc(-c3nnc4ncccn34)cc2)C(=O)O1,CHEMBL1770134,"Synthesis and in vitro activity of novel 1,2,4-triazolo[4,3-a]pyrimidine oxazolidinone antibacterial agents.",Bioorg. Med. Chem. Lett.,2011.0,21,10,2887,2889,10.1016/j.bmcl.2011.03.075,21507643.0,
6181385,CHEMBL1770750,"6-(4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline",CHEMBL1772189,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,35.0,%,CN1CCN(c2ccc(-c3ccc4c(c3)CCNC4)cc2C(F)(F)F)CC1,CHEMBL1770137,High concentration electrophysiology-based fragment screen: discovery of novel acid-sensing ion channel 3 (ASIC3) inhibitors.,Bioorg. Med. Chem. Lett.,2011.0,21,9,2646,2649,10.1016/j.bmcl.2010.12.115,21257308.0,
6181386,CHEMBL1770752,6-methyl-N-(4-(6-(piperazin-1-yl)pyridin-3-yl)phenyl)pyridin-2-amine,CHEMBL1772189,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,45.0,%,Cc1cccc(Nc2ccc(-c3ccc(N4CCNCC4)nc3)cc2)n1,CHEMBL1770137,High concentration electrophysiology-based fragment screen: discovery of novel acid-sensing ion channel 3 (ASIC3) inhibitors.,Bioorg. Med. Chem. Lett.,2011.0,21,9,2646,2649,10.1016/j.bmcl.2010.12.115,21257308.0,
6210810,CHEMBL1738703,"(16S)-5,5,9,16-tetramethyl-7-oxo-2,14,17-triazatetracyclo[16.3.1.0^{2,10}.0^{3,8}]docosa-1(22),3(8),9,18,20-pentaene-19-carboxamide",CHEMBL1780619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,25.0,%,Cc1c2c(n3c1CCCNC[C@H](C)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1777689,Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,12,3627,3631,10.1016/j.bmcl.2011.04.102,21605975.0,
6210811,CHEMBL1778208,"(16S)-5,5,9,16-tetramethyl-7,15-dioxo-2,14,17-triazatetracyclo[16.3.1.0^{2,10}.0^{3,8}]docosa-1(22),3(8),9,18,20-pentaene-19-carboxamide",CHEMBL1780619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,23.0,%,Cc1c2c(n3c1CCCNC(=O)[C@H](C)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1777689,Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,12,3627,3631,10.1016/j.bmcl.2011.04.102,21605975.0,
6210812,CHEMBL1738705,"(18R)-5,5,9-trimethyl-7-oxo-2,14,20-triazapentacyclo[19.3.1.0^{2,10}.0^{3,8}.0^{14,18}]pentacosa-1(25),3(8),9,21,23-pentaene-22-carboxamide",CHEMBL1780619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,6.0,%,Cc1c2c(n3c1CCCN1CCC[C@@H]1CNc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1777689,Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,12,3627,3631,10.1016/j.bmcl.2011.04.102,21605975.0,
6210814,CHEMBL1779532,"(19R)-5,5,9-trimethyl-7-oxo-2,14,21-triazapentacyclo[20.3.1.0^{2,10}.0^{3,8}.0^{14,19}]hexacosa-1(26),3(8),9,22,24-pentaene-23-carboxamide",CHEMBL1780619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,0.0,%,Cc1c2c(n3c1CCCN1CCCC[C@@H]1CNc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1777689,Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,12,3627,3631,10.1016/j.bmcl.2011.04.102,21605975.0,
6210815,CHEMBL1779533,"(19S)-5,5,9-trimethyl-7-oxo-17-oxa-2,14,21-triazapentacyclo[20.3.1.0^{2,10}.0^{3,8}.0^{14,19}]hexacosa-1(26),3(8),9,22,24-pentaene-23-carboxamide",CHEMBL1780619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,39.0,%,Cc1c2c(n3c1CCCN1CCOC[C@@H]1CNc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1777689,Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,12,3627,3631,10.1016/j.bmcl.2011.04.102,21605975.0,
6210816,CHEMBL1779534,"(19S)-5,5,9-trimethyl-7-oxo-2,14,17,21-tetraazapentacyclo[20.3.1.0^{2,10}.0^{3,8}.0^{14,19}]hexacosa-1(26),3(8),9,22,24-pentaene-23-carboxamide",CHEMBL1780619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,12.0,%,Cc1c2c(n3c1CCCN1CCNC[C@H]1CNc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1777689,Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,12,3627,3631,10.1016/j.bmcl.2011.04.102,21605975.0,
6210817,CHEMBL1779535,"(19S)-17-acetyl-5,5,9-trimethyl-7-oxo-2,14,17,21-tetraazapentacyclo[20.3.1.0^{2,10}.0^{3,8}.0^{14,19}]hexacosa-1(26),3(8),9,22,24-pentaene-23-carboxamide",CHEMBL1780619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,15.0,%,CC(=O)N1CCN2CCCc3c(C)c4c(n3-c3ccc(C(N)=O)c(c3)NC[C@H]2C1)CC(C)(C)CC4=O,CHEMBL1777689,Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,12,3627,3631,10.1016/j.bmcl.2011.04.102,21605975.0,
6210818,CHEMBL1779536,"(17R)-5,5,9-trimethyl-7-oxo-2,14,19-triazapentacyclo[18.3.1.1^{14,17}.0^{2,10}.0^{3,8}]pentacosa-1(24),3(8),9,20,22-pentaene-21-carboxamide",CHEMBL1780619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,2.0,%,Cc1c2c(n3c1CCCN1CC[C@H](CNc4cc-3ccc4C(N)=O)C1)CC(C)(C)CC2=O,CHEMBL1777689,Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,12,3627,3631,10.1016/j.bmcl.2011.04.102,21605975.0,
6210820,CHEMBL1779538,"(16R,18R)-16-hydroxy-5,5,9-trimethyl-7-oxo-2,14,20-triazapentacyclo[19.3.1.0^{2,10}.0^{3,8}.0^{14,18}]pentacosa-1(25),3(8),9,21,23-pentaene-22-carboxamide",CHEMBL1780619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,9.0,%,Cc1c2c(n3c1CCCN1C[C@H](O)C[C@@H]1CNc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1777689,Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,12,3627,3631,10.1016/j.bmcl.2011.04.102,21605975.0,
6210821,CHEMBL1779539,"(16S,18R)-16-fluoro-5,5,9-trimethyl-7-oxo-2,14,20-triazapentacyclo[19.3.1.0^{2,10}.0^{3,8}.0^{14,18}]pentacosa-1(25),3(8),9,21,23-pentaene-22-carboxamide",CHEMBL1780619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,46.0,%,Cc1c2c(n3c1CCCN1C[C@@H](F)C[C@@H]1CNc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1777689,Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,12,3627,3631,10.1016/j.bmcl.2011.04.102,21605975.0,
6210823,CHEMBL1779541,"(16S,18R)-5,5,9-trimethyl-7-oxo-16-(pyrrolidin-1-yl)-2,14,20-triazapentacyclo[19.3.1.0^{2,10}.0^{3,8}.0^{14,18}]pentacosa-1(25),3(8),9,21,23-pentaene-22-carboxamide",CHEMBL1780619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,3.0,%,Cc1c2c(n3c1CCCN1C[C@@H](N4CCCC4)C[C@@H]1CNc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1777689,Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,12,3627,3631,10.1016/j.bmcl.2011.04.102,21605975.0,
6210824,CHEMBL1779542,"(17R)-5,5,9-trimethyl-7-oxo-2,13,19-triazapentacyclo[18.3.1.0^{2,10}.0^{3,8}.0^{13,17}]tetracosa-1(24),3(8),9,20,22-pentaene-21-carboxamide",CHEMBL1780619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,0.0,%,Cc1c2c(n3c1CCN1CCC[C@@H]1CNc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1777689,Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,12,3627,3631,10.1016/j.bmcl.2011.04.102,21605975.0,
6210825,CHEMBL1779543,"(19R)-5,5,9-trimethyl-7-oxo-2,15,21-triazapentacyclo[20.3.1.0^{2,10}.0^{3,8}.0^{15,19}]hexacosa-1(26),3(8),9,22,24-pentaene-23-carboxamide",CHEMBL1780619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,0.0,%,Cc1c2c(n3c1CCCCN1CCC[C@@H]1CNc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1777689,Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,12,3627,3631,10.1016/j.bmcl.2011.04.102,21605975.0,
6210827,CHEMBL1779545,"(19R,20S)-5,5,9,20-tetramethyl-7-oxo-2,14,21-triazapentacyclo[20.3.1.0^{2,10}.0^{3,8}.0^{14,19}]hexacosa-1(26),3(8),9,22,24-pentaene-23-carboxamide",CHEMBL1780619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,4.0,%,Cc1c2c(n3c1CCCN1CCCC[C@@H]1[C@H](C)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1777689,Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,12,3627,3631,10.1016/j.bmcl.2011.04.102,21605975.0,
6210828,CHEMBL1779546,"(17S)-5,5,9-trimethyl-7-oxo-2,14,18-triazapentacyclo[17.3.1.1^{14,17}.0^{2,10}.0^{3,8}]tetracosa-1(23),3(8),9,19,21-pentaene-20-carboxamide",CHEMBL1780619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,25.0,%,Cc1c2c(n3c1CCCN1CC[C@@H](C1)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1777689,Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,12,3627,3631,10.1016/j.bmcl.2011.04.102,21605975.0,
6210829,CHEMBL1779547,"(18S)-5,5,9-trimethyl-7-oxo-2,14,19-triazapentacyclo[18.3.1.1^{14,18}.0^{2,10}.0^{3,8}]pentacosa-1(24),3(8),9,20,22-pentaene-21-carboxamide",CHEMBL1780619,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,74.0,%,Cc1c2c(n3c1CCCN1CCC[C@@H](C1)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1777689,Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,12,3627,3631,10.1016/j.bmcl.2011.04.102,21605975.0,
6212761,CHEMBL1782567,"cis-((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxytetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(2-(trifluoromethyl)pyridin-4-yl)piperazin-1-yl)methanone",CHEMBL1786263,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,<,3.0,%,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2CCN(c3ccnc(C(F)(F)F)c3)CC2)(C(C)C)C1,CHEMBL1782039,"Discovery of ((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxy-tetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(5-(trifluoromethyl)pyridazin-3-yl)piperazin-1-yl)methanone, PF-4254196, a CCR2 antagonist with an improved cardiovascular profile.",Bioorg. Med. Chem. Lett.,2011.0,21,9,2626,2630,10.1016/j.bmcl.2011.01.034,21315584.0,
6212762,CHEMBL1782572,"cis-(((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxy-tetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(5-(trifluoromethyl)pyridazin-3-yl)piperazin-1-yl)methanone)",CHEMBL1786263,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,<,3.0,%,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@@](C(=O)N2CCN(c3cc(C(F)(F)F)cnn3)CC2)(C(C)C)C1,CHEMBL1782039,"Discovery of ((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxy-tetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(5-(trifluoromethyl)pyridazin-3-yl)piperazin-1-yl)methanone, PF-4254196, a CCR2 antagonist with an improved cardiovascular profile.",Bioorg. Med. Chem. Lett.,2011.0,21,9,2626,2630,10.1016/j.bmcl.2011.01.034,21315584.0,
6271872,CHEMBL1801504,"4-((2-Cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one",CHEMBL1805941,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at >60 uM,Inhibition,<,50.0,%,O=c1cc(Cn2c(C3CCC3)nc3nccnc32)c2ccc(F)c(F)c2[nH]1,CHEMBL1800057,"Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) part 2: identification of a novel, potent, and selective series of benzimidazole-quinolinone iNOS/nNOS dimerization inhibitors that are orally active in pain models.",J. Med. Chem.,2010.0,53,21,7739,7755,10.1021/jm100828n,20931971.0,
6271873,CHEMBL1801060,"4-((2-Cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-8-fluoroquinolin-2(1H)-one",CHEMBL1805941,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at >60 uM,Inhibition,<,50.0,%,O=c1cc(Cn2c(C3CCC3)nc3nccnc32)c2cccc(F)c2[nH]1,CHEMBL1800057,"Discovery of dual inducible/neuronal nitric oxide synthase (iNOS/nNOS) inhibitor development candidate 4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one (KD7332) part 2: identification of a novel, potent, and selective series of benzimidazole-quinolinone iNOS/nNOS dimerization inhibitors that are orally active in pain models.",J. Med. Chem.,2010.0,53,21,7739,7755,10.1021/jm100828n,20931971.0,
6286751,CHEMBL1807797,"(15R,16S)-13-acetyl-5,5,9,15,16-pentamethyl-7-oxo-2,13,17-triazatetracyclo[16.3.1.0^{2,10}.0^{3,8}]docosa-1(22),3(8),9,18,20-pentaene-19-carboxamide",CHEMBL1810581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,27.0,%,CC(=O)N1CCc2c(C)c3c(n2-c2ccc(C(N)=O)c(c2)N[C@@H](C)[C@H](C)C1)CC(C)(C)CC3=O,CHEMBL1806368,Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,15,4602,4607,10.1016/j.bmcl.2011.05.102,21715165.0,
6286752,CHEMBL1807799,"(15R,16S)-13-(2-aminoacetyl)-5,5,9,15,16-pentamethyl-7-oxo-2,13,17-triazatetracyclo[16.3.1.0^{2,10}.0^{3,8}]docosa-1(22),3(8),9,18,20-pentaene-19-carboxamide",CHEMBL1810581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,100.0,%,Cc1c2c(n3c1CCN(C(=O)CN)C[C@@H](C)[C@H](C)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1806368,Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,15,4602,4607,10.1016/j.bmcl.2011.05.102,21715165.0,
6286753,CHEMBL1738703,"(16S)-5,5,9,16-tetramethyl-7-oxo-2,14,17-triazatetracyclo[16.3.1.0^{2,10}.0^{3,8}]docosa-1(22),3(8),9,18,20-pentaene-19-carboxamide",CHEMBL1810581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,25.0,%,Cc1c2c(n3c1CCCNC[C@H](C)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1806368,Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,15,4602,4607,10.1016/j.bmcl.2011.05.102,21715165.0,
6286754,CHEMBL1760603,"(16S)-5,5,9,16-tetramethyl-7-oxo-2,13,17-triazatetracyclo[16.3.1.0^{2,10}.0^{3,8}]docosa-1(22),3(8),9,18,20-pentaene-19-carboxamide",CHEMBL1810581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,57.0,%,Cc1c2c(n3c1CCNCC[C@H](C)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1806368,Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,15,4602,4607,10.1016/j.bmcl.2011.05.102,21715165.0,
6286755,CHEMBL1778194,"(16S)-13-[(2S)-2-aminopropanoyl]-5,5,9,16-tetramethyl-7-oxo-2,13,17-triazatetracyclo[16.3.1.0^{2,10}.0^{3,8}]docosa-1(22),3(8),9,18,20-pentaene-19-carboxamide",CHEMBL1810581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,0.0,%,Cc1c2c(n3c1CCN(C(=O)[C@H](C)N)CC[C@H](C)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1806368,Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,15,4602,4607,10.1016/j.bmcl.2011.05.102,21715165.0,
6286756,CHEMBL1779531,"(18S)-5,5,9-trimethyl-7-oxo-2,14,20-triazapentacyclo[19.3.1.0^{2,10}.0^{3,8}.0^{14,18}]pentacosa-1(25),3(8),9,21,23-pentaene-22-carboxamide",CHEMBL1810581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,6.0,%,Cc1c2c(n3c1CCCN1CCC[C@H]1CNc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1806368,Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,15,4602,4607,10.1016/j.bmcl.2011.05.102,21715165.0,
6286757,CHEMBL1807804,"(15R,16S)-13-[(2S)-2-aminopropanoyl]-5,5,9,15,16-pentamethyl-7-oxo-2,13,17-triazatetracyclo[16.3.1.0^{2,10}.0^{3,8}]docosa-1(22),3(8),9,18,20-pentaene-19-carboxamide",CHEMBL1810581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,6.0,%,Cc1c2c(n3c1CCN(C(=O)[C@H](C)N)C[C@@H](C)[C@H](C)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1806368,Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,15,4602,4607,10.1016/j.bmcl.2011.05.102,21715165.0,
6286758,CHEMBL1807805,"(15R,16S)-13-[(2S)-2-aminobutanoyl]-5,5,9,15,16-pentamethyl-7-oxo-2,13,17-triazatetracyclo[16.3.1.0^{2,10}.0^{3,8}]docosa-1(22),3(8),9,18,20-pentaene-19-carboxamide",CHEMBL1810581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,100.0,%,CC[C@H](N)C(=O)N1CCc2c(C)c3c(n2-c2ccc(C(N)=O)c(c2)N[C@@H](C)[C@H](C)C1)CC(C)(C)CC3=O,CHEMBL1806368,Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,15,4602,4607,10.1016/j.bmcl.2011.05.102,21715165.0,
6286759,CHEMBL1807806,"(15R,16S)-13-[(2S)-2-amino-3-methylbutanoyl]-5,5,9,15,16-pentamethyl-7-oxo-2,13,17-triazatetracyclo[16.3.1.0^{2,10}.0^{3,8}]docosa-1(22),3(8),9,18,20-pentaene-19-carboxamide",CHEMBL1810581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,2.0,%,Cc1c2c(n3c1CCN(C(=O)[C@@H](N)C(C)C)C[C@@H](C)[C@H](C)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1806368,Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,15,4602,4607,10.1016/j.bmcl.2011.05.102,21715165.0,
6286760,CHEMBL1807807,"(15R,16S)-13-(2-amino-2-methylpropanoyl)-5,5,9,15,16-pentamethyl-7-oxo-2,13,17-triazatetracyclo[16.3.1.0^{2,10}.0^{3,8}]docosa-1(22),3(8),9,18,20-pentaene-19-carboxamide",CHEMBL1810581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,11.0,%,Cc1c2c(n3c1CCN(C(=O)C(C)(C)N)C[C@@H](C)[C@H](C)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1806368,Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,15,4602,4607,10.1016/j.bmcl.2011.05.102,21715165.0,
6286761,CHEMBL1807808,"(15R,16S)-13-[(1-aminocyclopropyl)carbonyl]-5,5,9,15,16-pentamethyl-7-oxo-2,13,17-triazatetracyclo[16.3.1.0^{2,10}.0^{3,8}]docosa-1(22),3(8),9,18,20-pentaene-19-carboxamide",CHEMBL1810581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,100.0,%,Cc1c2c(n3c1CCN(C(=O)C1(N)CC1)C[C@@H](C)[C@H](C)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1806368,Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,15,4602,4607,10.1016/j.bmcl.2011.05.102,21715165.0,
6286762,CHEMBL1807809,"(15R,16S)-13-[(1-aminocyclopentyl)carbonyl]-5,5,9,15,16-pentamethyl-7-oxo-2,13,17-triazatetracyclo[16.3.1.0^{2,10}.0^{3,8}]docosa-1(22),3(8),9,18,20-pentaene-19-carboxamide",CHEMBL1810581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,13.0,%,Cc1c2c(n3c1CCN(C(=O)C1(N)CCCC1)C[C@@H](C)[C@H](C)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1806368,Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,15,4602,4607,10.1016/j.bmcl.2011.05.102,21715165.0,
6286763,CHEMBL1807810,"(15R,16S)-5,5,9,15,16-pentamethyl-7-oxo-13-{[(2S)-pyrrolidin-2-yl]carbonyl}-2,13,17-triazatetracyclo[16.3.1.0^{2,10}.0^{3,8}]docosa-1(22),3(8),9,18,20-pentaene-19-carboxamide",CHEMBL1810581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,2.0,%,Cc1c2c(n3c1CCN(C(=O)[C@@H]1CCCN1)C[C@@H](C)[C@H](C)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1806368,Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,15,4602,4607,10.1016/j.bmcl.2011.05.102,21715165.0,
6286764,CHEMBL1807811,"(15R,16S)-5,5,9,15,16-pentamethyl-7-oxo-13-{[(2R)-pyrrolidin-2-yl]carbonyl}-2,13,17-triazatetracyclo[16.3.1.0^{2,10}.0^{3,8}]docosa-1(22),3(8),9,18,20-pentaene-19-carboxamide",CHEMBL1810581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,8.0,%,Cc1c2c(n3c1CCN(C(=O)[C@H]1CCCN1)C[C@@H](C)[C@H](C)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1806368,Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,15,4602,4607,10.1016/j.bmcl.2011.05.102,21715165.0,
6286765,CHEMBL1806511,"(15R,16S)-13-{[(2S,4S)-4-fluoropyrrolidin-2-yl]carbonyl}-5,5,9,15,16-pentamethyl-7-oxo-2,13,17-triazatetracyclo[16.3.1.0^{2,10}.0^{3,8}]docosa-1(22),3(8),9,18,20-pentaene-19-carboxamide",CHEMBL1810581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,-4.0,%,Cc1c2c(n3c1CCN(C(=O)[C@@H]1C[C@H](F)CN1)C[C@@H](C)[C@H](C)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1806368,Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,15,4602,4607,10.1016/j.bmcl.2011.05.102,21715165.0,
6286766,CHEMBL1807812,"(15R,16S)-13-[(2S)-2-hydroxypropanoyl]-5,5,9,15,16-pentamethyl-7-oxo-2,13,17-triazatetracyclo[16.3.1.0^{2,10}.0^{3,8}]docosa-1(22),3(8),9,18,20-pentaene-19-carboxamide",CHEMBL1810581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,0.0,%,Cc1c2c(n3c1CCN(C(=O)[C@H](C)O)C[C@@H](C)[C@H](C)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1806368,Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,15,4602,4607,10.1016/j.bmcl.2011.05.102,21715165.0,
6286767,CHEMBL1807813,"(15R,16S)-13-[(2S)-2-hydroxy-3-methylbutanoyl]-5,5,9,15,16-pentamethyl-7-oxo-2,13,17-triazatetracyclo[16.3.1.0^{2,10}.0^{3,8}]docosa-1(22),3(8),9,18,20-pentaene-19-carboxamide",CHEMBL1810581,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,=,15.0,%,Cc1c2c(n3c1CCN(C(=O)[C@@H](O)C(C)C)C[C@@H](C)[C@H](C)Nc1cc-3ccc1C(N)=O)CC(C)(C)CC2=O,CHEMBL1806368,Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model.,Bioorg. Med. Chem. Lett.,2011.0,21,15,4602,4607,10.1016/j.bmcl.2011.05.102,21715165.0,
6319501,CHEMBL1813096,"(S)-N-(biphenyl-2-yl)-1,3-dioxo-2-((1S,2R)-2-phenylcyclopropyl)hexahydroimidazo[1,5-a]pyrazine-7(1H)-carboxamide",CHEMBL1816327,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,50.0,%,O=C(Nc1ccccc1-c1ccccc1)N1CCN2C(=O)N([C@H]3C[C@@H]3c3ccccc3)C(=O)[C@@H]2C1,CHEMBL1811786,"Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclo- propyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydro-imidazo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 2.",Bioorg. Med. Chem. Lett.,2011.0,21,15,4429,4435,10.1016/j.bmcl.2011.06.023,21737263.0,
6327619,CHEMBL1818294,tert-butyl(trans-4-((2-(4-(2-(dimethylamino)ethyl)piperazin-1-yl)quinoline-4-carboxamido)methyl)cyclohexyl)methylcarbamate,CHEMBL1820833,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 13 uM,Inhibition,<,50.0,%,CN(C)CCN1CCN(c2cc(C(=O)NC[C@H]3CC[C@H](CNC(=O)OC(C)(C)C)CC3)c3ccccc3n2)CC1,CHEMBL1817551,Design of small molecule inhibitors of acetyl-CoA carboxylase 1 and 2 showing reduction of hepatic malonyl-CoA levels in vivo in obese Zucker rats.,Bioorg. Med. Chem.,2011.0,19,10,3039,3053,10.1016/j.bmc.2011.04.014,21515056.0,
6327620,CHEMBL1818296,tert-Butyl{[trans-4-({[(2-{4-[2-(dimethylamino)ethyl]-piperidin-1-yl}quinolin-4-yl)carbonyl]-amino}methyl)cyclohexyl]-methyl}carbamate,CHEMBL1820833,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 13 uM,Inhibition,<,50.0,%,CN(C)CCC1CCN(c2cc(C(=O)NC[C@H]3CC[C@H](CNC(=O)OC(C)(C)C)CC3)c3ccccc3n2)CC1,CHEMBL1817551,Design of small molecule inhibitors of acetyl-CoA carboxylase 1 and 2 showing reduction of hepatic malonyl-CoA levels in vivo in obese Zucker rats.,Bioorg. Med. Chem.,2011.0,19,10,3039,3053,10.1016/j.bmc.2011.04.014,21515056.0,
6343308,CHEMBL1824615,"(S)-N-((3-(4-(5-([1,2,4]triazolo[4,3-a]pyrimidin-3-yl)thiophen-3-yl)-3-fluorophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide",CHEMBL1825726,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human cytochrome P450-2C9 at 10 uM by fluorimetric analysis,Inhibition,=,40.9,%,CC(=O)NC[C@H]1CN(c2ccc(-c3csc(-c4nnc5ncccn45)c3)c(F)c2)C(=O)O1,CHEMBL1821713,"Synthesis and in vitro activity of novel 1,2,4-triazolo[4,3-a]pyrimidine oxazolidinone antibacterial agents. Part II.",Bioorg. Med. Chem. Lett.,2011.0,21,18,5266,5269,10.1016/j.bmcl.2011.07.034,21835618.0,
6346448,CHEMBL1823575,rac-N-(3-cyano-4-(4-(2-(diethylamino)-2-oxo-1-phenylethyl)piperazin-1-yl)phenyl)-2-ethylbutanamide,CHEMBL1827518,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,>,75.0,%,CCC(CC)C(=O)Nc1ccc(N2CCN(C(C(=O)N(CC)CC)c3ccccc3)CC2)c(C#N)c1,CHEMBL1821563,"The discovery and synthesis of JNJ 31020028, a small molecule antagonist of the Neuropeptide Y Y₂ receptor.",Bioorg. Med. Chem. Lett.,2011.0,21,18,5552,5556,10.1016/j.bmcl.2011.06.136,21802951.0,
6346610,CHEMBL1823584,"N-(2-chlorophenyl)-4-(3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",CHEMBL1827531,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,62.0,%,O=C(Nc1ccccc1Cl)N1CCC(c2nc(-c3ccc4ccccc4n3)no2)CC1,CHEMBL1821555,"Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors.",Bioorg. Med. Chem. Lett.,2011.0,21,18,5274,5282,10.1016/j.bmcl.2011.07.031,21803580.0,
6346611,CHEMBL1823616,"N-(2-chlorophenyl)-4-(3-(1-methyl-1H-benzo[d]imidazol-2-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxamide",CHEMBL1827531,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,44.0,%,Cn1c(-c2noc(C3CCN(C(=O)Nc4ccccc4Cl)CC3)n2)nc2ccccc21,CHEMBL1821555,"Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors.",Bioorg. Med. Chem. Lett.,2011.0,21,18,5274,5282,10.1016/j.bmcl.2011.07.031,21803580.0,
6354046,CHEMBL1824249,trans-N-butyl-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)cyclohexanamine,CHEMBL1827183,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 1 uM,Inhibition,=,54.7,%,CCCCN[C@H]1CC[C@H](c2ccc(OCCCN3CCCCC3)cc2)CC1,CHEMBL1821619,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5384,5388,10.1016/j.bmcl.2011.06.102,21783360.0,
6354047,CHEMBL1824248,cis-N-butyl-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)cyclohexanamine,CHEMBL1827183,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 1 uM,Inhibition,=,53.9,%,CCCCN[C@H]1CC[C@@H](c2ccc(OCCCN3CCCCC3)cc2)CC1,CHEMBL1821619,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5384,5388,10.1016/j.bmcl.2011.06.102,21783360.0,
6354048,CHEMBL1824247,trans-N-benzyl-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)cyclohexanamine,CHEMBL1827183,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 1 uM,Inhibition,=,47.8,%,c1ccc(CN[C@H]2CC[C@H](c3ccc(OCCCN4CCCCC4)cc3)CC2)cc1,CHEMBL1821619,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5384,5388,10.1016/j.bmcl.2011.06.102,21783360.0,
6354049,CHEMBL1824245,trans-2-(4-(4-(3-(piperidin-1-yl)propoxy)phenyl)cyclohexyl)isoindoline,CHEMBL1827183,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 1 uM,Inhibition,=,25.1,%,c1ccc2c(c1)CN([C@H]1CC[C@H](c3ccc(OCCCN4CCCCC4)cc3)CC1)C2,CHEMBL1821619,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5384,5388,10.1016/j.bmcl.2011.06.102,21783360.0,
6354050,CHEMBL1824243,trans-1-(4-(4-(3-(piperidin-1-yl)propoxy)phenyl)cyclohexyl)piperidin-4-ol,CHEMBL1827183,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 1 uM,Inhibition,=,3.4,%,OC1CCN([C@H]2CC[C@H](c3ccc(OCCCN4CCCCC4)cc3)CC2)CC1,CHEMBL1821619,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5384,5388,10.1016/j.bmcl.2011.06.102,21783360.0,
6354051,CHEMBL1824239,trans-1-methyl-4-(-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)cyclohexyl)piperazine,CHEMBL1827183,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 1 uM,Inhibition,=,46.5,%,CN1CCN([C@H]2CC[C@H](c3ccc(OCCCN4CCCCC4)cc3)CC2)CC1,CHEMBL1821619,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5384,5388,10.1016/j.bmcl.2011.06.102,21783360.0,
6354052,CHEMBL1824237,"cis-4-methyl-1-((1s,4s)-4-(4-(3-(piperidin-1-yl)propoxy)phenyl)cyclohexyl)piperidine",CHEMBL1827183,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 1 uM,Inhibition,=,52.9,%,CC1CCN([C@H]2CC[C@@H](c3ccc(OCCCN4CCCCC4)cc3)CC2)CC1,CHEMBL1821619,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5384,5388,10.1016/j.bmcl.2011.06.102,21783360.0,
6354053,CHEMBL1824236,trans-1-(3-(4-(-4-(piperidin-1-yl)cyclohexyl)phenoxy)propyl)piperidine,CHEMBL1827183,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 1 uM,Inhibition,=,33.5,%,c1cc([C@H]2CC[C@H](N3CCCCC3)CC2)ccc1OCCCN1CCCCC1,CHEMBL1821619,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5384,5388,10.1016/j.bmcl.2011.06.102,21783360.0,
6354054,CHEMBL1824233,trans-1-(3-(4(4-(azetidin-1-yl)cyclohexyl)phenoxy)propyl)piperidine,CHEMBL1827183,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 1 uM,Inhibition,=,-12.1,%,c1cc([C@H]2CC[C@H](N3CCC3)CC2)ccc1OCCCN1CCCCC1,CHEMBL1821619,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5384,5388,10.1016/j.bmcl.2011.06.102,21783360.0,
6354055,CHEMBL1824229,4-(4-(3-(piperidin-1-yl)propoxy)phenyl)cyclohexanone,CHEMBL1827183,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 1 uM,Inhibition,=,21.4,%,O=C1CCC(c2ccc(OCCCN3CCCCC3)cc2)CC1,CHEMBL1821619,Novel and highly potent histamine H3 receptor ligands. Part 2: exploring the cyclohexylamine-based series.,Bioorg. Med. Chem. Lett.,2011.0,21,18,5384,5388,10.1016/j.bmcl.2011.06.102,21783360.0,
6361152,CHEMBL1766005,3-Imidazol-1-yl-2-methyl-3-[4-(naphthalen-2-ylamino)-phenyl]-propionic acid Methyl Ester,CHEMBL1833284,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 0.4 uM,Inhibition,=,41.0,%,COC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1ccnc1,CHEMBL1828563,"Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26).",J. Med. Chem.,2011.0,54,19,6803,6811,10.1021/jm200695m,21838328.0,
6361153,CHEMBL1831083,"Ethyl 3-(1H-Imidazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)-phenyl]propanoate",CHEMBL1833284,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 0.4 uM,Inhibition,=,43.0,%,CCOC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1ccnc1,CHEMBL1828563,"Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26).",J. Med. Chem.,2011.0,54,19,6803,6811,10.1021/jm200695m,21838328.0,
6361154,CHEMBL1831088,"3-(1H-Imidazol-1-yl)-N,2,2-trimethyl-3-[4-(naphthalen-2-ylamino)-phenyl]propanamide",CHEMBL1833284,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 0.4 uM,Inhibition,=,45.0,%,CNC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1ccnc1,CHEMBL1828563,"Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26).",J. Med. Chem.,2011.0,54,19,6803,6811,10.1021/jm200695m,21838328.0,
6361155,CHEMBL1831090,"3-(1H-Imidazol-1-yl)-N,N,2,2-tetramethyl-3-[4-(naphthalen-2-ylamino)phenyl]propanamide",CHEMBL1833284,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 0.4 uM,Inhibition,=,52.0,%,CN(C)C(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1ccnc1,CHEMBL1828563,"Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26).",J. Med. Chem.,2011.0,54,19,6803,6811,10.1021/jm200695m,21838328.0,
6361156,CHEMBL1831092,"Methyl 2,2-Dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]-3-(1H-1,2,4-triazol-1-yl)propanoate",CHEMBL1833284,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 0.4 uM,Inhibition,=,38.0,%,COC(=O)C(C)(C)C(c1ccc(Nc2ccc3ccccc3c2)cc1)n1cncn1,CHEMBL1828563,"Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26).",J. Med. Chem.,2011.0,54,19,6803,6811,10.1021/jm200695m,21838328.0,
6366534,CHEMBL449588,3-(4-(o-Tolylethynyl)phenyl)propanoic acid,CHEMBL1833357,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,-25.0,%,Cc1ccccc1C#Cc1ccc(CCC(=O)O)cc1,CHEMBL1828561,Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.,J. Med. Chem.,2011.0,54,19,6691,6703,10.1021/jm2005699,21854074.0,
6366535,CHEMBL1829170,"3-(4-((2,6-Dichloropyridin-4-yl)ethynyl)phenyl)propanoic Acid",CHEMBL1833357,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,-4.0,%,O=C(O)CCc1ccc(C#Cc2cc(Cl)nc(Cl)c2)cc1,CHEMBL1828561,Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.,J. Med. Chem.,2011.0,54,19,6691,6703,10.1021/jm2005699,21854074.0,
6372476,CHEMBL1738699,3-(5-(4-(1H-imidazol-1-yl)phenyl)-1-(4-carbamoyl-2-methylphenyl)-1H-pyrrol-2-yl)propanoic acid,CHEMBL1837191,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,81.0,%,Cc1cc(C(N)=O)ccc1-n1c(CCC(=O)O)ccc1-c1ccc(-n2ccnc2)cc1,CHEMBL1833839,Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities.,Bioorg. Med. Chem. Lett.,2011.0,21,19,5849,5853,10.1016/j.bmcl.2011.07.103,21855338.0,
6372477,CHEMBL1836778,3-(1-(4-carbamoyl-2-methylphenyl)-5-(4-(2-methyl-1H-imidazol-1-yl)phenyl)-1H-pyrrol-2-yl)propanoic acid,CHEMBL1837191,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,20.0,%,Cc1cc(C(N)=O)ccc1-n1c(CCC(=O)O)ccc1-c1ccc(-n2ccnc2C)cc1,CHEMBL1833839,Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities.,Bioorg. Med. Chem. Lett.,2011.0,21,19,5849,5853,10.1016/j.bmcl.2011.07.103,21855338.0,
6372478,CHEMBL1836779,3-(1-(4-carbamoyl-2-methylphenyl)-5-(4-(2-ethyl-1H-imidazol-1-yl)phenyl)-1H-pyrrol-2-yl)propanoic acid,CHEMBL1837191,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,15.0,%,CCc1nccn1-c1ccc(-c2ccc(CCC(=O)O)n2-c2ccc(C(N)=O)cc2C)cc1,CHEMBL1833839,Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities.,Bioorg. Med. Chem. Lett.,2011.0,21,19,5849,5853,10.1016/j.bmcl.2011.07.103,21855338.0,
6372479,CHEMBL1836777,3-(5-(5-(1H-imidazol-1-yl)thiophen-2-yl)-1-(4-carbamoyl-2-methylphenyl)-1H-pyrrol-2-yl)propanoic acid,CHEMBL1837191,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,92.0,%,Cc1cc(C(N)=O)ccc1-n1c(CCC(=O)O)ccc1-c1ccc(-n2ccnc2)s1,CHEMBL1833839,Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities.,Bioorg. Med. Chem. Lett.,2011.0,21,19,5849,5853,10.1016/j.bmcl.2011.07.103,21855338.0,
6372480,CHEMBL1836693,3-(1-(4-carbamoyl-2-methylphenyl)-5-(5-(2-methyl-1Himidazol-1-yl)thiophen-2-yl)-1H-pyrrol-2-yl)propanoic acid,CHEMBL1837191,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,15.0,%,Cc1cc(C(N)=O)ccc1-n1c(CCC(=O)O)ccc1-c1ccc(-n2ccnc2C)s1,CHEMBL1833839,Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities.,Bioorg. Med. Chem. Lett.,2011.0,21,19,5849,5853,10.1016/j.bmcl.2011.07.103,21855338.0,
6372481,CHEMBL1836695,3-(1-(4-carbamoyl-2-methylphenyl)-5-(4-(2-methyl-1H-imidazol-1-yl)thiophen-2-yl)-1H-pyrrol-2-yl)propanoic acid,CHEMBL1837191,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,13.0,%,Cc1cc(C(N)=O)ccc1-n1c(CCC(=O)O)ccc1-c1cc(-n2ccnc2C)cs1,CHEMBL1833839,Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities.,Bioorg. Med. Chem. Lett.,2011.0,21,19,5849,5853,10.1016/j.bmcl.2011.07.103,21855338.0,
6388893,CHEMBL1835153,"7-(2-Aminopyrimidin-5-yl)-1-{[(1R)-1-cyclopropyl-2,2,2-trifluoroethyl]amino}-5H-pyrido[4,3-b]indole-4-carboxamide",CHEMBL1840132,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,34.0,%,NC(=O)c1cnc(N[C@H](C2CC2)C(F)(F)F)c2c1[nH]c1cc(-c3cnc(N)nc3)ccc12,CHEMBL1833803,"Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.",J. Med. Chem.,2011.0,54,20,7334,7349,10.1021/jm200909u,21942426.0,
6388894,CHEMBL1835150,"7-(6-Aminopyridin-3-yl)-1-{[(1R)-1-cyclopropyl-2,2,2-trifluoroethyl]amino}-5H-pyrido[4,3-b]indole-4-carboxamide",CHEMBL1840132,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,41.0,%,NC(=O)c1cnc(N[C@H](C2CC2)C(F)(F)F)c2c1[nH]c1cc(-c3ccc(N)nc3)ccc12,CHEMBL1833803,"Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.",J. Med. Chem.,2011.0,54,20,7334,7349,10.1021/jm200909u,21942426.0,
6388895,CHEMBL1835149,"1-{[(1R)-1-Cyclopropyl-2,2,2-trifluoroethyl]amino}-7-(1H-pyrazol-4-yl)-5H-pyrido[4,3-b]indole-4-carboxamide",CHEMBL1840132,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,61.0,%,NC(=O)c1cnc(N[C@H](C2CC2)C(F)(F)F)c2c1[nH]c1cc(-c3cn[nH]c3)ccc12,CHEMBL1833803,"Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.",J. Med. Chem.,2011.0,54,20,7334,7349,10.1021/jm200909u,21942426.0,
6388896,CHEMBL1833986,"7-(2-Aminopyrimidin-5-yl)-1-[(dicyclopropylmethyl)amino]-5H-pyrido[4,3-b]indole-4-carboxamide",CHEMBL1840132,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,35.0,%,NC(=O)c1cnc(NC(C2CC2)C2CC2)c2c1[nH]c1cc(-c3cnc(N)nc3)ccc12,CHEMBL1833803,"Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.",J. Med. Chem.,2011.0,54,20,7334,7349,10.1021/jm200909u,21942426.0,
6388897,CHEMBL1835148,"7-(5-Aminopyrazin-2-yl)-1-[(dicyclopropylmethyl)amino]-5H-pyrido[4,3-b]indole-4-carboxamide",CHEMBL1840132,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,46.0,%,NC(=O)c1cnc(NC(C2CC2)C2CC2)c2c1[nH]c1cc(-c3cnc(N)cn3)ccc12,CHEMBL1833803,"Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.",J. Med. Chem.,2011.0,54,20,7334,7349,10.1021/jm200909u,21942426.0,
6388898,CHEMBL1835146,"1-[(Dicyclopropylmethyl)amino]-7-(1H-pyrazol-4-yl)-5H-pyrido[4,3-b]indole-4-carboxamide",CHEMBL1840132,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,80.0,%,NC(=O)c1cnc(NC(C2CC2)C2CC2)c2c1[nH]c1cc(-c3cn[nH]c3)ccc12,CHEMBL1833803,"Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.",J. Med. Chem.,2011.0,54,20,7334,7349,10.1021/jm200909u,21942426.0,
6388899,CHEMBL1835142,"1-{[(1R)-1-Cyclopropyl-2,2,2-trifluoroethyl]amino}-7-(1-methyl-1H-pyrazol-4-yl)-5H-pyrido[4,3-b]indole-4-carboxamide",CHEMBL1840132,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,66.0,%,Cn1cc(-c2ccc3c(c2)[nH]c2c(C(N)=O)cnc(N[C@H](C4CC4)C(F)(F)F)c23)cn1,CHEMBL1833803,"Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.",J. Med. Chem.,2011.0,54,20,7334,7349,10.1021/jm200909u,21942426.0,
6388900,CHEMBL1835141,"1-[(Dicyclopropylmethyl)amino]-7-(1-methyl-1H-pyrazol-4-yl)-5H-pyrido[4,3-b]indole-4-carboxamide",CHEMBL1840132,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,80.0,%,Cn1cc(-c2ccc3c(c2)[nH]c2c(C(N)=O)cnc(NC(C4CC4)C4CC4)c23)cn1,CHEMBL1833803,"Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.",J. Med. Chem.,2011.0,54,20,7334,7349,10.1021/jm200909u,21942426.0,
7844403,CHEMBL1910022,"(S)-4-(1-(7-(trifluoromethyl)-10,11-dihydrodibenzo[b,f]oxepine-4-carboxamido)ethyl)benzoic acid",CHEMBL1913426,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 at 3 uM by fluorimetry,Inhibition,=,21.0,%,C[C@H](NC(=O)c1cccc2c1Oc1cc(C(F)(F)F)ccc1CC2)c1ccc(C(=O)O)cc1,CHEMBL1909549,"Synthesis, pharmacophore modeling and in vitro activity of 10,11-dihydrodibenzo[b,f]oxepine-4-carboxamide derivatives as novel and potent antagonists of the prostaglandin EP4 receptor.",Bioorg. Med. Chem. Lett.,2011.0,21,21,6336,6340,10.1016/j.bmcl.2011.08.102,21930381.0,
7844404,CHEMBL1910023,"4-(1-(7-(trifluoromethyl)-10,11-dihydrodibenzo[b,f]oxepine-4-carboxamido)cyclopropyl)benzoic acid",CHEMBL1913426,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 at 3 uM by fluorimetry,Inhibition,=,11.0,%,O=C(O)c1ccc(C2(NC(=O)c3cccc4c3Oc3cc(C(F)(F)F)ccc3CC4)CC2)cc1,CHEMBL1909549,"Synthesis, pharmacophore modeling and in vitro activity of 10,11-dihydrodibenzo[b,f]oxepine-4-carboxamide derivatives as novel and potent antagonists of the prostaglandin EP4 receptor.",Bioorg. Med. Chem. Lett.,2011.0,21,21,6336,6340,10.1016/j.bmcl.2011.08.102,21930381.0,
7844405,CHEMBL1910024,"(S)-4-(1-(8-(trifluoromethyl)-10,11-dihydrodibenzo[b,f]oxepine-4-carboxamido)ethyl)benzoic acid",CHEMBL1913426,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 at 3 uM by fluorimetry,Inhibition,=,17.0,%,C[C@H](NC(=O)c1cccc2c1Oc1ccc(C(F)(F)F)cc1CC2)c1ccc(C(=O)O)cc1,CHEMBL1909549,"Synthesis, pharmacophore modeling and in vitro activity of 10,11-dihydrodibenzo[b,f]oxepine-4-carboxamide derivatives as novel and potent antagonists of the prostaglandin EP4 receptor.",Bioorg. Med. Chem. Lett.,2011.0,21,21,6336,6340,10.1016/j.bmcl.2011.08.102,21930381.0,
7844406,CHEMBL1910025,"4-(1-(8-(trifluoromethyl)-10,11-dihydrodibenzo[b,f]oxepine-4-carboxamido)cyclopropyl)benzoic acid",CHEMBL1913426,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 at 3 uM by fluorimetry,Inhibition,=,26.0,%,O=C(O)c1ccc(C2(NC(=O)c3cccc4c3Oc3ccc(C(F)(F)F)cc3CC4)CC2)cc1,CHEMBL1909549,"Synthesis, pharmacophore modeling and in vitro activity of 10,11-dihydrodibenzo[b,f]oxepine-4-carboxamide derivatives as novel and potent antagonists of the prostaglandin EP4 receptor.",Bioorg. Med. Chem. Lett.,2011.0,21,21,6336,6340,10.1016/j.bmcl.2011.08.102,21930381.0,
7929480,CHEMBL1916475,"8-(4-hydroxycyclohexylamino)-3-(6-methoxypyridin-3-yl)-5-(2-propoxyethyl)pyridazino[4,3-d]pyrimidin-6(5H)-one",CHEMBL1919542,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,9.0,%,CCCOCCn1c(=O)nc(NC2CCC(O)CC2)c2nnc(-c3ccc(OC)nc3)cc21,CHEMBL1914420,Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent region.,Bioorg. Med. Chem. Lett.,2011.0,21,21,6348,6352,10.1016/j.bmcl.2011.08.106,21955943.0,
7933263,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL1920118,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 5 uM by fluorsecence-based assay,Inhibition,=,69.0,%,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL1914358,"Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis.",J. Med. Chem.,2011.0,54,20,7193,7205,10.1021/jm200782y,21851064.0,
7933266,CHEMBL1916396,"((+/-)-3-(benzo[d][1,3]dioxol-5-yl)-N-(benzo[d][1,3]dioxol-5-ylmethyl)-4-phenylbutan-1-amine)",CHEMBL1920285,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 25 uM by fluorsecence-based assay,Inhibition,=,80.0,%,c1ccc(C[C@H](CCNCc2ccc3c(c2)OCO3)c2ccc3c(c2)OCO3)cc1,CHEMBL1914358,"Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis.",J. Med. Chem.,2011.0,54,20,7193,7205,10.1021/jm200782y,21851064.0,
7933267,CHEMBL1916397,"rac-4-(((3-(Benzo[d][1,3]dioxol-5-yl)-4-phenylbutyl)amino)-methyl)-N,N-dimethylaniline",CHEMBL1920285,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 25 uM by fluorsecence-based assay,Inhibition,=,80.0,%,CN(C)c1ccc(CNCCC(Cc2ccccc2)c2ccc3c(c2)OCO3)cc1,CHEMBL1914358,"Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis.",J. Med. Chem.,2011.0,54,20,7193,7205,10.1021/jm200782y,21851064.0,
7933268,CHEMBL1916398,"N-(3,5-Dimethylphenyl)-1-(4-isopropylphenyl)-5-(piperidin-4-yl)-1H-pyrazole-4-carboxamide",CHEMBL1920285,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 25 uM by fluorsecence-based assay,Inhibition,=,20.0,%,Cc1cc(C)cc(NC(=O)c2cnn(-c3ccc(C(C)C)cc3)c2C2CCNCC2)c1,CHEMBL1914358,"Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis.",J. Med. Chem.,2011.0,54,20,7193,7205,10.1021/jm200782y,21851064.0,
7947296,CHEMBL1923857,2-(difluoro(4-methylpyrimidin-2-ylthio)methyl)benzo[d]oxazole,CHEMBL1924371,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9,Inhibition,<,30.0,%,Cc1ccnc(SC(F)(F)c2nc3ccccc3o2)n1,CHEMBL1921681,Difluoromethylbenzoxazole pyrimidine thioether derivatives: a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.,J. Med. Chem.,2011.0,54,23,7974,7985,10.1021/jm200766b,22017513.0,
7949898,CHEMBL1922026,N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1H-indole-2-carboxamide,CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,87.0,%,COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)cc3[nH]2)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949899,CHEMBL1922029,N-(3-methoxybenzyl)-N-methyl-6-(1H-pyrazol-4-yl)-1H-indole-2-carboxamide,CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,27.0,%,COc1cccc(CN(C)C(=O)c2cc3ccc(-c4cn[nH]c4)cc3[nH]2)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949900,CHEMBL1922032,N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-N-(2-(pyrrolidin-1-yl)ethyl)-1H-indole-2-carboxamide,CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,65.0,%,COc1cccc(CN(CCN2CCCC2)C(=O)c2cc3ccc(-c4cn[nH]c4)cc3[nH]2)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949901,CHEMBL1922034,"N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide",CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,38.0,%,COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949902,CHEMBL1922035,"N-(3-methoxybenzyl)-1-methyl-6-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide",CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,76.0,%,COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3n2C)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949903,CHEMBL1922038,"1-(2-(dimethylamino)ethyl)-N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide",CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,46.0,%,COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3n2CCN(C)C)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949904,CHEMBL1922042,"N-(3-methoxybenzyl)-N-methyl-6-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide",CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,83.0,%,COc1cccc(CN(C)C(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949905,CHEMBL1922043,"N-cyclopropyl-N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide",CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,52.0,%,COc1cccc(CN(C(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)C2CC2)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949906,CHEMBL1922044,"N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-N-(2-(pyrrolidin-1-yl)ethyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide",CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,26.0,%,COc1cccc(CN(CCN2CCCC2)C(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949907,CHEMBL1922045,N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1H-indole-3-carboxamide,CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,97.0,%,COc1cccc(CNC(=O)c2c[nH]c3cc(-c4cn[nH]c4)ccc23)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949908,CHEMBL1922046,N-(3-methoxybenzyl)-N-methyl-6-(1H-pyrazol-4-yl)-1H-indole-3-carboxamide,CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,94.0,%,COc1cccc(CN(C)C(=O)c2c[nH]c3cc(-c4cn[nH]c4)ccc23)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949909,CHEMBL1922047,N-(3-methoxybenzyl)-1-methyl-6-(1H-pyrazol-4-yl)-1H-indole-3-carboxamide,CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,93.0,%,COc1cccc(CNC(=O)c2cn(C)c3cc(-c4cn[nH]c4)ccc23)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949910,CHEMBL1922124,"N-(3-methoxybenzyl)-N,1-dimethyl-6-(1H-pyrazol-4-yl)-1H-indole-3-carboxamide",CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,93.0,%,COc1cccc(CN(C)C(=O)c2cn(C)c3cc(-c4cn[nH]c4)ccc23)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949911,CHEMBL1922125,N-(3-methoxybenzyl)-1-phenyl-6-(1H-pyrazol-4-yl)-1H-indole-3-carboxamide,CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,96.0,%,COc1cccc(CNC(=O)c2cn(-c3ccccc3)c3cc(-c4cn[nH]c4)ccc23)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949912,CHEMBL1922126,N-(3-(dimethylamino)propyl)-N-(3-methoxybenzyl)-1-methyl-6-(1H-pyrazol-4-yl)-1H-indole-3-carboxamide,CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,28.0,%,COc1cccc(CN(CCCN(C)C)C(=O)c2cn(C)c3cc(-c4cn[nH]c4)ccc23)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949913,CHEMBL1922127,N-(2-(dimethylamino)ethyl)-N-(3-methoxybenzyl)-1-methyl-6-(1H-pyrazol-4-yl)-1H-indole-3-carboxamide,CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,62.0,%,COc1cccc(CN(CCN(C)C)C(=O)c2cn(C)c3cc(-c4cn[nH]c4)ccc23)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949914,CHEMBL1922128,1-(3-hydroxypropyl)-N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1H-indole-3-carboxamide,CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,87.0,%,COc1cccc(CNC(=O)c2cn(CCCO)c3cc(-c4cn[nH]c4)ccc23)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949915,CHEMBL1922129,1-(2-(dimethylamino)ethyl)-N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1H-indole-3-carboxamide,CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,91.0,%,COc1cccc(CNC(=O)c2cn(CCN(C)C)c3cc(-c4cn[nH]c4)ccc23)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949916,CHEMBL1922132,"N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide",CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,86.0,%,COc1cccc(CNC(=O)c2c[nH]c3nc(-c4cn[nH]c4)ccc23)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949917,CHEMBL1922133,"N-cyclopropyl-N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide",CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,91.0,%,COc1cccc(CN(C(=O)c2c[nH]c3nc(-c4cn[nH]c4)ccc23)C2CC2)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949918,CHEMBL1922136,"N-(3-methoxybenzyl)-1-methyl-6-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide",CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,77.0,%,COc1cccc(CNC(=O)c2cn(C)c3nc(-c4cn[nH]c4)ccc23)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949919,CHEMBL1922137,"N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1-(2-(pyrrolidin-1-yl)ethyl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide",CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,51.0,%,COc1cccc(CNC(=O)c2cn(CCN3CCCC3)c3nc(-c4cn[nH]c4)ccc23)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949920,CHEMBL1922138,3-((dimethylamino)methyl)-N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1H-indole-2-carboxamide,CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,27.0,%,COc1cccc(CNC(=O)c2[nH]c3cc(-c4cn[nH]c4)ccc3c2CN(C)C)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949921,CHEMBL1922139,N-(3-methoxybenzyl)-3-(morpholinomethyl)-6-(1H-pyrazol-4-yl)-1H-indole-2-carboxamide,CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,86.0,%,COc1cccc(CNC(=O)c2[nH]c3cc(-c4cn[nH]c4)ccc3c2CN2CCOCC2)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949922,CHEMBL1922140,N-(3-methoxybenzyl)-3-((4-methylpiperazin-1-yl)methyl)-6-(1H-pyrazol-4-yl)-1H-indole-2-carboxamide,CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,75.0,%,COc1cccc(CNC(=O)c2[nH]c3cc(-c4cn[nH]c4)ccc3c2CN2CCN(C)CC2)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949923,CHEMBL1922141,"3-((1,4-diazepan-1-yl)methyl)-N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1H-indole-2-carboxamide",CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,53.0,%,COc1cccc(CNC(=O)c2[nH]c3cc(-c4cn[nH]c4)ccc3c2CN2CCCNCC2)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949924,CHEMBL1922142,"N-(3-methoxybenzyl)-3-((4-methylpiperazin-1-yl)methyl)-6-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide",CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,-26.0,%,COc1cccc(CNC(=O)c2[nH]c3nc(-c4cn[nH]c4)ccc3c2CN2CCN(C)CC2)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7949925,CHEMBL1922143,"N-(3-methoxybenzyl)-3-(morpholinomethyl)-6-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide",CHEMBL1924559,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,9.0,%,COc1cccc(CNC(=O)c2[nH]c3nc(-c4cn[nH]c4)ccc3c2CN2CCOCC2)c1,CHEMBL1921670,Discovery and optimization of indole and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-II).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7113,7118,10.1016/j.bmcl.2011.09.084,22018789.0,
7957079,CHEMBL1922026,N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1H-indole-2-carboxamide,CHEMBL1925277,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,87.0,%,COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)cc3[nH]2)c1,CHEMBL1921667,Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7107,7112,10.1016/j.bmcl.2011.09.083,22004718.0,
7957080,CHEMBL1923053,6-(2-aminopyrimidin-4-yl)-N-(3-methoxybenzyl)-1H-indole-2-carboxamide,CHEMBL1925277,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,14.0,%,COc1cccc(CNC(=O)c2cc3ccc(-c4ccnc(N)n4)cc3[nH]2)c1,CHEMBL1921667,Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7107,7112,10.1016/j.bmcl.2011.09.083,22004718.0,
7957081,CHEMBL1922034,"N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide",CHEMBL1925277,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,38.0,%,COc1cccc(CNC(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)c1,CHEMBL1921667,Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7107,7112,10.1016/j.bmcl.2011.09.083,22004718.0,
7957082,CHEMBL1922045,N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1H-indole-3-carboxamide,CHEMBL1925277,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,97.0,%,COc1cccc(CNC(=O)c2c[nH]c3cc(-c4cn[nH]c4)ccc23)c1,CHEMBL1921667,Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7107,7112,10.1016/j.bmcl.2011.09.083,22004718.0,
7957083,CHEMBL1923167,N-(3-methoxybenzyl)-6-(pyridin-4-yl)-1H-indole-3-carboxamide,CHEMBL1925277,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,99.0,%,COc1cccc(CNC(=O)c2c[nH]c3cc(-c4ccncc4)ccc23)c1,CHEMBL1921667,Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7107,7112,10.1016/j.bmcl.2011.09.083,22004718.0,
7957084,CHEMBL1922132,"N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide",CHEMBL1925277,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,86.0,%,COc1cccc(CNC(=O)c2c[nH]c3nc(-c4cn[nH]c4)ccc23)c1,CHEMBL1921667,Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7107,7112,10.1016/j.bmcl.2011.09.083,22004718.0,
7957085,CHEMBL1923169,N-(2-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1H-indole-3-carboxamide,CHEMBL1925277,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,91.0,%,COc1ccccc1CNC(=O)c1c[nH]c2cc(-c3cn[nH]c3)ccc12,CHEMBL1921667,Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7107,7112,10.1016/j.bmcl.2011.09.083,22004718.0,
7957086,CHEMBL1923173,(R)-N-(1-(3-methoxyphenyl)ethyl)-6-(1H-pyrazol-4-yl)-1H-indole-3-carboxamide,CHEMBL1925277,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,90.0,%,COc1cccc([C@@H](C)NC(=O)c2c[nH]c3cc(-c4cn[nH]c4)ccc23)c1,CHEMBL1921667,Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7107,7112,10.1016/j.bmcl.2011.09.083,22004718.0,
7957087,CHEMBL1923181,"(R)-N-(1-(3-methoxyphenyl)ethyl)-6-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide",CHEMBL1925277,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,60.0,%,COc1cccc([C@@H](C)NC(=O)c2cc3ccc(-c4cn[nH]c4)nc3[nH]2)c1,CHEMBL1921667,Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).,Bioorg. Med. Chem. Lett.,2011.0,21,23,7107,7112,10.1016/j.bmcl.2011.09.083,22004718.0,
8001964,CHEMBL1940246,"(4-Amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-{6-[(1R,2R)-2-(4-fluorophenyl)cyclopentylamino]pyrazin-2-yl}-methanone",CHEMBL1942058,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,85.0,%,CC(C)n1cc(C(=O)c2cncc(N[C@@H]3CCC[C@@H]3c3ccc(F)cc3)n2)c2c(N)ncnc21,CHEMBL1938337,"Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).",J. Med. Chem.,2011.0,54,24,8490,8500,10.1021/jm201019k,22040023.0,
8001965,CHEMBL1938415,"(4-Amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl){6-[(3S,4R)-4-(4-fluorophenyl)tetrahydrofuran-3-ylamino]-pyrazin-2-yl}methanone",CHEMBL1942058,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,53.0,%,CC(C)n1cc(C(=O)c2cncc(N[C@@H]3COC[C@@H]3c3ccc(F)cc3)n2)c2c(N)ncnc21,CHEMBL1938337,"Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).",J. Med. Chem.,2011.0,54,24,8490,8500,10.1021/jm201019k,22040023.0,
8001966,CHEMBL1940248,"(4-Amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl){6-[(2R,3R)-2-(4-fluorophenyl)tetrahydrofuran-3-ylamino]-pyrazin-2-yl}methanone",CHEMBL1942058,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,23.0,%,CC(C)n1cc(C(=O)c2cncc(N[C@@H]3CCO[C@@H]3c3ccc(F)cc3)n2)c2c(N)ncnc21,CHEMBL1938337,"Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).",J. Med. Chem.,2011.0,54,24,8490,8500,10.1021/jm201019k,22040023.0,
8001967,CHEMBL1940249,"(4-Amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl){6-[(3S,4S)-4-(4-fluorophenyl)pyrrolidin-3-ylamino]pyrazin-2-yl}-methanone",CHEMBL1942058,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,27.0,%,CC(C)n1cc(C(=O)c2cncc(N[C@@H]3CNC[C@@H]3c3ccc(F)cc3)n2)c2c(N)ncnc21,CHEMBL1938337,"Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).",J. Med. Chem.,2011.0,54,24,8490,8500,10.1021/jm201019k,22040023.0,
8001968,CHEMBL1940250,"(4-Amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl){6-[(2R,3R)-2-(4-fluorophenyl)pyrrolidin-3-ylamino]pyrazin-2-yl}-methanone",CHEMBL1942058,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,27.0,%,CC(C)n1cc(C(=O)c2cncc(N[C@@H]3CCN[C@@H]3c3ccc(F)cc3)n2)c2c(N)ncnc21,CHEMBL1938337,"Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).",J. Med. Chem.,2011.0,54,24,8490,8500,10.1021/jm201019k,22040023.0,
8001969,CHEMBL1940251,"(2R,3R)-3-[6-(4-Amino-7-isopropyl-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonyl)pyrazin-2-ylamino]-2-(4-fluorophenyl)-pyrrolidine-1-carbaldehyde",CHEMBL1942058,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,38.0,%,CC(C)n1cc(C(=O)c2cncc(N[C@@H]3CCN(C=O)[C@@H]3c3ccc(F)cc3)n2)c2c(N)ncnc21,CHEMBL1938337,"Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).",J. Med. Chem.,2011.0,54,24,8490,8500,10.1021/jm201019k,22040023.0,
8001970,CHEMBL1940252,"1-[(2R,3R)-3-[6-(4-Amino-7-isopropyl-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonyl)pyrazin-2-ylamino]-2-(4-fluorophenyl)-pyrrolidin-1-yl]ethanone",CHEMBL1942058,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,37.0,%,CC(=O)N1CC[C@@H](Nc2cncc(C(=O)c3cn(C(C)C)c4ncnc(N)c34)n2)[C@H]1c1ccc(F)cc1,CHEMBL1938337,"Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).",J. Med. Chem.,2011.0,54,24,8490,8500,10.1021/jm201019k,22040023.0,
8001971,CHEMBL1940253,"1-{(2R,3R)-3-[6-(4-Amino-7-isopropyl-7H-pyrrolo[2,3-d]-pyrimidine-5-carbonyl)pyrazin-2-ylamino]-2-phenylpyrrolidin-1-yl}ethanone",CHEMBL1942058,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,54.0,%,CC(=O)N1CC[C@@H](Nc2cncc(C(=O)c3cn(C(C)C)c4ncnc(N)c34)n2)[C@H]1c1ccccc1,CHEMBL1938337,"Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).",J. Med. Chem.,2011.0,54,24,8490,8500,10.1021/jm201019k,22040023.0,
8036519,CHEMBL1230468,"2,6-Dichloro-4-(2-piperazin-1-yl-pyridin-4-yl)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-benzenesulfonamide",CHEMBL1954228,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM,Inhibition,<=,10.0,%,Cc1nn(C)c(C)c1NS(=O)(=O)c1c(Cl)cc(-c2ccnc(N3CCNCC3)c2)cc1Cl,CHEMBL1949590,Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors.,J. Med. Chem.,2012.0,55,1,140,152,10.1021/jm201091t,22148754.0,
8049914,CHEMBL1957497,"4-(6-(1H-indazol-4-yl)-2-((4-(methylsulfonyl)piperazin-1-yl)methyl)imidazo[1,2-a]pyrazin-8-yl)morpholine",CHEMBL1959996,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,25.0,%,CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3n2)CC1,CHEMBL1955823,"Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.",Bioorg. Med. Chem. Lett.,2012.0,22,5,1874,1878,10.1016/j.bmcl.2012.01.074,22325943.0,
8049915,CHEMBL1957500,"4-(5-chloro-6-(1H-indazol-4-yl)-2-((4-(methylsulfonyl)piperazin-1-yl)methyl)imidazo[1,2-a]pyrazin-8-yl)morpholine",CHEMBL1959996,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,25.0,%,CS(=O)(=O)N1CCN(Cc2cn3c(Cl)c(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3n2)CC1,CHEMBL1955823,"Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.",Bioorg. Med. Chem. Lett.,2012.0,22,5,1874,1878,10.1016/j.bmcl.2012.01.074,22325943.0,
8049916,CHEMBL1957507,"6-(1H-indazol-4-yl)-N-(2-methoxyethyl)-8-morpholinoimidazo[1,2-a]pyrazine-2-carboxamide",CHEMBL1959996,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,25.0,%,COCCNC(=O)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1,CHEMBL1955823,"Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.",Bioorg. Med. Chem. Lett.,2012.0,22,5,1874,1878,10.1016/j.bmcl.2012.01.074,22325943.0,
8049917,CHEMBL521851,"2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine",CHEMBL1959996,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,25.0,%,CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1,CHEMBL1955823,"Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.",Bioorg. Med. Chem. Lett.,2012.0,22,5,1874,1878,10.1016/j.bmcl.2012.01.074,22325943.0,
8055434,CHEMBL1955989,2-(2-cyclohexylvinyl)-5-(2-(trifluoromethyl)phenyl)-1H-benzo[d]imidazole,CHEMBL1958502,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 3.3 uM,Inhibition,=,62.0,%,FC(F)(F)c1ccccc1-c1ccc2[nH]c(/C=C/C3CCCCC3)nc2c1,CHEMBL1955797,Discovery of vinylcycloalkyl-substituted benzimidazole TRPM8 antagonists effective in the treatment of cold allodynia.,Bioorg. Med. Chem. Lett.,2012.0,22,5,1903,1907,10.1016/j.bmcl.2012.01.060,22330635.0,
10851394,CHEMBL2017653,"4-(2,4-dichlorophenyl)-2-morpholino-5-(1H-1,2,4-triazol-5-yl)thiophene-3-carbonitrile",CHEMBL2020208,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,<,30.0,%,N#Cc1c(N2CCOCC2)sc(-c2ncn[nH]2)c1-c1ccc(Cl)cc1Cl,CHEMBL2016534,Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity.,ACS Med. Chem. Lett.,2011.0,2,11,809,813,10.1021/ml200126j,24900269.0,
10865084,CHEMBL2022867,4-(1-phenyl-1H-pyrazol-4-yl)quinoline,CHEMBL2025322,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 5 uM,Inhibition,=,48.0,%,c1ccc(-n2cc(-c3ccnc4ccccc34)cn2)cc1,CHEMBL2021760,"4-(1-Phenyl-1H-pyrazol-4-yl)quinolines as novel, selective and brain penetrant metabotropic glutamate receptor 4 positive allosteric modulators.",Bioorg. Med. Chem. Lett.,2012.0,22,9,3235,3239,10.1016/j.bmcl.2012.03.032,22465637.0,
10865118,CHEMBL2023623,4-(1-phenyl-1H-pyrazol-4-yl)quinolin-7-yl diethylcarbamate,CHEMBL2025322,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 5 uM,Inhibition,=,88.0,%,CCN(CC)C(=O)Oc1ccc2c(-c3cnn(-c4ccccc4)c3)ccnc2c1,CHEMBL2021760,"4-(1-Phenyl-1H-pyrazol-4-yl)quinolines as novel, selective and brain penetrant metabotropic glutamate receptor 4 positive allosteric modulators.",Bioorg. Med. Chem. Lett.,2012.0,22,9,3235,3239,10.1016/j.bmcl.2012.03.032,22465637.0,
10868771,CHEMBL189475,Trifluoro-methanesulfonic acid 4-((R)-2-methanesulfonylamino-1-methyl-2-oxo-ethyl)-phenyl ester,CHEMBL2026797,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using 7MFC as substrate at 10 uM,Inhibition,<,5.0,%,C[C@@H](C(=O)NS(C)(=O)=O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1,CHEMBL2021812,Aryltriflates as a Neglected Moiety in Medicinal Chemistry: A Case Study from a Lead Optimization of CXCL8 Inhibitors.,ACS Med. Chem. Lett.,2011.0,2,10,768,773,10.1021/ml2001533,24900265.0,
10868810,CHEMBL2024080,"4-{(2R)-1-[(4-methyl-1,3-thiazol-2-yl)amino]-1-oxopropan-2-yl}phenyltrifluoromethanesulfonate",CHEMBL2026797,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using 7MFC as substrate at 10 uM,Inhibition,=,60.0,%,Cc1csc(NC(=O)[C@H](C)c2ccc(OS(=O)(=O)C(F)(F)F)cc2)n1,CHEMBL2021812,Aryltriflates as a Neglected Moiety in Medicinal Chemistry: A Case Study from a Lead Optimization of CXCL8 Inhibitors.,ACS Med. Chem. Lett.,2011.0,2,10,768,773,10.1021/ml2001533,24900265.0,
10868817,CHEMBL2024079,"4-[(2R)-1-oxo-1-{[4-(trifluoromethyl)-1,3-oxazol-2-yl]amino}propan-2-yl]phenyltrifluoromethanesulfonate",CHEMBL2026797,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using 7MFC as substrate at 10 uM,Inhibition,=,87.0,%,C[C@@H](C(=O)Nc1nc(C(F)(F)F)co1)c1ccc(OS(=O)(=O)C(F)(F)F)cc1,CHEMBL2021812,Aryltriflates as a Neglected Moiety in Medicinal Chemistry: A Case Study from a Lead Optimization of CXCL8 Inhibitors.,ACS Med. Chem. Lett.,2011.0,2,10,768,773,10.1021/ml2001533,24900265.0,
10868824,CHEMBL244554,"4-[(1R)-1-methyl-2-oxo-2-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}ethyl]phenyltrifluoromethanesulfonate",CHEMBL2026797,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using 7MFC as substrate at 10 uM,Inhibition,=,73.0,%,C[C@@H](C(=O)Nc1nc(C(F)(F)F)cs1)c1ccc(OS(=O)(=O)C(F)(F)F)cc1,CHEMBL2021812,Aryltriflates as a Neglected Moiety in Medicinal Chemistry: A Case Study from a Lead Optimization of CXCL8 Inhibitors.,ACS Med. Chem. Lett.,2011.0,2,10,768,773,10.1021/ml2001533,24900265.0,
10868838,CHEMBL2024077,"4-[(2R)-1-oxo-1-(4H-1,2,4-triazol-3-ylamino)propan-2-yl]phenyltrifluoromethanesulfonate",CHEMBL2026797,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using 7MFC as substrate at 10 uM,Inhibition,<,5.0,%,C[C@@H](C(=O)Nc1nnc[nH]1)c1ccc(OS(=O)(=O)C(F)(F)F)cc1,CHEMBL2021812,Aryltriflates as a Neglected Moiety in Medicinal Chemistry: A Case Study from a Lead Optimization of CXCL8 Inhibitors.,ACS Med. Chem. Lett.,2011.0,2,10,768,773,10.1021/ml2001533,24900265.0,
10868845,CHEMBL390859,"4-[(1R)-1-Methyl-2-(1,3-oxazol-2-ylamino)-2-oxoethyl]phenyl trifluoromethanesulfonate",CHEMBL2026797,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using 7MFC as substrate at 10 uM,Inhibition,=,70.0,%,C[C@@H](C(=O)Nc1ncco1)c1ccc(OS(=O)(=O)C(F)(F)F)cc1,CHEMBL2021812,Aryltriflates as a Neglected Moiety in Medicinal Chemistry: A Case Study from a Lead Optimization of CXCL8 Inhibitors.,ACS Med. Chem. Lett.,2011.0,2,10,768,773,10.1021/ml2001533,24900265.0,
10868852,CHEMBL2024076,"4-[(2R)-1-oxo-1-(1,3,4-thiadiazol-2-ylamino)propan-2-yl]phenyl trifluoromethanesulfonate",CHEMBL2026797,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using 7MFC as substrate at 10 uM,Inhibition,=,50.0,%,C[C@@H](C(=O)Nc1nncs1)c1ccc(OS(=O)(=O)C(F)(F)F)cc1,CHEMBL2021812,Aryltriflates as a Neglected Moiety in Medicinal Chemistry: A Case Study from a Lead Optimization of CXCL8 Inhibitors.,ACS Med. Chem. Lett.,2011.0,2,10,768,773,10.1021/ml2001533,24900265.0,
10868859,CHEMBL244553,"4-[(1R)-1-methyl-2-oxo-2-(1,3-thiazol-2-ylamino)ethyl]phenyl trifluoromethanesulfonate",CHEMBL2026797,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using 7MFC as substrate at 10 uM,Inhibition,=,53.0,%,C[C@@H](C(=O)Nc1nccs1)c1ccc(OS(=O)(=O)C(F)(F)F)cc1,CHEMBL2021812,Aryltriflates as a Neglected Moiety in Medicinal Chemistry: A Case Study from a Lead Optimization of CXCL8 Inhibitors.,ACS Med. Chem. Lett.,2011.0,2,10,768,773,10.1021/ml2001533,24900265.0,
10868866,CHEMBL244551,4-[(1R)-1-methyl-2-oxo-2-(pyridin-2-ylamino)ethyl]phenyl trifluoromethanesulfonate,CHEMBL2026797,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using 7MFC as substrate at 10 uM,Inhibition,=,37.0,%,C[C@@H](C(=O)Nc1ccccn1)c1ccc(OS(=O)(=O)C(F)(F)F)cc1,CHEMBL2021812,Aryltriflates as a Neglected Moiety in Medicinal Chemistry: A Case Study from a Lead Optimization of CXCL8 Inhibitors.,ACS Med. Chem. Lett.,2011.0,2,10,768,773,10.1021/ml2001533,24900265.0,
10868899,CHEMBL242613,(R)-2-(4-(trifluoromethylsulfonyloxy)phenyl)propanoic acid,CHEMBL2026797,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using 7MFC as substrate at 10 uM,Inhibition,<,5.0,%,C[C@@H](C(=O)O)c1ccc(OS(=O)(=O)C(F)(F)F)cc1,CHEMBL2021812,Aryltriflates as a Neglected Moiety in Medicinal Chemistry: A Case Study from a Lead Optimization of CXCL8 Inhibitors.,ACS Med. Chem. Lett.,2011.0,2,10,768,773,10.1021/ml2001533,24900265.0,
10872271,CHEMBL2024087,"3-[(2(S)-Azetidinyl)methoxy]-5-[(1S,2R)-2-(2-hydroxyethyl)-cyclopropyl]pyridine",CHEMBL2026519,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 up to 10 uM,Inhibition,<=,25.0,%,OCC[C@H]1C[C@@H]1c1cncc(OC[C@@H]2CCN2)c1,CHEMBL2021777,Chemistry and behavioral studies identify chiral cyclopropanes as selective α4β2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile.,J. Med. Chem.,2012.0,55,2,717,724,10.1021/jm201157c,22171543.0,
10872272,CHEMBL2024089,"3-[(2(S)-Azetidinyl)methoxy]-5-[(1S,2R)-2-[2-(N-methylcarbamoyloxy)ethyl]cyclopropyl]pyridine",CHEMBL2026519,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 up to 10 uM,Inhibition,<=,25.0,%,CNC(=O)OCC[C@H]1C[C@@H]1c1cncc(OC[C@@H]2CCN2)c1,CHEMBL2021777,Chemistry and behavioral studies identify chiral cyclopropanes as selective α4β2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile.,J. Med. Chem.,2012.0,55,2,717,724,10.1021/jm201157c,22171543.0,
10872273,CHEMBL2024094,"3-[(2(S)-Azetidinyl)methoxy]-5-[(1S,2R)-2-(2-methoxyethyl)-cyclopropyl]pyridine",CHEMBL2026519,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 up to 10 uM,Inhibition,<=,25.0,%,COCC[C@H]1C[C@@H]1c1cncc(OC[C@@H]2CCN2)c1,CHEMBL2021777,Chemistry and behavioral studies identify chiral cyclopropanes as selective α4β2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile.,J. Med. Chem.,2012.0,55,2,717,724,10.1021/jm201157c,22171543.0,
10883348,CHEMBL2029800,1-Isopentyl-4-(4-pyrid-4-yloxyphenyl)-2-oxopyridine-3-carbonitrile,CHEMBL2033875,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 1 uM,Inhibition,=,82.0,%,CC(C)CCn1ccc(-c2ccc(Oc3ccncc3)cc2)c(C#N)c1=O,CHEMBL2029212,"Discovery of 1,4-disubstituted 3-cyano-2-pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor.",J. Med. Chem.,2012.0,55,5,2388,2405,10.1021/jm2016864,22364337.0,
10883352,CHEMBL2029805,"1-Isopentyl-4-[4-(2-methylpyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carbonitrile",CHEMBL2033881,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 5 uM,Inhibition,<,50.0,%,Cc1cc(Oc2ccc(-c3ccn(CCC(C)C)c(=O)c3C#N)cc2)ccn1,CHEMBL2029212,"Discovery of 1,4-disubstituted 3-cyano-2-pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor.",J. Med. Chem.,2012.0,55,5,2388,2405,10.1021/jm2016864,22364337.0,
10911805,CHEMBL546284,TCMDC-123479,CHEMBL2038382,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,71.0,%,CCc1ccc(C(=O)NC(=O)c2ccccc2O)cc1,CHEMBL2034972,"Synthesis, biological evaluation, and structure-activity relationships of N-benzoyl-2-hydroxybenzamides as agents active against P. falciparum (K1 strain), Trypanosomes, and Leishmania.",J. Med. Chem.,2012.0,55,7,3088,3100,10.1021/jm2015183,22352841.0,
10926468,CHEMBL105592,"[1-(3-Benzo[1,3]dioxol-5-ylmethyl-3H-imidazol-4-ylmethyl)-4-naphthalen-1-yl-1H-pyrrol-3-yl]-(4-methyl-piperazin-1-yl)-methanone",CHEMBL2045908,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9-mediated diclofenac 4-hydroxylation in liver microsomes at 10 uM coincubated with substrate,Inhibition,=,30.0,%,CN1CCN(C(=O)c2cn(Cc3cncn3Cc3ccc4c(c3)OCO4)cc2-c2cccc3ccccc23)CC1,CHEMBL2040745,"Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities.",Bioorg. Med. Chem. Lett.,2012.0,22,9,3067,3071,10.1016/j.bmcl.2012.03.070,22497764.0,
10926469,CHEMBL105592,"[1-(3-Benzo[1,3]dioxol-5-ylmethyl-3H-imidazol-4-ylmethyl)-4-naphthalen-1-yl-1H-pyrrol-3-yl]-(4-methyl-piperazin-1-yl)-methanone",CHEMBL2045909,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9-mediated diclofenac 4-hydroxylation in liver microsomes at 10 uM preincubated for 15 mins prior substrate addition,Inhibition,=,29.8,%,CN1CCN(C(=O)c2cn(Cc3cncn3Cc3ccc4c(c3)OCO4)cc2-c2cccc3ccccc23)CC1,CHEMBL2040745,"Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities.",Bioorg. Med. Chem. Lett.,2012.0,22,9,3067,3071,10.1016/j.bmcl.2012.03.070,22497764.0,
10926470,CHEMBL105592,"[1-(3-Benzo[1,3]dioxol-5-ylmethyl-3H-imidazol-4-ylmethyl)-4-naphthalen-1-yl-1H-pyrrol-3-yl]-(4-methyl-piperazin-1-yl)-methanone",CHEMBL2045910,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9-mediated tolbutamide 6-hydroxylation in liver microsomes at 10 uM coincubated with substrate,Inhibition,=,49.6,%,CN1CCN(C(=O)c2cn(Cc3cncn3Cc3ccc4c(c3)OCO4)cc2-c2cccc3ccccc23)CC1,CHEMBL2040745,"Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities.",Bioorg. Med. Chem. Lett.,2012.0,22,9,3067,3071,10.1016/j.bmcl.2012.03.070,22497764.0,
10926471,CHEMBL105592,"[1-(3-Benzo[1,3]dioxol-5-ylmethyl-3H-imidazol-4-ylmethyl)-4-naphthalen-1-yl-1H-pyrrol-3-yl]-(4-methyl-piperazin-1-yl)-methanone",CHEMBL2045911,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9-mediated tolbutamide 6-hydroxylation in liver microsomes at 10 uM preincubated for 15 mins prior substrate addition,Inhibition,=,50.7,%,CN1CCN(C(=O)c2cn(Cc3cncn3Cc3ccc4c(c3)OCO4)cc2-c2cccc3ccccc23)CC1,CHEMBL2040745,"Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities.",Bioorg. Med. Chem. Lett.,2012.0,22,9,3067,3071,10.1016/j.bmcl.2012.03.070,22497764.0,
10942093,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL2050711,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,>,90.0,%,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL2046362,Synthesis and evaluation of novel potent HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,2012.0,22,14,4864,4868,10.1016/j.bmcl.2012.05.039,22704887.0,
10948245,CHEMBL2048746,3-(1-Benzenesulfonyl-1H-indol-5-yl)-N-hydroxyacrylamide,CHEMBL2050541,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,22.0,%,O=C(/C=C/c1ccc2c(ccn2S(=O)(=O)c2ccccc2)c1)NO,CHEMBL2046324,Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo.,J. Med. Chem.,2012.0,55,8,3777,3791,10.1021/jm300197a,22439863.0,
10960431,CHEMBL2058169,"6-(2-aminopyrimidin-5-yl)-8-morpholino-N-(2-morpholinoethyl)imidazo[1,2-a]pyrazine-2-carboxamide",CHEMBL2060313,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,6.0,%,Nc1ncc(-c2cn3cc(C(=O)NCCN4CCOCC4)nc3c(N3CCOCC3)n2)cn1,CHEMBL2057167,"Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.",Bioorg. Med. Chem. Lett.,2012.0,22,16,5208,5214,10.1016/j.bmcl.2012.06.093,22819764.0,
10960432,CHEMBL2058167,"6-(2-aminopyrimidin-5-yl)-N-(3-methoxypropyl)-8-morpholinoimidazo[1,2-a]pyrazine-2-carboxamide",CHEMBL2060313,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,10.0,%,COCCCNC(=O)c1cn2cc(-c3cnc(N)nc3)nc(N3CCOCC3)c2n1,CHEMBL2057167,"Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.",Bioorg. Med. Chem. Lett.,2012.0,22,16,5208,5214,10.1016/j.bmcl.2012.06.093,22819764.0,
10960433,CHEMBL2058166,"6-(2-aminopyrimidin-5-yl)-N-(2-methoxyethyl)-8-morpholinoimidazo[1,2-a]pyrazine-2-carboxamide",CHEMBL2060313,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,6.0,%,COCCNC(=O)c1cn2cc(-c3cnc(N)nc3)nc(N3CCOCC3)c2n1,CHEMBL2057167,"Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.",Bioorg. Med. Chem. Lett.,2012.0,22,16,5208,5214,10.1016/j.bmcl.2012.06.093,22819764.0,
10960434,CHEMBL2058165,"6-(2-aminopyrimidin-5-yl)-N-(3-(dimethylamino)propyl)-8-morpholinoimidazo[1,2-a]pyrazine-2-carboxamide",CHEMBL2060313,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,8.0,%,CN(C)CCCNC(=O)c1cn2cc(-c3cnc(N)nc3)nc(N3CCOCC3)c2n1,CHEMBL2057167,"Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.",Bioorg. Med. Chem. Lett.,2012.0,22,16,5208,5214,10.1016/j.bmcl.2012.06.093,22819764.0,
10960435,CHEMBL2058164,"6-(2-aminopyrimidin-5-yl)-N-(2-(dimethylamino)ethyl)-8-morpholinoimidazo[1,2-a]pyrazine-2-carboxamide",CHEMBL2060313,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,6.0,%,CN(C)CCNC(=O)c1cn2cc(-c3cnc(N)nc3)nc(N3CCOCC3)c2n1,CHEMBL2057167,"Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.",Bioorg. Med. Chem. Lett.,2012.0,22,16,5208,5214,10.1016/j.bmcl.2012.06.093,22819764.0,
10960436,CHEMBL2058163,"6-(2-aminopyrimidin-5-yl)-8-morpholinoimidazo[1,2-a]pyrazine-2-carboxamide",CHEMBL2060313,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,=,5.0,%,NC(=O)c1cn2cc(-c3cnc(N)nc3)nc(N3CCOCC3)c2n1,CHEMBL2057167,"Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.",Bioorg. Med. Chem. Lett.,2012.0,22,16,5208,5214,10.1016/j.bmcl.2012.06.093,22819764.0,
10978742,CHEMBL2063756,"1-Ethyl-3-{4-[4-((S)-3-methyl-morpholin-4-yl)-6,6-dioxo-5,6,7,8-tetrahydro-6lambda*6*-thiopyrano[4,3-d]pyrimidin-2-yl]-phenyl}-urea",CHEMBL2065067,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,<=,25.0,%,CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CS(=O)(=O)CC3)cc1,CHEMBL2062409,Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors.,Bioorg. Med. Chem. Lett.,2012.0,22,15,5114,5117,10.1016/j.bmcl.2012.05.104,22765900.0,
10989510,CHEMBL2069921,"5-((4-benzylpiperazin-1-yl)methyl)-3-phenyl-1,2,4-oxadiazole",CHEMBL2072918,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of human recombinant CYP2C9 coexpressed in Escherichia coli at 50 uM using diclofenac as probe,Inhibition,<,19.0,%,c1ccc(CN2CCN(Cc3nc(-c4ccccc4)no3)CC2)cc1,CHEMBL2069246,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,2012.0,55,5,1817,1830,10.1021/jm2013248,22185670.0,
10989511,CHEMBL2069806,"N-cyclohexyl-5-(phenylsulfonylmethyl)-1,3,4-oxadiazole-2-carboxamide",CHEMBL2072918,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of human recombinant CYP2C9 coexpressed in Escherichia coli at 50 uM using diclofenac as probe,Inhibition,<,19.0,%,O=C(NC1CCCCC1)c1nnc(CS(=O)(=O)c2ccccc2)o1,CHEMBL2069246,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,2012.0,55,5,1817,1830,10.1021/jm2013248,22185670.0,
10989512,CHEMBL2069805,"N-cyclohexyl-3-(phenylsulfonylmethyl)-1,2,4-oxadiazole-5-carboxamide",CHEMBL2072918,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of human recombinant CYP2C9 coexpressed in Escherichia coli at 50 uM using diclofenac as probe,Inhibition,<,19.0,%,O=C(NC1CCCCC1)c1nc(CS(=O)(=O)c2ccccc2)no1,CHEMBL2069246,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,2012.0,55,5,1817,1830,10.1021/jm2013248,22185670.0,
10989513,CHEMBL2069804,"2-cyclohexyl-5-(pyridin-4-yl)-1,3,4-oxadiazole",CHEMBL2072918,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of human recombinant CYP2C9 coexpressed in Escherichia coli at 50 uM using diclofenac as probe,Inhibition,<,19.0,%,c1cc(-c2nnc(C3CCCCC3)o2)ccn1,CHEMBL2069246,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,2012.0,55,5,1817,1830,10.1021/jm2013248,22185670.0,
10989514,CHEMBL2069803,"5-cyclohexyl-3-(pyridin-4-yl)-1,2,4-oxadiazole",CHEMBL2072918,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of human recombinant CYP2C9 coexpressed in Escherichia coli at 50 uM using diclofenac as probe,Inhibition,<,19.0,%,c1cc(-c2noc(C3CCCCC3)n2)ccn1,CHEMBL2069246,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,2012.0,55,5,1817,1830,10.1021/jm2013248,22185670.0,
10989515,CHEMBL2069802,"5-(phenylsulfonylmethyl)-N-(pyridin-4-ylmethyl)-1,3,4-oxadiazole-2-carboxamide",CHEMBL2072918,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of human recombinant CYP2C9 coexpressed in Escherichia coli at 50 uM using diclofenac as probe,Inhibition,<,19.0,%,O=C(NCc1ccncc1)c1nnc(CS(=O)(=O)c2ccccc2)o1,CHEMBL2069246,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,2012.0,55,5,1817,1830,10.1021/jm2013248,22185670.0,
10989516,CHEMBL2069801,"3-(phenylsulfonylmethyl)-N-(pyridin-4-ylmethyl)-1,2,4-oxadiazole-5-carboxamide",CHEMBL2072918,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of human recombinant CYP2C9 coexpressed in Escherichia coli at 50 uM using diclofenac as probe,Inhibition,<,19.0,%,O=C(NCc1ccncc1)c1nc(CS(=O)(=O)c2ccccc2)no1,CHEMBL2069246,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,2012.0,55,5,1817,1830,10.1021/jm2013248,22185670.0,
10989517,CHEMBL2069800,"2-(2-chloropyridin-4-yl)-5-((4-cyclopropyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,3,4-oxadiazole",CHEMBL2072918,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of human recombinant CYP2C9 coexpressed in Escherichia coli at 50 uM using diclofenac as probe,Inhibition,<,19.0,%,Clc1cc(-c2nnc(CSc3nnc(-c4ccncc4)n3C3CC3)o2)ccn1,CHEMBL2069246,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,2012.0,55,5,1817,1830,10.1021/jm2013248,22185670.0,
10989518,CHEMBL2069799,"5-(2-chloropyridin-4-yl)-3-((4-cyclopropyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole",CHEMBL2072918,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of human recombinant CYP2C9 coexpressed in Escherichia coli at 50 uM using diclofenac as probe,Inhibition,<,19.0,%,Clc1cc(-c2nc(CSc3nnc(-c4ccncc4)n3C3CC3)no2)ccn1,CHEMBL2069246,Oxadiazoles in medicinal chemistry.,J. Med. Chem.,2012.0,55,5,1817,1830,10.1021/jm2013248,22185670.0,
11013992,CHEMBL2087421,"4-Methoxy-N,2,6-trimethyl-N-[2-[2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethoxy]ethyl]benzenesulfonamide",CHEMBL2092289,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 5 uM,Inhibition,=,-19.0,%,COc1cc(C)c(S(=O)(=O)N(C)CCOCC(=O)N2CCN(C3CCN(C)CC3)CC2)c(C)c1,CHEMBL2086382,From bradykinin B2 receptor antagonists to orally active and selective bradykinin B1 receptor antagonists.,J. Med. Chem.,2012.0,55,6,2574,2584,10.1021/jm2016057,22369198.0,
11014545,CHEMBL2087438,5-Piperidin-1-ylpentanoic Acid[5-(4-Chlorophenyl)-2H-pyrazol-3-yl]Amide,CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,-3.0,%,O=C(CCCCN1CCCCC1)Nc1cc(-c2ccc(Cl)cc2)n[nH]1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014546,CHEMBL2087443,5-Piperidin-1-ylpentanoic Acid[5-(4-Methoxyphenyl)-2H-pyrazol-3-yl]Amide,CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,-1.0,%,COc1ccc(-c2cc(NC(=O)CCCCN3CCCCC3)[nH]n2)cc1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014547,CHEMBL2087444,5-Piperidin-1-ylpentanoic Acid[5-(3-Methoxyphenyl)-2H-pyrazol-3-yl]Amide,CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,-10.0,%,COc1cccc(-c2cc(NC(=O)CCCCN3CCCCC3)[nH]n2)c1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014548,CHEMBL2087445,5-Piperidin-1-ylpentanoic Acid[5-(2-Methoxyphenyl)-2H-pyrazol-3-yl]Amide,CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,-7.0,%,COc1ccccc1-c1cc(NC(=O)CCCCN2CCCCC2)[nH]n1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014549,CHEMBL2087446,5-Piperidin-1-ylpentanoic Acid[5-(4-Methoxyphenyl)-4-methyl-2H-pyrazol-3-yl]Amide,CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,-9.0,%,COc1ccc(-c2n[nH]c(NC(=O)CCCCN3CCCCC3)c2C)cc1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014550,CHEMBL2087447,5-Piperidin-1-ylpentanoic Acid[5-(4-Fluorophenyl)-2H-pyrazol-3-yl]Amide,CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,-33.0,%,O=C(CCCCN1CCCCC1)Nc1cc(-c2ccc(F)cc2)n[nH]1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014551,CHEMBL2087448,5-Piperidin-1-ylpentanoic Acid[5-(4-Bromophenyl)-2H-pyrazol-3-yl]Amide,CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,-25.0,%,O=C(CCCCN1CCCCC1)Nc1cc(-c2ccc(Br)cc2)n[nH]1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014552,CHEMBL2087449,5-Piperidin-1-ylpentanoic Acid(5-Pyridin-4-yl-2H-pyrazol-3-yl)Amide,CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,-10.0,%,O=C(CCCCN1CCCCC1)Nc1cc(-c2ccncc2)n[nH]1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014553,CHEMBL2087450,5-Piperidin-1-ylpentanoic Acid[5-(4-Trifluoromethylphenyl)-2H-pyrazol-3-yl]Amide,CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,11.0,%,O=C(CCCCN1CCCCC1)Nc1cc(-c2ccc(C(F)(F)F)cc2)n[nH]1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014554,CHEMBL2087451,5-Piperidin-1-ylpentanoic Acid(5-Furan-2-yl-2H-pyrazol-3-yl)Amide,CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,-33.0,%,O=C(CCCCN1CCCCC1)Nc1cc(-c2ccco2)n[nH]1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014555,CHEMBL2087452,5-(4-Methylpiperidin-1-yl)pentanoic Acid[5-(4-Methoxyphenyl)-2H-pyrazol-3-yl]Amide,CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,-15.0,%,COc1ccc(-c2cc(NC(=O)CCCCN3CCC(C)CC3)[nH]n2)cc1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014556,CHEMBL2087453,5-Morpholin-4-ylpentanoic Acid[5-(4-Methoxyphenyl)-2H-pyrazol-3-yl]Amide,CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,-24.0,%,COc1ccc(-c2cc(NC(=O)CCCCN3CCOCC3)[nH]n2)cc1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014557,CHEMBL2087454,5-(3-Oxopiperazin-1-yl)pentanoic Acid[5-(4-Methoxyphenyl)-2H-pyrazol-3-yl]Amide,CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,-22.0,%,COc1ccc(-c2cc(NC(=O)CCCCN3CCNC(=O)C3)[nH]n2)cc1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014558,CHEMBL2087455,1-{4-[5-(4-Methoxyphenyl)-2H-pyrazol-3-ylcarbamoyl]butyl}piperidine-4-carboxylic AcidAmide,CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,-15.0,%,COc1ccc(-c2cc(NC(=O)CCCCN3CCC(C(N)=O)CC3)[nH]n2)cc1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014559,CHEMBL2087456,5-Azepan-1-ylpentanoic Acid [5-(4-Methoxyphenyl)-2H-pyrazol-3-yl]Amide,CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,-2.0,%,COc1ccc(-c2cc(NC(=O)CCCCN3CCCCCC3)[nH]n2)cc1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014560,CHEMBL2087457,"5-[1,4]Oxazepan-4-ylpentanoic Acid[5-(4-Methoxyphenyl)-2H-pyrazol-3-yl]Amide",CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,-18.0,%,COc1ccc(-c2cc(NC(=O)CCCCN3CCCOCC3)[nH]n2)cc1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014561,CHEMBL2087458,"5-[1,4]Diazepan-1-ylpentanoic Acid[5-(4-Methoxyphenyl)-2H-pyrazol-3-yl]Amide",CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,-1.0,%,COc1ccc(-c2cc(NC(=O)CCCCN3CCCNCC3)[nH]n2)cc1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014562,CHEMBL2087459,"5-(5-Oxo[1,4]diazepan-1-yl)pentanoic Acid[5-(4-Methoxyphenyl)-2H-pyrazol-3-yl]Amide",CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,-28.0,%,COc1ccc(-c2cc(NC(=O)CCCCN3CCNC(=O)CC3)[nH]n2)cc1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014563,CHEMBL2086582,"5-(4-Acetyl-[1,4]diazepan-1-yl)pentanoic Acid[5-(4-Methoxyphenyl)-2H-pyrazol-3-yl]Amide",CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,-8.0,%,COc1ccc(-c2cc(NC(=O)CCCCN3CCCN(C(C)=O)CC3)[nH]n2)cc1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014564,CHEMBL2086583,"5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid[5-(4-Methoxyphenyl)-4-methyl-2H-pyrazol-3-yl]Amide",CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,-13.0,%,COc1ccc(-c2n[nH]c(NC(=O)CCCCN3CCCN(C(C)=O)CC3)c2C)cc1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014565,CHEMBL2086584,"5-(4-Acetyl[1,4]diazepan-1-yl)-2-methylpentanoic Acid[5-(4-Methoxyphenyl)-2H-pyrazol-3-yl]Amide",CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,2.0,%,COc1ccc(-c2cc(NC(=O)C(C)CCCN3CCCN(C(C)=O)CC3)[nH]n2)cc1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11014566,CHEMBL2086585,"5-(4-Acetyl[1,4]diazepan-1-yl)pentanoic Acid[5-(4-Methoxyphenyl)-1H-imidazol-2-yl]Amide",CHEMBL2091629,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 using MFC as substrate at 3 uM after 45 mins by Gentest method,Inhibition,=,12.0,%,COc1ccc(-c2cnc(NC(=O)CCCCN3CCCN(C(C)=O)CC3)[nH]2)cc1,CHEMBL2086339,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",J. Med. Chem.,2012.0,55,10,4806,4823,10.1021/jm300247y,22468936.0,
11016324,CHEMBL2087474,"5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine",CHEMBL2092086,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,30.0,%,CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1,CHEMBL2086238,"Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.",Bioorg. Med. Chem. Lett.,2012.0,22,10,3460,3466,10.1016/j.bmcl.2012.03.090,22520259.0,
11016325,CHEMBL2087479,"5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)-4-(trifluoromethyl)pyrimidin-2-amine",CHEMBL2092086,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,30.0,%,CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4C(F)(F)F)nc(N4CCOCC4)c3n2)CC1,CHEMBL2086238,"Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.",Bioorg. Med. Chem. Lett.,2012.0,22,10,3460,3466,10.1016/j.bmcl.2012.03.090,22520259.0,
11016329,CHEMBL2087490,"5-(2-((4-(ethylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine",CHEMBL2092086,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,30.0,%,CCS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1,CHEMBL2086238,"Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.",Bioorg. Med. Chem. Lett.,2012.0,22,10,3460,3466,10.1016/j.bmcl.2012.03.090,22520259.0,
11016330,CHEMBL2087491,"5-(3-bromo-2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine",CHEMBL2092086,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,30.0,%,CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn3c2Br)CC1,CHEMBL2086238,"Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.",Bioorg. Med. Chem. Lett.,2012.0,22,10,3460,3466,10.1016/j.bmcl.2012.03.090,22520259.0,
11016331,CHEMBL2087492,"5-(3-methyl-2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine",CHEMBL2092086,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,30.0,%,Cc1c(CN2CCN(S(C)(=O)=O)CC2)nc2c(N3CCOCC3)nc(-c3cnc(N)nc3)cn12,CHEMBL2086238,"Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.",Bioorg. Med. Chem. Lett.,2012.0,22,10,3460,3466,10.1016/j.bmcl.2012.03.090,22520259.0,
11016332,CHEMBL2087493,"5-(5-chloro-2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine",CHEMBL2092086,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,30.0,%,CS(=O)(=O)N1CCN(Cc2cn3c(Cl)c(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1,CHEMBL2086238,"Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.",Bioorg. Med. Chem. Lett.,2012.0,22,10,3460,3466,10.1016/j.bmcl.2012.03.090,22520259.0,
12037054,CHEMBL2147845,(Z)-2-[(1H-Indazol-3-yl)methylene]-6-methoxy-7-(piperazin-1-ylmethyl)benzofuran-3(2H)-one,CHEMBL2149347,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,1.0,%,COc1ccc2c(c1CN1CCNCC1)O/C(=C\c1n[nH]c3ccccc13)C2=O,CHEMBL2146430,Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound.,J. Med. Chem.,2012.0,55,11,5151,5164,10.1021/jm3001289,22540945.0,
12052160,CHEMBL2153191,2-[(3S)-1-[5-(Cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic Acid,CHEMBL2156392,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,25.0,%,CCCSc1nc(N2CCC[C@@H](CC(=O)O)C2)ccc1C(=O)NC1CCCCC1,CHEMBL2151015,"Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017).",J. Med. Chem.,2012.0,55,12,5951,5964,10.1021/jm300592r,22691057.0,
12071523,CHEMBL2158890,2-(Adamantan-1-yl)-N-methyl-N-(thiophen-2-ylmethyl)acetamide,CHEMBL2161926,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,49.0,%,CN(Cc1cccs1)C(=O)CC12CC3CC(CC(C3)C1)C2,CHEMBL2157887,Adamantyl carboxamides and acetamides as potent human 11β-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem.,2012.0,20,21,6394,6402,10.1016/j.bmc.2012.08.056,23040895.0,
12071524,CHEMBL2159075,Adamantane-1-carboxylic acid methyl-thiophen-2-ylmethyl-amide,CHEMBL2161926,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,62.0,%,CN(Cc1cccs1)C(=O)C12CC3CC(CC(C3)C1)C2,CHEMBL2157887,Adamantyl carboxamides and acetamides as potent human 11β-hydroxysteroid dehydrogenase type 1 inhibitors.,Bioorg. Med. Chem.,2012.0,20,21,6394,6402,10.1016/j.bmc.2012.08.056,23040895.0,
12073241,CHEMBL2158485,trans-4-cyclopropyl-N-(5-hydroxy-2-adamantyl)-2-morpholino-pyrimidine-5-carboxamide,CHEMBL2161681,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,25.0,%,O=C(N[C@H]1C2CC3CC1C[C@](O)(C3)C2)c1cnc(N2CCOCC2)nc1C1CC1,CHEMBL2157961,Optimisation of pharmacokinetic properties in a neutral series of 11β-HSD1 inhibitors.,Bioorg. Med. Chem. Lett.,2012.0,22,21,6756,6761,10.1016/j.bmcl.2012.08.070,23013933.0,
12083696,CHEMBL2163430,"(2R,3R,4R,5S)-1-(6-(Heptan-4-yloxy)hexyl)-2-(hydroxymethyl)piperidine-3,4,5-triol",CHEMBL2167921,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,43.5,%,CCCC(CCC)OCCCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,CHEMBL2163238,"Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.",J. Med. Chem.,2012.0,55,13,6061,6075,10.1021/jm300171v,22712544.0,
12083697,CHEMBL2163425,"(2R,3R,4R,5S)-2-(Hydroxymethyl)-1-(6-(3-(trifluoromethyl)phenoxy)hexyl)piperidine-3,4,5-triol",CHEMBL2167921,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,37.6,%,OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1CCCCCCOc1cccc(C(F)(F)F)c1,CHEMBL2163238,"Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.",J. Med. Chem.,2012.0,55,13,6061,6075,10.1021/jm300171v,22712544.0,
12083698,CHEMBL2165924,"(2R,3R,4R,5S)-2-(Hydroxymethyl)-1-(6-(2-methoxyphenoxy)hexyl)piperidine-3,4,5-triol",CHEMBL2167921,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,11.7,%,COc1ccccc1OCCCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,CHEMBL2163238,"Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.",J. Med. Chem.,2012.0,55,13,6061,6075,10.1021/jm300171v,22712544.0,
12083699,CHEMBL2165927,"(2R,3R,4R,5S)-1-(6-(Benzyloxy)hexyl)-2-(hydroxymethyl)piperidine-3,4,5-triol",CHEMBL2167921,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,10.7,%,OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1CCCCCCOCc1ccccc1,CHEMBL2163238,"Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.",J. Med. Chem.,2012.0,55,13,6061,6075,10.1021/jm300171v,22712544.0,
12083700,CHEMBL2165929,"(2R,3R,4R,5S)-2-(Hydroxymethyl)-1-(3-(3-propoxyphenyl)propyl)piperidine-3,4,5-triol",CHEMBL2167921,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,10.5,%,CCCOc1cccc(CCCN2C[C@H](O)[C@@H](O)[C@H](O)[C@H]2CO)c1,CHEMBL2163238,"Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.",J. Med. Chem.,2012.0,55,13,6061,6075,10.1021/jm300171v,22712544.0,
12083701,CHEMBL2163427,"(2R,3R,4R,5S)-1-(7-Ethyl-7-hydroxynonyl)-2-(hydroxymethyl)piperidine-3,4,5-triol",CHEMBL2167921,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,9.6,%,CCC(O)(CC)CCCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,CHEMBL2163238,"Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.",J. Med. Chem.,2012.0,55,13,6061,6075,10.1021/jm300171v,22712544.0,
12083702,CHEMBL2165947,"(2R,3R,4R,5S)-2-(Hydroxymethyl)-1-(6-(m-tolyloxy)hexyl)piperidine-3,4,5-triol",CHEMBL2167921,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,8.9,%,Cc1cccc(OCCCCCCN2C[C@H](O)[C@@H](O)[C@H](O)[C@H]2CO)c1,CHEMBL2163238,"Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.",J. Med. Chem.,2012.0,55,13,6061,6075,10.1021/jm300171v,22712544.0,
12083703,CHEMBL2163421,"(2R,3R,4R,5S)-1-(6-(2,5-Difluorophenoxy)hexyl)-2-(hydroxymethyl)piperidine-3,4,5-triol",CHEMBL2167921,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,7.1,%,OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1CCCCCCOc1cc(F)ccc1F,CHEMBL2163238,"Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.",J. Med. Chem.,2012.0,55,13,6061,6075,10.1021/jm300171v,22712544.0,
12083704,CHEMBL2163419,"(2R,3R,4R,5S)-1-(6-(3-Fluorophenoxy)hexyl)-2-(hydroxymethyl)piperidine-3,4,5-triol",CHEMBL2167921,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,6.2,%,OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1CCCCCCOc1cccc(F)c1,CHEMBL2163238,"Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.",J. Med. Chem.,2012.0,55,13,6061,6075,10.1021/jm300171v,22712544.0,
12083705,CHEMBL2165944,"(2R,3R,4R,5S)-1-(6-(Cycloheptyloxy)hexyl)-2-(hydroxymethyl)piperidine-3,4,5-triol",CHEMBL2167921,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,5.0,%,OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1CCCCCCOC1CCCCCC1,CHEMBL2163238,"Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection.",J. Med. Chem.,2012.0,55,13,6061,6075,10.1021/jm300171v,22712544.0,
12145896,CHEMBL1651219,"3-Chloro-3'-((2-cyclopentyl-3-oxo-2,3-dihydrobenzo[d]isothiazol-6-yloxy)methyl)biphenyl-4-carboxylic Acid",CHEMBL2183961,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM,Inhibition,=,93.0,%,O=C(O)c1cc(-c2cccc(COc3ccc4c(=O)n(C5CCCC5)sc4c3)c2)ccc1Cl,CHEMBL2177081,Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence.,J. Med. Chem.,2012.0,55,22,9434,9445,10.1021/jm3005306,23009245.0,
12145945,CHEMBL1651208,4-Chloro-3'-((2-cyclopentyl-1-oxoisoindolin-5-yloxy)methyl)-biphenyl-3-carboxylic Acid,CHEMBL2183961,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM,Inhibition,=,92.0,%,O=C(O)c1cc(-c2cccc(COc3ccc4c(c3)CN(C3CCCC3)C4=O)c2)ccc1Cl,CHEMBL2177081,Orally active metabotropic glutamate subtype 2 receptor positive allosteric modulators: structure-activity relationships and assessment in a rat model of nicotine dependence.,J. Med. Chem.,2012.0,55,22,9434,9445,10.1021/jm3005306,23009245.0,
12154405,CHEMBL2177609,4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]-benzoic Acid,CHEMBL2184985,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 10 uM,Inhibition,<,25.0,%,CC(C)(C)c1c(C(=O)NC2C3CC4CC(C3)CC2C4)cnn1-c1ccc(C(=O)O)cc1,CHEMBL2177022,Novel acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with reduced acyl glucuronide liability: the discovery of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid (AZD8329).,J. Med. Chem.,2012.0,55,22,10136,10147,10.1021/jm301252n,23088558.0,
12185287,CHEMBL2205784,"N-(4-((1R,2R)-2-(dimethylamino)-1-(1H-1,2,4-triazol-1-yl)propyl)phenyl)benzo[d]thiazol-2-amine",CHEMBL2214479,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 0.4 uM,Inhibition,=,3.0,%,C[C@H]([C@@H](c1ccc(Nc2nc3ccccc3s2)cc1)n1cncn1)N(C)C,CHEMBL2203049,"Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold.",Bioorg. Med. Chem.,2012.0,20,14,4201,4207,10.1016/j.bmc.2012.05.076,22727372.0,
12185288,CHEMBL2205775,"methyl-2,2-dimethyl-3-(4-(phenylamino)phenyl)-3-(1H-1,2,4-triazol-1-yl)propanoate",CHEMBL2214479,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 0.4 uM,Inhibition,=,19.0,%,COC(=O)C(C)(C)C(c1ccc(Nc2ccccc2)cc1)n1cncn1,CHEMBL2203049,"Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold.",Bioorg. Med. Chem.,2012.0,20,14,4201,4207,10.1016/j.bmc.2012.05.076,22727372.0,
12187040,CHEMBL2206420,"2-Methyl-8-(4-(pyrrolidin-1-yl)phenyl)chromeno[7,8-d]imidazol-6(1H)-one",CHEMBL2214398,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 30 uM,Inhibition,=,73.6,%,Cc1nc2ccc3c(=O)cc(-c4ccc(N5CCCC5)cc4)oc3c2[nH]1,CHEMBL2203249,"Optimization of a small tropomyosin-related kinase B (TrkB) agonist 7,8-dihydroxyflavone active in mouse models of depression.",J. Med. Chem.,2012.0,55,19,8524,8537,10.1021/jm301099x,22984948.0,
12187044,CHEMBL2206412,"2-(4-(pyrrolidin-1-yl)phenyl)pyrano[3,2-g]indol-4(9H)-one",CHEMBL2214398,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 30 uM,Inhibition,=,52.9,%,O=c1cc(-c2ccc(N3CCCC3)cc2)oc2c1ccc1cc[nH]c12,CHEMBL2203249,"Optimization of a small tropomyosin-related kinase B (TrkB) agonist 7,8-dihydroxyflavone active in mouse models of depression.",J. Med. Chem.,2012.0,55,19,8524,8537,10.1021/jm301099x,22984948.0,
12187055,CHEMBL2206420,"2-Methyl-8-(4-(pyrrolidin-1-yl)phenyl)chromeno[7,8-d]imidazol-6(1H)-one",CHEMBL2214156,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,12.4,%,Cc1nc2ccc3c(=O)cc(-c4ccc(N5CCCC5)cc4)oc3c2[nH]1,CHEMBL2203249,"Optimization of a small tropomyosin-related kinase B (TrkB) agonist 7,8-dihydroxyflavone active in mouse models of depression.",J. Med. Chem.,2012.0,55,19,8524,8537,10.1021/jm301099x,22984948.0,
12187056,CHEMBL2206412,"2-(4-(pyrrolidin-1-yl)phenyl)pyrano[3,2-g]indol-4(9H)-one",CHEMBL2214156,A,,,Cytochrome P450 2C9,Inhibition of CYP2C9 at 3 uM,Inhibition,=,11.9,%,O=c1cc(-c2ccc(N3CCCC3)cc2)oc2c1ccc1cc[nH]c12,CHEMBL2203249,"Optimization of a small tropomyosin-related kinase B (TrkB) agonist 7,8-dihydroxyflavone active in mouse models of depression.",J. Med. Chem.,2012.0,55,19,8524,8537,10.1021/jm301099x,22984948.0,
12615923,CHEMBL449588,3-(4-(o-Tolylethynyl)phenyl)propanoic acid,CHEMBL2320480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,-25.0,%,Cc1ccccc1C#Cc1ccc(CCC(=O)O)cc1,CHEMBL2311524,Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability.,J. Med. Chem.,2013.0,56,3,982,992,10.1021/jm301470a,23294321.0,
12615924,CHEMBL2315528,3-(4-((2-(Cyanomethyl)phenyl)ethynyl)phenyl)propanoic Acid,CHEMBL2320480,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,11.0,%,N#CCc1ccccc1C#Cc1ccc(CCC(=O)O)cc1,CHEMBL2311524,Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability.,J. Med. Chem.,2013.0,56,3,982,992,10.1021/jm301470a,23294321.0,
12626203,CHEMBL2313472,"2-(Pyridin-4-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole",CHEMBL2320894,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM,Inhibition,=,100.4,%,COc1cc(Sc2c(-c3ccncc3)[nH]c3ccccc23)cc(OC)c1OC,CHEMBL2311402,Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors.,J. Med. Chem.,2013.0,56,1,123,149,10.1021/jm3013097,23214452.0,
12626204,CHEMBL2313470,"2-(Pyridin-3-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole",CHEMBL2320894,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM,Inhibition,=,101.8,%,COc1cc(Sc2c(-c3cccnc3)[nH]c3ccccc23)cc(OC)c1OC,CHEMBL2311402,Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors.,J. Med. Chem.,2013.0,56,1,123,149,10.1021/jm3013097,23214452.0,
12626205,CHEMBL2313792,"2-(1H-1,2,4-Triazol-1-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole",CHEMBL2320894,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM,Inhibition,=,93.1,%,COc1cc(Sc2c(-n3cncn3)[nH]c3ccccc23)cc(OC)c1OC,CHEMBL2311402,Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors.,J. Med. Chem.,2013.0,56,1,123,149,10.1021/jm3013097,23214452.0,
12626206,CHEMBL2313790,"2-(1H-Imidazol-1-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole",CHEMBL2320894,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM,Inhibition,=,95.9,%,COc1cc(Sc2c(-n3ccnc3)[nH]c3ccccc23)cc(OC)c1OC,CHEMBL2311402,Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors.,J. Med. Chem.,2013.0,56,1,123,149,10.1021/jm3013097,23214452.0,
12626580,CHEMBL2312113,"3-(benzo[d][1,3]dioxol-5-yl)-1-(3,5-dimethylpiperidin-1-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)propan-1-one",CHEMBL2317466,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,92.0,%,COc1cc(O)c(C(CC(=O)N2CC(C)CC(C)C2)c2ccc3c(c2)OCO3)c(OC)c1,CHEMBL2311492,Small molecule amides as potent ROR-γ selective modulators.,Bioorg. Med. Chem. Lett.,2013.0,23,2,532,536,10.1016/j.bmcl.2012.11.025,23232056.0,
12626586,CHEMBL2312126,"1-(3,5-dimethylpiperidin-1-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)-3-(4-methoxyphenyl)propan-1-one",CHEMBL2317466,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,65.0,%,COc1ccc(C(CC(=O)N2CC(C)CC(C)C2)c2c(O)cc(OC)cc2OC)cc1,CHEMBL2311492,Small molecule amides as potent ROR-γ selective modulators.,Bioorg. Med. Chem. Lett.,2013.0,23,2,532,536,10.1016/j.bmcl.2012.11.025,23232056.0,
12626589,CHEMBL2312134,"1-(3,5-dimethylpiperidin-1-yl)-3-(2-hydroxy-4,6-dimethoxyphenyl)-3-(2-methoxyphenyl)propan-1-one",CHEMBL2317466,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,53.0,%,COc1cc(O)c(C(CC(=O)N2CC(C)CC(C)C2)c2ccccc2OC)c(OC)c1,CHEMBL2311492,Small molecule amides as potent ROR-γ selective modulators.,Bioorg. Med. Chem. Lett.,2013.0,23,2,532,536,10.1016/j.bmcl.2012.11.025,23232056.0,
12641463,CHEMBL229212,N-isopentyl-6-(4-(2-(trifluoromethyl)benzoyl)piperazin-1-yl)-pyridazine-3-carboxamide,CHEMBL2321453,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,<,50.0,%,CC(C)CCNC(=O)c1ccc(N2CCN(C(=O)c3ccccc3C(F)(F)F)CC2)nn1,CHEMBL2311383,Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome.,J. Med. Chem.,2013.0,56,2,568,583,10.1021/jm301661h,23245208.0,
12653086,CHEMBL2324520,"(R)-2-(1-(2-fluoro-4-(5-((4-fluoro-1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)phenyl)piperidin-4-ylidene)propanenitrile",CHEMBL2327764,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as residual activity at 10 uM,Inhibition,=,64.84,%,CC(C#N)=C1CCN(c2ccc(N3C[C@H](Cn4cc(F)nn4)OC3=O)cc2F)CC1,CHEMBL2321764,"Synthesis and antibacterial activities of new piperidine substituted (5R)-[1,2,3]triazolylmethyl and (5R)-[(4-F-[1,2,3]triazolyl)methyl] oxazolidinones.",Bioorg. Med. Chem. Lett.,2013.0,23,5,1193,1196,10.1016/j.bmcl.2013.01.033,23385213.0,
12653087,CHEMBL2324519,"(R)-2-(1-(4-(5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperidin-4-ylidene)propanenitrile",CHEMBL2327764,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as residual activity at 10 uM,Inhibition,=,61.49,%,CC(C#N)=C1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CC1,CHEMBL2321764,"Synthesis and antibacterial activities of new piperidine substituted (5R)-[1,2,3]triazolylmethyl and (5R)-[(4-F-[1,2,3]triazolyl)methyl] oxazolidinones.",Bioorg. Med. Chem. Lett.,2013.0,23,5,1193,1196,10.1016/j.bmcl.2013.01.033,23385213.0,
12653088,CHEMBL2324511,"(R)-2-(1-(2-fluoro-4-(5-((4-fluoro-1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)phenyl)piperidin-4-ylidene)acetonitrile",CHEMBL2327764,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as residual activity at 10 uM,Inhibition,=,66.57,%,N#CC=C1CCN(c2ccc(N3C[C@H](Cn4cc(F)nn4)OC3=O)cc2F)CC1,CHEMBL2321764,"Synthesis and antibacterial activities of new piperidine substituted (5R)-[1,2,3]triazolylmethyl and (5R)-[(4-F-[1,2,3]triazolyl)methyl] oxazolidinones.",Bioorg. Med. Chem. Lett.,2013.0,23,5,1193,1196,10.1016/j.bmcl.2013.01.033,23385213.0,
12653089,CHEMBL2324510,"(R)-2-(1-(4-(5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperidin-4-ylidene)acetonitrile",CHEMBL2327764,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as residual activity at 10 uM,Inhibition,=,88.01,%,N#CC=C1CCN(c2ccc(N3C[C@H](Cn4ccnn4)OC3=O)cc2F)CC1,CHEMBL2321764,"Synthesis and antibacterial activities of new piperidine substituted (5R)-[1,2,3]triazolylmethyl and (5R)-[(4-F-[1,2,3]triazolyl)methyl] oxazolidinones.",Bioorg. Med. Chem. Lett.,2013.0,23,5,1193,1196,10.1016/j.bmcl.2013.01.033,23385213.0,
12679650,CHEMBL2331646,"2-(ethylamino)-6-(3-(4-isopropylphenyl)propanoyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-4-carboxamide",CHEMBL2339914,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,<,20.0,%,CCNc1nc2c(c(C(N)=O)n1)CN(C(=O)CCc1ccc(C(C)C)cc1)CC2,CHEMBL2331085,"Identification of Tetrahydropyrido[4,3-d]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists.",ACS Med. Chem. Lett.,2013.0,4,1,63,68,10.1021/ml300277t,24900564.0,
12705894,CHEMBL2332097,3-(4-(1H-Pyrazol-4-yl)phenyl)-1-(3-methoxybenzyl)-1-methylurea,CHEMBL2341174,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin)-mediated tolbutamide hydroxylation to hydroxy tolbutamide at 10 uM relative to control,Inhibition,=,96.0,%,COc1cccc(CN(C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1,CHEMBL2331531,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,2013.0,56,9,3568,3581,10.1021/jm400062r,23570561.0,
12705895,CHEMBL2332065,3-(4-(1H-Pyrazol-4-yl)phenyl)-1-(2-hydroxyethyl)-1-(3-methoxybenzyl)urea,CHEMBL2341174,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin)-mediated tolbutamide hydroxylation to hydroxy tolbutamide at 10 uM relative to control,Inhibition,=,95.0,%,COc1cccc(CN(CCO)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1,CHEMBL2331531,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,2013.0,56,9,3568,3581,10.1021/jm400062r,23570561.0,
12705896,CHEMBL2331562,3-(4-(1H-Pyrazol-4-yl)phenyl)-1-benzyl-1-(2-hydroxyethyl)urea,CHEMBL2341174,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin)-mediated tolbutamide hydroxylation to hydroxy tolbutamide at 10 uM relative to control,Inhibition,=,93.0,%,O=C(Nc1ccc(-c2cn[nH]c2)cc1)N(CCO)Cc1ccccc1,CHEMBL2331531,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,2013.0,56,9,3568,3581,10.1021/jm400062r,23570561.0,
12705912,CHEMBL2332056,1-(4-(1H-Pyrazol-4-yl)phenyl)-3-(1-(3-fluorophenyl)-3-hydroxypropyl)urea,CHEMBL2341174,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin)-mediated tolbutamide hydroxylation to hydroxy tolbutamide at 10 uM relative to control,Inhibition,=,71.0,%,O=C(Nc1ccc(-c2cn[nH]c2)cc1)NC(CCO)c1cccc(F)c1,CHEMBL2331531,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,2013.0,56,9,3568,3581,10.1021/jm400062r,23570561.0,
12705913,CHEMBL2332071,3-(4-(1H-Pyrazol-4-yl)phenyl)-1-(3-methoxybenzyl)-1-(2-morpholinoethyl)urea,CHEMBL2341174,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin)-mediated tolbutamide hydroxylation to hydroxy tolbutamide at 10 uM relative to control,Inhibition,=,68.0,%,COc1cccc(CN(CCN2CCOCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1,CHEMBL2331531,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,2013.0,56,9,3568,3581,10.1021/jm400062r,23570561.0,
12705914,CHEMBL2332076,1-(4-(1H-Pyrazol-4-yl)phenyl)-3-(3-hydroxy-1-(3-methoxyphenyl)propyl)urea,CHEMBL2341174,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin)-mediated tolbutamide hydroxylation to hydroxy tolbutamide at 10 uM relative to control,Inhibition,=,67.0,%,COc1cccc(C(CCO)NC(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1,CHEMBL2331531,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,2013.0,56,9,3568,3581,10.1021/jm400062r,23570561.0,
12705916,CHEMBL2332060,(S)-1-Ethyl-1-(3-methoxybenzyl)-3-(2-(1-methylpyrrolidin-3-yloxy)-4-(1H-pyrazol-4-yl)-phenyl)urea,CHEMBL2341174,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin)-mediated tolbutamide hydroxylation to hydroxy tolbutamide at 10 uM relative to control,Inhibition,=,65.0,%,CCN(Cc1cccc(OC)c1)C(=O)Nc1ccc(-c2cn[nH]c2)cc1O[C@H]1CCN(C)C1,CHEMBL2331531,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,2013.0,56,9,3568,3581,10.1021/jm400062r,23570561.0,
12705923,CHEMBL2332073,3-(4-(1H-Pyrazol-4-yl)phenyl)-1-(3-methoxybenzyl)-1-(2-(piperidin-1-yl)ethyl)urea,CHEMBL2341174,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin)-mediated tolbutamide hydroxylation to hydroxy tolbutamide at 10 uM relative to control,Inhibition,=,56.0,%,COc1cccc(CN(CCN2CCCCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1,CHEMBL2331531,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,2013.0,56,9,3568,3581,10.1021/jm400062r,23570561.0,
12705942,CHEMBL2332068,3-(4-(1H-Pyrazol-4-yl)phenyl)-1-(2-(dimethylamino)ethyl)-1-(3-methoxybenzyl)urea,CHEMBL2341174,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin)-mediated tolbutamide hydroxylation to hydroxy tolbutamide at 10 uM relative to control,Inhibition,=,35.0,%,COc1cccc(CN(CCN(C)C)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1,CHEMBL2331531,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,2013.0,56,9,3568,3581,10.1021/jm400062r,23570561.0,
12705960,CHEMBL2332069,3-(4-(1H-Pyrazol-4-yl)phenyl)-1-(3-methoxybenzyl)-1-(2-(pyrrolidin-1-yl)ethyl)urea,CHEMBL2341174,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin)-mediated tolbutamide hydroxylation to hydroxy tolbutamide at 10 uM relative to control,Inhibition,=,24.0,%,COc1cccc(CN(CCN2CCCC2)C(=O)Nc2ccc(-c3cn[nH]c3)cc2)c1,CHEMBL2331531,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,2013.0,56,9,3568,3581,10.1021/jm400062r,23570561.0,
12705973,CHEMBL2332059,1-(4-(1H-Pyrazol-4-yl)phenyl)-3-(3-(dimethylamino)-1-phenylpropyl)urea,CHEMBL2341174,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin)-mediated tolbutamide hydroxylation to hydroxy tolbutamide at 10 uM relative to control,Inhibition,=,16.0,%,CN(C)CCC(NC(=O)Nc1ccc(-c2cn[nH]c2)cc1)c1ccccc1,CHEMBL2331531,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,2013.0,56,9,3568,3581,10.1021/jm400062r,23570561.0,
12706009,CHEMBL2332063,3-(5-(1H-Pyrazol-4-yl)pyridin-2-yl)-1-(2-(dimethylamino)ethyl)-1-(3-methoxybenzyl)urea,CHEMBL2341174,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin)-mediated tolbutamide hydroxylation to hydroxy tolbutamide at 10 uM relative to control,Inhibition,=,5.0,%,COc1cccc(CN(CCN(C)C)C(=O)Nc2ccc(-c3cn[nH]c3)cn2)c1,CHEMBL2331531,Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.,J. Med. Chem.,2013.0,56,9,3568,3581,10.1021/jm400062r,23570561.0,
12708284,CHEMBL2333879,"N,N-dimethyl-2-((3S,4R)-4-phenylpyrrolidin-3-yl)-6-(1H-pyrazol-4-yl)quinazolin-4-amine",CHEMBL2346258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,47.0,%,CN(C)c1nc([C@@H]2CNC[C@H]2c2ccccc2)nc2ccc(-c3cn[nH]c3)cc12,CHEMBL2331421,Amino acid derived quinazolines as Rock/PKA inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,6,1592,1599,10.1016/j.bmcl.2013.01.109,23416002.0,
12708285,CHEMBL2333887,"2-((3S,4R)-4-(4-methoxyphenyl)-1-methylpyrrolidin-3-yl)-6-(1H-pyrazol-4-yl)quinazolin-4(3H)-one",CHEMBL2346258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,55.0,%,COc1ccc([C@@H]2CN(C)C[C@H]2c2nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]2)cc1,CHEMBL2331421,Amino acid derived quinazolines as Rock/PKA inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,6,1592,1599,10.1016/j.bmcl.2013.01.109,23416002.0,
12708286,CHEMBL2333884,"4-(aminomethyl)-N-((4-chlorophenyl)(4-oxo-6-(1H-pyrazol-4-yl)-3,4-dihydroquinazolin-2-yl)methyl)benzamide",CHEMBL2346258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,94.0,%,NCc1ccc(C(=O)NC(c2ccc(Cl)cc2)c2nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]2)cc1,CHEMBL2331421,Amino acid derived quinazolines as Rock/PKA inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,6,1592,1599,10.1016/j.bmcl.2013.01.109,23416002.0,
12708287,CHEMBL2333882,"N-((4-chlorophenyl)(4-oxo-6-(1H-pyrazol-4-yl)-3,4-dihydroquinazolin-2-yl)methyl)-2-(dimethylamino)acetamide",CHEMBL2346258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,83.0,%,CN(C)CC(=O)NC(c1ccc(Cl)cc1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1,CHEMBL2331421,Amino acid derived quinazolines as Rock/PKA inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,6,1592,1599,10.1016/j.bmcl.2013.01.109,23416002.0,
12708288,CHEMBL2333898,"2-((3S,4R)-4-(4-chlorophenyl)pyrrolidin-3-yl)-6-(1H-pyrazol-4-yl)quinazolin-4(3H)-one",CHEMBL2346258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,34.0,%,O=c1[nH]c([C@@H]2CNC[C@H]2c2ccc(Cl)cc2)nc2ccc(-c3cn[nH]c3)cc12,CHEMBL2331421,Amino acid derived quinazolines as Rock/PKA inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,6,1592,1599,10.1016/j.bmcl.2013.01.109,23416002.0,
12708289,CHEMBL2333896,2-(amino(3-chlorophenyl)methyl)-8-methoxy-6-(1H-pyrazol-4-yl)quinazolin-4(3H)-one,CHEMBL2346258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,79.0,%,COc1cc(-c2cn[nH]c2)cc2c(=O)[nH]c(C(N)c3cccc(Cl)c3)nc12,CHEMBL2331421,Amino acid derived quinazolines as Rock/PKA inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,6,1592,1599,10.1016/j.bmcl.2013.01.109,23416002.0,
12708290,CHEMBL2333894,2-(amino(3-chlorophenyl)methyl)-6-(1H-pyrazol-4-yl)quinazolin-4(3H)-one,CHEMBL2346258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,84.0,%,NC(c1cccc(Cl)c1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1,CHEMBL2331421,Amino acid derived quinazolines as Rock/PKA inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,6,1592,1599,10.1016/j.bmcl.2013.01.109,23416002.0,
12708291,CHEMBL2333909,(S)-2-(1-amino-2-(4-methoxyphenyl)ethyl)-6-(1H-pyrazol-4-yl)quinazolin-4(3H)-one,CHEMBL2346258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,52.0,%,COc1ccc(C[C@H](N)c2nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]2)cc1,CHEMBL2331421,Amino acid derived quinazolines as Rock/PKA inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,6,1592,1599,10.1016/j.bmcl.2013.01.109,23416002.0,
12708292,CHEMBL2333908,(R)-2-(1-amino-2-(3-fluorophenyl)ethyl)-8-methoxy-6-(1H-pyrazol-4-yl)quinazolin-4(3H)-one,CHEMBL2346258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,10.0,%,COc1cc(-c2cn[nH]c2)cc2c(=O)[nH]c([C@H](N)Cc3cccc(F)c3)nc12,CHEMBL2331421,Amino acid derived quinazolines as Rock/PKA inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,6,1592,1599,10.1016/j.bmcl.2013.01.109,23416002.0,
12708293,CHEMBL2333906,(R)-2-(1-amino-2-(4-fluorophenyl)ethyl)-6-(1H-pyrazol-4-yl)quinazolin-4(3H)-one,CHEMBL2346258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,36.0,%,N[C@H](Cc1ccc(F)cc1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1,CHEMBL2331421,Amino acid derived quinazolines as Rock/PKA inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,6,1592,1599,10.1016/j.bmcl.2013.01.109,23416002.0,
12708294,CHEMBL2333905,(S)-2-(1-amino-2-(4-fluorophenyl)ethyl)-6-(1H-pyrazol-4-yl)quinazolin-4(3H)-one,CHEMBL2346258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,38.0,%,N[C@@H](Cc1ccc(F)cc1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1,CHEMBL2331421,Amino acid derived quinazolines as Rock/PKA inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,6,1592,1599,10.1016/j.bmcl.2013.01.109,23416002.0,
12708295,CHEMBL2334293,(S)-2-(1-amino-2-(4-chlorophenyl)ethyl)-6-(1H-pyrazol-4-yl)quinazolin-4(3H)-one,CHEMBL2346258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,54.0,%,N[C@@H](Cc1ccc(Cl)cc1)c1nc2ccc(-c3cn[nH]c3)cc2c(=O)[nH]1,CHEMBL2331421,Amino acid derived quinazolines as Rock/PKA inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,6,1592,1599,10.1016/j.bmcl.2013.01.109,23416002.0,
12708296,CHEMBL2334292,"2-((3S,4R)-4-phenylpyrrolidin-3-yl)-6-(1H-pyrazol-4-yl)quinazolin-4(3H)-one",CHEMBL2346258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,5.0,%,O=c1[nH]c([C@@H]2CNC[C@H]2c2ccccc2)nc2ccc(-c3cn[nH]c3)cc12,CHEMBL2331421,Amino acid derived quinazolines as Rock/PKA inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,6,1592,1599,10.1016/j.bmcl.2013.01.109,23416002.0,
12708297,CHEMBL2334288,2-(amino(4-methoxyphenyl)methyl)-6-(1H-pyrazol-4-yl)quinazolin-4(3H)-one,CHEMBL2346258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,37.0,%,COc1ccc(C(N)c2nc3ccc(-c4cn[nH]c4)cc3c(=O)[nH]2)cc1,CHEMBL2331421,Amino acid derived quinazolines as Rock/PKA inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,6,1592,1599,10.1016/j.bmcl.2013.01.109,23416002.0,
12721986,CHEMBL2347763,"8-Chloroindolo[2,1-b]quinazolin-6(12H)-one",CHEMBL2350100,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM incubated for 80 mins at 37 degC using 7-methoxy-4-trifluoromethylcoumarin substrate,Inhibition,=,27.0,%,O=C1C2=Nc3ccccc3CN2c2ccc(Cl)cc21,CHEMBL2346548,"Design, synthesis, and structure-activity relationship studies of tryptanthrins as antitubercular agents.",J. Nat. Prod.,2013.0,76,3,354,367,10.1021/np3007167,23360475.0,
12721987,CHEMBL2347776,"8-Chloroindolo[2,1-b]-4-azaquinazoline-6,12-dione",CHEMBL2350100,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM incubated for 80 mins at 37 degC using 7-methoxy-4-trifluoromethylcoumarin substrate,Inhibition,=,54.0,%,O=C1c2cc(Cl)ccc2-n2c1nc1ncccc1c2=O,CHEMBL2346548,"Design, synthesis, and structure-activity relationship studies of tryptanthrins as antitubercular agents.",J. Nat. Prod.,2013.0,76,3,354,367,10.1021/np3007167,23360475.0,
12721988,CHEMBL2347777,"8-Bromoindolo[2,1-b]-2-azaquinazoline-6,12-dione",CHEMBL2350100,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM incubated for 80 mins at 37 degC using 7-methoxy-4-trifluoromethylcoumarin substrate,Inhibition,=,10.0,%,O=C1c2cc(Br)ccc2-n2c1nc1ccncc1c2=O,CHEMBL2346548,"Design, synthesis, and structure-activity relationship studies of tryptanthrins as antitubercular agents.",J. Nat. Prod.,2013.0,76,3,354,367,10.1021/np3007167,23360475.0,
12721989,CHEMBL1276265,"9-Chloro-indolo[2,1-b]quinazoline-6,12-dione",CHEMBL2350100,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM incubated for 80 mins at 37 degC using 7-methoxy-4-trifluoromethylcoumarin substrate,Inhibition,=,25.0,%,O=C1c2ccc(Cl)cc2-n2c1nc1ccccc1c2=O,CHEMBL2346548,"Design, synthesis, and structure-activity relationship studies of tryptanthrins as antitubercular agents.",J. Nat. Prod.,2013.0,76,3,354,367,10.1021/np3007167,23360475.0,
12721990,CHEMBL77939,"2-Bromo-indolo[2,1-b]quinazoline-6,12-dione",CHEMBL2350100,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM incubated for 80 mins at 37 degC using 7-methoxy-4-trifluoromethylcoumarin substrate,Inhibition,=,20.0,%,O=C1c2ccccc2-n2c1nc1ccc(Br)cc1c2=O,CHEMBL2346548,"Design, synthesis, and structure-activity relationship studies of tryptanthrins as antitubercular agents.",J. Nat. Prod.,2013.0,76,3,354,367,10.1021/np3007167,23360475.0,
12721991,CHEMBL307480,"8-Chloro-indolo[2,1-b]quinazoline-6,12-dione",CHEMBL2350100,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM incubated for 80 mins at 37 degC using 7-methoxy-4-trifluoromethylcoumarin substrate,Inhibition,=,38.0,%,O=C1c2cc(Cl)ccc2-n2c1nc1ccccc1c2=O,CHEMBL2346548,"Design, synthesis, and structure-activity relationship studies of tryptanthrins as antitubercular agents.",J. Nat. Prod.,2013.0,76,3,354,367,10.1021/np3007167,23360475.0,
12721992,CHEMBL2347792,"Ethyl 6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazoline-8-carboxylate",CHEMBL2350100,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM incubated for 80 mins at 37 degC using 7-methoxy-4-trifluoromethylcoumarin substrate,Inhibition,=,38.0,%,CCOC(=O)c1ccc2c(c1)C(=O)c1nc3ccccc3c(=O)n1-2,CHEMBL2346548,"Design, synthesis, and structure-activity relationship studies of tryptanthrins as antitubercular agents.",J. Nat. Prod.,2013.0,76,3,354,367,10.1021/np3007167,23360475.0,
12721993,CHEMBL306946,"Indolo[2,1-b]quinazoline-6,12-dione",CHEMBL2350100,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM incubated for 80 mins at 37 degC using 7-methoxy-4-trifluoromethylcoumarin substrate,Inhibition,=,25.0,%,O=C1c2ccccc2-n2c1nc1ccccc1c2=O,CHEMBL2346548,"Design, synthesis, and structure-activity relationship studies of tryptanthrins as antitubercular agents.",J. Nat. Prod.,2013.0,76,3,354,367,10.1021/np3007167,23360475.0,
12722510,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL2350016,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,>,90.0,%,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL2346553,Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.,Bioorg. Med. Chem. Lett.,2013.0,23,7,2031,2034,10.1016/j.bmcl.2013.02.023,23466233.0,
12729600,CHEMBL2348780,"(8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one",CHEMBL2351339,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 mM relative to control,Inhibition,=,1.9,%,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@@]1(O)C(=O)CO,CHEMBL2346557,"VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.",Bioorg. Med. Chem.,2013.0,21,8,2241,2249,10.1016/j.bmc.2013.02.009,23498916.0,
12733066,CHEMBL2349361,"N-(3-(2-oxo-2,3-dihydrothiazol-4-yl)-5-(thiophene-2-sulfonamido)phenyl)thiophene-2-carboxamide",CHEMBL2351091,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin)-mediated diclofenac metabolite conversion at 10 uM after 20 mins relative to control,Inhibition,=,41.0,%,O=C(Nc1cc(NS(=O)(=O)c2cccs2)cc(-c2csc(=O)[nH]2)c1)c1cccs1,CHEMBL2346589,Fragment-based drug discovery of 2-thiazolidinones as inhibitors of the histone reader BRD4 bromodomain.,J. Med. Chem.,2013.0,56,10,3833,3851,10.1021/jm301793a,23530754.0,
12733067,CHEMBL2349349,"N-(3-(2-Oxo-2,3-dihydrothiazol-4-yl)phenyl)thiophene-2-sulfonamide",CHEMBL2351091,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin)-mediated diclofenac metabolite conversion at 10 uM after 20 mins relative to control,Inhibition,=,34.0,%,O=c1[nH]c(-c2cccc(NS(=O)(=O)c3cccs3)c2)cs1,CHEMBL2346589,Fragment-based drug discovery of 2-thiazolidinones as inhibitors of the histone reader BRD4 bromodomain.,J. Med. Chem.,2013.0,56,10,3833,3851,10.1021/jm301793a,23530754.0,
13311382,CHEMBL2381085,(S)-4-(pyrimidin-2-yl)-3-(6-((5-(trifluoromethyl)pyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptane-5-carbonyl)benzonitrile,CHEMBL2384500,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 3 uM by fluorimetric assay,Inhibition,<,32.0,%,N#Cc1ccc(-c2ncccn2)c(C(=O)N2CC3(CC3)C[C@H]2CNc2ccc(C(F)(F)F)cn2)c1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311384,CHEMBL2381083,(S)-(6-methyl-3-(thiazol-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)methanone,CHEMBL2384500,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 3 uM by fluorimetric assay,Inhibition,<,89.0,%,Cc1ccc(-c2nccs2)c(C(=O)N2CC3(CC3)C[C@H]2CNc2ccc(C(F)(F)F)cn2)n1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311385,CHEMBL2381082,(S)-(4-(methylsulfonyl)biphenyl-2-yl)(6-((5-(trifluoromethyl)pyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)methanone,CHEMBL2384500,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 3 uM by fluorimetric assay,Inhibition,<,41.0,%,CS(=O)(=O)c1ccc(-c2ccccc2)c(C(=O)N2CC3(CC3)C[C@H]2CNc2ccc(C(F)(F)F)cn2)c1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311386,CHEMBL2381081,(S)-(3-(benzyloxy)-6-methylpyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)methanone,CHEMBL2384500,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 3 uM by fluorimetric assay,Inhibition,<,71.0,%,Cc1ccc(OCc2ccccc2)c(C(=O)N2CC3(CC3)C[C@H]2CNc2ccc(C(F)(F)F)cn2)n1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311387,CHEMBL2381080,(S)-(3-(pyrimidin-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)methanone,CHEMBL2384500,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 3 uM by fluorimetric assay,Inhibition,<,47.0,%,O=C(c1ncccc1-c1ncccn1)N1CC2(CC2)C[C@H]1CNc1ccc(C(F)(F)F)cn1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311388,CHEMBL2381079,(S)-(3-(pyrimidin-2-yl)-6-(trifluoromethoxy)pyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)methanone,CHEMBL2384500,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 3 uM by fluorimetric assay,Inhibition,<,58.0,%,O=C(c1nc(OC(F)(F)F)ccc1-c1ncccn1)N1CC2(CC2)C[C@H]1CNc1ccc(C(F)(F)F)cn1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311389,CHEMBL2381078,(S)-(6-methyl-3-(4-methyl-1H-pyrazol-1-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)methanone,CHEMBL2384500,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 3 uM by fluorimetric assay,Inhibition,<,85.0,%,Cc1cnn(-c2ccc(C)nc2C(=O)N2CC3(CC3)C[C@H]2CNc2ccc(C(F)(F)F)cn2)c1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311390,CHEMBL2381077,(S)-(3-(pyrimidin-2-yl)-6-(trifluoromethyl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)methanone,CHEMBL2384500,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 3 uM by fluorimetric assay,Inhibition,<,39.0,%,O=C(c1nc(C(F)(F)F)ccc1-c1ncccn1)N1CC2(CC2)C[C@H]1CNc1ccc(C(F)(F)F)cn1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311391,CHEMBL2381076,(S)-(6-methyl-3-phenylpyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)methanone,CHEMBL2384500,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 3 uM by fluorimetric assay,Inhibition,<,20.0,%,Cc1ccc(-c2ccccc2)c(C(=O)N2CC3(CC3)C[C@H]2CNc2ccc(C(F)(F)F)cn2)n1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311392,CHEMBL2381075,(S)-(5-chloro-2-(pyrimidin-2-yl)phenyl)(6-((5-(trifluoromethyl)pyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)methanone,CHEMBL2384500,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 3 uM by fluorimetric assay,Inhibition,<,22.0,%,O=C(c1cc(Cl)ccc1-c1ncccn1)N1CC2(CC2)C[C@H]1CNc1ccc(C(F)(F)F)cn1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311393,CHEMBL2381074,(S)-(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)(6-((5-(trifluoromethyl)pyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)methanone,CHEMBL2384500,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 3 uM by fluorimetric assay,Inhibition,<,28.0,%,Cc1ccc(-c2ncccn2)c(C(=O)N2CC3(CC3)C[C@H]2CNc2ccc(C(F)(F)F)cn2)n1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311394,CHEMBL2381100,(S)-(2-methyl-5-phenylthiazol-4-yl)(6-((5-(trifluoromethyl)pyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)methanone,CHEMBL2384500,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 3 uM by fluorimetric assay,Inhibition,<,20.0,%,Cc1nc(C(=O)N2CC3(CC3)C[C@H]2CNc2ccc(C(F)(F)F)cn2)c(-c2ccccc2)s1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311674,CHEMBL2381091,(S)-(5-chloro-2-(pyrimidin-2-yl)phenyl)(6-((4-(trifluoromethyl)pyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)methanone,CHEMBL2384506,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 1 uM by fluorimetric assay,Inhibition,<,57.0,%,O=C(c1cc(Cl)ccc1-c1ncccn1)N1CC2(CC2)C[C@H]1CNc1cc(C(F)(F)F)ccn1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311675,CHEMBL2381090,(S)-(5-methyl-2-(pyrimidin-2-yl)phenyl)(6-((4-(trifluoromethyl)pyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)methanone,CHEMBL2384506,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 1 uM by fluorimetric assay,Inhibition,<,72.0,%,Cc1ccc(-c2ncccn2)c(C(=O)N2CC3(CC3)C[C@H]2CNc2cc(C(F)(F)F)ccn2)c1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311676,CHEMBL2381089,(S)-(6-((6-methyl-4-(trifluoromethyl)pyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)(2-methyl-5-phenylthiazol-4-yl)methanone,CHEMBL2384506,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 1 uM by fluorimetric assay,Inhibition,<,69.0,%,Cc1cc(C(F)(F)F)cc(NC[C@@H]2CC3(CC3)CN2C(=O)c2nc(C)sc2-c2ccccc2)n1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311677,CHEMBL2381088,(S)-(2-methyl-5-phenylthiazol-4-yl)(6-((4-(trifluoromethyl)pyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)methanone,CHEMBL2384506,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 1 uM by fluorimetric assay,Inhibition,<,55.0,%,Cc1nc(C(=O)N2CC3(CC3)C[C@H]2CNc2cc(C(F)(F)F)ccn2)c(-c2ccccc2)s1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311678,CHEMBL2381087,(S)-(6-methyl-3-(pyrimidin-2-yl)pyridin-2-yl)(6-((4-(trifluoromethyl)pyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)methanone,CHEMBL2384506,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 1 uM by fluorimetric assay,Inhibition,<,39.0,%,Cc1ccc(-c2ncccn2)c(C(=O)N2CC3(CC3)C[C@H]2CNc2cc(C(F)(F)F)ccn2)n1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311679,CHEMBL2381086,(S)-2-((5-(6-methyl-3-(pyrimidin-2-yl)picolinoyl)-5-azaspiro[2.4]heptan-6-yl)methylamino)isonicotinonitrile,CHEMBL2384506,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 1 uM by fluorimetric assay,Inhibition,<,17.0,%,Cc1ccc(-c2ncccn2)c(C(=O)N2CC3(CC3)C[C@H]2CNc2cc(C#N)ccn2)n1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311680,CHEMBL2381071,"(S)-(6-((4,6-dimethylpyrimidin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)(2-methyl-5-phenylthiazol-4-yl)methanone",CHEMBL2384506,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 1 uM by fluorimetric assay,Inhibition,<,16.0,%,Cc1cc(C)nc(NC[C@@H]2CC3(CC3)CN2C(=O)c2nc(C)sc2-c2ccccc2)n1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311681,CHEMBL2381100,(S)-(2-methyl-5-phenylthiazol-4-yl)(6-((5-(trifluoromethyl)pyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)methanone,CHEMBL2384506,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 1 uM by fluorimetric assay,Inhibition,<,20.0,%,Cc1nc(C(=O)N2CC3(CC3)C[C@H]2CNc2ccc(C(F)(F)F)cn2)c(-c2ccccc2)s1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311682,CHEMBL2381096,"(S)-(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)(6-((6-methylpyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)methanone",CHEMBL2384506,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 1 uM by fluorimetric assay,Inhibition,<,34.0,%,Cc1ccc(-n2nccn2)c(C(=O)N2CC3(CC3)C[C@H]2CNc2cccc(C)n2)c1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13311683,CHEMBL2381093,(S)-(6-((5-chloropyridin-2-ylamino)methyl)-5-azaspiro[2.4]heptan-5-yl)(5-methyl-2-(pyrimidin-2-yl)phenyl)methanone,CHEMBL2384506,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 1 uM by fluorimetric assay,Inhibition,<,53.0,%,Cc1ccc(-c2ncccn2)c(C(=O)N2CC3(CC3)C[C@H]2CNc2ccc(Cl)cn2)c1,CHEMBL2380240,"Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,9,2653,2658,10.1016/j.bmcl.2013.02.093,23535328.0,
13325606,CHEMBL2386162,6-Methoxy-2-methyl-3-[(1S)-3-methyl-1-[(3S)-pyrrolidin-3-yl]butoxy]pyridine,CHEMBL2389155,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,<,30.0,%,COc1ccc(O[C@@H](CC(C)C)[C@H]2CCNC2)c(C)n1,CHEMBL2384999,"Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor.",ACS Med. Chem. Lett.,2013.0,4,6,560,564,10.1021/ml400049p,24900709.0,
13326476,CHEMBL2386353,3-(4-((2-(cyanomethyl)phenyl)ethynyl)-2-fluorophenyl)propanoic acid,CHEMBL2387812,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,-33.0,%,N#CCc1ccccc1C#Cc1ccc(CCC(=O)O)c(F)c1,CHEMBL2384913,Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes.,ACS Med. Chem. Lett.,2013.0,4,5,441,445,10.1021/ml4000673,23687558.0,
13326477,CHEMBL2315528,3-(4-((2-(Cyanomethyl)phenyl)ethynyl)phenyl)propanoic Acid,CHEMBL2387812,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,11.0,%,N#CCc1ccccc1C#Cc1ccc(CCC(=O)O)cc1,CHEMBL2384913,Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes.,ACS Med. Chem. Lett.,2013.0,4,5,441,445,10.1021/ml4000673,23687558.0,
13338247,CHEMBL2391315,"(2S)-2-(3-tert-butyl-5-methyl-4,5-dihydroisoxazole-5-carboxamido)-3-(4-(2,6-dichlorobenzamido)phenyl)propanoic acid",CHEMBL2394664,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,7.0,%,CC(C)(C)C1=NOC(C)(C(=O)N[C@@H](Cc2ccc(NC(=O)c3c(Cl)cccc3Cl)cc2)C(=O)O)C1,CHEMBL2390876,"Synthesis and evaluation of 4,5-dihydro-5-methylisoxazolin-5-carboxamide derivatives as VLA-4 antagonists.",Bioorg. Med. Chem. Lett.,2013.0,23,5,1482,1485,10.1016/j.bmcl.2012.12.043,23312947.0,
13350190,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL2399577,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using (S)-warfarin as substrate after 30 mins,Inhibition,=,67.0,%,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL2396584,"Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle.",Bioorg. Med. Chem.,2013.0,21,13,3919,3926,10.1016/j.bmc.2013.04.017,23673225.0,
13387631,CHEMBL2409627,"3-[(1-Methyl-2(S)-pyrrolidinyl)methoxy]-5-[(1S,2R)-2-(2-methoxyethyl)cyclopropyl]pyridine Trifluoroacetate",CHEMBL2412553,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,30.0,%,COCC[C@H]1C[C@@H]1c1cncc(OC[C@@H]2CCCN2C)c1.O=C(O)C(F)(F)F,CHEMBL2407064,"Chemistry, pharmacology, and behavioral studies identify chiral cyclopropanes as selective α4β2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile. Part II.",J. Med. Chem.,2013.0,56,13,5495,5504,10.1021/jm400510u,23734673.0,
13388494,CHEMBL2407803,"N-((3-Chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-2,7-dimethylimidazo[1,2-a]pyridine-3-carboxamide",CHEMBL2411241,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate at 10 uM after 10 mins,Inhibition,=,0.0,%,Cc1ccn2c(C(=O)NCc3ncc(C(F)(F)F)cc3Cl)c(C)nc2c1,CHEMBL2407022,"Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis.",ACS Med. Chem. Lett.,2013.0,4,7,675,679,10.1021/ml400088y,23930153.0,
13388495,CHEMBL2407803,"N-((3-Chloro-5-(trifluoromethyl)pyridin-2-yl)methyl)-2,7-dimethylimidazo[1,2-a]pyridine-3-carboxamide",CHEMBL2411242,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate at 10 uM after 10 mins,Inhibition,=,11.5,%,Cc1ccn2c(C(=O)NCc3ncc(C(F)(F)F)cc3Cl)c(C)nc2c1,CHEMBL2407022,"Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis.",ACS Med. Chem. Lett.,2013.0,4,7,675,679,10.1021/ml400088y,23930153.0,
13464485,CHEMBL2431652,(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)cyclohexanecarboxamide,CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,92.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)C1CCCCC1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13464486,CHEMBL2431652,(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)cyclohexanecarboxamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,99.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)C1CCCCC1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13464487,CHEMBL2431651,(S)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)cyclohexanecarboxamide,CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,92.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)C1CCCCC1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13464488,CHEMBL2431651,(S)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)cyclohexanecarboxamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,99.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)C1CCCCC1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13464563,CHEMBL405845,"3-(furan-2-ylmethyl)-1,8-dimethyl-1H-purine-2,6(3H,7H)-dione",CHEMBL2434290,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 40 uM after 10 mins relative to control,Inhibition,=,5.0,%,Cc1nc2c([nH]1)c(=O)n(C)c(=O)n2Cc1ccco1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465665,CHEMBL2431530,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2-fluoro-4-(4-(4-fluorobenzyl)piperazin-1-yl)benzamide Hydrochloride,CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,87.0,%,Cl.O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(N2CCN(Cc3ccc(F)cc3)CC2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465666,CHEMBL2431542,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2-fluoro-4-(piperazin-1-yl)benzamide Hydrochloride,CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,16.0,%,Cl.O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(N2CCNCC2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465667,CHEMBL2431541,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2-fluoro-4-(4-(phenylsulfonyl)piperazin-1-yl)benzamide,CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,97.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(N2CCN(S(=O)(=O)c3ccccc3)CC2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465668,CHEMBL2431540,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2-fluoro-4-morpholinobenzamide,CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,74.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(N2CCOCC2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465669,CHEMBL2431539,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2-fluoro-4-(phenylamino)benzamide,CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,94.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(Nc2ccccc2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465670,CHEMBL2431538,"(S,E)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-chlorostyryl)-2-fluorobenzamide",CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,90.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(/C=C/c2ccc(Cl)cc2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465671,CHEMBL2431537,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2-fluoro-4-(phenylethynyl)benzamide,CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,88.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(C#Cc2ccccc2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465672,CHEMBL2431536,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4'-amino-3-fluoro-[1,1'-biphenyl]-4-carboxamide",CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,91.0,%,Nc1ccc(-c2ccc(C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)Nc3ccncc3)c(F)c2)cc1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465673,CHEMBL2431535,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3,3'-difluoro-4'-hydroxy-[1,1'-biphenyl]-4-carboxamide",CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,94.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2ccc(O)c(F)c2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465674,CHEMBL2431534,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4'-(benzyloxy)-3,3'-difluoro-[1,1'-biphenyl]-4-carboxamide",CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,85.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2ccc(OCc3ccccc3)c(F)c2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465675,CHEMBL2431533,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3'-cyano-3-fluoro-[1,1'-biphenyl]-4-carboxamide",CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,87.0,%,N#Cc1cccc(-c2ccc(C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)Nc3ccncc3)c(F)c2)c1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465676,CHEMBL2431532,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3,3'-difluoro-4'-methoxy-[1,1'-biphenyl]-4-carboxamide",CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,91.0,%,COc1ccc(-c2ccc(C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)Nc3ccncc3)c(F)c2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465677,CHEMBL2431531,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3,3',4'-trifluoro-[1,1'-biphenyl]-4-carboxamide",CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,93.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2ccc(F)c(F)c2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465678,CHEMBL2431624,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2'-chloro-3-fluoro-[1,1'-biphenyl]-4-carboxamide",CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,92.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2ccccc2Cl)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465679,CHEMBL2431623,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3'-chloro-3-fluoro-[1,1'-biphenyl]-4-carboxamide",CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,80.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2cccc(Cl)c2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465680,CHEMBL2431622,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4'-chloro-3-fluoro-[1,1'-biphenyl]-4-carboxamide",CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,75.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2ccc(Cl)cc2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465681,CHEMBL2431621,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2',3,5'-trifluoro-[1,1'-biphenyl]-4-carboxamide",CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,77.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2cc(F)ccc2F)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465682,CHEMBL2431549,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3,3',5'-trifluoro-[1,1'-biphenyl]-4-carboxamide",CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,71.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2cc(F)cc(F)c2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465683,CHEMBL2431548,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2',3-difluoro-[1,1'-biphenyl]-4-carboxamide",CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,85.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2ccccc2F)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465684,CHEMBL2431547,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3,4'-difluoro-[1,1'-biphenyl]-4-carboxamide",CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,87.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2ccc(F)cc2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465685,CHEMBL2431546,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3,3'-difluoro-[1,1'-biphenyl]-4-carboxamide",CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,85.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2cccc(F)c2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465686,CHEMBL2431545,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3-fluoro-[1,1'-biphenyl]-4-carboxamide",CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,82.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2ccccc2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465687,CHEMBL2431544,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2-fluoro-[1,1'-biphenyl]-4-carboxamide",CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,87.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2ccccc2)c(F)c1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465688,CHEMBL2431637,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-6-bromo-2-naphthamide,CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,95.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc2cc(Br)ccc2c1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465689,CHEMBL2431636,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-6-fluoro-2-naphthamide,CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,94.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc2cc(F)ccc2c1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465690,CHEMBL2431635,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-1-fluoro-2-naphthamide,CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,97.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc2ccccc2c1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465691,CHEMBL2431633,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-bromo-2-fluorobenzamide,CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,93.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(Br)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465692,CHEMBL2431632,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-5-bromo-2-fluorobenzamide,CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,94.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1cc(Br)ccc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465693,CHEMBL2431631,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2,4-difluorobenzamide",CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,89.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(F)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465694,CHEMBL2431630,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2,5-difluorobenzamide",CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,86.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1cc(F)ccc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465695,CHEMBL157101,"1-(4-{4-[2-(2,4-Dichloro-phenyl)-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethoxy]-phenyl}-piperazin-1-yl)-ethanone (ketoconazole)",CHEMBL2432690,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins relative to control,Inhibition,=,22.0,%,CC(=O)N1CCN(c2ccc(OCC3COC(Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465696,CHEMBL2431542,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2-fluoro-4-(piperazin-1-yl)benzamide Hydrochloride,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,71.0,%,Cl.O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(N2CCNCC2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465697,CHEMBL2431540,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2-fluoro-4-morpholinobenzamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,98.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(N2CCOCC2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465698,CHEMBL2431538,"(S,E)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-chlorostyryl)-2-fluorobenzamide",CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,94.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(/C=C/c2ccc(Cl)cc2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465699,CHEMBL2431537,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2-fluoro-4-(phenylethynyl)benzamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,96.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(C#Cc2ccccc2)cc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465700,CHEMBL2431543,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-[1,1'-biphenyl]-3-carboxamide",CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,99.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1cccc(-c2ccccc2)c1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465701,CHEMBL2429885,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-[1,1'-biphenyl]-4-carboxamide",CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,99.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2ccccc2)cc1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465702,CHEMBL2431634,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2-naphthamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,99.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc2ccccc2c1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465703,CHEMBL2431629,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2-chlorobenzamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,96.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccccc1Cl,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465704,CHEMBL2431628,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-methoxybenzamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,99.0,%,COc1ccc(C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)Nc2ccncc2)cc1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465705,CHEMBL2431627,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(trifluoromethyl)benzamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,99.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(C(F)(F)F)cc1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465706,CHEMBL2431626,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3-phenoxybenzamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,99.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1cccc(Oc2ccccc2)c1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465707,CHEMBL2431625,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3-fluorobenzamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,99.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1cccc(F)c1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465708,CHEMBL2431650,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2-fluorobenzamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,98.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccccc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465709,CHEMBL2431649,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-benzamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,95.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccccc1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465710,CHEMBL2431648,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-fluorophenyl)butanamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,96.0,%,O=C(CCCc1ccc(F)cc1)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465711,CHEMBL2431647,(S)-3-(1H-Indol-3-yl)-N-(pyridin-4-yl)-2-(3-(4-(trifluoromethyl)-phenyl)propanamido)propanamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,96.0,%,O=C(CCc1ccc(C(F)(F)F)cc1)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465712,CHEMBL2431646,(S)-3-(1H-Indol-3-yl)-2-(3-(4-methoxyphenyl)propanamido)-N-(pyridin-4-yl)propanamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,99.0,%,COc1ccc(CCC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)Nc2ccncc2)cc1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465713,CHEMBL2431645,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-phenylbutanamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,99.0,%,O=C(CCCc1ccccc1)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465714,CHEMBL2431644,(S)-3-(1H-Indol-3-yl)-2-(3-phenylpropanamido)-N-(pyridin-4-yl)-propanamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,98.0,%,O=C(CCc1ccccc1)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465715,CHEMBL2431643,(S)-3-(1H-Indol-3-yl)-2-(2-phenylacetamido)-N-(pyridin-4-yl)-propanamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,99.0,%,O=C(Cc1ccccc1)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465716,CHEMBL2431642,"(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4,4-difluorocyclohexanecarboxamide",CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,98.0,%,O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)C1CCC(F)(F)CC1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465717,CHEMBL2429886,(S)-N-(3-(5-(Benzyloxy)-1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)cyclohexanecarboxamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,99.0,%,O=C(N[C@@H](Cc1c[nH]c2ccc(OCc3ccccc3)cc12)C(=O)Nc1ccncc1)C1CCCCC1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465718,CHEMBL2431641,(S)-N-(3-(5-Hydroxy-1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)-propan-2-yl)cyclohexanecarboxamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,98.0,%,O=C(N[C@@H](Cc1c[nH]c2ccc(O)cc12)C(=O)Nc1ccncc1)C1CCCCC1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465719,CHEMBL2431640,(S)-N-(3-(1-Methyl-1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)-propan-2-yl)cyclohexanecarboxamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,96.0,%,Cn1cc(C[C@H](NC(=O)C2CCCCC2)C(=O)Nc2ccncc2)c2ccccc21,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465720,CHEMBL2431658,(S)-2-((2-Fluorobenzyl)amino)-3-(1H-indol-3-yl)-N-(pyridin-4-yl)-propanamide hydrochloride,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,13.0,%,Cl.O=C(Nc1ccncc1)[C@H](Cc1c[nH]c2ccccc12)NCc1ccccc1F,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465721,CHEMBL2431657,rac-N-((S)-3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-1-methylpiperidine-3-carboxamide hydrochloride,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,61.0,%,CN1CCCC(C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)Nc2ccncc2)C1.Cl,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465722,CHEMBL2431656,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-1-methylpiperidine-4-carboxamide hydrochloride,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,25.0,%,CN1CCC(C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)Nc2ccncc2)CC1.Cl,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465723,CHEMBL2431655,(S)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-piperidine-4-carboxamide hydrochloride,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,25.0,%,Cl.O=C(N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)C1CCNCC1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465724,CHEMBL2431654,"(S)-N-(1-(3,5-dimethylisoxazol-4-ylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)cyclohexanecarboxamide",CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,39.0,%,Cc1noc(C)c1NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)C1CCCCC1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465725,CHEMBL2431653,(S)-N-(3-(1H-Indol-3-yl)-1-((2-methoxypyridin-4-yl)amino)-1-oxopropan-2-yl)cyclohexanecarboxamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,16.0,%,COc1cc(NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)C2CCCCC2)ccn1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465726,CHEMBL1294,(6-Methoxy-quinolin-4-yl)-(5-vinyl-1-aza-bicyclo[2.2.2]oct-2-yl)-methanol,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,9.0,%,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13465727,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL2432691,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 10 uM after 10 mins relative to control,Inhibition,=,92.0,%,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL2429844,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,J. Med. Chem.,2013.0,56,19,7651,7668,10.1021/jm401067s,24079662.0,
13500238,CHEMBL2442495,"2-(4-Methyl-3,5-diphenyl-1H-pyrazol-1-yl)thiazole-4-carboxylic acid",CHEMBL2443714,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),Inhibition,>,10.0,%,Cc1c(-c2ccccc2)nn(-c2nc(C(=O)O)cs2)c1-c1ccccc1,CHEMBL2440026,Hit-to-lead optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as a novel class of EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,2013.0,23,22,6064,6067,10.1016/j.bmcl.2013.09.032,24094816.0,
13500239,CHEMBL2442490,2-(3-(2-hydroxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)thiazole-4-carboxylic acid,CHEMBL2443714,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),Inhibition,>,10.0,%,O=C(O)c1csc(-n2nc(-c3ccccc3O)cc2C(F)(F)F)n1,CHEMBL2440026,Hit-to-lead optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as a novel class of EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,2013.0,23,22,6064,6067,10.1016/j.bmcl.2013.09.032,24094816.0,
13500240,CHEMBL1479261,SID24802261,CHEMBL2443714,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),Inhibition,>,10.0,%,O=C(O)c1csc(-n2nc(-c3ccccc3)cc2C(F)(F)F)n1,CHEMBL2440026,Hit-to-lead optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as a novel class of EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,2013.0,23,22,6064,6067,10.1016/j.bmcl.2013.09.032,24094816.0,
13500241,CHEMBL2442485,2-(5-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)thiazole-4-carboxylic acid,CHEMBL2443714,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),Inhibition,>,10.0,%,COc1ccc(-c2cc(C(F)(F)F)nn2-c2nc(C(=O)O)cs2)cc1,CHEMBL2440026,Hit-to-lead optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as a novel class of EP1 receptor antagonists.,Bioorg. Med. Chem. Lett.,2013.0,23,22,6064,6067,10.1016/j.bmcl.2013.09.032,24094816.0,
13500827,CHEMBL2442249,5-chloro-7-((4-ethylpiperazin-1-yl)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol,CHEMBL2445375,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,24.0,%,CCN1CCN(C(c2ccc(C(F)(F)F)cc2)c2cc(Cl)c3cccnc3c2O)CC1,CHEMBL2439986,Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker.,Bioorg. Med. Chem.,2013.0,21,21,6642,6649,10.1016/j.bmc.2013.08.017,23993674.0,
13835701,CHEMBL3086027,"N-(4-(2,4-dimethyl-1H-imidazol-1-yl)benzyl)-2,5-difluorobenzenesulfonamide",CHEMBL3090237,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,<,5.0,%,Cc1cn(-c2ccc(CNS(=O)(=O)c3cc(F)ccc3F)cc2)c(C)n1,CHEMBL3085697,Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists.,Bioorg. Med. Chem. Lett.,2013.0,23,23,6239,6242,10.1016/j.bmcl.2013.09.099,24157365.0,
13841862,CHEMBL3093133,"4-(4-hydroxy-3-methoxy-9-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5H-benzo[7]annulen-8-yl)butanenitrile",CHEMBL3095759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,=,23.7,%,COc1ccc2c(c1O)CCCC(CCCC#N)=C2c1cc(OC)c(OC)c(OC)c1,CHEMBL3091388,"New cytotoxic benzosuberene analogs. Synthesis, molecular modeling and biological evaluation.",Bioorg. Med. Chem. Lett.,2013.0,23,24,6688,6694,10.1016/j.bmcl.2013.10.039,24210503.0,
13841863,CHEMBL3093137,"3-(4-hydroxy-3-methoxy-9-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5H-benzo[7]annulen-8-yl)propanenitrile",CHEMBL3095759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,=,75.7,%,COc1ccc2c(c1O)CCCC(CCC#N)=C2c1cc(OC)c(OC)c(OC)c1,CHEMBL3091388,"New cytotoxic benzosuberene analogs. Synthesis, molecular modeling and biological evaluation.",Bioorg. Med. Chem. Lett.,2013.0,23,24,6688,6694,10.1016/j.bmcl.2013.10.039,24210503.0,
13841864,CHEMBL3093140,"rac-3-(4-hydroxy-3-methoxy-9-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5H-benzo[7]annulen-8-yl)propane-1,2-diol",CHEMBL3095759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,=,6.1,%,COc1ccc2c(c1O)CCCC(CC(O)CO)=C2c1cc(OC)c(OC)c(OC)c1,CHEMBL3091388,"New cytotoxic benzosuberene analogs. Synthesis, molecular modeling and biological evaluation.",Bioorg. Med. Chem. Lett.,2013.0,23,24,6688,6694,10.1016/j.bmcl.2013.10.039,24210503.0,
13841865,CHEMBL3093141,"8-benzyl-3-methoxy-9-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5H-benzo[7]annulen-4-ol",CHEMBL3095759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,=,55.3,%,COc1ccc2c(c1O)CCCC(Cc1ccccc1)=C2c1cc(OC)c(OC)c(OC)c1,CHEMBL3091388,"New cytotoxic benzosuberene analogs. Synthesis, molecular modeling and biological evaluation.",Bioorg. Med. Chem. Lett.,2013.0,23,24,6688,6694,10.1016/j.bmcl.2013.10.039,24210503.0,
13841866,CHEMBL3093142,"8-ethyl-3-methoxy-9-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5H-benzo[7]annulen-4-ol",CHEMBL3095759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,=,75.0,%,CCC1=C(c2cc(OC)c(OC)c(OC)c2)c2ccc(OC)c(O)c2CCC1,CHEMBL3091388,"New cytotoxic benzosuberene analogs. Synthesis, molecular modeling and biological evaluation.",Bioorg. Med. Chem. Lett.,2013.0,23,24,6688,6694,10.1016/j.bmcl.2013.10.039,24210503.0,
13841867,CHEMBL3093143,"3-methoxy-8-methyl-9-(3,4,5-trimethoxyphenyl)-6,7-dihydro-5H-benzo[7]annulen-4-ol",CHEMBL3095759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,=,91.5,%,COc1ccc2c(c1O)CCCC(C)=C2c1cc(OC)c(OC)c(OC)c1,CHEMBL3091388,"New cytotoxic benzosuberene analogs. Synthesis, molecular modeling and biological evaluation.",Bioorg. Med. Chem. Lett.,2013.0,23,24,6688,6694,10.1016/j.bmcl.2013.10.039,24210503.0,
13841868,CHEMBL518054,"2-Methoxy-5-(3',4',5'-trimethoxyphenyl)-6,7,8,9-tetrahydro-5H-benzocyclohepten-1-ol",CHEMBL3095759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,=,89.7,%,COc1ccc2c(c1O)CCCC=C2c1cc(OC)c(OC)c(OC)c1,CHEMBL3091388,"New cytotoxic benzosuberene analogs. Synthesis, molecular modeling and biological evaluation.",Bioorg. Med. Chem. Lett.,2013.0,23,24,6688,6694,10.1016/j.bmcl.2013.10.039,24210503.0,
13841869,CHEMBL107,"N-(1,2,3,10-Tetramethoxy-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl)-acetamide",CHEMBL3095759,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,=,11.1,%,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2,CHEMBL3091388,"New cytotoxic benzosuberene analogs. Synthesis, molecular modeling and biological evaluation.",Bioorg. Med. Chem. Lett.,2013.0,23,24,6688,6694,10.1016/j.bmcl.2013.10.039,24210503.0,
13844197,CHEMBL3093304,rac-2-(3-(4-Fluorobenzyl)pyrrolidin-1-yl)-5-(trifluoromethyl)benzoic acid,CHEMBL3095185,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,86.0,%,O=C(O)c1cc(C(F)(F)F)ccc1N1CCC(Cc2ccc(F)cc2)C1,CHEMBL3091416,Discovery of XEN445: a potent and selective endothelial lipase inhibitor raises plasma HDL-cholesterol concentration in mice.,Bioorg. Med. Chem.,2013.0,21,24,7724,7734,10.1016/j.bmc.2013.10.023,24211162.0,
13940691,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL3128584,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,75.79,%,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL3124886,Potent Hepatitis C Virus NS5A Inhibitors Containing a Benzidine Core.,ACS Med. Chem. Lett.,2014.0,5,3,255,258,10.1021/ml4003293,24900814.0,
13940692,CHEMBL3125176,"dimethyl(1R,1'R)-2,2'-((2S,2'S)-2,2'-(biphenyl-4,4'-diylbis(azanediyl))bis(oxomethylene)bis(pyrrolidine-2,1-diyl))bis(2-oxo-1-phenylethane-2,1-diyl)dicarbamate",CHEMBL3128584,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,0.0,%,COC(=O)N[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc(-c2ccc(NC(=O)[C@@H]3CCCN3C(=O)[C@H](NC(=O)OC)c3ccccc3)cc2)cc1)c1ccccc1,CHEMBL3124886,Potent Hepatitis C Virus NS5A Inhibitors Containing a Benzidine Core.,ACS Med. Chem. Lett.,2014.0,5,3,255,258,10.1021/ml4003293,24900814.0,
13960695,CHEMBL3127986,"(2S,4S)-1-[(2S)-2-Amino-3-(thiazol-4-yl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile",CHEMBL3130756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 100 uM relative to control,Inhibition,=,11.2,%,N#C[C@@H]1C[C@H](F)CN1C(=O)[C@@H](N)Cc1cscn1,CHEMBL3124820,"Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.",Eur. J. Med. Chem.,2014.0,75,,111,122,10.1016/j.ejmech.2014.01.021,24531224.0,
13960750,CHEMBL3127992,"(2S,4S)-1-[(2S)-2-Amino-3-(6-bromobenzo[d][1,3]dioxol-5-yl)propanoyl]-4-fluoropyrrolidine-2-carbonitrile",CHEMBL3130756,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 100 uM relative to control,Inhibition,=,-20.3,%,N#C[C@@H]1C[C@H](F)CN1C(=O)[C@@H](N)Cc1cc2c(cc1Br)OCO2,CHEMBL3124820,"Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.",Eur. J. Med. Chem.,2014.0,75,,111,122,10.1016/j.ejmech.2014.01.021,24531224.0,
14543880,CHEMBL3218118,"4-[1-(2,4-Dichloro-benzenesulfonyl)-3-hydroxy-azetidin-3-ylmethoxy]-2-fuoro-benzonitrile",CHEMBL3227123,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,<,20.0,%,N#Cc1ccc(OCC2(O)CN(S(=O)(=O)c3ccc(Cl)cc3Cl)C2)cc1F,CHEMBL3217745,Identification of false positives in HTS hits to lead: The application of Bayesian models in HTS triage to rapidly deliver a series of selective TRPV4 antagonists,MedChemComm,2013.0,4,1,244,251,10.1039/C2MD20259J,,
14551018,CHEMBL3220543,"(1S,5R)-3-[5-(2-adamantylcarbamoyl)-6-methylsulfanyl-pyridin-2-yl]-3-azabicyclo[3.1.0]hexane-6-carboxylic acid",CHEMBL3227910,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,25.0,%,CSc1nc(N2C[C@H]3[C@@H](C2)[C@@H]3C(=O)O)ccc1C(=O)NC12CC3CC(CC(C3)C1)C2,CHEMBL3217743,Reduction of acyl glucuronidation in a series of acidic 11-hydroxysteroid dehydrogenase type 1 (11-HSD1) inhibitors: the discovery of AZD6925,MedChemComm,2012.0,3,10,1264,1269,10.1039/C2MD20154B,,
14552159,CHEMBL1760434,"4-amino-1-benzyl-6-(trifluoromethyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one",CHEMBL3224585,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,<,15.0,%,Nc1nc(C(F)(F)F)cc2c1[nH]c(=O)n2Cc1ccccc1,CHEMBL3217697,The discovery of a novel prototype small molecule TLR7 agonist for the treatment of hepatitis C virus infection,MedChemComm,2011.0,2,3,185,189,10.1039/C0MD00197J,,
14647585,CHEMBL3260480,"(2,4-dihydroxy-5-(1H-indol-1-yl)phenyl)(isoindolin-2-yl)methanone",CHEMBL3266924,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate at 10 uM,Inhibition,=,73.0,%,O=C(c1cc(-n2ccc3ccccc32)c(O)cc1O)N1Cc2ccccc2C1,CHEMBL3259726,Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization.,Bioorg. Med. Chem. Lett.,2014.0,24,11,2525,2529,10.1016/j.bmcl.2014.03.100,24751441.0,
14647586,CHEMBL3260486,"(5-(4-bromo-1H-indol-1-yl)-2,4-dihydroxyphenyl)(isoindolin-2-yl)methanone",CHEMBL3266924,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate at 10 uM,Inhibition,=,54.0,%,O=C(c1cc(-n2ccc3c(Br)cccc32)c(O)cc1O)N1Cc2ccccc2C1,CHEMBL3259726,Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization.,Bioorg. Med. Chem. Lett.,2014.0,24,11,2525,2529,10.1016/j.bmcl.2014.03.100,24751441.0,
14647587,CHEMBL3260487,"(2,4-dihydroxy-5-(4-nitro-1H-indol-1-yl)phenyl)(isoindolin-2-yl)methanone",CHEMBL3266924,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate at 10 uM,Inhibition,=,74.0,%,O=C(c1cc(-n2ccc3c([N+](=O)[O-])cccc32)c(O)cc1O)N1Cc2ccccc2C1,CHEMBL3259726,Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization.,Bioorg. Med. Chem. Lett.,2014.0,24,11,2525,2529,10.1016/j.bmcl.2014.03.100,24751441.0,
14647588,CHEMBL3260490,"(5-(5-bromo-1H-indol-1-yl)-2,4-dihydroxyphenyl)(isoindolin-2-yl)methanone",CHEMBL3266924,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate at 10 uM,Inhibition,=,78.0,%,O=C(c1cc(-n2ccc3cc(Br)ccc32)c(O)cc1O)N1Cc2ccccc2C1,CHEMBL3259726,Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization.,Bioorg. Med. Chem. Lett.,2014.0,24,11,2525,2529,10.1016/j.bmcl.2014.03.100,24751441.0,
14647589,CHEMBL3260491,"(2,4-dihydroxy-5-(5-methyl-1H-indol-1-yl)phenyl)(isoindolin-2-yl)methanone",CHEMBL3266924,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate at 10 uM,Inhibition,=,68.0,%,Cc1ccc2c(ccn2-c2cc(C(=O)N3Cc4ccccc4C3)c(O)cc2O)c1,CHEMBL3259726,Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization.,Bioorg. Med. Chem. Lett.,2014.0,24,11,2525,2529,10.1016/j.bmcl.2014.03.100,24751441.0,
14647590,CHEMBL3260492,"(2,4-dihydroxy-5-(phenylamino)phenyl)(isoindolin-2-yl)methanone",CHEMBL3266924,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate at 10 uM,Inhibition,=,68.0,%,O=C(c1cc(Nc2ccccc2)c(O)cc1O)N1Cc2ccccc2C1,CHEMBL3259726,Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization.,Bioorg. Med. Chem. Lett.,2014.0,24,11,2525,2529,10.1016/j.bmcl.2014.03.100,24751441.0,
14647591,CHEMBL3260493,"(2,4-dihydroxy-5-(p-tolylamino)phenyl)(isoindolin-2-yl)methanone",CHEMBL3266924,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate at 10 uM,Inhibition,=,75.0,%,Cc1ccc(Nc2cc(C(=O)N3Cc4ccccc4C3)c(O)cc2O)cc1,CHEMBL3259726,Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization.,Bioorg. Med. Chem. Lett.,2014.0,24,11,2525,2529,10.1016/j.bmcl.2014.03.100,24751441.0,
14647592,CHEMBL3260494,"(5-(2,4-dichlorophenylamino)-2,4-dihydroxyphenyl)(isoindolin-2-yl)methanone",CHEMBL3266924,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate at 10 uM,Inhibition,=,73.0,%,O=C(c1cc(Nc2ccc(Cl)cc2Cl)c(O)cc1O)N1Cc2ccccc2C1,CHEMBL3259726,Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization.,Bioorg. Med. Chem. Lett.,2014.0,24,11,2525,2529,10.1016/j.bmcl.2014.03.100,24751441.0,
14658548,CHEMBL3259944,"(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3,3'-difluorobiphenyl-4-carboxamide",CHEMBL3268923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins in presence of NADPH,Inhibition,=,91.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2cccc(F)c2)cc1F,CHEMBL3259625,R-Configuration of 4-Aminopyridyl-Based Inhibitors of CYP51 Confers Superior Efficacy Against Trypanosoma cruzi.,ACS Med. Chem. Lett.,2014.0,5,4,434,439,10.1021/ml500010m,24900854.0,
14658549,CHEMBL3259945,"(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2',3,5'-trifluorobiphenyl-4-carboxamide",CHEMBL3268923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins in presence of NADPH,Inhibition,=,92.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2cc(F)ccc2F)cc1F,CHEMBL3259625,R-Configuration of 4-Aminopyridyl-Based Inhibitors of CYP51 Confers Superior Efficacy Against Trypanosoma cruzi.,ACS Med. Chem. Lett.,2014.0,5,4,434,439,10.1021/ml500010m,24900854.0,
14658550,CHEMBL3259946,"(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3,3',4'-trifluorobiphenyl-4-carboxamide",CHEMBL3268923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins in presence of NADPH,Inhibition,=,90.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2ccc(F)c(F)c2)cc1F,CHEMBL3259625,R-Configuration of 4-Aminopyridyl-Based Inhibitors of CYP51 Confers Superior Efficacy Against Trypanosoma cruzi.,ACS Med. Chem. Lett.,2014.0,5,4,434,439,10.1021/ml500010m,24900854.0,
14658551,CHEMBL3259947,"(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3,3'-difluoro-4'-(trifluoromethyl)biphenyl-4-carboxamide",CHEMBL3268923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins in presence of NADPH,Inhibition,=,92.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2ccc(C(F)(F)F)c(F)c2)cc1F,CHEMBL3259625,R-Configuration of 4-Aminopyridyl-Based Inhibitors of CYP51 Confers Superior Efficacy Against Trypanosoma cruzi.,ACS Med. Chem. Lett.,2014.0,5,4,434,439,10.1021/ml500010m,24900854.0,
14658552,CHEMBL3259948,(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2-fluoro-4-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)benzamide,CHEMBL3268923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins in presence of NADPH,Inhibition,=,96.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(N2CCN(c3cccc(C(F)(F)F)c3)CC2)cc1F,CHEMBL3259625,R-Configuration of 4-Aminopyridyl-Based Inhibitors of CYP51 Confers Superior Efficacy Against Trypanosoma cruzi.,ACS Med. Chem. Lett.,2014.0,5,4,434,439,10.1021/ml500010m,24900854.0,
14658553,CHEMBL3259949,"(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4'-(2,4-difluorobenzyloxy)-3,3'-difluorobiphenyl-4-carboxamide",CHEMBL3268923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins in presence of NADPH,Inhibition,=,84.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2ccc(OCc3ccc(F)cc3F)c(F)c2)cc1F,CHEMBL3259625,R-Configuration of 4-Aminopyridyl-Based Inhibitors of CYP51 Confers Superior Efficacy Against Trypanosoma cruzi.,ACS Med. Chem. Lett.,2014.0,5,4,434,439,10.1021/ml500010m,24900854.0,
14658554,CHEMBL3259950,(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3-fluoro-4'-(4-fluorobenzyloxy)-3'-(trifluoromethyl)biphenyl-4-carboxamide,CHEMBL3268923,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide hydroxylation to hydroxytolbutamide at 1 uM after 10 mins in presence of NADPH,Inhibition,=,41.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2ccc(OCc3ccc(F)cc3)c(C(F)(F)F)c2)cc1F,CHEMBL3259625,R-Configuration of 4-Aminopyridyl-Based Inhibitors of CYP51 Confers Superior Efficacy Against Trypanosoma cruzi.,ACS Med. Chem. Lett.,2014.0,5,4,434,439,10.1021/ml500010m,24900854.0,
14660366,CHEMBL3260567,"N-((4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline",CHEMBL3270812,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate at 10 uM incubated for 5 mins prior to substrate addition measured after 10 mins by LC/MS/MS analysis,Inhibition,=,30.1,%,Cc1cccc(-c2[nH]c(CNc3ccccc3F)nc2-c2ccc3ncnn3c2)n1,CHEMBL3259733,"Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.",J. Med. Chem.,2014.0,57,10,4213,4238,10.1021/jm500115w,24786585.0,
14669167,CHEMBL3262125,Rac-2-(2-((Pyridin-3-yloxy)methyl)piperazin-1-yl)benzo[d]oxazole,CHEMBL3268321,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,20.0,%,c1cncc(OCC2CNCCN2c2nc3ccccc3o2)c1,CHEMBL3259628,Discovery of novel 2-((pyridin-3-yloxy)methyl)piperazines as α7 nicotinic acetylcholine receptor modulators for the treatment of inflammatory disorders.,J. Med. Chem.,2014.0,57,10,3966,3983,10.1021/jm5004599,24814197.0,
14669168,CHEMBL3262132,"(R)-2-(2-((Pyridin-3-yloxy)methyl)piperazin-1-yl)oxazolo[4,5-b]-pyridine Hydrochloride",CHEMBL3268321,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,22.0,%,Cl.c1cncc(OC[C@H]2CNCCN2c2nc3ncccc3o2)c1,CHEMBL3259628,Discovery of novel 2-((pyridin-3-yloxy)methyl)piperazines as α7 nicotinic acetylcholine receptor modulators for the treatment of inflammatory disorders.,J. Med. Chem.,2014.0,57,10,3966,3983,10.1021/jm5004599,24814197.0,
14669169,CHEMBL3262135,(R)-6-Methoxy-2-(2-((pyridin-3-yloxy)methyl)piperazin-1-yl)-benzo[d]thiazole Hydrochloride,CHEMBL3268321,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,33.0,%,COc1ccc2nc(N3CCNC[C@@H]3COc3cccnc3)sc2c1.Cl,CHEMBL3259628,Discovery of novel 2-((pyridin-3-yloxy)methyl)piperazines as α7 nicotinic acetylcholine receptor modulators for the treatment of inflammatory disorders.,J. Med. Chem.,2014.0,57,10,3966,3983,10.1021/jm5004599,24814197.0,
14669170,CHEMBL3262143,Rac-4-Fluoro-2-(2-((pyridin-3-yloxy)methyl)piperazin-1-yl)benzo[d]-thiazole Hydrochloride,CHEMBL3268321,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,28.0,%,Cl.Fc1cccc2sc(N3CCNCC3COc3cccnc3)nc12,CHEMBL3259628,Discovery of novel 2-((pyridin-3-yloxy)methyl)piperazines as α7 nicotinic acetylcholine receptor modulators for the treatment of inflammatory disorders.,J. Med. Chem.,2014.0,57,10,3966,3983,10.1021/jm5004599,24814197.0,
14669171,CHEMBL3262144,"Rac-4,6-Difluoro-2-(2-((pyridin-3-yloxy)methyl)piperazin-1-yl)benzo-[d]thiazole Hydrochloride",CHEMBL3268321,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,26.0,%,Cl.Fc1cc(F)c2nc(N3CCNCC3COc3cccnc3)sc2c1,CHEMBL3259628,Discovery of novel 2-((pyridin-3-yloxy)methyl)piperazines as α7 nicotinic acetylcholine receptor modulators for the treatment of inflammatory disorders.,J. Med. Chem.,2014.0,57,10,3966,3983,10.1021/jm5004599,24814197.0,
14669172,CHEMBL3262162,Rac-N-(4-Methoxyphenyl)-2-((pyridin-3-yloxy)methyl)piperazine-1-carboxamide Dihydrochloride,CHEMBL3268321,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,14.0,%,COc1ccc(NC(=O)N2CCNCC2COc2cccnc2)cc1.Cl,CHEMBL3259628,Discovery of novel 2-((pyridin-3-yloxy)methyl)piperazines as α7 nicotinic acetylcholine receptor modulators for the treatment of inflammatory disorders.,J. Med. Chem.,2014.0,57,10,3966,3983,10.1021/jm5004599,24814197.0,
14669173,CHEMBL3262168,Rac-N-(3-Chloro-4-methoxyphenyl)-2-((pyridin-3-yloxy)methyl)-piperazine-1-carboxamide Dihydrochloride,CHEMBL3268321,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,10.0,%,COc1ccc(NC(=O)N2CCNCC2COc2cccnc2)cc1Cl.Cl,CHEMBL3259628,Discovery of novel 2-((pyridin-3-yloxy)methyl)piperazines as α7 nicotinic acetylcholine receptor modulators for the treatment of inflammatory disorders.,J. Med. Chem.,2014.0,57,10,3966,3983,10.1021/jm5004599,24814197.0,
14669174,CHEMBL3262171,Rac-N-(4-Bromo-3-methylphenyl)-2-((pyridin-3-yloxy)methyl)-piperazine-1-carboxamide Dihydrochloride,CHEMBL3268321,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,21.0,%,Cc1cc(NC(=O)N2CCNCC2COc2cccnc2)ccc1Br.Cl,CHEMBL3259628,Discovery of novel 2-((pyridin-3-yloxy)methyl)piperazines as α7 nicotinic acetylcholine receptor modulators for the treatment of inflammatory disorders.,J. Med. Chem.,2014.0,57,10,3966,3983,10.1021/jm5004599,24814197.0,
14669175,CHEMBL3262172,Rac-N-(4-Bromo-2-fluorophenyl)-2-((pyridin-3-yloxy)methyl)-piperazine-1-carboxamide Dihydrochloride,CHEMBL3268321,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,7.0,%,Cl.O=C(Nc1ccc(Br)cc1F)N1CCNCC1COc1cccnc1,CHEMBL3259628,Discovery of novel 2-((pyridin-3-yloxy)methyl)piperazines as α7 nicotinic acetylcholine receptor modulators for the treatment of inflammatory disorders.,J. Med. Chem.,2014.0,57,10,3966,3983,10.1021/jm5004599,24814197.0,
14669176,CHEMBL3262174,Rac-N-(4-Benzoylphenyl)-2-((pyridin-3-yloxy)methyl)piperazine-1-carboxamide Dihydrochloride,CHEMBL3268321,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,62.0,%,Cl.O=C(c1ccccc1)c1ccc(NC(=O)N2CCNCC2COc2cccnc2)cc1,CHEMBL3259628,Discovery of novel 2-((pyridin-3-yloxy)methyl)piperazines as α7 nicotinic acetylcholine receptor modulators for the treatment of inflammatory disorders.,J. Med. Chem.,2014.0,57,10,3966,3983,10.1021/jm5004599,24814197.0,
14723017,CHEMBL3286556,"2-Benzyl-9-(S)-methyl-4-(methylamino)-5,6,8,9-tetrahydro-7H-pyrimido[4,5-d]azepine",CHEMBL3294598,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,<,10.0,%,CNc1nc(Cc2ccccc2)nc2c1CCNC[C@@H]2C,CHEMBL3286089,"Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT₂C) receptor agonists with exquisite functional selectivity over 5-HT₂A and 5-HT₂B receptors.",J. Med. Chem.,2014.0,57,12,5258,5269,10.1021/jm5003292,24878222.0,
14723018,CHEMBL3286557,"2-[Difluoro(phenyl)methyl]-N-methyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine",CHEMBL3294598,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,<,10.0,%,CNc1nc(C(F)(F)c2ccccc2)nc2c1CCNCC2,CHEMBL3286089,"Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT₂C) receptor agonists with exquisite functional selectivity over 5-HT₂A and 5-HT₂B receptors.",J. Med. Chem.,2014.0,57,12,5258,5269,10.1021/jm5003292,24878222.0,
14737240,CHEMBL3287548,"5-(3-(4-chlorophenoxy)propyl)-8-fluoro-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole",CHEMBL3292272,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide conversion to 4-hydroxy tolbutamide at 25 uM preincubated for 10 mins followed by NADPH addition measured after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,36.0,%,Fc1ccc2c(c1)c1c(n2CCCOc2ccc(Cl)cc2)CCNC1,CHEMBL3286225,"Novel carboline derivatives as potent antifungal lead compounds: design, synthesis, and biological evaluation.",ACS Med. Chem. Lett.,2014.0,5,5,506,511,10.1021/ml400492t,24900870.0,
14737244,CHEMBL3287548,"5-(3-(4-chlorophenoxy)propyl)-8-fluoro-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole",CHEMBL3292541,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide conversion to 4-hydroxy tolbutamide at 2.5 uM preincubated for 10 mins followed by NADPH addition measured after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,8.0,%,Fc1ccc2c(c1)c1c(n2CCCOc2ccc(Cl)cc2)CCNC1,CHEMBL3286225,"Novel carboline derivatives as potent antifungal lead compounds: design, synthesis, and biological evaluation.",ACS Med. Chem. Lett.,2014.0,5,5,506,511,10.1021/ml400492t,24900870.0,
14737248,CHEMBL3287548,"5-(3-(4-chlorophenoxy)propyl)-8-fluoro-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole",CHEMBL3292545,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as tolbutamide conversion to 4-hydroxy tolbutamide at 0.25 uM preincubated for 10 mins followed by NADPH addition measured after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,-2.0,%,Fc1ccc2c(c1)c1c(n2CCCOc2ccc(Cl)cc2)CCNC1,CHEMBL3286225,"Novel carboline derivatives as potent antifungal lead compounds: design, synthesis, and biological evaluation.",ACS Med. Chem. Lett.,2014.0,5,5,506,511,10.1021/ml400492t,24900870.0,
14745845,CHEMBL3288273,"N-(4-Fluorobenzyl)-2,3-dihydroxy-7-nitro-1-oxo-1,2-dihydroisoquinoline-4-carboxamide",CHEMBL3294170,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant CYP2C9 (unknown origin) using 7-methoxy-4-trifluoromethylcoumarin as substrate at 10 uM relative to control,Inhibition,=,76.5,%,COc1ccc2c(C(=O)NCc3ccc(F)cc3)c(O)n(O)c(=O)c2c1,CHEMBL3286274,"Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.",J. Med. Chem.,2014.0,57,11,4640,4660,10.1021/jm500109z,24793360.0,
14926993,CHEMBL3347513,"3-(4-Amino-benzo[4,5]thieno[3,2-d]pyrimidin-7-yl)-N-(2-pyridin-3-yl-ethyl)-benzamide",CHEMBL3391346,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in apparent rate of formation of metabolites using diclofenac as substrate at 20 uM by LC-MS analysis,Inhibition,=,62.0,%,Nc1ncnc2c1sc1cc(-c3cccc(C(=O)NCCc4cccnc4)c3)ccc12,CHEMBL3390844,"Development of substituted 7-phenyl-4-aminobenzothieno[3,2-d] pyrimidines as potent LIMK1 inhibitors",MedChemComm,2011.0,2,10,982,986,10.1039/C1MD00138H,,
14926994,CHEMBL3347694,"3-(4-Amino-benzo[4,5]thieno[3,2-d]pyrimidin-7-yl)-N-(2-morpholin-4-yl-2-oxo-ethyl)-benzamide",CHEMBL3391346,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in apparent rate of formation of metabolites using diclofenac as substrate at 20 uM by LC-MS analysis,Inhibition,=,16.0,%,Nc1ncnc2c1sc1cc(-c3cccc(C(=O)NCC(=O)N4CCOCC4)c3)ccc12,CHEMBL3390844,"Development of substituted 7-phenyl-4-aminobenzothieno[3,2-d] pyrimidines as potent LIMK1 inhibitors",MedChemComm,2011.0,2,10,982,986,10.1039/C1MD00138H,,
14926995,CHEMBL3347683,"4-Methyl-piperazine-1-carboxylic acid [3-(4-amino-benzo[4,5]thieno[3,2-d]pyrimidin-7-yl)-phenyl]-amide",CHEMBL3391346,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in apparent rate of formation of metabolites using diclofenac as substrate at 20 uM by LC-MS analysis,Inhibition,=,32.0,%,CN1CCN(C(=O)Nc2cccc(-c3ccc4c(c3)sc3c(N)ncnc34)c2)CC1,CHEMBL3390844,"Development of substituted 7-phenyl-4-aminobenzothieno[3,2-d] pyrimidines as potent LIMK1 inhibitors",MedChemComm,2011.0,2,10,982,986,10.1039/C1MD00138H,,
14926996,CHEMBL3347669,"Pyrrolidine-1-carboxylic acid [3-(4-amino-benzo[4,5]thieno[3,2-d]pyrimidin-7-yl)-phenyl]-amid",CHEMBL3391346,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in apparent rate of formation of metabolites using diclofenac as substrate at 20 uM by LC-MS analysis,Inhibition,=,75.0,%,Nc1ncnc2c1sc1cc(-c3cccc(NC(=O)N4CCCC4)c3)ccc12,CHEMBL3390844,"Development of substituted 7-phenyl-4-aminobenzothieno[3,2-d] pyrimidines as potent LIMK1 inhibitors",MedChemComm,2011.0,2,10,982,986,10.1039/C1MD00138H,,
14998699,CHEMBL3318100,"(1-(3-Aminophenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)-methanone",CHEMBL3378034,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using sulfaphenazole as substrate at 1 uM,Inhibition,=,28.9,%,COc1cc(C(=O)c2ccn(-c3cccc(N)c3)c2)cc(OC)c1OC,CHEMBL3351435,New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer.,J. Med. Chem.,2014.0,57,15,6531,6552,10.1021/jm500561a,25025991.0,
15006770,CHEMBL3310483,3-(2-(4-chloro-3-fluorophenyl)-2-(3-chlorophenoxy)ethyl)azetidine,CHEMBL3364223,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 preincubated at 10 uM for 5 mins before fluorescent substrate addition by fluorescence assay,Inhibition,=,4.2,%,Fc1cc(C(CC2CNC2)Oc2cccc(Cl)c2)ccc1Cl,CHEMBL3352322,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3234,3237,10.1016/j.bmcl.2014.06.026,24974340.0,
15006771,CHEMBL3310484,3-(2-(4-chloro-3-fluorophenyl)-2-(2-fluorophenoxy)ethyl)azetidine,CHEMBL3364223,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 preincubated at 10 uM for 5 mins before fluorescent substrate addition by fluorescence assay,Inhibition,=,12.0,%,Fc1cc(C(CC2CNC2)Oc2ccccc2F)ccc1Cl,CHEMBL3352322,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3234,3237,10.1016/j.bmcl.2014.06.026,24974340.0,
15006772,CHEMBL3310485,3-(2-(4-chloro-3-fluorophenyl)-2-(3-fluorophenoxy)ethyl)azetidine,CHEMBL3364223,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 preincubated at 10 uM for 5 mins before fluorescent substrate addition by fluorescence assay,Inhibition,=,11.0,%,Fc1cccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)c1,CHEMBL3352322,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3234,3237,10.1016/j.bmcl.2014.06.026,24974340.0,
15006773,CHEMBL3310487,3-(2-(4-chloro-3-fluorophenyl)-2-(2-chlorophenoxy)ethyl)azetidine,CHEMBL3364223,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 preincubated at 10 uM for 5 mins before fluorescent substrate addition by fluorescence assay,Inhibition,=,18.0,%,Fc1cc(C(CC2CNC2)Oc2ccccc2Cl)ccc1Cl,CHEMBL3352322,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3234,3237,10.1016/j.bmcl.2014.06.026,24974340.0,
15006774,CHEMBL3310488,3-(2-(4-chloro-3-fluorophenyl)-2-(o-tolyloxy)ethyl)azetidine,CHEMBL3364223,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 preincubated at 10 uM for 5 mins before fluorescent substrate addition by fluorescence assay,Inhibition,=,32.0,%,Cc1ccccc1OC(CC1CNC1)c1ccc(Cl)c(F)c1,CHEMBL3352322,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3234,3237,10.1016/j.bmcl.2014.06.026,24974340.0,
15006775,CHEMBL3310489,3-(2-(4-chloro-3-fluorophenyl)-2-(m-tolyloxy)ethyl)azetidine,CHEMBL3364223,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 preincubated at 10 uM for 5 mins before fluorescent substrate addition by fluorescence assay,Inhibition,=,6.8,%,Cc1cccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)c1,CHEMBL3352322,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3234,3237,10.1016/j.bmcl.2014.06.026,24974340.0,
15006776,CHEMBL3310490,3-(2-(4-chloro-3-fluorophenyl)-2-(p-tolyloxy)ethyl)azetidine,CHEMBL3364223,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 preincubated at 10 uM for 5 mins before fluorescent substrate addition by fluorescence assay,Inhibition,=,19.0,%,Cc1ccc(OC(CC2CNC2)c2ccc(Cl)c(F)c2)cc1,CHEMBL3352322,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3234,3237,10.1016/j.bmcl.2014.06.026,24974340.0,
15006793,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL3364223,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 preincubated at 10 uM for 5 mins before fluorescent substrate addition by fluorescence assay,Inhibition,=,11.3,%,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL3352322,Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.,Bioorg. Med. Chem. Lett.,2014.0,24,15,3234,3237,10.1016/j.bmcl.2014.06.026,24974340.0,
15018149,CHEMBL3326044,"(2R,3S,4S,4aR,10bS)-7-((diethylamino)methyl)-3,4,8,10-tetrahydroxy-2-(hydroxymethyl)-9-methoxy-2,3,4,4a-tetrahydropyrano[3,2-c]isochromen-6(10bH)-one",CHEMBL3369245,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,32.0,%,CCN(CC)Cc1c(O)c(OC)c(O)c2c1C(=O)O[C@H]1[C@H]2O[C@H](CO)[C@@H](O)[C@@H]1O,CHEMBL3351580,"Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity.",J. Med. Chem.,2014.0,57,16,7085,7097,10.1021/jm500901e,25111439.0,
15056845,CHEMBL3259944,"(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3,3'-difluorobiphenyl-4-carboxamide",CHEMBL3366947,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM,Inhibition,=,91.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2cccc(F)c2)cc1F,CHEMBL3352430,4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.,J. Med. Chem.,2014.0,57,16,6989,7005,10.1021/jm500448u,25101801.0,
15056846,CHEMBL3259945,"(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2',3,5'-trifluorobiphenyl-4-carboxamide",CHEMBL3366947,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM,Inhibition,=,92.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2cc(F)ccc2F)cc1F,CHEMBL3352430,4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.,J. Med. Chem.,2014.0,57,16,6989,7005,10.1021/jm500448u,25101801.0,
15056847,CHEMBL3259946,"(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3,3',4'-trifluorobiphenyl-4-carboxamide",CHEMBL3366947,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM,Inhibition,=,90.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2ccc(F)c(F)c2)cc1F,CHEMBL3352430,4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.,J. Med. Chem.,2014.0,57,16,6989,7005,10.1021/jm500448u,25101801.0,
15056848,CHEMBL3337532,"(R)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3-fluoro-3'-(trifluoromethyl)-[1,1'-biphenyl]-4-carboxamide",CHEMBL3366947,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM,Inhibition,=,92.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2cccc(C(F)(F)F)c2)cc1F,CHEMBL3352430,4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.,J. Med. Chem.,2014.0,57,16,6989,7005,10.1021/jm500448u,25101801.0,
15056849,CHEMBL3337533,"(R)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3,3'-difluoro-4'-((4-fluorobenzyl)oxy)-[1,1'-biphenyl]-4-carboxamide",CHEMBL3366947,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM,Inhibition,=,89.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2ccc(OCc3ccc(F)cc3)c(F)c2)cc1F,CHEMBL3352430,4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.,J. Med. Chem.,2014.0,57,16,6989,7005,10.1021/jm500448u,25101801.0,
15056850,CHEMBL3337534,"(R)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2',3-difluoro-5'-(trifluoromethyl)-[1,1'-biphenyl]-4-carboxamide",CHEMBL3366947,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM,Inhibition,=,90.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2cc(C(F)(F)F)ccc2F)cc1F,CHEMBL3352430,4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.,J. Med. Chem.,2014.0,57,16,6989,7005,10.1021/jm500448u,25101801.0,
15056851,CHEMBL3337535,"(R)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3,4'-difluoro-3'-(trifluoromethyl)-[1,1'-biphenyl]-4-carboxamide",CHEMBL3366947,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM,Inhibition,=,96.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2ccc(F)c(C(F)(F)F)c2)cc1F,CHEMBL3352430,4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.,J. Med. Chem.,2014.0,57,16,6989,7005,10.1021/jm500448u,25101801.0,
15056852,CHEMBL3337536,"(R)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-3'-chloro-3,4'-difluoro-[1,1'-biphenyl]-4-carboxamide",CHEMBL3366947,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM,Inhibition,=,93.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(-c2ccc(F)c(Cl)c2)cc1F,CHEMBL3352430,4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.,J. Med. Chem.,2014.0,57,16,6989,7005,10.1021/jm500448u,25101801.0,
15056853,CHEMBL3337537,(R)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2-fluoro-4-(4-(3-fluorophenyl)piperazin-1-yl)benzamide,CHEMBL3366947,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM,Inhibition,=,95.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(N2CCN(c3cccc(F)c3)CC2)cc1F,CHEMBL3352430,4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.,J. Med. Chem.,2014.0,57,16,6989,7005,10.1021/jm500448u,25101801.0,
15056854,CHEMBL3337538,(R)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-acetylpiperazin-1-yl)-2-fluorobenzamide,CHEMBL3366947,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM,Inhibition,=,76.0,%,CC(=O)N1CCN(c2ccc(C(=O)N[C@H](Cc3c[nH]c4ccccc34)C(=O)Nc3ccncc3)c(F)c2)CC1,CHEMBL3352430,4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.,J. Med. Chem.,2014.0,57,16,6989,7005,10.1021/jm500448u,25101801.0,
15056855,CHEMBL3337539,(R)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-(3-chlorophenyl)piperazin-1-yl)-2-fluorobenzamide,CHEMBL3366947,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM,Inhibition,=,95.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(N2CCN(c3cccc(Cl)c3)CC2)cc1F,CHEMBL3352430,4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.,J. Med. Chem.,2014.0,57,16,6989,7005,10.1021/jm500448u,25101801.0,
15056856,CHEMBL3337540,"(R)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-(3,4-difluorophenyl)piperazin-1-yl)-2-fluorobenzamide",CHEMBL3366947,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM,Inhibition,=,94.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(N2CCN(c3ccc(F)c(F)c3)CC2)cc1F,CHEMBL3352430,4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.,J. Med. Chem.,2014.0,57,16,6989,7005,10.1021/jm500448u,25101801.0,
15056857,CHEMBL3337541,"(R)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-(2,4-difluorophenyl)piperazin-1-yl)-2-fluorobenzamide",CHEMBL3366947,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM,Inhibition,=,96.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(N2CCN(c3ccc(F)cc3F)CC2)cc1F,CHEMBL3352430,4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.,J. Med. Chem.,2014.0,57,16,6989,7005,10.1021/jm500448u,25101801.0,
15069107,CHEMBL1515648,SID24394346,CHEMBL3388344,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 20 uM,Inhibition,=,17.0,%,COC(=O)c1ccc(CSc2nc3c(c(=O)[nH]2)CCC3)cc1,CHEMBL3352788,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,2014.0,57,22,9598,9611,10.1021/jm501284e,25330343.0,
15069142,CHEMBL514794,"pyrimidine-4,6-dicarboxylic acid bis(4-fluoro-3-methylbenzylamide)",CHEMBL3388344,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 20 uM,Inhibition,=,10.0,%,Cc1cc(CNC(=O)c2cc(C(=O)NCc3ccc(F)c(C)c3)ncn2)ccc1F,CHEMBL3352788,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,2014.0,57,22,9598,9611,10.1021/jm501284e,25330343.0,
15069175,CHEMBL496942,"4-((1-methyl-2,4-dioxo-6-(3-phenylprop-1-ynyl)-1,2-dihydroquinazolin-3(4H)-yl)methyl)benzoic acid",CHEMBL3388352,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 2.5 uM,Inhibition,<,50.0,%,Cn1c(=O)n(Cc2ccc(C(=O)O)cc2)c(=O)c2cc(C#CCc3ccccc3)ccc21,CHEMBL3352788,Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.,J. Med. Chem.,2014.0,57,22,9598,9611,10.1021/jm501284e,25330343.0,
15071370,CHEMBL3325522,"2,5-difluoro-4-(((trans)-4-phenylpiperidin-3-yl)methoxy)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,81.0,%,O=S(=O)(Nc1ncns1)c1cc(F)c(OC[C@@H]2CNCC[C@H]2c2ccccc2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071371,CHEMBL3325523,"2,5-difluoro-4-(((trans)-4-(4-fluorophenyl)piperidin-3-yl)methoxy)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,100.0,%,O=S(=O)(Nc1ncns1)c1cc(F)c(OC[C@@H]2CNCC[C@H]2c2ccc(F)cc2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071372,CHEMBL3325524,"4-(((3S,4R)-4-(4-chlorophenyl)piperidin-3-yl)methoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,100.0,%,O=S(=O)(Nc1ncns1)c1cc(F)c(OC[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071374,CHEMBL3325524,"4-(((3S,4R)-4-(4-chlorophenyl)piperidin-3-yl)methoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,100.0,%,O=S(=O)(Nc1ncns1)c1cc(F)c(OC[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071375,CHEMBL3325527,"4-(((trans)-4-(3,4-difluorophenyl)piperidin-3-yl)methoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,96.0,%,O=S(=O)(Nc1ncns1)c1cc(F)c(OC[C@H]2CNCC[C@@H]2c2ccc(F)c(F)c2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071376,CHEMBL3325528,"4-(((trans)-4-(4-chloro-3-fluorophenyl)piperidin-3-yl)methoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,100.0,%,O=S(=O)(Nc1ncns1)c1cc(F)c(OC[C@H]2CNCC[C@@H]2c2ccc(Cl)c(F)c2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071377,CHEMBL3325529,"2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)-4-(((trans)-4-p-tolylpiperidin-3-yl)methoxy)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,100.0,%,Cc1ccc([C@H]2CCNC[C@@H]2COc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)cc1,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071378,CHEMBL3325530,"2,5-difluoro-4-((3-fluoro-4-(4-fluorophenyl)piperidin-3-yl)methoxy)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,99.0,%,O=S(=O)(Nc1ncns1)c1cc(F)c(OCC2(F)CNCCC2c2ccc(F)cc2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071379,CHEMBL3325531,"2,5-difluoro-4-(((trans)-4-(4-fluorophenyl)-6-oxopiperidin-3-yl)methoxy)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,58.0,%,O=C1C[C@@H](c2ccc(F)cc2)[C@H](COc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)CN1,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071380,CHEMBL3325532,"2,5-difluoro-4-(((trans)-3-(4-fluorophenyl)piperidin-4-yl)methoxy)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,97.0,%,O=S(=O)(Nc1ncns1)c1cc(F)c(OC[C@@H]2CCNC[C@H]2c2ccc(F)cc2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071381,CHEMBL3325533,"4-(((trans)-4-(4-chlorophenyl)pyrrolidin-3-yl)methoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,100.0,%,O=S(=O)(Nc1ncns1)c1cc(F)c(OC[C@@H]2CNC[C@H]2c2ccc(Cl)cc2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071382,CHEMBL3325534,"4-(((trans)-2-(4-chlorophenyl)cyclohexyl)methoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,100.0,%,O=S(=O)(Nc1ncns1)c1cc(F)c(OC[C@@H]2CCCC[C@H]2c2ccc(Cl)cc2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071383,CHEMBL3325535,"(trans)-tert-butyl 3-((4-(N-1,2,4-thiadiazol-5-ylsulfamoyl)-2,5-difluorophenoxy)methyl)-4-(4-chlorophenyl)piperidine-1-carboxylate",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,100.0,%,CC(C)(C)OC(=O)N1CC[C@@H](c2ccc(Cl)cc2)[C@H](COc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)C1,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071384,CHEMBL3325536,"4-(((trans)-4-(4-chlorophenyl)-1-methylpiperidin-3-yl)methoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,97.0,%,CN1CC[C@@H](c2ccc(Cl)cc2)[C@H](COc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)C1,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071385,CHEMBL3325536,"4-(((trans)-4-(4-chlorophenyl)-1-methylpiperidin-3-yl)methoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,93.0,%,CN1CC[C@@H](c2ccc(Cl)cc2)[C@H](COc2cc(F)c(S(=O)(=O)Nc3ncns3)cc2F)C1,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071386,CHEMBL3325538,"4-(((trans)-4-(4-chlorophenyl)-1-(2-fluoroethyl)piperidin-3-yl)methoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,97.0,%,O=S(=O)(Nc1ncns1)c1cc(F)c(OC[C@@H]2CN(CCF)CC[C@H]2c2ccc(Cl)cc2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071387,CHEMBL3325539,"4-(((trans)-4-(4-chlorophenyl)-1-(2,2-difluoroethyl)piperidin-3-yl)methoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,100.0,%,O=S(=O)(Nc1ncns1)c1cc(F)c(OC[C@@H]2CN(CC(F)F)CC[C@H]2c2ccc(Cl)cc2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071388,CHEMBL3325540,"4-(((trans)-4-(4-chlorophenyl)-1-(2,2,2-trifluoroethyl)piperidin-3-yl)methoxy)-2,5-difluoro-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,100.0,%,O=S(=O)(Nc1ncns1)c1cc(F)c(OC[C@@H]2CN(CC(F)(F)F)CC[C@H]2c2ccc(Cl)cc2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071389,CHEMBL3325541,"4-(((trans)-4-(4-chlorophenyl)piperidin-3-yl)methoxy)-2,5-difluoro-N-(3-methyl-1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,100.0,%,Cc1nsc(NS(=O)(=O)c2cc(F)c(OC[C@@H]3CNCC[C@H]3c3ccc(Cl)cc3)cc2F)n1,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071390,CHEMBL3325542,"4-(((trans)-4-(4-chlorophenyl)piperidin-3-yl)methoxy)-2,5-difluoro-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,99.0,%,O=S(=O)(Nc1nncs1)c1cc(F)c(OC[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071391,CHEMBL3325543,"4-(((trans)-4-(4-chlorophenyl)piperidin-3-yl)methoxy)-2,5-difluoro-N-(5-methylthiazol-2-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,99.0,%,Cc1cnc(NS(=O)(=O)c2cc(F)c(OC[C@@H]3CNCC[C@H]3c3ccc(Cl)cc3)cc2F)s1,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071392,CHEMBL3325544,"4-(((trans)-4-(4-chlorophenyl)piperidin-3-yl)methoxy)-N-(5-chlorothiazol-2-yl)-2,5-difluorobenzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,100.0,%,O=S(=O)(Nc1ncc(Cl)s1)c1cc(F)c(OC[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071393,CHEMBL3325545,"4-(((trans)-4-(4-chlorophenyl)piperidin-3-yl)methoxy)-2,5-difluoro-N-(5-methylisoxazol-3-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,80.0,%,Cc1cc(NS(=O)(=O)c2cc(F)c(OC[C@@H]3CNCC[C@H]3c3ccc(Cl)cc3)cc2F)no1,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071394,CHEMBL3325546,"4-(((trans)-4-(4-chlorophenyl)piperidin-3-yl)methoxy)-2,5-difluoro-N-(5-fluoropyridin-2-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,99.0,%,O=S(=O)(Nc1ccc(F)cn1)c1cc(F)c(OC[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071395,CHEMBL3325547,"4-(((trans)-4-(4-chlorophenyl)piperidin-3-yl)methoxy)-2,5-difluoro-N-(pyridazin-3-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,49.0,%,O=S(=O)(Nc1cccnn1)c1cc(F)c(OC[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071396,CHEMBL3325548,"4-(((trans)-4-(4-chlorophenyl)piperidin-3-yl)methoxy)-2,5-difluoro-N-(pyrimidin-4-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,91.0,%,O=S(=O)(Nc1ccncn1)c1cc(F)c(OC[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071397,CHEMBL3325549,"4-(((trans)-4-(4-chlorophenyl)piperidin-3-yl)methoxy)-2,5-difluoro-N-(pyrimidin-2-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,60.0,%,O=S(=O)(Nc1ncccn1)c1cc(F)c(OC[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15071398,CHEMBL3325550,"4-(((trans)-4-(4-chlorophenyl)piperidin-3-yl)methoxy)-2,5-difluoro-N-(5-fluoropyrimidin-2-yl)benzenesulfonamide",CHEMBL3390677,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,=,73.0,%,O=S(=O)(Nc1ncc(F)cn1)c1cc(F)c(OC[C@@H]2CNCC[C@H]2c2ccc(Cl)cc2)cc1F,CHEMBL3352194,The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.,Bioorg. Med. Chem. Lett.,2014.0,24,18,4397,4401,10.1016/j.bmcl.2014.08.017,25176194.0,
15074284,CHEMBL3355156,3-(4-(3-(2-Chlorophenyl)ureido)-1H-pyrazol-1-yl)-4-fluoro-N-(6-methylpyridin-3-yl)benzamide,CHEMBL3372275,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,76.0,%,Cc1ccc(NC(=O)c2ccc(F)c(-n3cc(NC(=O)Nc4ccccc4Cl)cn3)c2)cn1,CHEMBL3352539,Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives.,J. Med. Chem.,2014.0,57,23,10013,10030,10.1021/jm501256y,25393557.0,
15074285,CHEMBL3355165,3-(4-(3-(2-Chlorophenyl)ureido)-1H-pyrazol-1-yl)-N-(2-methylpyridin-4-yl)benzamide,CHEMBL3372275,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,60.0,%,Cc1cc(NC(=O)c2cccc(-n3cc(NC(=O)Nc4ccccc4Cl)cn3)c2)ccn1,CHEMBL3352539,Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives.,J. Med. Chem.,2014.0,57,23,10013,10030,10.1021/jm501256y,25393557.0,
15074286,CHEMBL3355166,"3-(4-(3-(2-Chlorophenyl)ureido)-1H-pyrazol-1-yl)-N-(2,6-dimethylpyridin-4-yl)benzamide",CHEMBL3372275,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,19.0,%,Cc1cc(NC(=O)c2cccc(-n3cc(NC(=O)Nc4ccccc4Cl)cn3)c2)cc(C)n1,CHEMBL3352539,Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives.,J. Med. Chem.,2014.0,57,23,10013,10030,10.1021/jm501256y,25393557.0,
15074287,CHEMBL3355168,3-(4-(3-(2-Chlorophenyl)ureido)-1H-pyrazol-1-yl)-N-((6-methylpyridin-3-yl)methyl)benzamide,CHEMBL3372275,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,48.0,%,Cc1ccc(CNC(=O)c2cccc(-n3cc(NC(=O)Nc4ccccc4Cl)cn3)c2)cn1,CHEMBL3352539,Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives.,J. Med. Chem.,2014.0,57,23,10013,10030,10.1021/jm501256y,25393557.0,
15074288,CHEMBL3355174,3-(4-(3-(2-Chlorophenyl)ureido)-1H-pyrazol-1-yl)-N-(1-isopropyl-1H-pyrazol-4-yl)benzamide,CHEMBL3372275,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,49.0,%,CC(C)n1cc(NC(=O)c2cccc(-n3cc(NC(=O)Nc4ccccc4Cl)cn3)c2)cn1,CHEMBL3352539,Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives.,J. Med. Chem.,2014.0,57,23,10013,10030,10.1021/jm501256y,25393557.0,
15074289,CHEMBL3352845,3-(4-(3-(2-Chlorophenyl)ureido)-1H-pyrazol-1-yl)-N-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)benzamide,CHEMBL3372275,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,12.0,%,CN(C)CCn1cc(NC(=O)c2cccc(-n3cc(NC(=O)Nc4ccccc4Cl)cn3)c2)cn1,CHEMBL3352539,Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives.,J. Med. Chem.,2014.0,57,23,10013,10030,10.1021/jm501256y,25393557.0,
15074290,CHEMBL3355177,3-(4-(3-(2-Chlorophenyl)ureido)-1H-pyrazol-1-yl)-N-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)benzamide,CHEMBL3372275,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,22.0,%,O=C(Nc1cnn(-c2cccc(C(=O)Nc3cnn(C4CCNCC4)c3)c2)c1)Nc1ccccc1Cl,CHEMBL3352539,Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives.,J. Med. Chem.,2014.0,57,23,10013,10030,10.1021/jm501256y,25393557.0,
15074291,CHEMBL3355178,3-(4-(3-(2-Chlorophenyl)ureido)-1H-pyrazol-1-yl)-N-(1-(pyrrolidin-3-yl)-1H-pyrazol-4-yl)benzamide,CHEMBL3372275,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,66.0,%,O=C(Nc1cnn(-c2cccc(C(=O)Nc3cnn(C4CCNC4)c3)c2)c1)Nc1ccccc1Cl,CHEMBL3352539,Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives.,J. Med. Chem.,2014.0,57,23,10013,10030,10.1021/jm501256y,25393557.0,
15074292,CHEMBL3355179,3-(4-(3-(2-Chlorophenyl)ureido)-1H-pyrazol-1-yl)-N-(2-(diethylamino)ethyl)benzamide,CHEMBL3372275,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,-1.0,%,CCN(CC)CCNC(=O)c1cccc(-n2cc(NC(=O)Nc3ccccc3Cl)cn2)c1,CHEMBL3352539,Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives.,J. Med. Chem.,2014.0,57,23,10013,10030,10.1021/jm501256y,25393557.0,
15074293,CHEMBL3355181,3-(4-(3-(2-Chlorophenyl)ureido)-1H-pyrazol-1-yl)-N-(piperidin-4-ylmethyl)benzamide,CHEMBL3372275,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,1.0,%,O=C(Nc1cnn(-c2cccc(C(=O)NCC3CCNCC3)c2)c1)Nc1ccccc1Cl,CHEMBL3352539,Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives.,J. Med. Chem.,2014.0,57,23,10013,10030,10.1021/jm501256y,25393557.0,
15074476,CHEMBL3355185,(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-(4-chlorophenyl)piperazin-1-yl)-2-fluorobenzamide,CHEMBL3375953,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM,Inhibition,=,90.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(N2CCN(c3ccc(Cl)cc3)CC2)cc1F,CHEMBL3351584,Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.,J. Med. Chem.,2014.0,57,23,10162,10175,10.1021/jm501568b,25393646.0,
15074477,CHEMBL3355186,(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2-fluoro-4-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)benzamide,CHEMBL3375953,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM,Inhibition,=,86.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(N2CCN(c3ccc(C(F)(F)F)cc3)CC2)cc1F,CHEMBL3351584,Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.,J. Med. Chem.,2014.0,57,23,10162,10175,10.1021/jm501568b,25393646.0,
15074478,CHEMBL3355187,(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-(2-chlorophenyl)piperazin-1-yl)-2-fluorobenzamide,CHEMBL3375953,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM,Inhibition,=,93.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(N2CCN(c3ccccc3Cl)CC2)cc1F,CHEMBL3351584,Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.,J. Med. Chem.,2014.0,57,23,10162,10175,10.1021/jm501568b,25393646.0,
15074479,CHEMBL3355188,"(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-(3,4-dichlorophenyl)piperazin-1-yl)-2-fluorobenzamide",CHEMBL3375953,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM,Inhibition,=,89.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(N2CCN(c3ccc(Cl)c(Cl)c3)CC2)cc1F,CHEMBL3351584,Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.,J. Med. Chem.,2014.0,57,23,10162,10175,10.1021/jm501568b,25393646.0,
15074480,CHEMBL3355189,"(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-(2,4-dichlorophenyl)piperazin-1-yl)-2-fluorobenzamide",CHEMBL3375953,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM,Inhibition,=,82.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(N2CCN(c3ccc(Cl)cc3Cl)CC2)cc1F,CHEMBL3351584,Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.,J. Med. Chem.,2014.0,57,23,10162,10175,10.1021/jm501568b,25393646.0,
15074481,CHEMBL3355190,(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-2-fluoro-4-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)benzamide,CHEMBL3375953,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM,Inhibition,=,98.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(N2CCN(c3ccc(C(F)(F)F)cn3)CC2)cc1F,CHEMBL3351584,Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.,J. Med. Chem.,2014.0,57,23,10162,10175,10.1021/jm501568b,25393646.0,
15074482,CHEMBL3355191,"(R)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-(3,5-dichlorophenyl)piperazin-1-yl)-2-fluorobenzamide",CHEMBL3375953,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM,Inhibition,=,69.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(N2CCN(c3cc(Cl)cc(Cl)c3)CC2)cc1F,CHEMBL3351584,Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.,J. Med. Chem.,2014.0,57,23,10162,10175,10.1021/jm501568b,25393646.0,
15074483,CHEMBL3355192,(R)-N-(3-(1H-Indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-(5-chloro-2-methylphenyl)piperazin-1-yl)-2-fluorobenzamide,CHEMBL3375953,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM,Inhibition,=,83.0,%,Cc1ccc(Cl)cc1N1CCN(c2ccc(C(=O)N[C@H](Cc3c[nH]c4ccccc34)C(=O)Nc3ccncc3)c(F)c2)CC1,CHEMBL3351584,Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.,J. Med. Chem.,2014.0,57,23,10162,10175,10.1021/jm501568b,25393646.0,
15078899,CHEMBL3355193,"(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-(2,3-dichlorophenyl)piperazin-1-yl)-2-fluorobenzamide",CHEMBL3375953,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM,Inhibition,=,84.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(N2CCN(c3cccc(Cl)c3Cl)CC2)cc1F,CHEMBL3351584,Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.,J. Med. Chem.,2014.0,57,23,10162,10175,10.1021/jm501568b,25393646.0,
15078900,CHEMBL3355194,(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-(3-chloro-4-fluorophenyl)piperazin-1-yl)-2-fluorobenzamide,CHEMBL3375953,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM,Inhibition,=,90.0,%,O=C(N[C@H](Cc1c[nH]c2ccccc12)C(=O)Nc1ccncc1)c1ccc(N2CCN(c3ccc(F)c(Cl)c3)CC2)cc1F,CHEMBL3351584,Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.,J. Med. Chem.,2014.0,57,23,10162,10175,10.1021/jm501568b,25393646.0,
15078901,CHEMBL3355195,(R)-N-(3-(1H-indol-3-yl)-1-oxo-1-(pyridin-4-ylamino)propan-2-yl)-4-(4-(5-chloro-2-methoxyphenyl)piperazin-1-yl)-2-fluorobenzamide,CHEMBL3375953,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM,Inhibition,=,93.0,%,COc1ccc(Cl)cc1N1CCN(c2ccc(C(=O)N[C@H](Cc3c[nH]c4ccccc34)C(=O)Nc3ccncc3)c(F)c2)CC1,CHEMBL3351584,Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.,J. Med. Chem.,2014.0,57,23,10162,10175,10.1021/jm501568b,25393646.0,
15102446,CHEMBL3342554,"(1S,2S)-1-(4-fluorobenzamido)-7-(4-(oxetan-3-yl)piperazin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-yl methylcarbamate",CHEMBL3387378,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,<,15.0,%,CNC(=O)O[C@H]1CCc2ccc(N3CCN(C4COC4)CC3)cc2[C@@H]1NC(=O)c1ccc(F)cc1,CHEMBL3351795,Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.,ACS Med. Chem. Lett.,2014.0,5,10,1138,1142,10.1021/ml500283g,25313327.0,
15102447,CHEMBL3342553,"(3R,4S)-4-(4-fluorobenzamido)-6-(4-(oxetan-3-yl)piperazin-1-yl)chroman-3-yl methylcarbamate",CHEMBL3387378,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) using diclofenac substrate at 10 uM,Inhibition,<,15.0,%,CNC(=O)O[C@H]1COc2ccc(N3CCN(C4COC4)CC3)cc2[C@@H]1NC(=O)c1ccc(F)cc1,CHEMBL3351795,Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.,ACS Med. Chem. Lett.,2014.0,5,10,1138,1142,10.1021/ml500283g,25313327.0,
15111825,CHEMBL3342720,"N-(3-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-(morpholinomethyl)phenyl)isoxazol-5-yl)cyclopropanecarboxamide",CHEMBL3373958,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins,Inhibition,=,66.0,%,CC(C)c1cc(-c2noc(NC(=O)C3CC3)c2-c2ccc(CN3CCOCC3)cc2)c(O)cc1O,CHEMBL3352482,Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors.,Eur. J. Med. Chem.,2014.0,87,,765,781,10.1016/j.ejmech.2014.09.065,25313505.0,
15111959,CHEMBL213805,biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-methyl-amide,CHEMBL3383256,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM,Inhibition,=,51.0,%,CN(CCc1c[nH]c2ccccc12)C(=O)c1ccc(-c2ccccc2)cc1,CHEMBL3351368,"Biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-methylamide (CA224), a nonplanar analogue of fascaplysin, inhibits Cdk4 and tubulin polymerization: evaluation of in vitro and in vivo anticancer activity.",J. Med. Chem.,2014.0,57,22,9658,9672,10.1021/jm5014743,25368960.0,
15116317,CHEMBL3342735,"N-(3-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-((4-morpholinopiperidin-1-yl)methyl)phenyl)isoxazol-5-yl)cyclopropanecarboxamide",CHEMBL3373958,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins,Inhibition,=,20.0,%,CC(C)c1cc(-c2noc(NC(=O)C3CC3)c2-c2ccc(CN3CCC(N4CCOCC4)CC3)cc2)c(O)cc1O,CHEMBL3352482,Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors.,Eur. J. Med. Chem.,2014.0,87,,765,781,10.1016/j.ejmech.2014.09.065,25313505.0,
15116347,CHEMBL252164,"5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide",CHEMBL3373958,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins,Inhibition,=,46.0,%,CCNC(=O)c1noc(-c2cc(C(C)C)c(O)cc2O)c1-c1ccc(CN2CCOCC2)cc1,CHEMBL3352482,Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors.,Eur. J. Med. Chem.,2014.0,87,,765,781,10.1016/j.ejmech.2014.09.065,25313505.0,
15121868,CHEMBL3358155,"5-Chloro-N-[[(4R)-2,5-dioxo-4-thiazol-2-yl-imidazolidin-4-yl]methyl]benzofuran-2-carboxamide",CHEMBL3389532,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,Inhibition,=,6.0,%,O=C1NC(=O)[C@](CNC(=O)c2cc3cc(Cl)ccc3o2)(c2nccs2)N1,CHEMBL3351955,Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.,J. Med. Chem.,2014.0,57,24,10476,10485,10.1021/jm501522n,25415648.0,
15121869,CHEMBL3358156,"5-Chloro-N-[[(4S)-4-(1-methylimidazol-2-yl)-2,5-dioxo-imidazolidin-4-yl]methyl]benzofuran-2-carboxamide",CHEMBL3389532,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,Inhibition,<,5.0,%,Cn1ccnc1[C@]1(CNC(=O)c2cc3cc(Cl)ccc3o2)NC(=O)NC1=O,CHEMBL3351955,Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.,J. Med. Chem.,2014.0,57,24,10476,10485,10.1021/jm501522n,25415648.0,
15121870,CHEMBL3358158,"N-[[(4S)-4-(1-methylimidazol-2-yl)-2,5-dioxo-imidazolidin-4-yl]methyl]-5-(trifluoromethyl)benzofuran-2-carboxamide",CHEMBL3389532,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9,Inhibition,<,5.0,%,Cn1ccnc1[C@]1(CNC(=O)c2cc3cc(C(F)(F)F)ccc3o2)NC(=O)NC1=O,CHEMBL3351955,Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.,J. Med. Chem.,2014.0,57,24,10476,10485,10.1021/jm501522n,25415648.0,
15133675,CHEMBL3186763,SID144087340,CHEMBL3389065,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,7.0,%,CN1CCN(C)/C(=N/c2ccc([N+](=O)[O-])cc2C(=O)Nc2ccccc2)C1,CHEMBL3352189,"Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as potent inhibitors of venezuelan equine encephalitis virus.",J. Med. Chem.,2014.0,57,20,8608,8621,10.1021/jm501203v,25244572.0,
15133781,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL3389065,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,96.0,%,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL3352189,"Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as potent inhibitors of venezuelan equine encephalitis virus.",J. Med. Chem.,2014.0,57,20,8608,8621,10.1021/jm501203v,25244572.0,
15146596,CHEMBL3394724,"rac-N-(4-(1-isobutylpiperidin-4-ylsulfinyl)benzyl)furo[2,3-c]pyridine-2-carboxamide",CHEMBL3396940,A,,Homo sapiens,Cytochrome P450 2C9,Time-dependent inhibition of CYP2C9 in human liver microsomes assessed as AUC shift,Inhibition,=,20.0,%,CC(C)CN1CCC([S+]([O-])c2ccc(CNC(=O)c3cc4ccncc4o3)cc2)CC1,CHEMBL3393056,Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.,Bioorg. Med. Chem. Lett.,2015.0,25,3,529,541,10.1016/j.bmcl.2014.12.026,25556090.0,
15164769,CHEMBL2206995,"1-[(2S)-2-{[(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-11-hydroxy-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-18-yl]oxy}morpholin-4-yl]-2-methylpropan-1-one",CHEMBL3404692,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated at 10 uM for 5 mins before substrate addition by LC-MS/MS analysis,Inhibition,=,26.0,%,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C(=O)C(C)C)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,CHEMBL3400044,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,2015.0,25,7,1621,1626,10.1016/j.bmcl.2015.01.051,25708617.0,
15164775,CHEMBL2207065,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-18-{[(2S)-4-(oxetan-3-yl)morpholin-2-yl]oxy}-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",CHEMBL3404692,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated at 10 uM for 5 mins before substrate addition by LC-MS/MS analysis,Inhibition,=,22.0,%,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6COC6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,CHEMBL3400044,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,2015.0,25,7,1621,1626,10.1016/j.bmcl.2015.01.051,25708617.0,
15164782,CHEMBL2207043,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-18-{[(2S)-4-ethylmorpholin-2-yl]oxy}-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",CHEMBL3404692,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated at 10 uM for 5 mins before substrate addition by LC-MS/MS analysis,Inhibition,=,21.0,%,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,CHEMBL3400044,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,2015.0,25,7,1621,1626,10.1016/j.bmcl.2015.01.051,25708617.0,
15164789,CHEMBL2207042,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-18-{[(2S)-4-methylmorpholin-2-yl]oxy}-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",CHEMBL3404692,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated at 10 uM for 5 mins before substrate addition by LC-MS/MS analysis,Inhibition,=,21.0,%,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,CHEMBL3400044,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,2015.0,25,7,1621,1626,10.1016/j.bmcl.2015.01.051,25708617.0,
15164796,CHEMBL2207069,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-18-[(2S)-morpholin-2-yloxy]-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",CHEMBL3404692,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated at 10 uM for 5 mins before substrate addition by LC-MS/MS analysis,Inhibition,=,31.0,%,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CNCCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,CHEMBL3400044,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,2015.0,25,7,1621,1626,10.1016/j.bmcl.2015.01.051,25708617.0,
15164804,CHEMBL2206994,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-18-{[(2S)-4-(1-methylazetidin-3-yl)morpholin-2-yl]oxy}-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",CHEMBL3404692,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated at 10 uM for 5 mins before substrate addition by LC-MS/MS analysis,Inhibition,=,0.0,%,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CN(C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,CHEMBL3400044,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,2015.0,25,7,1621,1626,10.1016/j.bmcl.2015.01.051,25708617.0,
15164812,CHEMBL2207044,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-18-{[(2S)-4-(2-methoxyethyl)morpholin-2-yl]oxy}-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",CHEMBL3404692,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated at 10 uM for 5 mins before substrate addition by LC-MS/MS analysis,Inhibition,=,30.0,%,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CCOC)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,CHEMBL3400044,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,2015.0,25,7,1621,1626,10.1016/j.bmcl.2015.01.051,25708617.0,
15164822,CHEMBL2206986,"1-(azetidin-1-yl)-2-[(2S)-2-{[(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-11-hydroxy-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-18-yl]oxy}morpholin-4-yl]ethan-1-one",CHEMBL3404692,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated at 10 uM for 5 mins before substrate addition by LC-MS/MS analysis,Inhibition,=,44.0,%,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC(=O)N6CCC6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,CHEMBL3400044,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,2015.0,25,7,1621,1626,10.1016/j.bmcl.2015.01.051,25708617.0,
15164829,CHEMBL2207050,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-18-{[(2S)-4-[2-(azetidin-1-yl)ethyl]morpholin-2-yl]oxy}-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",CHEMBL3404692,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated at 10 uM for 5 mins before substrate addition by LC-MS/MS analysis,Inhibition,=,2.0,%,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CCN6CCC6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,CHEMBL3400044,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,2015.0,25,7,1621,1626,10.1016/j.bmcl.2015.01.051,25708617.0,
15164836,CHEMBL2206992,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-18-{[(2S)-4-(3-methyloxetan-3-yl)morpholin-2-yl]oxy}-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",CHEMBL3404692,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated at 10 uM for 5 mins before substrate addition by LC-MS/MS analysis,Inhibition,=,14.0,%,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6(C)COC6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,CHEMBL3400044,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,2015.0,25,7,1621,1626,10.1016/j.bmcl.2015.01.051,25708617.0,
15164843,CHEMBL2206993,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-18-{[(2S)-4-(azetidin-3-yl)morpholin-2-yl]oxy}-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",CHEMBL3404692,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated at 10 uM for 5 mins before substrate addition by LC-MS/MS analysis,Inhibition,=,91.0,%,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(C6CNC6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,CHEMBL3400044,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,2015.0,25,7,1621,1626,10.1016/j.bmcl.2015.01.051,25708617.0,
15164850,CHEMBL3403815,"(1S,4R,5R,6R,8R,10S,11R,12S,13R,16R,18S,21R)-8-[(1S)-1-ethoxy-2-hydroxy-2-methylpropyl]-4,6,12,17,17-pentamethyl-18-{[(2S)-4-[(1-methylazetidin-3-yl)methyl]morpholin-2-yl]oxy}-9-oxahexacyclo[11.9.0.0^{1,21}.0^{4,12}.0^{5,10}.0^{16,21}]docosan-11-ol",CHEMBL3404692,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated at 10 uM for 5 mins before substrate addition by LC-MS/MS analysis,Inhibition,=,2.0,%,CCO[C@@H]([C@H]1C[C@@H](C)[C@H]2[C@H](O1)[C@H](O)[C@@]1(C)[C@@H]3CC[C@H]4C(C)(C)[C@@H](O[C@H]5CN(CC6CN(C)C6)CCO5)CC[C@@]45C[C@@]35CC[C@]21C)C(C)(C)O,CHEMBL3400044,Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators.,Bioorg. Med. Chem. Lett.,2015.0,25,7,1621,1626,10.1016/j.bmcl.2015.01.051,25708617.0,
15185054,CHEMBL3401745,"4-Ethoxy-N-(6-hydroxyhexyl)-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)benzenesulfonamide",CHEMBL3404109,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,56.0,%,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)NCCCCCCO)ccc3OCC)nc12,CHEMBL3400105,Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.,Bioorg. Med. Chem.,2015.0,23,9,2121,2128,10.1016/j.bmc.2015.03.005,25801159.0,
15188621,CHEMBL1951346,"N-isopropyl-3-(3-(4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)ureido)benzamide",CHEMBL3411304,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as reduction in tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,49.0,%,Cc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c12,CHEMBL3407489,Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.,J. Med. Chem.,2015.0,58,4,1846,1861,10.1021/jm501680m,25621531.0,
15188622,CHEMBL3410025,"3-(3-(4-(5,6-Dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-phenyl)ureido)-N-isopropylbenzamide",CHEMBL3411304,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as reduction in tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,42.0,%,Cc1[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)cc3)c2c1C,CHEMBL3407489,Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.,J. Med. Chem.,2015.0,58,4,1846,1861,10.1021/jm501680m,25621531.0,
15188623,CHEMBL3407526,"3-(3-(2-Fluoro-4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-phenyl)ureido)-N-isopropylbenzamide",CHEMBL3411304,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as reduction in tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,35.0,%,Cc1c[nH]c2ncnc(-c3ccc(NC(=O)Nc4cccc(C(=O)NC(C)C)c4)c(F)c3)c12,CHEMBL3407489,Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.,J. Med. Chem.,2015.0,58,4,1846,1861,10.1021/jm501680m,25621531.0,
15188624,CHEMBL3410036,"1-(2-Hydroxyethyl)-3-(4-(5-methyl-7H-pyrrolo[2,3-d]-pyrimidin-4-yl)phenyl)-1-phenylurea",CHEMBL3411304,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as reduction in tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,14.0,%,Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4ccccc4)cc3)c12,CHEMBL3407489,Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.,J. Med. Chem.,2015.0,58,4,1846,1861,10.1021/jm501680m,25621531.0,
15188625,CHEMBL3410039,"1-(4-Fluorophenyl)-1-(2-hydroxyethyl)-3-(4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)urea",CHEMBL3411304,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as reduction in tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,13.0,%,Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4ccc(F)cc4)cc3)c12,CHEMBL3407489,Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.,J. Med. Chem.,2015.0,58,4,1846,1861,10.1021/jm501680m,25621531.0,
15188626,CHEMBL3410040,"1-(2-Chlorophenyl)-1-(2-hydroxyethyl)-3-(4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)urea",CHEMBL3411304,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as reduction in tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,39.0,%,Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4ccccc4Cl)cc3)c12,CHEMBL3407489,Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.,J. Med. Chem.,2015.0,58,4,1846,1861,10.1021/jm501680m,25621531.0,
15188627,CHEMBL3410041,"1-(3-Chlorophenyl)-1-(2-hydroxyethyl)-3-(4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)urea",CHEMBL3411304,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as reduction in tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,31.0,%,Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4cccc(Cl)c4)cc3)c12,CHEMBL3407489,Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.,J. Med. Chem.,2015.0,58,4,1846,1861,10.1021/jm501680m,25621531.0,
15188628,CHEMBL3410042,"1-(4-Chlorophenyl)-1-(2-hydroxyethyl)-3-(4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)urea",CHEMBL3411304,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as reduction in tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,23.0,%,Cc1c[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4ccc(Cl)cc4)cc3)c12,CHEMBL3407489,Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.,J. Med. Chem.,2015.0,58,4,1846,1861,10.1021/jm501680m,25621531.0,
15188629,CHEMBL3410045,"1-(2-Hydroxyethyl)-3-(4-(5-methyl-7H-pyrrolo[2,3-d]-pyrimidin-4-yl)phenyl)-1-p-tolylurea",CHEMBL3411304,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as reduction in tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,24.0,%,Cc1ccc(N(CCO)C(=O)Nc2ccc(-c3ncnc4[nH]cc(C)c34)cc2)cc1,CHEMBL3407489,Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.,J. Med. Chem.,2015.0,58,4,1846,1861,10.1021/jm501680m,25621531.0,
15188630,CHEMBL3410047,"1-(2-Hydroxyethyl)-1-(3-methoxyphenyl)-3-(4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)urea",CHEMBL3411304,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as reduction in tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,17.0,%,COc1cccc(N(CCO)C(=O)Nc2ccc(-c3ncnc4[nH]cc(C)c34)cc2)c1,CHEMBL3407489,Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.,J. Med. Chem.,2015.0,58,4,1846,1861,10.1021/jm501680m,25621531.0,
15188631,CHEMBL3410048,"1-(2-Hydroxyethyl)-1-(4-methoxyphenyl)-3-(4-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)urea",CHEMBL3411304,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as reduction in tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,8.0,%,COc1ccc(N(CCO)C(=O)Nc2ccc(-c3ncnc4[nH]cc(C)c34)cc2)cc1,CHEMBL3407489,Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.,J. Med. Chem.,2015.0,58,4,1846,1861,10.1021/jm501680m,25621531.0,
15188632,CHEMBL3410053,"1-(4-Chlorophenyl)-3-(4-(5,6-dimethyl-7H-pyrrolo[2,3-d]-pyrimidin-4-yl)-2-fluorophenyl)-1-(2-hydroxyethyl)urea",CHEMBL3411304,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as reduction in tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,13.0,%,Cc1[nH]c2ncnc(-c3ccc(NC(=O)N(CCO)c4ccc(Cl)cc4)c(F)c3)c2c1C,CHEMBL3407489,Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.,J. Med. Chem.,2015.0,58,4,1846,1861,10.1021/jm501680m,25621531.0,
15188633,CHEMBL3410054,"1-(2-Aminoethyl)-1-(4-chlorophenyl)-3-[4-(5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2-fluorophenyl]urea",CHEMBL3411304,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as reduction in tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,24.0,%,Cc1[nH]c2ncnc(-c3ccc(NC(=O)N(CCN)c4ccc(Cl)cc4)c(F)c3)c2c1C,CHEMBL3407489,Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.,J. Med. Chem.,2015.0,58,4,1846,1861,10.1021/jm501680m,25621531.0,
15188634,CHEMBL3410055,"1-(4-Chlorophenyl)-3-(4-(5,6-dimethyl-7H-pyrrolo[2,3-d]-pyrimidin-4-yl)-2-fluorophenyl)-1-(2-(dimethylamino)ethyl)-urea",CHEMBL3411304,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as reduction in tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,-23.0,%,Cc1[nH]c2ncnc(-c3ccc(NC(=O)N(CCN(C)C)c4ccc(Cl)cc4)c(F)c3)c2c1C,CHEMBL3407489,Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.,J. Med. Chem.,2015.0,58,4,1846,1861,10.1021/jm501680m,25621531.0,
15188635,CHEMBL3410056,"1-(4-Chlorophenyl)-3-(4-(5,6-dimethyl-7H-pyrrolo[2,3-d]-pyrimidin-4-yl)-2-fluorophenyl)-1-(2-methoxyethyl)urea",CHEMBL3411304,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as reduction in tolbutamide hydroxylation to hydrocytolbutamide at 10 uM,Inhibition,=,50.0,%,COCCN(C(=O)Nc1ccc(-c2ncnc3[nH]c(C)c(C)c23)cc1F)c1ccc(Cl)cc1,CHEMBL3407489,Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.,J. Med. Chem.,2015.0,58,4,1846,1861,10.1021/jm501680m,25621531.0,
15193255,CHEMBL3407785,"(1S,2R,3S,4R,5S)-4-(2-((5-Bromothiophen-2-yl)ethynyl)-6-(methylamino)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]-hexane-1-carboxamide",CHEMBL3414387,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human microsomes preincubated at 10 uM for 5 mins before substrate addition measured after 10 mins by LC/MS/MS analysis,Inhibition,=,24.2,%,CNC(=O)[C@@]12C[C@@H]1[C@@H](n1cnc3c(NC)nc(C#Cc4ccc(Br)s4)nc31)[C@H](O)[C@@H]2O,CHEMBL3407461,In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.,J. Med. Chem.,2014.0,57,23,9901,9914,10.1021/jm501021n,25422861.0,
15193593,CHEMBL1957266,"(+)-tert-butyl 2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate",CHEMBL3414225,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition,Inhibition,=,18.0,%,Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n1-2,CHEMBL3407418,Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.,J. Med. Chem.,2015.0,58,3,1281,1297,10.1021/jm501504k,25559428.0,
15193594,CHEMBL2017291,"7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1R)-1-(2-pyridinyl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one",CHEMBL3414225,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition,Inhibition,=,33.0,%,COc1cc2c(cc1-c1c(C)noc1C)ncc1[nH]c(=O)n([C@H](C)c3ccccn3)c12,CHEMBL3407418,Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.,J. Med. Chem.,2015.0,58,3,1281,1297,10.1021/jm501504k,25559428.0,
15193596,CHEMBL3409993,"N-Cyclopentyl-2-methoxy-5-(2-oxo-2,3-dihydrothiazol-4-yl)benzenesulfonamide",CHEMBL3414225,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition,Inhibition,=,10.0,%,COc1ccc(-c2csc(=O)[nH]2)cc1S(=O)(=O)NC1CCCC1,CHEMBL3407418,Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.,J. Med. Chem.,2015.0,58,3,1281,1297,10.1021/jm501504k,25559428.0,
15193597,CHEMBL3409996,"2-Amino-N-cyclopentyl-5-(2-oxo-2,3-dihydrothiazol-4-yl)-benzenesulfonamide",CHEMBL3414225,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition,Inhibition,=,74.0,%,Nc1ccc(-c2csc(=O)[nH]2)cc1S(=O)(=O)NC1CCCC1,CHEMBL3407418,Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.,J. Med. Chem.,2015.0,58,3,1281,1297,10.1021/jm501504k,25559428.0,
15193600,CHEMBL3410003,"N-(3-(N-Cyclopentylsulfamoyl)-5-(2-oxo-2,3-dihydrothiazol-4-yl)-phenyl)cyclopropanecarboxamide",CHEMBL3414225,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition,Inhibition,=,14.0,%,O=C(Nc1cc(-c2csc(=O)[nH]2)cc(S(=O)(=O)NC2CCCC2)c1)C1CC1,CHEMBL3407418,Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.,J. Med. Chem.,2015.0,58,3,1281,1297,10.1021/jm501504k,25559428.0,
15193601,CHEMBL3410007,"N-(3-(N-Cyclopentylsulfamoyl)-5-(2-oxo-2,3-dihydrothiazol-4-yl)-phenyl)thiophene-2-carboxamide",CHEMBL3414225,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition,Inhibition,=,57.0,%,O=C(Nc1cc(-c2csc(=O)[nH]2)cc(S(=O)(=O)NC2CCCC2)c1)c1cccs1,CHEMBL3407418,Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.,J. Med. Chem.,2015.0,58,3,1281,1297,10.1021/jm501504k,25559428.0,
15206536,CHEMBL3407652,"2-(4-Ethyl-6,6-dimethyl-2-oxomorpholin-3-yl)-N-(4-isopropylphenyl)acetamide",CHEMBL3411136,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,<,40.0,%,CCN1CC(C)(C)OC(=O)C1CC(=O)Nc1ccc(C(C)C)cc1,CHEMBL3407422,2-(2-oxo-morpholin-3-yl)-acetamide derivatives as broad-spectrum antifungal agents.,J. Med. Chem.,2015.0,58,3,1502,1512,10.1021/jm501814x,25585716.0,
15225343,CHEMBL3416055,"(+)-((1S,2S)-2-(5-chloro-2-(2-fluoroethoxy)phenyl)cyclopropyl)methanamine hydrochloride",CHEMBL3420147,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using diclofenac as substrate at 10 uM,Inhibition,=,33.0,%,Cl.NC[C@H]1C[C@@H]1c1cc(Cl)ccc1OCCF,CHEMBL3414471,Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.,J. Med. Chem.,2015.0,58,4,1992,2002,10.1021/jm5019274,25633969.0,
15225377,CHEMBL3416051,"(+)-((1S,2S)-2-(5-chloro-2-(2-fluoroallyloxy)phenyl)cyclopropyl)methanamine hydrochloride",CHEMBL3420147,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using diclofenac as substrate at 10 uM,Inhibition,=,51.0,%,C=C(F)COc1ccc(Cl)cc1[C@H]1C[C@@H]1CN.Cl,CHEMBL3414471,Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.,J. Med. Chem.,2015.0,58,4,1992,2002,10.1021/jm5019274,25633969.0,
15225396,CHEMBL3416047,"(+)-((1S,2S)-2-(2-(allyloxy)-5-chlorophenyl)cyclopropyl)methanamine trifluoroacetate",CHEMBL3420147,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using diclofenac as substrate at 10 uM,Inhibition,=,56.0,%,C=CCOc1ccc(Cl)cc1[C@H]1C[C@@H]1CN.O=C(O)C(F)(F)F,CHEMBL3414471,Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.,J. Med. Chem.,2015.0,58,4,1992,2002,10.1021/jm5019274,25633969.0,
15226766,CHEMBL3416063,"(+)-((1S,2S)-2-(2-(allyloxy)-5-fluorophenyl)cyclopropyl)methanamine hydrochloride",CHEMBL3420147,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using diclofenac as substrate at 10 uM,Inhibition,=,35.0,%,C=CCOc1ccc(F)cc1[C@H]1C[C@@H]1CN.Cl,CHEMBL3414471,Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.,J. Med. Chem.,2015.0,58,4,1992,2002,10.1021/jm5019274,25633969.0,
15226767,CHEMBL3416067,"(+)-((1S,2S)-2-(5-fluoro-2-(2-fluoroethoxy)phenyl)cyclopropyl)methanamine hydrochloride",CHEMBL3420147,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using diclofenac as substrate at 10 uM,Inhibition,=,16.0,%,Cl.NC[C@H]1C[C@@H]1c1cc(F)ccc1OCCF,CHEMBL3414471,Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.,J. Med. Chem.,2015.0,58,4,1992,2002,10.1021/jm5019274,25633969.0,
15227124,CHEMBL3417742,3-[4-(4-Methoxyphenoxy)phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid,CHEMBL3419065,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomal CYP2C9 at 10 uM after 10 mins by LC-MS/MS analysis,Inhibition,=,0.0,%,COc1ccc(Oc2ccc(S(=O)(=O)C3(C(=O)NO)CCC4(CCNCC4)C3)cc2)cc1,CHEMBL3414522,"Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.",J. Med. Chem.,2015.0,58,5,2465,2488,10.1021/jm501940y,25686153.0,
15227125,CHEMBL3417745,3-[4-[4-(Trifluoromethoxy)phenoxy]phenyl]sulfonyl-8-azaspiro-[4.5]decane-3-carbohydroxamic Acid,CHEMBL3419065,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomal CYP2C9 at 10 uM after 10 mins by LC-MS/MS analysis,Inhibition,=,7.4,%,O=C(NO)C1(S(=O)(=O)c2ccc(Oc3ccc(OC(F)(F)F)cc3)cc2)CCC2(CCNCC2)C1,CHEMBL3414522,"Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.",J. Med. Chem.,2015.0,58,5,2465,2488,10.1021/jm501940y,25686153.0,
15227126,CHEMBL3417746,3-[4-[[4-(Trifluoromethoxy)phenyl]methoxy]phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid,CHEMBL3419065,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomal CYP2C9 at 10 uM after 10 mins by LC-MS/MS analysis,Inhibition,=,8.8,%,O=C(NO)C1(S(=O)(=O)c2ccc(OCc3ccc(OC(F)(F)F)cc3)cc2)CCC2(CCNCC2)C1,CHEMBL3414522,"Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.",J. Med. Chem.,2015.0,58,5,2465,2488,10.1021/jm501940y,25686153.0,
15227127,CHEMBL3417751,N-hydroxy-2-(4-(4-(methylcarbamoyl)phenoxy)phenylsulfonyl)-8-azaspiro[4.5]decane-2-carboxamide,CHEMBL3419065,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomal CYP2C9 at 10 uM after 10 mins by LC-MS/MS analysis,Inhibition,=,0.0,%,CNC(=O)c1ccc(Oc2ccc(S(=O)(=O)C3(C(=O)NO)CCC4(CCNCC4)C3)cc2)cc1,CHEMBL3414522,"Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.",J. Med. Chem.,2015.0,58,5,2465,2488,10.1021/jm501940y,25686153.0,
15227128,CHEMBL3417752,3-[4-[4-(Pyrrolidine-1-carbonyl)phenoxy]phenyl]sulfonyl-8-azaspiro[4.5]decane-3-carbohydroxamic Acid,CHEMBL3419065,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomal CYP2C9 at 10 uM after 10 mins by LC-MS/MS analysis,Inhibition,=,0.0,%,O=C(c1ccc(Oc2ccc(S(=O)(=O)C3(C(=O)NO)CCC4(CCNCC4)C3)cc2)cc1)N1CCCC1,CHEMBL3414522,"Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.",J. Med. Chem.,2015.0,58,5,2465,2488,10.1021/jm501940y,25686153.0,
15227129,CHEMBL3417761,4-[[4-[[3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]-sulfonyl]phenoxy]methyl]-N-methylbenzamide,CHEMBL3419065,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomal CYP2C9 at 10 uM after 10 mins by LC-MS/MS analysis,Inhibition,=,12.3,%,CNC(=O)c1ccc(COc2ccc(S(=O)(=O)C3(C(=O)NO)CCC4(CCNCC4)C3)cc2)cc1,CHEMBL3414522,"Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.",J. Med. Chem.,2015.0,58,5,2465,2488,10.1021/jm501940y,25686153.0,
15227130,CHEMBL3417767,[4-[[3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenyl]-4-methoxybenzoate,CHEMBL3419065,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomal CYP2C9 at 10 uM after 10 mins by LC-MS/MS analysis,Inhibition,=,0.0,%,COc1ccc(C(=O)Oc2ccc(S(=O)(=O)C3(C(=O)NO)CCC4(CCNCC4)C3)cc2)cc1,CHEMBL3414522,"Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.",J. Med. Chem.,2015.0,58,5,2465,2488,10.1021/jm501940y,25686153.0,
15227131,CHEMBL3417769,4-[4-[[(3S)-3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]-sulfonyl]phenoxy]-N-methylbenzamide,CHEMBL3419065,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomal CYP2C9 at 10 uM after 10 mins by LC-MS/MS analysis,Inhibition,=,8.2,%,CNC(=O)c1ccc(Oc2ccc(S(=O)(=O)[C@@]3(C(=O)NO)CCC4(CCNCC4)C3)cc2)cc1,CHEMBL3414522,"Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.",J. Med. Chem.,2015.0,58,5,2465,2488,10.1021/jm501940y,25686153.0,
15227132,CHEMBL3417770,4-[4-[[(3R)-3-(Hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]-sulfonyl]phenoxy]-N-methylbenzamide,CHEMBL3419065,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomal CYP2C9 at 10 uM after 10 mins by LC-MS/MS analysis,Inhibition,=,9.4,%,CNC(=O)c1ccc(Oc2ccc(S(=O)(=O)[C@]3(C(=O)NO)CCC4(CCNCC4)C3)cc2)cc1,CHEMBL3414522,"Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.",J. Med. Chem.,2015.0,58,5,2465,2488,10.1021/jm501940y,25686153.0,
15247183,CHEMBL3092559,"1-(2-chlorophenyl)-4-methylpyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazine",CHEMBL3430121,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 5 uM,Inhibition,<,50.0,%,Cc1nc2ccncc2n2c(-c3ccccc3Cl)nnc12,CHEMBL3425427,"Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors.",ACS Med. Chem. Lett.,2015.0,6,3,282,286,10.1021/ml500463t,25815146.0,
15247999,CHEMBL3039518,BATEFENTEROL,CHEMBL3429787,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 600 nM,Inhibition,<,20.0,%,COc1cc(NC(=O)CCN2CCC(OC(=O)Nc3ccccc3-c3ccccc3)CC2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,CHEMBL3425497,"Discovery of (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate (TD-5959, GSK961081, batefenterol): first-in-class dual pharmacology multivalent muscarinic antagonist and β₂ agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD).",J. Med. Chem.,2015.0,58,6,2609,2622,10.1021/jm501915g,25629394.0,
15443474,CHEMBL1639,aliskiren,CHEMBL3509377,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C8 in human liver microsomes from 10 healthy donors at 200 uM aliskiren (SPP100),Inhibition,=,4.5,%,COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,CHEMBL3508693,FDA drug approval package for Aliskiren hemifumarate,,,,,,,,,
15443475,CHEMBL1639,aliskiren,CHEMBL3509378,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes from 10 healthy donors at 200 uM aliskiren (SPP100),Inhibition,=,32.1,%,COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,CHEMBL3508693,FDA drug approval package for Aliskiren hemifumarate,,,,,,,,,
15443904,CHEMBL1639,aliskiren,CHEMBL3508911,A,Lymphoblastoid cell line,Homo sapiens,Cytochrome P450 2C9,Inhibitory activity of 20 uM SPP100 on 227 Pmoles of cDNA-derived CYP2C9 enzyme in microsome prepared from human lymphoblastoid cell line,Inhibition,=,13.1,%,COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,CHEMBL3508693,FDA drug approval package for Aliskiren hemifumarate,,,,,,,,,
15443905,CHEMBL1639,aliskiren,CHEMBL3508912,A,Lymphoblastoid cell line,Homo sapiens,Cytochrome P450 2C9,Inhibitory activity of 20 uM SPP100 on 259 Pmoles of cDNA-derived CYP2C9 enzyme in microsome prepared from human lymphoblastoid cell line,Inhibition,=,0.9,%,COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,CHEMBL3508693,FDA drug approval package for Aliskiren hemifumarate,,,,,,,,,
15443906,CHEMBL1639,aliskiren,CHEMBL3508913,A,Lymphoblastoid cell line,Homo sapiens,Cytochrome P450 2C9,Inhibitory activity of 20 uM SPP100 on 258 Pmoles of cDNA-derived CYP2C9 enzyme in microsome prepared from human lymphoblastoid cell line,Inhibition,=,1.3,%,COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,CHEMBL3508693,FDA drug approval package for Aliskiren hemifumarate,,,,,,,,,
15443907,CHEMBL1639,aliskiren,CHEMBL3508914,A,Lymphoblastoid cell line,Homo sapiens,Cytochrome P450 2C9,Inhibitory activity of 200 uM SPP100 on 222 Pmoles of cDNA-derived CYP2C9 enzyme in microsome prepared from human lymphoblastoid cell line,Inhibition,=,14.9,%,COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,CHEMBL3508693,FDA drug approval package for Aliskiren hemifumarate,,,,,,,,,
15443908,CHEMBL1639,aliskiren,CHEMBL3508915,A,Lymphoblastoid cell line,Homo sapiens,Cytochrome P450 2C9,Inhibitory activity of 200 uM SPP100 on 201 Pmoles of cDNA-derived CYP2C9 enzyme in microsome prepared from human lymphoblastoid cell line,Inhibition,=,23.0,%,COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,CHEMBL3508693,FDA drug approval package for Aliskiren hemifumarate,,,,,,,,,
15443909,CHEMBL1639,aliskiren,CHEMBL3508916,A,Lymphoblastoid cell line,Homo sapiens,Cytochrome P450 2C9,Inhibitory activity of 200 uM SPP100 on 220 Pmoles of cDNA-derived CYP2C9 enzyme in microsome prepared from human lymphoblastoid cell line,Inhibition,=,15.8,%,COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,CHEMBL3508693,FDA drug approval package for Aliskiren hemifumarate,,,,,,,,,
15443910,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL3508953,A,Lymphoblastoid cell line,Homo sapiens,Cytochrome P450 2C9,Inhibitory activity of 3 uM sulfaphenazole on 56 Pmoles of cDNA-derived CYP2C9 enzyme in microsome prepared from human lymphoblastoid cell line,Inhibition,=,83.0,%,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL3508693,FDA drug approval package for Aliskiren hemifumarate,,,,,,,,,
15443911,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL3508954,A,Lymphoblastoid cell line,Homo sapiens,Cytochrome P450 2C9,Inhibitory activity of 3 uM sulfaphenazole on 59 Pmoles of cDNA-derived CYP2C9 enzyme in microsome prepared from human lymphoblastoid cell line,Inhibition,=,82.0,%,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL3508693,FDA drug approval package for Aliskiren hemifumarate,,,,,,,,,
15443912,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL3508955,A,Lymphoblastoid cell line,Homo sapiens,Cytochrome P450 2C9,Inhibitory activity of 3 uM sulfaphenazole on 80 Pmoles of cDNA-derived CYP2C9 enzyme in microsome prepared from human lymphoblastoid cell line,Inhibition,=,75.0,%,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL3508693,FDA drug approval package for Aliskiren hemifumarate,,,,,,,,,
15445921,CHEMBL296419,[1-(4-Fluoro-benzyl)-1H-benzoimidazol-2-yl]-{1-[2-(4-methoxy-phenyl)-ethyl]-piperidin-4-yl}-amine,CHEMBL3535107,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9-mediated diclofenac metabolite formation in human liver microsomes at 0.3 uM after 8 mins by LC-MS/MS analysis relative to control,Inhibition,=,-2.7,%,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15447677,CHEMBL267744,"[2,3-Dichloro-4-(thiophene-2-carbonyl)-phenoxy]-acetic acid (ticrynafen)",CHEMBL3534898,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 10 uM by LC/MS system,Inhibition,=,28.0,%,O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15447678,CHEMBL163,"((1R,2R,4R)-1-Benzyl-2-hydroxy-4-{(R)-2-[3-(2-isopropyl-1lambda*4*-[1,3]thiazin-5-ylmethyl)-3-methyl-ureido]-3-methyl-butyrylamino}-5-phenyl-pentyl)-carbamic acid thiazol-5-ylmethyl ester",CHEMBL3534897,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 3 uM by LC/MS system,Inhibition,<,10.0,%,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15447679,CHEMBL388590,benzbromarone,CHEMBL3534896,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 1 uM by LC/MS system,Inhibition,<,10.0,%,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15447680,CHEMBL1491,"(Amlodipine) 2-(2-Amino-ethoxymethyl)-4-(2-chloro-phenyl)-6-methyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester",CHEMBL3534895,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 30 uM by LC/MS system,Inhibition,<,10.0,%,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15447683,CHEMBL112,N-(4-Hydroxy-phenyl)-acetamide,CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,CC(=O)Nc1ccc(O)cc1,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15447789,CHEMBL19490,"[5-(4-Chloro-benzoyl)-1,4-dimethyl-1H-pyrrol-2-yl]-acetic acid",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,Cc1cc(CC(=O)O)n(C)c1C(=O)c1ccc(Cl)cc1,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15455089,CHEMBL3527048,"1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine",CHEMBL3532537,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of human CYP2C9 diclofenac 4'-hydroxylase activity assessed as decrease in enzyme activity at 100 uM preincubated for 30 mins by IC25-shift assay,Inhibition,=,5.4,%,Cc1ccc(-c2c(-c3nn(C)c4ncnc(N5CC[C@H](N6CCCCC6)C5)c34)cnn2C)cc1,CHEMBL3526089,Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.,Drug Metab. Dispos.,2012.0,40,9,1686,1697,10.1124/dmd.112.045302,22645092.0,
15455194,CHEMBL1200374,Exemestane,CHEMBL3528382,A,,Homo sapiens,Cytochrome P450 2C9,Drug metabolism assessed as human recombinant CYP2C9-mediated 17-hydroexemestane and 6-Hydroxymethylexemestane formation assessed as inhibition of metabolite formation at 10 uM after 10 mins by Michaelis-Menten saturation curve analysis in presence of 50 uM sulfaphenazole,Inhibition,<,20.0,%,C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,CHEMBL3525953,In vitro cytochrome P450-mediated metabolism of exemestane.,Drug Metab. Dispos.,2011.0,39,1,98,105,10.1124/dmd.110.032276,20876785.0,
15459783,CHEMBL1464,4-Hydroxy-3-(3-oxo-1-phenyl-butyl)-chromen-2-one,CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15459784,CHEMBL6966,"2-(3,4-Dimethoxy-phenyl)-5-{[2-(3,4-dimethoxy-phenyl)-ethyl]-methyl-amino}-2-isopropyl-pentanenitrile",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15459785,CHEMBL1069,3-Methyl-2-{pentanoyl-[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]-amino}-butyric acid,CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15459786,CHEMBL109,2-Propyl-pentanoic acid,CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,CCCC(CCC)C(=O)O,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15459787,CHEMBL833,"5-(2-Chloro-benzyl)-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,Clc1ccccc1CN1CCc2sccc2C1,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15459788,CHEMBL83,"{2-[4-(1,2-Diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15459789,CHEMBL95,"1,2,3,4-Tetrahydro-acridin-9-ylamine",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,Nc1c2c(nc3ccccc13)CCCC2,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15459790,CHEMBL443,4-Amino-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide,CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15459791,CHEMBL121,"5-{4-[2-(Methyl-pyridin-2-yl-amino)-ethoxy]-benzyl}-thiazolidine-2,4-dione",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15459792,CHEMBL27,1-Isopropylamino-3-(naphthalen-1-yloxy)-propan-2-ol,CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,CC(C)NCC(O)COc1cccc2ccccc12,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15459793,CHEMBL640,4-Amino-N-(2-diethylamino-ethyl)-benzamide,CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,CCN(CC)CCNC(=O)c1ccc(N)cc1,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15459794,CHEMBL1144,"2-Methyl-butyric acid 3-hydroxy-8-[2-(4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-7-methyl-1,2,3,7,8,8a-hexahydro-naphthalen-1-yl ester",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15459795,CHEMBL595,"5-{4-[2-(5-Ethyl-pyridin-2-yl)-ethoxy]-benzyl}-thiazolidine-2,4-dione",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15459796,CHEMBL16,"5,5-Diphenyl-imidazolidine-2,4-dione",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,O=C1N=C(O)NC1(c1ccccc1)c1ccccc1,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15459797,CHEMBL1516,5-(1-Hydroxy-1-methyl-ethyl)-2-propyl-3-[2'-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-imidazole-4-carboxylic acid,CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15464470,CHEMBL484853,"2-((4aR,10aS)-5,6-dihydroxy-7-isopropyl-1,1-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthren-4a-yl)acetic acid",CHEMBL3541524,A,Hepatocyte,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 activity in human hepatocytes after 30 mins by liquid chromatography/tandem mass spectroscopy,Inhibition,<,11.0,%,CC(C)c1cc2c(c(O)c1O)[C@@]1(C(=O)O)CCCC(C)(C)[C@@H]1CC2,CHEMBL3526111,"In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties.",Drug Metab. Dispos.,2012.0,40,7,1263,1267,10.1124/dmd.112.044909,22531045.0,
15464697,CHEMBL633,"(2-Butyl-benzofuran-3-yl)-[4-(2-diethylamino-ethoxy)-3,5-diiodo-phenyl]-methanone",CHEMBL3535106,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9-mediated diclofenac metabolite formation in human liver microsomes at 5 uM after 8 mins by LC-MS/MS analysis relative to control,Inhibition,=,68.3,%,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,CHEMBL3526133,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,Drug Metab. Dispos.,2012.0,40,5,943,951,10.1124/dmd.111.043505,22328583.0,
15466669,CHEMBL1229211,DOLUTEGRAVIR,CHEMBL3529389,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate at 100 uM preincubated for 20 mins with substrate prior to initiation of reaction with NADPH by HPLC analysis,Inhibition,=,20.0,%,C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,CHEMBL3526034,"In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.",Drug Metab. Dispos.,2013.0,41,2,353,361,10.1124/dmd.112.048918,23132334.0,
15468479,CHEMBL715,"2-Methyl-10-(4-methyl-piperazin-1-yl)-4H-3-thia-4,9-diaza-benzo[f]azulene",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15468480,CHEMBL57,"5-Cyclopropyl-9-methyl-5,10-dihydro-4,5,6,10-tetraaza-dibenzo[a,d]cyclohepten-11-one",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15468481,CHEMBL33,"(S)-8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15468482,CHEMBL6,[1-(4-Chloro-benzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-acetic acid,CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15468483,CHEMBL11,"[3-(10,11-Dihydro-dibenzo[b,f]azepin-5-yl)-propyl]-dimethyl-amine",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,CN(C)CCCN1c2ccccc2CCc2ccccc21,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15468484,CHEMBL35,4-Chloro-2-[(furan-2-ylmethyl)-amino]-5-sulfamoyl-benzoic acid,CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15468485,CHEMBL806,N-(4-Nitro-3-trifluoromethyl-phenyl)-isobutyramide,CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15468486,CHEMBL41,Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine,CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15468487,CHEMBL532,"6-(4-Dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydro-pyran-2-yloxy)-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15468488,CHEMBL502,"2-(1-Benzyl-piperidin-4-ylmethyl)-5,6-dimethoxy-indan-1-one",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15468489,CHEMBL139,"[2-(2,6-Dichloro-phenylamino)-phenyl]-acetic acid",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15468490,CHEMBL42,"8-Chloro-11-(4-methyl-piperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15468491,CHEMBL1771,Clopidogrel,CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15468492,CHEMBL108,"Dibenzo[b,f]azepine-5-carboxylic acid amide",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,NC(=O)N1c2ccccc2C=Cc2ccccc21,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15468493,CHEMBL113,"1,3,7-Trimethyl-3,7-dihydro-purine-2,6-dione",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,Cn1c(=O)c2c(ncn2C)n(C)c1=O,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15468494,CHEMBL1487,"(3R,5R)-7-[2-(4-Fluoro-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid anion",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15468495,CHEMBL682,AMODIAQUINE,CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15468496,CHEMBL288470,"4-Dimethylamino-1,5-dimethyl-2-phenyl-1,2-dihydro-pyrazol-3-one; 4-(dimethylamino)antipyrine",CHEMBL3534884,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Inhibition,<,10.0,%,Cc1c(N(C)C)c(=O)n(-c2ccccc2)n1C,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15468589,CHEMBL118,4-(5-p-Tolyl-3-trifluoromethyl-pyrazol-1-yl)-benzenesulfonamide,CHEMBL3534895,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 30 uM by LC/MS system,Inhibition,<,10.0,%,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15468591,CHEMBL691,"17-Ethynyl-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol",CHEMBL3534895,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 30 uM by LC/MS system,Inhibition,=,27.0,%,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15468593,CHEMBL603,{3-[2-Methoxy-4-(toluene-2-sulfonylaminocarbonyl)-benzyl]-1-methyl-1H-indol-5-yl}-carbamic acid cyclopentyl ester,CHEMBL3534898,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent inhibition of CYP2C9 (unknown origin) at 10 uM by LC/MS system,Inhibition,<,10.0,%,COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,CHEMBL3526118,Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.,Drug Metab. Dispos.,2011.0,39,7,1247,1254,10.1124/dmd.111.039180,21467212.0,
15607982,CHEMBL3577855,"(trans)-4-((7-cyclopropylpyrido[2,3-d]pyrimidin-2-yl)amino)cyclohexanol",CHEMBL3578957,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as tolbutamide hydroxylation to hydrocytolbutamide at 10 uM relative to control,Inhibition,=,18.0,%,CC(C)n1c(=O)ccc2cnc(N[C@H]3CC[C@H](O)CC3)nc21,CHEMBL3576797,Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) Inhibitors.,ACS Med. Chem. Lett.,2015.0,6,4,413,418,10.1021/ml500474d,25893042.0,
15607983,CHEMBL3577866,"(trans)-N-[4-(8-Isopropyl-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino)-cyclohexyl]-isobutyramide",CHEMBL3578957,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as tolbutamide hydroxylation to hydrocytolbutamide at 10 uM relative to control,Inhibition,=,28.0,%,CC(C)C(=O)N[C@H]1CC[C@H](Nc2ncc3ccc(=O)n(C(C)C)c3n2)CC1,CHEMBL3576797,Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) Inhibitors.,ACS Med. Chem. Lett.,2015.0,6,4,413,418,10.1021/ml500474d,25893042.0,
15607984,CHEMBL3577867,"(trans)-1-Ethyl-3-[4-(8-isopropyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-ylamino)cyclohexyl]urea",CHEMBL3578957,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as tolbutamide hydroxylation to hydrocytolbutamide at 10 uM relative to control,Inhibition,=,19.0,%,CCNC(=O)N[C@H]1CC[C@H](Nc2ncc3ccc(=O)n(C(C)C)c3n2)CC1,CHEMBL3576797,Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) Inhibitors.,ACS Med. Chem. Lett.,2015.0,6,4,413,418,10.1021/ml500474d,25893042.0,
15607985,CHEMBL3577868,"(trans)-1-Isopropyl-3-[4-(8-isopropyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-ylamino)cyclohexyl]urea",CHEMBL3578957,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as tolbutamide hydroxylation to hydrocytolbutamide at 10 uM relative to control,Inhibition,=,-26.0,%,CC(C)NC(=O)N[C@H]1CC[C@H](Nc2ncc3ccc(=O)n(C(C)C)c3n2)CC1,CHEMBL3576797,Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) Inhibitors.,ACS Med. Chem. Lett.,2015.0,6,4,413,418,10.1021/ml500474d,25893042.0,
15607986,CHEMBL3577871,"(cis)-1-Ethyl-3-[4-(8-isopropyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-ylamino)-cyclohexyl]urea",CHEMBL3578957,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as tolbutamide hydroxylation to hydrocytolbutamide at 10 uM relative to control,Inhibition,=,47.0,%,CCNC(=O)N[C@H]1CC[C@@H](Nc2ncc3ccc(=O)n(C(C)C)c3n2)CC1,CHEMBL3576797,Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) Inhibitors.,ACS Med. Chem. Lett.,2015.0,6,4,413,418,10.1021/ml500474d,25893042.0,
15607987,CHEMBL3577873,"N-ethyl-4-((8-isopropyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)piperidine-1-carboxamide",CHEMBL3578957,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as tolbutamide hydroxylation to hydrocytolbutamide at 10 uM relative to control,Inhibition,=,10.0,%,CCNC(=O)N1CCC(Nc2ncc3ccc(=O)n(C(C)C)c3n2)CC1,CHEMBL3576797,Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) Inhibitors.,ACS Med. Chem. Lett.,2015.0,6,4,413,418,10.1021/ml500474d,25893042.0,
15607988,CHEMBL3577877,"(trans)-1-[4-(8-Cyclopentyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-ylamino)cyclohexyl]-3-isopropyl-urea",CHEMBL3578957,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as tolbutamide hydroxylation to hydrocytolbutamide at 10 uM relative to control,Inhibition,=,-7.0,%,CC(C)NC(=O)N[C@H]1CC[C@H](Nc2ncc3ccc(=O)n(C4CCCC4)c3n2)CC1,CHEMBL3576797,Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) Inhibitors.,ACS Med. Chem. Lett.,2015.0,6,4,413,418,10.1021/ml500474d,25893042.0,
15608181,CHEMBL3577885,(R)-3-((N-(1-(4-fluorophenyl)ethyl)quinoline-3-carboxamido)methyl)benzoic acid,CHEMBL3579084,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,=,0.0,%,C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1,CHEMBL3576831,Discovery of a Selective TRPM8 Antagonist with Clinical Efficacy in Cold-Related Pain.,ACS Med. Chem. Lett.,2015.0,6,4,419,424,10.1021/ml500479v,25893043.0,
15608186,CHEMBL3577902,(R)-3-((N-(1-(3-chlorophenyl)ethyl)quinoline-3-carboxamido)methyl)benzoic acid,CHEMBL3579084,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,=,0.0,%,C[C@H](c1cccc(Cl)c1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1,CHEMBL3576831,Discovery of a Selective TRPM8 Antagonist with Clinical Efficacy in Cold-Related Pain.,ACS Med. Chem. Lett.,2015.0,6,4,419,424,10.1021/ml500479v,25893043.0,
15608187,CHEMBL3577904,"(R)-3-((N-(1-(2,4-difluorophenyl)ethyl)isoquinoline-3-carboxamido)methyl)benzoic acid",CHEMBL3579084,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,=,0.0,%,C[C@H](c1ccc(F)cc1F)N(Cc1cccc(C(=O)O)c1)C(=O)c1cc2ccccc2cn1,CHEMBL3576831,Discovery of a Selective TRPM8 Antagonist with Clinical Efficacy in Cold-Related Pain.,ACS Med. Chem. Lett.,2015.0,6,4,419,424,10.1021/ml500479v,25893043.0,
15608188,CHEMBL3577905,"(R)-3-((N-(1-(2,4-difluorophenyl)propyl)pyrazolo[1,5-a]pyridine-2-carboxamido)methyl)benzoic acid",CHEMBL3579084,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,=,0.0,%,CC[C@H](c1ccc(F)cc1F)N(Cc1cccc(C(=O)O)c1)C(=O)c1cc2ccccn2n1,CHEMBL3576831,Discovery of a Selective TRPM8 Antagonist with Clinical Efficacy in Cold-Related Pain.,ACS Med. Chem. Lett.,2015.0,6,4,419,424,10.1021/ml500479v,25893043.0,
15608190,CHEMBL3577907,"(R)-6-((N-(1-(2,4-difluorophenyl)ethyl)isoquinoline-3-carboxamido)methyl)picolinic acid",CHEMBL3579084,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,=,0.0,%,C[C@H](c1ccc(F)cc1F)N(Cc1cccc(C(=O)O)n1)C(=O)c1cc2ccccc2cn1,CHEMBL3576831,Discovery of a Selective TRPM8 Antagonist with Clinical Efficacy in Cold-Related Pain.,ACS Med. Chem. Lett.,2015.0,6,4,419,424,10.1021/ml500479v,25893043.0,
15653653,CHEMBL52229,7-Methoxy-8-(3-methyl-but-2-enyl)-chromen-2-one,CHEMBL3599702,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM preincubated for 10 mins with cofactor followed by mixture of enzyme-substrate addition by fluorescence assay relative to control,Inhibition,=,39.8,%,COc1ccc2ccc(=O)oc2c1CC=C(C)C,CHEMBL3596129,Osthol and curcumin as inhibitors of human Pgp and multidrug efflux pumps of Staphylococcus aureus: reversing the resistance against frontline antibacterial drugs,MedChemComm,2014.0,5,10,1540,1547,10.1039/C4MD00196F,,
15653657,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL3599702,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM preincubated for 10 mins with cofactor followed by mixture of enzyme-substrate addition by fluorescence assay relative to control,Inhibition,=,93.7,%,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL3596129,Osthol and curcumin as inhibitors of human Pgp and multidrug efflux pumps of Staphylococcus aureus: reversing the resistance against frontline antibacterial drugs,MedChemComm,2014.0,5,10,1540,1547,10.1039/C4MD00196F,,
15673903,CHEMBL3600993,3-(4-((5-methyl-2-phenyloxazol-4-yl)methoxy)phenyl)propanoic acid,CHEMBL3602527,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 5 uM by luminescent readout-based method,Inhibition,=,10.78,%,Cc1oc(-c2ccccc2)nc1COc1ccc(CCC(=O)O)cc1,CHEMBL3600322,"Phenoxymethyl 1,3-oxazoles and 1,2,4-oxadiazoles as potent and selective agonists of free fatty acid receptor 1 (GPR40).",Bioorg. Med. Chem. Lett.,2015.0,25,16,3105,3111,10.1016/j.bmcl.2015.06.018,26096679.0,
15673904,CHEMBL3601001,"3-(4-((3-(p-Tolyl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)propanoic acid",CHEMBL3602527,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 5 uM by luminescent readout-based method,Inhibition,=,4.26,%,Cc1ccc(-c2noc(COc3ccc(CCC(=O)O)cc3)n2)cc1,CHEMBL3600322,"Phenoxymethyl 1,3-oxazoles and 1,2,4-oxadiazoles as potent and selective agonists of free fatty acid receptor 1 (GPR40).",Bioorg. Med. Chem. Lett.,2015.0,25,16,3105,3111,10.1016/j.bmcl.2015.06.018,26096679.0,
15673905,CHEMBL3601003,"3-(4-((3-(4-Chlorophenyl)-1,2,4-oxadiazol-5-yl)methoxy)phenyl)propanoic acid",CHEMBL3602527,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 5 uM by luminescent readout-based method,Inhibition,=,16.22,%,O=C(O)CCc1ccc(OCc2nc(-c3ccc(Cl)cc3)no2)cc1,CHEMBL3600322,"Phenoxymethyl 1,3-oxazoles and 1,2,4-oxadiazoles as potent and selective agonists of free fatty acid receptor 1 (GPR40).",Bioorg. Med. Chem. Lett.,2015.0,25,16,3105,3111,10.1016/j.bmcl.2015.06.018,26096679.0,
15673915,CHEMBL106,"2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol",CHEMBL3602532,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 120 uM by luminescent readout-based method,Inhibition,=,89.09,%,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,CHEMBL3600322,"Phenoxymethyl 1,3-oxazoles and 1,2,4-oxadiazoles as potent and selective agonists of free fatty acid receptor 1 (GPR40).",Bioorg. Med. Chem. Lett.,2015.0,25,16,3105,3111,10.1016/j.bmcl.2015.06.018,26096679.0,
15674982,CHEMBL3427712,"(3S)-3-Ethoxy-3-(4-{[(1R)-4-(trifluoromethyl)-2,3-dihydro-1H-inden-1-yl]oxy}phenyl)propanoic acid",CHEMBL3607685,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,21.0,%,CCO[C@@H](CC(=O)O)c1ccc(O[C@@H]2CCc3c2cccc3C(F)(F)F)cc1,CHEMBL3603738,Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558.,Bioorg. Med. Chem.,2015.0,23,17,5546,5565,10.1016/j.bmc.2015.07.028,26234904.0,
15675641,CHEMBL3604137,N-(5-fluoropyridin-2-yl)-1H-pyrazole-3-carboxamide,CHEMBL3606433,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,26.0,%,O=C(Nc1ccc(F)cn1)c1cc[nH]n1,CHEMBL3603736,3-Substituted pyrazoles and 4-substituted triazoles as inhibitors of human 15-lipoxygenase-1.,Bioorg. Med. Chem. Lett.,2015.0,25,15,3024,3029,10.1016/j.bmcl.2015.05.004,26037322.0,
15696095,CHEMBL3609637,"6-fluoro-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",CHEMBL3611646,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,68.0,%,COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,CHEMBL3608254,Discovery of novel triazolobenzazepinones as γ-secretase modulators with central Aβ42 lowering in rodents and rhesus monkeys.,Bioorg. Med. Chem. Lett.,2015.0,25,17,3488,3494,10.1016/j.bmcl.2015.07.003,26212776.0,
15697450,CHEMBL3609749,"(S)-6-fluoro-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",CHEMBL3611884,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,82.0,%,COc1cc(-c2cn([C@H]3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,CHEMBL3608233,Potent benzoazepinone γ-secretase modulators with improved bioavailability.,Bioorg. Med. Chem. Lett.,2015.0,25,17,3495,3500,10.1016/j.bmcl.2015.06.032,26142947.0,
15697451,CHEMBL3608384,"(S)-6-fluoro-3-(4-(4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",CHEMBL3611884,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,54.0,%,Cc1cn(-c2ccc(-c3cn([C@H]4CCc5c(F)cccc5N(CC(F)(F)F)C4=O)nn3)cc2)cn1,CHEMBL3608233,Potent benzoazepinone γ-secretase modulators with improved bioavailability.,Bioorg. Med. Chem. Lett.,2015.0,25,17,3495,3500,10.1016/j.bmcl.2015.06.032,26142947.0,
15697452,CHEMBL3609752,"(S)-6-fluoro-3-(4-(2-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",CHEMBL3611884,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,65.0,%,COc1cc(-n2cnc(C)c2)ccc1-c1cn([C@H]2CCc3c(F)cccc3N(CC(F)(F)F)C2=O)nn1,CHEMBL3608233,Potent benzoazepinone γ-secretase modulators with improved bioavailability.,Bioorg. Med. Chem. Lett.,2015.0,25,17,3495,3500,10.1016/j.bmcl.2015.06.032,26142947.0,
15697453,CHEMBL3608385,"(S)-6-fluoro-3-(4-(4-(4-methyl-1H-imidazol-1-yl)-3-(2,2,2-trifluoroethoxy)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",CHEMBL3611884,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,68.0,%,Cc1cn(-c2ccc(-c3cn([C@H]4CCc5c(F)cccc5N(CC(F)(F)F)C4=O)nn3)cc2OCC(F)(F)F)cn1,CHEMBL3608233,Potent benzoazepinone γ-secretase modulators with improved bioavailability.,Bioorg. Med. Chem. Lett.,2015.0,25,17,3495,3500,10.1016/j.bmcl.2015.06.032,26142947.0,
15697454,CHEMBL3609754,"(S)-6-fluoro-3-(4-(2-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",CHEMBL3611884,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,85.0,%,Cc1cn(-c2ccc(-c3cn([C@H]4CCc5c(F)cccc5N(CC(F)(F)F)C4=O)nn3)c(F)c2)cn1,CHEMBL3608233,Potent benzoazepinone γ-secretase modulators with improved bioavailability.,Bioorg. Med. Chem. Lett.,2015.0,25,17,3495,3500,10.1016/j.bmcl.2015.06.032,26142947.0,
15697455,CHEMBL3609755,"(S)-6-fluoro-3-(4-(3-fluoro-2-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",CHEMBL3611884,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,67.0,%,COc1c(-c2cn([C@H]3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc(-n2cnc(C)c2)c1F,CHEMBL3608233,Potent benzoazepinone γ-secretase modulators with improved bioavailability.,Bioorg. Med. Chem. Lett.,2015.0,25,17,3495,3500,10.1016/j.bmcl.2015.06.032,26142947.0,
15697456,CHEMBL3609759,"(S)-6-fluoro-3-(4-(3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",CHEMBL3611884,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,77.0,%,COc1cc(-c2cn([C@H]3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)n1,CHEMBL3608233,Potent benzoazepinone γ-secretase modulators with improved bioavailability.,Bioorg. Med. Chem. Lett.,2015.0,25,17,3495,3500,10.1016/j.bmcl.2015.06.032,26142947.0,
15697457,CHEMBL3609749,"(S)-6-fluoro-3-(4-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",CHEMBL3611885,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 1 uM relative to control,Inhibition,=,28.0,%,COc1cc(-c2cn([C@H]3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1,CHEMBL3608233,Potent benzoazepinone γ-secretase modulators with improved bioavailability.,Bioorg. Med. Chem. Lett.,2015.0,25,17,3495,3500,10.1016/j.bmcl.2015.06.032,26142947.0,
15697458,CHEMBL3608384,"(S)-6-fluoro-3-(4-(4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",CHEMBL3611885,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 1 uM relative to control,Inhibition,=,23.0,%,Cc1cn(-c2ccc(-c3cn([C@H]4CCc5c(F)cccc5N(CC(F)(F)F)C4=O)nn3)cc2)cn1,CHEMBL3608233,Potent benzoazepinone γ-secretase modulators with improved bioavailability.,Bioorg. Med. Chem. Lett.,2015.0,25,17,3495,3500,10.1016/j.bmcl.2015.06.032,26142947.0,
15697459,CHEMBL3609752,"(S)-6-fluoro-3-(4-(2-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",CHEMBL3611885,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 1 uM relative to control,Inhibition,=,25.0,%,COc1cc(-n2cnc(C)c2)ccc1-c1cn([C@H]2CCc3c(F)cccc3N(CC(F)(F)F)C2=O)nn1,CHEMBL3608233,Potent benzoazepinone γ-secretase modulators with improved bioavailability.,Bioorg. Med. Chem. Lett.,2015.0,25,17,3495,3500,10.1016/j.bmcl.2015.06.032,26142947.0,
15697460,CHEMBL3608385,"(S)-6-fluoro-3-(4-(4-(4-methyl-1H-imidazol-1-yl)-3-(2,2,2-trifluoroethoxy)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",CHEMBL3611885,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 1 uM relative to control,Inhibition,=,19.0,%,Cc1cn(-c2ccc(-c3cn([C@H]4CCc5c(F)cccc5N(CC(F)(F)F)C4=O)nn3)cc2OCC(F)(F)F)cn1,CHEMBL3608233,Potent benzoazepinone γ-secretase modulators with improved bioavailability.,Bioorg. Med. Chem. Lett.,2015.0,25,17,3495,3500,10.1016/j.bmcl.2015.06.032,26142947.0,
15697461,CHEMBL3609754,"(S)-6-fluoro-3-(4-(2-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",CHEMBL3611885,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 1 uM relative to control,Inhibition,=,17.0,%,Cc1cn(-c2ccc(-c3cn([C@H]4CCc5c(F)cccc5N(CC(F)(F)F)C4=O)nn3)c(F)c2)cn1,CHEMBL3608233,Potent benzoazepinone γ-secretase modulators with improved bioavailability.,Bioorg. Med. Chem. Lett.,2015.0,25,17,3495,3500,10.1016/j.bmcl.2015.06.032,26142947.0,
15697462,CHEMBL3609755,"(S)-6-fluoro-3-(4-(3-fluoro-2-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",CHEMBL3611885,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 1 uM relative to control,Inhibition,=,19.0,%,COc1c(-c2cn([C@H]3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc(-n2cnc(C)c2)c1F,CHEMBL3608233,Potent benzoazepinone γ-secretase modulators with improved bioavailability.,Bioorg. Med. Chem. Lett.,2015.0,25,17,3495,3500,10.1016/j.bmcl.2015.06.032,26142947.0,
15697463,CHEMBL3609759,"(S)-6-fluoro-3-(4-(3-methoxy-4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)-1H-1,2,3-triazol-1-yl)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one",CHEMBL3611885,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 1 uM relative to control,Inhibition,=,20.0,%,COc1cc(-c2cn([C@H]3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)n1,CHEMBL3608233,Potent benzoazepinone γ-secretase modulators with improved bioavailability.,Bioorg. Med. Chem. Lett.,2015.0,25,17,3495,3500,10.1016/j.bmcl.2015.06.032,26142947.0,
15698683,CHEMBL3613703,N-(3-Fluorophenethyl)-2-(2-(3-methoxyphenyl)acetyl)-isoindoline-5-sulfonamide,CHEMBL3616248,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,=,35.0,%,COc1cccc(CC(=O)N2Cc3ccc(S(=O)(=O)NCCc4cccc(F)c4)cc3C2)c1,CHEMBL3612040,Discovery of Selective Small Molecule Inhibitors of Monoacylglycerol Acyltransferase 3.,J. Med. Chem.,2015.0,58,18,7164,7172,10.1021/acs.jmedchem.5b01008,26258602.0,
15698700,CHEMBL3613706,"2-(2-(3-Methoxyphenyl)acetyl)-N-(2-phenyl-2H-1,2,3-triazol-4-yl)isoindoline-5-sulfonamide",CHEMBL3616248,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,=,88.0,%,COc1cccc(CC(=O)N2Cc3ccc(S(=O)(=O)Nc4cnn(-c5ccccc5)n4)cc3C2)c1,CHEMBL3612040,Discovery of Selective Small Molecule Inhibitors of Monoacylglycerol Acyltransferase 3.,J. Med. Chem.,2015.0,58,18,7164,7172,10.1021/acs.jmedchem.5b01008,26258602.0,
15698709,CHEMBL3613707,"N-(2-(4-Fluorophenyl)-2H-1,2,3-triazol-4-yl)-2-(2-(3-methoxyphenyl)acetyl)isoindoline-5-sulfonamide",CHEMBL3616248,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,=,95.0,%,COc1cccc(CC(=O)N2Cc3ccc(S(=O)(=O)Nc4cnn(-c5ccc(F)cc5)n4)cc3C2)c1,CHEMBL3612040,Discovery of Selective Small Molecule Inhibitors of Monoacylglycerol Acyltransferase 3.,J. Med. Chem.,2015.0,58,18,7164,7172,10.1021/acs.jmedchem.5b01008,26258602.0,
15705195,CHEMBL3613349,(E)-4-(4-{2-[(biphenyl-4-carbonyl)amino]ethylcarbamoyl}phenoxy)adamantane-1-carboxylic acid,CHEMBL3616171,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,41.9,%,O=C(NCCNC(=O)c1ccc(-c2ccccc2)cc1)c1ccc(O[C@H]2C3CC4CC2C[C@](C(=O)O)(C4)C3)cc1,CHEMBL3611966,Discovery and optimization of adamantane carboxylic acid derivatives as potent diacylglycerol acyltransferase 1 inhibitors for the potential treatment of obesity and diabetes.,Eur. J. Med. Chem.,2015.0,101,,716,735,10.1016/j.ejmech.2015.06.043,26218650.0,
15722443,CHEMBL3616847,"(1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid",CHEMBL3618717,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,<,10.0,%,N[C@@]1(C(=O)O)C[C@@H](Sc2nnc[nH]2)[C@H]2[C@H](C(=O)O)[C@H]21,CHEMBL3616378,"Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist.",J. Med. Chem.,2015.0,58,18,7526,7548,10.1021/acs.jmedchem.5b01124,26313429.0,
16379565,CHEMBL2147845,(Z)-2-[(1H-Indazol-3-yl)methylene]-6-methoxy-7-(piperazin-1-ylmethyl)benzofuran-3(2H)-one,CHEMBL3738386,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,<,1.0,%,COc1ccc2c(c1CN1CCNCC1)O/C(=C\c1n[nH]c3ccccc13)C2=O,CHEMBL3734671,Design and synthesis of an in vivo-efficacious PIM3 kinase inhibitor as a candidate anti-pancreatic cancer agent.,Bioorg. Med. Chem. Lett.,2015.0,25,24,5687,5693,10.1016/j.bmcl.2015.10.098,26547690.0,
16379566,CHEMBL3735816,"(Z)-2-[(1H-pyrazolo[3,4-b]pyridin-3-yl)methylene]-6-methoxy-7-(piperazin-1-ylmethyl)benzofuran-3(2H)-one",CHEMBL3738386,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,<,1.0,%,COc1ccc2c(c1CN1CCNCC1)O/C(=C\c1n[nH]c3ncccc13)C2=O,CHEMBL3734671,Design and synthesis of an in vivo-efficacious PIM3 kinase inhibitor as a candidate anti-pancreatic cancer agent.,Bioorg. Med. Chem. Lett.,2015.0,25,24,5687,5693,10.1016/j.bmcl.2015.10.098,26547690.0,
16379567,CHEMBL3735890,"(Z)-2-[(1H-pyrazolo[3,4-b]pyridin-3-yl)methylene]-6-methoxy-7-[1-(piperazin-1-yl)ethyl]benzofuran-3(2H)-one",CHEMBL3738386,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,<,1.0,%,COc1ccc2c(c1C(C)N1CCNCC1)O/C(=C\c1n[nH]c3ncccc13)C2=O,CHEMBL3734671,Design and synthesis of an in vivo-efficacious PIM3 kinase inhibitor as a candidate anti-pancreatic cancer agent.,Bioorg. Med. Chem. Lett.,2015.0,25,24,5687,5693,10.1016/j.bmcl.2015.10.098,26547690.0,
16379568,CHEMBL3735657,"(Z)-2-[(1H-pyrazolo[3,4-b]pyridin-3-yl)methylene]-6-(2-methoxyethoxy)-7-[1-(piperazin-1-yl)ethyl]benzofuran-3(2H)-one",CHEMBL3738386,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,<,1.0,%,COCCOc1ccc2c(c1C(C)N1CCNCC1)O/C(=C\c1n[nH]c3ncccc13)C2=O,CHEMBL3734671,Design and synthesis of an in vivo-efficacious PIM3 kinase inhibitor as a candidate anti-pancreatic cancer agent.,Bioorg. Med. Chem. Lett.,2015.0,25,24,5687,5693,10.1016/j.bmcl.2015.10.098,26547690.0,
16440901,CHEMBL3754515,"5-(4-Chlorophenyl)-[3,3'-bipyridine]-6,6'-diamine",CHEMBL3755440,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,<,15.0,%,Nc1ccc(-c2cnc(N)c(-c3ccc(Cl)cc3)c2)cn1,CHEMBL3751803,Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment.,ACS Med. Chem. Lett.,2015.0,6,11,1128,1133,10.1021/acsmedchemlett.5b00215,26617966.0,
16440902,CHEMBL3754123,5-(6-Amino-5-(4-chlorophenyl)pyridin-3-yl)pyrimidin-2-amine,CHEMBL3755440,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,<,15.0,%,Nc1ncc(-c2cnc(N)c(-c3ccc(Cl)cc3)c2)cn1,CHEMBL3751803,Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment.,ACS Med. Chem. Lett.,2015.0,6,11,1128,1133,10.1021/acsmedchemlett.5b00215,26617966.0,
16443763,CHEMBL3188597,SID174006367,CHEMBL3757627,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins,Inhibition,=,5.0,%,O=C(O)CCNc1cc(N2CCc3ccccc3CC2)nc(-c2ccccn2)n1,CHEMBL3751830,Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors.,Bioorg. Med. Chem. Lett.,2016.0,26,3,721,725,10.1016/j.bmcl.2016.01.006,26776360.0,
16443764,CHEMBL3752893,"N-[4-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-6-(1,3-thiazol-2-yl)pyrimidin-2-yl]-beta-alanine",CHEMBL3757627,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins,Inhibition,=,9.0,%,O=C(O)CCNc1nc(-c2nccs2)cc(N2CCc3ccccc3CC2)n1,CHEMBL3751830,Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors.,Bioorg. Med. Chem. Lett.,2016.0,26,3,721,725,10.1016/j.bmcl.2016.01.006,26776360.0,
16443765,CHEMBL3753391,"N-[4-(1H-pyrazol-1-yl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)pyrimidin-2-yl]-beta-alanine",CHEMBL3757627,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins,Inhibition,=,5.0,%,O=C(O)CCNc1nc(N2CCc3ccccc3CC2)cc(-n2cccn2)n1,CHEMBL3751830,Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors.,Bioorg. Med. Chem. Lett.,2016.0,26,3,721,725,10.1016/j.bmcl.2016.01.006,26776360.0,
16443766,CHEMBL3753740,"N-[4-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-6-(2H-1,2,3-triazol-2-yl)pyrimidin-2-yl]-beta-alanine",CHEMBL3757627,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins,Inhibition,=,4.0,%,O=C(O)CCNc1nc(N2CCc3ccccc3CC2)cc(-n2nccn2)n1,CHEMBL3751830,Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors.,Bioorg. Med. Chem. Lett.,2016.0,26,3,721,725,10.1016/j.bmcl.2016.01.006,26776360.0,
16443767,CHEMBL3752179,"N-[4-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-6-(1H-1,2,3-triazol-1-yl)pyrimidin-2-yl]-beta-alanine",CHEMBL3757627,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins,Inhibition,=,1.0,%,O=C(O)CCNc1nc(N2CCc3ccccc3CC2)cc(-n2ccnn2)n1,CHEMBL3751830,Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors.,Bioorg. Med. Chem. Lett.,2016.0,26,3,721,725,10.1016/j.bmcl.2016.01.006,26776360.0,
16443768,CHEMBL3754555,"N-[4-(2H-indazol-2-yl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)pyrimidin-2-yl]-beta-alaninate",CHEMBL3757627,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins,Inhibition,=,17.0,%,O=C(O)CCNc1nc(N2CCc3ccccc3CC2)cc(-n2cc3ccccc3n2)n1,CHEMBL3751830,Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors.,Bioorg. Med. Chem. Lett.,2016.0,26,3,721,725,10.1016/j.bmcl.2016.01.006,26776360.0,
16457830,CHEMBL3758508,N-Benzyl-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)methyl)-2Htetrazol-5-yl)-6-methylpicolinamide,CHEMBL3761851,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction of diclofenac metabolism at 3 uM after 8 mins,Inhibition,=,78.0,%,Cc1cc(-c2nnn(C[C@H]3CC[C@H](CO)CC3)n2)cc(C(=O)NCc2ccccc2)n1,CHEMBL3758105,"Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.",J. Med. Chem.,2016.0,59,1,313,327,10.1021/acs.jmedchem.5b01434,26653735.0,
16457831,CHEMBL3759445,N-(4-Fluorobenzyl)-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)-methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide,CHEMBL3761851,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction of diclofenac metabolism at 3 uM after 8 mins,Inhibition,=,56.0,%,Cc1cc(-c2nnn(C[C@H]3CC[C@H](CO)CC3)n2)cc(C(=O)NCc2ccc(F)cc2)n1,CHEMBL3758105,"Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.",J. Med. Chem.,2016.0,59,1,313,327,10.1021/acs.jmedchem.5b01434,26653735.0,
16457834,CHEMBL3758273,N-(3-Methylbenzyl)-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)-methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide,CHEMBL3761851,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction of diclofenac metabolism at 3 uM after 8 mins,Inhibition,=,93.0,%,Cc1cccc(CNC(=O)c2cc(-c3nnn(C[C@H]4CC[C@H](CO)CC4)n3)cc(C)n2)c1,CHEMBL3758105,"Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.",J. Med. Chem.,2016.0,59,1,313,327,10.1021/acs.jmedchem.5b01434,26653735.0,
16457835,CHEMBL3759910,N-(3-(Trifluoromethyl)benzyl)-4-(2-(((trans)-4-(hydroxymethyl)-cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide,CHEMBL3761851,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction of diclofenac metabolism at 3 uM after 8 mins,Inhibition,=,94.0,%,Cc1cc(-c2nnn(C[C@H]3CC[C@H](CO)CC3)n2)cc(C(=O)NCc2cccc(C(F)(F)F)c2)n1,CHEMBL3758105,"Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.",J. Med. Chem.,2016.0,59,1,313,327,10.1021/acs.jmedchem.5b01434,26653735.0,
16457836,CHEMBL3758783,"N-(3,4-Difluorobenzyl)-4-(2-(((trans)-4-(hydroxymethyl)-cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide",CHEMBL3761851,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction of diclofenac metabolism at 3 uM after 8 mins,Inhibition,=,83.0,%,Cc1cc(-c2nnn(C[C@H]3CC[C@H](CO)CC3)n2)cc(C(=O)NCc2ccc(F)c(F)c2)n1,CHEMBL3758105,"Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.",J. Med. Chem.,2016.0,59,1,313,327,10.1021/acs.jmedchem.5b01434,26653735.0,
16457837,CHEMBL3759741,N-(3-Chloro-4-fluorobenzyl)-4-(2-(((trans)-4-(hydroxymethyl)-cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide,CHEMBL3761851,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction of diclofenac metabolism at 3 uM after 8 mins,Inhibition,=,90.0,%,Cc1cc(-c2nnn(C[C@H]3CC[C@H](CO)CC3)n2)cc(C(=O)NCc2ccc(F)c(Cl)c2)n1,CHEMBL3758105,"Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.",J. Med. Chem.,2016.0,59,1,313,327,10.1021/acs.jmedchem.5b01434,26653735.0,
16457838,CHEMBL3759011,N-(4-Fluoro-3-methylbenzyl)-4-(2-(((trans)-4-(hydroxymethyl)-cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide,CHEMBL3761851,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction of diclofenac metabolism at 3 uM after 8 mins,Inhibition,=,96.0,%,Cc1cc(-c2nnn(C[C@H]3CC[C@H](CO)CC3)n2)cc(C(=O)NCc2ccc(F)c(C)c2)n1,CHEMBL3758105,"Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.",J. Med. Chem.,2016.0,59,1,313,327,10.1021/acs.jmedchem.5b01434,26653735.0,
16457839,CHEMBL3758441,N-(4-Fluoro-3-(trifluoromethyl)benzyl)-4-(2-(((trans)-4-(hydroxymethyl)cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide,CHEMBL3761851,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction of diclofenac metabolism at 3 uM after 8 mins,Inhibition,=,90.0,%,Cc1cc(-c2nnn(C[C@H]3CC[C@H](CO)CC3)n2)cc(C(=O)NCc2ccc(F)c(C(F)(F)F)c2)n1,CHEMBL3758105,"Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.",J. Med. Chem.,2016.0,59,1,313,327,10.1021/acs.jmedchem.5b01434,26653735.0,
16457840,CHEMBL3759811,N-(4-Fluoro-3-methoxybenzyl)-4-(2-(((trans)-4-(hydroxymethyl)-cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide,CHEMBL3761851,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction of diclofenac metabolism at 3 uM after 8 mins,Inhibition,=,39.0,%,COc1cc(CNC(=O)c2cc(-c3nnn(C[C@H]4CC[C@H](CO)CC4)n3)cc(C)n2)ccc1F,CHEMBL3758105,"Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.",J. Med. Chem.,2016.0,59,1,313,327,10.1021/acs.jmedchem.5b01434,26653735.0,
16457945,CHEMBL3759520,N-(3-Methoxybenzyl)-4-(2-(((trans)-4-(hydroxymethyl)-cyclohexyl)methyl)-2H-tetrazol-5-yl)-6-methylpicolinamide,CHEMBL3761851,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction of diclofenac metabolism at 3 uM after 8 mins,Inhibition,=,66.0,%,COc1cccc(CNC(=O)c2cc(-c3nnn(C[C@H]4CC[C@H](CO)CC4)n3)cc(C)n2)c1,CHEMBL3758105,"Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.",J. Med. Chem.,2016.0,59,1,313,327,10.1021/acs.jmedchem.5b01434,26653735.0,
16475456,CHEMBL3137320,TALAZOPARIB,CHEMBL3767917,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,<,12.0,%,Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1,CHEMBL3763037,"Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.",J. Med. Chem.,2016.0,59,1,335,357,10.1021/acs.jmedchem.5b01498,26652717.0,
16484889,CHEMBL3769968,"(-)-[2-[2-(Allyloxy)-4,5-difluorophenyl]cyclopropyl]methanamine Hydrochloride",CHEMBL3774205,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate at 10 uM,Inhibition,=,29.2,%,C=CCOc1cc(F)c(F)cc1C1CC1CN.Cl,CHEMBL3769385,"Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.",J. Med. Chem.,2016.0,59,2,578,591,10.1021/acs.jmedchem.5b01153,26704965.0,
16510668,CHEMBL103667,1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea,CHEMBL3783194,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 30 uM,Inhibition,=,13.0,%,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1,CHEMBL3779765,Discovery of Narrow Spectrum Kinase Inhibitors: New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma.,J. Med. Chem.,2016.0,59,5,1727,1746,10.1021/acs.jmedchem.5b01029,26800309.0,
16510669,CHEMBL143134,1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-pyridin-4-yl-ethoxy)-naphthalen-1-yl]-urea,CHEMBL3783194,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 30 uM,Inhibition,=,31.0,%,Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCc3ccncc3)c3ccccc23)cc1,CHEMBL3779765,Discovery of Narrow Spectrum Kinase Inhibitors: New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma.,J. Med. Chem.,2016.0,59,5,1727,1746,10.1021/acs.jmedchem.5b01029,26800309.0,
16510670,CHEMBL3781430,N-(4-(2-((4-(3-(3-(tert-Butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-ureido)naphthalen-1-yl)oxy)ethyl)pyridin-2-yl)acetamide,CHEMBL3783194,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 30 uM,Inhibition,=,23.0,%,CC(=O)Nc1cc(CCOc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(C)cc3)c3ccccc23)ccn1,CHEMBL3779765,Discovery of Narrow Spectrum Kinase Inhibitors: New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma.,J. Med. Chem.,2016.0,59,5,1727,1746,10.1021/acs.jmedchem.5b01029,26800309.0,
16510671,CHEMBL3782036,N-(4-(2-((4-(3-(3-(tert-Butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-ureido)naphthalen-1-yl)oxy)ethyl)pyridin-3-yl)-2-methoxyacetamide,CHEMBL3783194,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 30 uM,Inhibition,=,37.0,%,COCC(=O)Nc1cnccc1CCOc1ccc(NC(=O)Nc2cc(C(C)(C)C)nn2-c2ccc(C)cc2)c2ccccc12,CHEMBL3779765,Discovery of Narrow Spectrum Kinase Inhibitors: New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma.,J. Med. Chem.,2016.0,59,5,1727,1746,10.1021/acs.jmedchem.5b01029,26800309.0,
16534368,CHEMBL3785774,"(E)-5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(3-methoxy-5,5-dimethyl-6-((4-methylpiperazin-1-yl)imino)-5,6,7,8-tetrahydronaphthalen-2-yl)pyrimidine-2,4-diamine",CHEMBL3789030,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,17.1,%,COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CC/C(=N\N1CCN(C)CC1)C2(C)C,CHEMBL3784918,"Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies.",Bioorg. Med. Chem. Lett.,2016.0,26,7,1720,1725,10.1016/j.bmcl.2016.02.052,26923695.0,
16534369,CHEMBL3786892,"N2-(6-amino-3-methoxy-5,5-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-5-chloro-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine",CHEMBL3789030,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,38.0,%,COc1cc2c(cc1Nc1ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n1)CCC(N)C2(C)C,CHEMBL3784918,"Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies.",Bioorg. Med. Chem. Lett.,2016.0,26,7,1720,1725,10.1016/j.bmcl.2016.02.052,26923695.0,
16559597,CHEMBL3792850,N-{4-[(4-phenylpiperazin-1-yl)methyl]phenyl}-1H-indazole-3-carboxamide,CHEMBL3794753,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM relative to control,Inhibition,=,36.0,%,O=C(Nc1ccc(CN2CCN(c3ccccc3)CC2)cc1)c1n[nH]c2ccccc12,CHEMBL3792292,Development of a potent and selective FLT3 kinase inhibitor by systematic expansion of a non-selective fragment-screening hit.,Bioorg. Med. Chem. Lett.,2016.0,26,9,2370,2374,10.1016/j.bmcl.2016.03.006,26995531.0,
16579766,CHEMBL3798025,(4-benzhydrylpiperazin-1-yl)(5-(pyridin-3-yl)-1H-pyrazol-3-yl)methanone,CHEMBL3804693,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,=,43.0,%,O=C(c1cc(-c2cccnc2)[nH]n1)N1CCN(C(c2ccccc2)c2ccccc2)CC1,CHEMBL3797081,Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies.,Bioorg. Med. Chem. Lett.,2016.0,26,12,2920,2926,10.1016/j.bmcl.2016.04.039,27158141.0,
16579767,CHEMBL3800338,N-(4-butylphenyl)-2-(pyridin-3-yl)cyclopropanecarboxamide,CHEMBL3804693,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,=,31.0,%,CCCCc1ccc(NC(=O)C2CC2c2cccnc2)cc1,CHEMBL3797081,Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies.,Bioorg. Med. Chem. Lett.,2016.0,26,12,2920,2926,10.1016/j.bmcl.2016.04.039,27158141.0,
16584254,CHEMBL3805993,"N-Hexyl-2-hydroxy-1,3-dioxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide",CHEMBL3807258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using MFC as substrate at 10 uM incubated for 40 mins by fluorimetry relative to control,Inhibition,=,25.3,%,CCCCCCNC(=O)C1C(=O)N(O)C(=O)c2ccccc21,CHEMBL3804820,"2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.",Eur. J. Med. Chem.,2016.0,117,,256,268,10.1016/j.ejmech.2016.03.083,27105029.0,
16584255,CHEMBL2407287,"N-(4-Fluorobenzyl)-2-hydroxy-1,3-dioxo-1,2,3,4-tetrahydroisoquinoline-4-carboxamide",CHEMBL3807258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 using MFC as substrate at 10 uM incubated for 40 mins by fluorimetry relative to control,Inhibition,=,6.4,%,O=C(NCc1ccc(F)cc1)C1C(=O)N(O)C(=O)c2ccccc21,CHEMBL3804820,"2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.",Eur. J. Med. Chem.,2016.0,117,,256,268,10.1016/j.ejmech.2016.03.083,27105029.0,
16588524,CHEMBL3805328,"3-{5-[(3'-Methylbiphenyl-3-yl)carbamoyl]-1,3,4-thiadiazol-2-yl}propanoic acid",CHEMBL3807176,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 20 uM by P450-glo assay,Inhibition,=,9.8,%,Cc1cccc(-c2cccc(NC(=O)c3nnc(CCC(=O)O)s3)c2)c1,CHEMBL3804779,"Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold.",Bioorg. Med. Chem.,2016.0,24,13,2954,2963,10.1016/j.bmc.2016.04.065,27229618.0,
16588525,CHEMBL3805879,"3-{5-[(4'-Fluorobiphenyl-3-yl)carbamoyl]-1,3,4-thiadiazol-2-yl}propanoic acid",CHEMBL3807176,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 20 uM by P450-glo assay,Inhibition,=,-1.9,%,O=C(O)CCc1nnc(C(=O)Nc2cccc(-c3ccc(F)cc3)c2)s1,CHEMBL3804779,"Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold.",Bioorg. Med. Chem.,2016.0,24,13,2954,2963,10.1016/j.bmc.2016.04.065,27229618.0,
16588526,CHEMBL3805888,"3-[4-({5-[(2-Fluorophenyl)carbamoyl]-1,3,4-thiadiazol-2-yl}methoxy)phenyl]propanoic acid",CHEMBL3807176,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 20 uM by P450-glo assay,Inhibition,=,12.8,%,O=C(O)CCc1ccc(OCc2nnc(C(=O)Nc3ccccc3F)s2)cc1,CHEMBL3804779,"Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold.",Bioorg. Med. Chem.,2016.0,24,13,2954,2963,10.1016/j.bmc.2016.04.065,27229618.0,
16588527,CHEMBL3805377,"3-[4-({5-[(3-Chlorophenyl)carbamoyl]-1,3,4-thiadiazol-2-yl}methoxy)phenyl]propanoic acid",CHEMBL3807176,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 20 uM by P450-glo assay,Inhibition,=,85.0,%,O=C(O)CCc1ccc(OCc2nnc(C(=O)Nc3cccc(Cl)c3)s2)cc1,CHEMBL3804779,"Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold.",Bioorg. Med. Chem.,2016.0,24,13,2954,2963,10.1016/j.bmc.2016.04.065,27229618.0,
16588542,CHEMBL106,"2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol",CHEMBL3807181,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 120 uM by P450-glo assay,Inhibition,=,89.09,%,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,CHEMBL3804779,"Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold.",Bioorg. Med. Chem.,2016.0,24,13,2954,2963,10.1016/j.bmc.2016.04.065,27229618.0,
16599804,CHEMBL3809730,5-fluoro-2-(1-(2-fluorobenzyl)-5-(isoxazol-3-yl)-1H-pyrazol-3-yl)pyrimidin-4-ol,CHEMBL3810963,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,<,20.0,%,Oc1nc(-c2cc(-c3ccon3)n(Cc3ccccc3F)n2)ncc1F,CHEMBL3808387,"Discovery of IWP-051, a Novel Orally Bioavailable sGC Stimulator with Once-Daily Dosing Potential in Humans.",ACS Med. Chem. Lett.,2016.0,7,5,465,469,10.1021/acsmedchemlett.5b00479,27190594.0,
16621978,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL3820781,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate at 10 uM preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis relative to control,Inhibition,=,98.0,%,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL3817743,Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibition by Optimization of the 2-Aminopyridine-Based Scaffold with a Pyridine Linker.,J. Med. Chem.,2016.0,59,10,4913,4925,10.1021/acs.jmedchem.6b00273,27050842.0,
16621979,CHEMBL3818373,4-Methyl-6-(2-(5-(3-(methylamino)propyl)pyridin-3-yl)-ethyl)pyridin-2-amine,CHEMBL3820781,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate at 10 uM preincubated for 5 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis relative to control,Inhibition,=,0.0,%,CNCCCc1cncc(CCc2cc(C)cc(N)n2)c1,CHEMBL3817743,Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibition by Optimization of the 2-Aminopyridine-Based Scaffold with a Pyridine Linker.,J. Med. Chem.,2016.0,59,10,4913,4925,10.1021/acs.jmedchem.6b00273,27050842.0,
16626968,CHEMBL3818307,"N-[trans-4-(3-Chloro-4-cyanophenoxy)cyclohexyl]-1,1,1-trifluoromethanesulfonamide",CHEMBL3821896,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,=,77.0,%,N#Cc1ccc(O[C@H]2CC[C@H](NS(=O)(=O)C(F)(F)F)CC2)cc1Cl,CHEMBL3817830,"Discovery of a novel binding pocket for CYP 2C9 inhibitors: crystallography, pharmacophore modelling and inhibitor SAR",MedChemComm,2016.0,7,5,813,819,10.1039/C6MD00011H,,
16626969,CHEMBL3818248,"N-[4-(3-Chloro-4-cyanophenoxy)-3,5-dimethoxyphenyl]-1,1,1-trifluoromethanesulfonamide",CHEMBL3821896,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,=,95.0,%,COc1cc(NS(=O)(=O)C(F)(F)F)cc(OC)c1Oc1ccc(C#N)c(Cl)c1,CHEMBL3817830,"Discovery of a novel binding pocket for CYP 2C9 inhibitors: crystallography, pharmacophore modelling and inhibitor SAR",MedChemComm,2016.0,7,5,813,819,10.1039/C6MD00011H,,
16626970,CHEMBL3818319,N-[trans-4-(3-Chloro-4-cyanophenoxy)cyclohexyl]-methanesulfonamide,CHEMBL3821896,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,=,0.0,%,CS(=O)(=O)N[C@H]1CC[C@H](Oc2ccc(C#N)c(Cl)c2)CC1,CHEMBL3817830,"Discovery of a novel binding pocket for CYP 2C9 inhibitors: crystallography, pharmacophore modelling and inhibitor SAR",MedChemComm,2016.0,7,5,813,819,10.1039/C6MD00011H,,
16626971,CHEMBL3818341,"N-[4-(3-Chloro-4-cyanophenoxy)-3,5-dimethoxyphenyl]-methane sulfonamide",CHEMBL3821896,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,=,9.0,%,COc1cc(NS(C)(=O)=O)cc(OC)c1Oc1ccc(C#N)c(Cl)c1,CHEMBL3817830,"Discovery of a novel binding pocket for CYP 2C9 inhibitors: crystallography, pharmacophore modelling and inhibitor SAR",MedChemComm,2016.0,7,5,813,819,10.1039/C6MD00011H,,
16631493,CHEMBL3818665,"5-(4-(4-methoxyphenyl)piperazin-1-yl)-2,2,4,6,7-pentamethyl-1-benzofuran-3(2H)-one",CHEMBL3820238,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM incubated for 30 mins by HPLC analysis,Inhibition,=,83.4,%,COc1ccc(N2CCN(c3c(C)c(C)c4c(c3C)C(=O)C(C)(C)O4)CC2)cc1,CHEMBL3817802,Discovery of Benzofuran Derivatives that Collaborate with Insulin-Like Growth Factor 1 (IGF-1) to Promote Neuroprotection.,J. Med. Chem.,2016.0,59,10,5109,5114,10.1021/acs.jmedchem.6b00191,27163512.0,
16631494,CHEMBL3819377,"6-(4-(4-methoxyphenyl)piperazin-1-yl)-3,3,5,7,8-pentamethyl-2,3-dihydro-4H-chromen-4-one",CHEMBL3820238,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM incubated for 30 mins by HPLC analysis,Inhibition,=,42.1,%,COc1ccc(N2CCN(c3c(C)c(C)c4c(c3C)C(=O)C(C)(C)CO4)CC2)cc1,CHEMBL3817802,Discovery of Benzofuran Derivatives that Collaborate with Insulin-Like Growth Factor 1 (IGF-1) to Promote Neuroprotection.,J. Med. Chem.,2016.0,59,10,5109,5114,10.1021/acs.jmedchem.6b00191,27163512.0,
16631495,CHEMBL3818676,"1-(4-methoxyphenyl)-4-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-yl)piperazine",CHEMBL3820238,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM incubated for 30 mins by HPLC analysis,Inhibition,=,-0.9,%,COc1ccc(N2CCN(c3c(C)c(C)c4c(c3C)CC(C)(C)O4)CC2)cc1,CHEMBL3817802,Discovery of Benzofuran Derivatives that Collaborate with Insulin-Like Growth Factor 1 (IGF-1) to Promote Neuroprotection.,J. Med. Chem.,2016.0,59,10,5109,5114,10.1021/acs.jmedchem.6b00191,27163512.0,
16663708,CHEMBL3971610,N-(Quinolin-3-yl)-2-(trifluoromethyl)benzenesulfonamide,CHEMBL3853556,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,=,39.0,%,O=S(=O)(Nc1cnc2ccccc2c1)c1ccccc1C(F)(F)F,CHEMBL3853265,,MedChemComm,2016.0,7,8,1572,1579,10.1039/C6MD00191B,,
16663712,CHEMBL3900479,N-(4-Cyano-3-(trifluoromethyl)phenyl)-2-(trifluoromethyl)benzenesulfonamide,CHEMBL3853556,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,=,61.0,%,N#Cc1ccc(NS(=O)(=O)c2ccccc2C(F)(F)F)cc1C(F)(F)F,CHEMBL3853265,,MedChemComm,2016.0,7,8,1572,1579,10.1039/C6MD00191B,,
16663716,CHEMBL3935920,N-(2-Cyanophenyl)-2-(trifluoromethyl)benzenesulfon amide,CHEMBL3853556,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,=,11.0,%,N#Cc1ccccc1NS(=O)(=O)c1ccccc1C(F)(F)F,CHEMBL3853265,,MedChemComm,2016.0,7,8,1572,1579,10.1039/C6MD00191B,,
16663720,CHEMBL3965811,N-(3-Cyanophenyl)-2-(trifluoromethyl)benzenesulfon amide,CHEMBL3853556,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,=,28.0,%,N#Cc1cccc(NS(=O)(=O)c2ccccc2C(F)(F)F)c1,CHEMBL3853265,,MedChemComm,2016.0,7,8,1572,1579,10.1039/C6MD00191B,,
16663724,CHEMBL3902419,N-(2-Fluorophenyl)-2-(trifluoromethyl)benzenesulfon amide,CHEMBL3853556,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,=,15.0,%,O=S(=O)(Nc1ccccc1F)c1ccccc1C(F)(F)F,CHEMBL3853265,,MedChemComm,2016.0,7,8,1572,1579,10.1039/C6MD00191B,,
16663730,CHEMBL3962348,N-[3-(Trifluoromethoxy)phenyl]-2-(trifluoromethyl)benzenesulfonamide,CHEMBL3853556,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,=,81.0,%,O=S(=O)(Nc1cccc(OC(F)(F)F)c1)c1ccccc1C(F)(F)F,CHEMBL3853265,,MedChemComm,2016.0,7,8,1572,1579,10.1039/C6MD00191B,,
16663735,CHEMBL3973326,N-(3-Cyano-4-(trifluoromethyl)phenyl)-2-(trifluoromethyl)benzenesulfonamide,CHEMBL3853556,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,=,86.0,%,N#Cc1cc(NS(=O)(=O)c2ccccc2C(F)(F)F)ccc1C(F)(F)F,CHEMBL3853265,,MedChemComm,2016.0,7,8,1572,1579,10.1039/C6MD00191B,,
16663739,CHEMBL3902309,N-(3-Chloro-4-cyanophenyl)-2-(trifluoromethyl)benzenesulfonamide,CHEMBL3853556,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,=,92.0,%,N#Cc1ccc(NS(=O)(=O)c2ccccc2C(F)(F)F)cc1Cl,CHEMBL3853265,,MedChemComm,2016.0,7,8,1572,1579,10.1039/C6MD00191B,,
16663743,CHEMBL3899557,N-(4-Chloro-3-cyanophenyl)-2-(trifluoromethyl)benzenesulfonamide,CHEMBL3853556,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,=,76.0,%,N#Cc1cc(NS(=O)(=O)c2ccccc2C(F)(F)F)ccc1Cl,CHEMBL3853265,,MedChemComm,2016.0,7,8,1572,1579,10.1039/C6MD00191B,,
16663747,CHEMBL3978281,N-(3-Chloro-2-cyanophenyl)-2-(trifluoromethyl)benzene sulfonamide,CHEMBL3853556,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,=,86.0,%,N#Cc1c(Cl)cccc1NS(=O)(=O)c1ccccc1C(F)(F)F,CHEMBL3853265,,MedChemComm,2016.0,7,8,1572,1579,10.1039/C6MD00191B,,
16663753,CHEMBL3979882,N-(2-chloro-4-cyanophenyl)-2-(trifluoromethyl)benzenesulfonamide,CHEMBL3853556,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,=,82.0,%,N#Cc1ccc(NS(=O)(=O)c2ccccc2C(F)(F)F)c(Cl)c1,CHEMBL3853265,,MedChemComm,2016.0,7,8,1572,1579,10.1039/C6MD00191B,,
16663768,CHEMBL3892944,N-(5-Methoxypyridin-3-yl)-2-(trifluoromethyl)benzenesulfonamide,CHEMBL3853556,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,=,18.0,%,COc1cncc(NS(=O)(=O)c2ccccc2C(F)(F)F)c1,CHEMBL3853265,,MedChemComm,2016.0,7,8,1572,1579,10.1039/C6MD00191B,,
16663776,CHEMBL3984949,N-(5-Bromopyridin-3-yl)-2-(trifluoromethyl)benzenesulfonamide,CHEMBL3853556,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,=,38.0,%,O=S(=O)(Nc1cncc(Br)c1)c1ccccc1C(F)(F)F,CHEMBL3853265,,MedChemComm,2016.0,7,8,1572,1579,10.1039/C6MD00191B,,
16663781,CHEMBL3924161,2-(Trifluoromethyl)-N-(5-(trifluoromethyl)pyridin-2-yl)-benzenesulfonamide,CHEMBL3853556,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,=,24.0,%,O=S(=O)(Nc1ccc(C(F)(F)F)nc1)c1ccccc1C(F)(F)F,CHEMBL3853265,,MedChemComm,2016.0,7,8,1572,1579,10.1039/C6MD00191B,,
16663862,CHEMBL3929544,2-(Trifluoromethyl)-N-(5-(trifluoromethyl)pyridin-3-yl)-benzenesulfonamide,CHEMBL3853556,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,=,43.0,%,O=S(=O)(Nc1cncc(C(F)(F)F)c1)c1ccccc1C(F)(F)F,CHEMBL3853265,,MedChemComm,2016.0,7,8,1572,1579,10.1039/C6MD00191B,,
16744924,CHEMBL3938686,"(S)-N-((cis)-4-(hydroxymethyl)cyclohexyl)-3,3-dimethyl-1-(8-methylquinolin-2-yl)piperidine-4-carboxamide",CHEMBL3858514,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human hepatic microsomes assessed as reduction in probe substrate metabolism at 10 uM,Inhibition,=,54.0,%,Cc1cccc2ccc(N3CC[C@H](C(=O)N[C@H]4CC[C@@H](CO)CC4)C(C)(C)C3)nc12,CHEMBL3856235,"Characterization of 3,3-dimethyl substituted N-aryl piperidines as potent microsomal prostaglandin E synthase-1 inhibitors.",Bioorg Med Chem Lett,2016.0,26,19,4824,4828,10.1016/j.bmcl.2016.08.023,27554445.0,
16744925,CHEMBL3956184,"(S)-N-((1S,3S)-3-(hydroxymethyl)cyclohexyl)-3,3-dimethyl-1-(8-methylquinolin-2-yl)piperidine-4-carboxamide",CHEMBL3858514,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human hepatic microsomes assessed as reduction in probe substrate metabolism at 10 uM,Inhibition,=,64.0,%,Cc1cccc2ccc(N3CC[C@H](C(=O)N[C@H]4CCC[C@H](CO)C4)C(C)(C)C3)nc12,CHEMBL3856235,"Characterization of 3,3-dimethyl substituted N-aryl piperidines as potent microsomal prostaglandin E synthase-1 inhibitors.",Bioorg Med Chem Lett,2016.0,26,19,4824,4828,10.1016/j.bmcl.2016.08.023,27554445.0,
16744926,CHEMBL3928608,"(S)-N-((2S,4S)-2-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)-3,3-dimethyl-1-(8-methylquinolin-2-yl)piperidine-4-carboxamide",CHEMBL3858514,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human hepatic microsomes assessed as reduction in probe substrate metabolism at 10 uM,Inhibition,=,15.0,%,Cc1cccc2ccc(N3CC[C@H](C(=O)N[C@H]4CCO[C@H](CO)C4)C(C)(C)C3)nc12,CHEMBL3856235,"Characterization of 3,3-dimethyl substituted N-aryl piperidines as potent microsomal prostaglandin E synthase-1 inhibitors.",Bioorg Med Chem Lett,2016.0,26,19,4824,4828,10.1016/j.bmcl.2016.08.023,27554445.0,
16757151,CHEMBL3893901,"1-(4-Isopropylbenzyl)-5-nitro-2-oxo-N-phenethyl-1,2-dihydroquinoline-3-carboxamide",CHEMBL3861329,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculosomes at 1 uM preincubated with protein prior to substrate addition measured after 40 mins in presence of NADP regeneration system by fluorimetric analysis,Inhibition,=,30.0,%,CC(C)c1ccc(Cn2c(=O)c(C(=O)NCCc3ccccc3)cc3c([N+](=O)[O-])cccc32)cc1,CHEMBL3860071,Discovery and structure-activity relationship studies of quinolinone derivatives as potent IL-2 suppressive agents.,Bioorg Med Chem,2016.0,24,21,5357,5367,10.1016/j.bmc.2016.08.051,27647370.0,
16757154,CHEMBL3893901,"1-(4-Isopropylbenzyl)-5-nitro-2-oxo-N-phenethyl-1,2-dihydroquinoline-3-carboxamide",CHEMBL3861326,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculosomes at 10 uM preincubated with protein prior to substrate addition measured after 40 mins in presence of NADP regeneration system by fluorimetric analysis,Inhibition,=,65.0,%,CC(C)c1ccc(Cn2c(=O)c(C(=O)NCCc3ccccc3)cc3c([N+](=O)[O-])cccc32)cc1,CHEMBL3860071,Discovery and structure-activity relationship studies of quinolinone derivatives as potent IL-2 suppressive agents.,Bioorg Med Chem,2016.0,24,21,5357,5367,10.1016/j.bmc.2016.08.051,27647370.0,
16758525,CHEMBL3929479,N-(4-(2-Methylpyridin-4-yl)benzyl)-9H-carbazole-2-carboxamide,CHEMBL3861552,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,Inhibition,=,-22.0,%,Cc1cc(-c2ccc(CNC(=O)c3ccc4c(c3)[nH]c3ccccc34)cc2)ccn1,CHEMBL3860088,"Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the 'reversed' amide scaffold.",Bioorg Med Chem,2016.0,24,22,5861,5872,10.1016/j.bmc.2016.09.041,27692509.0,
16758526,CHEMBL3972086,"N-((3-Fluoro-2'-methyl-[2,4'-bipyridin]-5-yl)methyl)-9H-carbazole-2-carboxamide",CHEMBL3861552,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,Inhibition,=,31.0,%,Cc1cc(-c2ncc(CNC(=O)c3ccc4c(c3)[nH]c3ccccc34)cc2F)ccn1,CHEMBL3860088,"Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the 'reversed' amide scaffold.",Bioorg Med Chem,2016.0,24,22,5861,5872,10.1016/j.bmc.2016.09.041,27692509.0,
16801635,CHEMBL3962279,6-(1H-Indol-5-yl)-4-(4-cyanomethyl)phenylaminoquinazoline,CHEMBL3868840,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM after 10 mins by fluorescence assay,Inhibition,=,88.0,%,N#CCc1ccc(Nc2ncnc3ccc(-c4ccc5[nH]ccc5c4)cc23)cc1,CHEMBL3868583,6-Aryl substituted 4-(4-cyanomethyl) phenylamino quinazolines as a new class of isoform-selective PI3K-alpha inhibitors.,Eur J Med Chem,2016.0,122,,731,743,10.1016/j.ejmech.2016.07.006,27479483.0,
16801636,CHEMBL3974237,6-(Isoquinolin-4-yl)-4-(4-cyanomethyl)phenylaminoquinazoline,CHEMBL3868840,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM after 10 mins by fluorescence assay,Inhibition,=,87.0,%,N#CCc1ccc(Nc2ncnc3ccc(-c4cncc5ccccc45)cc23)cc1,CHEMBL3868583,6-Aryl substituted 4-(4-cyanomethyl) phenylamino quinazolines as a new class of isoform-selective PI3K-alpha inhibitors.,Eur J Med Chem,2016.0,122,,731,743,10.1016/j.ejmech.2016.07.006,27479483.0,
16803701,CHEMBL3947221,"(1S,2R,3S,4S,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-4-hydroxybicyclo[3.1.0]hexane-2,6-dicarboxylic acid",CHEMBL3869586,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,<,5.0,%,N[C@@]1(C(=O)O)[C@H](OCc2ccc(Cl)c(Cl)c2)[C@@H](O)[C@@H]2[C@H]1[C@H]2C(=O)O,CHEMBL3868610,Novel bicyclo[3.1.0]hexane analogs as antagonists of metabotropic glutamate 2/3 receptors for the treatment of depression.,Bioorg Med Chem Lett,2016.0,26,23,5663,5668,10.1016/j.bmcl.2016.10.067,27836401.0,
16824140,CHEMBL3925606,"2-((2-Chloro-6-fluorophenyl)amino)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-7,8-dihydro-1H-[1,4]dioxino[2',3':3,4]benzo[1,2-d]imidazole-5-carboxamide",CHEMBL3873589,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC/MS/MS analysis,Inhibition,=,49.12,%,O=C(Nc1ccc(F)c(C(F)(F)F)c1)c1cc2nc(Nc3c(F)cccc3Cl)[nH]c2c2c1OCCO2,CHEMBL3872236,"Discovery of 2-((2-chloro-6-fluorophenyl)amino)-N-(3-fluoro-5-(trifluoromethyl)phenyl)-1-methyl-7,8-dihydro-1H-[1,4]dioxino[2',3':3,4]benzo[1,2-d]imidazole-5-carboxamide as potent, selective and efficacious microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor.",Bioorg Med Chem Lett,2016.0,26,24,5977,5984,10.1016/j.bmcl.2016.10.079,27865703.0,
16824141,CHEMBL3898125,"2-((2-Chloro-6-fluorophenyl)amino)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-1-methyl-7,8-dihydro-1H-[1,4]dioxino[2',3':3,4]benzo[1,2-d]imidazole-5-carboxamide",CHEMBL3873589,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC/MS/MS analysis,Inhibition,=,29.76,%,Cn1c(Nc2c(F)cccc2Cl)nc2cc(C(=O)Nc3ccc(F)c(C(F)(F)F)c3)c3c(c21)OCCO3,CHEMBL3872236,"Discovery of 2-((2-chloro-6-fluorophenyl)amino)-N-(3-fluoro-5-(trifluoromethyl)phenyl)-1-methyl-7,8-dihydro-1H-[1,4]dioxino[2',3':3,4]benzo[1,2-d]imidazole-5-carboxamide as potent, selective and efficacious microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor.",Bioorg Med Chem Lett,2016.0,26,24,5977,5984,10.1016/j.bmcl.2016.10.079,27865703.0,
16824142,CHEMBL3926203,"2-((2-Chloro-6-fluorophenyl)amino)-N-(3-fluoro-5-(trifluoromethyl)phenyl)-7,8-dihydro-1H-[1,4]dioxino[2',3':3,4]benzo[1,2-d]imidazole-5-carboxamide",CHEMBL3873589,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC/MS/MS analysis,Inhibition,=,12.5,%,O=C(Nc1cc(F)cc(C(F)(F)F)c1)c1cc2nc(Nc3c(F)cccc3Cl)[nH]c2c2c1OCCO2,CHEMBL3872236,"Discovery of 2-((2-chloro-6-fluorophenyl)amino)-N-(3-fluoro-5-(trifluoromethyl)phenyl)-1-methyl-7,8-dihydro-1H-[1,4]dioxino[2',3':3,4]benzo[1,2-d]imidazole-5-carboxamide as potent, selective and efficacious microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor.",Bioorg Med Chem Lett,2016.0,26,24,5977,5984,10.1016/j.bmcl.2016.10.079,27865703.0,
16824143,CHEMBL3897959,"2-((2-Chloro-6-fluorophenyl)amino)-N-(3-fluoro-5-(trifluoromethyl)phenyl)-1-methyl-7,8-dihydro-1H-[1,4]dioxino[2',3':3,4]benzo[1,2-d]imidazole-5-carboxamide",CHEMBL3873589,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC/MS/MS analysis,Inhibition,=,38.54,%,Cn1c(Nc2c(F)cccc2Cl)nc2cc(C(=O)Nc3cc(F)cc(C(F)(F)F)c3)c3c(c21)OCCO3,CHEMBL3872236,"Discovery of 2-((2-chloro-6-fluorophenyl)amino)-N-(3-fluoro-5-(trifluoromethyl)phenyl)-1-methyl-7,8-dihydro-1H-[1,4]dioxino[2',3':3,4]benzo[1,2-d]imidazole-5-carboxamide as potent, selective and efficacious microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor.",Bioorg Med Chem Lett,2016.0,26,24,5977,5984,10.1016/j.bmcl.2016.10.079,27865703.0,
16824144,CHEMBL3916119,"2-((2-Chloro-6-fluorophenyl)amino)-N-(4-(cyclopropylethynyl)-3-fluorophenyl)-7,8-dihydro-1H-[1,4]dioxino[2',3':3,4]benzo[1,2-d]imidazole-5-carboxamide",CHEMBL3873589,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC/MS/MS analysis,Inhibition,=,27.07,%,O=C(Nc1ccc(C#CC2CC2)c(F)c1)c1cc2nc(Nc3c(F)cccc3Cl)[nH]c2c2c1OCCO2,CHEMBL3872236,"Discovery of 2-((2-chloro-6-fluorophenyl)amino)-N-(3-fluoro-5-(trifluoromethyl)phenyl)-1-methyl-7,8-dihydro-1H-[1,4]dioxino[2',3':3,4]benzo[1,2-d]imidazole-5-carboxamide as potent, selective and efficacious microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor.",Bioorg Med Chem Lett,2016.0,26,24,5977,5984,10.1016/j.bmcl.2016.10.079,27865703.0,
16824145,CHEMBL3984373,"2-((2-Chloro-6-fluorophenyl)amino)-N-(4,4-dimethylcyclohexyl)-1-methyl-7,8-dihydro-1H-[1,4]dioxino[2,3-d]imidazo[4,5-b]pyridine-5-carboxamide",CHEMBL3873589,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC/MS/MS analysis,Inhibition,=,27.78,%,Cn1c(Nc2c(F)cccc2Cl)nc2cc(C(=O)NC3CCC(C)(C)CC3)c3c(c21)OCCO3,CHEMBL3872236,"Discovery of 2-((2-chloro-6-fluorophenyl)amino)-N-(3-fluoro-5-(trifluoromethyl)phenyl)-1-methyl-7,8-dihydro-1H-[1,4]dioxino[2',3':3,4]benzo[1,2-d]imidazole-5-carboxamide as potent, selective and efficacious microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor.",Bioorg Med Chem Lett,2016.0,26,24,5977,5984,10.1016/j.bmcl.2016.10.079,27865703.0,
16824146,CHEMBL3987179,"2-((2-Chloro-6-fluorophenyl)amino)-1-methyl-N-(trans-4-(trifluoromethyl)cyclohexyl)-7,8-dihydro-1H-[1,4]dioxino[2',3':3,4]benzo[1,2-d]imidazole-5-carboxamide",CHEMBL3873589,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC/MS/MS analysis,Inhibition,=,39.4,%,Cn1c(Nc2c(F)cccc2Cl)nc2cc(C(=O)N[C@H]3CC[C@H](C(F)(F)F)CC3)c3c(c21)OCCO3,CHEMBL3872236,"Discovery of 2-((2-chloro-6-fluorophenyl)amino)-N-(3-fluoro-5-(trifluoromethyl)phenyl)-1-methyl-7,8-dihydro-1H-[1,4]dioxino[2',3':3,4]benzo[1,2-d]imidazole-5-carboxamide as potent, selective and efficacious microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor.",Bioorg Med Chem Lett,2016.0,26,24,5977,5984,10.1016/j.bmcl.2016.10.079,27865703.0,
17961531,CHEMBL4063997,8-cyclopentyl-2-[(2-methyl-3-pyridyl)oxy]-1-propyl-7H-purin-6-one,CHEMBL3994408,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 5 uM relative to control,Inhibition,=,4.0,%,CCCn1c(Oc2cccnc2C)nc2nc(C3CCCC3)[nH]c2c1=O,CHEMBL3992564,"Design and synthesis of novel, potent and selective hypoxanthine analogs as adenosine A1 receptor antagonists and their biological evaluation.",Bioorg Med Chem,2017.0,25,6,1963,1975,10.1016/j.bmc.2017.02.029,28238512.0,
17961532,CHEMBL4068469,8-cyclopentyl-2-(3-hydroxycyclopentoxy)-1-propyl-7H-purin-6-one,CHEMBL3994408,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 5 uM relative to control,Inhibition,=,4.0,%,CCCn1c(OC2CCC(O)C2)nc2nc(C3CCCC3)[nH]c2c1=O,CHEMBL3992564,"Design and synthesis of novel, potent and selective hypoxanthine analogs as adenosine A1 receptor antagonists and their biological evaluation.",Bioorg Med Chem,2017.0,25,6,1963,1975,10.1016/j.bmc.2017.02.029,28238512.0,
17961533,CHEMBL4065762,8-cyclopentyl-2-(3-methoxyphenyl)-1-propyl-7H-purin-6-one,CHEMBL3994408,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 5 uM relative to control,Inhibition,=,7.0,%,CCCn1c(-c2cccc(OC)c2)nc2nc(C3CCCC3)[nH]c2c1=O,CHEMBL3992564,"Design and synthesis of novel, potent and selective hypoxanthine analogs as adenosine A1 receptor antagonists and their biological evaluation.",Bioorg Med Chem,2017.0,25,6,1963,1975,10.1016/j.bmc.2017.02.029,28238512.0,
17966143,CHEMBL4079675,"(5-(3,5-Dichloro-4-methoxy-phenyl)-thiophen-2-yl)-(2,6-difluoro-3-hydroxy-phenyl)-methanone",CHEMBL3995168,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculovirus infected insect cell microsomes at 1 uM relative to control,Inhibition,=,0.0,%,COc1c(Cl)cc(-c2ccc(C(=O)c3c(F)ccc(O)c3F)s2)cc1Cl,CHEMBL3994586,"Treatment of estrogen-dependent diseases: Design, synthesis and profiling of a selective 17β-HSD1 inhibitor with sub-nanomolar IC50 for a proof-of-principle study.",Eur J Med Chem,2017.0,127,,944,957,10.1016/j.ejmech.2016.11.004,27852458.0,
17976249,CHEMBL4099851,(S)-4-(1-(5-chloro-2-(3-fluorophenoxy)nicotinamido)ethyl)benzoic acid,CHEMBL3997158,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 1 uM relative to control,Inhibition,<,5.0,%,C[C@H](NC(=O)c1cc(Cl)cnc1Oc1cccc(F)c1)c1ccc(C(=O)O)cc1,CHEMBL3994644,"Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist.",Bioorg Med Chem Lett,2017.0,27,5,1186,1192,10.1016/j.bmcl.2017.01.067,28169162.0,
17979218,CHEMBL4084567,"Tetraethyl 2-phenylethene-1,1-diyldiphosphonate",CHEMBL3998020,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 at 10 uM by fluorescence analysis relative to control,Inhibition,=,0.0,%,CCOP(=O)(OCC)C(=Cc1ccccc1)P(=O)(OCC)OCC,CHEMBL3997764,,MedChemComm,2016.0,7,10,1910,1915,10.1039/C6MD00300A,,
17981078,CHEMBL594853,2'-Hydroxy-3-methoxy-chalcone,CHEMBL3998587,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect cells at 10 uM using Luciferin-H as substrate in presence of NADPH by P450-Glo luminescence assay relative to control,Inhibition,=,17.1,%,COc1cccc(/C=C/C(=O)c2ccccc2O)c1,CHEMBL3997782,Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.,Eur J Med Chem,2017.0,126,,1129,1135,10.1016/j.ejmech.2016.12.017,28064141.0,
17981079,CHEMBL260597,1-(2-hydroxy-4-methoxyphenyl)-3-(3-methoxyphenyl)prop-2-en-1-one,CHEMBL3998587,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect cells at 10 uM using Luciferin-H as substrate in presence of NADPH by P450-Glo luminescence assay relative to control,Inhibition,=,47.4,%,COc1cccc(/C=C/C(=O)c2ccc(OC)cc2O)c1,CHEMBL3997782,Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.,Eur J Med Chem,2017.0,126,,1129,1135,10.1016/j.ejmech.2016.12.017,28064141.0,
17981080,CHEMBL3125824,(E)-1-(2-Hydroxy-5-methoxyphenyl)-3-(3-methoxyphenyl)prop-2-en-1-one,CHEMBL3998587,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect cells at 10 uM using Luciferin-H as substrate in presence of NADPH by P450-Glo luminescence assay relative to control,Inhibition,=,-31.7,%,COc1cccc(/C=C/C(=O)c2cc(OC)ccc2O)c1,CHEMBL3997782,Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.,Eur J Med Chem,2017.0,126,,1129,1135,10.1016/j.ejmech.2016.12.017,28064141.0,
17981081,CHEMBL4071093,"(2E)-1-(2-hydroxy-4,5-dimethoxyphenyl)-3-(3-methoxyphenyl)prop-2-en-1-one",CHEMBL3998587,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect cells at 10 uM using Luciferin-H as substrate in presence of NADPH by P450-Glo luminescence assay relative to control,Inhibition,=,19.0,%,COc1cccc(/C=C/C(=O)c2cc(OC)c(OC)cc2O)c1,CHEMBL3997782,Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.,Eur J Med Chem,2017.0,126,,1129,1135,10.1016/j.ejmech.2016.12.017,28064141.0,
17981082,CHEMBL229907,1-(2-hydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one,CHEMBL3998587,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect cells at 10 uM using Luciferin-H as substrate in presence of NADPH by P450-Glo luminescence assay relative to control,Inhibition,=,21.7,%,COc1ccc(/C=C/C(=O)c2ccc(OC)cc2O)cc1,CHEMBL3997782,Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.,Eur J Med Chem,2017.0,126,,1129,1135,10.1016/j.ejmech.2016.12.017,28064141.0,
17981083,CHEMBL4082217,(2E)-1-(2-hydroxy-5-methoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one,CHEMBL3998587,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect cells at 10 uM using Luciferin-H as substrate in presence of NADPH by P450-Glo luminescence assay relative to control,Inhibition,=,25.8,%,COc1ccc(/C=C/C(=O)c2cc(OC)ccc2O)cc1,CHEMBL3997782,Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.,Eur J Med Chem,2017.0,126,,1129,1135,10.1016/j.ejmech.2016.12.017,28064141.0,
17981084,CHEMBL264704,"3-(2,6-dimethoxyphenyl)-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one",CHEMBL3998587,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect cells at 10 uM using Luciferin-H as substrate in presence of NADPH by P450-Glo luminescence assay relative to control,Inhibition,=,-25.6,%,COc1ccc(C(=O)/C=C/c2c(OC)cccc2OC)c(O)c1,CHEMBL3997782,Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.,Eur J Med Chem,2017.0,126,,1129,1135,10.1016/j.ejmech.2016.12.017,28064141.0,
17981085,CHEMBL4090067,"(2E)-3-(2,6-dimethoxyphenyl)-1-(2-hydroxy-5-methoxyphenyl)prop-2-en-1-one",CHEMBL3998587,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect cells at 10 uM using Luciferin-H as substrate in presence of NADPH by P450-Glo luminescence assay relative to control,Inhibition,=,36.9,%,COc1ccc(O)c(C(=O)/C=C/c2c(OC)cccc2OC)c1,CHEMBL3997782,Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.,Eur J Med Chem,2017.0,126,,1129,1135,10.1016/j.ejmech.2016.12.017,28064141.0,
17981086,CHEMBL262597,"3-(3,4-dimethoxyphenyl)-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one",CHEMBL3998587,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect cells at 10 uM using Luciferin-H as substrate in presence of NADPH by P450-Glo luminescence assay relative to control,Inhibition,=,10.7,%,COc1ccc(C(=O)/C=C/c2ccc(OC)c(OC)c2)c(O)c1,CHEMBL3997782,Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.,Eur J Med Chem,2017.0,126,,1129,1135,10.1016/j.ejmech.2016.12.017,28064141.0,
17981087,CHEMBL4063079,"(2E)-3-(3,4-dimethoxyphenyl)-1-(2-hydroxy-5-methoxyphenyl)prop-2-en-1-one",CHEMBL3998587,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect cells at 10 uM using Luciferin-H as substrate in presence of NADPH by P450-Glo luminescence assay relative to control,Inhibition,=,-26.9,%,COc1ccc(O)c(C(=O)/C=C/c2ccc(OC)c(OC)c2)c1,CHEMBL3997782,Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.,Eur J Med Chem,2017.0,126,,1129,1135,10.1016/j.ejmech.2016.12.017,28064141.0,
17981088,CHEMBL260867,"1-(2-hydroxy-4-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one",CHEMBL3998587,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect cells at 10 uM using Luciferin-H as substrate in presence of NADPH by P450-Glo luminescence assay relative to control,Inhibition,=,57.6,%,COc1ccc(C(=O)/C=C/c2cc(OC)c(OC)c(OC)c2)c(O)c1,CHEMBL3997782,Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.,Eur J Med Chem,2017.0,126,,1129,1135,10.1016/j.ejmech.2016.12.017,28064141.0,
17981089,CHEMBL4071694,"(2E)-1-(2-hydroxy-5-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one",CHEMBL3998587,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect cells at 10 uM using Luciferin-H as substrate in presence of NADPH by P450-Glo luminescence assay relative to control,Inhibition,=,60.9,%,COc1ccc(O)c(C(=O)/C=C/c2cc(OC)c(OC)c(OC)c2)c1,CHEMBL3997782,Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.,Eur J Med Chem,2017.0,126,,1129,1135,10.1016/j.ejmech.2016.12.017,28064141.0,
17981090,CHEMBL4098711,"(2E)-1-(2-hydroxy-4,5-dimethoxyphenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one",CHEMBL3998587,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in baculovirus-infected insect cells at 10 uM using Luciferin-H as substrate in presence of NADPH by P450-Glo luminescence assay relative to control,Inhibition,=,27.0,%,COc1cc(O)c(C(=O)/C=C/c2cc(OC)c(OC)c(OC)c2)cc1OC,CHEMBL3997782,Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.,Eur J Med Chem,2017.0,126,,1129,1135,10.1016/j.ejmech.2016.12.017,28064141.0,
17987222,CHEMBL4067045,"4-chloro-2-(((1S,2S)-2-(1-phenylpiperidine-4-carboxamido)cyclopentyl)methylamino)benzoic acid",CHEMBL3999543,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) in microsomes at 10 uM relative to control,Inhibition,=,46.0,%,O=C(O)c1ccc(Cl)cc1NC[C@@H]1CCC[C@@H]1NC(=O)C1CCN(c2ccccc2)CC1,CHEMBL3997816,Discovery and characterization of [(cyclopentyl)ethyl]benzoic acid inhibitors of microsomal prostaglandin E synthase-1.,Bioorg Med Chem Lett,2017.0,27,6,1478,1483,10.1016/j.bmcl.2016.11.011,28190634.0,
17987223,CHEMBL4094518,"4-chloro-2-(((1S,2S)-2-(1-(4-(trifluoromethyl)phenyl)piperidine-4-carboxamido)cyclopentyl)methylamino)benzoic acid",CHEMBL3999543,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) in microsomes at 10 uM relative to control,Inhibition,=,71.0,%,O=C(O)c1ccc(Cl)cc1NC[C@@H]1CCC[C@@H]1NC(=O)C1CCN(c2ccc(C(F)(F)F)cc2)CC1,CHEMBL3997816,Discovery and characterization of [(cyclopentyl)ethyl]benzoic acid inhibitors of microsomal prostaglandin E synthase-1.,Bioorg Med Chem Lett,2017.0,27,6,1478,1483,10.1016/j.bmcl.2016.11.011,28190634.0,
17987224,CHEMBL4078000,"4-chloro-2-(((1R,2S)-2-(1-(4-(trifluoromethyl)phenyl)piperidine-4-carboxamido)cyclopentyl)methoxy)benzoic acid",CHEMBL3999543,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) in microsomes at 10 uM relative to control,Inhibition,=,39.0,%,O=C(O)c1ccc(Cl)cc1OC[C@@H]1CCC[C@@H]1NC(=O)C1CCN(c2ccc(C(F)(F)F)cc2)CC1,CHEMBL3997816,Discovery and characterization of [(cyclopentyl)ethyl]benzoic acid inhibitors of microsomal prostaglandin E synthase-1.,Bioorg Med Chem Lett,2017.0,27,6,1478,1483,10.1016/j.bmcl.2016.11.011,28190634.0,
17987225,CHEMBL4102262,"4-chloro-2-(2-((1S,2S)-2-(1-(4-(trifluoromethyl)phenyl)piperidine-4-carboxamido)cyclopentyl)ethyl)benzoic acid",CHEMBL3999543,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) in microsomes at 10 uM relative to control,Inhibition,=,51.0,%,O=C(O)c1ccc(Cl)cc1CC[C@@H]1CCC[C@@H]1NC(=O)C1CCN(c2ccc(C(F)(F)F)cc2)CC1,CHEMBL3997816,Discovery and characterization of [(cyclopentyl)ethyl]benzoic acid inhibitors of microsomal prostaglandin E synthase-1.,Bioorg Med Chem Lett,2017.0,27,6,1478,1483,10.1016/j.bmcl.2016.11.011,28190634.0,
17987226,CHEMBL4085873,"4-methyl-2-(2-((1S,2S)-2-(1-(4-(trifluoromethyl)phenyl)piperidine-4-carboxamido)cyclopentyl)ethyl)benzoic acid",CHEMBL3999543,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) in microsomes at 10 uM relative to control,Inhibition,=,56.0,%,Cc1ccc(C(=O)O)c(CC[C@@H]2CCC[C@@H]2NC(=O)C2CCN(c3ccc(C(F)(F)F)cc3)CC2)c1,CHEMBL3997816,Discovery and characterization of [(cyclopentyl)ethyl]benzoic acid inhibitors of microsomal prostaglandin E synthase-1.,Bioorg Med Chem Lett,2017.0,27,6,1478,1483,10.1016/j.bmcl.2016.11.011,28190634.0,
17987227,CHEMBL4064335,"4-fluoro-2-(2-((1S,2S)-2-(1-(4-(trifluoromethyl)phenyl)piperidine-4-carboxamido)cyclopentyl)ethyl)benzoic acid",CHEMBL3999543,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) in microsomes at 10 uM relative to control,Inhibition,=,40.0,%,O=C(O)c1ccc(F)cc1CC[C@@H]1CCC[C@@H]1NC(=O)C1CCN(c2ccc(C(F)(F)F)cc2)CC1,CHEMBL3997816,Discovery and characterization of [(cyclopentyl)ethyl]benzoic acid inhibitors of microsomal prostaglandin E synthase-1.,Bioorg Med Chem Lett,2017.0,27,6,1478,1483,10.1016/j.bmcl.2016.11.011,28190634.0,
17987228,CHEMBL4071976,"2-(2-((1S,2S)-2-(1-(4-(trifluoromethyl)phenyl)piperidine-4-carboxamido)cyclopentyl)ethyl)benzoic acid",CHEMBL3999543,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) in microsomes at 10 uM relative to control,Inhibition,=,5.0,%,O=C(O)c1ccccc1CC[C@@H]1CCC[C@@H]1NC(=O)C1CCN(c2ccc(C(F)(F)F)cc2)CC1,CHEMBL3997816,Discovery and characterization of [(cyclopentyl)ethyl]benzoic acid inhibitors of microsomal prostaglandin E synthase-1.,Bioorg Med Chem Lett,2017.0,27,6,1478,1483,10.1016/j.bmcl.2016.11.011,28190634.0,
17987230,CHEMBL4063350,"2-(2-((1S,2S)-2-(1-(5-(trifluoromethyl)pyridin-2-yl)piperidine-4-carboxamido)cyclopentyl)ethyl)benzoic acid",CHEMBL3999543,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) in microsomes at 10 uM relative to control,Inhibition,=,22.0,%,O=C(O)c1ccccc1CC[C@@H]1CCC[C@@H]1NC(=O)C1CCN(c2ccc(C(F)(F)F)cn2)CC1,CHEMBL3997816,Discovery and characterization of [(cyclopentyl)ethyl]benzoic acid inhibitors of microsomal prostaglandin E synthase-1.,Bioorg Med Chem Lett,2017.0,27,6,1478,1483,10.1016/j.bmcl.2016.11.011,28190634.0,
17987231,CHEMBL4084995,"2-(2-((1S,2S)-2-(1-(4-(trifluoromethoxy)phenyl)piperidine-4-carboxamido)cyclopentyl)ethyl)benzoic acid",CHEMBL3999543,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) in microsomes at 10 uM relative to control,Inhibition,=,32.0,%,O=C(O)c1ccccc1CC[C@@H]1CCC[C@@H]1NC(=O)C1CCN(c2ccc(OC(F)(F)F)cc2)CC1,CHEMBL3997816,Discovery and characterization of [(cyclopentyl)ethyl]benzoic acid inhibitors of microsomal prostaglandin E synthase-1.,Bioorg Med Chem Lett,2017.0,27,6,1478,1483,10.1016/j.bmcl.2016.11.011,28190634.0,
17987232,CHEMBL4101413,"2-(2-((1S,2S)-2-(1-(8-methylquinolin-2-yl)piperidine-4-carboxamido)cyclopentyl)ethyl)benzoic acid",CHEMBL3999543,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) in microsomes at 10 uM relative to control,Inhibition,=,14.0,%,Cc1cccc2ccc(N3CCC(C(=O)N[C@H]4CCC[C@H]4CCc4ccccc4C(=O)O)CC3)nc12,CHEMBL3997816,Discovery and characterization of [(cyclopentyl)ethyl]benzoic acid inhibitors of microsomal prostaglandin E synthase-1.,Bioorg Med Chem Lett,2017.0,27,6,1478,1483,10.1016/j.bmcl.2016.11.011,28190634.0,
18009092,CHEMBL4064207,"4-Hydroxy-N-(4-methoxy-7-morpholino-1,3-benzothiazol-2-yl)-1,4-dimethyl-cyclohexanecarboxamide",CHEMBL4003850,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 5 to 25 uM using diclofenac as substrate preincubated for 5 mins with substrate followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,Inhibition,>,25.0,%,COc1ccc(N2CCOCC2)c2sc(NC(=O)C3(C)CCC(C)(O)CC3)nc12,CHEMBL4002602,"Design, Synthesis of Novel, Potent, Selective, Orally Bioavailable Adenosine A2A Receptor Antagonists and Their Biological Evaluation.",J Med Chem,2017.0,60,2,681,694,10.1021/acs.jmedchem.6b01584,28055204.0,
18009093,CHEMBL4095355,"4-(Diethylamino)-N-(4-methoxy-7-morpholino-1,3-benzothiazol-2-yl)-1-methyl-cyclohexanecarboxamide",CHEMBL4003850,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 5 to 25 uM using diclofenac as substrate preincubated for 5 mins with substrate followed by NADPH addition measured after 10 mins by LC-MS/MS analysis,Inhibition,>,50.0,%,CCN(CC)C1CCC(C)(C(=O)Nc2nc3c(OC)ccc(N4CCOCC4)c3s2)CC1,CHEMBL4002602,"Design, Synthesis of Novel, Potent, Selective, Orally Bioavailable Adenosine A2A Receptor Antagonists and Their Biological Evaluation.",J Med Chem,2017.0,60,2,681,694,10.1021/acs.jmedchem.6b01584,28055204.0,
18022470,CHEMBL1231562,3-Carboxy-4-methyl-5-propyl-2-furanpropanoic acid,CHEMBL4006167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 at 10 uM after 10 mins by single quad LC/MS analysis,Inhibition,=,0.0,%,CCCc1oc(CCC(=O)O)c(C(=O)O)c1C,CHEMBL4004837,Synthesis and Characterization of Urofuranoic Acids: In Vivo Metabolism of 2-(2-Carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic Acid (CMPF) and Effects on in Vitro Insulin Secretion.,J Med Chem,2017.0,60,5,1860,1875,10.1021/acs.jmedchem.6b01668,28171722.0,
18022471,CHEMBL4097863,2-(2-Carboxyethyl)-4-methyl-5-pentylfuran-3-carboxylic Acid,CHEMBL4006167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 at 10 uM after 10 mins by single quad LC/MS analysis,Inhibition,=,9.0,%,CCCCCc1oc(CCC(=O)O)c(C(=O)O)c1C,CHEMBL4004837,Synthesis and Characterization of Urofuranoic Acids: In Vivo Metabolism of 2-(2-Carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic Acid (CMPF) and Effects on in Vitro Insulin Secretion.,J Med Chem,2017.0,60,5,1860,1875,10.1021/acs.jmedchem.6b01668,28171722.0,
18022472,CHEMBL4062120,2-(2-Carboxyethyl)-4-methyl-5-propanoylfuran-3-carboxylic Acid,CHEMBL4006167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 at 10 uM after 10 mins by single quad LC/MS analysis,Inhibition,=,10.0,%,CCC(=O)c1oc(CCC(=O)O)c(C(=O)O)c1C,CHEMBL4004837,Synthesis and Characterization of Urofuranoic Acids: In Vivo Metabolism of 2-(2-Carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic Acid (CMPF) and Effects on in Vitro Insulin Secretion.,J Med Chem,2017.0,60,5,1860,1875,10.1021/acs.jmedchem.6b01668,28171722.0,
18022473,CHEMBL4077965,Methyl 2-(3-Methoxy-3-oxopropyl)-4-methyl-5-pentylfuran-3-carboxylate,CHEMBL4006167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 at 10 uM after 10 mins by single quad LC/MS analysis,Inhibition,=,27.0,%,CCCCCc1oc(CCC(=O)OC)c(C(=O)OC)c1C,CHEMBL4004837,Synthesis and Characterization of Urofuranoic Acids: In Vivo Metabolism of 2-(2-Carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic Acid (CMPF) and Effects on in Vitro Insulin Secretion.,J Med Chem,2017.0,60,5,1860,1875,10.1021/acs.jmedchem.6b01668,28171722.0,
18022474,CHEMBL4102226,"Methyl 2-(3-Methoxy-3-oxopropyl)-4,5-dimethylfuran-3-carboxylate",CHEMBL4006167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 at 10 uM after 10 mins by single quad LC/MS analysis,Inhibition,=,3.0,%,COC(=O)CCc1oc(C)c(C)c1C(=O)OC,CHEMBL4004837,Synthesis and Characterization of Urofuranoic Acids: In Vivo Metabolism of 2-(2-Carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic Acid (CMPF) and Effects on in Vitro Insulin Secretion.,J Med Chem,2017.0,60,5,1860,1875,10.1021/acs.jmedchem.6b01668,28171722.0,
18022475,CHEMBL4070555,"Methyl 2-(3-Methoxy-3-oxopropyl)-4,5,6,7-tetrahydrobenzofuran-3-carboxylate",CHEMBL4006167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 at 10 uM after 10 mins by single quad LC/MS analysis,Inhibition,=,2.0,%,COC(=O)CCc1oc2c(c1C(=O)OC)CCCC2,CHEMBL4004837,Synthesis and Characterization of Urofuranoic Acids: In Vivo Metabolism of 2-(2-Carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic Acid (CMPF) and Effects on in Vitro Insulin Secretion.,J Med Chem,2017.0,60,5,1860,1875,10.1021/acs.jmedchem.6b01668,28171722.0,
18022476,CHEMBL4091466,Methyl 2-(3-Hydroxypropyl)-4-methyl-5-propylfuran-3-carboxylate,CHEMBL4006167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 at 10 uM after 10 mins by single quad LC/MS analysis,Inhibition,=,0.0,%,CCCc1oc(CCCO)c(C(=O)OC)c1C,CHEMBL4004837,Synthesis and Characterization of Urofuranoic Acids: In Vivo Metabolism of 2-(2-Carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic Acid (CMPF) and Effects on in Vitro Insulin Secretion.,J Med Chem,2017.0,60,5,1860,1875,10.1021/acs.jmedchem.6b01668,28171722.0,
18022477,CHEMBL4083685,"2-(2-Carboxyethyl)-4,5-diethylfuran-3-carboxylic Acid",CHEMBL4006167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 at 10 uM after 10 mins by single quad LC/MS analysis,Inhibition,=,17.0,%,CCc1oc(CCC(=O)O)c(C(=O)O)c1CC,CHEMBL4004837,Synthesis and Characterization of Urofuranoic Acids: In Vivo Metabolism of 2-(2-Carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic Acid (CMPF) and Effects on in Vitro Insulin Secretion.,J Med Chem,2017.0,60,5,1860,1875,10.1021/acs.jmedchem.6b01668,28171722.0,
18022478,CHEMBL4100126,"2-(2-Carboxyethyl)-4,5-dipropylfuran-3-carboxylic Acid",CHEMBL4006167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 at 10 uM after 10 mins by single quad LC/MS analysis,Inhibition,=,0.0,%,CCCc1oc(CCC(=O)O)c(C(=O)O)c1CCC,CHEMBL4004837,Synthesis and Characterization of Urofuranoic Acids: In Vivo Metabolism of 2-(2-Carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic Acid (CMPF) and Effects on in Vitro Insulin Secretion.,J Med Chem,2017.0,60,5,1860,1875,10.1021/acs.jmedchem.6b01668,28171722.0,
18022479,CHEMBL4073282,2-(3-Hydroxypropyl)-4-methyl-5-propylfuran-3-carboxylic Acid,CHEMBL4006167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 at 10 uM after 10 mins by single quad LC/MS analysis,Inhibition,=,3.0,%,CCCc1oc(CCCO)c(C(=O)O)c1C,CHEMBL4004837,Synthesis and Characterization of Urofuranoic Acids: In Vivo Metabolism of 2-(2-Carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic Acid (CMPF) and Effects on in Vitro Insulin Secretion.,J Med Chem,2017.0,60,5,1860,1875,10.1021/acs.jmedchem.6b01668,28171722.0,
18022480,CHEMBL4064689,"4-Methyl-2,5-dipropylfuran-3-carboxylic Acid",CHEMBL4006167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 at 10 uM after 10 mins by single quad LC/MS analysis,Inhibition,=,18.0,%,CCCc1oc(CCC)c(C(=O)O)c1C,CHEMBL4004837,Synthesis and Characterization of Urofuranoic Acids: In Vivo Metabolism of 2-(2-Carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic Acid (CMPF) and Effects on in Vitro Insulin Secretion.,J Med Chem,2017.0,60,5,1860,1875,10.1021/acs.jmedchem.6b01668,28171722.0,
18022481,CHEMBL4103093,4-(3-Acetyl-4-methyl-5-propyl-2-furyl)butan-2-one,CHEMBL4006167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 at 10 uM after 10 mins by single quad LC/MS analysis,Inhibition,=,0.0,%,CCCc1oc(CCC(C)=O)c(C(C)=O)c1C,CHEMBL4004837,Synthesis and Characterization of Urofuranoic Acids: In Vivo Metabolism of 2-(2-Carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic Acid (CMPF) and Effects on in Vitro Insulin Secretion.,J Med Chem,2017.0,60,5,1860,1875,10.1021/acs.jmedchem.6b01668,28171722.0,
18022482,CHEMBL4062828,3-(4-Methyl-5-propyl-2-furyl)propanoic Acid,CHEMBL4006167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 at 10 uM after 10 mins by single quad LC/MS analysis,Inhibition,=,9.0,%,CCCc1oc(CCC(=O)O)cc1C,CHEMBL4004837,Synthesis and Characterization of Urofuranoic Acids: In Vivo Metabolism of 2-(2-Carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic Acid (CMPF) and Effects on in Vitro Insulin Secretion.,J Med Chem,2017.0,60,5,1860,1875,10.1021/acs.jmedchem.6b01668,28171722.0,
18022483,CHEMBL4092893,"3,4-Dimethyl-5-propylfuran-2-carboxylate",CHEMBL4006167,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 at 10 uM after 10 mins by single quad LC/MS analysis,Inhibition,=,0.0,%,CCCc1oc(C(=O)O)c(C)c1C,CHEMBL4004837,Synthesis and Characterization of Urofuranoic Acids: In Vivo Metabolism of 2-(2-Carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic Acid (CMPF) and Effects on in Vitro Insulin Secretion.,J Med Chem,2017.0,60,5,1860,1875,10.1021/acs.jmedchem.6b01668,28171722.0,
18048940,CHEMBL4073198,"2-(4-isopropyl-4H-1,2,4-triazol-3-yl)-N-(1-(2-methoxyethyl)-1H-pyrazol-4-yl)thiazole-4-carboxamide",CHEMBL4011133,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,36.0,%,COCCn1cc(NC(=O)c2csc(-c3nncn3C(C)C)n2)cn1,CHEMBL4007491,Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy.,Bioorg Med Chem Lett,2017.0,27,8,1709,1713,10.1016/j.bmcl.2017.02.079,28291695.0,
18057192,CHEMBL4082403,"rac-2,2,2-Trifluoro-1-{4-[(4-fluorophenyl)amino]pyrimidin-5-yl}-1-[1-(methylsulfonyl)piperidin-4-yl]ethanol",CHEMBL4012488,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,3.4,%,CS(=O)(=O)N1CCC(C(O)(c2cncnc2Nc2ccc(F)cc2)C(F)(F)F)CC1,CHEMBL4011612,"4-Anilino-pyrimidine, novel aldosterone synthase (CYP11B2) inhibitors bearing pyrimidine structures.",Bioorg Med Chem Lett,2017.0,27,9,1902,1906,10.1016/j.bmcl.2017.03.034,28359792.0,
18063762,CHEMBL4072722,"(+)-1-[(1S,2S)-2-(5-Fluoro-2-methoxyphenyl)cyclopropyl]-N-(2-methoxybenzyl)methanamine Hydrochloride",CHEMBL4013780,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsomes CYP2C9 using tolbutamide as substrate at 10 uM,Inhibition,=,9.3,%,COc1ccccc1CNC[C@H]1C[C@@H]1c1cc(F)ccc1OC.Cl,CHEMBL4011649,Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.,J Med Chem,2017.0,60,14,6273,6288,10.1021/acs.jmedchem.7b00584,28657744.0,
18068734,CHEMBL1429848,SID4262088,CHEMBL4014733,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay relative to control,Inhibition,=,2.0,%,Oc1nc(-c2cccnc2)nc2ccccc12,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068735,CHEMBL1164165,2-(4-Chlorophenyl)quinazolin-4(3H)-one,CHEMBL4014733,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay relative to control,Inhibition,=,0.0,%,O=c1[nH]c(-c2ccc([N+](=O)[O-])cc2)nc2ccccc12,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068736,CHEMBL2058057,2-(4-bromophenyl)quinazolin-4(3H)-one,CHEMBL4014733,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay relative to control,Inhibition,=,0.0,%,O=c1[nH]c(-c2ccc(Br)cc2)nc2ccccc12,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068737,CHEMBL3289108,2-(4'-Hydroxyphenyl)quinazolin-4(3H)-one,CHEMBL4014733,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay relative to control,Inhibition,=,0.0,%,O=c1[nH]c(-c2ccc(O)cc2)nc2ccccc12,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068738,CHEMBL3289110,2-(3'-Hydroxyphenyl)quinazolin-4(3H)-one,CHEMBL4014733,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay relative to control,Inhibition,=,0.0,%,O=c1[nH]c(-c2cccc(O)c2)nc2ccccc12,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068739,CHEMBL3289112,2-[3'-Hydroxy-4'-(methyloxy)phenyl]quinazolin-4(3H)-one,CHEMBL4014733,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay relative to control,Inhibition,=,3.0,%,COc1ccc(-c2nc3ccccc3c(=O)[nH]2)cc1O,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068740,CHEMBL4081914,(2-(4-hydroxy-3-methoxyphenyl)quinazolin-4(3H)-one),CHEMBL4014733,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay relative to control,Inhibition,=,0.0,%,COc1cc(-c2nc3ccccc3c(=O)[nH]2)ccc1O,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068741,CHEMBL4074105,2-(4-(prop-2-ynyloxy)phenyl)quinazolin-4(3H)-one,CHEMBL4014733,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay relative to control,Inhibition,=,0.0,%,C#CCOc1ccc(-c2nc3ccccc3c(=O)[nH]2)cc1,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068742,CHEMBL4100866,"2-(4-(2,4-dichlorophenoxy)phenyl)quinazolin-4(3H)-one",CHEMBL4014733,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay relative to control,Inhibition,=,5.0,%,O=c1[nH]c(-c2ccc(Oc3ccc(Cl)cc3Cl)cc2)nc2ccccc12,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068743,CHEMBL4084413,"2-(4-(2,4-difluorobenzyloxy)phenyl)quinazolin-4(3H)-one",CHEMBL4014733,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay relative to control,Inhibition,=,8.0,%,O=c1[nH]c(-c2ccc(OCc3ccc(F)cc3F)cc2)nc2ccccc12,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068744,CHEMBL4062727,"(4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenyl benzenesulfonate)",CHEMBL4014733,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay relative to control,Inhibition,=,2.0,%,O=c1[nH]c(-c2ccc(OS(=O)(=O)c3ccccc3)cc2)nc2ccccc12,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068745,CHEMBL4103323,2-(4-(4-fluorobenzyloxy)-3-methoxyphenyl)quinazolin-4(3H)-one,CHEMBL4014733,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay relative to control,Inhibition,=,1.5,%,COc1cc(-c2nc3ccccc3c(=O)[nH]2)ccc1OCc1ccc(F)cc1,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068746,CHEMBL4085392,"2-(4-(2,4-dichlorobenzyloxy)-3-methoxyphenyl)quinazolin-4(3H)-one",CHEMBL4014733,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay relative to control,Inhibition,=,3.0,%,COc1cc(-c2nc3ccccc3c(=O)[nH]2)ccc1OCc1ccc(Cl)cc1Cl,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068747,CHEMBL4074003,2-(4-(benzyloxy)-3-methoxyphenyl)quinazolin-4(3H)-one,CHEMBL4014733,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay relative to control,Inhibition,=,0.0,%,COc1cc(-c2nc3ccccc3c(=O)[nH]2)ccc1OCc1ccccc1,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068748,CHEMBL4100017,"2-(4-(2,4-difluorobenzyloxy)-3-methoxyphenyl)quinazolin-4(3H)-one",CHEMBL4014733,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay relative to control,Inhibition,=,0.0,%,COc1cc(-c2nc3ccccc3c(=O)[nH]2)ccc1OCc1ccc(F)cc1F,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068749,CHEMBL4061054,"2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenylmethanesulfonate",CHEMBL4014733,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay relative to control,Inhibition,=,0.0,%,COc1cc(-c2nc3ccccc3c(=O)[nH]2)ccc1OS(C)(=O)=O,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068750,CHEMBL4082934,2-(4-methoxy-3-(prop-2-ynyloxy)phenyl)quinazolin-4(3H)-one,CHEMBL4014733,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay relative to control,Inhibition,=,0.0,%,C#CCOc1cc(-c2nc3ccccc3c(=O)[nH]2)ccc1OC,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068751,CHEMBL4088288,2-(3-(4-fluorobenzyloxy)-4-methoxyphenyl)quinazolin-4(3H)-one,CHEMBL4014733,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay relative to control,Inhibition,=,0.0,%,COc1ccc(-c2nc3ccccc3c(=O)[nH]2)cc1Oc1ccc(F)cc1,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068752,CHEMBL4060053,"2-(3-(2,4-dichlorobenzyloxy)-4-methoxyphenyl)quinazolin-4(3H)-one",CHEMBL4014733,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay relative to control,Inhibition,=,0.0,%,COc1ccc(-c2nc3ccccc3c(=O)[nH]2)cc1Oc1ccc(Cl)cc1Cl,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18068753,CHEMBL4080435,"2-(3-(2,4-difluorobenzyloxy)-4-methoxyphenyl)quinazolin-4(3H)-one",CHEMBL4014733,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 expressed in yeast microsomal membranes at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorescence assay relative to control,Inhibition,=,0.0,%,COc1ccc(-c2nc3ccccc3c(=O)[nH]2)cc1OCc1ccc(F)cc1F,CHEMBL4014284,Quinazoline derivatives as selective CYP1B1 inhibitors.,Eur J Med Chem,2017.0,130,,320,327,10.1016/j.ejmech.2017.02.032,28259840.0,
18073869,CHEMBL4081711,"1-(((2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide",CHEMBL4015971,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 3 uM,Inhibition,<,5.0,%,CC[C@H]1[C@@H](COc2nccc3cc(C(N)=O)c(OC)cc23)NC(=O)[C@H]1F,CHEMBL4014327,"Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.",J Med Chem,2017.0,60,13,5521,5542,10.1021/acs.jmedchem.7b00231,28498658.0,
18073876,CHEMBL4092338,(S)-7-Isopropoxy-1-((5-oxopyrrolidin-2-yl)methoxy)isoquinoline-6-carboxamide,CHEMBL4015971,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 3 uM,Inhibition,=,13.6,%,CC(C)Oc1cc2c(OC[C@@H]3CCC(=O)N3)nccc2cc1C(N)=O,CHEMBL4014327,"Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.",J Med Chem,2017.0,60,13,5521,5542,10.1021/acs.jmedchem.7b00231,28498658.0,
18078702,CHEMBL4097298,5-((5-Methoxypyridin-3-yl)methyl)-3-phenylisoxazole,CHEMBL4016919,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculovirus infected insect cell microsomes at 1 uM relative to control,Inhibition,=,17.0,%,COc1cncc(Cc2cc(-c3ccccc3)no2)c1,CHEMBL4014346,Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing's Disease.,J Med Chem,2017.0,60,12,5086,5098,10.1021/acs.jmedchem.7b00437,28570067.0,
18078703,CHEMBL4079276,5-((5-Methylpyridin-3-yl)methyl)-3-phenylisoxazole,CHEMBL4016919,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baculovirus infected insect cell microsomes at 1 uM relative to control,Inhibition,=,28.0,%,Cc1cncc(Cc2cc(-c3ccccc3)no2)c1,CHEMBL4014346,Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing's Disease.,J Med Chem,2017.0,60,12,5086,5098,10.1021/acs.jmedchem.7b00437,28570067.0,
18079007,CHEMBL4090593,"4,6-dichloro-N-cycloheptyl-1H-indole-2-carboxamide",CHEMBL4017011,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes preincubated for 5 mins followed by NADPH addition at 10 uM measured after 10 mins by LC-MS/MS analysis relative to control,Inhibition,=,6.0,%,O=C(NC1CCCCCC1)c1cc2c(Cl)cc(Cl)cc2[nH]1,CHEMBL4014347,Targeting Mycolic Acid Transport by Indole-2-carboxamides for the Treatment of Mycobacterium abscessus Infections.,J Med Chem,2017.0,60,13,5876,5888,10.1021/acs.jmedchem.7b00582,28574259.0,
18079362,CHEMBL2381192,"4-(azetidin-1-yl)-1-methyl-3-(1-methyl-5-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidine",CHEMBL4017071,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,=,7.0,%,Cn1ncc(-c2nn(C)c3ncnc(N4CCC4)c23)c1-c1ccc(C(F)(F)F)cc1,CHEMBL4014349,"Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.",J Med Chem,2017.0,60,13,5673,5698,10.1021/acs.jmedchem.7b00397,28574706.0,
18083298,CHEMBL2087474,"5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine",CHEMBL4018040,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,30.0,%,CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1,CHEMBL4017467,"Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy.",Bioorg Med Chem Lett,2017.0,27,11,2536,2543,10.1016/j.bmcl.2017.03.090,28404374.0,
18083301,CHEMBL4083480,"N-{2-[3-(2-Amino-pyrimidin-5-yl)-1-morpholin-4-yl-5,8-dihydro-6H-2,4a,7,9-tetraaza-fluoren-7-yl]-ethyl}-methanesulfonamide",CHEMBL4018040,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,30.0,%,CS(=O)(=O)NCCN1CCc2c(nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn23)C1,CHEMBL4017467,"Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy.",Bioorg Med Chem Lett,2017.0,27,11,2536,2543,10.1016/j.bmcl.2017.03.090,28404374.0,
18083302,CHEMBL4088855,"5-[7-(4-Fluoro-phenyl)-1-morpholin-4-yl-5,6,7,8-tetrahydro-2,4a,7,9-tetraaza-fluoren-3-yl]-pyrimidin-2-ylamine",CHEMBL4018040,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,30.0,%,Nc1ncc(-c2cn3c4c(nc3c(N3CCOCC3)n2)CN(c2ccc(F)cc2)CC4)cn1,CHEMBL4017467,"Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy.",Bioorg Med Chem Lett,2017.0,27,11,2536,2543,10.1016/j.bmcl.2017.03.090,28404374.0,
18096228,CHEMBL4070051,"2-Fluoro-4-(1-(1-(3-(1-methyl-1H-pyrazol-4-yl)quinolin-6-yl)ethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)benzamide",CHEMBL4021208,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins by in presence of NADPH LC-MS/MS analysis,Inhibition,<,50.0,%,CC(c1ccc2ncc(-c3cnn(C)c3)cc2c1)n1nnc2ncc(-c3ccc(C(N)=O)c(F)c3)nc21,CHEMBL4020721,"Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.",Eur J Med Chem,2017.0,134,,147,158,10.1016/j.ejmech.2017.03.085,28411455.0,
18096229,CHEMBL4083235,"7-Fluoro-3-(1-methyl-1H-pyrazol-4-yl)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline",CHEMBL4021208,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins by in presence of NADPH LC-MS/MS analysis,Inhibition,<,50.0,%,CC(c1cc2cc(-c3cnn(C)c3)cnc2cc1F)n1nnc2ncc(-c3cnn(C)c3)nc21,CHEMBL4020721,"Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.",Eur J Med Chem,2017.0,134,,147,158,10.1016/j.ejmech.2017.03.085,28411455.0,
18096230,CHEMBL4074262,"2-(4-(1-(1-(7-Fluoro-3-(1-methyl-1H-pyrazol-4-yl)quinolin-6-yl)ethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethan-1-ol",CHEMBL4021208,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins by in presence of NADPH LC-MS/MS analysis,Inhibition,<,50.0,%,CC(c1cc2cc(-c3cnn(C)c3)cnc2cc1F)n1nnc2ncc(-c3cnn(CCO)c3)nc21,CHEMBL4020721,"Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.",Eur J Med Chem,2017.0,134,,147,158,10.1016/j.ejmech.2017.03.085,28411455.0,
18096231,CHEMBL4060354,"2-Fluoro-4-(1-(1-(7-fluoro-3-(1-methyl-1H-pyrazol-4-yl)quinolin-6-yl)ethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)benzamide",CHEMBL4021208,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins by in presence of NADPH LC-MS/MS analysis,Inhibition,<,50.0,%,CC(c1cc2cc(-c3cnn(C)c3)cnc2cc1F)n1nnc2ncc(-c3ccc(C(N)=O)c(F)c3)nc21,CHEMBL4020721,"Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.",Eur J Med Chem,2017.0,134,,147,158,10.1016/j.ejmech.2017.03.085,28411455.0,
18096232,CHEMBL4092293,"2-Fluoro-4-(1-(1-(7-fluoro-3-(1-methyl-1H-pyrazol-4-yl)quinolin-6-yl)ethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-N-methylbenzamide",CHEMBL4021208,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins by in presence of NADPH LC-MS/MS analysis,Inhibition,<,50.0,%,CNC(=O)c1ccc(-c2cnc3nnn(C(C)c4cc5cc(-c6cnn(C)c6)cnc5cc4F)c3n2)cc1F,CHEMBL4020721,"Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.",Eur J Med Chem,2017.0,134,,147,158,10.1016/j.ejmech.2017.03.085,28411455.0,
18096236,CHEMBL4104884,"4-(1-(1-(5,7-Difluoro-3-(1-methyl-1H-pyrazol-4-yl)quinolin-6-yl)ethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-2-fluorobenzamide",CHEMBL4021208,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins by in presence of NADPH LC-MS/MS analysis,Inhibition,<,50.0,%,CC(c1c(F)cc2ncc(-c3cnn(C)c3)cc2c1F)n1nnc2ncc(-c3ccc(C(N)=O)c(F)c3)nc21,CHEMBL4020721,"Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.",Eur J Med Chem,2017.0,134,,147,158,10.1016/j.ejmech.2017.03.085,28411455.0,
18096274,CHEMBL4064183,"2-(4-(1-(1-(3-(1-Methyl-1H-pyrazol-4-yl)quinolin-6-yl)ethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethan-1-ol",CHEMBL4021198,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent irreversible inhibition of CYP2C9 in human liver microsomes at 10 uM preincubated with compound followed by NADPH addition by LC-MS/MS analysis,Inhibition,<,50.0,%,CC(c1ccc2ncc(-c3cnn(C)c3)cc2c1)n1nnc2ncc(-c3cnn(CCO)c3)nc21,CHEMBL4020721,"Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.",Eur J Med Chem,2017.0,134,,147,158,10.1016/j.ejmech.2017.03.085,28411455.0,
18096276,CHEMBL4091023,"2-Fluoro-N-methyl-4-(1-(1-(3-(1-methyl-1H-pyrazol-4-yl)quinolin-6-yl)ethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)benzamide",CHEMBL4021198,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent irreversible inhibition of CYP2C9 in human liver microsomes at 10 uM preincubated with compound followed by NADPH addition by LC-MS/MS analysis,Inhibition,<,50.0,%,CNC(=O)c1ccc(-c2cnc3nnn(C(C)c4ccc5ncc(-c6cnn(C)c6)cc5c4)c3n2)cc1F,CHEMBL4020721,"Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.",Eur J Med Chem,2017.0,134,,147,158,10.1016/j.ejmech.2017.03.085,28411455.0,
18096277,CHEMBL4061378,"3-(1-Methyl-1H-pyrazol-4-yl)-6-(1-(6-(pyridin-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline",CHEMBL4021198,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent irreversible inhibition of CYP2C9 in human liver microsomes at 10 uM preincubated with compound followed by NADPH addition by LC-MS/MS analysis,Inhibition,<,50.0,%,CC(c1ccc2ncc(-c3cnn(C)c3)cc2c1)n1nnc2ncc(-c3ccncc3)nc21,CHEMBL4020721,"Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.",Eur J Med Chem,2017.0,134,,147,158,10.1016/j.ejmech.2017.03.085,28411455.0,
18096278,CHEMBL4074262,"2-(4-(1-(1-(7-Fluoro-3-(1-methyl-1H-pyrazol-4-yl)quinolin-6-yl)ethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethan-1-ol",CHEMBL4021198,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent irreversible inhibition of CYP2C9 in human liver microsomes at 10 uM preincubated with compound followed by NADPH addition by LC-MS/MS analysis,Inhibition,<,50.0,%,CC(c1cc2cc(-c3cnn(C)c3)cnc2cc1F)n1nnc2ncc(-c3cnn(CCO)c3)nc21,CHEMBL4020721,"Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.",Eur J Med Chem,2017.0,134,,147,158,10.1016/j.ejmech.2017.03.085,28411455.0,
18096279,CHEMBL4060354,"2-Fluoro-4-(1-(1-(7-fluoro-3-(1-methyl-1H-pyrazol-4-yl)quinolin-6-yl)ethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)benzamide",CHEMBL4021198,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent irreversible inhibition of CYP2C9 in human liver microsomes at 10 uM preincubated with compound followed by NADPH addition by LC-MS/MS analysis,Inhibition,<,50.0,%,CC(c1cc2cc(-c3cnn(C)c3)cnc2cc1F)n1nnc2ncc(-c3ccc(C(N)=O)c(F)c3)nc21,CHEMBL4020721,"Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.",Eur J Med Chem,2017.0,134,,147,158,10.1016/j.ejmech.2017.03.085,28411455.0,
18096280,CHEMBL4092293,"2-Fluoro-4-(1-(1-(7-fluoro-3-(1-methyl-1H-pyrazol-4-yl)quinolin-6-yl)ethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-N-methylbenzamide",CHEMBL4021198,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent irreversible inhibition of CYP2C9 in human liver microsomes at 10 uM preincubated with compound followed by NADPH addition by LC-MS/MS analysis,Inhibition,<,50.0,%,CNC(=O)c1ccc(-c2cnc3nnn(C(C)c4cc5cc(-c6cnn(C)c6)cnc5cc4F)c3n2)cc1F,CHEMBL4020721,"Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.",Eur J Med Chem,2017.0,134,,147,158,10.1016/j.ejmech.2017.03.085,28411455.0,
18096281,CHEMBL4068290,"7-Fluoro-3-(1-methyl-1H-pyrazol-4-yl)-6-(1-(6-(pyridin-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline",CHEMBL4021198,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent irreversible inhibition of CYP2C9 in human liver microsomes at 10 uM preincubated with compound followed by NADPH addition by LC-MS/MS analysis,Inhibition,<,50.0,%,CC(c1cc2cc(-c3cnn(C)c3)cnc2cc1F)n1nnc2ncc(-c3ccncc3)nc21,CHEMBL4020721,"Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.",Eur J Med Chem,2017.0,134,,147,158,10.1016/j.ejmech.2017.03.085,28411455.0,
18096282,CHEMBL4070258,"2-(4-(1-(1-(5,7-Difluoro-3-(1-methyl-1H-pyrazol-4-yl)quinolin-6-yl)ethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethan-1-ol",CHEMBL4021198,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent irreversible inhibition of CYP2C9 in human liver microsomes at 10 uM preincubated with compound followed by NADPH addition by LC-MS/MS analysis,Inhibition,<,50.0,%,CC(c1c(F)cc2ncc(-c3cnn(C)c3)cc2c1F)n1nnc2ncc(-c3cnn(CCO)c3)nc21,CHEMBL4020721,"Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.",Eur J Med Chem,2017.0,134,,147,158,10.1016/j.ejmech.2017.03.085,28411455.0,
18096363,CHEMBL4075149,"4-(1-(1-(5,7-Difluoro-3-(1-methyl-1H-pyrazol-4-yl)quinolin-6-yl)ethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-2-fluoro-Nmethylbenzamide",CHEMBL4021198,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent irreversible inhibition of CYP2C9 in human liver microsomes at 10 uM preincubated with compound followed by NADPH addition by LC-MS/MS analysis,Inhibition,<,50.0,%,CNC(=O)c1ccc(-c2cnc3nnn(C(C)c4c(F)cc5ncc(-c6cnn(C)c6)cc5c4F)c3n2)cc1F,CHEMBL4020721,"Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.",Eur J Med Chem,2017.0,134,,147,158,10.1016/j.ejmech.2017.03.085,28411455.0,
18096364,CHEMBL4076438,"5,7-Difluoro-3-(1-methyl-1H-pyrazol-4-yl)-6-(1-(6-(pyridin-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline",CHEMBL4021198,A,,Homo sapiens,Cytochrome P450 2C9,Time dependent irreversible inhibition of CYP2C9 in human liver microsomes at 10 uM preincubated with compound followed by NADPH addition by LC-MS/MS analysis,Inhibition,<,50.0,%,CC(c1c(F)cc2ncc(-c3cnn(C)c3)cc2c1F)n1nnc2ncc(-c3ccncc3)nc21,CHEMBL4020721,"Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.",Eur J Med Chem,2017.0,134,,147,158,10.1016/j.ejmech.2017.03.085,28411455.0,
18100458,CHEMBL4097866,3-Chloro-4-fluoro-N-(5-(1-hydroxycyclobutyl)thiazol-2-yl)benzamide,CHEMBL4021962,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,<,50.0,%,O=C(Nc1ncc(C2(O)CCC2)s1)c1ccc(F)c(Cl)c1,CHEMBL4020760,Discovery of a Small Molecule Probe That Post-Translationally Stabilizes the Survival Motor Neuron Protein for the Treatment of Spinal Muscular Atrophy.,J Med Chem,2017.0,60,11,4594,4610,10.1021/acs.jmedchem.6b01885,28481536.0,
18106251,CHEMBL4063104,"N-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3R)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide",CHEMBL4022813,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM relative to control,Inhibition,<,10.0,%,O=c1[nH]ccc2cc(F)c(NS(=O)(=O)c3ccc(N4CC[C@@H](O)C4)s3)cc12,CHEMBL4020815,"Discovery of N-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3R)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (LSN 3213128), a Potent and Selective Nonclassical Antifolate Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase (AICARFT) Inhibitor Effective at Tumor Suppression in a Cancer Xenograft Model.",J Med Chem,2017.0,60,23,9599,9616,10.1021/acs.jmedchem.7b01046,29072452.0,
18108127,CHEMBL4081453,"(1S,2S,4S,5R,6S)-2-Amino-4-[(3-methoxybenzoyl)amino]-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid",CHEMBL4023259,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,3.5,%,COc1cccc(C(=O)N[C@H]2C[C@@](N)(C(=O)O)[C@@H]3[C@@H](C(=O)O)[C@H]23)c1,CHEMBL4020826,"Synthesis and Pharmacological Characterization of C4β-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1 S,2 S,4 S,5 R,6 S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu3 Receptor Agonist.",J Med Chem,2018.0,61,6,2303,2328,10.1021/acs.jmedchem.7b01481,29350927.0,
18115426,CHEMBL4101612,"6-Fluoro-2-(pyridin-3-ylmethyl)-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]pyridine",CHEMBL4025657,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human hepatic CYP2C9 at 1 uM relative to control,Inhibition,=,6.6,%,Fc1ccc2sc3c(c2c1)CCN(Cc1cccnc1)C3,CHEMBL4024710,"Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.",Eur J Med Chem,2017.0,132,,157,172,10.1016/j.ejmech.2017.03.037,28350999.0,
18115427,CHEMBL4064141,"2-(Pyridin-3-ylmethyl)-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]pyridin-6-ol",CHEMBL4025657,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human hepatic CYP2C9 at 1 uM relative to control,Inhibition,=,0.0,%,Oc1ccc2sc3c(c2c1)CCN(Cc1cccnc1)C3,CHEMBL4024710,"Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.",Eur J Med Chem,2017.0,132,,157,172,10.1016/j.ejmech.2017.03.037,28350999.0,
18115428,CHEMBL4059780,"6-Fluoro-2-((4-methylpyridin-3-yl)methyl)-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]pyridine",CHEMBL4025657,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human hepatic CYP2C9 at 1 uM relative to control,Inhibition,=,0.0,%,Cc1ccncc1CN1CCc2c(sc3ccc(F)cc23)C1,CHEMBL4024710,"Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.",Eur J Med Chem,2017.0,132,,157,172,10.1016/j.ejmech.2017.03.037,28350999.0,
18115429,CHEMBL4091726,"6-Fluoro-2-((5-fluoropyridin-3-yl)methyl)-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]pyridine",CHEMBL4025657,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human hepatic CYP2C9 at 1 uM relative to control,Inhibition,=,0.0,%,Fc1cncc(CN2CCc3c(sc4ccc(F)cc34)C2)c1,CHEMBL4024710,"Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.",Eur J Med Chem,2017.0,132,,157,172,10.1016/j.ejmech.2017.03.037,28350999.0,
18115430,CHEMBL4063960,"6-Fluoro-2-[(5-methoxypyridin-3-yl)methyl]-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]-pyridine",CHEMBL4025657,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human hepatic CYP2C9 at 1 uM relative to control,Inhibition,=,0.0,%,COc1cncc(CN2CCc3c(sc4ccc(F)cc34)C2)c1,CHEMBL4024710,"Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.",Eur J Med Chem,2017.0,132,,157,172,10.1016/j.ejmech.2017.03.037,28350999.0,
18115431,CHEMBL4068802,"2-[(1H-Imidazol-4-yl)methyl]-6-fluoro-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]-pyridine",CHEMBL4025657,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human hepatic CYP2C9 at 1 uM relative to control,Inhibition,=,98.5,%,Fc1ccc2sc3c(c2c1)CCN(Cc1c[nH]cn1)C3,CHEMBL4024710,"Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.",Eur J Med Chem,2017.0,132,,157,172,10.1016/j.ejmech.2017.03.037,28350999.0,
18115432,CHEMBL254328,"10,13-Dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol",CHEMBL4025657,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human hepatic CYP2C9 at 1 uM relative to control,Inhibition,=,31.6,%,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,CHEMBL4024710,"Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.",Eur J Med Chem,2017.0,132,,157,172,10.1016/j.ejmech.2017.03.037,28350999.0,
18115433,CHEMBL4101612,"6-Fluoro-2-(pyridin-3-ylmethyl)-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]pyridine",CHEMBL4025658,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human hepatic CYP2C9 at 10 uM relative to control,Inhibition,=,53.2,%,Fc1ccc2sc3c(c2c1)CCN(Cc1cccnc1)C3,CHEMBL4024710,"Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.",Eur J Med Chem,2017.0,132,,157,172,10.1016/j.ejmech.2017.03.037,28350999.0,
18115434,CHEMBL4064141,"2-(Pyridin-3-ylmethyl)-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]pyridin-6-ol",CHEMBL4025658,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human hepatic CYP2C9 at 10 uM relative to control,Inhibition,=,17.5,%,Oc1ccc2sc3c(c2c1)CCN(Cc1cccnc1)C3,CHEMBL4024710,"Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.",Eur J Med Chem,2017.0,132,,157,172,10.1016/j.ejmech.2017.03.037,28350999.0,
18115435,CHEMBL4059780,"6-Fluoro-2-((4-methylpyridin-3-yl)methyl)-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]pyridine",CHEMBL4025658,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human hepatic CYP2C9 at 10 uM relative to control,Inhibition,=,21.8,%,Cc1ccncc1CN1CCc2c(sc3ccc(F)cc23)C1,CHEMBL4024710,"Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.",Eur J Med Chem,2017.0,132,,157,172,10.1016/j.ejmech.2017.03.037,28350999.0,
18115436,CHEMBL4091726,"6-Fluoro-2-((5-fluoropyridin-3-yl)methyl)-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]pyridine",CHEMBL4025658,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human hepatic CYP2C9 at 10 uM relative to control,Inhibition,=,51.6,%,Fc1cncc(CN2CCc3c(sc4ccc(F)cc34)C2)c1,CHEMBL4024710,"Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.",Eur J Med Chem,2017.0,132,,157,172,10.1016/j.ejmech.2017.03.037,28350999.0,
18115437,CHEMBL4063960,"6-Fluoro-2-[(5-methoxypyridin-3-yl)methyl]-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]-pyridine",CHEMBL4025658,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human hepatic CYP2C9 at 10 uM relative to control,Inhibition,=,53.8,%,COc1cncc(CN2CCc3c(sc4ccc(F)cc34)C2)c1,CHEMBL4024710,"Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.",Eur J Med Chem,2017.0,132,,157,172,10.1016/j.ejmech.2017.03.037,28350999.0,
18115438,CHEMBL4068802,"2-[(1H-Imidazol-4-yl)methyl]-6-fluoro-1,2,3,4-tetrahydrobenzo[4,5]thieno[2,3-c]-pyridine",CHEMBL4025658,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human hepatic CYP2C9 at 10 uM relative to control,Inhibition,=,100.5,%,Fc1ccc2sc3c(c2c1)CCN(Cc1c[nH]cn1)C3,CHEMBL4024710,"Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.",Eur J Med Chem,2017.0,132,,157,172,10.1016/j.ejmech.2017.03.037,28350999.0,
18115439,CHEMBL254328,"10,13-Dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol",CHEMBL4025658,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human hepatic CYP2C9 at 10 uM relative to control,Inhibition,=,82.5,%,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,CHEMBL4024710,"Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.",Eur J Med Chem,2017.0,132,,157,172,10.1016/j.ejmech.2017.03.037,28350999.0,
18120558,CHEMBL4064555,"5-[(4S,5S)-5-(4-Fluorophenyl)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]benzene-1,3-dicarbonitrile",CHEMBL4026586,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,28.5,%,C[C@H]1[C@H](c2ccc(F)cc2)OC(=O)N1c1cc(C#N)cc(C#N)c1,CHEMBL4024749,"Discovery of 3,5-Diphenyl-4-methyl-1,3-oxazolidin-2-ones as Novel, Potent, and Orally Available Δ-5 Desaturase (D5D) Inhibitors.",J Med Chem,2017.0,60,21,8963,8981,10.1021/acs.jmedchem.7b01210,29023121.0,
18120559,CHEMBL4084502,"3-(4S,5S)-Chloro-5-[5-(4-fluorophenyl)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]benzonitrile",CHEMBL4026586,B,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,44.2,%,C[C@H]1[C@H](c2ccc(F)cc2)OC(=O)N1c1cc(Cl)cc(C#N)c1,CHEMBL4024749,"Discovery of 3,5-Diphenyl-4-methyl-1,3-oxazolidin-2-ones as Novel, Potent, and Orally Available Δ-5 Desaturase (D5D) Inhibitors.",J Med Chem,2017.0,60,21,8963,8981,10.1021/acs.jmedchem.7b01210,29023121.0,
18124629,CHEMBL4098647,"N-(1-(2-(4-(3-(Cyclopropylmethoxy)phenoxy)phenyl)-1,3-benzoxazol-6-yl)ethyl)acetamide",CHEMBL4027529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,89.9,%,CC(=O)NC(C)c1ccc2nc(-c3ccc(Oc4cccc(OCC5CC5)c4)cc3)oc2c1,CHEMBL4024776,Discovery of Novel Selective Acetyl-CoA Carboxylase (ACC) 1 Inhibitors.,J Med Chem,2018.0,61,3,1098,1117,10.1021/acs.jmedchem.7b01547,29232514.0,
18124630,CHEMBL4082153,"N-(1-(2-(5-(3-(Cyclopropylmethoxy)phenoxy)pyridin-2-yl)-1,3-benzoxazol-6-yl)ethyl)acetamide",CHEMBL4027529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,90.6,%,CC(=O)NC(C)c1ccc2nc(-c3ccc(Oc4cccc(OCC5CC5)c4)cn3)oc2c1,CHEMBL4024776,Discovery of Novel Selective Acetyl-CoA Carboxylase (ACC) 1 Inhibitors.,J Med Chem,2018.0,61,3,1098,1117,10.1021/acs.jmedchem.7b01547,29232514.0,
18124631,CHEMBL4060253,"N-(1-(2-(6-(3-(Cyclopropylmethoxy)phenoxy)pyridin-3-yl)-1,3-benzoxazol-6-yl)ethyl)acetamide",CHEMBL4027529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,87.0,%,CC(=O)NC(C)c1ccc2nc(-c3ccc(Oc4cccc(OCC5CC5)c4)nc3)oc2c1,CHEMBL4024776,Discovery of Novel Selective Acetyl-CoA Carboxylase (ACC) 1 Inhibitors.,J Med Chem,2018.0,61,3,1098,1117,10.1021/acs.jmedchem.7b01547,29232514.0,
18124632,CHEMBL4101119,"N-(1-(2-(6-(3-(Cyclopropylmethoxy)phenoxy)pyridin-3-yl)-1,3-benzothiazol-5-yl)ethyl)acetamide",CHEMBL4027529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,44.8,%,CC(=O)NC(C)c1ccc2sc(-c3ccc(Oc4cccc(OCC5CC5)c4)nc3)nc2c1,CHEMBL4024776,Discovery of Novel Selective Acetyl-CoA Carboxylase (ACC) 1 Inhibitors.,J Med Chem,2018.0,61,3,1098,1117,10.1021/acs.jmedchem.7b01547,29232514.0,
18124633,CHEMBL4083131,N-(1-(2-(4-(3-(Cyclopropylmethoxy)phenoxy)phenyl)-1-benzothiophen-5-yl)ethyl)acetamide,CHEMBL4027529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,33.5,%,CC(=O)NC(C)c1ccc2sc(-c3ccc(Oc4cccc(OCC5CC5)c4)cc3)cc2c1,CHEMBL4024776,Discovery of Novel Selective Acetyl-CoA Carboxylase (ACC) 1 Inhibitors.,J Med Chem,2018.0,61,3,1098,1117,10.1021/acs.jmedchem.7b01547,29232514.0,
18124634,CHEMBL4062997,N-(1-(3-((4-(3-(Cyclopropylmethoxy)phenoxy)benzyl)oxy)-phenyl)ethyl)acetamide,CHEMBL4027529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,0.2,%,CC(=O)NC(C)c1cccc(OCc2ccc(Oc3cccc(OCC4CC4)c3)cc2)c1,CHEMBL4024776,Discovery of Novel Selective Acetyl-CoA Carboxylase (ACC) 1 Inhibitors.,J Med Chem,2018.0,61,3,1098,1117,10.1021/acs.jmedchem.7b01547,29232514.0,
18124635,CHEMBL4090919,"N-(4-(2-(4-(3-(Cyclopropylmethoxy)phenoxy)phenyl)-1,3-oxazol-5-yl)butan-2-yl)acetamide",CHEMBL4027529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,22.4,%,CC(=O)NC(C)CCc1cnc(-c2ccc(Oc3cccc(OCC4CC4)c3)cc2)o1,CHEMBL4024776,Discovery of Novel Selective Acetyl-CoA Carboxylase (ACC) 1 Inhibitors.,J Med Chem,2018.0,61,3,1098,1117,10.1021/acs.jmedchem.7b01547,29232514.0,
18124636,CHEMBL4085633,"N-((2S)-1-((2-(4-(3-(Cyclopropylmethoxy)phenoxy)phenyl)-1,3-oxazol-5-yl)oxy)propan-2-yl)acetamide",CHEMBL4027529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,19.6,%,CC(=O)N[C@@H](C)COc1cnc(-c2ccc(Oc3cccc(OCC4CC4)c3)cc2)o1,CHEMBL4024776,Discovery of Novel Selective Acetyl-CoA Carboxylase (ACC) 1 Inhibitors.,J Med Chem,2018.0,61,3,1098,1117,10.1021/acs.jmedchem.7b01547,29232514.0,
18124638,CHEMBL4064621,"N-((2S)-1-((2-(5-(3-(Cyclopropylmethoxy)phenoxy)pyridin-2-yl)-1,3-oxazol-5-yl)oxy)propan-2-yl)acetamide",CHEMBL4027529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,2.4,%,CC(=O)N[C@@H](C)COc1cnc(-c2ccc(Oc3cccc(OCC4CC4)c3)cn2)o1,CHEMBL4024776,Discovery of Novel Selective Acetyl-CoA Carboxylase (ACC) 1 Inhibitors.,J Med Chem,2018.0,61,3,1098,1117,10.1021/acs.jmedchem.7b01547,29232514.0,
18124639,CHEMBL4086127,"N-((2S)-1-((2-(6-(3-(Cyclopropylmethoxy)phenoxy)pyridin-3-yl)-1,3-oxazol-5-yl)oxy)propan-2-yl)acetamide",CHEMBL4027529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,26.2,%,CC(=O)N[C@@H](C)COc1cnc(-c2ccc(Oc3cccc(OCC4CC4)c3)nc2)o1,CHEMBL4024776,Discovery of Novel Selective Acetyl-CoA Carboxylase (ACC) 1 Inhibitors.,J Med Chem,2018.0,61,3,1098,1117,10.1021/acs.jmedchem.7b01547,29232514.0,
18124640,CHEMBL4073202,"1-((2S)-1-((2-(4-(3-(Cyclopropylmethoxy)phenoxy)phenyl)-1,3-oxazol-5-yl)oxy)propan-2-yl)urea",CHEMBL4027529,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,14.8,%,C[C@@H](COc1cnc(-c2ccc(Oc3cccc(OCC4CC4)c3)cc2)o1)NC(N)=O,CHEMBL4024776,Discovery of Novel Selective Acetyl-CoA Carboxylase (ACC) 1 Inhibitors.,J Med Chem,2018.0,61,3,1098,1117,10.1021/acs.jmedchem.7b01547,29232514.0,
18126754,CHEMBL2181928,"6-((2R,5R)-2-methyl-5-phenylmorpholino)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one",CHEMBL4028155,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,<,20.0,%,C[C@@H]1CN(c2ccc3c(n2)NC(=O)CO3)[C@H](c2ccccc2)CO1,CHEMBL4024791,"Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists.",J Med Chem,2018.0,61,3,1086,1097,10.1021/acs.jmedchem.7b01515,29300474.0,
18126755,CHEMBL4062345,"(R)-6-(3-Phenylmorpholino)-2H-benzo[b][1,4]oxazin-3(4H)-one",CHEMBL4028155,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,<,10.0,%,O=C1COc2ccc(N3CCOC[C@H]3c3ccccc3)cc2N1,CHEMBL4024791,"Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists.",J Med Chem,2018.0,61,3,1086,1097,10.1021/acs.jmedchem.7b01515,29300474.0,
18136065,CHEMBL4067927,"7-((5-chloro-2-fluorophenyl)ethynyl)-2-(2-chloro-6-fluorophenyl)-4,4-dimethyl-1,4-dihydrochromeno[3,4-d]imidazole",CHEMBL4029868,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM measured after 20 mins in presence of NADPH by LC/MS/MS analysis relative to control,Inhibition,=,33.3,%,CC1(C)Oc2cc(C#Cc3cc(Cl)ccc3F)ccc2-c2[nH]c(-c3c(F)cccc3Cl)nc21,CHEMBL4028818,"Tricyclic 4,4-dimethyl-3,4-dihydrochromeno[3,4-d]imidazole derivatives as microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors: SAR and in vivo efficacy in hyperalgesia pain model.",Bioorg Med Chem Lett,2017.0,27,11,2594,2601,10.1016/j.bmcl.2017.03.068,28400234.0,
18136066,CHEMBL4100563,"2-(4,4-dimethyl-7-((2-(trifluoromethyl)phenyl)ethynyl)-3,4-dihydrochromeno[3,4-d]imidazol-2-yl)isophthalonitrile",CHEMBL4029868,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM measured after 20 mins in presence of NADPH by LC/MS/MS analysis relative to control,Inhibition,=,32.0,%,CC1(C)Oc2cc(C#Cc3ccccc3C(F)(F)F)ccc2-c2nc(-c3c(C#N)cccc3C#N)[nH]c21,CHEMBL4028818,"Tricyclic 4,4-dimethyl-3,4-dihydrochromeno[3,4-d]imidazole derivatives as microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors: SAR and in vivo efficacy in hyperalgesia pain model.",Bioorg Med Chem Lett,2017.0,27,11,2594,2601,10.1016/j.bmcl.2017.03.068,28400234.0,
18136081,CHEMBL4069833,"2-(2-Chloro-6-fluorophenyl)-4,4-dimethyl-7-(3-(trifluoromethoxy)phenyl)-1,4-dihydrochromeno-[3,4-d]imidazole",CHEMBL4029868,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM measured after 20 mins in presence of NADPH by LC/MS/MS analysis relative to control,Inhibition,=,45.4,%,CC1(C)Oc2cc(-c3cccc(OC(F)(F)F)c3)ccc2-c2[nH]c(-c3c(F)cccc3Cl)nc21,CHEMBL4028818,"Tricyclic 4,4-dimethyl-3,4-dihydrochromeno[3,4-d]imidazole derivatives as microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors: SAR and in vivo efficacy in hyperalgesia pain model.",Bioorg Med Chem Lett,2017.0,27,11,2594,2601,10.1016/j.bmcl.2017.03.068,28400234.0,
18136082,CHEMBL4103621,"2-(2-Chloro-6-fluorophenyl)-4,4-dimethyl-7-(3-(trifluoromethyl)phenyl)-1,4-dihydrochromeno[3,4-d]imidazole",CHEMBL4029868,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM measured after 20 mins in presence of NADPH by LC/MS/MS analysis relative to control,Inhibition,=,35.0,%,CC1(C)Oc2cc(-c3cccc(C(F)(F)F)c3)ccc2-c2[nH]c(-c3c(F)cccc3Cl)nc21,CHEMBL4028818,"Tricyclic 4,4-dimethyl-3,4-dihydrochromeno[3,4-d]imidazole derivatives as microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors: SAR and in vivo efficacy in hyperalgesia pain model.",Bioorg Med Chem Lett,2017.0,27,11,2594,2601,10.1016/j.bmcl.2017.03.068,28400234.0,
18139177,CHEMBL432798,N-{4-[5-(4-Fluoro-phenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide,CHEMBL4030400,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM by fluorimetric assay relative to control,Inhibition,=,46.0,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(C)=O)c2)n1C,CHEMBL4028848,"Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases.",J Med Chem,2017.0,60,13,5290,5305,10.1021/acs.jmedchem.6b01647,28613871.0,
18139182,CHEMBL321494,{4-[5-(4-Fluoro-phenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-phenyl-amine,CHEMBL4030400,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM by fluorimetric assay relative to control,Inhibition,=,60.0,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(Nc3ccccc3)c2)[nH]1,CHEMBL4028848,"Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases.",J Med Chem,2017.0,60,13,5290,5305,10.1021/acs.jmedchem.6b01647,28613871.0,
18149816,CHEMBL4077555,(R)-(6-Chloro-4-((5-cyclopropyl-1H-pyrazol-3-yl)amino)-quinazolin-2-yl)(3-methylpiperazin-1-yl)methanone Hydrochloride,CHEMBL4033398,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS method,Inhibition,=,15.1,%,C[C@@H]1CN(C(=O)c2nc(Nc3cc(C4CC4)[nH]n3)c3cc(Cl)ccc3n2)CCN1.Cl,CHEMBL4028914,Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives as Potent and Selective p21-Activated Kinase 4 (PAK4) Inhibitors.,J Med Chem,2018.0,61,1,265,285,10.1021/acs.jmedchem.7b01342,29190083.0,
18165435,CHEMBL4104795,"5-(3,4-dichlorobenzyl)-2-(piperidin-1-ylcarbonyl)-6,7-dihydropyrazolo{1,5-a}pyrazin-4(5H)-one",CHEMBL4036478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM,Inhibition,=,11.0,%,O=C(c1cc2n(n1)CCN(Cc1ccc(Cl)c(Cl)c1)C2=O)N1CCCCC1,CHEMBL4033732,Identification and synthesis of novel inhibitors of mycobacterium ATP synthase.,Bioorg Med Chem Lett,2017.0,27,15,3454,3459,10.1016/j.bmcl.2017.05.081,28587823.0,
18165436,CHEMBL4087055,"5-(4-tert-butylbenzyl)-2-(piperidin-1-ylcarbonyl)-6,7-dihydropyrazolo{1,5-a}pyrazin-4(5H)-one",CHEMBL4036478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM,Inhibition,=,19.0,%,CC(C)(C)c1ccc(CN2CCn3nc(C(=O)N4CCCCC4)cc3C2=O)cc1,CHEMBL4033732,Identification and synthesis of novel inhibitors of mycobacterium ATP synthase.,Bioorg Med Chem Lett,2017.0,27,15,3454,3459,10.1016/j.bmcl.2017.05.081,28587823.0,
18165437,CHEMBL4059988,"5-(3,4-Dichlorobenzyl)-2-(piperidin-1-ylcarbonyl)-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-4-one",CHEMBL4036478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM,Inhibition,=,13.0,%,O=C(c1cc2n(n1)CCCN(Cc1ccc(Cl)c(Cl)c1)C2=O)N1CCCCC1,CHEMBL4033732,Identification and synthesis of novel inhibitors of mycobacterium ATP synthase.,Bioorg Med Chem Lett,2017.0,27,15,3454,3459,10.1016/j.bmcl.2017.05.081,28587823.0,
18165438,CHEMBL4105198,"5-(3,4-dichlorobenzyl)-7-hydroxy-2-(piperidin-1-ylcarbonyl)-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one",CHEMBL4036478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM,Inhibition,=,24.0,%,O=C(c1cc2n(n1)C(O)CN(Cc1ccc(Cl)c(Cl)c1)C2=O)N1CCCCC1,CHEMBL4033732,Identification and synthesis of novel inhibitors of mycobacterium ATP synthase.,Bioorg Med Chem Lett,2017.0,27,15,3454,3459,10.1016/j.bmcl.2017.05.081,28587823.0,
18165439,CHEMBL4087342,"5-(4-tert-butylbenzyl)-7-hydroxy-2-(piperidin-1-ylcarbonyl)-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one",CHEMBL4036478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM,Inhibition,=,29.0,%,CC(C)(C)c1ccc(CN2CC(O)n3nc(C(=O)N4CCCCC4)cc3C2=O)cc1,CHEMBL4033732,Identification and synthesis of novel inhibitors of mycobacterium ATP synthase.,Bioorg Med Chem Lett,2017.0,27,15,3454,3459,10.1016/j.bmcl.2017.05.081,28587823.0,
18165440,CHEMBL4097497,"5-(3,4-dichlorobenzyl)-2-(piperidin-1-ylcarbonyl)pyrazolo[1,5-a]pyrazin-4(5H)-one",CHEMBL4036478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM,Inhibition,=,28.0,%,O=C(c1cc2c(=O)n(Cc3ccc(Cl)c(Cl)c3)ccn2n1)N1CCCCC1,CHEMBL4033732,Identification and synthesis of novel inhibitors of mycobacterium ATP synthase.,Bioorg Med Chem Lett,2017.0,27,15,3454,3459,10.1016/j.bmcl.2017.05.081,28587823.0,
18165441,CHEMBL4079461,"5-(4-tert-butylbenzyl)-2-(piperidin-1-ylcarbonyl)pyrazolo[1,5-a]pyrazin-4(5H)-one",CHEMBL4036478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM,Inhibition,=,46.0,%,CC(C)(C)c1ccc(Cn2ccn3nc(C(=O)N4CCCCC4)cc3c2=O)cc1,CHEMBL4033732,Identification and synthesis of novel inhibitors of mycobacterium ATP synthase.,Bioorg Med Chem Lett,2017.0,27,15,3454,3459,10.1016/j.bmcl.2017.05.081,28587823.0,
18165442,CHEMBL4078500,"7-(3,4-dichlorobenzyl)-2-(piperidin-1-ylcarbonyl)imidazo[1,2-a]pyrazin-8(7H)-one",CHEMBL4036478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM,Inhibition,=,0.0,%,O=C(c1cn2ccn(Cc3ccc(Cl)c(Cl)c3)c(=O)c2n1)N1CCCCC1,CHEMBL4033732,Identification and synthesis of novel inhibitors of mycobacterium ATP synthase.,Bioorg Med Chem Lett,2017.0,27,15,3454,3459,10.1016/j.bmcl.2017.05.081,28587823.0,
18165443,CHEMBL4102782,"7-(4-tert-butylbenzyl)-2-(piperidin-1-ylcarbonyl)imidazo[1,2-a]pyrazin-8(7H)-one",CHEMBL4036478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM,Inhibition,=,2.0,%,CC(C)(C)c1ccc(Cn2ccn3cc(C(=O)N4CCCCC4)nc3c2=O)cc1,CHEMBL4033732,Identification and synthesis of novel inhibitors of mycobacterium ATP synthase.,Bioorg Med Chem Lett,2017.0,27,15,3454,3459,10.1016/j.bmcl.2017.05.081,28587823.0,
18172152,CHEMBL4079080,"(2R)-1,1,1-Trifluoro-3-hydroxypropan-2-yl (1R,5S,6r)-6-[1-(4-Fluorophenyl)-1H-pyrazol-3-yl]-3-azabicyclo[3.1.0]hexane-3-carboxylate",CHEMBL4037998,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM,Inhibition,<,10.0,%,O=C(O[C@H](CO)C(F)(F)F)N1C[C@H]2[C@@H](C1)[C@@H]2c1ccn(-c2ccc(F)cc2)n1,CHEMBL4033794,Discovery of Trifluoromethyl Glycol Carbamates as Potent and Selective Covalent Monoacylglycerol Lipase (MAGL) Inhibitors for Treatment of Neuroinflammation.,J Med Chem,2018.0,61,7,3008,3026,10.1021/acs.jmedchem.8b00070,29498843.0,
18207518,CHEMBL4086541,"(+)-(2S)-1-Benzyl-4-(4-methoxybenzyl)-2-methyl-1,4-diazepane",CHEMBL4044930,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition on CYP2C9 (unknown origin) at 1 uM,Inhibition,=,0.0,%,COc1ccc(CN2CCCN(Cc3ccccc3)[C@@H](C)C2)cc1,CHEMBL4043136,"Chiral-pool synthesis of 1,2,4-trisubstituted 1,4-diazepanes as novel σ1 receptor ligands.",Bioorg Med Chem,2017.0,25,17,4778,4799,10.1016/j.bmc.2017.07.027,28764962.0,
18234180,CHEMBL4080076,"2-(4-(3,3-Difluoropyrrolidin-1-yl)phenyl)-5,7-difluoro-3-methylquinolin-4(1H)-one",CHEMBL4050721,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in insect cells at 10 uM using OOMR as substrate measured every minute for 1 hr by fluorescence-based assay,Inhibition,=,0.0,%,Cc1c(-c2ccc(N3CCC(F)(F)C3)cc2)[nH]c2cc(F)cc(F)c2c1=O,CHEMBL4049411,"Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of Mycobacterium tuberculosis.",J Med Chem,2017.0,60,9,3703,3726,10.1021/acs.jmedchem.6b01718,28304162.0,
18235114,CHEMBL4067502,(R)-N-(3-(1-hydroxy-2-(2-(3-methyl-1H-indazol-6-yloxy)ethylamino)ethyl)phenyl)cyclobutanesulfonamide,CHEMBL4051056,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,34.0,%,Cc1n[nH]c2cc(OCCNC[C@H](O)c3cccc(NS(=O)(=O)C4CCC4)c3)ccc12,CHEMBL4049422,Discovery of Novel Indazole Derivatives as Orally Available β3-Adrenergic Receptor Agonists Lacking Off-Target-Based Cardiovascular Side Effects.,J Med Chem,2017.0,60,8,3252,3265,10.1021/acs.jmedchem.6b01197,28355078.0,
18290811,CHEMBL4128481,"(S)-7,8-Dimethoxy-N-(1-(5-methyl-1H-pyrazol-3-yl)propan-2-yl)quinazolin-4-amine",CHEMBL4122594,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM relative to control,Inhibition,<,50.0,%,COc1ccc2c(N[C@@H](C)Cc3cc(C)[nH]n3)ncnc2c1OC,CHEMBL4118152,Discovery of Potent and Selective Periphery-Restricted Quinazoline Inhibitors of the Cyclic Nucleotide Phosphodiesterase PDE1.,J Med Chem,2018.0,61,10,4635,4640,10.1021/acs.jmedchem.8b00374,29718668.0,
18300439,CHEMBL4128250,(R)-N-(isoquinolin-1-yl)-3-(4-methoxyphenyl)-N-(piperidin-3-yl)propanamide,CHEMBL4124684,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,<,20.0,%,COc1ccc(CCC(=O)N(c2nccc3ccccc23)[C@@H]2CCCNC2)cc1,CHEMBL4118248,Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents.,J Med Chem,2018.0,61,13,5704,5718,10.1021/acs.jmedchem.8b00650,29878763.0,
18300440,CHEMBL4107559,"US9227956, 9",CHEMBL4124684,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,<,13.0,%,Cc1cnc2c(c1)nnn2-c1ccc(C(=O)N(c2ncccc2Cl)[C@@H]2CCCNC2)nc1,CHEMBL4118248,Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents.,J Med Chem,2018.0,61,13,5704,5718,10.1021/acs.jmedchem.8b00650,29878763.0,
18325309,CHEMBL4176986,"2-Amino-11-hydroxy-6H-naphtho[2',3':4,5]furo[3,2-c]chromene-6,7,12-trione",CHEMBL4135223,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM by P450-Glo assay relative to control,Inhibition,=,85.92,%,Nc1ccc2oc(=O)c3c4c(oc3c2c1)C(=O)c1c(O)cccc1C4=O,CHEMBL4130494,Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity.,Eur J Med Chem,2017.0,141,,138,148,10.1016/j.ejmech.2017.10.005,29031061.0,
18325310,CHEMBL4163702,"8-Acetoxy-6H-naphtho[2',3':4,5]furo[3,2-c]chromene-6,7,12-trione",CHEMBL4135223,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM by P450-Glo assay relative to control,Inhibition,=,92.52,%,CC(=O)Oc1cccc2c1C(=O)c1c(oc3c1c(=O)oc1ccccc13)C2=O,CHEMBL4130494,Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity.,Eur J Med Chem,2017.0,141,,138,148,10.1016/j.ejmech.2017.10.005,29031061.0,
18325311,CHEMBL4175082,"11-Acetoxy-6H-naphtho[2',3':4,5]furo[3,2-c]chromene-6,7,12-trione",CHEMBL4135223,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM by P450-Glo assay relative to control,Inhibition,=,99.25,%,CC(=O)Oc1cccc2c1C(=O)c1oc3c(c1C2=O)c(=O)oc1ccccc13,CHEMBL4130494,Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity.,Eur J Med Chem,2017.0,141,,138,148,10.1016/j.ejmech.2017.10.005,29031061.0,
18325312,CHEMBL4160332,"8-Hydroxy-6H-naphtho[2',3':4,5]furo[3,2-c]chromene-6,7,12-trione",CHEMBL4135223,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM by P450-Glo assay relative to control,Inhibition,=,44.6,%,O=C1c2cccc(O)c2C(=O)c2c1oc1c2c(=O)oc2ccccc21,CHEMBL4130494,Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity.,Eur J Med Chem,2017.0,141,,138,148,10.1016/j.ejmech.2017.10.005,29031061.0,
18325313,CHEMBL4160100,"11-Hydroxy-6H-naphtho[2',3':4,5]furo[3,2-c]chromene-6,7,12-trione",CHEMBL4135223,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM by P450-Glo assay relative to control,Inhibition,=,61.55,%,O=C1c2oc3c(c2C(=O)c2cccc(O)c21)c(=O)oc1ccccc13,CHEMBL4130494,Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity.,Eur J Med Chem,2017.0,141,,138,148,10.1016/j.ejmech.2017.10.005,29031061.0,
18325314,CHEMBL4170742,"8-Methoxy-6H-naphtho[2',3':4,5]furo[3,2-c]chromene-6,7,12-trione",CHEMBL4135223,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM by P450-Glo assay relative to control,Inhibition,=,61.6,%,COc1cccc2c1C(=O)c1c(oc3c1c(=O)oc1ccccc13)C2=O,CHEMBL4130494,Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity.,Eur J Med Chem,2017.0,141,,138,148,10.1016/j.ejmech.2017.10.005,29031061.0,
18325315,CHEMBL4170316,"11-Methoxy-6H-naphtho[2',3':4,5]furo[3,2-c]chromene-6,7,12-trione",CHEMBL4135223,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM by P450-Glo assay relative to control,Inhibition,=,89.34,%,COc1cccc2c1C(=O)c1oc3c(c1C2=O)c(=O)oc1ccccc13,CHEMBL4130494,Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity.,Eur J Med Chem,2017.0,141,,138,148,10.1016/j.ejmech.2017.10.005,29031061.0,
18325316,CHEMBL4162394,"6H-anthra[2',3':4,5]furo[3,2-c]chromene-6,7,14-trione",CHEMBL4135223,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM by P450-Glo assay relative to control,Inhibition,=,42.43,%,O=C1c2cc3ccccc3cc2C(=O)c2c1oc1c2c(=O)oc2ccccc21,CHEMBL4130494,Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity.,Eur J Med Chem,2017.0,141,,138,148,10.1016/j.ejmech.2017.10.005,29031061.0,
18325317,CHEMBL4166917,"6H-naphtho[2',3':4,5]furo[3,2-c]chromene-6,7,12-trione",CHEMBL4135223,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM by P450-Glo assay relative to control,Inhibition,=,32.35,%,O=C1c2ccccc2C(=O)c2c1oc1c2c(=O)oc2ccccc21,CHEMBL4130494,Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity.,Eur J Med Chem,2017.0,141,,138,148,10.1016/j.ejmech.2017.10.005,29031061.0,
18331286,CHEMBL4172937,"(R)-6-(2-fluoro-4-(5-(hydroxymethyl)-2-oxooxazolidin-3-yl)phenyl)-2H-benzo[b][1,4]oxazin-3(4H)-one",CHEMBL4136330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,12.0,%,O=C1COc2ccc(-c3ccc(N4C[C@H](CO)OC4=O)cc3F)cc2N1,CHEMBL4130562,"Design, Synthesis, and Antibacterial Evaluation of Oxazolidinones with Fused Heterocyclic C-Ring Substructure.",ACS Med Chem Lett,2017.0,8,11,1153,1158,10.1021/acsmedchemlett.7b00263,29152047.0,
18331287,CHEMBL4168515,"(S)-N-((3-(3-fluoro-4-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)acetamide",CHEMBL4136330,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,=,13.0,%,CC(=O)NC[C@H]1CN(c2ccc(-c3ccc4c(c3)NC(=O)CO4)c(F)c2)C(=O)O1,CHEMBL4130562,"Design, Synthesis, and Antibacterial Evaluation of Oxazolidinones with Fused Heterocyclic C-Ring Substructure.",ACS Med Chem Lett,2017.0,8,11,1153,1158,10.1021/acsmedchemlett.7b00263,29152047.0,
18337839,CHEMBL4170114,N-(1-isopropylpiperidin-4-yl)-6-methoxy-2-(5-methylfuran-2-yl)-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-amine,CHEMBL4137493,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 10 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,0.56,%,COc1cc2c(NC3CCN(C)CC3)cc(-c3ccc(C)o3)nc2cc1OCCCN1CCCC1,CHEMBL4130634,Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.,J Med Chem,2018.0,61,15,6518,6545,10.1021/acs.jmedchem.7b01926,29953809.0,
18337840,CHEMBL4160008,2-(5-Ethyl-2-furyl)-6-methoxy-N-(1-methyl-4-piperidyl)-7-(3-pyrrolidin-1-ylpropoxy)quinolin-4-amine,CHEMBL4137493,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 10 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,0.0,%,CCc1ccc(-c2cc(NC3CCN(C)CC3)c3cc(OC)c(OCCCN4CCCC4)cc3n2)o1,CHEMBL4130634,Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.,J Med Chem,2018.0,61,15,6518,6545,10.1021/acs.jmedchem.7b01926,29953809.0,
18337841,CHEMBL4171233,N-(1-Isopropyl-4-piperidyl)-6-methoxy-2-(5-methyl-2-furyl)-7-(3-pyrrolidin-1-ylpropoxy)quinolin-4-amine,CHEMBL4137493,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 10 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,6.1,%,COc1cc2c(NC3CCN(C(C)C)CC3)cc(-c3ccc(C)o3)nc2cc1OCCCN1CCCC1,CHEMBL4130634,Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.,J Med Chem,2018.0,61,15,6518,6545,10.1021/acs.jmedchem.7b01926,29953809.0,
18337842,CHEMBL4162911,N-(1-Cyclopropyl-4-piperidyl)-6-methoxy-2-(5-methyl-2-furyl)-7-(3-pyrrolidin-1-ylpropoxy)quinolin-4-amine,CHEMBL4137493,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 10 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,8.0,%,COc1cc2c(NC3CCN(C4CC4)CC3)cc(-c3ccc(C)o3)nc2cc1OCCCN1CCCC1,CHEMBL4130634,Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.,J Med Chem,2018.0,61,15,6518,6545,10.1021/acs.jmedchem.7b01926,29953809.0,
18445647,CHEMBL4080520,"(S)-5-(3-fluoro-4-((4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-ylthio)methyl)phenyl)-N-(3-methyl-1-(methylamino)-1-oxobutan-2-yl)furan-2-carboxamide",CHEMBL4158236,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide as substrate after 10 mins in presence of NADPH relative to control,Inhibition,=,60.0,%,CNC(=O)[C@@H](NC(=O)c1ccc(-c2ccc(CSc3nc4c(c(=O)[nH]3)CCC4)c(F)c2)o1)C(C)C,CHEMBL4152369,Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.,Bioorg Med Chem,2018.0,26,18,4984,4995,10.1016/j.bmc.2018.08.020,30249495.0,
18445648,CHEMBL4169495,"(S)-N-(3,3-Dimethyl-1-(methylamino)-1-oxobutan-2-yl)-5-(3-fluoro-4-(((4-oxo-4,5,6,7-tetrahydro-3Hcyclopenta[d]pyrimidin-2-yl)thio)methyl)phenyl)furan-2-carboxamide",CHEMBL4158236,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide as substrate after 10 mins in presence of NADPH relative to control,Inhibition,=,75.0,%,CNC(=O)[C@@H](NC(=O)c1ccc(-c2ccc(CSc3nc4c(c(=O)[nH]3)CCC4)c(F)c2)o1)C(C)(C)C,CHEMBL4152369,Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.,Bioorg Med Chem,2018.0,26,18,4984,4995,10.1016/j.bmc.2018.08.020,30249495.0,
18445649,CHEMBL4172893,"(S)-5-(3-Fluoro-4-(((4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)thio)methyl)phenyl)-N-(2-(methylamino)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethyl)furan-2-carboxamide",CHEMBL4158236,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide as substrate after 10 mins in presence of NADPH relative to control,Inhibition,=,35.0,%,CNC(=O)[C@@H](NC(=O)c1ccc(-c2ccc(CSc3nc4c(c(=O)[nH]3)CCC4)c(F)c2)o1)C1CCOCC1,CHEMBL4152369,Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.,Bioorg Med Chem,2018.0,26,18,4984,4995,10.1016/j.bmc.2018.08.020,30249495.0,
18445650,CHEMBL4164905,"(S)-N-(1-Cyclopropyl-2-(methylamino)-2-oxoethyl)-5-(3-fluoro-4-(((4-oxo-4,5,6,7-tetrahydro-3Hcyclopenta[d]pyrimidin-2-yl)thio)methyl)phenyl)furan-2-carboxamide",CHEMBL4158236,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide as substrate after 10 mins in presence of NADPH relative to control,Inhibition,=,29.0,%,CNC(=O)[C@@H](NC(=O)c1ccc(-c2ccc(CSc3nc4c(c(=O)[nH]3)CCC4)c(F)c2)o1)C1CC1,CHEMBL4152369,Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.,Bioorg Med Chem,2018.0,26,18,4984,4995,10.1016/j.bmc.2018.08.020,30249495.0,
18445651,CHEMBL4172804,"(S)-5-(3-Fluoro-4-(((4-oxo-4,5,6,7-tetrahydro-3H-cyclopenta[d]pyrimidin-2-yl)thio)methyl)phenyl)-N-(3-hydroxy-3-methyl-1-(methylamino)-1-oxobutan-2-yl)furan-2-carboxamide",CHEMBL4158236,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide as substrate after 10 mins in presence of NADPH relative to control,Inhibition,=,25.0,%,CNC(=O)[C@@H](NC(=O)c1ccc(-c2ccc(CSc3nc4c(c(=O)[nH]3)CCC4)c(F)c2)o1)C(C)(C)O,CHEMBL4152369,Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.,Bioorg Med Chem,2018.0,26,18,4984,4995,10.1016/j.bmc.2018.08.020,30249495.0,
18450722,CHEMBL3989970,MAVELERTINIB,CHEMBL4178379,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,<,30.0,%,C=CC(=O)N[C@@H]1CN(c2nc(Nc3cn(C)nc3OC)c3ncn(C)c3n2)C[C@H]1F,CHEMBL4177539,"Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.",J Med Chem,2017.0,60,7,3002,3019,10.1021/acs.jmedchem.6b01894,28287730.0,
18457648,CHEMBL2087474,"5-(2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholinoimidazo[1,2-a]pyrazin-6-yl)pyrimidin-2-amine",CHEMBL4179666,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,25.0,%,CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1,CHEMBL4177600,Identification of novel PI3K inhibitors through a scaffold hopping strategy.,Bioorg Med Chem Lett,2017.0,27,21,4794,4799,10.1016/j.bmcl.2017.09.059,29017786.0,
18457649,CHEMBL4212439,"5-[2-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-ylpyrazolo[1,5-a]pyrazin-6-yl]-pyrimidin-2-ylamine",CHEMBL4179666,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,25.0,%,CS(=O)(=O)N1CCN(Cc2cc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn3n2)CC1,CHEMBL4177600,Identification of novel PI3K inhibitors through a scaffold hopping strategy.,Bioorg Med Chem Lett,2017.0,27,21,4794,4799,10.1016/j.bmcl.2017.09.059,29017786.0,
18457650,CHEMBL4217392,"5-[2-(4-Methanesulfonylpiperazin-1-ylmethyl)-8-morpholin-4-yl-[1,2,4]triazolo[1,5-a]pyrazin-6-yl]-pyrimidin-2-ylamine",CHEMBL4179666,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,25.0,%,CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn3n2)CC1,CHEMBL4177600,Identification of novel PI3K inhibitors through a scaffold hopping strategy.,Bioorg Med Chem Lett,2017.0,27,21,4794,4799,10.1016/j.bmcl.2017.09.059,29017786.0,
18457651,CHEMBL4208064,"5-[6-(4-Methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-ylimidazo[2,1-f][1,2,4]triazin-2-yl]-pyrimidin-2-ylamine",CHEMBL4179666,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,25.0,%,CS(=O)(=O)N1CCN(Cc2cn3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1,CHEMBL4177600,Identification of novel PI3K inhibitors through a scaffold hopping strategy.,Bioorg Med Chem Lett,2017.0,27,21,4794,4799,10.1016/j.bmcl.2017.09.059,29017786.0,
18457652,CHEMBL4212973,"5-(7-chloro-2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrazolo[1,5-a]pyrazin-6-yl)pyrimidin-2-amine",CHEMBL4179666,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,25.0,%,CS(=O)(=O)N1CCN(Cc2cc3c(N4CCOCC4)nc(-c4cnc(N)nc4)c(Cl)n3n2)CC1,CHEMBL4177600,Identification of novel PI3K inhibitors through a scaffold hopping strategy.,Bioorg Med Chem Lett,2017.0,27,21,4794,4799,10.1016/j.bmcl.2017.09.059,29017786.0,
18457653,CHEMBL4205584,"5-(5-chloro-2-((4-(methylsulfonyl)piperazin-1-yl)methyl)-8-morpholino-[1,2,4]triazolo[1,5-a]pyrazin-6-yl)pyrimidin-2-amine",CHEMBL4179666,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,25.0,%,CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)c(Cl)n3n2)CC1,CHEMBL4177600,Identification of novel PI3K inhibitors through a scaffold hopping strategy.,Bioorg Med Chem Lett,2017.0,27,21,4794,4799,10.1016/j.bmcl.2017.09.059,29017786.0,
18464163,CHEMBL4211033,"2-((2,6-Dichlorophenyl)amino)-7-methyl-N-(3-(trifluoromethyl)phenyl)-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4181296,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in 4hydroxy-diclofenac formation at 10 uM measured after 20 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,40.0,%,Cc1cc2c(o1)c(C(=O)Nc1cccc(C(F)(F)F)c1)cc1nc(Nc3c(Cl)cccc3Cl)[nH]c12,CHEMBL4177660,Discovery of furan and dihydrofuran-fused tricyclic benzo[d]imidazole derivatives as potent and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-1.,Bioorg Med Chem Lett,2017.0,27,23,5131,5138,10.1016/j.bmcl.2017.10.062,29100801.0,
18464164,CHEMBL4203493,"2-((2,6-Dichlorophenyl)amino)-7,7-dimethyl-N-(2,2,3,3,3-pentafluoropropyl)-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4181296,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in 4hydroxy-diclofenac formation at 10 uM measured after 20 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,81.0,%,CC1(C)Cc2c(c(C(=O)NCC(F)(F)C(F)(F)F)cc3nc(Nc4c(Cl)cccc4Cl)[nH]c23)O1,CHEMBL4177660,Discovery of furan and dihydrofuran-fused tricyclic benzo[d]imidazole derivatives as potent and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-1.,Bioorg Med Chem Lett,2017.0,27,23,5131,5138,10.1016/j.bmcl.2017.10.062,29100801.0,
18464165,CHEMBL4206581,"2-((2,6-Dichlorophenyl)amino)-7,7-dimethyl-N-(4-(trifluoromethyl)phenyl)-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4181296,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in 4hydroxy-diclofenac formation at 10 uM measured after 20 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,82.0,%,CC1(C)Cc2c(c(C(=O)Nc3ccc(C(F)(F)F)cc3)cc3nc(Nc4c(Cl)cccc4Cl)[nH]c23)O1,CHEMBL4177660,Discovery of furan and dihydrofuran-fused tricyclic benzo[d]imidazole derivatives as potent and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-1.,Bioorg Med Chem Lett,2017.0,27,23,5131,5138,10.1016/j.bmcl.2017.10.062,29100801.0,
18464166,CHEMBL3931344,"2-(2-chloro-6-fluorophenylamino)-7,7-dimethyl-N-(4-(trifluoromethyl)phenyl)-7,8-dihydro-1H-benzofuro[5,4-d]imidazole-5-carboxamide",CHEMBL4181296,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in 4hydroxy-diclofenac formation at 10 uM measured after 20 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,72.0,%,CC1(C)Cc2c(c(C(=O)Nc3ccc(C(F)(F)F)cc3)cc3nc(Nc4c(F)cccc4Cl)[nH]c23)O1,CHEMBL4177660,Discovery of furan and dihydrofuran-fused tricyclic benzo[d]imidazole derivatives as potent and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-1.,Bioorg Med Chem Lett,2017.0,27,23,5131,5138,10.1016/j.bmcl.2017.10.062,29100801.0,
18464167,CHEMBL4218836,"2-((3,5-Dichloropyridin-4-yl)amino)-7,7-dimethyl-N-(4-(trifluoromethyl)phenyl)-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4181296,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in 4hydroxy-diclofenac formation at 10 uM measured after 20 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,57.0,%,CC1(C)Cc2c(c(C(=O)Nc3ccc(C(F)(F)F)cc3)cc3nc(Nc4c(Cl)cncc4Cl)[nH]c23)O1,CHEMBL4177660,Discovery of furan and dihydrofuran-fused tricyclic benzo[d]imidazole derivatives as potent and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-1.,Bioorg Med Chem Lett,2017.0,27,23,5131,5138,10.1016/j.bmcl.2017.10.062,29100801.0,
18464168,CHEMBL4209884,"2-(2-chloro-6-fluorophenylamino)-N-(3-cyclohexylphenyl)-7,7-dimethyl-7,8-dihydro-1H-benzofuro[5,4-d]imidazole-5-carboxamide",CHEMBL4181296,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in 4hydroxy-diclofenac formation at 10 uM measured after 20 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,69.0,%,CC1(C)Cc2c(c(C(=O)Nc3cccc(C4CCCCC4)c3)cc3nc(Nc4c(F)cccc4Cl)[nH]c23)O1,CHEMBL4177660,Discovery of furan and dihydrofuran-fused tricyclic benzo[d]imidazole derivatives as potent and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-1.,Bioorg Med Chem Lett,2017.0,27,23,5131,5138,10.1016/j.bmcl.2017.10.062,29100801.0,
18464169,CHEMBL4205280,"2-((2-Chloro-6-fluorophenyl)amino)-N-(6-(difluoromethoxy)pyridin-3-yl)-7,7-dimethyl-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4181296,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in 4hydroxy-diclofenac formation at 10 uM measured after 20 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,77.0,%,CC1(C)Cc2c(c(C(=O)Nc3ccc(C(F)F)nc3)cc3nc(Nc4c(F)cccc4Cl)[nH]c23)O1,CHEMBL4177660,Discovery of furan and dihydrofuran-fused tricyclic benzo[d]imidazole derivatives as potent and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-1.,Bioorg Med Chem Lett,2017.0,27,23,5131,5138,10.1016/j.bmcl.2017.10.062,29100801.0,
18464170,CHEMBL4217361,"2-((2,6-Dichlorophenyl)amino)-7,7-dimethyl-N-(6-(trifluoromethyl)pyridin-3-yl)-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4181296,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in 4hydroxy-diclofenac formation at 10 uM measured after 20 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,75.0,%,CC1(C)Cc2c(c(C(=O)Nc3ccc(C(F)(F)F)nc3)cc3nc(Nc4c(Cl)cccc4Cl)[nH]c23)O1,CHEMBL4177660,Discovery of furan and dihydrofuran-fused tricyclic benzo[d]imidazole derivatives as potent and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-1.,Bioorg Med Chem Lett,2017.0,27,23,5131,5138,10.1016/j.bmcl.2017.10.062,29100801.0,
18479954,CHEMBL4211961,N-(3-(quinazolin-2-ylamino)phenyl)acetamide,CHEMBL4184758,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,20.0,%,CC(=O)Nc1cccc(Nc2ncc3ccccc3n2)c1,CHEMBL4184100,Discovery of 2-arylquinazoline derivatives as a new class of ASK1 inhibitors.,Bioorg Med Chem Lett,2018.0,28,3,400,404,10.1016/j.bmcl.2017.12.026,29277458.0,
18479955,CHEMBL4215414,N-(3-((6-(1H-pyrazol-4-yl)quinazolin-2-yl)amino)phenyl)acetamide,CHEMBL4184758,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,98.0,%,CC(=O)Nc1cccc(Nc2ncc3cc(-c4cn[nH]c4)ccc3n2)c1,CHEMBL4184100,Discovery of 2-arylquinazoline derivatives as a new class of ASK1 inhibitors.,Bioorg Med Chem Lett,2018.0,28,3,400,404,10.1016/j.bmcl.2017.12.026,29277458.0,
18479956,CHEMBL4217652,"N1-(6-(1H-pyrazol-4-yl)quinazolin-2-yl)benzene-1,3-diamine",CHEMBL4184758,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,93.0,%,Nc1cccc(Nc2ncc3cc(-c4cn[nH]c4)ccc3n2)c1,CHEMBL4184100,Discovery of 2-arylquinazoline derivatives as a new class of ASK1 inhibitors.,Bioorg Med Chem Lett,2018.0,28,3,400,404,10.1016/j.bmcl.2017.12.026,29277458.0,
18532513,CHEMBL4170114,N-(1-isopropylpiperidin-4-yl)-6-methoxy-2-(5-methylfuran-2-yl)-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-amine,CHEMBL4195579,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 10 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,0.56,%,COc1cc2c(NC3CCN(C)CC3)cc(-c3ccc(C)o3)nc2cc1OCCCN1CCCC1,CHEMBL4190398,Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.,J Med Chem,2018.0,61,15,6546,6573,10.1021/acs.jmedchem.7b01925,29890830.0,
18532514,CHEMBL4217332,4-[[6-Methoxy-2-(5-methyl-2-furyl)-7-(3-pyrrolidin-1-ylpropoxy)-4-quinolyl]amino]-1-methyl-piperidin-2-one,CHEMBL4195579,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 10 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,3.2,%,COc1cc2c(NC3CCN(C)C(=O)C3)cc(-c3ccc(C)o3)nc2cc1OCCCN1CCCC1,CHEMBL4190398,Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.,J Med Chem,2018.0,61,15,6546,6573,10.1021/acs.jmedchem.7b01925,29890830.0,
18532515,CHEMBL4212905,2-(5-Ethyl-2-furyl)-6-methoxy-N-[(1-methyl-4-piperidyl)methyl]-7-(3-pyrrolidin-1-ylpropoxy)quinolin-4-amine,CHEMBL4195579,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 10 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,16.8,%,CCc1ccc(-c2cc(NCC3CCN(C)CC3)c3cc(OC)c(OCCCN4CCCC4)cc3n2)o1,CHEMBL4190398,Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.,J Med Chem,2018.0,61,15,6546,6573,10.1021/acs.jmedchem.7b01925,29890830.0,
18532516,CHEMBL4206035,6-Methoxy-N-(7-methyl-7-azaspiro[3.5]nonan-2-yl)-2-(5-methyl-2-furyl)-7-(3-pyrrolidin-1-ylpropoxy)quinolin-4-amine,CHEMBL4195579,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 10 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,0.0,%,COc1cc2c(NC3CC4(CCN(C)CC4)C3)cc(-c3ccc(C)o3)nc2cc1OCCCN1CCCC1,CHEMBL4190398,Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.,J Med Chem,2018.0,61,15,6546,6573,10.1021/acs.jmedchem.7b01925,29890830.0,
18532517,CHEMBL4208812,6-Methoxy-N-(7-methyl-7-azaspiro[3.5]nonan-3-yl)-2-(5-methyl-2-furyl)-7-(3-pyrrolidin-1-ylpropoxy)quinolin-4-amine,CHEMBL4195579,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 10 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,0.0,%,COc1cc2c(NC3CCC34CCN(C)CC4)cc(-c3ccc(C)o3)nc2cc1OCCCN1CCCC1,CHEMBL4190398,Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.,J Med Chem,2018.0,61,15,6546,6573,10.1021/acs.jmedchem.7b01925,29890830.0,
18532518,CHEMBL4205373,6-Methoxy-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-2-(5-methyl-2-furyl)-7-(3-pyrrolidin-1-ylpropoxy)quinolin-4-amine,CHEMBL4195579,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 10 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,0.0,%,COc1cc2c(NC3CC4CCC(C3)N4C)cc(-c3ccc(C)o3)nc2cc1OCCCN1CCCC1,CHEMBL4190398,Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.,J Med Chem,2018.0,61,15,6546,6573,10.1021/acs.jmedchem.7b01925,29890830.0,
18532519,CHEMBL4215377,6-Chloro-2-(5-methyl-2-furyl)-N-(1-methyl-4-piperidyl)-7-(3-pyrrolidin-1-ylpropoxy)quinolin-4-amine,CHEMBL4195579,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 10 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,3.8,%,Cc1ccc(-c2cc(NC3CCN(C)CC3)c3cc(Cl)c(OCCCN4CCCC4)cc3n2)o1,CHEMBL4190398,Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.,J Med Chem,2018.0,61,15,6546,6573,10.1021/acs.jmedchem.7b01925,29890830.0,
18532520,CHEMBL4215326,6-Methoxy-7-[(2-methyl-2-azaspiro[3.3]heptan-6-yl)oxy]-2-(5-methyl-2-furyl)-N-(1-methyl-4-piperidyl)quinolin-4-amine,CHEMBL4195579,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 10 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,6.3,%,COc1cc2c(NC3CCN(C)CC3)cc(-c3ccc(C)o3)nc2cc1OC1CC2(C1)CN(C)C2,CHEMBL4190398,Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.,J Med Chem,2018.0,61,15,6546,6573,10.1021/acs.jmedchem.7b01925,29890830.0,
18535836,CHEMBL91844,2-(trifluoromethyl)benzaldehyde thiosemicarbazone,CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,-7.51,%,N/C(S)=N/N=C/c1cccc(Br)c1,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535837,CHEMBL398205,(E)-1-(2-methoxybenzylidene)thiosemicarbazide,CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,-19.77,%,COc1ccccc1/C=N/NC(N)=S,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535838,CHEMBL242115,"(E)-1-(3,4-dimethoxybenzylidene)thiosemicarbazide",CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,-19.16,%,COc1ccc(/C=N/NC(N)=S)cc1OC,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535839,CHEMBL4207338,"(E)-2-(2,6-dimethoxybenzylidene)hydrazinecarbothioamide",CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,-9.43,%,COc1cccc(OC)c1/C=N/NC(N)=S,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535840,CHEMBL499789,"3,4,5-trimethoxybenzaldehyde thiosemicarbazone",CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,-6.01,%,COc1cc(/C=N/NC(N)=S)cc(OC)c1OC,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535841,CHEMBL243187,"(E)-1-(3,4-dihydroxybenzylidene)thiosemicarbazide",CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,-7.51,%,NC(=S)N/N=C/c1ccc(O)c(O)c1,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535842,CHEMBL415311,"3,4-dichlorobenzaldehyde thiosemicarbazone",CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,24.26,%,N/C(S)=N/N=C/c1ccc(Cl)c(Cl)c1,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535843,CHEMBL1818876,1-(Furan-2-ylmethylene)thiosemicarbazone,CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,-12.23,%,NC(=S)N/N=C/c1ccco1,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535844,CHEMBL1276230,N1-[3-(phenyl)propenilidene]thiosemicarbazide,CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,9.11,%,NC(=S)N/N=C/C=C/c1ccccc1,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535845,CHEMBL4165401,"2-([1,1'-biphenyl]-4-ylmethylene)hydrazine-1-carbothioamide",CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,98.38,%,NC(=S)N/N=C/c1ccc(-c2ccccc2)cc1,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535846,CHEMBL4217990,"(E)-2-([1,1'-biphenyl]-3-ylmethylene)hydrazinecarbothioamide",CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,14.67,%,NC(=S)N/N=C/c1cccc(-c2ccccc2)c1,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535847,CHEMBL4206286,"(E)-2-((3',4'-dimethoxy-[1,10-biphenyl]-3-yl)methylene)hydrazinecarbothioamide",CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,56.76,%,COc1ccc(-c2cccc(/C=N/NC(N)=S)c2)cc1OC,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535848,CHEMBL4205778,"(E)-2-(3-(benzo[d][1,3]dioxol-5-yl)benzylidene)hydrazine-1-carbothioamide",CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,45.27,%,NC(=S)N/N=C/c1cccc(-c2ccc3c(c2)OCO3)c1,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535849,CHEMBL4210646,"(E)-2-(4-((3,4-dichlorobenzyl)oxy)benzylidene)hydrazinecarbothioamide",CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,18.93,%,NC(=S)N/N=C/c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535850,CHEMBL242113,(E)-1-(4-hydroxybenzylidene)thiosemicarbazide,CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,-21.07,%,NC(=S)N/N=C/c1ccc(O)cc1,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535851,CHEMBL4215074,"(E)-2-(2,3,4,5-tetrahydroxypentylidene)hydrazinecarbothioamide",CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,-19.72,%,NC(=S)N/N=C/C(O)C(O)C(O)CO,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535852,CHEMBL3194855,SID24784097,CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,-4.92,%,NC(=S)N/N=C/c1ccccc1[N+](=O)[O-],CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535853,CHEMBL242104,(E)-1-(4-hydroxy-3-methoxybenzylidene)thiosemicarbazide,CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,-7.31,%,COc1cc(/C=N/NC(N)=S)ccc1O,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535854,CHEMBL242112,(E)-1-(2-hydroxybenzylidene)thiosemicarbazide,CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,-6.44,%,NC(=S)N/N=C/c1ccccc1O,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535855,CHEMBL193804,4-nitrobenzaldehyde thiosemicarbazone,CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,-3.66,%,N/C(S)=N/N=C/c1ccc([N+](=O)[O-])cc1,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535856,CHEMBL4208462,(E)-2-(4-aminobenzylidene)hydrazinecarbothioamide,CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,3.06,%,NC(=S)N/N=C/c1ccc(N)cc1,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535857,CHEMBL4203577,(E)-2-(4-(methylthio)benzylidene)hydrazinecarbothioamide,CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,12.38,%,CSc1ccc(/C=N/NC(N)=S)cc1,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535858,CHEMBL4204121,(E)-2-(quinolin-6-ylmethylene)hydrazinecarbothioamide,CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,3.32,%,NC(=S)N/N=C/c1ccc2ncccc2c1,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535859,CHEMBL330453,4-(dimethylamino)-1-naphthaldehyde thiosemicarbazone,CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,10.02,%,CN(C)c1ccc(/C=N/N=C(/N)S)c2ccccc12,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535860,CHEMBL4216320,(E)-2-(benzo[b]thiophen-3-ylmethylene)hydrazinecarbothioamide,CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,14.56,%,NC(=S)N/N=C/c1csc2ccccc12,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535861,CHEMBL4211350,(E)-2-((3-methylthiophen-2-yl)methylene)hydrazinecarbothioamide,CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,4.24,%,Cc1ccsc1/C=N/NC(N)=S,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535862,CHEMBL4210257,(E)-2-(1-(4-hydroxyphenyl)ethylidene)hydrazinecarbothioamide,CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,-9.01,%,C/C(=N\NC(N)=S)c1ccc(O)cc1,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18535863,CHEMBL2420104,4-Aminoacetophenone thiosemicarbazone,CHEMBL4196393,A,BTI-TN-5B1-4,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected BTI-TN-5B1-4 cells at 10 uM incubated for 30 mins by luciferase assay relative to control,Inhibition,=,7.46,%,C/C(=N\NC(N)=S)c1ccc(N)cc1,CHEMBL4196006,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,Eur J Med Chem,2018.0,146,,423,434,10.1016/j.ejmech.2018.01.043,29407968.0,
18546266,CHEMBL4216192,"4-cyclopentyl-N-(2,4-dimethylphenyl)-1,3-dimethyl-2-oxo-1,2,3,4-tetrahydroquinoxaline-6-carboxamide",CHEMBL4198478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 20 mins relative to control,Inhibition,=,74.0,%,Cc1ccc(NC(=O)c2ccc3c(c2)N(C2CCCC2)C(C)C(=O)N3C)c(C)c1,CHEMBL4196075,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,Eur J Med Chem,2018.0,150,,156,175,10.1016/j.ejmech.2018.02.070,29525435.0,
18546267,CHEMBL4210440,"4-cyclopropyl-N-(3-fluoro-4-methylphenyl)-1,3-dimethyl-2-oxo-1,2,3,4-tetrahydroquinoxaline-6-carboxamide",CHEMBL4198478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 20 mins relative to control,Inhibition,=,23.0,%,Cc1ccc(NC(=O)c2ccc3c(c2)N(C2CC2)C(C)C(=O)N3C)cc1F,CHEMBL4196075,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,Eur J Med Chem,2018.0,150,,156,175,10.1016/j.ejmech.2018.02.070,29525435.0,
18546268,CHEMBL4212712,"4-cyclopropyl-N,1,3-trimethyl-2-oxo-N-phenyl-1,2,3,4-tetrahydroquinoxaline-6-carboxamide",CHEMBL4198478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 20 mins relative to control,Inhibition,=,1.0,%,CC1C(=O)N(C)c2ccc(C(=O)N(C)c3ccccc3)cc2N1C1CC1,CHEMBL4196075,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,Eur J Med Chem,2018.0,150,,156,175,10.1016/j.ejmech.2018.02.070,29525435.0,
18546269,CHEMBL4207810,"4-cyclopropyl-N,1,3-trimethyl-2-oxo-N-(p-tolyl)-1,2,3,4-tetrahydroquinoxaline-6-carboxamide",CHEMBL4198478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 20 mins relative to control,Inhibition,=,20.0,%,Cc1ccc(N(C)C(=O)c2ccc3c(c2)N(C2CC2)C(C)C(=O)N3C)cc1,CHEMBL4196075,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,Eur J Med Chem,2018.0,150,,156,175,10.1016/j.ejmech.2018.02.070,29525435.0,
18546270,CHEMBL4208320,"4-cyclopropyl-N-ethyl-1,3-dimethyl-2-oxo-N-(p-tolyl)-1,2,3,4-tetrahydroquinoxaline-6-carboxamide",CHEMBL4198478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 20 mins relative to control,Inhibition,=,48.0,%,CCN(C(=O)c1ccc2c(c1)N(C1CC1)C(C)C(=O)N2C)c1ccc(C)cc1,CHEMBL4196075,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,Eur J Med Chem,2018.0,150,,156,175,10.1016/j.ejmech.2018.02.070,29525435.0,
18546271,CHEMBL4204922,"N-cyclohexyl-4-cyclopropyl-N,1,3-trimethyl-2-oxo-1,2,3,4-tetrahydroquinoxaline-6-carboxamide",CHEMBL4198478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 20 mins relative to control,Inhibition,=,11.0,%,CC1C(=O)N(C)c2ccc(C(=O)N(C)C3CCCCC3)cc2N1C1CC1,CHEMBL4196075,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,Eur J Med Chem,2018.0,150,,156,175,10.1016/j.ejmech.2018.02.070,29525435.0,
18546272,CHEMBL4204578,"N-cyclohexyl-4-cyclopropyl-N-ethyl-1,3-dimethyl-2-oxo-1,2,3,4-tetrahydroquinoxaline-6-carboxamide",CHEMBL4198478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 20 mins relative to control,Inhibition,=,3.0,%,CCN(C(=O)c1ccc2c(c1)N(C1CC1)C(C)C(=O)N2C)C1CCCCC1,CHEMBL4196075,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,Eur J Med Chem,2018.0,150,,156,175,10.1016/j.ejmech.2018.02.070,29525435.0,
18546273,CHEMBL4207666,"4-cyclopropyl-N,1,3-trimethyl-N-(4-methylcyclohexyl)-2-oxo-1,2,3,4-tetrahydroquinoxaline-6-carboxamide",CHEMBL4198478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 20 mins relative to control,Inhibition,=,13.0,%,CC1CCC(N(C)C(=O)c2ccc3c(c2)N(C2CC2)C(C)C(=O)N3C)CC1,CHEMBL4196075,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,Eur J Med Chem,2018.0,150,,156,175,10.1016/j.ejmech.2018.02.070,29525435.0,
18546274,CHEMBL4211379,"4-cyclopropyl-6-(indoline-1-carbonyl)-1,3-dimethyl-3,4-dihydroquinoxalin-2(1H)-one",CHEMBL4198478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 20 mins relative to control,Inhibition,=,33.0,%,CC1C(=O)N(C)c2ccc(C(=O)N3CCc4ccccc43)cc2N1C1CC1,CHEMBL4196075,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,Eur J Med Chem,2018.0,150,,156,175,10.1016/j.ejmech.2018.02.070,29525435.0,
18546275,CHEMBL4208894,"4-cyclopropyl-1,3-dimethyl-6-(2-methylindoline-1-carbonyl)-3,4-dihydroquinoxalin-2(1H)-one",CHEMBL4198478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 20 mins relative to control,Inhibition,=,32.0,%,CC1Cc2ccccc2N1C(=O)c1ccc2c(c1)N(C1CC1)C(C)C(=O)N2C,CHEMBL4196075,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,Eur J Med Chem,2018.0,150,,156,175,10.1016/j.ejmech.2018.02.070,29525435.0,
18546276,CHEMBL4212617,"4-cyclopropyl-1,3-dimethyl-6-(4-methylindoline-1-carbonyl)-3,4-dihydroquinoxalin-2(1H)-one",CHEMBL4198478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 20 mins relative to control,Inhibition,=,38.0,%,Cc1cccc2c1CCN2C(=O)c1ccc2c(c1)N(C1CC1)C(C)C(=O)N2C,CHEMBL4196075,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,Eur J Med Chem,2018.0,150,,156,175,10.1016/j.ejmech.2018.02.070,29525435.0,
18546277,CHEMBL4212538,"4-cyclopropyl-1,3-dimethyl-6-(5-methylindoline-1-carbonyl)-3,4-dihydroquinoxalin-2(1H)-one",CHEMBL4198478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 20 mins relative to control,Inhibition,=,42.0,%,Cc1ccc2c(c1)CCN2C(=O)c1ccc2c(c1)N(C1CC1)C(C)C(=O)N2C,CHEMBL4196075,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,Eur J Med Chem,2018.0,150,,156,175,10.1016/j.ejmech.2018.02.070,29525435.0,
18546278,CHEMBL4217497,"4-cyclopropyl-6-(2,5-dimethylindoline-1-carbonyl)-1,3-dimethyl-3,4-dihydroquinoxalin-2(1H)-one",CHEMBL4198478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 20 mins relative to control,Inhibition,=,15.0,%,Cc1ccc2c(c1)CC(C)N2C(=O)c1ccc2c(c1)N(C1CC1)C(C)C(=O)N2C,CHEMBL4196075,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,Eur J Med Chem,2018.0,150,,156,175,10.1016/j.ejmech.2018.02.070,29525435.0,
18546279,CHEMBL4208164,"4-cyclopropyl-6-(5-fluoroindoline-1-carbonyl)-1,3-dimethyl-3,4-dihydroquinoxalin-2(1H)-one",CHEMBL4198478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 20 mins relative to control,Inhibition,=,44.0,%,CC1C(=O)N(C)c2ccc(C(=O)N3CCc4cc(F)ccc43)cc2N1C1CC1,CHEMBL4196075,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,Eur J Med Chem,2018.0,150,,156,175,10.1016/j.ejmech.2018.02.070,29525435.0,
18546280,CHEMBL4213080,"4-cyclopentyl-6-(indoline-1-carbonyl)-1,3-dimethyl-3,4-dihydroquinoxalin-2(1H)-one",CHEMBL4198478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 20 mins relative to control,Inhibition,=,65.0,%,CC1C(=O)N(C)c2ccc(C(=O)N3CCc4ccccc43)cc2N1C1CCCC1,CHEMBL4196075,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,Eur J Med Chem,2018.0,150,,156,175,10.1016/j.ejmech.2018.02.070,29525435.0,
18546281,CHEMBL4213524,"4-cyclopropyl-1,3-dimethyl-6-(5-methylindoline-1-carbonyl)-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-one",CHEMBL4198478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 20 mins relative to control,Inhibition,=,26.0,%,Cc1ccc2c(c1)CCN2C(=O)c1ccc2c(n1)N(C1CC1)C(C)C(=O)N2C,CHEMBL4196075,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,Eur J Med Chem,2018.0,150,,156,175,10.1016/j.ejmech.2018.02.070,29525435.0,
18546282,CHEMBL4218450,"4-cyclopropyl-6-(2,5-dimethylindoline-1-carbonyl)-1,3-dimethyl-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-one",CHEMBL4198478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 20 mins relative to control,Inhibition,=,14.0,%,Cc1ccc2c(c1)CC(C)N2C(=O)c1ccc2c(n1)N(C1CC1)C(C)C(=O)N2C,CHEMBL4196075,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,Eur J Med Chem,2018.0,150,,156,175,10.1016/j.ejmech.2018.02.070,29525435.0,
18546444,CHEMBL4215726,"4-cyclopentyl-1,3-dimethyl-2-oxo-N-(p-tolyl)-1,2,3,4-tetrahydroquinoxaline-6-carboxamide",CHEMBL4198478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 20 mins relative to control,Inhibition,=,48.0,%,Cc1ccc(NC(=O)c2ccc3c(c2)N(C2CCCC2)C(C)C(=O)N3C)cc1,CHEMBL4196075,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,Eur J Med Chem,2018.0,150,,156,175,10.1016/j.ejmech.2018.02.070,29525435.0,
18546445,CHEMBL4204052,"4-cyclopropyl-N-(2,4-dimethylphenyl)-1,3-dimethyl-2-oxo-1,2,3,4-tetrahydroquinoxaline-6-carboxamide",CHEMBL4198478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 20 mins relative to control,Inhibition,=,22.0,%,Cc1ccc(NC(=O)c2ccc3c(c2)N(C2CC2)C(C)C(=O)N3C)c(C)c1,CHEMBL4196075,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,Eur J Med Chem,2018.0,150,,156,175,10.1016/j.ejmech.2018.02.070,29525435.0,
18546446,CHEMBL4202403,"4-cyclopropyl-1,3-dimethyl-2-oxo-N-p-tolyl-1,2,3,4-tetrahydroquinoxaline-6-carboxamide",CHEMBL4198478,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured after 20 mins relative to control,Inhibition,=,17.0,%,Cc1ccc(NC(=O)c2ccc3c(c2)N(C2CC2)C(C)C(=O)N3C)cc1,CHEMBL4196075,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,Eur J Med Chem,2018.0,150,,156,175,10.1016/j.ejmech.2018.02.070,29525435.0,
18549645,CHEMBL4212186,"5-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl]methyl]thiophene-2-carbohydroxamic acid",CHEMBL4198934,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 10 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,<,50.0,%,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(Cc4ccc(C(=O)NO)s4)ccc3OCC)nc12,CHEMBL4196089,"Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.",Eur J Med Chem,2018.0,150,,506,524,10.1016/j.ejmech.2018.03.005,29549837.0,
18561025,CHEMBL4212107,"rac-1-(1-(1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)ethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one",CHEMBL4201560,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide hydroxylation to hydroxytolbutamide at 1 uM incubated for 10 mins,Inhibition,=,-30.0,%,CC(c1ccc2c(c1)OCO2)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,CHEMBL4196199,Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias.,J Med Chem,2018.0,61,19,8895,8907,10.1021/acs.jmedchem.8b01136,30199635.0,
18561026,CHEMBL4216374,rac-1-(1-(1-(4-(Trifluoromethoxy)phenyl)ethyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,CHEMBL4201560,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide hydroxylation to hydroxytolbutamide at 1 uM incubated for 10 mins,Inhibition,=,1.0,%,CC(c1ccc(OC(F)(F)F)cc1)N1CCC(n2c(=O)[nH]c3ccccc32)CC1,CHEMBL4196199,Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias.,J Med Chem,2018.0,61,19,8895,8907,10.1021/acs.jmedchem.8b01136,30199635.0,
18561027,CHEMBL4207047,4-Chloro-1-(1-(2-chlorobenzyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,CHEMBL4201560,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide hydroxylation to hydroxytolbutamide at 1 uM incubated for 10 mins,Inhibition,=,55.0,%,O=c1[nH]c2c(Cl)cccc2n1C1CCN(Cc2ccccc2Cl)CC1,CHEMBL4196199,Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias.,J Med Chem,2018.0,61,19,8895,8907,10.1021/acs.jmedchem.8b01136,30199635.0,
18561028,CHEMBL4205961,5-Chloro-1-(1-(2-chlorobenzyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,CHEMBL4201560,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide hydroxylation to hydroxytolbutamide at 1 uM incubated for 10 mins,Inhibition,=,20.0,%,O=c1[nH]c2cc(Cl)ccc2n1C1CCN(Cc2ccccc2Cl)CC1,CHEMBL4196199,Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias.,J Med Chem,2018.0,61,19,8895,8907,10.1021/acs.jmedchem.8b01136,30199635.0,
18561029,CHEMBL4203641,6-Chloro-1-(1-(2-chlorobenzyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,CHEMBL4201560,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide hydroxylation to hydroxytolbutamide at 1 uM incubated for 10 mins,Inhibition,=,34.0,%,O=c1[nH]c2ccc(Cl)cc2n1C1CCN(Cc2ccccc2Cl)CC1,CHEMBL4196199,Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias.,J Med Chem,2018.0,61,19,8895,8907,10.1021/acs.jmedchem.8b01136,30199635.0,
18561030,CHEMBL4202958,rac-5-Chloro-1-(1-(4-bromo-2-fluorobenzyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,CHEMBL4201560,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide hydroxylation to hydroxytolbutamide at 1 uM incubated for 10 mins,Inhibition,=,41.0,%,O=c1[nH]c2cc(Cl)ccc2n1C1CCN(Cc2ccc(Br)cc2F)CC1,CHEMBL4196199,Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias.,J Med Chem,2018.0,61,19,8895,8907,10.1021/acs.jmedchem.8b01136,30199635.0,
18561031,CHEMBL4210060,"rac-5,6-Dichloro-1-(1-(4-bromo-2-fluorobenzyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one",CHEMBL4201560,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide hydroxylation to hydroxytolbutamide at 1 uM incubated for 10 mins,Inhibition,=,-1.0,%,O=c1[nH]c2cc(Cl)c(Cl)cc2n1C1CCN(Cc2ccc(Br)cc2F)CC1,CHEMBL4196199,Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias.,J Med Chem,2018.0,61,19,8895,8907,10.1021/acs.jmedchem.8b01136,30199635.0,
18561032,CHEMBL4217435,"5,6-Dichloro-1-(1-(4-bromobenzyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one",CHEMBL4201560,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide hydroxylation to hydroxytolbutamide at 1 uM incubated for 10 mins,Inhibition,=,14.0,%,O=c1[nH]c2cc(Cl)c(Cl)cc2n1C1CCN(Cc2ccc(Br)cc2)CC1,CHEMBL4196199,Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias.,J Med Chem,2018.0,61,19,8895,8907,10.1021/acs.jmedchem.8b01136,30199635.0,
18575780,CHEMBL4226878,"2-((2,6-dichlorophenyl)amino)-N-(2,6-difluorophenyl)-7,7-dimethyl-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,35.0,%,CC1(C)Cc2c(c(C(=O)Nc3c(F)cccc3F)cc3nc(Nc4c(Cl)cccc4Cl)[nH]c23)O1,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18575781,CHEMBL4225008,"2-((2,6-dichlorophenyl)amino)-7,7-dimethyl-N-(2-(trifluoromethyl)phenyl)-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,16.0,%,CC1(C)Cc2c(c(C(=O)Nc3ccccc3C(F)(F)F)cc3nc(Nc4c(Cl)cccc4Cl)[nH]c23)O1,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18575782,CHEMBL4224733,"2-((2-chloro-6-fluorophenyl)amino)-7,7-dimethyl-N-(2-(trifluoromethyl)phenyl)-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,29.0,%,CC1(C)Cc2c(c(C(=O)Nc3ccccc3C(F)(F)F)cc3nc(Nc4c(F)cccc4Cl)[nH]c23)O1,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18575783,CHEMBL4228804,"2-((2-chloro-6-fluorophenyl)amino)-N-(2-fluoro-5-(trifluoromethyl)phenyl)-7,7-dimethyl-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,35.0,%,CC1(C)Cc2c(c(C(=O)Nc3cc(C(F)(F)F)ccc3F)cc3nc(Nc4c(F)cccc4Cl)[nH]c23)O1,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18575784,CHEMBL4226379,"2-((2-chloro-6-fluorophenyl)amino)-N-(5-(difluoromethyl)-2-fluorophenyl)-7,7-dimethyl-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,42.0,%,CC1(C)Cc2c(c(C(=O)Nc3cc(C(F)F)ccc3F)cc3nc(Nc4c(F)cccc4Cl)[nH]c23)O1,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18575785,CHEMBL4225183,"2-((2-chloro-6-fluorophenyl)amino)-N-(5-cyclopropyl-2-fluorophenyl)-7,7-dimethyl-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,42.0,%,CC1(C)Cc2c(c(C(=O)Nc3cc(C4CC4)ccc3F)cc3nc(Nc4c(F)cccc4Cl)[nH]c23)O1,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18575786,CHEMBL4226536,"N-(5-cyclopropyl-2-fluorophenyl)-2-((2,6-dichlorophenyl)amino)-7,7-dimethyl-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,26.0,%,CC1(C)Cc2c(c(C(=O)Nc3cc(C4CC4)ccc3F)cc3nc(Nc4c(Cl)cccc4Cl)[nH]c23)O1,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18575787,CHEMBL4227545,"2-((2-chloro-6-fluorophenyl)amino)-N-(2-fluoro-4-(trifluoromethyl)phenyl)-7,7-dimethyl-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,39.0,%,CC1(C)Cc2c(c(C(=O)Nc3ccc(C(F)(F)F)cc3F)cc3nc(Nc4c(F)cccc4Cl)[nH]c23)O1,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18575788,CHEMBL4227610,"2-((2-chloro-6-fluorophenyl)amino)-7,7-dimethyl-N-(2-methyl-4-(trifluoromethyl)phenyl)-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,1.0,%,Cc1cc(C(F)(F)F)ccc1NC(=O)c1cc2nc(Nc3c(F)cccc3Cl)[nH]c2c2c1OC(C)(C)C2,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18575789,CHEMBL4224969,"2-((2-chloro-6-fluorophenyl)amino)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-7,7-dimethyl-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,48.0,%,CC1(C)Cc2c(c(C(=O)Nc3ccc(F)c(C(F)(F)F)c3)cc3nc(Nc4c(F)cccc4Cl)[nH]c23)O1,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18575790,CHEMBL4225834,"2-((2-chloro-6-methylphenyl)amino)-7,7-dimethyl-N-(4-(trifluoromethyl)phenyl)-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,46.0,%,Cc1cccc(Cl)c1Nc1nc2cc(C(=O)Nc3ccc(C(F)(F)F)cc3)c3c(c2[nH]1)CC(C)(C)O3,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18575791,CHEMBL4226526,"2-((2-chloro-6-methylphenyl)amino)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-7,7-dimethyl-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,47.0,%,Cc1cccc(Cl)c1Nc1nc2cc(C(=O)Nc3ccc(F)c(C(F)(F)F)c3)c3c(c2[nH]1)CC(C)(C)O3,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18575792,CHEMBL4226545,"2-((2-chloro-6-methylphenyl)amino)-N-(2-fluoro-5-(trifluoromethyl)phenyl)-7,7-dimethyl-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,15.0,%,Cc1cccc(Cl)c1Nc1nc2cc(C(=O)Nc3cc(C(F)(F)F)ccc3F)c3c(c2[nH]1)CC(C)(C)O3,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18575793,CHEMBL4226413,"2-((2-chloro-6-methylphenyl)amino)-N-(5-(difluoromethyl)-2-fluorophenyl)-7,7-dimethyl-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,28.0,%,Cc1cccc(Cl)c1Nc1nc2cc(C(=O)Nc3cc(C(F)F)ccc3F)c3c(c2[nH]1)CC(C)(C)O3,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18575794,CHEMBL4224767,"2-((2-chloro-6-methylphenyl)amino)-N-(5-cyclopropyl-2-fluorophenyl)-7,7-dimethyl-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,12.0,%,Cc1cccc(Cl)c1Nc1nc2cc(C(=O)Nc3cc(C4CC4)ccc3F)c3c(c2[nH]1)CC(C)(C)O3,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18575795,CHEMBL4229061,"2-((2,6-dichlorophenyl)amino)-7,7-dimethyl-N-(5-(trifluoromethyl)pyridin-2-yl)-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,56.0,%,CC1(C)Cc2c(c(C(=O)Nc3ccc(C(F)(F)F)cn3)cc3nc(Nc4c(Cl)cccc4Cl)[nH]c23)O1,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18575796,CHEMBL3961834,"2-(2-chloro-6-fluorophenylamino)-1,7,7-trimethyl-N-(4-(trifluoromethyl)phenyl)-7,8-dihydro-1H-benzofuro[5,4-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,44.0,%,Cn1c(Nc2c(F)cccc2Cl)nc2cc(C(=O)Nc3ccc(C(F)(F)F)cc3)c3c(c21)CC(C)(C)O3,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18575797,CHEMBL4228430,"2-((2-chloro-6-fluorophenyl)amino)-1,7,7-trimethyl-N-(3-(trifluoromethyl)phenyl)-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,19.0,%,Cn1c(Nc2c(F)cccc2Cl)nc2cc(C(=O)Nc3cccc(C(F)(F)F)c3)c3c(c21)CC(C)(C)O3,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18575798,CHEMBL4225160,"2-((2-chloro-6-fluorophenyl)amino)-N-(4-cyclopropylphenyl)-1,7,7-trimethyl-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,47.0,%,Cn1c(Nc2c(F)cccc2Cl)nc2cc(C(=O)Nc3ccc(C4CC4)cc3)c3c(c21)CC(C)(C)O3,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18575799,CHEMBL4227388,"2-((2-chloro-6-fluorophenyl)amino)-N-(2-fluoro-4-methylphenyl)-1,7,7-trimethyl-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,52.0,%,Cc1ccc(NC(=O)c2cc3nc(Nc4c(F)cccc4Cl)n(C)c3c3c2OC(C)(C)C3)c(F)c1,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18575800,CHEMBL4225710,"2-((2-chloro-6-fluorophenyl)amino)-1,7,7-trimethyl-N-(5-(trifluoromethyl)pyridin-2-yl)-7,8-dihydro-1H-benzofuro[4,5-d]imidazole-5-carboxamide",CHEMBL4221866,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,=,52.0,%,Cn1c(Nc2c(F)cccc2Cl)nc2cc(C(=O)Nc3ccc(C(F)(F)F)cn3)c3c(c21)CC(C)(C)O3,CHEMBL4219124,"Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series - Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2.",Bioorg Med Chem Lett,2018.0,28,7,1211,1218,10.1016/j.bmcl.2018.02.048,29519738.0,
18672457,CHEMBL4243419,"2-(2-methyl-4-((2-phenyl-1-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)ethyl)thio)phenoxy)acetic acid",CHEMBL4234945,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of tolbutamide 4-hydroxylase activity of CYP2C9 in human liver microsomes at 10 uM preincubated for 5 mins followed by NADPH addition measured after 15 mins by LC-MS/MS analysis,Inhibition,=,35.5,%,Cc1cc(SC(Cc2ccccc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2)ccc1OCC(=O)O,CHEMBL4229483,"Synthesis and evaluation of an orally available ""Y""-shaped biaryl peroxisome proliferator-activated receptor δ agonist.",Bioorg Med Chem,2018.0,26,15,4382,4389,10.1016/j.bmc.2018.06.044,30054191.0,
18675636,CHEMBL4248694,"(S)-2-(6-((3-(2-benzyl-1,2,3,4-tetrahydroisoquinolin-6-yl)benzyl)oxy)-2,3-dihydrobenzofuran-3-yl)acetic acid hydrochloride",CHEMBL4235685,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 5 uM using diclofenac sodium as substrate by LC-MS/MS analysis relative to control,Inhibition,=,16.25,%,Cl.O=C(O)C[C@@H]1COc2cc(OCc3cccc(-c4ccc5c(c4)CCN(Cc4ccccc4)C5)c3)ccc21,CHEMBL4229516,"Design, synthesis and biological evaluation of a series of novel GPR40 agonists containing nitrogen heterocyclic rings.",Bioorg Med Chem Lett,2018.0,28,18,3050,3056,10.1016/j.bmcl.2018.07.048,30097366.0,
18675637,CHEMBL4244619,"(S)-2-(6-((3-(2-benzyl-1,2,3,4-tetrahydroisoquinolin-7-yl)benzyl)oxy)-2,3-dihydrobenzofuran-3-yl)acetic acid hydrochloride",CHEMBL4235685,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 5 uM using diclofenac sodium as substrate by LC-MS/MS analysis relative to control,Inhibition,=,3.94,%,Cl.O=C(O)C[C@@H]1COc2cc(OCc3cccc(-c4ccc5c(c4)CN(Cc4ccccc4)CC5)c3)ccc21,CHEMBL4229516,"Design, synthesis and biological evaluation of a series of novel GPR40 agonists containing nitrogen heterocyclic rings.",Bioorg Med Chem Lett,2018.0,28,18,3050,3056,10.1016/j.bmcl.2018.07.048,30097366.0,
18675638,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4235685,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 5 uM using diclofenac sodium as substrate by LC-MS/MS analysis relative to control,Inhibition,=,94.9,%,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4229516,"Design, synthesis and biological evaluation of a series of novel GPR40 agonists containing nitrogen heterocyclic rings.",Bioorg Med Chem Lett,2018.0,28,18,3050,3056,10.1016/j.bmcl.2018.07.048,30097366.0,
18675639,CHEMBL1829174,"(S)-2-(6-((2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)biphenyl-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid",CHEMBL4235685,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 5 uM using diclofenac sodium as substrate by LC-MS/MS analysis relative to control,Inhibition,=,21.02,%,Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c1cccc(COc2ccc3c(c2)OC[C@H]3CC(=O)O)c1,CHEMBL4229516,"Design, synthesis and biological evaluation of a series of novel GPR40 agonists containing nitrogen heterocyclic rings.",Bioorg Med Chem Lett,2018.0,28,18,3050,3056,10.1016/j.bmcl.2018.07.048,30097366.0,
18676362,CHEMBL4248604,4-(4-((trans)-4-(5-(trifluoromethyl)pyridin-2-ylamino)cyclohexylsulfonyl)phenyl)picolinamide,CHEMBL4235816,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,51.0,%,NC(=O)c1cc(-c2ccc(S(=O)(=O)[C@H]3CC[C@H](Nc4ccc(C(F)(F)F)cn4)CC3)cc2)ccn1,CHEMBL4229521,Identification of a novel series of potent and selective CCR6 inhibitors as biological probes.,Bioorg Med Chem Lett,2018.0,28,18,3067,3072,10.1016/j.bmcl.2018.07.042,30098865.0,
18704908,CHEMBL4286199,"N-((1r,4r)-4-(4-(5-methyl-3-phenylisoxazol-4-yl)pyrimidin-2-ylamino)cyclohexyl)acetamide",CHEMBL4255744,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 5 uM relative to control,Inhibition,=,59.0,%,CC(=O)N[C@H]1CC[C@H](Nc2nccc(-c3c(-c4ccccc4)noc3C)n2)CC1,CHEMBL4251696,Discovery of a Stress-Activated Protein Kinase Inhibitor for Lymphatic Filariasis.,ACS Med Chem Lett,2018.0,9,3,210,214,10.1021/acsmedchemlett.7b00477,29541362.0,
18718630,CHEMBL3617053,"2,2-diphenyl-N-(4-(N-thiazol-2-ylsulfamoyl)phenyl)acetamide",CHEMBL4257716,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM by high throughput assay relative to control,Inhibition,=,79.0,%,O=C(Nc1ccc(S(=O)(=O)Nc2nccs2)cc1)C(c1ccccc1)c1ccccc1,CHEMBL4257443,The discovery of a potent Na<sub>v</sub>1.3 inhibitor with good oral pharmacokinetics.,MedChemComm,2017.0,8,6,1255,1267,10.1039/C7MD00131B,30108836.0,
18718668,CHEMBL4276884,N-(3-chloro-4-(trifluoromethoxy)benzyl)-3-fluoro-4-(N-thiazol-2-ylsulfamoyl)benzamide,CHEMBL4257716,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM by high throughput assay relative to control,Inhibition,=,66.0,%,O=C(NCc1ccc(OC(F)(F)F)c(Cl)c1)c1ccc(S(=O)(=O)Nc2nccs2)c(F)c1,CHEMBL4257443,The discovery of a potent Na<sub>v</sub>1.3 inhibitor with good oral pharmacokinetics.,MedChemComm,2017.0,8,6,1255,1267,10.1039/C7MD00131B,30108836.0,
18718703,CHEMBL4293085,"4-(N-1,2,4-thiadiazol-5-ylsulfamoyl)-N-(3-chloro-4-(trifluoromethoxy)benzyl)-3-fluorobenzamide",CHEMBL4257716,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM by high throughput assay relative to control,Inhibition,=,88.0,%,O=C(NCc1ccc(OC(F)(F)F)c(Cl)c1)c1ccc(S(=O)(=O)Nc2ncns2)c(F)c1,CHEMBL4257443,The discovery of a potent Na<sub>v</sub>1.3 inhibitor with good oral pharmacokinetics.,MedChemComm,2017.0,8,6,1255,1267,10.1039/C7MD00131B,30108836.0,
18718752,CHEMBL4276813,"4-(3-chloro-4-(trifluoromethoxy)benzyloxy)-N-(1,2,4-thiadiazol-5-yl)benzenesulfonamide",CHEMBL4257716,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM by high throughput assay relative to control,Inhibition,=,85.0,%,O=S(=O)(Nc1ncns1)c1ccc(OCc2ccc(OC(F)(F)F)c(Cl)c2)cc1,CHEMBL4257443,The discovery of a potent Na<sub>v</sub>1.3 inhibitor with good oral pharmacokinetics.,MedChemComm,2017.0,8,6,1255,1267,10.1039/C7MD00131B,30108836.0,
18720547,CHEMBL4294195,6-Methoxy chelerythrine,CHEMBL4257969,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 3-cyano-7-ethoxycoumarin substrate by EROD assay relative to control,Inhibition,=,4.0,%,COc1ccc2c(c1OC)C(OC)N(C)c1c-2ccc2cc3c(cc12)OCO3,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720548,CHEMBL44541,4-(5-Bromo-1H-indol-3-yl)-pyrimidin-2-ylamine,CHEMBL4257969,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 3-cyano-7-ethoxycoumarin substrate by EROD assay relative to control,Inhibition,=,3.0,%,Nc1nccc(-c2c[nH]c3ccc(Br)cc23)n1,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720549,CHEMBL4282750,Karanjin,CHEMBL4257969,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 3-cyano-7-ethoxycoumarin substrate by EROD assay relative to control,Inhibition,=,0.0,%,COc1c(-c2ccccc2)oc2c(ccc3ccoc32)c1=O,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720550,CHEMBL44746,"4,9-Dimethoxy-7-methyl-furo[3,2-g]chromen-5-one",CHEMBL4257969,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 3-cyano-7-ethoxycoumarin substrate by EROD assay relative to control,Inhibition,=,12.0,%,COc1c2occc2c(OC)c2c(=O)cc(C)oc12,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720551,CHEMBL226508,"5-hydroxy-6,7,3',4'-tetramethoxyflavone",CHEMBL4257969,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 3-cyano-7-ethoxycoumarin substrate by EROD assay relative to control,Inhibition,=,7.0,%,COc1ccc(-c2cc(=O)c3c(O)c(OC)c(OC)cc3o2)cc1OC,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720552,CHEMBL4285296,Pongamol,CHEMBL4257969,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 3-cyano-7-ethoxycoumarin substrate by EROD assay relative to control,Inhibition,=,0.0,%,COc1c(C(=O)CC(=O)c2ccccc2)ccc2occc12,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720553,CHEMBL24171,"4-Methoxy-furo[3,2-g]chromen-7-one",CHEMBL4257969,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 3-cyano-7-ethoxycoumarin substrate by EROD assay relative to control,Inhibition,=,4.0,%,COc1c2ccoc2cc2oc(=O)ccc12,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720554,CHEMBL452751,phellopterin,CHEMBL4257969,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 3-cyano-7-ethoxycoumarin substrate by EROD assay relative to control,Inhibition,=,3.0,%,COc1c2ccoc2c(OCC=C(C)C)c2oc(=O)ccc12,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720555,CHEMBL140796,"4,9-Dimethoxy-furo[3,2-g]chromen-7-one",CHEMBL4257969,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 3-cyano-7-ethoxycoumarin substrate by EROD assay relative to control,Inhibition,=,0.0,%,COc1c2ccoc2c(OC)c2oc(=O)ccc12,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720556,CHEMBL295316,"5-Hydroxy-2-methyl-[1,4]naphthoquinone",CHEMBL4257969,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 3-cyano-7-ethoxycoumarin substrate by EROD assay relative to control,Inhibition,=,11.0,%,CC1=CC(=O)c2c(O)cccc2C1=O,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720557,CHEMBL274056,"5,8-Dihydroxy-[1,4]naphthoquinone",CHEMBL4257969,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 3-cyano-7-ethoxycoumarin substrate by EROD assay relative to control,Inhibition,=,5.0,%,O=C1C=CC(=O)c2c(O)ccc(O)c21,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18720558,CHEMBL283196,2-Phenyl-benzo[h]chromen-4-one,CHEMBL4257969,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 3-cyano-7-ethoxycoumarin substrate by EROD assay relative to control,Inhibition,=,10.0,%,O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12,CHEMBL4257453,Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy <i>via</i> screening of a natural product repository.,MedChemComm,2018.0,9,2,371,382,10.1039/C7MD00388A,30108931.0,
18732822,CHEMBL4290516,"5-(4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-2H-tetrazole",CHEMBL4260548,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC/MS/MS analysis relative to control,Inhibition,=,77.0,%,c1cn(-c2ccc(-c3ccc(-c4nn[nH]n4)cc3)cc2)cn1,CHEMBL4257571,"Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD.",Bioorg Med Chem Lett,2018.0,28,23-24,3766,3773,10.1016/j.bmcl.2018.10.012,30340896.0,
18732842,CHEMBL4294284,"5-(4'-(2-Methyl-1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-2H-tetrazole",CHEMBL4260548,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC/MS/MS analysis relative to control,Inhibition,=,18.0,%,Cc1nccn1-c1ccc(-c2ccc(-c3nnn[nH]3)cc2)cc1,CHEMBL4257571,"Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD.",Bioorg Med Chem Lett,2018.0,28,23-24,3766,3773,10.1016/j.bmcl.2018.10.012,30340896.0,
18732855,CHEMBL4290485,"5-(2-Chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole",CHEMBL4260548,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC/MS/MS analysis relative to control,Inhibition,=,86.0,%,Clc1cc(-c2nnn[nH]2)ccc1-c1ccc(-n2ccnc2)cc1,CHEMBL4257571,"Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD.",Bioorg Med Chem Lett,2018.0,28,23-24,3766,3773,10.1016/j.bmcl.2018.10.012,30340896.0,
18732909,CHEMBL4283157,"4'-(1H-imidazol-1-yl)-2'-methyl-[1,1'-biphenyl]-4-carboxylic acid",CHEMBL4260548,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC/MS/MS analysis relative to control,Inhibition,=,37.0,%,Cc1cc(-n2ccnc2)ccc1-c1ccc(C(=O)O)cc1,CHEMBL4257571,"Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD.",Bioorg Med Chem Lett,2018.0,28,23-24,3766,3773,10.1016/j.bmcl.2018.10.012,30340896.0,
18732919,CHEMBL4283184,"5-(4'-(1H-imidazol-1-yl)-2'-methyl-[1,1'-biphenyl]-4-yl)-1H-tetrazole",CHEMBL4260548,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC/MS/MS analysis relative to control,Inhibition,=,86.0,%,Cc1cc(-n2ccnc2)ccc1-c1ccc(-c2nnn[nH]2)cc1,CHEMBL4257571,"Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD.",Bioorg Med Chem Lett,2018.0,28,23-24,3766,3773,10.1016/j.bmcl.2018.10.012,30340896.0,
18732928,CHEMBL4291042,"5-(2'-Ethyl-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole",CHEMBL4260548,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC/MS/MS analysis relative to control,Inhibition,=,94.0,%,CCc1cc(-n2ccnc2)ccc1-c1ccc(-c2nnn[nH]2)cc1,CHEMBL4257571,"Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD.",Bioorg Med Chem Lett,2018.0,28,23-24,3766,3773,10.1016/j.bmcl.2018.10.012,30340896.0,
18732937,CHEMBL4286551,"5-(2'-Ethyl-4'-(2-methyl-1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole",CHEMBL4260548,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC/MS/MS analysis relative to control,Inhibition,=,48.0,%,CCc1cc(-n2ccnc2C)ccc1-c1ccc(-c2nnn[nH]2)cc1,CHEMBL4257571,"Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD.",Bioorg Med Chem Lett,2018.0,28,23-24,3766,3773,10.1016/j.bmcl.2018.10.012,30340896.0,
18732946,CHEMBL4294439,"5-(2-Chloro-4'-(1H-imidazol-1-yl)-2'-methyl-[1,1'-biphenyl]-4-yl)-1H-tetrazole",CHEMBL4260548,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC/MS/MS analysis relative to control,Inhibition,=,83.0,%,Cc1cc(-n2ccnc2)ccc1-c1ccc(-c2nnn[nH]2)cc1Cl,CHEMBL4257571,"Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD.",Bioorg Med Chem Lett,2018.0,28,23-24,3766,3773,10.1016/j.bmcl.2018.10.012,30340896.0,
18732955,CHEMBL4289979,"5-(2'-Ethyl-2-fluoro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole",CHEMBL4260548,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC/MS/MS analysis relative to control,Inhibition,=,78.0,%,CCc1cc(-n2ccnc2)ccc1-c1ccc(-c2nnn[nH]2)cc1F,CHEMBL4257571,"Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD.",Bioorg Med Chem Lett,2018.0,28,23-24,3766,3773,10.1016/j.bmcl.2018.10.012,30340896.0,
18732971,CHEMBL4278220,2-(4-(1H-tetrazol-5-yl)phenyl)-3-chloro-5-(1H-imidazol-1-yl)pyridine,CHEMBL4260548,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC/MS/MS analysis relative to control,Inhibition,=,64.0,%,Clc1cc(-n2ccnc2)cnc1-c1ccc(-c2nnn[nH]2)cc1,CHEMBL4257571,"Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD.",Bioorg Med Chem Lett,2018.0,28,23-24,3766,3773,10.1016/j.bmcl.2018.10.012,30340896.0,
18732980,CHEMBL4286132,2-(4-(1H-tetrazol-5-yl)phenyl)-5-(1H-imidazol-1-yl)-3-methylpyridine,CHEMBL4260548,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC/MS/MS analysis relative to control,Inhibition,=,61.0,%,Cc1cc(-n2ccnc2)cnc1-c1ccc(-c2nnn[nH]2)cc1,CHEMBL4257571,"Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD.",Bioorg Med Chem Lett,2018.0,28,23-24,3766,3773,10.1016/j.bmcl.2018.10.012,30340896.0,
18732989,CHEMBL4289333,2-(2-Fluoro-4-(1H-tetrazol-5-yl)phenyl)-5-(1H-imidazol-1-yl)-3-methylpyridine,CHEMBL4260548,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC/MS/MS analysis relative to control,Inhibition,=,60.0,%,Cc1cc(-n2ccnc2)cnc1-c1ccc(-c2nnn[nH]2)cc1F,CHEMBL4257571,"Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD.",Bioorg Med Chem Lett,2018.0,28,23-24,3766,3773,10.1016/j.bmcl.2018.10.012,30340896.0,
18733007,CHEMBL4281451,3-Chloro-2-(2-fluoro-4-(1H-tetrazol-5-yl)phenyl)-5-(1H-imidazol-1-yl)pyridine,CHEMBL4260548,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins in presence of NADPH by LC/MS/MS analysis relative to control,Inhibition,=,50.0,%,Fc1cc(-c2nnn[nH]2)ccc1-c1ncc(-n2ccnc2)cc1Cl,CHEMBL4257571,"Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD.",Bioorg Med Chem Lett,2018.0,28,23-24,3766,3773,10.1016/j.bmcl.2018.10.012,30340896.0,
18741899,CHEMBL4216951,"4-(1-methyl-1H-pyrazol-5-yl)-1-(2-(piperidin-1-yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidine",CHEMBL4262395,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 at 1 uM relative to control,Inhibition,<,50.0,%,Cn1nccc1-c1ncnc2c1cnn2CCN1CCCCC1,CHEMBL4261508,"Pyrazolo[3,4-<i>d</i>]pyrimidines as sigma-1 receptor ligands for the treatment of pain. Part 2: Introduction of cyclic substituents in position 4.",MedChemComm,2017.0,8,6,1246,1254,10.1039/C7MD00078B,30108835.0,
18803123,CHEMBL4283244,"4'-Fluoro-N-(2-methyl-5-(3-(3,4,5-trimethoxybenzoyl)guanidino)phenyl)biphenyl-4-carboxamide Hydrochloride",CHEMBL4274779,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in insect cell microsomes at 1 uM using Luciferin-H as substrate preincubated for 30 mins followed by NADPH addition measured after 30 mins by luminometric method,Inhibition,=,63.0,%,COc1cc(C(=O)NC(=N)Nc2ccc(C)c(NC(=O)c3ccc(-c4ccc(F)cc4)cc3)c2)cc(OC)c1OC.Cl,CHEMBL4270604,Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.,Eur J Med Chem,2018.0,157,,368,379,10.1016/j.ejmech.2018.07.053,30099257.0,
18803124,CHEMBL4293834,"N-(2-Methyl-5-(3-(3,4,5-trimethoxybenzoyl)guanidino)phenyl)biphenyl-4-carboxamide Hydrochloride",CHEMBL4274779,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in insect cell microsomes at 1 uM using Luciferin-H as substrate preincubated for 30 mins followed by NADPH addition measured after 30 mins by luminometric method,Inhibition,=,43.0,%,COc1cc(C(=O)NC(=N)Nc2ccc(C)c(NC(=O)c3ccc(-c4ccccc4)cc3)c2)cc(OC)c1OC.Cl,CHEMBL4270604,Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.,Eur J Med Chem,2018.0,157,,368,379,10.1016/j.ejmech.2018.07.053,30099257.0,
18803125,CHEMBL4287905,"3,4,5-trimethoxy-N-(N-(4-methyl-3-(4-phenethylbenzamido)phenyl)carbamimidoyl)benzamide hydrochloride",CHEMBL4274779,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in insect cell microsomes at 1 uM using Luciferin-H as substrate preincubated for 30 mins followed by NADPH addition measured after 30 mins by luminometric method,Inhibition,=,68.0,%,COc1cc(C(=O)NC(=N)Nc2ccc(C)c(NC(=O)c3ccc(CCc4ccccc4)cc3)c2)cc(OC)c1OC.Cl,CHEMBL4270604,Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.,Eur J Med Chem,2018.0,157,,368,379,10.1016/j.ejmech.2018.07.053,30099257.0,
18803126,CHEMBL2031263,"4'-Fluoro-N-(2-methyl-5-(3-(3,4,5-trimethoxybenzoyl)thioureido)phenyl)biphenyl-4-carboxamide",CHEMBL4274779,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in insect cell microsomes at 1 uM using Luciferin-H as substrate preincubated for 30 mins followed by NADPH addition measured after 30 mins by luminometric method,Inhibition,=,63.0,%,COc1cc(C(=O)NC(=S)Nc2ccc(C)c(NC(=O)c3ccc(-c4ccc(F)cc4)cc3)c2)cc(OC)c1OC,CHEMBL4270604,Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.,Eur J Med Chem,2018.0,157,,368,379,10.1016/j.ejmech.2018.07.053,30099257.0,
18803127,CHEMBL4283244,"4'-Fluoro-N-(2-methyl-5-(3-(3,4,5-trimethoxybenzoyl)guanidino)phenyl)biphenyl-4-carboxamide Hydrochloride",CHEMBL4274780,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in insect cell microsomes at 5 uM using Luciferin-H as substrate preincubated for 30 mins followed by NADPH addition measured after 30 mins by luminometric method,Inhibition,=,76.0,%,COc1cc(C(=O)NC(=N)Nc2ccc(C)c(NC(=O)c3ccc(-c4ccc(F)cc4)cc3)c2)cc(OC)c1OC.Cl,CHEMBL4270604,Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.,Eur J Med Chem,2018.0,157,,368,379,10.1016/j.ejmech.2018.07.053,30099257.0,
18803128,CHEMBL4293834,"N-(2-Methyl-5-(3-(3,4,5-trimethoxybenzoyl)guanidino)phenyl)biphenyl-4-carboxamide Hydrochloride",CHEMBL4274780,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in insect cell microsomes at 5 uM using Luciferin-H as substrate preincubated for 30 mins followed by NADPH addition measured after 30 mins by luminometric method,Inhibition,=,71.0,%,COc1cc(C(=O)NC(=N)Nc2ccc(C)c(NC(=O)c3ccc(-c4ccccc4)cc3)c2)cc(OC)c1OC.Cl,CHEMBL4270604,Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.,Eur J Med Chem,2018.0,157,,368,379,10.1016/j.ejmech.2018.07.053,30099257.0,
18803129,CHEMBL4287905,"3,4,5-trimethoxy-N-(N-(4-methyl-3-(4-phenethylbenzamido)phenyl)carbamimidoyl)benzamide hydrochloride",CHEMBL4274780,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in insect cell microsomes at 5 uM using Luciferin-H as substrate preincubated for 30 mins followed by NADPH addition measured after 30 mins by luminometric method,Inhibition,=,81.0,%,COc1cc(C(=O)NC(=N)Nc2ccc(C)c(NC(=O)c3ccc(CCc4ccccc4)cc3)c2)cc(OC)c1OC.Cl,CHEMBL4270604,Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.,Eur J Med Chem,2018.0,157,,368,379,10.1016/j.ejmech.2018.07.053,30099257.0,
18803130,CHEMBL2031263,"4'-Fluoro-N-(2-methyl-5-(3-(3,4,5-trimethoxybenzoyl)thioureido)phenyl)biphenyl-4-carboxamide",CHEMBL4274780,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in insect cell microsomes at 5 uM using Luciferin-H as substrate preincubated for 30 mins followed by NADPH addition measured after 30 mins by luminometric method,Inhibition,=,69.0,%,COc1cc(C(=O)NC(=S)Nc2ccc(C)c(NC(=O)c3ccc(-c4ccc(F)cc4)cc3)c2)cc(OC)c1OC,CHEMBL4270604,Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.,Eur J Med Chem,2018.0,157,,368,379,10.1016/j.ejmech.2018.07.053,30099257.0,
18803131,CHEMBL4283244,"4'-Fluoro-N-(2-methyl-5-(3-(3,4,5-trimethoxybenzoyl)guanidino)phenyl)biphenyl-4-carboxamide Hydrochloride",CHEMBL4274781,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in insect cell microsomes at 10 uM using Luciferin-H as substrate preincubated for 30 mins followed by NADPH addition measured after 30 mins by luminometric method,Inhibition,=,79.0,%,COc1cc(C(=O)NC(=N)Nc2ccc(C)c(NC(=O)c3ccc(-c4ccc(F)cc4)cc3)c2)cc(OC)c1OC.Cl,CHEMBL4270604,Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.,Eur J Med Chem,2018.0,157,,368,379,10.1016/j.ejmech.2018.07.053,30099257.0,
18803132,CHEMBL4293834,"N-(2-Methyl-5-(3-(3,4,5-trimethoxybenzoyl)guanidino)phenyl)biphenyl-4-carboxamide Hydrochloride",CHEMBL4274781,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in insect cell microsomes at 10 uM using Luciferin-H as substrate preincubated for 30 mins followed by NADPH addition measured after 30 mins by luminometric method,Inhibition,=,74.0,%,COc1cc(C(=O)NC(=N)Nc2ccc(C)c(NC(=O)c3ccc(-c4ccccc4)cc3)c2)cc(OC)c1OC.Cl,CHEMBL4270604,Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.,Eur J Med Chem,2018.0,157,,368,379,10.1016/j.ejmech.2018.07.053,30099257.0,
18803133,CHEMBL4287905,"3,4,5-trimethoxy-N-(N-(4-methyl-3-(4-phenethylbenzamido)phenyl)carbamimidoyl)benzamide hydrochloride",CHEMBL4274781,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in insect cell microsomes at 10 uM using Luciferin-H as substrate preincubated for 30 mins followed by NADPH addition measured after 30 mins by luminometric method,Inhibition,=,83.0,%,COc1cc(C(=O)NC(=N)Nc2ccc(C)c(NC(=O)c3ccc(CCc4ccccc4)cc3)c2)cc(OC)c1OC.Cl,CHEMBL4270604,Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.,Eur J Med Chem,2018.0,157,,368,379,10.1016/j.ejmech.2018.07.053,30099257.0,
18803134,CHEMBL2031263,"4'-Fluoro-N-(2-methyl-5-(3-(3,4,5-trimethoxybenzoyl)thioureido)phenyl)biphenyl-4-carboxamide",CHEMBL4274781,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in insect cell microsomes at 10 uM using Luciferin-H as substrate preincubated for 30 mins followed by NADPH addition measured after 30 mins by luminometric method,Inhibition,=,71.0,%,COc1cc(C(=O)NC(=S)Nc2ccc(C)c(NC(=O)c3ccc(-c4ccc(F)cc4)cc3)c2)cc(OC)c1OC,CHEMBL4270604,Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.,Eur J Med Chem,2018.0,157,,368,379,10.1016/j.ejmech.2018.07.053,30099257.0,
18803135,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4274781,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in insect cell microsomes at 10 uM using Luciferin-H as substrate preincubated for 30 mins followed by NADPH addition measured after 30 mins by luminometric method,Inhibition,=,98.0,%,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4270604,Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.,Eur J Med Chem,2018.0,157,,368,379,10.1016/j.ejmech.2018.07.053,30099257.0,
18851386,CHEMBL4448494,"6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine",CHEMBL4305868,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes using sulfaphenazole as substrate incubated for 20 mins in presence of NADPH by LC-MS/MS analysis,Inhibition,<,15.0,%,Cc1nc2c(F)cc(-c3nc(Nc4ccc5c(n4)CCN(CCN(C)C)C5)ncc3F)cc2n1C(C)C,CHEMBL4304763,"Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.",Eur J Med Chem,2019.0,178,,352,364,10.1016/j.ejmech.2019.06.005,31200237.0,
18860187,CHEMBL4483032,5-(2-(Cyclopropanecarboxamido)pyridin-4-yl)-4-cyclopropyl-1H-imidazole-2-carboxamide,CHEMBL4308536,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 at 10 uM using 3-cyano-7-ethoxycoumarin as substrate by fluorimetric analysis,Inhibition,=,0.8,%,NC(=O)c1nc(C2CC2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,CHEMBL4304830,Pyridinylimidazoles as GSK3β Inhibitors: The Impact of Tautomerism on Compound Activity via Water Networks.,ACS Med Chem Lett,2019.0,10,10,1407,1414,10.1021/acsmedchemlett.9b00177,31620226.0,
18888919,CHEMBL4531258,2-(furan-2-yl)-3-hydroxy-6-methoxy-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,71.3,%,COc1ccc2oc(-c3ccco3)c(O)c(=O)c2c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888920,CHEMBL4465877,2-(furan-2-yl)-3-hydroxy-7-methoxy-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,46.27,%,COc1ccc2c(=O)c(O)c(-c3ccco3)oc2c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888921,CHEMBL4459417,"2-(furan-2-yl)-3,6-dihydroxy-4H-chromen-4-one",CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,47.58,%,O=c1c(O)c(-c2ccco2)oc2ccc(O)cc12,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888922,CHEMBL4450073,"2-(furan-2-yl)-3,7-dihydroxy-4H-chromen-4-one",CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,83.65,%,O=c1c(O)c(-c2ccco2)oc2cc(O)ccc12,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888923,CHEMBL4444621,3-hydroxy-6-methoxy-2-(4-methylthiophen-2-yl)-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,29.22,%,COc1ccc2oc(-c3cc(C)cs3)c(O)c(=O)c2c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888924,CHEMBL4439388,3-hydroxy-7-methoxy-2-(4-methylthiophen-2-yl)-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,59.6,%,COc1ccc2c(=O)c(O)c(-c3cc(C)cs3)oc2c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888925,CHEMBL4471364,"3,6-dihydroxy-2-(4-methylthiophen-2-yl)-4H-chromen-4-one",CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,40.11,%,Cc1csc(-c2oc3ccc(O)cc3c(=O)c2O)c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888926,CHEMBL4539604,3-hydroxy-6-methyl-2-(4-methylthiophen-2-yl)-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,35.08,%,Cc1csc(-c2oc3ccc(C)cc3c(=O)c2O)c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888927,CHEMBL4588892,3-hydroxy-5-methoxy-2-(4-methylthiophen-2-yl)-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,53.53,%,COc1cccc2oc(-c3cc(C)cs3)c(O)c(=O)c12,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888928,CHEMBL4445329,"3,5-dihydroxy-2-(4-methylthiophen-2-yl)-4H-chromen-4-one",CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,71.83,%,Cc1csc(-c2oc3cccc(O)c3c(=O)c2O)c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888929,CHEMBL4446646,3-hydroxy-7-methoxy-2-(3-methylthiophen-2-yl)-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,45.5,%,COc1ccc2c(=O)c(O)c(-c3sccc3C)oc2c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888930,CHEMBL4438959,"3,7-dihydroxy-2-(3-methylthiophen-2-yl)-4H-chromen-4-one",CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,43.8,%,Cc1ccsc1-c1oc2cc(O)ccc2c(=O)c1O,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888931,CHEMBL4453866,3-hydroxy-6-methyl-2-(5-methylthiophen-2-yl)-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,6.64,%,Cc1ccc2oc(-c3ccc(C)s3)c(O)c(=O)c2c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888932,CHEMBL4590171,"2-(3',4'-dimethoxy-[1,1'-biphenyl]-3-yl)-3-hydroxy-6-methoxy-4H-chromen-4-one",CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,40.13,%,COc1ccc2oc(-c3cccc(-c4ccc(OC)c(OC)c4)c3)c(O)c(=O)c2c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888933,CHEMBL4565781,"2-(3',4'-dihydroxy-[1,1'-biphenyl]-3-yl)-3,6-dihydroxy-4H-chromen-4-one",CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,-22.64,%,O=c1c(O)c(-c2cccc(-c3ccc(O)c(O)c3)c2)oc2ccc(O)cc12,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888934,CHEMBL4575126,"2-(3-(benzo[d][1,3]dioxol-5-yl)phenyl)-3-hydroxy-6-methoxy-4H-chromen-4-one",CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,25.83,%,COc1ccc2oc(-c3cccc(-c4ccc5c(c4)OCO5)c3)c(O)c(=O)c2c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888935,CHEMBL4450031,"2-(benzo[d][1,3]dioxol-5-yl)-3-hydroxy-7-methoxy-4H-chromen-4-one",CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,72.72,%,COc1ccc2c(=O)c(O)c(-c3ccc4c(c3)OCO4)oc2c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888936,CHEMBL4519474,3-hydroxy-6-methoxy-2-(quinolin-6-yl)-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,-3.36,%,COc1ccc2oc(-c3ccc4ncccc4c3)c(O)c(=O)c2c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888937,CHEMBL4464312,2-(benzo[b]thiophen-3-yl)-3-hydroxy-6-methoxy-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,-10.02,%,COc1ccc2oc(-c3csc4ccccc34)c(O)c(=O)c2c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888938,CHEMBL4473268,3-hydroxy-2-(1H-indol-3-yl)-6-methoxy-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,28.84,%,COc1ccc2oc(-c3c[nH]c4ccccc34)c(O)c(=O)c2c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888939,CHEMBL4448565,"3,6-dihydroxy-2-(1H-indol-3-yl)-4H-chromen-4-one",CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,40.18,%,O=c1c(O)c(-c2c[nH]c3ccccc23)oc2ccc(O)cc12,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888940,CHEMBL4563463,3-hydroxy-6-methoxy-2-(1-methyl-1H-indol-3-yl)-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,-0.02,%,COc1ccc2oc(-c3cn(C)c4ccccc34)c(O)c(=O)c2c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888941,CHEMBL4439246,2-(benzo[b]thiophen-3-yl)-3-hydroxy-6-methyl-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,19.43,%,Cc1ccc2oc(-c3csc4ccccc34)c(O)c(=O)c2c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888942,CHEMBL4447054,2-(benzo[b]thiophen-3-yl)-6-bromo-3-hydroxy-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,25.33,%,O=c1c(O)c(-c2csc3ccccc23)oc2ccc(Br)cc12,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888943,CHEMBL4469979,2-(benzo[b]thiophen-3-yl)-6-fluoro-3-hydroxy-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,25.43,%,O=c1c(O)c(-c2csc3ccccc23)oc2ccc(F)cc12,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888944,CHEMBL4575467,2-(benzo[b]thiophen-3-yl)-6-chloro-3-hydroxy-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,28.55,%,O=c1c(O)c(-c2csc3ccccc23)oc2ccc(Cl)cc12,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888945,CHEMBL4458341,2-(benzo[b]thiophen-3-yl)-3-hydroxy-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,28.9,%,O=c1c(O)c(-c2csc3ccccc23)oc2ccccc12,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888946,CHEMBL4592506,2-(benzo[b]thiophen-3-yl)-3-hydroxy-7-methoxy-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,28.12,%,COc1ccc2c(=O)c(O)c(-c3csc4ccccc34)oc2c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888947,CHEMBL4541910,2-(benzo[b]thiophen-3-yl)-3-hydroxy-7-methyl-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,37.05,%,Cc1ccc2c(=O)c(O)c(-c3csc4ccccc34)oc2c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888948,CHEMBL4517741,2-(benzo[b]thiophen-3-yl)-7-fluoro-3-hydroxy-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,26.47,%,O=c1c(O)c(-c2csc3ccccc23)oc2cc(F)ccc12,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888949,CHEMBL4448476,2-(benzo[b]thiophen-3-yl)-7-chloro-3-hydroxy-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,5.82,%,O=c1c(O)c(-c2csc3ccccc23)oc2cc(Cl)ccc12,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888950,CHEMBL4520438,2-(benzo[b]thiophen-3-yl)-7-ethoxy-3-hydroxy-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,23.01,%,CCOc1ccc2c(=O)c(O)c(-c3csc4ccccc34)oc2c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888951,CHEMBL4441917,2-(benzo[b]thiophen-3-yl)-6-methoxy-4-oxo-4H-chromen-3-yl acetate,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,-229.45,%,COc1ccc2oc(-c3csc4ccccc34)c(OC(C)=O)c(=O)c2c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888952,CHEMBL4592720,2-(benzo[b]thiophen-3-yl)-6-methoxy-4-oxo-4H-chromen-3-yl pivalate,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,33.61,%,COc1ccc2oc(-c3csc4ccccc34)c(OC(=O)C(C)(C)C)c(=O)c2c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888953,CHEMBL4567447,2-(benzo[b]thiophen-3-yl)-6-methoxy-4-oxo-4H-chromen-3-yl pentanoate,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,48.32,%,CCCCC(=O)Oc1c(-c2csc3ccccc23)oc2ccc(OC)cc2c1=O,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888954,CHEMBL4457377,2-(benzo[b]thiophen-3-yl)-6-methoxy-4-oxo-4H-chromen-3-yl dimethylcarbamate,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,-6.48,%,COc1ccc2oc(-c3csc4ccccc34)c(OC(=O)N(C)C)c(=O)c2c1,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888955,CHEMBL4538581,2-(benzo[b]thiophen-3-yl)-3-ethoxy-6-methoxy-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,14.1,%,CCOc1c(-c2csc3ccccc23)oc2ccc(OC)cc2c1=O,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18888956,CHEMBL4567834,2-(benzo[b]thiophen-3-yl)-6-methoxy-3-propoxy-4H-chromen-4-one,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,19.57,%,CCCOc1c(-c2csc3ccccc23)oc2ccc(OC)cc2c1=O,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18889235,CHEMBL125,hexadecyloxy-2-trimethylammonioethylphosphorate,CHEMBL4313842,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human microsomal CYP2C9 expressed in baculovirus infected insect cells at 10 uM using luciferin-H as substrate preincubated with enzyme/substrate mixture for 30 mins followed by further incubation with NADPH for 30 mins by CYP450 luciferase Glo assay relative to control,Inhibition,=,-0.8,%,CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C,CHEMBL4311972,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",Eur J Med Chem,2019.0,183,,111676,111676,10.1016/j.ejmech.2019.111676,31542713.0,
18890182,CHEMBL4448754,"4-((4-((2-(Dimethylphosphoryl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-N-(piperidin-4-yl)benzamide",CHEMBL4314043,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human pooled liver microsomes at 10 uM using diclofenac as substrate preincubated for 10 mins followed by NADPH addition and measured after 15 mins by LC/MS/MS analysis relative to control,Inhibition,=,11.5,%,COc1cc(C(=O)NC2CCNCC2)ccc1Nc1nc(Nc2ccccc2P(C)(C)=O)c2cc[nH]c2n1,CHEMBL4311976,"Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents.",Eur J Med Chem,2019.0,183,,111716,111716,10.1016/j.ejmech.2019.111716,31550660.0,
18924536,CHEMBL4455109,NA,CHEMBL4324231,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in pooled human liver microsomes at 10 uM pre-incubated for 5 mins before NADPH addition and measured after 10 mins by UPLC-MS/MS analysis relative to control,Inhibition,=,0.0,%,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc3c(c2)OCC(C)(C)COc2cc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)ccc2-3)[nH]1)C(C)C,CHEMBL4321845,Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate.,J Med Chem,2019.0,62,23,10563,10582,10.1021/acs.jmedchem.9b01562,31710479.0,
18924537,CHEMBL4535441,"Dimethyl ((2S,2'S)-((2S,2'S)-2,2'-(5,5'-(7,7-Dimethyl-7,8-dihydro-6H-dibenzo[f,h][1,5]dioxonine-3,11-diyl)bis(4-chloro-1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate",CHEMBL4324231,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in pooled human liver microsomes at 10 uM pre-incubated for 5 mins before NADPH addition and measured after 10 mins by UPLC-MS/MS analysis relative to control,Inhibition,=,29.0,%,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(Cl)c(-c2ccc3c(c2)OCC(C)(C)COc2cc(-c4[nH]c([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)nc4Cl)ccc2-3)[nH]1)C(C)C,CHEMBL4321845,Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate.,J Med Chem,2019.0,62,23,10563,10582,10.1021/acs.jmedchem.9b01562,31710479.0,
18924538,CHEMBL4573283,"Dimethyl ((2S,2'S)-((2S,2'S)-((4,5-Dihydronaphtho[1,2-b]-thiophene-2,7-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-1,2-diyl))dicarbamate",CHEMBL4324231,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in pooled human liver microsomes at 10 uM pre-incubated for 5 mins before NADPH addition and measured after 10 mins by UPLC-MS/MS analysis relative to control,Inhibition,=,35.0,%,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc3c(c2)CCc2cc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)sc2-3)[nH]1)C(C)C,CHEMBL4321845,Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate.,J Med Chem,2019.0,62,23,10563,10582,10.1021/acs.jmedchem.9b01562,31710479.0,
18924539,CHEMBL4473049,"Dimethyl ((2S,2'S)-((2S,2'S)-(naphtho[1,2-b]thiophene-2,7-diylbis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3-methyl-1-oxobutane-1,2-diyl))dicarbamate",CHEMBL4324231,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in pooled human liver microsomes at 10 uM pre-incubated for 5 mins before NADPH addition and measured after 10 mins by UPLC-MS/MS analysis relative to control,Inhibition,=,42.0,%,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc3c(ccc4cc(-c5cnc([C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]5)sc43)c2)[nH]1)C(C)C,CHEMBL4321845,Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate.,J Med Chem,2019.0,62,23,10563,10582,10.1021/acs.jmedchem.9b01562,31710479.0,
18924540,CHEMBL4574210,"Dimethyl ((2S,2'S)-((2S,2'S)-((4H-Thieno[3,2-c]chromene-2,7-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))-bis(3-methyl-1-oxobutane-1,2-diyl))dicarbamate",CHEMBL4324231,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in pooled human liver microsomes at 10 uM pre-incubated for 5 mins before NADPH addition and measured after 10 mins by UPLC-MS/MS analysis relative to control,Inhibition,=,41.0,%,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc3c(c2)OCc2cc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)sc2-3)[nH]1)C(C)C,CHEMBL4321845,Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate.,J Med Chem,2019.0,62,23,10563,10582,10.1021/acs.jmedchem.9b01562,31710479.0,
19006056,CHEMBL4584645,[8-[4-[3-(Aminomethyl)phenyl]piperidine-1-carbonyl]naphthalen-2-yl]boronic Acid,CHEMBL4344474,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,97.0,%,NCc1cccc(C2CCN(C(=O)c3cccc4ccc(B(O)O)cc34)CC2)c1,CHEMBL4342466,"Novel, Self-Assembling Dimeric Inhibitors of Human β Tryptase.",J Med Chem,2020.0,63,6,3004,3027,10.1021/acs.jmedchem.9b01689,32057241.0,
19006057,CHEMBL4459083,"(E)-1-[4-[3-(Aminomethyl)phenyl]piperidin-1-yl]-3-(3,4-dihydroxyphenyl)prop-2-en-1-one",CHEMBL4344474,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,75.0,%,NCc1cccc(C2CCN(C(=O)/C=C/c3ccc(O)c(O)c3)CC2)c1,CHEMBL4342466,"Novel, Self-Assembling Dimeric Inhibitors of Human β Tryptase.",J Med Chem,2020.0,63,6,3004,3027,10.1021/acs.jmedchem.9b01689,32057241.0,
19056192,CHEMBL4461774,"8-(2-Fluorophenethyl)-12-(2-(trifluoromethyl)pyridin-3-yl)-4-oxa-8,12-diazadispiro[2.1.5.3]tridecan-13-one",CHEMBL4356668,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 using fluorometric substrate,Inhibition,<,50.0,%,O=C1N(c2cccnc2C(F)(F)F)CC2(CCN(CCc3ccccc3F)CC2)OC12CC2,CHEMBL4354824,"4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ1 Receptor Antagonists for the Treatment of Pain.",J Med Chem,2020.0,63,5,2434,2454,10.1021/acs.jmedchem.9b01256,31743642.0,
19065822,CHEMBL4451408,"(S)-2-((1-(6-Chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-4-methoxypyrimidine-5-carbonitrile",CHEMBL4360317,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,13.6,%,COc1nc(N[C@@H](C)c2cc3cc(Cl)ccc3[nH]c2=O)ncc1C#N,CHEMBL4359816,"Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.",J Med Chem,2019.0,62,14,6575,6596,10.1021/acs.jmedchem.9b00362,31199148.0,
19110669,CHEMBL4438566,4-[(10H-Phenothiazin-10-yl)methyl]-N-hydroxybenzamide,CHEMBL4370393,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 in human liver microsomes at 10 uM relative to control,Inhibition,=,24.4,%,O=C(NO)c1ccc(CN2c3ccccc3Sc3ccccc32)cc1,CHEMBL4368915,Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.,J Med Chem,2019.0,62,3,1138,1166,10.1021/acs.jmedchem.8b01090,30645113.0,
19110670,CHEMBL4457162,"4-((10H-benzo[e]pyrido[3,2-b][1,4]thiazin-10-yl)methyl)-N-hydroxybenzamide",CHEMBL4370393,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 in human liver microsomes at 10 uM relative to control,Inhibition,=,3.4,%,O=C(NO)c1ccc(CN2c3ccccc3Sc3cccnc32)cc1,CHEMBL4368915,Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.,J Med Chem,2019.0,62,3,1138,1166,10.1021/acs.jmedchem.8b01090,30645113.0,
19110712,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4370398,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 in human liver microsomes at 50 times IC50 concentration relative to control,Inhibition,=,96.5,%,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4368915,Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.,J Med Chem,2019.0,62,3,1138,1166,10.1021/acs.jmedchem.8b01090,30645113.0,
19152643,CHEMBL3670685,"US8686018, 107",CHEMBL4380442,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 20 uM using tolbutamide as substrate incubated for 60 mins by HPLC analysis relative to control,Inhibition,=,67.0,%,C[C@H](NC(=O)c1c(C(F)F)nn(C)c1Oc1cccc(C(F)(F)F)c1)c1ccc(C(=O)O)cc1,CHEMBL4376865,"Discovery and Characterization of 1<i>H</i>-1,2,3-Triazole Derivatives as Novel Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy.",J Med Chem,2020.0,63,2,569,590,10.1021/acs.jmedchem.9b01269,31855426.0,
19152644,CHEMBL4457944,"(S)-4-(1-(4-Phenyl-1-(2-(3-(trifluoromethyl)phenoxy)ethyl)-1H-1,2,3-triazole-5-carboxamido)ethyl)benzoic Acid",CHEMBL4380442,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 20 uM using tolbutamide as substrate incubated for 60 mins by HPLC analysis relative to control,Inhibition,=,67.0,%,C[C@H](NC(=O)c1c(-c2ccccc2)nnn1CCOc1cccc(C(F)(F)F)c1)c1ccc(C(=O)O)cc1,CHEMBL4376865,"Discovery and Characterization of 1<i>H</i>-1,2,3-Triazole Derivatives as Novel Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy.",J Med Chem,2020.0,63,2,569,590,10.1021/acs.jmedchem.9b01269,31855426.0,
19152645,CHEMBL4564092,"(S)-4-(1-(4-(Thiophen-3-yl)-1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazole-5-carboxamido)ethyl)benzoic Acid",CHEMBL4380442,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 20 uM using tolbutamide as substrate incubated for 60 mins by HPLC analysis relative to control,Inhibition,=,48.0,%,C[C@H](NC(=O)c1c(-c2ccsc2)nnn1Cc1ccc(C(F)(F)F)cc1)c1ccc(C(=O)O)cc1,CHEMBL4376865,"Discovery and Characterization of 1<i>H</i>-1,2,3-Triazole Derivatives as Novel Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy.",J Med Chem,2020.0,63,2,569,590,10.1021/acs.jmedchem.9b01269,31855426.0,
19152646,CHEMBL4535971,"(S,E)-4-(1-(4-(Prop-1-en-1-yl)-1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazole-5-carboxamido)ethyl)benzoic Acid",CHEMBL4380442,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 20 uM using tolbutamide as substrate incubated for 60 mins by HPLC analysis relative to control,Inhibition,=,33.0,%,C/C=C/c1nnn(Cc2ccc(C(F)(F)F)cc2)c1C(=O)N[C@@H](C)c1ccc(C(=O)O)cc1,CHEMBL4376865,"Discovery and Characterization of 1<i>H</i>-1,2,3-Triazole Derivatives as Novel Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy.",J Med Chem,2020.0,63,2,569,590,10.1021/acs.jmedchem.9b01269,31855426.0,
19152647,CHEMBL4591792,"(S)-4-(1-(4-(Prop-1-yn-1-yl)-1-(4-(trifluoromethyl)benzyl)-1H-1,2,3-triazole-5-carboxamido)ethyl)benzoic Acid",CHEMBL4380442,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 20 uM using tolbutamide as substrate incubated for 60 mins by HPLC analysis relative to control,Inhibition,=,69.0,%,CC#Cc1nnn(Cc2ccc(C(F)(F)F)cc2)c1C(=O)N[C@@H](C)c1ccc(C(=O)O)cc1,CHEMBL4376865,"Discovery and Characterization of 1<i>H</i>-1,2,3-Triazole Derivatives as Novel Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy.",J Med Chem,2020.0,63,2,569,590,10.1021/acs.jmedchem.9b01269,31855426.0,
19159142,CHEMBL4516287,N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide,CHEMBL4382335,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide 4-hydroxylase as substrate preincubated for 5 mins followed by NADPH addition measured after 15 mins by LC/MS/MS analysis relative to control,Inhibition,=,90.0,%,C=CC(=O)Nc1cc(Nc2nccc(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C,CHEMBL4382192,Discovery of a potent dual ALK and EGFR T790M inhibitor.,Eur J Med Chem,2017.0,136,,497,510,10.1016/j.ejmech.2017.04.079,28528303.0,
19159143,CHEMBL4448107,N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((5-fluoro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide,CHEMBL4382335,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide 4-hydroxylase as substrate preincubated for 5 mins followed by NADPH addition measured after 15 mins by LC/MS/MS analysis relative to control,Inhibition,=,94.0,%,C=CC(=O)Nc1cc(Nc2ncc(F)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C,CHEMBL4382192,Discovery of a potent dual ALK and EGFR T790M inhibitor.,Eur J Med Chem,2017.0,136,,497,510,10.1016/j.ejmech.2017.04.079,28528303.0,
19159144,CHEMBL4473365,N-(5-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,CHEMBL4382335,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide 4-hydroxylase as substrate preincubated for 5 mins followed by NADPH addition measured after 15 mins by LC/MS/MS analysis relative to control,Inhibition,=,83.0,%,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C,CHEMBL4382192,Discovery of a potent dual ALK and EGFR T790M inhibitor.,Eur J Med Chem,2017.0,136,,497,510,10.1016/j.ejmech.2017.04.079,28528303.0,
19159145,CHEMBL4531697,N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((5-iodo-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide,CHEMBL4382335,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide 4-hydroxylase as substrate preincubated for 5 mins followed by NADPH addition measured after 15 mins by LC/MS/MS analysis relative to control,Inhibition,=,88.0,%,C=CC(=O)Nc1cc(Nc2ncc(I)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C,CHEMBL4382192,Discovery of a potent dual ALK and EGFR T790M inhibitor.,Eur J Med Chem,2017.0,136,,497,510,10.1016/j.ejmech.2017.04.079,28528303.0,
19159146,CHEMBL4465103,N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide,CHEMBL4382335,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide 4-hydroxylase as substrate preincubated for 5 mins followed by NADPH addition measured after 15 mins by LC/MS/MS analysis relative to control,Inhibition,=,90.0,%,C=CC(=O)Nc1cc(Nc2nccc(Nc3ccccc3P(C)(C)=O)n2)c(OC)cc1N(C)CCN(C)C,CHEMBL4382192,Discovery of a potent dual ALK and EGFR T790M inhibitor.,Eur J Med Chem,2017.0,136,,497,510,10.1016/j.ejmech.2017.04.079,28528303.0,
19159147,CHEMBL4558227,N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-((2-(dimethylphosphoryl)phenyl)amino)-5-fluoropyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide,CHEMBL4382335,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide 4-hydroxylase as substrate preincubated for 5 mins followed by NADPH addition measured after 15 mins by LC/MS/MS analysis relative to control,Inhibition,>,100.0,%,C=CC(=O)Nc1cc(Nc2ncc(F)c(Nc3ccccc3P(C)(C)=O)n2)c(OC)cc1N(C)CCN(C)C,CHEMBL4382192,Discovery of a potent dual ALK and EGFR T790M inhibitor.,Eur J Med Chem,2017.0,136,,497,510,10.1016/j.ejmech.2017.04.079,28528303.0,
19159148,CHEMBL4520341,N-(5-((5-Chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide,CHEMBL4382335,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide 4-hydroxylase as substrate preincubated for 5 mins followed by NADPH addition measured after 15 mins by LC/MS/MS analysis relative to control,Inhibition,>,100.0,%,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3P(C)(C)=O)n2)c(OC)cc1N(C)CCN(C)C,CHEMBL4382192,Discovery of a potent dual ALK and EGFR T790M inhibitor.,Eur J Med Chem,2017.0,136,,497,510,10.1016/j.ejmech.2017.04.079,28528303.0,
19159149,CHEMBL4581316,N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-((2-(dimethylphosphoryl)phenyl)amino)-5-iodopyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide,CHEMBL4382335,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide 4-hydroxylase as substrate preincubated for 5 mins followed by NADPH addition measured after 15 mins by LC/MS/MS analysis relative to control,Inhibition,>,100.0,%,C=CC(=O)Nc1cc(Nc2ncc(I)c(Nc3ccccc3P(C)(C)=O)n2)c(OC)cc1N(C)CCN(C)C,CHEMBL4382192,Discovery of a potent dual ALK and EGFR T790M inhibitor.,Eur J Med Chem,2017.0,136,,497,510,10.1016/j.ejmech.2017.04.079,28528303.0,
19159150,CHEMBL4540442,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-((2-(N,N-dimethylsulfamoyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide",CHEMBL4382335,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide 4-hydroxylase as substrate preincubated for 5 mins followed by NADPH addition measured after 15 mins by LC/MS/MS analysis relative to control,Inhibition,=,88.0,%,C=CC(=O)Nc1cc(Nc2nccc(Nc3ccccc3S(=O)(=O)N(C)C)n2)c(OC)cc1N(C)CCN(C)C,CHEMBL4382192,Discovery of a potent dual ALK and EGFR T790M inhibitor.,Eur J Med Chem,2017.0,136,,497,510,10.1016/j.ejmech.2017.04.079,28528303.0,
19159151,CHEMBL4565984,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-((2-(N,N-dimethylsulfamoyl)phenyl)amino)-5-fluoropyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide",CHEMBL4382335,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide 4-hydroxylase as substrate preincubated for 5 mins followed by NADPH addition measured after 15 mins by LC/MS/MS analysis relative to control,Inhibition,=,88.0,%,C=CC(=O)Nc1cc(Nc2ncc(F)c(Nc3ccccc3S(=O)(=O)N(C)C)n2)c(OC)cc1N(C)CCN(C)C,CHEMBL4382192,Discovery of a potent dual ALK and EGFR T790M inhibitor.,Eur J Med Chem,2017.0,136,,497,510,10.1016/j.ejmech.2017.04.079,28528303.0,
19159152,CHEMBL4449391,"N-(5-((5-Chloro-4-((2-(N,N-dimethylsulfamoyl)phenyl)amino)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide",CHEMBL4382335,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide 4-hydroxylase as substrate preincubated for 5 mins followed by NADPH addition measured after 15 mins by LC/MS/MS analysis relative to control,Inhibition,=,59.0,%,C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)N(C)C)n2)c(OC)cc1N(C)CCN(C)C,CHEMBL4382192,Discovery of a potent dual ALK and EGFR T790M inhibitor.,Eur J Med Chem,2017.0,136,,497,510,10.1016/j.ejmech.2017.04.079,28528303.0,
19159153,CHEMBL4467561,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-5-((4-((2-(N,N-dimethylsulfamoyl)phenyl)amino)-5-iodopyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide",CHEMBL4382335,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide 4-hydroxylase as substrate preincubated for 5 mins followed by NADPH addition measured after 15 mins by LC/MS/MS analysis relative to control,Inhibition,=,85.0,%,C=CC(=O)Nc1cc(Nc2ncc(I)c(Nc3ccccc3S(=O)(=O)N(C)C)n2)c(OC)cc1N(C)CCN(C)C,CHEMBL4382192,Discovery of a potent dual ALK and EGFR T790M inhibitor.,Eur J Med Chem,2017.0,136,,497,510,10.1016/j.ejmech.2017.04.079,28528303.0,
19190146,CHEMBL1409708,SID14732296,CHEMBL4388743,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,0.0,%,CN(C)c1ccnc2sc(C(N)=O)c(N)c12,CHEMBL4387729,"Synthesis and structure-activity relationship of 4-alkoxy-thieno[2,3-b]pyridine derivatives as potent alkaline phosphatase enhancers for osteoporosis treatment.",Bioorg Med Chem Lett,2019.0,29,14,1769,1773,10.1016/j.bmcl.2019.05.014,31101474.0,
19190147,CHEMBL4530951,"3-amino-4-[(oxan-4-yl)oxy]thieno[2,3-b]pyridine-2-carboxamide",CHEMBL4388743,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,1.0,%,NC(=O)c1sc2nccc(OC3CCOCC3)c2c1N,CHEMBL4387729,"Synthesis and structure-activity relationship of 4-alkoxy-thieno[2,3-b]pyridine derivatives as potent alkaline phosphatase enhancers for osteoporosis treatment.",Bioorg Med Chem Lett,2019.0,29,14,1769,1773,10.1016/j.bmcl.2019.05.014,31101474.0,
19190148,CHEMBL4563006,"3-amino-4-phenoxythieno[2,3-b]pyridine-2-carboxamide",CHEMBL4388743,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,13.0,%,NC(=O)c1sc2nccc(Oc3ccccc3)c2c1N,CHEMBL4387729,"Synthesis and structure-activity relationship of 4-alkoxy-thieno[2,3-b]pyridine derivatives as potent alkaline phosphatase enhancers for osteoporosis treatment.",Bioorg Med Chem Lett,2019.0,29,14,1769,1773,10.1016/j.bmcl.2019.05.014,31101474.0,
19190149,CHEMBL4441738,"3-amino-4-[4-(2-hydroxyethyl)phenoxy]thieno[2,3-b]pyridine-2-carboxamide",CHEMBL4388743,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,7.0,%,NC(=O)c1sc2nccc(Oc3ccc(CCO)cc3)c2c1N,CHEMBL4387729,"Synthesis and structure-activity relationship of 4-alkoxy-thieno[2,3-b]pyridine derivatives as potent alkaline phosphatase enhancers for osteoporosis treatment.",Bioorg Med Chem Lett,2019.0,29,14,1769,1773,10.1016/j.bmcl.2019.05.014,31101474.0,
19190150,CHEMBL4442570,"3-amino-4-{4-[4-(dimethylamino)-4-oxobutyl]-2-fluorophenoxy}-6-methylthieno[2,3-b]pyridine-2-carboxamide",CHEMBL4388743,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,17.0,%,Cc1cc(Oc2ccc(CCCC(=O)N(C)C)cc2F)c2c(N)c(C(N)=O)sc2n1,CHEMBL4387729,"Synthesis and structure-activity relationship of 4-alkoxy-thieno[2,3-b]pyridine derivatives as potent alkaline phosphatase enhancers for osteoporosis treatment.",Bioorg Med Chem Lett,2019.0,29,14,1769,1773,10.1016/j.bmcl.2019.05.014,31101474.0,
19190151,CHEMBL4449502,"3-amino-4-{2-chloro-4-[4-(dimethylamino)-4-oxobutyl]phenoxy}-6-methylthieno[2,3-b]pyridine-2-carboxamide",CHEMBL4388743,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,30.0,%,Cc1cc(Oc2ccc(CCCC(=O)N(C)C)cc2Cl)c2c(N)c(C(N)=O)sc2n1,CHEMBL4387729,"Synthesis and structure-activity relationship of 4-alkoxy-thieno[2,3-b]pyridine derivatives as potent alkaline phosphatase enhancers for osteoporosis treatment.",Bioorg Med Chem Lett,2019.0,29,14,1769,1773,10.1016/j.bmcl.2019.05.014,31101474.0,
19190152,CHEMBL2348339,"3-Amino-4-(4-phenyl-1,4-diazepan-1-yl)thieno[2,3-b]pyridine-2-carboxamide",CHEMBL4388743,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,71.0,%,NC(=O)c1sc2nccc(N3CCCN(c4ccccc4)CC3)c2c1N,CHEMBL4387729,"Synthesis and structure-activity relationship of 4-alkoxy-thieno[2,3-b]pyridine derivatives as potent alkaline phosphatase enhancers for osteoporosis treatment.",Bioorg Med Chem Lett,2019.0,29,14,1769,1773,10.1016/j.bmcl.2019.05.014,31101474.0,
19207757,CHEMBL4560054,"N-(2-methoxy-5-(3-(4-methoxybenzyl)-1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinolin-8-yl)pyridin-3-yl)methanesulfonamide",CHEMBL4392579,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using testosterone/dextromethorphan as probe substrate measured after 10 mins relative to control,Inhibition,<,10.0,%,COc1ccc(Cn2c(=O)n(C)c3c4cc(-c5cnc(OC)c(NS(C)(=O)=O)c5)ccc4ncc32)cc1,CHEMBL4390691,"Discovery of 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-ones based novel, potent and PI3Kδ selective inhibitors.",Bioorg Med Chem Lett,2019.0,29,11,1313,1319,10.1016/j.bmcl.2019.04.007,30975623.0,
19217441,CHEMBL4441529,"N-((1S,2R)-2-Methylcyclohexyl)-1-(5-(5-(((5-methylpyridin-2-yl)amino)methyl)-1H-pyrazol-1-yl)-1,3,4-thiadiazol-2-yl)piperidine-4-carboxamide",CHEMBL4394247,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,26.0,%,Cc1ccc(NCc2ccnn2-c2nnc(N3CCC(C(=O)N[C@H]4CCCC[C@H]4C)CC3)s2)nc1,CHEMBL4393662,Structural optimization on a virtual screening hit of smoothened receptor.,Eur J Med Chem,2019.0,172,,1,15,10.1016/j.ejmech.2019.03.057,30939349.0,
19225432,CHEMBL4474903,N-(4-(4-(4-Fluorophenyl)-2-(methylthio)-1H-imidazol-5-yl)pyridin-2-yl)cyclopropanecarboxamide,CHEMBL4395859,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus infected insect cells using OOMR as substrate at 10 uM in presence of NADPH by fluorimetric analysis relative to control,Inhibition,=,77.7,%,CSc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,CHEMBL4393708,Pyridinylimidazoles as dual glycogen synthase kinase 3β/p38α mitogen-activated protein kinase inhibitors.,Eur J Med Chem,2019.0,175,,309,329,10.1016/j.ejmech.2019.04.035,31096153.0,
19225433,CHEMBL4536012,N-(4-(2-Ethyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)pyridin-2-yl)cyclopropanecarboxamide,CHEMBL4395859,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human recombinant CYP2C9 expressed in baculovirus infected insect cells using OOMR as substrate at 10 uM in presence of NADPH by fluorimetric analysis relative to control,Inhibition,=,83.6,%,CCc1nc(-c2ccc(F)cc2)c(-c2ccnc(NC(=O)C3CC3)c2)[nH]1,CHEMBL4393708,Pyridinylimidazoles as dual glycogen synthase kinase 3β/p38α mitogen-activated protein kinase inhibitors.,Eur J Med Chem,2019.0,175,,309,329,10.1016/j.ejmech.2019.04.035,31096153.0,
19267731,CHEMBL4557050,"(R)-2-(4-(2-Hydroxy-3-(4-methylpiperazin-1-yl)propoxy)-3,5-dimethylphenyl)-5,7-dimethoxy-4H-chromen-4-one",CHEMBL4405954,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,1.9,%,COc1cc(OC)c2c(=O)cc(-c3cc(C)c(OC[C@H](O)CN4CCN(C)CC4)c(C)c3)oc2c1,CHEMBL4402595,"Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation.",J Med Chem,2020.0,63,10,5242,5256,10.1021/acs.jmedchem.0c00035,32255647.0,
19288389,CHEMBL4528475,1-(1-(2-(6-(3-(Cyclopropylmethoxy)phenoxy)pyridin-3-yl)benzoxazol-6-yl)ethyl)urea,CHEMBL4410477,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,-10.7,%,CC(NC(N)=O)c1ccc2nc(-c3ccc(Oc4cccc(OCC5CC5)c4)nc3)oc2c1,CHEMBL4406889,"The identification and pharmacological evaluation of potent, selective and orally available ACC1 inhibitor.",Bioorg Med Chem Lett,2019.0,29,23,126749,126749,10.1016/j.bmcl.2019.126749,31672259.0,
19295961,CHEMBL4534119,3-(3-(1-cyclopropyl-1H-pyrazol-4-yl)-1H-indazol-6-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide,CHEMBL4412438,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes at 1 mM using diclofenac as substrate preincubated for 5 to 30 mins followed by NADPH addition and measured after 20 mins by LC-MS/MS analysis relative to control,Inhibition,=,83.0,%,Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1ccc2c(-c3cnn(C4CC4)c3)n[nH]c2c1,CHEMBL4411287,Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.,Eur J Med Chem,2019.0,163,,671,689,10.1016/j.ejmech.2018.12.015,30572178.0,
19295967,CHEMBL4534119,3-(3-(1-cyclopropyl-1H-pyrazol-4-yl)-1H-indazol-6-yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide,CHEMBL4412444,A,,Homo sapiens,Cytochrome P450 2C9,Time-dependant irreversible inhibition of CYP2C9 in human liver microsomes at 1 mM using diclofenac as substrate preincubated for 5 to 30 mins followed by NADPH addition and measured after 20 mins by LC-MS/MS analysis relative to control,Inhibition,=,100.0,%,Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1-c1ccc2c(-c3cnn(C4CC4)c3)n[nH]c2c1,CHEMBL4411287,Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.,Eur J Med Chem,2019.0,163,,671,689,10.1016/j.ejmech.2018.12.015,30572178.0,
19302143,CHEMBL3932162,4-[(Z)-1-[4-(2-dimethylaminoethyloxy)phenyl]-5-hydroxy-2-phenyl-pent-1-enyl]phenol hydrochloride salt,CHEMBL4413812,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide 4-hydroxylase activity at 10 uM preincubated for 5 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,27.1,%,CN(C)CCOc1ccc(/C(=C(/CCCO)c2ccccc2)c2ccc(O)cc2)cc1.Cl,CHEMBL4411321,"Discovery of Potent, Selective, and Orally Bioavailable Estrogen-Related Receptor-γ Inverse Agonists To Restore the Sodium Iodide Symporter Function in Anaplastic Thyroid Cancer.",J Med Chem,2019.0,62,4,1837,1858,10.1021/acs.jmedchem.8b01296,30657313.0,
19302144,CHEMBL4585424,(E)-5-(4-bromophenyl)-4-phenyl-5-(4-(piperazin-1-yl)phenyl)pent-4-en-1-ol dihydrochloride,CHEMBL4413812,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide 4-hydroxylase activity at 10 uM preincubated for 5 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,24.0,%,Cl.Cl.OCCC/C(=C(\c1ccc(Br)cc1)c1ccc(N2CCNCC2)cc1)c1ccccc1,CHEMBL4411321,"Discovery of Potent, Selective, and Orally Bioavailable Estrogen-Related Receptor-γ Inverse Agonists To Restore the Sodium Iodide Symporter Function in Anaplastic Thyroid Cancer.",J Med Chem,2019.0,62,4,1837,1858,10.1021/acs.jmedchem.8b01296,30657313.0,
19302145,CHEMBL4443694,(Z)-4-phenyl-5-(4-(piperazin-1-yl)phenyl)-5-p-tolylpent-4-en-1-ol dihydrochloride,CHEMBL4413812,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide 4-hydroxylase activity at 10 uM preincubated for 5 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,39.3,%,Cc1ccc(/C(=C(\CCCO)c2ccccc2)c2ccc(N3CCNCC3)cc2)cc1.Cl.Cl,CHEMBL4411321,"Discovery of Potent, Selective, and Orally Bioavailable Estrogen-Related Receptor-γ Inverse Agonists To Restore the Sodium Iodide Symporter Function in Anaplastic Thyroid Cancer.",J Med Chem,2019.0,62,4,1837,1858,10.1021/acs.jmedchem.8b01296,30657313.0,
19302146,CHEMBL4472718,(Z)-5-(4-(4-methylpiperazin-1-yl)phenyl)-4-phenyl-5-p-tolylpent-4-en-1-ol dihydrochloride,CHEMBL4413812,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide 4-hydroxylase activity at 10 uM preincubated for 5 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,37.7,%,Cc1ccc(/C(=C(\CCCO)c2ccccc2)c2ccc(N3CCN(C)CC3)cc2)cc1.Cl.Cl,CHEMBL4411321,"Discovery of Potent, Selective, and Orally Bioavailable Estrogen-Related Receptor-γ Inverse Agonists To Restore the Sodium Iodide Symporter Function in Anaplastic Thyroid Cancer.",J Med Chem,2019.0,62,4,1837,1858,10.1021/acs.jmedchem.8b01296,30657313.0,
19302147,CHEMBL4436391,(E)-4-(5-hydroxy-1-(4-(4-isopropylpiperazin-1-yl)phenyl)-2-phenylpent-1-enyl)phenol dihydrochloride,CHEMBL4413812,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide 4-hydroxylase activity at 10 uM preincubated for 5 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,13.9,%,CC(C)N1CCN(c2ccc(/C(=C(/CCCO)c3ccccc3)c3ccc(O)cc3)cc2)CC1.Cl.Cl,CHEMBL4411321,"Discovery of Potent, Selective, and Orally Bioavailable Estrogen-Related Receptor-γ Inverse Agonists To Restore the Sodium Iodide Symporter Function in Anaplastic Thyroid Cancer.",J Med Chem,2019.0,62,4,1837,1858,10.1021/acs.jmedchem.8b01296,30657313.0,
19302148,CHEMBL4541589,(E)-5-(4-bromophenyl)-5-(4-(4-isopropylpiperazin-1-yl)phenyl)-4-phenylpent-4-en-1-ol dihydrochloride,CHEMBL4413812,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide 4-hydroxylase activity at 10 uM preincubated for 5 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,3.1,%,CC(C)N1CCN(c2ccc(/C(=C(/CCCO)c3ccccc3)c3ccc(Br)cc3)cc2)CC1.Cl.Cl,CHEMBL4411321,"Discovery of Potent, Selective, and Orally Bioavailable Estrogen-Related Receptor-γ Inverse Agonists To Restore the Sodium Iodide Symporter Function in Anaplastic Thyroid Cancer.",J Med Chem,2019.0,62,4,1837,1858,10.1021/acs.jmedchem.8b01296,30657313.0,
19302149,CHEMBL4437929,(Z)-5-(4-(4-isopropylpiperazin-1-yl)phenyl)-4-phenyl-5-p-tolylpent-4-en-1-ol dihydrochloride,CHEMBL4413812,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide 4-hydroxylase activity at 10 uM preincubated for 5 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,26.6,%,Cc1ccc(/C(=C(\CCCO)c2ccccc2)c2ccc(N3CCN(C(C)C)CC3)cc2)cc1.Cl.Cl,CHEMBL4411321,"Discovery of Potent, Selective, and Orally Bioavailable Estrogen-Related Receptor-γ Inverse Agonists To Restore the Sodium Iodide Symporter Function in Anaplastic Thyroid Cancer.",J Med Chem,2019.0,62,4,1837,1858,10.1021/acs.jmedchem.8b01296,30657313.0,
19302150,CHEMBL4580171,(Z)-5-(4-(4-ethylpiperazin-1-yl)phenyl)-4-phenyl-5-p-tolylpent-4-en-1-ol dihydrochloride,CHEMBL4413812,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide 4-hydroxylase activity at 10 uM preincubated for 5 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,13.0,%,CCN1CCN(c2ccc(/C(=C(/CCCO)c3ccccc3)c3ccc(C)cc3)cc2)CC1.Cl.Cl,CHEMBL4411321,"Discovery of Potent, Selective, and Orally Bioavailable Estrogen-Related Receptor-γ Inverse Agonists To Restore the Sodium Iodide Symporter Function in Anaplastic Thyroid Cancer.",J Med Chem,2019.0,62,4,1837,1858,10.1021/acs.jmedchem.8b01296,30657313.0,
19302151,CHEMBL4451327,(E)-3-(5-hydroxy-1-(4-(4-isopropylpiperazin-1-yl)phenyl)-2-phenylpent-1-enyl)phenol dihydrochloride,CHEMBL4413812,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide 4-hydroxylase activity at 10 uM preincubated for 5 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,24.1,%,CC(C)N1CCN(c2ccc(/C(=C(/CCCO)c3ccccc3)c3cccc(O)c3)cc2)CC1.Cl.Cl,CHEMBL4411321,"Discovery of Potent, Selective, and Orally Bioavailable Estrogen-Related Receptor-γ Inverse Agonists To Restore the Sodium Iodide Symporter Function in Anaplastic Thyroid Cancer.",J Med Chem,2019.0,62,4,1837,1858,10.1021/acs.jmedchem.8b01296,30657313.0,
19302152,CHEMBL4579002,(E)-5-(3-bromophenyl)-5-(4-(4-isopropylpiperazin-1-yl)phenyl)-4-phenylpent-4-en-1-ol dihydrochloride,CHEMBL4413812,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide 4-hydroxylase activity at 10 uM preincubated for 5 mins followed by NADPH addition and measured after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,27.0,%,CC(C)N1CCN(c2ccc(/C(=C(/CCCO)c3ccccc3)c3cccc(Br)c3)cc2)CC1.Cl.Cl,CHEMBL4411321,"Discovery of Potent, Selective, and Orally Bioavailable Estrogen-Related Receptor-γ Inverse Agonists To Restore the Sodium Iodide Symporter Function in Anaplastic Thyroid Cancer.",J Med Chem,2019.0,62,4,1837,1858,10.1021/acs.jmedchem.8b01296,30657313.0,
19307810,CHEMBL4578490,"4-Cyclopropyl-1,3-dimethyl-6-(5-methyl-4-(p-tolyl)-4H-1,2,4-triazol-3-yl)-3,4-dihydroquinoxalin-2(1H)-one",CHEMBL4415473,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH generating system addition and measured after 20 mins relative to control,Inhibition,=,10.0,%,Cc1ccc(-n2c(C)nnc2-c2ccc3c(c2)N(C2CC2)C(C)C(=O)N3C)cc1,CHEMBL4414574,Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.,J Med Chem,2019.0,62,18,8642,8663,10.1021/acs.jmedchem.9b01094,31490070.0,
19307811,CHEMBL4556261,"4-Cyclopropyl-1,3-dimethyl-6-(3-(4-methylpiperazine-1-carbonyl)-1-(p-tolyl)-1H-1,2,4-triazol-5-yl)-3,4-dihydroquinoxalin-2(1H)-one",CHEMBL4415473,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH generating system addition and measured after 20 mins relative to control,Inhibition,=,6.0,%,Cc1ccc(-n2nc(C(=O)N3CCN(C)CC3)nc2-c2ccc3c(c2)N(C2CC2)C(C)C(=O)N3C)cc1,CHEMBL4414574,Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.,J Med Chem,2019.0,62,18,8642,8663,10.1021/acs.jmedchem.9b01094,31490070.0,
19307812,CHEMBL4573400,"(R)-4-Cyclopentyl-1,3-dimethyl-6-(3-(4-methylpiperazine-1-carbonyl)-1-(p-tolyl)-1H-1,2,4-triazol-5-yl)-3,4-dihydroquinoxalin-2(1H)-one",CHEMBL4415473,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH generating system addition and measured after 20 mins relative to control,Inhibition,=,30.0,%,Cc1ccc(-n2nc(C(=O)N3CCN(C)CC3)nc2-c2ccc3c(c2)N(C2CCCC2)[C@H](C)C(=O)N3C)cc1,CHEMBL4414574,Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.,J Med Chem,2019.0,62,18,8642,8663,10.1021/acs.jmedchem.9b01094,31490070.0,
19307813,CHEMBL4451357,"(R)-4-Cyclopentyl-6-(3-((3S,5R)-3,5-dimethylpiperazine-1-carbonyl)-1-(p-tolyl)-1H-1,2,4-triazol-5-yl)-1,3-dimethyl-3,4-dihydroquinoxalin-2(1H)-one",CHEMBL4415473,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH generating system addition and measured after 20 mins relative to control,Inhibition,=,28.0,%,Cc1ccc(-n2nc(C(=O)N3C[C@H](C)N[C@H](C)C3)nc2-c2ccc3c(c2)N(C2CCCC2)[C@H](C)C(=O)N3C)cc1,CHEMBL4414574,Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.,J Med Chem,2019.0,62,18,8642,8663,10.1021/acs.jmedchem.9b01094,31490070.0,
19308050,CHEMBL4463165,"(R)-4-Cyclopentyl-1,3-dimethyl-6-(5-methyl-4-(p-tolyl)-4H-1,2,4-triazol-3-yl)-3,4-dihydroquinoxalin-2(1H)-one",CHEMBL4415473,A,,Homo sapiens,Cytochrome P450 2C9,Reversible inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH generating system addition and measured after 20 mins relative to control,Inhibition,>,50.0,%,Cc1ccc(-n2c(C)nnc2-c2ccc3c(c2)N(C2CCCC2)[C@H](C)C(=O)N3C)cc1,CHEMBL4414574,Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.,J Med Chem,2019.0,62,18,8642,8663,10.1021/acs.jmedchem.9b01094,31490070.0,
19368301,CHEMBL4576339,"(1S,2S)-2-((1-(6-Ethyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)piperidin-4-yl)amino)cyclohexanol",CHEMBL4424283,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide as substrate after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,-13.0,%,CCc1ccc2nc(N3CCC(N[C@H]4CCCC[C@@H]4O)CC3)c(-c3nc(C)no3)cc2c1,CHEMBL4422661,Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140).,J Med Chem,2019.0,62,4,1761,1780,10.1021/acs.jmedchem.8b01679,30707578.0,
19368302,CHEMBL4434885,"1-(6-Ethyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)-quinolin-2-yl)-N-((3-methyloxetan-3-yl)methyl)piperidin-4-amine",CHEMBL4424283,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide as substrate after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,-11.0,%,CCc1ccc2nc(N3CCC(NCC4(C)COC4)CC3)c(-c3nc(C)no3)cc2c1,CHEMBL4422661,Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140).,J Med Chem,2019.0,62,4,1761,1780,10.1021/acs.jmedchem.8b01679,30707578.0,
19368303,CHEMBL4459625,"(R)-1-(6-Ethyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)-quinolin-2-yl)-N-(tetrahydro-2H-pyran-3-yl)piperidin-4-amine",CHEMBL4424283,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide as substrate after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,-18.0,%,CCc1ccc2nc(N3CCC(N[C@@H]4CCCOC4)CC3)c(-c3nc(C)no3)cc2c1,CHEMBL4422661,Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140).,J Med Chem,2019.0,62,4,1761,1780,10.1021/acs.jmedchem.8b01679,30707578.0,
19368304,CHEMBL4440935,"1-(6-Methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)piperidin-4-amine",CHEMBL4424283,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide as substrate after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,-6.0,%,Cc1ccc2nc(N3CCC(NC4CCOCC4)CC3)c(-c3nc(C)no3)cc2c1,CHEMBL4422661,Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140).,J Med Chem,2019.0,62,4,1761,1780,10.1021/acs.jmedchem.8b01679,30707578.0,
19435701,CHEMBL2407899,(E/Z)-3-((3-((E)-2-(6-(4-Methylpiperazin-1-yl)pyridin-3-yl)-vinyl)-1H-indazol-6-yl)methylene)-indolin-2-one,CHEMBL4430373,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 1 uM,Inhibition,=,67.0,%,CN1CCN(c2ccc(/C=C/c3n[nH]c4cc(/C=C5/C(=O)Nc6ccccc65)ccc34)cn2)CC1,CHEMBL4428091,"Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy.",Bioorg Med Chem Lett,2016.0,26,19,4625,4630,10.1016/j.bmcl.2016.08.063,27592744.0,
19435702,CHEMBL4434704,(E/Z)-5-methoxy-3-((3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indazol-6-yl)methylene)indolin-2-one,CHEMBL4430373,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 1 uM,Inhibition,=,60.0,%,COc1ccc2c(c1)C(=Cc1ccc3c(-c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2,CHEMBL4428091,"Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy.",Bioorg Med Chem Lett,2016.0,26,19,4625,4630,10.1016/j.bmcl.2016.08.063,27592744.0,
19435703,CHEMBL4516793,"(rac)-(1R,2S)-5'-methoxy-2-(3-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL4430373,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 1 uM,Inhibition,=,34.0,%,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(-c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2,CHEMBL4428091,"Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy.",Bioorg Med Chem Lett,2016.0,26,19,4625,4630,10.1016/j.bmcl.2016.08.063,27592744.0,
19435704,CHEMBL4448596,"(1R,2S)-5'-methoxy-2-(3-(4-(4-methylpiperazin-1-yl)phenyl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL4430373,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 1 uM,Inhibition,=,35.0,%,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(-c4ccc(N5CCN(C)CC5)cc4)n[nH]c3c1)C(=O)N2,CHEMBL4428091,"Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy.",Bioorg Med Chem Lett,2016.0,26,19,4625,4630,10.1016/j.bmcl.2016.08.063,27592744.0,
19435706,CHEMBL4440053,"(1R,2S)-2-(3-(4-((3S,5R)-3,5-dimethylpiperazin-1-yl)phenyl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL4430373,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 1 uM,Inhibition,=,44.0,%,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(-c4ccc(N5C[C@H](C)N[C@H](C)C5)cc4)n[nH]c3c1)C(=O)N2,CHEMBL4428091,"Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy.",Bioorg Med Chem Lett,2016.0,26,19,4625,4630,10.1016/j.bmcl.2016.08.063,27592744.0,
19435707,CHEMBL4440812,"(1R,2S)-2-(3-(4-(4-ethylpiperazin-1-yl)phenyl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL4430373,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 1 uM,Inhibition,=,37.0,%,CCN1CCN(c2ccc(-c3n[nH]c4cc([C@@H]5C[C@@]56C(=O)Nc5ccc(OC)cc56)ccc34)cc2)CC1,CHEMBL4428091,"Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy.",Bioorg Med Chem Lett,2016.0,26,19,4625,4630,10.1016/j.bmcl.2016.08.063,27592744.0,
19435708,CHEMBL4470693,"(1R,2S)-2-(3-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL4430373,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 1 uM,Inhibition,=,41.0,%,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(-c4ccc(N5CCN(CCO)CC5)cc4)n[nH]c3c1)C(=O)N2,CHEMBL4428091,"Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy.",Bioorg Med Chem Lett,2016.0,26,19,4625,4630,10.1016/j.bmcl.2016.08.063,27592744.0,
19435709,CHEMBL3353341,"(1R*,2S*)-5'-Methoxy-2-(3-((E)-2-(6-(4-methylpiperazin-1-yl)-pyridin-3-yl)vinyl)-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one",CHEMBL4430373,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 1 uM,Inhibition,=,73.0,%,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(N5CCN(C)CC5)nc4)n[nH]c3c1)C(=O)N2,CHEMBL4428091,"Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy.",Bioorg Med Chem Lett,2016.0,26,19,4625,4630,10.1016/j.bmcl.2016.08.063,27592744.0,
19453409,CHEMBL4546069,"3-(4'-((2-butyl-5-((3-tert-butyl-1,2,4-oxadiazol-5-yl)methyl)-4-methyl-6-oxopyrimidin-1(6H)-yl)methyl)biphenyl-2-yl)-1,2,4-oxadiazol-5(4H)-one",CHEMBL4434345,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as enzyme remaining activity at 10 uM,Inhibition,=,57.0,%,CCCCc1nc(C)c(Cc2nc(C(C)(C)C)no2)c(=O)n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1,CHEMBL4433251,"Discovery of BR102375, a new class of non-TZD PPARγ full agonist for the treatment of type 2 diabetes.",Bioorg Med Chem Lett,2019.0,29,16,2275,2282,10.1016/j.bmcl.2019.06.027,31253533.0,
19453410,CHEMBL4465311,"3-(4'-((2-butyl-5-((3-tert-butyl-1,2,4-oxadiazol-5-yl)methyl)-4-isopropyl-6-oxopyrimidin-1(6H)-yl)methyl)biphenyl-2-yl)-1,2,4-oxadiazol-5(4H)-one",CHEMBL4434345,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as enzyme remaining activity at 10 uM,Inhibition,=,33.0,%,CCCCc1nc(C(C)C)c(Cc2nc(C(C)(C)C)no2)c(=O)n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1,CHEMBL4433251,"Discovery of BR102375, a new class of non-TZD PPARγ full agonist for the treatment of type 2 diabetes.",Bioorg Med Chem Lett,2019.0,29,16,2275,2282,10.1016/j.bmcl.2019.06.027,31253533.0,
19469491,CHEMBL4464873,"4,6-difluoro-N-((1R,2R,3R,5S)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl)-1H-indole-2-carboxamide",CHEMBL4478360,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin),Inhibition,=,-5.2,%,C[C@H]1[C@H](NC(=O)c2cc3c(F)cc(F)cc3[nH]2)C[C@@H]2C[C@H]1C2(C)C,CHEMBL4477209,Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.,J Med Chem,2016.0,59,13,6232,6247,10.1021/acs.jmedchem.6b00415,27275668.0,
20638740,CHEMBL4637258,"N-(1-(1,1-Di(pyridin-2-yl)ethyl)-6-(1-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-3-yl)-1H-indol-4-yl)-ethanesulfonamide Hydrochloride",CHEMBL4612558,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,30.74,%,CCS(=O)(=O)Nc1cc(-c2cn(C)c3c(=O)[nH]ccc23)cc2c1ccn2C(C)(c1ccccn1)c1ccccn1.Cl,CHEMBL4610112,Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.,J Med Chem,2020.0,63,13,7186,7210,10.1021/acs.jmedchem.0c00456,32453591.0,
20638747,CHEMBL782,N-[(butylamino)carbonyl]-4-methylbenzenesulfonamide,CHEMBL4612558,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM,Inhibition,=,87.68,%,CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,CHEMBL4610112,Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.,J Med Chem,2020.0,63,13,7186,7210,10.1021/acs.jmedchem.0c00456,32453591.0,
20651759,CHEMBL4640019,5-(5-(Hydroxymethyl)pyridin-3-yl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1H-indazole-3-carboxamide,CHEMBL4615939,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM incubated for 20-50 mins along with substrate by HPLC-MS/MS analysis relative to control,Inhibition,=,31.0,%,O=C(NCC1CCOCC1)c1n[nH]c2ccc(-c3cncc(CO)c3)cc12,CHEMBL4613299,Optimization of Indazole-Based GSK-3 Inhibitors with Mitigated hERG Issue and <i>In Vivo</i> Activity in a Mood Disorder Model.,ACS Med Chem Lett,2020.0,11,5,825,831,10.1021/acsmedchemlett.9b00633,32435391.0,
20672076,CHEMBL4647898,"2,9-Dichloro-5,5-dimethyl-7-[4-[2-(tetrahydropyran-4-ylamino)ethylamino]phenyl]pyrido[2,3-d][1]benzazepin-6-one",CHEMBL4620806,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,50.0,%,CC1(C)C(=O)N(c2ccc(NCCNC3CCOCC3)cc2)c2cc(Cl)ccc2-c2cc(Cl)cnc21,CHEMBL4619754,"Discovery of novel, potent, and orally bioavailable pyrido[2,3-d][1]benzazepin-6-one antagonists for parathyroid hormone receptor 1.",Bioorg Med Chem,2020.0,28,11,115524,115524,10.1016/j.bmc.2020.115524,32345459.0,
20683627,CHEMBL4644985,"(R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridine hydrochloride",CHEMBL4623604,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,79.0,%,C[C@@H](Oc1cncc(-c2cnn(C3CCNCC3)c2)c1)c1c(Cl)ccc(F)c1Cl.Cl,CHEMBL4622864,Synthesis and biological evaluation of quinoxaline derivatives as specific c-Met kinase inhibitors.,Bioorg Med Chem Lett,2020.0,30,13,127189,127189,10.1016/j.bmcl.2020.127189,32371098.0,
20684853,CHEMBL4632675,"rac-2,5-Difluoro-4-[[(1S*,2R*)-2-(1-methyl-1H-pyrazol-5-yl)cyclopentyl]oxy]-N-(1,2,4-thiadiazol-5-yl)benzene-1-sulfonamide",CHEMBL4623827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,93.0,%,Cn1nccc1[C@H]1CCC[C@@H]1Oc1cc(F)c(S(=O)(=O)Nc2ncns2)cc1F,CHEMBL4622872,"Discovery of DS-1971a, a Potent, Selective Na<sub>V</sub>1.7 Inhibitor.",J Med Chem,2020.0,63,18,10204,10220,10.1021/acs.jmedchem.0c00259,32392056.0,
20684854,CHEMBL4642571,"rac-2,5-Difluoro-4-[[(1S*,2R*)-2-(1-methyl-1H-pyrazol-5-yl)cyclohexyl]oxy]-N-(1,2,4-thiadiazol-5-yl)benzene-1-sulfonamide",CHEMBL4623827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,87.4,%,Cn1nccc1[C@H]1CCCC[C@@H]1Oc1cc(F)c(S(=O)(=O)Nc2ncns2)cc1F,CHEMBL4622872,"Discovery of DS-1971a, a Potent, Selective Na<sub>V</sub>1.7 Inhibitor.",J Med Chem,2020.0,63,18,10204,10220,10.1021/acs.jmedchem.0c00259,32392056.0,
20684855,CHEMBL4641238,"rac-2,5-Difluoro-4-[[(1S*,2R*)-2-(1-methyl-1H-pyrazol-5-yl)cyclopentyl]oxy]-N-(3-methyl-1,2,4-thiadiazol-5-yl)benzene-1-sulfonamide",CHEMBL4623827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,89.2,%,Cc1nsc(NS(=O)(=O)c2cc(F)c(O[C@H]3CCC[C@@H]3c3ccnn3C)cc2F)n1,CHEMBL4622872,"Discovery of DS-1971a, a Potent, Selective Na<sub>V</sub>1.7 Inhibitor.",J Med Chem,2020.0,63,18,10204,10220,10.1021/acs.jmedchem.0c00259,32392056.0,
20684856,CHEMBL4633573,"rac-2,5-Difluoro-4-[[(1S*,2R*)-2-(1-methyl-1H-pyrazol-5-yl)cyclopentyl]oxy]-N-(1,3-thiazol-2-yl)benzene-1-sulfonamide",CHEMBL4623827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,>,90.0,%,Cn1nccc1[C@H]1CCC[C@@H]1Oc1cc(F)c(S(=O)(=O)Nc2nccs2)cc1F,CHEMBL4622872,"Discovery of DS-1971a, a Potent, Selective Na<sub>V</sub>1.7 Inhibitor.",J Med Chem,2020.0,63,18,10204,10220,10.1021/acs.jmedchem.0c00259,32392056.0,
20684857,CHEMBL4635030,"rac-2,5-Difluoro-4-[[(1S*,2R*)-2-(1-methyl-1H-pyrazol-5-yl)cyclohexyl]oxy]-N-(1,3-thiazol-4-yl)benzene-1-sulfonamide",CHEMBL4623827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,66.2,%,Cn1nccc1[C@H]1CCCC[C@@H]1Oc1cc(F)c(S(=O)(=O)Nc2cscn2)cc1F,CHEMBL4622872,"Discovery of DS-1971a, a Potent, Selective Na<sub>V</sub>1.7 Inhibitor.",J Med Chem,2020.0,63,18,10204,10220,10.1021/acs.jmedchem.0c00259,32392056.0,
20684858,CHEMBL4642726,"rac-2,5-Difluoro-4-[[(1S*,2R*)-2-(1-methyl-1H-pyrazol-5-yl)cyclopentyl]oxy]-N-(pyrimidin-4-yl)benzene-1-sulfonamide",CHEMBL4623827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,86.3,%,Cn1nccc1[C@H]1CCC[C@@H]1Oc1cc(F)c(S(=O)(=O)Nc2ccncn2)cc1F,CHEMBL4622872,"Discovery of DS-1971a, a Potent, Selective Na<sub>V</sub>1.7 Inhibitor.",J Med Chem,2020.0,63,18,10204,10220,10.1021/acs.jmedchem.0c00259,32392056.0,
20684859,CHEMBL4640756,"rac-2,5-Difluoro-4-[[(1S*,2R*)-2-(1-methyl-1H-pyrazol-5-yl)cyclohexyl]oxy]-N-(pyrimidin-4-yl)benzene-1-sulfonamide",CHEMBL4623827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,76.0,%,Cn1nccc1[C@H]1CCCC[C@@H]1Oc1cc(F)c(S(=O)(=O)Nc2ccncn2)cc1F,CHEMBL4622872,"Discovery of DS-1971a, a Potent, Selective Na<sub>V</sub>1.7 Inhibitor.",J Med Chem,2020.0,63,18,10204,10220,10.1021/acs.jmedchem.0c00259,32392056.0,
20684861,CHEMBL4648771,"rac-2,3-Difluoro-4-[[(1S*,2R*)-2-(1-methyl-1H-pyrazol-5-yl)cyclopentyl]oxy]-N-(pyrimidin-4-yl)benzene-1-sulfonamide",CHEMBL4623827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,>,90.0,%,Cn1nccc1[C@H]1CCC[C@@H]1Oc1ccc(S(=O)(=O)Nc2ccncn2)c(F)c1F,CHEMBL4622872,"Discovery of DS-1971a, a Potent, Selective Na<sub>V</sub>1.7 Inhibitor.",J Med Chem,2020.0,63,18,10204,10220,10.1021/acs.jmedchem.0c00259,32392056.0,
20684862,CHEMBL4645788,"rac-2,6-Difluoro-4-[[(1S*,2R*)-2-(1-methyl-1H-pyrazol-5-yl)cyclopentyl]oxy]-N-(pyrimidin-4-yl)benzene-1-sulfonamide",CHEMBL4623827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,75.0,%,Cn1nccc1[C@H]1CCC[C@@H]1Oc1cc(F)c(S(=O)(=O)Nc2ccncn2)c(F)c1,CHEMBL4622872,"Discovery of DS-1971a, a Potent, Selective Na<sub>V</sub>1.7 Inhibitor.",J Med Chem,2020.0,63,18,10204,10220,10.1021/acs.jmedchem.0c00259,32392056.0,
20684863,CHEMBL4648397,"rac-2,6-Difluoro-4-[[(1S*,2R*)-2-(1-methyl-1H-pyrazol-5-yl)cyclohexyl]oxy]-N-(pyrimidin-4-yl)benzene-1-sulfonamide",CHEMBL4623827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,65.9,%,Cn1nccc1[C@H]1CCCC[C@@H]1Oc1cc(F)c(S(=O)(=O)Nc2ccncn2)c(F)c1,CHEMBL4622872,"Discovery of DS-1971a, a Potent, Selective Na<sub>V</sub>1.7 Inhibitor.",J Med Chem,2020.0,63,18,10204,10220,10.1021/acs.jmedchem.0c00259,32392056.0,
20684864,CHEMBL4642940,"rac-2,6-Difluoro-4-[[(1S*,2R*)-2-(1-methyl-1H-pyrazol-5-yl)cycloheptyl]oxy]-N-(pyrimidin-4-yl)benzene-1-sulfonamide",CHEMBL4623827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,80.4,%,Cn1nccc1[C@H]1CCCCC[C@@H]1Oc1cc(F)c(S(=O)(=O)Nc2ccncn2)c(F)c1,CHEMBL4622872,"Discovery of DS-1971a, a Potent, Selective Na<sub>V</sub>1.7 Inhibitor.",J Med Chem,2020.0,63,18,10204,10220,10.1021/acs.jmedchem.0c00259,32392056.0,
20684865,CHEMBL4637909,"rac-5-Chloro-2-fluoro-4-[[(1S*,2R*)-2-(1-methyl-1H-pyrazol-5-yl)cyclopentyl]oxy]-N-(pyrimidin-4-yl)benzene-1-sulfonamide",CHEMBL4623827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,>,90.0,%,Cn1nccc1[C@H]1CCC[C@@H]1Oc1cc(F)c(S(=O)(=O)Nc2ccncn2)cc1Cl,CHEMBL4622872,"Discovery of DS-1971a, a Potent, Selective Na<sub>V</sub>1.7 Inhibitor.",J Med Chem,2020.0,63,18,10204,10220,10.1021/acs.jmedchem.0c00259,32392056.0,
20684866,CHEMBL4633566,"rac-5-Chloro-2-fluoro-4-[[(1S*,2R*)-2-(1-methyl-1H-pyrazol-5-yl)cyclohexyl]oxy]-N-(pyrimidin-4-yl)benzene-1-sulfonamide",CHEMBL4623827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,86.8,%,Cn1nccc1[C@H]1CCCC[C@@H]1Oc1cc(F)c(S(=O)(=O)Nc2ccncn2)cc1Cl,CHEMBL4622872,"Discovery of DS-1971a, a Potent, Selective Na<sub>V</sub>1.7 Inhibitor.",J Med Chem,2020.0,63,18,10204,10220,10.1021/acs.jmedchem.0c00259,32392056.0,
20684867,CHEMBL4633566,"rac-5-Chloro-2-fluoro-4-[[(1S*,2R*)-2-(1-methyl-1H-pyrazol-5-yl)cyclohexyl]oxy]-N-(pyrimidin-4-yl)benzene-1-sulfonamide",CHEMBL4623827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,70.0,%,Cn1nccc1[C@H]1CCCC[C@@H]1Oc1cc(F)c(S(=O)(=O)Nc2ccncn2)cc1Cl,CHEMBL4622872,"Discovery of DS-1971a, a Potent, Selective Na<sub>V</sub>1.7 Inhibitor.",J Med Chem,2020.0,63,18,10204,10220,10.1021/acs.jmedchem.0c00259,32392056.0,
20684868,CHEMBL4637488,"rac-2-Fluoro-5-methyl-4-[[(1S*,2R*)-2-(1-methyl-1H-pyrazol-5-yl)cyclopentyl]oxy]-N-(pyrimidin-4-yl)benzene-1-sulfonamide",CHEMBL4623827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,79.8,%,Cc1cc(S(=O)(=O)Nc2ccncn2)c(F)cc1O[C@H]1CCC[C@@H]1c1ccnn1C,CHEMBL4622872,"Discovery of DS-1971a, a Potent, Selective Na<sub>V</sub>1.7 Inhibitor.",J Med Chem,2020.0,63,18,10204,10220,10.1021/acs.jmedchem.0c00259,32392056.0,
20684869,CHEMBL4639987,"rac-2-Fluoro-5-methyl-4-[[(1S*,2R*)-2-(1-methyl-1H-pyrazol-5-yl)cyclohexyl]oxy]-N-(pyrimidin-4-yl)benzene-1-sulfonamide",CHEMBL4623827,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,70.6,%,Cc1cc(S(=O)(=O)Nc2ccncn2)c(F)cc1O[C@H]1CCCC[C@@H]1c1ccnn1C,CHEMBL4622872,"Discovery of DS-1971a, a Potent, Selective Na<sub>V</sub>1.7 Inhibitor.",J Med Chem,2020.0,63,18,10204,10220,10.1021/acs.jmedchem.0c00259,32392056.0,
20687100,CHEMBL4640428,"(S)-(3-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)azetidin-1-yl)(2-methoxy-3-(methylsulfonyl)-6-(1,1,1-trifluoropropan-2-yloxy)phenyl)methanone",CHEMBL4624503,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM,Inhibition,<,20.0,%,COc1c(S(C)(=O)=O)ccc(O[C@@H](C)C(F)(F)F)c1C(=O)N1CC(c2ncc(C(F)(F)F)cc2Cl)C1,CHEMBL4622900,Azetidine-based selective glycine transporter-1 (GlyT1) inhibitors with memory enhancing properties.,Bioorg Med Chem Lett,2020.0,30,14,127214,127214,10.1016/j.bmcl.2020.127214,32527538.0,
20688593,CHEMBL4633717,"(2,4-cis)-N-((S)-2,3-Dihydroxypropyl)-4-phenylpiperidine-2-carboxamide",CHEMBL4624902,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,0.0,%,O=C(NC[C@H](O)CO)[C@@H]1C[C@H](c2ccccc2)CCN1,CHEMBL4622923,Discovery of 4-Phenylpiperidine-2-Carboxamide Analogues as Serotonin 5-HT<sub>2C</sub> Receptor-Positive Allosteric Modulators with Enhanced Drug-like Properties.,J Med Chem,2020.0,63,14,7529,7544,10.1021/acs.jmedchem.9b01953,32567857.0,
20702654,CHEMBL4647315,"N-((1R,3S)-3-(1,4-dimethyl-1H-imidazol-5-ylcarbamoyl)cyclohexyl)-N-methyl-3-(trifluoromethyl)benzamide",CHEMBL4627659,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,14.0,%,Cc1ncn(C)c1NC(=O)[C@H]1CCC[C@@H](N(C)C(=O)c2cccc(C(F)(F)F)c2)C1,CHEMBL4627259,Discovery of LY3325656: A GPR142 agonist suitable for clinical testing in human.,Bioorg Med Chem Lett,2020.0,30,5,126857,126857,10.1016/j.bmcl.2019.126857,31982234.0,
20702655,CHEMBL4647456,"3-chloro-N-((1R,3S)-3-(5-(1,4-dimethyl-1H-imidazol-5-yl)-4H-1,2,4-triazol-3-yl)cyclohexyl)-N-methylbenzamide",CHEMBL4627659,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,0.0,%,Cc1ncn(C)c1-c1nnc([C@H]2CCC[C@@H](N(C)C(=O)c3cccc(Cl)c3)C2)[nH]1,CHEMBL4627259,Discovery of LY3325656: A GPR142 agonist suitable for clinical testing in human.,Bioorg Med Chem Lett,2020.0,30,5,126857,126857,10.1016/j.bmcl.2019.126857,31982234.0,
20702656,CHEMBL4633161,"N-((2S,4R)-2-(5-(1,4-dimethyl-1H-imidazol-5-yl)-4H-1,2,4-triazol-3-yl)tetrahydro-2H-pyran-4-yl)-N-methyl-3-(trifluoromethyl)benzamide",CHEMBL4627659,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,11.0,%,Cc1ncn(C)c1-c1nnc([C@@H]2C[C@H](N(C)C(=O)c3cccc(C(F)(F)F)c3)CCO2)[nH]1,CHEMBL4627259,Discovery of LY3325656: A GPR142 agonist suitable for clinical testing in human.,Bioorg Med Chem Lett,2020.0,30,5,126857,126857,10.1016/j.bmcl.2019.126857,31982234.0,
20713620,CHEMBL4639153,(S)-4-(2-(1-Methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,51.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@@H]1CCOc2cc(S(=O)(=O)Nc3nccs3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713621,CHEMBL4646742,(R)-4-(2-(1-Methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,46.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3nccs3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713623,CHEMBL4635247,(R)-N-(Thiazol-2-yl)-4-(2-(thiazol-2-yl)-4-(trifluoromethyl)phenyl)chromane-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,88.0,%,O=S(=O)(Nc1nccs1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-c1nccs1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713624,CHEMBL4636271,(S)-4-(2-(2-Methyloxazol-4-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,54.0,%,Cc1nc(-c2cc(C(F)(F)F)ccc2[C@@H]2CCOc3cc(S(=O)(=O)Nc4nccs4)ccc32)co1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713625,CHEMBL4639228,(R)-4-(2-(2-Methyloxazol-4-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,45.0,%,Cc1nc(-c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4nccs4)ccc32)co1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713627,CHEMBL4642748,"(R)-4-(2-(1H-1,2,3-Triazol-1-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide",CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,42.0,%,O=S(=O)(Nc1nccs1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-n1ccnn1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713628,CHEMBL4642271,(S)-4-(2-(6-Fluoropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,70.0,%,O=S(=O)(Nc1nccs1)c1ccc2c(c1)OCC[C@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)nc1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713629,CHEMBL4634421,(R)-4-(2-(6-Fluoropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,48.0,%,O=S(=O)(Nc1nccs1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)nc1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713630,CHEMBL4641467,(R)-4-(2-(5-Fluoropyridin-2-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,38.0,%,O=S(=O)(Nc1nccs1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)cn1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713631,CHEMBL4647064,"(S)-4-(4'-Fluoro-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl)-N-(thiazol-2-yl)chromane-7-sulfonamide",CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,68.0,%,O=S(=O)(Nc1nccs1)c1ccc2c(c1)OCC[C@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)cc1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713632,CHEMBL4636838,"(R)-4-(4'-Fluoro-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl)-N-(thiazol-2-yl)chromane-7-sulfonamide",CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,62.0,%,O=S(=O)(Nc1nccs1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)cc1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713633,CHEMBL4639688,(R)-4-(2-(3-Oxomorpholino)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chroman-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,1.0,%,O=C1COCCN1c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3nccs3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713634,CHEMBL4641628,(R)-4-(2-(2-Oxooxazolidin-3-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,19.0,%,O=C1OCCN1c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3nccs3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713635,CHEMBL4642855,"(R)-4-[2-(1,1-Dioxo-1lambda(6)-thiomorpholin-4-yl)-4-trifluoromethyl-phenyl]-chroman-7-sulfonic acid thiazol-2-ylamide",CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,4.0,%,O=S1(=O)CCN(c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4nccs4)ccc32)CC1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713636,CHEMBL4649638,(R)-4-(2-(Piperazin-1-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,33.0,%,O=S(=O)(Nc1nccs1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1N1CCNCC1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713637,CHEMBL4632456,(R)-4-(2-(4-Methylpiperazin-1-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,10.0,%,CN1CCN(c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4nccs4)ccc32)CC1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713638,CHEMBL4632819,(R)-4-(2-(1-Methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)chromane-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,7.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3ncccn3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713639,CHEMBL4641367,(R)-N-(5-Fluoropyrimidin-2-yl)-4-(2-(1-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)Chroman-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,13.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3ncc(F)cn3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713640,CHEMBL4648205,(R)-4-(2-(1-Methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-4-yl)Chroman-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,10.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3ccncn3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713641,CHEMBL4633605,(R)-4-(2-(1-Methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-N-(pyridazin-3-yl)chromane-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,19.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3cccnn3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713642,CHEMBL4646718,(R)-4-(2-(1-Methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-N-(pyrazin-2-yl)Chromane-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,32.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3cnccn3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713643,CHEMBL4633361,(R)-N-(6-Fluoropyridin-2-yl)-4-(2-(1-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)Chroman-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,33.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3cccc(F)n3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713644,CHEMBL4633814,(R)-N-(5-Fluoropyridin-2-yl)-4-(2-(1-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)Chroman-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,31.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3ccc(F)cn3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713645,CHEMBL4640134,(R)-N-(4-Fluoropyridin-2-yl)-4-(2-(1-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)Chroman-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,33.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3cc(F)ccn3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713646,CHEMBL4638025,(R)-4-(2-(2-Methyloxazol-4-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)chroman-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,2.0,%,Cc1nc(-c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4ncccn4)ccc32)co1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713647,CHEMBL4645317,(R)-N-(5-Fluoropyrimidin-2-yl)-4-(2-(2-methyloxazol-4-yl)-4-(trifluoromethyl)phenyl)Chroman-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,4.0,%,Cc1nc(-c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4ncc(F)cn4)ccc32)co1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713648,CHEMBL4647620,(R)-4-(2-(2-Methyloxazol-4-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-4-yl)chroman-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,86.0,%,Cc1nc(-c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4ccncn4)ccc32)co1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713649,CHEMBL4639872,(R)-N-(6-Fluoropyridin-2-yl)-4-(2-(2-methyloxazol-4-yl)-4-(trifluoromethyl)phenyl)Chroman-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,27.0,%,Cc1nc(-c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4cccc(F)n4)ccc32)co1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713650,CHEMBL4637917,(R)-4-(2-(6-Fluoropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)chromane-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,0.0,%,O=S(=O)(Nc1ncccn1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)nc1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713651,CHEMBL4644526,(R)-4-(2-(6-Fluoropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(5-fluoropyrimidin-2-yl)Chromane-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,8.0,%,O=S(=O)(Nc1ncc(F)cn1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)nc1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713652,CHEMBL4640389,(R)-4-(2-(6-Fluoropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-4-yl)chromane-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,90.0,%,O=S(=O)(Nc1ccncn1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)nc1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713653,CHEMBL4649472,(R)-4-(2-(6-Methylpyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)chromane-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,-1.0,%,Cc1ccc(-c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4ncccn4)ccc32)cn1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713654,CHEMBL4638356,(R)-N-(5-Fluoropyrimidin-2-yl)-4-(2-(6-methylpyridin-3-yl)-4-(trifluoromethyl)phenyl)chroman-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,2.0,%,Cc1ccc(-c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4ncc(F)cn4)ccc32)cn1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713655,CHEMBL4640506,(R)-4-(2-(6-Methylpyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-4-yl)chroman-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,90.0,%,Cc1ccc(-c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4ccncn4)ccc32)cn1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713656,CHEMBL4639765,(R)-N-(6-Fluoropyridin-2-yl)-4-(2-(6-methylpyridin-3-yl)-4-(trifluoromethyl)phenyl)chroman-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,22.0,%,Cc1ccc(-c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4cccc(F)n4)ccc32)cn1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713657,CHEMBL4644542,(R)-4-(2-(5-Fluoropyridin-2-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)chroman-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,4.0,%,O=S(=O)(Nc1ncccn1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)cn1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713658,CHEMBL4634870,(R)-4-(2-(5-Fluoropyridin-2-yl)-4-(trifluoromethyl)phenyl)-N-(5-fluoropyrimidin-2-yl)chroman-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,6.0,%,O=S(=O)(Nc1ncc(F)cn1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)cn1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713659,CHEMBL4635396,(R)-4-(2-(5-Fluoropyridin-2-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-4-yl)chroman-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,0.0,%,O=S(=O)(Nc1ccncn1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)cn1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713660,CHEMBL4637586,(R)-4-(2-Morpholino-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)chroman-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,13.0,%,O=S(=O)(Nc1ncccn1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1N1CCOCC1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713661,CHEMBL4632408,(R)-N-(5-Fluoropyrimidin-2-yl)-4-(2-morpholino-4-(trifluoromethyl)phenyl)Chroman-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,83.0,%,O=S(=O)(Nc1ncc(F)cn1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1N1CCOCC1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713662,CHEMBL4647267,(R)-4-(2-Morpholino-4-(trifluoromethyl)phenyl)-N-(pyrimidin-4-yl)Chroman-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,74.0,%,O=S(=O)(Nc1ccncn1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1N1CCOCC1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713663,CHEMBL4641925,(R)-N-(6-Fluoropyridin-2-yl)-4-(2-morpholino-4-(trifluoromethyl)phenyl)Chroman-7-sulfonamide,CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,58.0,%,O=S(=O)(Nc1cccc(F)n1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1N1CCOCC1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713664,CHEMBL4637997,"(S)-1-(2-(1-Methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide",CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,3.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@H]1CCc2cc(S(=O)(=O)Nc3ncccn3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713665,CHEMBL4633186,"(S)-1-(2-(6-Fluoropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide",CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,5.0,%,O=S(=O)(Nc1ncccn1)c1ccc2c(c1)CC[C@@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)nc1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713666,CHEMBL4646308,"(S)-1-(2-(6-Methylpyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide",CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,8.0,%,Cc1ccc(-c2cc(C(F)(F)F)ccc2[C@H]2CCc3cc(S(=O)(=O)Nc4ncccn4)ccc32)cn1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713667,CHEMBL4632563,"(S)-1-(2-Morpholino-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide",CHEMBL4629719,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 1 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,7.0,%,O=S(=O)(Nc1ncccn1)c1ccc2c(c1)CC[C@@H]2c1ccc(C(F)(F)F)cc1N1CCOCC1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713668,CHEMBL4639153,(S)-4-(2-(1-Methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,92.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@@H]1CCOc2cc(S(=O)(=O)Nc3nccs3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713669,CHEMBL4646742,(R)-4-(2-(1-Methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,93.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3nccs3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713671,CHEMBL4635247,(R)-N-(Thiazol-2-yl)-4-(2-(thiazol-2-yl)-4-(trifluoromethyl)phenyl)chromane-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,99.0,%,O=S(=O)(Nc1nccs1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-c1nccs1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713672,CHEMBL4636271,(S)-4-(2-(2-Methyloxazol-4-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,91.0,%,Cc1nc(-c2cc(C(F)(F)F)ccc2[C@@H]2CCOc3cc(S(=O)(=O)Nc4nccs4)ccc32)co1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713673,CHEMBL4639228,(R)-4-(2-(2-Methyloxazol-4-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,88.0,%,Cc1nc(-c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4nccs4)ccc32)co1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713675,CHEMBL4642748,"(R)-4-(2-(1H-1,2,3-Triazol-1-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide",CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,87.0,%,O=S(=O)(Nc1nccs1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-n1ccnn1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713676,CHEMBL4642271,(S)-4-(2-(6-Fluoropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,97.0,%,O=S(=O)(Nc1nccs1)c1ccc2c(c1)OCC[C@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)nc1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713677,CHEMBL4634421,(R)-4-(2-(6-Fluoropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,90.0,%,O=S(=O)(Nc1nccs1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)nc1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713678,CHEMBL4641467,(R)-4-(2-(5-Fluoropyridin-2-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,86.0,%,O=S(=O)(Nc1nccs1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)cn1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713679,CHEMBL4647064,"(S)-4-(4'-Fluoro-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl)-N-(thiazol-2-yl)chromane-7-sulfonamide",CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,94.0,%,O=S(=O)(Nc1nccs1)c1ccc2c(c1)OCC[C@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)cc1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713680,CHEMBL4636838,"(R)-4-(4'-Fluoro-5-(trifluoromethyl)[1,1'-biphenyl]-2-yl)-N-(thiazol-2-yl)chromane-7-sulfonamide",CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,94.0,%,O=S(=O)(Nc1nccs1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)cc1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713681,CHEMBL4639688,(R)-4-(2-(3-Oxomorpholino)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chroman-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,32.0,%,O=C1COCCN1c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3nccs3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713682,CHEMBL4641628,(R)-4-(2-(2-Oxooxazolidin-3-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,60.0,%,O=C1OCCN1c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3nccs3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713683,CHEMBL4642855,"(R)-4-[2-(1,1-Dioxo-1lambda(6)-thiomorpholin-4-yl)-4-trifluoromethyl-phenyl]-chroman-7-sulfonic acid thiazol-2-ylamide",CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,68.0,%,O=S1(=O)CCN(c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4nccs4)ccc32)CC1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713684,CHEMBL4649638,(R)-4-(2-(Piperazin-1-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,83.0,%,O=S(=O)(Nc1nccs1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1N1CCNCC1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713685,CHEMBL4632456,(R)-4-(2-(4-Methylpiperazin-1-yl)-4-(trifluoromethyl)phenyl)-N-(thiazol-2-yl)chromane-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,52.0,%,CN1CCN(c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4nccs4)ccc32)CC1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713686,CHEMBL4632819,(R)-4-(2-(1-Methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)chromane-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,36.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3ncccn3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713687,CHEMBL4641367,(R)-N-(5-Fluoropyrimidin-2-yl)-4-(2-(1-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)Chroman-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,28.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3ncc(F)cn3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713688,CHEMBL4648205,(R)-4-(2-(1-Methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-4-yl)Chroman-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,69.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3ccncn3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713689,CHEMBL4633605,(R)-4-(2-(1-Methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-N-(pyridazin-3-yl)chromane-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,56.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3cccnn3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713690,CHEMBL4646718,(R)-4-(2-(1-Methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-N-(pyrazin-2-yl)Chromane-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,74.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3cnccn3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713691,CHEMBL4633361,(R)-N-(6-Fluoropyridin-2-yl)-4-(2-(1-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)Chroman-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,86.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3cccc(F)n3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713692,CHEMBL4633814,(R)-N-(5-Fluoropyridin-2-yl)-4-(2-(1-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)Chroman-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,87.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3ccc(F)cn3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713693,CHEMBL4640134,(R)-N-(4-Fluoropyridin-2-yl)-4-(2-(1-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)Chroman-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,81.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@H]1CCOc2cc(S(=O)(=O)Nc3cc(F)ccn3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713694,CHEMBL4638025,(R)-4-(2-(2-Methyloxazol-4-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)chroman-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,24.0,%,Cc1nc(-c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4ncccn4)ccc32)co1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713695,CHEMBL4645317,(R)-N-(5-Fluoropyrimidin-2-yl)-4-(2-(2-methyloxazol-4-yl)-4-(trifluoromethyl)phenyl)Chroman-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,41.0,%,Cc1nc(-c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4ncc(F)cn4)ccc32)co1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713696,CHEMBL4647620,(R)-4-(2-(2-Methyloxazol-4-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-4-yl)chroman-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,98.0,%,Cc1nc(-c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4ccncn4)ccc32)co1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713697,CHEMBL4639872,(R)-N-(6-Fluoropyridin-2-yl)-4-(2-(2-methyloxazol-4-yl)-4-(trifluoromethyl)phenyl)Chroman-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,88.0,%,Cc1nc(-c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4cccc(F)n4)ccc32)co1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713698,CHEMBL4637917,(R)-4-(2-(6-Fluoropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)chromane-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,18.0,%,O=S(=O)(Nc1ncccn1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)nc1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713699,CHEMBL4644526,(R)-4-(2-(6-Fluoropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(5-fluoropyrimidin-2-yl)Chromane-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,38.0,%,O=S(=O)(Nc1ncc(F)cn1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)nc1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713700,CHEMBL4640389,(R)-4-(2-(6-Fluoropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-4-yl)chromane-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,99.0,%,O=S(=O)(Nc1ccncn1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)nc1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713701,CHEMBL4649472,(R)-4-(2-(6-Methylpyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)chromane-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,28.0,%,Cc1ccc(-c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4ncccn4)ccc32)cn1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713702,CHEMBL4638356,(R)-N-(5-Fluoropyrimidin-2-yl)-4-(2-(6-methylpyridin-3-yl)-4-(trifluoromethyl)phenyl)chroman-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,68.0,%,Cc1ccc(-c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4ncc(F)cn4)ccc32)cn1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713703,CHEMBL4640506,(R)-4-(2-(6-Methylpyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-4-yl)chroman-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,99.0,%,Cc1ccc(-c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4ccncn4)ccc32)cn1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713704,CHEMBL4639765,(R)-N-(6-Fluoropyridin-2-yl)-4-(2-(6-methylpyridin-3-yl)-4-(trifluoromethyl)phenyl)chroman-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,85.0,%,Cc1ccc(-c2cc(C(F)(F)F)ccc2[C@H]2CCOc3cc(S(=O)(=O)Nc4cccc(F)n4)ccc32)cn1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713705,CHEMBL4644542,(R)-4-(2-(5-Fluoropyridin-2-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)chroman-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,33.0,%,O=S(=O)(Nc1ncccn1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)cn1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713706,CHEMBL4634870,(R)-4-(2-(5-Fluoropyridin-2-yl)-4-(trifluoromethyl)phenyl)-N-(5-fluoropyrimidin-2-yl)chroman-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,49.0,%,O=S(=O)(Nc1ncc(F)cn1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)cn1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713707,CHEMBL4635396,(R)-4-(2-(5-Fluoropyridin-2-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-4-yl)chroman-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,44.0,%,O=S(=O)(Nc1ccncn1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)cn1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713708,CHEMBL4637586,(R)-4-(2-Morpholino-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)chroman-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,54.0,%,O=S(=O)(Nc1ncccn1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1N1CCOCC1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713709,CHEMBL4632408,(R)-N-(5-Fluoropyrimidin-2-yl)-4-(2-morpholino-4-(trifluoromethyl)phenyl)Chroman-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,98.0,%,O=S(=O)(Nc1ncc(F)cn1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1N1CCOCC1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713710,CHEMBL4647267,(R)-4-(2-Morpholino-4-(trifluoromethyl)phenyl)-N-(pyrimidin-4-yl)Chroman-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,97.0,%,O=S(=O)(Nc1ccncn1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1N1CCOCC1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713711,CHEMBL4641925,(R)-N-(6-Fluoropyridin-2-yl)-4-(2-morpholino-4-(trifluoromethyl)phenyl)Chroman-7-sulfonamide,CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,95.0,%,O=S(=O)(Nc1cccc(F)n1)c1ccc2c(c1)OCC[C@@H]2c1ccc(C(F)(F)F)cc1N1CCOCC1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713712,CHEMBL4637997,"(S)-1-(2-(1-Methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide",CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,-8.0,%,Cn1nccc1-c1cc(C(F)(F)F)ccc1[C@H]1CCc2cc(S(=O)(=O)Nc3ncccn3)ccc21,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713713,CHEMBL4633186,"(S)-1-(2-(6-Fluoropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide",CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,41.0,%,O=S(=O)(Nc1ncccn1)c1ccc2c(c1)CC[C@@H]2c1ccc(C(F)(F)F)cc1-c1ccc(F)nc1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713714,CHEMBL4646308,"(S)-1-(2-(6-Methylpyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide",CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,47.0,%,Cc1ccc(-c2cc(C(F)(F)F)ccc2[C@H]2CCc3cc(S(=O)(=O)Nc4ncccn4)ccc32)cn1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
20713715,CHEMBL4632563,"(S)-1-(2-Morpholino-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide",CHEMBL4629720,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac sodium as substrate preincubated for 5 mins followed by NADPH addition and measured after 10 mins by UPLC/MS-MS analysis relative to control,Inhibition,=,43.0,%,O=S(=O)(Nc1ncccn1)c1ccc2c(c1)CC[C@@H]2c1ccc(C(F)(F)F)cc1N1CCOCC1,CHEMBL4627393,"Discovery of Potent, Selective, and State-Dependent NaV1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides.",J Med Chem,2020.0,63,11,6107,6133,10.1021/acs.jmedchem.0c00361,32368909.0,
22392460,CHEMBL4745208,"(2S)-1-[2,4-dichloro-3-[[2-isopropyl-4-(3-methylimidazol-4-yl)-8-quinolyl]oxymethyl]phenyl]sulfonyl-N-methyl-pyrrolidine-2-carboxamide",CHEMBL4667366,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 1 uM relative to control,Inhibition,=,100.0,%,CNC(=O)[C@@H]1CCCN1S(=O)(=O)c1ccc(Cl)c(COc2cccc3c(-c4cncn4C)cc(C(C)C)nc23)c1Cl,CHEMBL4665652,"Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORγ inverse agonists.",Bioorg Med Chem Lett,2019.0,29,14.0,1799,1806,10.1016/j.bmcl.2019.05.015,31101472.0,
22407408,CHEMBL4748782,2-(5-(cyclopropylmethyl)-3-(4-fluoro-3-((5-methylthiophen-2-yl)ethynyl)phenyl)-4-(3-fluoro-4-sulfamoylbenzyl)-1H-pyrazol-1-yl)thiazole-4-carboxylic acid,CHEMBL4670736,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,45.0,%,Cc1ccc(C#Cc2cc(-c3nn(-c4nc(C(=O)O)cs4)c(CC4CC4)c3Cc3ccc(S(N)(=O)=O)c(F)c3)ccc2F)s1,CHEMBL4665801,Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties.,J Med Chem,2020.0,63,19.0,10984,11011,10.1021/acs.jmedchem.0c00916,32902275.0,
22407535,CHEMBL4739983,N-((2-Methoxy-4-methylphenyl)sulfonyl)-2-(4-((4-methoxy-N-(2-((4-methoxyphenyl)sulfonamido)-2-oxoethyl)phenyl)-sulfonamido)indolin-1-yl)-2-(3-methoxyphenyl)acetamide,CHEMBL4670751,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM using sulfaphenazole as substrate preincubated for 5 mins followed by NADPH addition and measured after 20 mins by LC-MS/MS analysis relative to control,Inhibition,=,30.26,%,COc1ccc(S(=O)(=O)NC(=O)CN(c2cccc3c2CCN3C(C(=O)NS(=O)(=O)c2ccc(C)cc2OC)c2cccc(OC)c2)S(=O)(=O)c2ccc(OC)cc2)cc1,CHEMBL4665802,"Design, Synthesis, and Structure-Activity Relationships of Indoline-Based Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors.",J Med Chem,2020.0,63,19.0,11149,11168,10.1021/acs.jmedchem.0c01116,32902980.0,
22417739,CHEMBL4788385,"(RS)-(1-Methylsulfonylindol-5-yl)-[3-([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-1-piperidyl]methanone",CHEMBL4672646,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS analysis at 10 uM relative to control,Inhibition,=,2.0,%,CS(=O)(=O)n1ccc2cc(C(=O)N3CCCC(c4ccnc5ncnn45)C3)ccc21,CHEMBL4665888,"[1,2,4]Triazolo[1,5-a]pyrimidine Phosphodiesterase 2A Inhibitors: Structure and Free-Energy Perturbation-Guided Exploration.",J Med Chem,2020.0,63,21.0,12887,12910,10.1021/acs.jmedchem.0c01272,33105987.0,
22417740,CHEMBL4761967,"4,5,6,7-Tetrahydrobenzothiophen-2-yl-[(3S)-([1,2,4]triazolo[1,5-a]pyrimidin-7-yl)-1-piperidyl]methanone",CHEMBL4672646,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS analysis at 10 uM relative to control,Inhibition,=,44.0,%,O=C(c1cc2c(s1)CCCC2)N1CCC[C@H](c2ccnc3ncnn23)C1,CHEMBL4665888,"[1,2,4]Triazolo[1,5-a]pyrimidine Phosphodiesterase 2A Inhibitors: Structure and Free-Energy Perturbation-Guided Exploration.",J Med Chem,2020.0,63,21.0,12887,12910,10.1021/acs.jmedchem.0c01272,33105987.0,
22417741,CHEMBL4755779,"(RS)-[3-[5-(Difluoromethyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]-1-piperidyl]-(4,5,6,7-tetrahydrobenzothiophen-2-yl)methanone",CHEMBL4672646,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes by LC-MS analysis at 10 uM relative to control,Inhibition,=,31.0,%,O=C(c1cc2c(s1)CCCC2)N1CCCC(c2cc(C(F)F)nc3ncnn23)C1,CHEMBL4665888,"[1,2,4]Triazolo[1,5-a]pyrimidine Phosphodiesterase 2A Inhibitors: Structure and Free-Energy Perturbation-Guided Exploration.",J Med Chem,2020.0,63,21.0,12887,12910,10.1021/acs.jmedchem.0c01272,33105987.0,
22419459,CHEMBL4783351,"(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide",CHEMBL4673055,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 1 uM relative to control,Inhibition,<,5.0,%,Cc1cc(-c2nc(C(=O)Nc3cc4oc(N5CCOCC5)nc4nc3N3CC[C@@H](O)C3)co2)ccn1,CHEMBL4665913,"Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies.",ACS Med Chem Lett,2020.0,11,12.0,2374,2381,10.1021/acsmedchemlett.0c00255,33335659.0,
22429566,CHEMBL1871173,SID124384890,CHEMBL4675916,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using probe substrate and in presence of co-factor measured after 20 mins by LC-MS/MS analysis relative to control,Inhibition,<,33.0,%,COc1cc2c(cc1OC)-c1cc(NCc3ccccc3)nc(=O)n1CC2,CHEMBL4673243,"Discovery of 9-Cyclopropylethynyl-2-((S)-1-[1,4]dioxan-2-ylmethoxy)-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (GLPG1205), a Unique GPR84 Negative Allosteric Modulator Undergoing Evaluation in a Phase II Clinical Trial.",J Med Chem,2020.0,63,22,13526,13545,10.1021/acs.jmedchem.0c00272,32902984.0,
22431382,CHEMBL4781352,"(R)-9-(2,5-Difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",CHEMBL4676409,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM relative to control,Inhibition,<,50.0,%,CCN1CC2(CCN(CCc3cc(F)ccc3F)CC2)O[C@H](C)C1=O,CHEMBL4673253,"Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ Receptor Antagonist Clinical Candidate for the Treatment of Pain.",J Med Chem,2020.0,63,24,15508,15526,10.1021/acs.jmedchem.0c01127,33064947.0,
22432706,CHEMBL4776820,"(R)-4-(4-(3-(5-oxo-5,6-dihydro-1,6-naphthyridin-7-yl)cyclopent-2-en-1-yl)piperazin-1-yl)benzonitrile",CHEMBL4676684,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<=,23.0,%,N#Cc1ccc(N2CCN([C@H]3C=C(c4cc5ncccc5c(=O)[nH]4)CC3)CC2)cc1,CHEMBL4673259,Discovery of isoquinolinone and naphthyridinone-based inhibitors of poly(ADP-ribose) polymerase-1 (PARP1) as anticancer agents: Structure activity relationship and preclinical characterization.,Bioorg Med Chem,2020.0,28,24,115819,115819,10.1016/j.bmc.2020.115819,33120078.0,
22442348,CHEMBL4765165,Ethyl 1-[(4-Cyanobenzyl)oxy]-2-(3-cyanophenyl)-4-methyl-1H-imidazole-5-carboxylate,CHEMBL4678957,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide as substrate preincubated for 5 mins followed by NADPH generating system addition and measured after 120 mins by LC-MS/MS analysis relative to control,Inhibition,=,0.024,%,CCOC(=O)c1c(C)nc(-c2cccc(C#N)c2)n1OCc1ccc(C#N)cc1,CHEMBL4673353,Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y and P2Y as an Oral Antiplatelet Agent with a Wider Therapeutic Window in Rats than Ticagrelor.,J Med Chem,2020.0,63,24,15752,15772,10.1021/acs.jmedchem.0c01524,33307675.0,
22442349,CHEMBL4786038,1-[(4-Cyanobenzyl)oxy]-2-(3-cyanophenyl)-4-methyl-1H-imidazole-5-carboxylic acid,CHEMBL4678957,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide as substrate preincubated for 5 mins followed by NADPH generating system addition and measured after 120 mins by LC-MS/MS analysis relative to control,Inhibition,=,0.41,%,Cc1nc(-c2cccc(C#N)c2)n(OCc2ccc(C#N)cc2)c1C(=O)O,CHEMBL4673353,Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y and P2Y as an Oral Antiplatelet Agent with a Wider Therapeutic Window in Rats than Ticagrelor.,J Med Chem,2020.0,63,24,15752,15772,10.1021/acs.jmedchem.0c01524,33307675.0,
22453287,CHEMBL4790844,(E)-5-(4-Bromophenyl)-5-(4-(2-(1-methylpyrrolidin-2-yl)-ethoxy)phenyl)-4-phenylpent-4-en-1-ol Hydrochloride Salt,CHEMBL4681578,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide 4-hydroxylase activity at 10 uM preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,3.0,%,CN1CCCC1CCOc1ccc(/C(=C(/CCCO)c2ccccc2)c2ccc(Br)cc2)cc1.Cl,CHEMBL4680094,Insights of a Lead Optimization Study and Biological Evaluation of Novel 4-Hydroxytamoxifen Analogs as Estrogen-Related Receptor γ (ERRγ) Inverse Agonists.,J Med Chem,2016.0,59,22,10209,10227,10.1021/acs.jmedchem.6b01204,27805390.0,
22453288,CHEMBL4791571,"(S,E)-5-(4-Bromophenyl)-5-(4-((1-methylpyrrolidin-2-yl)-methoxy)phenyl)-4-phenylpent-4-en-1-ol Hydrochloride Salt",CHEMBL4681578,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide 4-hydroxylase activity at 10 uM preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,37.3,%,CN1CCC[C@H]1COc1ccc(/C(=C(/CCCO)c2ccccc2)c2ccc(Br)cc2)cc1.Cl,CHEMBL4680094,Insights of a Lead Optimization Study and Biological Evaluation of Novel 4-Hydroxytamoxifen Analogs as Estrogen-Related Receptor γ (ERRγ) Inverse Agonists.,J Med Chem,2016.0,59,22,10209,10227,10.1021/acs.jmedchem.6b01204,27805390.0,
22453289,CHEMBL4757503,(Z)-4-(5-Hydroxy-1-(4-(2-(1-methylpyrrolidin-2-yl)ethoxy)-phenyl)-2-phenylpent-1-en-1-yl)phenol Hydrochloride Salt,CHEMBL4681578,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide 4-hydroxylase activity at 10 uM preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,24.6,%,CN1CCCC1CCOc1ccc(/C(=C(/CCCO)c2ccccc2)c2ccc(O)cc2)cc1.Cl,CHEMBL4680094,Insights of a Lead Optimization Study and Biological Evaluation of Novel 4-Hydroxytamoxifen Analogs as Estrogen-Related Receptor γ (ERRγ) Inverse Agonists.,J Med Chem,2016.0,59,22,10209,10227,10.1021/acs.jmedchem.6b01204,27805390.0,
22453290,CHEMBL4759824,"(R,Z)-4-(5-Hydroxy-1-(4-((1-methylpyrrolidin-2-yl)methoxy)-phenyl)-2-phenylpent-1-en-1-yl)phenol Hydrochloride Salt",CHEMBL4681578,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide 4-hydroxylase activity at 10 uM preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,13.3,%,CN1CCC[C@@H]1COc1ccc(/C(=C(/CCCO)c2ccccc2)c2ccc(O)cc2)cc1.Cl,CHEMBL4680094,Insights of a Lead Optimization Study and Biological Evaluation of Novel 4-Hydroxytamoxifen Analogs as Estrogen-Related Receptor γ (ERRγ) Inverse Agonists.,J Med Chem,2016.0,59,22,10209,10227,10.1021/acs.jmedchem.6b01204,27805390.0,
22453291,CHEMBL4791981,"(S,Z)-4-(5-Hydroxy-1-(4-((1-methylpyrrolidin-2-yl)methoxy)-phenyl)-2-phenylpent-1-en-1-yl)phenol Hydrochloride Salt",CHEMBL4681578,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide 4-hydroxylase activity at 10 uM preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,37.2,%,CN1CCC[C@H]1COc1ccc(/C(=C(/CCCO)c2ccccc2)c2ccc(O)cc2)cc1.Cl,CHEMBL4680094,Insights of a Lead Optimization Study and Biological Evaluation of Novel 4-Hydroxytamoxifen Analogs as Estrogen-Related Receptor γ (ERRγ) Inverse Agonists.,J Med Chem,2016.0,59,22,10209,10227,10.1021/acs.jmedchem.6b01204,27805390.0,
22453292,CHEMBL201013,4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-5-hydroxy-2-phenylpent-1-enyl)phenol,CHEMBL4681578,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes assessed as reduction in tolbutamide 4-hydroxylase activity at 10 uM preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by LC-MS/MS analysis relative to control,Inhibition,=,27.1,%,CN(C)CCOc1ccc(/C(=C(/CCCO)c2ccccc2)c2ccc(O)cc2)cc1,CHEMBL4680094,Insights of a Lead Optimization Study and Biological Evaluation of Novel 4-Hydroxytamoxifen Analogs as Estrogen-Related Receptor γ (ERRγ) Inverse Agonists.,J Med Chem,2016.0,59,22,10209,10227,10.1021/acs.jmedchem.6b01204,27805390.0,
22455899,CHEMBL4746566,2-{4-[6-Amino-5-(4-chlorophenyl)pyridin-3-yl]phenoxy}-2-methylpropanoic Acid,CHEMBL4682024,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,<,15.0,%,CC(C)(Oc1ccc(-c2cnc(N)c(-c3ccc(Cl)cc3)c2)cc1)C(=O)O,CHEMBL4680107,2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety.,J Med Chem,2018.0,61,7,3114,3125,10.1021/acs.jmedchem.8b00152,29570292.0,
22455900,CHEMBL3754515,"5-(4-Chlorophenyl)-[3,3'-bipyridine]-6,6'-diamine",CHEMBL4682024,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,<,15.0,%,Nc1ccc(-c2cnc(N)c(-c3ccc(Cl)cc3)c2)cn1,CHEMBL4680107,2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety.,J Med Chem,2018.0,61,7,3114,3125,10.1021/acs.jmedchem.8b00152,29570292.0,
22464602,CHEMBL4778737,"2-(4-(4-hydroxybenzyl)-3,5-dimerhylphenoxy)acetic acid",CHEMBL4683748,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,50.0,%,Cc1cc(OCC(=O)O)cc(C)c1Cc1ccc(O)cc1,CHEMBL4680157,"Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.",Eur J Med Chem,2020.0,188,,112006,112006,10.1016/j.ejmech.2019.112006,31931337.0,
22464603,CHEMBL4790769,"2-(4-(4-aminobenzyl)-3,5-dimethylphenoxy)acetic acid",CHEMBL4683748,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,50.0,%,Cc1cc(OCC(=O)O)cc(C)c1Cc1ccc(N)cc1,CHEMBL4680157,"Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.",Eur J Med Chem,2020.0,188,,112006,112006,10.1016/j.ejmech.2019.112006,31931337.0,
22464604,CHEMBL4757446,2-(4-(4-aminobenzyl)-3-fluorophenoxy)acetic acid,CHEMBL4683748,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,51.0,%,Nc1ccc(Cc2ccc(OCC(=O)O)cc2F)cc1,CHEMBL4680157,"Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.",Eur J Med Chem,2020.0,188,,112006,112006,10.1016/j.ejmech.2019.112006,31931337.0,
22464605,CHEMBL4740833,4-(4-(2-aminoethoxy)-2-(trifluoromethyl)benzyl)aniline,CHEMBL4683748,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,>,91.0,%,NCCOc1ccc(Cc2ccc(N)cc2)c(C(F)(F)F)c1,CHEMBL4680157,"Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.",Eur J Med Chem,2020.0,188,,112006,112006,10.1016/j.ejmech.2019.112006,31931337.0,
22464606,CHEMBL4753224,"4-(4-(2-aminoethoxy)-2,6-dimethylbenzyl)phenol",CHEMBL4683748,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,>,91.0,%,Cc1cc(OCCN)cc(C)c1Cc1ccc(O)cc1,CHEMBL4680157,"Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.",Eur J Med Chem,2020.0,188,,112006,112006,10.1016/j.ejmech.2019.112006,31931337.0,
22464607,CHEMBL4744643,4-(4-(2-aminoethoxy)-2-(trifluoromethyl)benzyl)-N-ethyl-2-isopropylaniline,CHEMBL4683748,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,>,91.0,%,CCNc1ccc(Cc2ccc(OCC(=O)O)cc2)cc1C(C)C,CHEMBL4680157,"Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.",Eur J Med Chem,2020.0,188,,112006,112006,10.1016/j.ejmech.2019.112006,31931337.0,
22464608,CHEMBL4799761,"4-(4-(2-aminoethoxy)-2,6-dimethylbenzyl)-N-ethyl-2-isopropylaniline",CHEMBL4683748,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,>,91.0,%,CCNc1ccc(Cc2c(C)cc(OCC(=O)O)cc2C)cc1C(C)C,CHEMBL4680157,"Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.",Eur J Med Chem,2020.0,188,,112006,112006,10.1016/j.ejmech.2019.112006,31931337.0,
22464609,CHEMBL4750819,2-(4-(4-amino-3-isopropylbenzyl)phenoxy)acetic acid,CHEMBL4683748,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,50.0,%,CC(C)c1cc(Cc2ccc(OCC(=O)O)cc2)ccc1N,CHEMBL4680157,"Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.",Eur J Med Chem,2020.0,188,,112006,112006,10.1016/j.ejmech.2019.112006,31931337.0,
22464610,CHEMBL4792416,"2-(4-(4-amino-3-isopropylbenzyl)-3,5-dimethylphenoxy)acetic acid",CHEMBL4683748,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,50.0,%,Cc1cc(OCC(=O)O)cc(C)c1Cc1ccc(N)c(C(C)C)c1,CHEMBL4680157,"Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.",Eur J Med Chem,2020.0,188,,112006,112006,10.1016/j.ejmech.2019.112006,31931337.0,
22464611,CHEMBL4756150,2-(4-(4-acetamido-3-isopropylbenzyl)phenoxy)acetic acid,CHEMBL4683748,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,50.0,%,CC(=O)Nc1ccc(Cc2ccc(OCC(=O)O)cc2)cc1C(C)C,CHEMBL4680157,"Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.",Eur J Med Chem,2020.0,188,,112006,112006,10.1016/j.ejmech.2019.112006,31931337.0,
22464612,CHEMBL4764051,"2-(4-(4-acetamido-3-isopropylbenzyl)-3,5-dimethylphenoxy)acetic acid",CHEMBL4683748,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,50.0,%,CC(=O)Nc1ccc(Cc2c(C)cc(OCC(=O)O)cc2C)cc1C(C)C,CHEMBL4680157,"Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.",Eur J Med Chem,2020.0,188,,112006,112006,10.1016/j.ejmech.2019.112006,31931337.0,
22478275,CHEMBL4742730,"5-fluoro-1-methyl-N-(1-(4-(piperidin-4-yloxy)benzyl)-1,2,3,4-tetrahydroquinolin-8-yl)-1H-indole-2-carboxamide",CHEMBL4686647,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using CYP substrate preincubated for 10 mins followed by NADPH generating system addition and measured after 10 mins by LC-MS/MS analysis relative to control,Inhibition,=,0.0,%,Cn1c(C(=O)Nc2cccc3c2N(Cc2ccc(OC4CCNCC4)cc2)CCC3)cc2cc(F)ccc21,CHEMBL4680245,"Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.",Eur J Med Chem,2020.0,194,,112243,112243,10.1016/j.ejmech.2020.112243,32229389.0,
22757450,CHEMBL4757016,N-(2-acetyl-2-azaspiro[3.3]heptan-6-yl)-3-phenylisoxazole-5-carboxamide,CHEMBL4701227,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,0.0,%,CC(=O)N1CC2(CC(NC(=O)c3cc(-c4ccccc4)no3)C2)C1,CHEMBL4699452,"Design, synthesis, and optimization of a series of 2-azaspiro[3.3]heptane derivatives as orally bioavailable fetal hemoglobin inducers.",Bioorg Med Chem Lett,2020.0,30,19,127425,127425,10.1016/j.bmcl.2020.127425,32717372.0,
22757451,CHEMBL4755066,N-(2-acetyl-2-azaspiro[3.3]heptan-6-yl)-3-(4-fluorophenyl)isoxazole-5-carboxamide,CHEMBL4701227,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,0.0,%,CC(=O)N1CC2(CC(NC(=O)c3cc(-c4ccc(F)cc4)no3)C2)C1,CHEMBL4699452,"Design, synthesis, and optimization of a series of 2-azaspiro[3.3]heptane derivatives as orally bioavailable fetal hemoglobin inducers.",Bioorg Med Chem Lett,2020.0,30,19,127425,127425,10.1016/j.bmcl.2020.127425,32717372.0,
22757452,CHEMBL4763980,N-(3-(dimethylamino)-3-oxopropyl)-3-(4-fluorophenyl)isoxazole-5-carboxamide,CHEMBL4701227,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,6.0,%,CN(C)C(=O)CCNC(=O)c1cc(-c2ccc(F)cc2)no1,CHEMBL4699452,"Design, synthesis, and optimization of a series of 2-azaspiro[3.3]heptane derivatives as orally bioavailable fetal hemoglobin inducers.",Bioorg Med Chem Lett,2020.0,30,19,127425,127425,10.1016/j.bmcl.2020.127425,32717372.0,
22758805,CHEMBL4746217,(+/-)-6-Methyl-2-(3-((2-(trifluoromethyl)phenoxy)methyl)-pyrrolidin-1-yl)pyrimidine-4-carboxylic Acid,CHEMBL4701515,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of recombinant human CYP2C9 expressed in insect cell microsomes at 10 uM using 7-methoxy-4-trifluoromethylcoumarin as substrate measured after 15 to 45 mins in presence of NADPH by fluorescence assay relative to control,Inhibition,=,0.0,%,Cc1cc(C(=O)O)nc(N2CCC(COc3ccccc3C(F)(F)F)C2)n1,CHEMBL4699473,"Discovery of Bispecific Antagonists of Retinol Binding Protein 4 That Stabilize Transthyretin Tetramers: Scaffolding Hopping, Optimization, and Preclinical Pharmacological Evaluation as a Potential Therapy for Two Common Age-Related Comorbidities.",J Med Chem,2020.0,63,19,11054,11084,10.1021/acs.jmedchem.0c00996,32878437.0,
22780226,CHEMBL4797252,"(2,4-Dihydroxy-5-isopropylphenyl)(4-(ethylamino)-2-(2-methoxyethoxy)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)methanone",CHEMBL4707031,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition and measured after 20 mins by LC-MS/MS analysis relative to control,Inhibition,=,36.0,%,CCNc1nc(OCCOC)nc2c1CN(C(=O)c1cc(C(C)C)c(O)cc1O)CC2,CHEMBL4706476,"Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90.",J Med Chem,2016.0,59,23.0,10498,10519,10.1021/acs.jmedchem.6b00912,27933959.0,
22780227,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4707031,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition and measured after 20 mins by LC-MS/MS analysis relative to control,Inhibition,=,82.0,%,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4706476,"Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90.",J Med Chem,2016.0,59,23.0,10498,10519,10.1021/acs.jmedchem.6b00912,27933959.0,
22789897,CHEMBL4799011,4-(1-(4-(1-cyclopropylpyrrolidin-3-yl)phenyl)-5-hydroxy-2-phenylpent-1-enyl)phenol hydrochloride,CHEMBL4709246,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) in liver microsomes at 10 uM incubated for 15 mins relative to control,Inhibition,=,47.2,%,Cl.OCCC/C(=C(\c1ccc(O)cc1)c1ccc(C2CCN(C3CC3)C2)cc1)c1ccccc1,CHEMBL4706533,An orally available inverse agonist of estrogen-related receptor gamma showed expanded efficacy for the radioiodine therapy of poorly differentiated thyroid cancer.,Eur J Med Chem,2020.0,205,,112501,112501,10.1016/j.ejmech.2020.112501,32758860.0,
22789898,CHEMBL4743534,4-(5-hydroxy-2-phenyl-1-(4-(piperidin-4-yl)phenyl)pent-1-enyl)phenol hydrochloride,CHEMBL4709246,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) in liver microsomes at 10 uM incubated for 15 mins relative to control,Inhibition,=,22.9,%,Cl.OCCC/C(=C(\c1ccc(O)cc1)c1ccc(C2CCNCC2)cc1)c1ccccc1,CHEMBL4706533,An orally available inverse agonist of estrogen-related receptor gamma showed expanded efficacy for the radioiodine therapy of poorly differentiated thyroid cancer.,Eur J Med Chem,2020.0,205,,112501,112501,10.1016/j.ejmech.2020.112501,32758860.0,
22789899,CHEMBL4750724,4-(5-hydroxy-1-(4-(1-isopropylpiperidin-4-yl)phenyl)-2-phenylpent-1-enyl)phenol hydrochloride,CHEMBL4709246,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) in liver microsomes at 10 uM incubated for 15 mins relative to control,Inhibition,=,13.6,%,CC(C)N1CCC(c2ccc(/C(=C(/CCCO)c3ccccc3)c3ccc(O)cc3)cc2)CC1.Cl,CHEMBL4706533,An orally available inverse agonist of estrogen-related receptor gamma showed expanded efficacy for the radioiodine therapy of poorly differentiated thyroid cancer.,Eur J Med Chem,2020.0,205,,112501,112501,10.1016/j.ejmech.2020.112501,32758860.0,
22789900,CHEMBL4763285,4-(1-(4-(1-cyclopropylpiperidin-4-yl)phenyl)-5-hydroxy-2-phenylpent-1-enyl)phenol hydrochloride,CHEMBL4709246,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) in liver microsomes at 10 uM incubated for 15 mins relative to control,Inhibition,=,35.9,%,Cl.OCCC/C(=C(\c1ccc(O)cc1)c1ccc(C2CCN(C3CC3)CC2)cc1)c1ccccc1,CHEMBL4706533,An orally available inverse agonist of estrogen-related receptor gamma showed expanded efficacy for the radioiodine therapy of poorly differentiated thyroid cancer.,Eur J Med Chem,2020.0,205,,112501,112501,10.1016/j.ejmech.2020.112501,32758860.0,
22789901,CHEMBL4793030,"3-(5-hydroxy-1-(4-(1-isopropyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)-2-phenylpent-1-enyl)phenol hydrochloride",CHEMBL4709246,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) in liver microsomes at 10 uM incubated for 15 mins relative to control,Inhibition,=,19.7,%,CC(C)N1CC=C(c2ccc(/C(=C(/CCCO)c3ccccc3)c3cccc(O)c3)cc2)CC1.Cl,CHEMBL4706533,An orally available inverse agonist of estrogen-related receptor gamma showed expanded efficacy for the radioiodine therapy of poorly differentiated thyroid cancer.,Eur J Med Chem,2020.0,205,,112501,112501,10.1016/j.ejmech.2020.112501,32758860.0,
22789902,CHEMBL4741828,"4-(5-hydroxy-1-(4-(1-isopropyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)-2-phenylpent-1-enyl)phenol hydrochloride",CHEMBL4709246,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) in liver microsomes at 10 uM incubated for 15 mins relative to control,Inhibition,=,3.0,%,CC(C)N1CC=C(c2ccc(/C(=C(/CCCO)c3ccccc3)c3ccc(O)cc3)cc2)CC1.Cl,CHEMBL4706533,An orally available inverse agonist of estrogen-related receptor gamma showed expanded efficacy for the radioiodine therapy of poorly differentiated thyroid cancer.,Eur J Med Chem,2020.0,205,,112501,112501,10.1016/j.ejmech.2020.112501,32758860.0,
22789903,CHEMBL4746975,4-(2-(4-fluorophenyl)-5-hydroxy-1-(4-(1-isopropylpiperidin-4-yl)phenyl)pent-1-enyl)phenol hydrochloride,CHEMBL4709246,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) in liver microsomes at 10 uM incubated for 15 mins relative to control,Inhibition,=,0.0,%,CC(C)N1CCC(c2ccc(/C(=C(/CCCO)c3ccc(F)cc3)c3ccc(O)cc3)cc2)CC1.Cl,CHEMBL4706533,An orally available inverse agonist of estrogen-related receptor gamma showed expanded efficacy for the radioiodine therapy of poorly differentiated thyroid cancer.,Eur J Med Chem,2020.0,205,,112501,112501,10.1016/j.ejmech.2020.112501,32758860.0,
22789904,CHEMBL4746616,"4-(2-(2,4-difluorophenyl)-5-hydroxy-1-(4-(1-isopropylpiperidin-4-yl)phenyl)pent-1-enyl)phenol hydrochloride",CHEMBL4709246,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) in liver microsomes at 10 uM incubated for 15 mins relative to control,Inhibition,=,0.0,%,CC(C)N1CCC(c2ccc(/C(=C(/CCCO)c3ccc(F)cc3F)c3ccc(O)cc3)cc2)CC1.Cl,CHEMBL4706533,An orally available inverse agonist of estrogen-related receptor gamma showed expanded efficacy for the radioiodine therapy of poorly differentiated thyroid cancer.,Eur J Med Chem,2020.0,205,,112501,112501,10.1016/j.ejmech.2020.112501,32758860.0,
22789905,CHEMBL4597874,3-(5-hydroxy-1-(4-(4-isopropylpiperazin-1-yl)phenyl)-2-phenylpent-1-enyl)phenol,CHEMBL4709246,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) in liver microsomes at 10 uM incubated for 15 mins relative to control,Inhibition,<,53.0,%,CC(C)N1CCN(c2ccc(/C(=C(/CCCO)c3ccccc3)c3cccc(O)c3)cc2)CC1,CHEMBL4706533,An orally available inverse agonist of estrogen-related receptor gamma showed expanded efficacy for the radioiodine therapy of poorly differentiated thyroid cancer.,Eur J Med Chem,2020.0,205,,112501,112501,10.1016/j.ejmech.2020.112501,32758860.0,
22789906,CHEMBL201013,4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-5-hydroxy-2-phenylpent-1-enyl)phenol,CHEMBL4709246,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) in liver microsomes at 10 uM incubated for 15 mins relative to control,Inhibition,=,27.1,%,CN(C)CCOc1ccc(/C(=C(/CCCO)c2ccccc2)c2ccc(O)cc2)cc1,CHEMBL4706533,An orally available inverse agonist of estrogen-related receptor gamma showed expanded efficacy for the radioiodine therapy of poorly differentiated thyroid cancer.,Eur J Med Chem,2020.0,205,,112501,112501,10.1016/j.ejmech.2020.112501,32758860.0,
22807899,CHEMBL4790492,"(S)-2-amino-3-(4-(5-(4'-hydroxy-6-methoxy-[1,1'-biphenyl]-3-yl)-1,2,4-oxadiazol-3-yl)phenyl)propanoic acid hydrochloride",CHEMBL4712952,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,<,1.0,%,COc1ccc(-c2nc(-c3ccc(C[C@H](N)C(=O)O)cc3)no2)cc1-c1ccc(O)cc1.Cl,CHEMBL4706651,Peripheral Selective Oxadiazolylphenyl Alanine Derivatives as Tryptophan Hydroxylase 1 Inhibitors for Obesity and Fatty Liver Disease.,J Med Chem,2021.0,64,2.0,1037,1053,10.1021/acs.jmedchem.0c01560,33417443.0,
22809723,CHEMBL4761365,"4-((cis-1-(4-Chlorobenzyl)-2-methylpiperidin-4-yl)amino)-N-methyl-1H-pyrrolo[2,3-b]pyridine-5-carboxamide",CHEMBL4713258,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,70.0,%,CNC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(Cc2ccc(Cl)cc2)[C@H](C)C1,CHEMBL4706658,"Discovery and Biological Evaluation of N-Methyl-pyrrolo[2,3-b]pyridine-5-carboxamide Derivatives as JAK1-Selective Inhibitors.",J Med Chem,2021.0,64,2.0,958,979,10.1021/acs.jmedchem.0c01026,33428419.0,
22812504,CHEMBL4752759,(S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea,CHEMBL4714106,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 7 uM relative to control,Inhibition,=,25.0,%,CC[C@H](C)C(=O)N1CCC(NC(=O)Nc2ccc(OC(F)(F)F)c(F)c2)CC1,CHEMBL4706685,Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative.,J Med Chem,2021.0,64,4.0,1856,1872,10.1021/acs.jmedchem.0c01886,33550801.0,
22813052,CHEMBL4761964,"2-(Ethylamino)-9-methyl-6-(3-(5-methyl-1,3,4-oxadiazol-2-yl)-phenyl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-e][1,4]diazepin-5-one",CHEMBL4714164,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM relative to control,Inhibition,<,50.0,%,CCNc1ncc2c(n1)N(C)CCN(c1cccc(-c3nnc(C)o3)c1)C2=O,CHEMBL4706691,Bicyclic Diazepinones as Dual Ligands of the α2δ-1 Subunit of Voltage-Gated Calcium Channels and the Norepinephrine Transporter.,J Med Chem,2021.0,64,4.0,2167,2185,10.1021/acs.jmedchem.0c01867,33591743.0,
22813053,CHEMBL4745144,"(S)-2-amino-9-methyl-6-(3-(3-(methylamino)-1-(thiophen-2-yl)propoxy)phenyl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-e][1,4]diazepin-5-one",CHEMBL4714164,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM relative to control,Inhibition,<,50.0,%,CNCC[C@H](Oc1cccc(N2CCN(C)c3nc(N)ncc3C2=O)c1)c1cccs1,CHEMBL4706691,Bicyclic Diazepinones as Dual Ligands of the α2δ-1 Subunit of Voltage-Gated Calcium Channels and the Norepinephrine Transporter.,J Med Chem,2021.0,64,4.0,2167,2185,10.1021/acs.jmedchem.0c01867,33591743.0,
22813054,CHEMBL4792765,"(S)-1-Methyl-4-(3-(3-(methylamino)-1-(thiophen-2-yl)propoxy)-phenyl)-3,4-dihydro-1H-pyrido[2,3-e][1,4]diazepin-5(2H)-one",CHEMBL4714164,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM relative to control,Inhibition,<,50.0,%,CNCC[C@H](Oc1cccc(N2CCN(C)c3ncccc3C2=O)c1)c1cccs1,CHEMBL4706691,Bicyclic Diazepinones as Dual Ligands of the α2δ-1 Subunit of Voltage-Gated Calcium Channels and the Norepinephrine Transporter.,J Med Chem,2021.0,64,4.0,2167,2185,10.1021/acs.jmedchem.0c01867,33591743.0,
22813124,CHEMBL4742712,"2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide",CHEMBL4714209,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 2.5 uM relative to control,Inhibition,=,41.0,%,O=C1CCC(N2Cc3cc(CNC(=O)C(F)(F)c4ccc(Cl)cc4)ccc3C2=O)C(=O)N1,CHEMBL4706692,CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia.,J Med Chem,2021.0,64,4.0,1835,1843,10.1021/acs.jmedchem.0c01489,33591756.0,
22813212,CHEMBL4742115,"N-{1-[4-({4-[3-(Cyclopropylmethoxy)phenoxy]-2,6-difluorophenyl}methoxy)phenyl]ethyl}acetamide",CHEMBL4714246,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) relative to control,Inhibition,=,-22.7,%,CC(=O)NC(C)c1ccc(OCc2c(F)cc(Oc3cccc(OCC4CC4)c3)cc2F)cc1,CHEMBL4706693,Design and synthesis of a monocyclic derivative as a selective ACC1 inhibitor by chemical modification of biphenyl ACC1/2 dual inhibitors.,Bioorg Med Chem,2021.0,35,,116056,116056,10.1016/j.bmc.2021.116056,33607488.0,
22813213,CHEMBL4762802,"N-{1-[6-({4-[3-(Cyclopropylmethoxy)phenoxy]-2,6-difluorophenyl}methoxy)pyridin-3-yl]ethyl}acetamide",CHEMBL4714246,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) relative to control,Inhibition,=,-13.8,%,CC(=O)NC(C)c1ccc(OCc2c(F)cc(Oc3cccc(OCC4CC4)c3)cc2F)nc1,CHEMBL4706693,Design and synthesis of a monocyclic derivative as a selective ACC1 inhibitor by chemical modification of biphenyl ACC1/2 dual inhibitors.,Bioorg Med Chem,2021.0,35,,116056,116056,10.1016/j.bmc.2021.116056,33607488.0,
22819204,CHEMBL480746,"N-(3,5-difluoro-4-(1H-pyrazol-4-yl)phenyl)chroman-3-carboxamide",CHEMBL4716024,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using tolubutamide as substrate at 10 uM by cocktail inhibition assay,Inhibition,=,84.0,%,O=C(Nc1cc(F)c(-c2cn[nH]c2)c(F)c1)C1COc2ccccc2C1,CHEMBL4715684,Computer-aided discovery of phenylpyrazole based amides as potent S6K1 inhibitors,RSC Med Chem,2020.0,11,5.0,583,590,10.1039/c9md00537d,33479660.0,
22819205,CHEMBL4799316,"N-(3,5-Difluoro-4-(1H-pyrazol-4-yl)phenyl)-6-methoxychromane-3-carboxamide",CHEMBL4716024,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using tolubutamide as substrate at 10 uM by cocktail inhibition assay,Inhibition,=,63.0,%,COc1ccc2c(c1)CC(C(=O)Nc1cc(F)c(-c3cn[nH]c3)c(F)c1)CO2,CHEMBL4715684,Computer-aided discovery of phenylpyrazole based amides as potent S6K1 inhibitors,RSC Med Chem,2020.0,11,5.0,583,590,10.1039/c9md00537d,33479660.0,
22842030,CHEMBL4751065,"(1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)-sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride",CHEMBL4719985,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM relative to control,Inhibition,<,10.0,%,Cl.N[C@@]1(C(=O)O)[C@H](CSc2ccc(F)c(F)c2)[C@@H](O)[C@@H]2[C@H]1[C@H]2C(=O)O,CHEMBL4715808,"Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.",J Med Chem,2016.0,59,24.0,10974,10993,10.1021/acs.jmedchem.6b01119,28002967.0,
22845816,CHEMBL4649683,(R)-3-methyl-6-(2-((5-methyl-2-(4-(trifluoromethoxy)phenyl)-1H-imidazol-1-yl)methyl)phenoxy)hexanoic acid,CHEMBL4721913,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,56.0,%,Cc1cnc(-c2ccc(OC(F)(F)F)cc2)n1Cc1ccccc1OCCC[C@@H](C)CC(=O)O,CHEMBL4715826,Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD).,ACS Med Chem Lett,2018.0,9,9.0,935,940,10.1021/acsmedchemlett.8b00287,30258544.0,
22847234,CHEMBL4754082,"7-methoxy-1-(3,4,5-trimethoxyphenyl)isoquinolin-6-ol",CHEMBL4722401,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 10 uM relative to control,Inhibition,=,16.0,%,COc1cc2c(-c3cc(OC)c(OC)c(OC)c3)nccc2cc1O,CHEMBL4715832,Isoquinoline-based biaryls as a robust scaffold for microtubule inhibitors.,Eur J Med Chem,2020.0,186,,111865,111865,10.1016/j.ejmech.2019.111865,31735573.0,
22855083,CHEMBL4749547,(R)-4-(4-(3-(2-chloro-6-fluorophenyl)ureido)-1H-pyrazol-1-yl)-5-methyl-N-(tetrahydrofuran-3-yl)thiophene-2-carboxamide,CHEMBL4724638,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as formation of hydroxytolbutamide at 10 uM using tolbutamide as substrate relative to control,Inhibition,=,35.0,%,Cc1sc(C(=O)N[C@@H]2CCOC2)cc1-n1cc(NC(=O)Nc2c(F)cccc2Cl)cn1,CHEMBL4715902,"Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors.",ACS Med Chem Lett,2021.0,12,1.0,24,29,10.1021/acsmedchemlett.0c00533,33488960.0,
22855084,CHEMBL4784092,4-(4-(3-(2-chloro-6-fluorophenyl)ureido)-1H-pyrazol-1-yl)-5-methyl-N-(oxetan-3-yl)thiophene-2-carboxamide,CHEMBL4724638,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as formation of hydroxytolbutamide at 10 uM using tolbutamide as substrate relative to control,Inhibition,=,33.0,%,Cc1sc(C(=O)NC2COC2)cc1-n1cc(NC(=O)Nc2c(F)cccc2Cl)cn1,CHEMBL4715902,"Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors.",ACS Med Chem Lett,2021.0,12,1.0,24,29,10.1021/acsmedchemlett.0c00533,33488960.0,
22855085,CHEMBL4754908,4-(4-(3-(2-chloro-4-fluorophenyl)ureido)-1H-pyrazol-1-yl)-N-(oxetan-3-yl)thiophene-2-carboxamide,CHEMBL4724638,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as formation of hydroxytolbutamide at 10 uM using tolbutamide as substrate relative to control,Inhibition,=,47.0,%,O=C(Nc1cnn(-c2csc(C(=O)NC3COC3)c2)c1)Nc1ccc(F)cc1Cl,CHEMBL4715902,"Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors.",ACS Med Chem Lett,2021.0,12,1.0,24,29,10.1021/acsmedchemlett.0c00533,33488960.0,
22855086,CHEMBL4778645,4-(4-(3-(2-chloro-6-fluorophenyl)ureido)-1H-pyrazol-1-yl)-N-(oxetan-3-yl)thiophene-2-carboxamide,CHEMBL4724638,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as formation of hydroxytolbutamide at 10 uM using tolbutamide as substrate relative to control,Inhibition,=,48.0,%,O=C(Nc1cnn(-c2csc(C(=O)NC3COC3)c2)c1)Nc1c(F)cccc1Cl,CHEMBL4715902,"Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors.",ACS Med Chem Lett,2021.0,12,1.0,24,29,10.1021/acsmedchemlett.0c00533,33488960.0,
22855087,CHEMBL4744992,4-(4-(3-(2-chlorophenyl)ureido)-1H-pyrazol-1-yl)-N-((tetrahydro-2H-pyran-4-yl)methyl)thiophene-2-carboxamide,CHEMBL4724638,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as formation of hydroxytolbutamide at 10 uM using tolbutamide as substrate relative to control,Inhibition,=,64.0,%,O=C(Nc1cnn(-c2csc(C(=O)NCC3CCOCC3)c2)c1)Nc1ccccc1Cl,CHEMBL4715902,"Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors.",ACS Med Chem Lett,2021.0,12,1.0,24,29,10.1021/acsmedchemlett.0c00533,33488960.0,
22855088,CHEMBL4753641,4-(4-(3-(2-chlorophenyl)ureido)-1H-pyrazol-1-yl)-N-(oxetan-3-yl)thiophene-2-carboxamide,CHEMBL4724638,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as formation of hydroxytolbutamide at 10 uM using tolbutamide as substrate relative to control,Inhibition,=,8.0,%,O=C(Nc1cnn(-c2csc(C(=O)NC3COC3)c2)c1)Nc1ccccc1Cl,CHEMBL4715902,"Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors.",ACS Med Chem Lett,2021.0,12,1.0,24,29,10.1021/acsmedchemlett.0c00533,33488960.0,
22855089,CHEMBL4753310,(R)-4-(4-(3-(2-chlorophenyl)ureido)-1H-pyrazol-1-yl)-N-(tetrahydrofuran-3-yl)thiophene-2-carboxamide,CHEMBL4724638,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as formation of hydroxytolbutamide at 10 uM using tolbutamide as substrate relative to control,Inhibition,=,38.0,%,O=C(Nc1cnn(-c2csc(C(=O)N[C@@H]3CCOC3)c2)c1)Nc1ccccc1Cl,CHEMBL4715902,"Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors.",ACS Med Chem Lett,2021.0,12,1.0,24,29,10.1021/acsmedchemlett.0c00533,33488960.0,
22855090,CHEMBL4762965,4-(4-(3-(2-chlorophenyl)ureido)-1H-pyrazol-1-yl)-N-(tetrahydro-2H-pyran-4-yl)thiophene-2-carboxamide,CHEMBL4724638,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as formation of hydroxytolbutamide at 10 uM using tolbutamide as substrate relative to control,Inhibition,=,7.0,%,O=C(Nc1cnn(-c2csc(C(=O)NC3CCOCC3)c2)c1)Nc1ccccc1Cl,CHEMBL4715902,"Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors.",ACS Med Chem Lett,2021.0,12,1.0,24,29,10.1021/acsmedchemlett.0c00533,33488960.0,
22855091,CHEMBL4759538,4-(4-(3-(2-chlorophenyl)ureido)-1H-pyrazol-1-yl)-N-(1-methylpiperidin-4-yl)thiophene-2-carboxamide,CHEMBL4724638,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as formation of hydroxytolbutamide at 10 uM using tolbutamide as substrate relative to control,Inhibition,=,-19.0,%,CN1CCC(NC(=O)c2cc(-n3cc(NC(=O)Nc4ccccc4Cl)cn3)cs2)CC1,CHEMBL4715902,"Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors.",ACS Med Chem Lett,2021.0,12,1.0,24,29,10.1021/acsmedchemlett.0c00533,33488960.0,
22855092,CHEMBL4754584,(S)-4-(4-(3-(2-chlorophenyl)ureido)-1H-pyrazol-1-yl)-N-(1-methylpyrrolidin-3-yl)thiophene-2-carboxamide,CHEMBL4724638,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as formation of hydroxytolbutamide at 10 uM using tolbutamide as substrate relative to control,Inhibition,=,-9.0,%,CN1CC[C@H](NC(=O)c2cc(-n3cc(NC(=O)Nc4ccccc4Cl)cn3)cs2)C1,CHEMBL4715902,"Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors.",ACS Med Chem Lett,2021.0,12,1.0,24,29,10.1021/acsmedchemlett.0c00533,33488960.0,
22855093,CHEMBL4793809,4-(4-(3-(2-chlorophenyl)ureido)-1H-pyrazol-1-yl)-N-cyclopropylthiophene-2-carboxamide,CHEMBL4724638,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) assessed as formation of hydroxytolbutamide at 10 uM using tolbutamide as substrate relative to control,Inhibition,=,-4.0,%,O=C(Nc1cnn(-c2csc(C(=O)NC3CC3)c2)c1)Nc1ccccc1Cl,CHEMBL4715902,"Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors.",ACS Med Chem Lett,2021.0,12,1.0,24,29,10.1021/acsmedchemlett.0c00533,33488960.0,
22885394,CHEMBL4759665,"N2-[4-methoxy-3-(3-pyrrolidin-1-ylpropoxy)phenyl]-N4,6-dimethyl-pyrimidine-2,4-diamine",CHEMBL4728063,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,0.0,%,CNc1cc(C)nc(Nc2ccc(OC)c(OCCCN3CCCC3)c2)n1,CHEMBL4725338,"Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines.",Bioorg Med Chem Lett,2020.0,30,20,127475,127475,10.1016/j.bmcl.2020.127475,32781218.0,
22885396,CHEMBL4741874,"N2-[4-methoxy-3-(2,3,4,7-tetrahydro-1H-azepin-5-yl)phenyl]-N4,6-dimethyl-pyrimidine-2,4-diamine",CHEMBL4728063,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,0.0,%,CNc1cc(C)nc(Nc2ccc(OC)c(C3=CCNCCC3)c2)n1,CHEMBL4725338,"Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines.",Bioorg Med Chem Lett,2020.0,30,20,127475,127475,10.1016/j.bmcl.2020.127475,32781218.0,
22897869,CHEMBL282567,2-Benzhydryl-pentanoic acid 2-diethylamino-ethyl ester,CHEMBL4730944,A,HepaRG,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in HBV-infected human HepaRG cells at 50 uM using luciferin-H as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed by treatment for 1 hr on day 8 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days in presence of 10 mM ABT and measured on day 11 post-infection by P450-Glo chemiluminescent assay relative to control,Inhibition,=,82.1,%,CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1,CHEMBL4725437,P450s under Restriction (PURE) Screen Using HepaRG and Primary Human Hepatocytes for Discovery of Novel HBV Antivirals.,ACS Med Chem Lett,2020.0,11,10,1919,1927,10.1021/acsmedchemlett.9b00630,33062174.0,
22897870,CHEMBL282567,2-Benzhydryl-pentanoic acid 2-diethylamino-ethyl ester,CHEMBL4730945,A,HepaRG,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in HBV-infected human HepaRG cells at 50 uM using luciferin-H as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days in presence of 10 mM ABT by P450-Glo chemiluminescent assay relative to control,Inhibition,=,36.9,%,CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1,CHEMBL4725437,P450s under Restriction (PURE) Screen Using HepaRG and Primary Human Hepatocytes for Discovery of Novel HBV Antivirals.,ACS Med Chem Lett,2020.0,11,10,1919,1927,10.1021/acsmedchemlett.9b00630,33062174.0,
22897871,CHEMBL101168,"1H-1,2,3-benzotriazol-1-amine",CHEMBL4730946,A,HepaRG,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in HBV-infected human HepaRG cells at 10 mM using luciferin-H as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed by treatment for 1 hr on day 8 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days in presence of 50 uM SKF-525A and measured on day 11 post-infection by P450-Glo chemiluminescent assay relative to control,Inhibition,=,82.1,%,Nn1nnc2ccccc21,CHEMBL4725437,P450s under Restriction (PURE) Screen Using HepaRG and Primary Human Hepatocytes for Discovery of Novel HBV Antivirals.,ACS Med Chem Lett,2020.0,11,10,1919,1927,10.1021/acsmedchemlett.9b00630,33062174.0,
22897872,CHEMBL101168,"1H-1,2,3-benzotriazol-1-amine",CHEMBL4730947,A,HepaRG,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in HBV-infected human HepaRG cells at 10 mM using luciferin-H as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days in presence of 50 uM SKF-525A by P450-Glo chemiluminescent assay relative to control,Inhibition,=,36.9,%,Nn1nnc2ccccc21,CHEMBL4725437,P450s under Restriction (PURE) Screen Using HepaRG and Primary Human Hepatocytes for Discovery of Novel HBV Antivirals.,ACS Med Chem Lett,2020.0,11,10,1919,1927,10.1021/acsmedchemlett.9b00630,33062174.0,
22897879,CHEMBL282567,2-Benzhydryl-pentanoic acid 2-diethylamino-ethyl ester,CHEMBL4730954,A,HepaRG,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in HBV-infected human HepaRG cells at 50 uM using luciferin-H as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed by treatment for 1 hr on day 8 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days and measured on day 11 post-infection by P450-Glo chemiluminescent assay relative to control,Inhibition,=,42.2,%,CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1,CHEMBL4725437,P450s under Restriction (PURE) Screen Using HepaRG and Primary Human Hepatocytes for Discovery of Novel HBV Antivirals.,ACS Med Chem Lett,2020.0,11,10,1919,1927,10.1021/acsmedchemlett.9b00630,33062174.0,
22897880,CHEMBL282567,2-Benzhydryl-pentanoic acid 2-diethylamino-ethyl ester,CHEMBL4730955,A,HepaRG,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in HBV-infected human HepaRG cells at 50 uM using luciferin-H as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days by P450-Glo chemiluminescent assay relative to control,Inhibition,=,21.4,%,CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c1ccccc1,CHEMBL4725437,P450s under Restriction (PURE) Screen Using HepaRG and Primary Human Hepatocytes for Discovery of Novel HBV Antivirals.,ACS Med Chem Lett,2020.0,11,10,1919,1927,10.1021/acsmedchemlett.9b00630,33062174.0,
22897885,CHEMBL101168,"1H-1,2,3-benzotriazol-1-amine",CHEMBL4730960,A,HepaRG,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in HBV-infected human HepaRG cells at 10 mM using luciferin-H as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days then followed by treatment for 1 hr on day 8 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days and measured on day 11 post-infection by P450-Glo chemiluminescent assay relative to control,Inhibition,=,67.5,%,Nn1nnc2ccccc21,CHEMBL4725437,P450s under Restriction (PURE) Screen Using HepaRG and Primary Human Hepatocytes for Discovery of Novel HBV Antivirals.,ACS Med Chem Lett,2020.0,11,10,1919,1927,10.1021/acsmedchemlett.9b00630,33062174.0,
22897886,CHEMBL101168,"1H-1,2,3-benzotriazol-1-amine",CHEMBL4730961,A,HepaRG,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in HBV-infected human HepaRG cells at 10 mM using luciferin-H as substrate treated for 1 hr on day 5 post-infection followed by removal of media and supplemented with fresh media and further incubated for 3 days by P450-Glo chemiluminescent assay relative to control,Inhibition,=,-9.4,%,Nn1nnc2ccccc21,CHEMBL4725437,P450s under Restriction (PURE) Screen Using HepaRG and Primary Human Hepatocytes for Discovery of Novel HBV Antivirals.,ACS Med Chem Lett,2020.0,11,10,1919,1927,10.1021/acsmedchemlett.9b00630,33062174.0,
22920151,CHEMBL4784911,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(methyl-d3)-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide-3,3-d2 methanesulfonate",CHEMBL4736460,A,,Homo sapiens,Cytochrome P450 2C9,"Inhibition of CYP2C9-mediated 3,3-dideuterio-N-[2-(2-dimethylaminoethylamino)-4-methoxy-5-[[4-[1-(trideuteriomethyl)indol-3-yl]pyrimidin-2-yl]amino]phenyl]prop-2-enamide metabolite formation in human liver microsomes at 1 uM preincubated for 10 mins in presence of sulphaphenazole followed by NADPH and compound addition measured up to 60 mins by LC-MS/MS analysis relative to control",Inhibition,=,27.1,%,CS(=O)(=O)O.[2H]C([2H])=CC(=O)Nc1cc(Nc2nccc(-c3cn(C([2H])([2H])[2H])c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,CHEMBL4732150,"Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer.",J Med Chem,2021.0,64,2.0,925,937,10.1021/acs.jmedchem.0c02005,33459024.0,
22920154,CHEMBL4784911,"N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(methyl-d3)-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide-3,3-d2 methanesulfonate",CHEMBL4736463,A,,Homo sapiens,Cytochrome P450 2C9,"Inhibition of CYP2C9-mediated 3,3-dideuterio-N-[4-methoxy-2-(methylamino)-5-[[4-[1-(trideuteriomethyl)indol-3-yl]pyrimidin-2-yl]amino]phenyl]prop-2-enamide metabolite formation in human liver microsomes at 1 uM preincubated for 10 mins in presence of sulphaphenazole followed by NADPH and compound addition measured up to 60 mins by LC-MS/MS analysis relative to control",Inhibition,=,23.7,%,CS(=O)(=O)O.[2H]C([2H])=CC(=O)Nc1cc(Nc2nccc(-c3cn(C([2H])([2H])[2H])c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C,CHEMBL4732150,"Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer.",J Med Chem,2021.0,64,2.0,925,937,10.1021/acs.jmedchem.0c02005,33459024.0,
22930388,CHEMBL4800099,3-((4-(1H-imidazol-1-yl)benzamido)methyl)benzoic acid,CHEMBL4738571,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 at 1 uM using luciferin-H as substrate by enzyme bag based one point inhibition assay relative to control,Inhibition,=,-0.2,%,O=C(O)c1cccc(CNC(=O)c2ccc(-n3ccnc3)cc2)c1,CHEMBL4732227,Discovery of a novel potent cytochrome P450 CYP4Z1 inhibitor.,Eur J Med Chem,2021.0,215,,113255,113255,10.1016/j.ejmech.2021.113255,33611185.0,
22933909,CHEMBL4741240,"7-chloro-2-(3,5-dichlorophenylamino)quinazolin-4(3H)-one",CHEMBL4739126,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,18.0,%,O=c1[nH]c(Nc2cc(Cl)cc(Cl)c2)nc2cc(Cl)ccc12,CHEMBL4732249,"Design, synthesis and biological evaluation of 2-aminoquinazolin-4(3H)-one derivatives as potential SARS-CoV-2 and MERS-CoV treatments.",Bioorg Med Chem Lett,2021.0,39,,127885,127885,10.1016/j.bmcl.2021.127885,33662537.0,
22933910,CHEMBL4761264,"2-(3,5-dichlorophenylamino)-5-hydroxyquinazolin-4(3H)-one",CHEMBL4739126,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,34.0,%,O=c1[nH]c(Nc2cc(Cl)cc(Cl)c2)nc2cccc(O)c12,CHEMBL4732249,"Design, synthesis and biological evaluation of 2-aminoquinazolin-4(3H)-one derivatives as potential SARS-CoV-2 and MERS-CoV treatments.",Bioorg Med Chem Lett,2021.0,39,,127885,127885,10.1016/j.bmcl.2021.127885,33662537.0,
22934672,CHEMBL4754235,N-(1-phenyl-1H-pyrazol-5-yl)-4-(piperidine-1-carbonyl)benzenesulfonamide,CHEMBL4739295,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 0.5 uM relative to control,Inhibition,=,0.2,%,O=C(c1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1)N1CCCCC1,CHEMBL4732257,The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition.,Bioorg Med Chem Lett,2021.0,40,,127924,127924,10.1016/j.bmcl.2021.127924,33705901.0,
22934673,CHEMBL1109,4-Amino-N-(2-phenyl-2H-pyrazol-3-yl)-benzenesulfonamide,CHEMBL4739295,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 0.5 uM relative to control,Inhibition,=,48.3,%,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1,CHEMBL4732257,The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition.,Bioorg Med Chem Lett,2021.0,40,,127924,127924,10.1016/j.bmcl.2021.127924,33705901.0,
22934674,CHEMBL4792383,4-amino-N-(1-p-tolyl-1H-pyrazol-5-yl)benzenesulfonamide,CHEMBL4739295,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 0.5 uM relative to control,Inhibition,=,52.3,%,Cc1ccc(-n2nccc2NS(=O)(=O)c2ccc(N)cc2)cc1,CHEMBL4732257,The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition.,Bioorg Med Chem Lett,2021.0,40,,127924,127924,10.1016/j.bmcl.2021.127924,33705901.0,
22934675,CHEMBL4778117,4-amino-N-(1-(4-methoxyphenyl)-1H-pyrazol-5-yl)benzenesulfonamide,CHEMBL4739295,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 0.5 uM relative to control,Inhibition,=,9.1,%,COc1ccc(-n2nccc2NS(=O)(=O)c2ccc(N)cc2)cc1,CHEMBL4732257,The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition.,Bioorg Med Chem Lett,2021.0,40,,127924,127924,10.1016/j.bmcl.2021.127924,33705901.0,
22934676,CHEMBL4778871,4-amino-N-(1-(4-fluorophenyl)-1H-pyrazol-5-yl)benzenesulfonamide,CHEMBL4739295,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 0.5 uM relative to control,Inhibition,=,45.7,%,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccc(F)cc2)cc1,CHEMBL4732257,The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition.,Bioorg Med Chem Lett,2021.0,40,,127924,127924,10.1016/j.bmcl.2021.127924,33705901.0,
22934677,CHEMBL4740006,4-amino-N-(1-(4'-methylbiphenyl-4-yl)-1H-pyrazol-5-yl)benzenesulfonamide,CHEMBL4739295,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 0.5 uM relative to control,Inhibition,=,2.2,%,Cc1ccc(-c2ccc(-n3nccc3NS(=O)(=O)c3ccc(N)cc3)cc2)cc1,CHEMBL4732257,The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition.,Bioorg Med Chem Lett,2021.0,40,,127924,127924,10.1016/j.bmcl.2021.127924,33705901.0,
22934678,CHEMBL2104908,SULFAZAMET,CHEMBL4739295,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 0.5 uM relative to control,Inhibition,=,45.0,%,Cc1cc(NS(=O)(=O)c2ccc(N)cc2)n(-c2ccccc2)n1,CHEMBL4732257,The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition.,Bioorg Med Chem Lett,2021.0,40,,127924,127924,10.1016/j.bmcl.2021.127924,33705901.0,
22934679,CHEMBL4741484,4-amino-N-(benzo[d]thiazol-2-yl)benzenesulfonamide,CHEMBL4739295,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 0.5 uM relative to control,Inhibition,=,4.8,%,Nc1ccc(S(=O)(=O)Nc2nc3ccccc3s2)cc1,CHEMBL4732257,The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition.,Bioorg Med Chem Lett,2021.0,40,,127924,127924,10.1016/j.bmcl.2021.127924,33705901.0,
22950273,CHEMBL4777385,"(R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)-methyl)-2-methyl-1-(1-(1-(3,3,3-trifluoropropyl)piperidin-4-yl)-ethyl)-1H-indole-3-carboxamide",CHEMBL4766063,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,11.6,%,COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCN(CCC(F)(F)F)CC2)c2ccccc12,CHEMBL4765232,"Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas.",J Med Chem,2016.0,59,21.0,9928,9941,10.1021/acs.jmedchem.6b01315,27739677.0,
22950274,CHEMBL4794859,"(R)-1-(1-(1-(2,2-Difluoropropyl)piperidin-4-yl)ethyl)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1H-indole-3-carboxamide",CHEMBL4766063,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,5.0,%,COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCN(CC(C)(F)F)CC2)c2ccccc12,CHEMBL4765232,"Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas.",J Med Chem,2016.0,59,21.0,9928,9941,10.1021/acs.jmedchem.6b01315,27739677.0,
22950275,CHEMBL4797333,"(R)-1-(1-(1-(2,2-Difluoroethyl)piperidin-4-yl)ethyl)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1H-indole-3-carboxamide",CHEMBL4766063,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,25.4,%,COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCN(CC(F)F)CC2)c2ccccc12,CHEMBL4765232,"Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas.",J Med Chem,2016.0,59,21.0,9928,9941,10.1021/acs.jmedchem.6b01315,27739677.0,
22950276,CHEMBL4297463,CPI-1205,CHEMBL4766063,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 10 uM relative to control,Inhibition,=,11.1,%,COc1cc(C)[nH]c(=O)c1CNC(=O)c1c(C)n([C@H](C)C2CCN(CC(F)(F)F)CC2)c2ccccc12,CHEMBL4765232,"Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas.",J Med Chem,2016.0,59,21.0,9928,9941,10.1021/acs.jmedchem.6b01315,27739677.0,
22960114,CHEMBL4778367,"1-(8-isopropyl-5-methyl-2-((4-(piperazin-1-yl)phenyl)amino)imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin-6-yl)ethan-1-one",CHEMBL4768591,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM measured after 20 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,11.0,%,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n2cc(C(C)C)nc12,CHEMBL4765279,"Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.",Eur J Med Chem,2020.0,193,,112239,112239,10.1016/j.ejmech.2020.112239,32200202.0,
22960115,CHEMBL4776781,"1-(8-(tert-butyl)-5-methyl-2((4-(piperazin-1-yl)phenyl)amino)imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin-6-yl)ethan-1-one",CHEMBL4768591,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM measured after 20 mins in presence of NADPH by LC-MS/MS analysis relative to control,Inhibition,=,12.0,%,CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n2cc(C(C)(C)C)nc12,CHEMBL4765279,"Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.",Eur J Med Chem,2020.0,193,,112239,112239,10.1016/j.ejmech.2020.112239,32200202.0,
22967620,CHEMBL4788651,"(3R,3aS,6S,6aR)-6-((2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)methylamino)-3-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)hexahydrofuro[3,2-b]furan-3-ol",CHEMBL4769943,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human liver microsome CYP2C9 at 10 uM in presence of NADPH incubated for 10 to 30 mins by LC-MS-MS analysis,Inhibition,<,50.0,%,COc1ccc2ncc(F)c(CC[C@@]3(O)CO[C@@H]4[C@@H](NCc5cc6c(cn5)OCCO6)CO[C@@H]43)c2n1,CHEMBL4765317,Novel bacterial topoisomerase inhibitors derived from isomannide.,Eur J Med Chem,2020.0,199,,112324,112324,10.1016/j.ejmech.2020.112324,32402932.0,
22976278,CHEMBL4798308,4-(Thiophen-2-yl)-1-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)butan-1-one,CHEMBL4771893,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of human CYP2C9 using fluorogenic substrate incubated for 60 mins in presence of NADPH by fluorescence assay relative to control,Inhibition,=,74.2,%,O=C(CCCc1cccs1)N1CCN(c2ccc(C(F)(F)F)cc2)CC1,CHEMBL4765370,"Design, synthesis, and biological evaluation of aryl piperazines with potential as antidiabetic agents via the stimulation of glucose uptake and inhibition of NADH:ubiquinone oxidoreductase.",Eur J Med Chem,2020.0,202,,112416,112416,10.1016/j.ejmech.2020.112416,32645646.0,
22983649,CHEMBL4799439,(S)-2-Methyl-4-(4-methylpiperazin-1-yl)-6-((2-(3-methylpyridin-2-yl)pyrrolidin-1-yl)methyl)pyrimidine,CHEMBL4773470,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 in human liver microsomes at 10 uM using tolbutamide as substrate preincubated for 10 mins followed by NADPH addition measured after 10 mins by LC-MS/MS analysis relative to control,Inhibition,=,1.0,%,Cc1nc(CN2CCC[C@H]2c2ncccc2C)cc(N2CCN(C)CC2)n1,CHEMBL4765416,"Design, synthesis, and evaluation of pyrrolidine based CXCR4 antagonists with in vivo anti-tumor metastatic activity.",Eur J Med Chem,2020.0,205,,112537,112537,10.1016/j.ejmech.2020.112537,32768738.0,
22992013,CHEMBL4787096,(S)-3-(1-(5-fluoro-2-(1H-pyrazol-1-yl)phenyl)ethoxy)-5-(3-methyl-1H-pyrazol-4-yl)pyridin-2-amine,CHEMBL4775386,A,,Homo sapiens,Cytochrome P450 2C9,Inhibition of CYP2C9 (unknown origin) at 3 uM relative to control,Inhibition,<,50.0,%,Cc1n[nH]cc1-c1cnc(N)c(O[C@@H](C)c2cc(F)ccc2-n2cccn2)c1,CHEMBL4765473,PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease.,J Med Chem,2021.0,64,1.0,326,342,10.1021/acs.jmedchem.0c01518,33356244.0,
23063435,CHEMBL4537788,BAY_784,CHEMBL4508920,B,,Homo sapiens,Cytochrome P450 2C9,"CYP450, 2C9 Eurofins-Panlabs enzyme assay",Inhibition,,32.0,%,O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1,CHEMBL4507266,Data for DCP probe BAY-784,,2021.0,,,,,10.6019/CHEMBL4507266,,
23097332,CHEMBL3286797,1-(4-fluorobenzoyl)-3-((6-methoxynaphthalen-2-yloxy)methyl)azetidine-3-carboxylic acid,CHEMBL4510879,B,,,Cytochrome P450 2C9,CYP2C9 inhibition CEREP ligand profiling,Inhibition,,41.0,%,COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1,CHEMBL4507298,Data for DCP probe PF-04418948,,2021.0,,,,,10.6019/CHEMBL4507298,,
